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Vascular Biology/Atherosclerosis/
Thrombosis/Endothelium
Sunday, March 30, 2008, 9:00 a.m.-12:30 p.m.
McCormick Place, South Hall 
10:00 a.m.
1007-157 Effects of Cigarette Smoke Exposure on The 
Dynamics and Strength of Clot Formation. An Ex-Vivo 
Investigation
Rajat S. Barua, Usman Javed, Cyrus Buhari, Sundararajan Srikanth, Fridolin Sy, John A. 
Ambrose, University of California San Francisco - Fresno, Fresno, CA
Introduction: The mechanism(s) leading to a prothrombogenic state in cigarette smokers 
(CS) is unknown. Utilizing thromboelastography (TEG) and GP IIb/IIIa inhibition the 
effect(s) of cigarette smoke exposure (CSE) on the dynamics of clot formation was 
examined ex-vivo and the relative contribution of platelets and fibrinogen was quantified.
Methods: A baseline blood was drawn from young healthy CS (n=34) and nonsmokers 
(NS) (n=34). CS had a second blood draw after smoking two regular cigarettes. TEG 
provides viscoelastic properties of a clot. The parameters measured: R: initial fibrin 
formation time, k: kinetics of clot formation, Alpha angle: rapidity fibrin buildup and cross-
linking and G: maximum clot strength. In additional experiments, abciximab (20ug/ml) 
was added to the CS samples (n=23) to eliminate platelet function from the parameters. 
The G obtained with addition of abciximab was the function of fibrinogen on clot strength 
(GF). By subtracting GF from G, the specific contribution of platelets to clot strength (GP) 
was ascertained.
Results: Shown in Table 1.
Conclusions: The above data suggest that acute CSE significantly changes clot dynamics 
by shortening the time for fibrin formation, increasing fibrin cross-linking, hastening clot 
build up time and increasing the clot strength. These results suggest for the first time 
that not only platelets but also functional changes in fibrinogen play an important role in 
increasing the prothrombotic state in smokers.
Table 1. 
Nonsmoker 
(n=34)
Smoker 
(n=34)
Age 29±1 27±1
Cigarette/day 14±1 0
Hemoglobin (g/dL) 15.9±0.1 15.7±0.2
White blood cell (K/uL) 6.4±0.2 7.6±0.4*
Platelet (K/uL) 228±6 242±8
Fibrinogen 
(mg/dL) 237±8 259±11
Pre-smoking Post-smoking
R (min.) 5.7±0.3 5.5±0.3 4.8±0.3*
K (min.) 2.9±0.1 2.8±0.1 2.4±0.1*
Alpha Angle (degree) 54±1 55±1 59±1*
G (dyne/cm2) 6.5±0.2 6.8±0.2 7.3±0.3*
GF (dyne/cm2) 
(n=23) 0.97±0.08 1.05±0.07*
GP (dyne/cm2) 
(n=23) 5.99±0.3 6.33±0.3*
Results are presented as mean±SEM. Unpaired Student’s t test, * P<0.05 vs. 
nonsmoker and paired Student’s t test, * P<0.05 vs. presmoking
10:00 a.m.
1007-158 Thrombomodulin Expresses in Neointima and 
Promotes Vascular Smooth Muscle Cell Migration
Yi-Heng Li, Shu-Lin Liu, Guey-Yueh Shi, Hua-Lin Wu, National Cheng Kung University 
Medical Center, Tainan, Taiwan,ROC
Background: Vascular smooth muscle cells (SMCs) migration from media into neointima is 
an important event in the pathogenesis of atherosclerosis and restenosis. Thrombomodulin 
(TM), traditionally known as an anticoagulant protein that only appears on endothelium 
in normal artery, expresses large amount in SMCs in atherosclerotic plaque. We tried 
to understand the physiological significance of TM expression on SMCs. Methods 
and Results: We used mouse carotid ligation model to produce SMC-rich neointima. 
Immunohistochemical study at 1 and 6 weeks after ligation was performed to stain smooth 
muscle-myosin heavy chain (SM-MHC), non muscle-myosin heavy chain (NM-MHC), 
and TM. We found that the TM expression in neointima was associated with a decreased 
staining of SM-MHC, a SMC contractile phenotype marker and an increased staining of NM-
MHC, a SMC synthetic phenotype marker. Boyden chamber assay shows TM, especially 
the TMD23 fragment significantly promoted SMC migration. Inhibition of α
v
β3 integrin 
resulted in a significant decrease in TM-induced SMC migration. Using anti-paxillin antibody 
staining and confocal microscope, we found TM treatment induced a redistribution of focal 
adhesions to the leading edges of SMC in association with the phosphorylation of paxillin 
and focal adhesion kinase (FAK). TM-induced SMC migration was significantly reduced by 
pretreatment of SMCs with the extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor, 
UO126, the phosphatidylinositol-3 kinase (PI3-K)-protein kinase B/Akt (Akt) inhibitor, 
LY294002 and the p38 inhibitor, SB203580. TM treatment significantly increased the ERK1/2, 
Akt, and p38 phosphorylation in SMCs. TM treatment also significantly induced SMC 
matrix metalloproteinase (MMP)-2 expression. Conclusions: TM expression in neointima 
is associated with SMC synthetic phenotype change and promotes SMC migration. TM 
promotes SMC migration through the α
v
β3 integrin, paxillin and FAK activation. TM activates 
ERK1/2, Akt and p38 signaling pathways in SMCs and induces SMC MMP-2 production. 
Our results indicated that TM may play a role as a chemotactic factor for recruiting SMCs in 
the development of neointima after vascular injury.
10:00 a.m.
1007-159 Aortic Atheromatous Plaque Volume Increases With 
History of Personal and Parental Smoking in Men but 
Not in Women
Michael L. Chuang, Noriko Oyama, Philimon Gona, Carol J. Salton, Susan J. Blease, 
Daniel Levy, Anya R. Manning, Martin G. Larson, Christopher J. O’Donnell, Warren J. 
Manning, Beth Israel Deaconess Medical Center, Boston, MA, the NHLBI’s Framingham 
Heart Study, Framingham, MA
Background: Smoking is associated with increased atherosclerosis. We used 
cardiovascular magnetic resonance (CMR) to determine whether exposure to parental 
smoking affects aortic plaque prevalence and volume.
Methods: 1270 members of the Framingham Heart Study Offspring cohort underwent CMR 
using an ECG-gated 2D T2W black-blood sequence to image the descending thoracic 
and abdominal aorta. A single, blinded, expert observer determined plaque prevalence 
and total aortic plaque volume. Smoking was defined as having ever smoked tobacco 
regularly. Subjects were grouped by history of personal smoking (S+) or nonsmoking (S-) 
and parental smoking (P+) or nonsmoking (P-). Age-adjusted plaque prevalence by group 
was compared by Chi-square test.
Results: Subjects (609 men, 661 women) were aged 64±9 years; 604 (47.6%) had 
aortic plaque by CMR. There were no significant between-group differences in plaque 
prevalence for either sex. However, total plaque volume was positively and significantly 
(p<0.05) related to personal and parental smoking in men, but not women (Figure).
Conclusions: In men, a personal smoking history is associated with greater aortic plaque 
volume than exposure to parental smoking only. However, among both smokers and 
nonsmokers, a history of parental smoking is associated with greater plaque burden 
than no parental smoking. The apparent sex-specific difference in relationship between 
smoking exposure and aortic plaque burden remains to be further elucidated. 
10:00 a.m.
1007-160 Chronic smoking-yielded electronegative LDL induces 
MEK/ERK-mediated metalloproteinase activation in 
human endothelial progenitor cells
Daming Tang, Hsin-Hung Chen, Jonathan Lu, David A. Engler, Tatsuya Sawamura, 
Henry J. Pownall, Chao-Yuh Yang, Chu-Huang Chen, Baylor College of Medicine, 
Houston, TX
Background: Endothelial progenitor cells (EPCs) play a key role in tissue stabilization, but 
the effect is often minimized in smokers. To identify the mechanistic link between smoking 
and lesion stability, we tested the effects of electronegative LDL, circulating in smokers 
but not healthy nonsmokers, on signaling in EPCs.
Methods and Results: LDL isolated from adult smokers was subfractionated by ion-exchange 
chromatography into L1-L5, with increasing electronegativity. The majority (>95%) of LDL 
appeared as L1, which was harmless to monocyte-derived EPCs at all concentrations 
tested. In contrast, the most electronegative L5 was proapoptotic at higher concentrations. 
To examine the effect of L5 on metalloproteinase activity in 21-day EPCs, subapoptotic 
concentrations of L5 was used. Whereas L1 had no effects, L5 inhibited Akt but stimulated 
MEK/ERK phosphorylation in a concentration-dependent (1-10 µg/mL) manner. This led to 
the enhancement of MMP-2 synthesis and activity, resulting in accelerated EPC invasion and 
migration in Matrigel. Concentration-dependently, L5 also increased EPC expression of lectin-
like oxidized LDL receptor-1 (LOX-1), through which, internalization of fluorescence-labeled L5 
was visualized. Neutralizing LOX-1 with its antibody TS20 or silencing it with specific siRNAs 
(siLOX-1) blunted LOX-1 expression and stopped L5 internalization. In TS20-treated or siLOX-
1-transfected EPCs, L5 failed to either dephosphorylate Akt or phosphorylate MEK/ERK, and 
was thus unable to stimulate the synthesis or bioactivities of MMP-2. MMP-2 activation was 
profoundly attenuated by MEK inhibitor PD 98059, but unaffected by phosphatidylinositol-
3-kinase (PI3K) inhibitors LY294002 and wortmannin. In EPCs whose PI3K signaling was 
interrupted by a dominant-negative Akt vector, phosphorylation of MEK/ERK, as well as its 
upstream kinase c-Raf, was further enhanced by L5.
Conclusions: Smoker electronegative LDL activates the c-Raf/MEK/ERK signaling 
pathway in EPCs through LOX-1, thereby increasing production of MMP-2, which 
promotes EPC invasion and migration in a 3D microenvironment. The findings suggest a 
new mechanism of smoking-mediated plaque instability.
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1007-161 Alcohol Consumption and Atherosclerotic Burden in 
the Proximal Thoracic Aorta
Shun Kohsaka, Zhezhen Jin, Shunichi Homma, Ralph L. Sacco, Marco R. Di Tullio, 
Columbia University, New York, NY
Background: Aortic arch plaques (AAP) are a risk factor for ischemic stroke (IS). 
Observational studies suggest that light-to-moderate alcohol intake decreases the risk of 
IS. We conducted a cross-sectional analysis in a population-based sample to evaluate the 
possible association between alcohol consumption and AAP.
Methods: As part of the NINDS-funded Aortic Plaques and Risk of Ischemic Stroke 
(APRIS) study, 464 subjects over the age of 55 were studied (mean age 69.1±9.0 with 
251 males), including 255 patients with first IS and 209 stroke-free controls. TEE was 
performed for the detection of AAP. Alcohol consumption was measured in number of 
drinks during the previous year using a standardized questionnaire, and categorized as 
(1) none or light (less than 1 drink/month) (2) moderate (more than 1 drink/month and 
less than 2 drinks/day) or (3) heavy (more than 2 drinks/day). Multivariate conditional 
logistic regression analysis was used to calculate the odds ratios (ORs) for alcohol 
consumption and AAP after adjustment for the potential confounding risk factors (age, 
sex, hypertension, diabetes, dyslipidemia, and smoking).
Results: Overall, AAP were detected in 326 subjects (70.4%), and 174 subjects (37.6%) 
had AAP >4mm, which carry higher stroke risk. In 241 subjects (53.2%), no or only light 
amount of alcohol was consumed, and 177 subjects (39.0%) had moderate consumption. 
Prevalence of alcohol consumption was lower in subjects who had AAP (41.6% vs. 58.8% 
in subjects w/o AAP, p=0.008). After adjustment, alcohol consumption of any degree was 
inversely associated with AAP (OR 0.61; 95%CI 0.37-0.98, p=0.042). The significance of 
the association was borderline for AAP >4mm (OR 0.64, 95%CI 0.41-1.00, p=0.054). In 
the dose-response analysis, only moderate alcohol consumption remained significantly 
associated with a lower risk of having any AAP (adjusted OR 0.45; 95%CI 0.29-0.68, 
p<0.001) or AAP ≥ 4mm (adjusted OR 0.51; 95%CI 0.34-0.77, p=0.001).
Conclusions: Our data indicate that moderate alcohol consumption is associated with 
lower atherosclerotic burden in the proximal aortic arch. This observation may explain at 
least in part the lower risk of IS observed in moderate alcohol consumers.
10:00 a.m.
1007-162 Marked Impairment of Thrombin-Mediated Endothelial 
Vasomotor and Fibrinolytic Function in Cigarette 
Smokers
Ninian N. Lang, Ingibjorg J. Gudmundsdottir, Nicholas A. Boon, Christopher A. Ludlam, 
Keith A. Fox, David E. Newby, University of Edinburgh, Edinburgh, United Kingdom, 
Royal Infirmary of Edinburgh, Edinburgh, United Kingdom
Background: Distinct from its role in the coagulation cascade, thrombin exerts major 
vascular actions via protease activated receptor type 1 (PAR-1). PAR-1 activation causes 
endothelium dependent arterial vasodilatation and release of fibrinolytic factors. We 
hypothesised that cigarette smoking adversely alters these effects in man.
Methods: Forearm blood flow was measured by venous occlusion plethysmography in 
12 smokers and 12 age and sex matched non smokers during intrabrachial infusions of 
PAR-1 activating peptide (SFLLRN; 5-50 nmol/min), bradykinin (BK; 100-1000 pmol/min) 
and sodium nitroprusside (SNP; 2-8 Âµg/min). Plasma tissue plasminogen activator (tPA) 
and plasminogen activator inhibitor 1 (PAI-1) were measured at intervals.
Results: Whilst BK and SNP caused similar vasodilatation, SFLLRN induced 
vasodilatation was attenuated in smokers (P=0.04). In addition to modest reductions in 
bradykinin induced active tPA release (-37%; P=0.03), smokers had marked impairment 
of SFLLRN induced tPA antigen (-96%; P=0.02) and activity (-68%; P=0.006). SFLLRN 
caused similar increases in inactive PAI-1 in both groups (Pâ‰¤0.002 for both). 
Conclusions: Cigarette smoking causes marked impairment of PAR-1 mediated endothelial 
vasomotor and fibrinolytic function. Relative arterial stasis and near abolition of t-PA release 
will promote clot expansion and vessel occlusion. This suggests a major contribution of 
impaired endothelial PAR-1 action to the increased atherothrombotic risk of smokers.
10:00 a.m.
1007-163 Exploring the Links Between Low-Grade Inflammation, 
Endothelial and Cardiorenal Dysfunction: The 
Role of Asymmetric Dimethylarginine in Essential 
Hypertension
Costas Tsioufis, Kyriakos Dimitriadis, Maria Selima, Costas Thomopoulos, Dimitris 
Tsiachris, Karmen Vasiliadou, Christodoulos Stefanadis, Ioannis Kallikazaros, 
Department of Cardiology, Hippokration Hospital, Athens, Greece
Background: Asymmetric dimethylarginine (ADMA) is related to atherosclerosis 
progression and emerges as a marker of cardiovascular risk. We investigated the 
associations of urinary albumin excretion, expressed as the albumin to creatinine ratio 
(ACR), with high-sensitivity C-reactive protein (hs-CRP), adiponectin and ADMA in 
essential hypertensives.
Methods: Our population consisted of 158 newly diagnosed untreated non-diabetic 
patients with stage I to II essential hypertension [106 men, mean age=49 years, office 
blood pressure (BP)=151/97 mmHg]. According to the ACR values determined as the 
mean of two non-consecutive morning spot urine samples, the study population was 
divided into microalbuminurics (n=32) (mean ACR=30-300 mg/g) and normoalbuminurics 
(n=126) (mean ACR<30 mg/g).
Results: Microalbuminurics compared to normoalbuminurics were older (53±7 vs 49±6 
years, p<0.05), had higher 24-h systolic BP (144±11 vs 133±12 mmHg, p=0.001), while 
did not differ regarding metabolic profile (p=NS). Moreover, microalbuminurics compared 
to normoalbuminurics exhibited higher levels of ADMA (0.61±0.04 vs 0.55±0.03 µmol/l, 
p=0.001) and hs-CRP (4.5±1.7 vs 2±1.1 mg/l, p<0.0001), whereas had lower adiponectin 
values (5.8±1.5 vs 9±2.6 µg/ml, p=0.019). In the total population, ACR was related to 
24-h systolic BP (r=0.263, p<0.0001), ADMA (r=0.366, p<0.0001), hs-CRP (r=0.318, 
p<0.0001) and adiponectin (r=-0.169, p=0.004). Regarding ADMA, it was associated with 
24-h pulse pressure (r=0.404, p<0.0001), hs-CRP (r=0.221, p<0.0001) and adiponectin 
(r=-0.222, p<0.0001). Multiple regression analysis revealed that 24-h systolic BP, hs-CRP 
and ADMA were the independent predictors of ACR (R2=0.58, p<0.0001). Furthermore, 
analysis of covariance showed that ADMA, adiponectin and hs-CRP values were 
significantly different between groups after adjustment for confounders (p<0.05).
Conclusion: Microalbuminuric hypertensives exhibit pronounced inflammatory activation, 
endothelial dysregulation and hypoadiponectinemia. The association of ADMA with hs-
CRP and adiponectin, establishes endothelial dysfunction as an integrative factor in the 
interpretation of ACR-related risk.
10:00 a.m.
1007-164 Factor XIII Val34Leu Polymorphism and the Risk of 
Myocardial Infarction Under the age of 36 Years
Loukianos S. Rallidis, Marianna Politou, Christoforos Komporozos, Chrisoula Belesi, 
Anthi Travlou, Ioannis Lekakis, Dimitrios T. Kremastinos, University General Hospital 
Attikon, Athens, Greece, General Hospital of Nikea, Piraeus, Greece
Background: There are limited and controversial data regarding the impact of factor XIII 
(FXII) Val34Leu polymorphism in the pathogenesis of premature myocardial infarction 
(MI). We examined whether FXIII Val34Leu polymorphism is associated with the 
development of MI ≤35 years of age.
Methods: We recruited 137 consecutive patients who had survived their first MI ≤35 years 
of age (mean age=32.6±3.3 years). The control group consisted of 96 healthy individuals 
matched with cases for age and sex and without a family history of premature coronary 
heart disease (CHD). FXIII Val34Leu polymorphism was tested with polymerase chain 
reaction and reverse hybridization. 
Results: The table presents the prevalence of major cardiovascular risk factors and 
factor XIII Val34Leu polymorphism in young survivors of MI and controls. There was 
a higher prevalence of carriers of the Leu34 allele in controls than in patients (odds 
ratio [OR] 0.46, 95% confidence interval [CI], 0.27 to 0.79, p=0.005). FXIII Val34Leu 
polymorphism was associated with lower risk for acute MI (OR 0.43, 95% CI, 0.19-0.97, 
p=0.04) after adjusting for major cardiovascular risk factors. FXIII Val34Leu polymorphism 
was associated with even lower risk for MI when only patients with premature MI and 
angiographically significant CHD (n=108) were included in analysis (adjusted OR 0.25, 
95% CI, 0.09-0.73, p=0.01).
Patients (n=137) Controls (n=96) p
Current smokers (%) 95.6 51 <0.001
Hypercholesterolaemia (%) 65.7 27.1 <0.001
Hypertension (%) 10.9 2.1 0.02
Diabetes mellitus (%) 2.9 0 n/a
Val/Val (%) 69.4 51 0.007
Val/Leu+Leu/Leu (%) 27.7+2.9 43.8+5.2 0.007
Frequency of Leu allele 0.168 0.271 0.01
Conclusions: Our data indicate that FXIII Val34Leu polymorphism has a protective effect 
against the development of MI under the age of 36 years.
10:00 a.m.
1007-165 The Contribution of Endothelium-Derived 
Hyperpolarizing Factor and Nitric Oxide to Exercise-
induced Vasodilation.
Muhiddin A. Ozkor, Nino Kavtaradze, Jonathan Murrow, Jesse Jorgensen, Khan Pohlel, 
Kostantinos Aznaouridis, Amita Matanunga, Arshed A. Quyyumi, Emory University, 
Atlanta, GA
Background: Although nitric oxide (NO) is known to contribute to forearm vasodilation 
during exercise, the contribution of non-NO endothelial factors such as endothelium-
derived hyperpolarizing factor (EDHF) remains unknown. We hypothesized that EDHF 
contributes to exercise-induced vasodilation by activating calcium-dependent potassium 
channels that can be inhibited by tetraethylammonium (TEA).
Methods: In 21 healthy subjects, we measured forearm blood flow (FBF) using venous 
occlusion strain gauge plethysmography at rest and during handgrip exercise (performed 
at 15%, 30% and 45% of maximum grip strength). Exercise was repeated after NO 
blockade with intra-arterial LNGmonomethyl arginine (L-NMMA) at 16 µmol/min, followed 
by combined NO and calcium-dependent potassium channel blockade with L-NMMA 
and TEA (1mg/min). In separate experiments, blockade with TEA preceded combined 
blockade with L-NMMA and TEA. Responses were compared using two-way ANOVA.
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Results: L-NMMA and TEA independently reduced resting FBF (29% and 33%, 
p<0.001). The addition of L-NMMA to TEA produced a further reduction in resting FBF 
(20%, p=0.04), but addition of TEA to L-NMMA produced no further vasoconstriction. 
When administered alone, both L-NMMA and TEA inhibited exercise-induced forearm 
vasodilation, with a 20% (p=0.008) and 28% (p=0.001) reduction in FBF at peak exercise, 
respectively. The addition of L-NMMA to TEA further reduced peak FBF 11% (p=0.04); 
however, addition of TEA to L-NMMA produced no significant additional inhibition 
during exercise. Endothelium-independent vasodilation with sodium nitroprusside was 
unchanged after L-NMMA and/or TEA.
Conclusions: Both NO and EDHF contribute to resting vasodilator tone in healthy subjects. 
We also demonstrate that both NO and EDHF equally contribute to exercise-induced 
vasodilation. After blockade of EDHF, there is further contribution of NO to exercise-
induced vasodilation, however, after blockade of NO, no additional contribution of EDHF 
to exercise is observed. Whether the contribution of EDHF to exercise is modulated by 
risk factors that affect NO activity needs to be investigated.
10:00 a.m.
1007-166 Myocardial and Somatic Expression of Stem Cell-
Related Surface Antigens in the Mouse
Michael P. Flaherty, Greg Hunt, Smita Ranjan, Timothy A. Graubert, Roberto Bolli, 
Buddhadeb Dawn, University of Louisville, Louisville, KY
Background: The cell surface glycoprotein stem cell antigen-1 (Sca-1) is widely regarded 
as a phenotypic marker of stemness. Both Sca-1 and c-kit, a receptor tyrosine kinase, 
are used as markers to identify progenitor cells in adult hearts. We characterized the 
pattern of somatic and myocardial Sca-1 and c-kit expression. Methods: Immunostaining 
and Western analysis were performed on tissue samples from the heart, lung, spleen, 
kidney, and thymus of heterozygous transgenic mice expressing EGFP driven by the 
Sca-1 promoter (Sca-1-GFP) and age-matched WT controls. Results: Cardiac Sca-1 
fluorescence colocalized mainly with that of CD31 (Fig A-C) and lectin on the endothelial 
surface of myocardial arteries, veins, and capillaries. In contrast, c-kit-positive cells 
were infrequent and were found in small niches within the myocardial parenchyma. A 
similar staining pattern was noted in renal, pulmonary, splenic and thymic tissues; but 
Sca-1 expression was more abundant in extramedullary hematopoietic tissues. Sca-1 
expression was confirmed by concomitant translational expression of GFP in Sca-1-GFP 
mice (Fig D). Conclusions: Our results suggest that in contrast to c-kit-positive cells, 
Sca-1-positive cells in the heart primarily represent mature endothelial cells, and Sca-1 
alone may not be a suitable marker for the identification of cardiac progenitor cells from 
the adult heart. Instead, Sca-1 expression may be utilized to delineate the endothelial 
surface of the myocardial vasculature in adults. 
10:00 a.m.
1007-167 Endothelial Dysfunction in Human Arterioles Following 
Exposure to Primary Amyloid Light Chain Is Improved 
by Mitochondria-Targeted Antioxidant
Raymond Q. Migrino, Megan Bright, Parameswaran Hari, Jingli Wang, Balaraman 
Kalyanaraman, David D. Gutterman, Lawreen Connors, Shane A. Phillips, Medical 
College of Wisconsin, Milwaukee, WI, Boston University, Boston, MA
Background: Primary amyloidosis (AL) is often a fatal disease and is associated with 
diffuse perivascular amyloid light chain (LC) deposition. We recently demonstrated 
endothelial dysfunction and oxidative stress following LC exposure in human arterioles. 
We determined the effect of mitoquinone (mitochondria targeted antioxidant) on 
endothelial function in arterioles exposed to LC.
Methods: LC was isolated from the urine of 3 biopsy-proven AL subjects. Dilator response 
of mesenteric adipose arterioles from discarded tissue in subjects without known amyloid 
or vascular disease undergoing routine surgery were measured before (C) and following 
30-minute exposure to LC (20 µg/mL), mitoquinone (M, 0.1 µM), LC+M and M alone. 
Dilator response (%maximum dilation) was performed as follows: preconstriction with 
endothelin-1 followed by acetylcholine (endothelium-dependent) then papaverine (Pap 
10-6M, endothelium-independent). Arterioles were pressure mounted (60 mm Hg), 
dilation was measured using videomicroscopy and compared among groups.
Results: (Figure). There is reduced dilator response to acetylcholine but not to papaverine 
in arterioles exposed to LC. Mitoquinone co-administration restores endothelial function.
Conclusions: Amyloid LC cause impaired endothelium-dependent but not endothelium-
independent dilation. Endothelial function is restored by mitoquinone. Mitochondria-
targeted antioxidant therapy may be useful in vascular dysfunction caused by primary 
amyloidosis.
10:00 a.m.
1007-168 The Effect of Darapladib on Plasma Lipoprotein-
Associated Phospholipase A2 Activity and 
Cardiovascular Biomarkers in Patients With Coronary 
Heart Disease or Risk Equivalent
Emile R. Mohler, III, Christie Ballantyne, Michael Davidson, Markolf Hanefeld, Luis 
Ruilope, Joel Johnson, Andrew Zalewski for the Darapladib Investigators, University of 
Pennsylvania, Philadelphia, PA
Background: High plasma levels of lipoprotein-associated phospholipase A2 (Lp-PLA2) 
are associated with increased risk of cardiovascular (CV) events. Sustained inhibition of 
this pro-inflammatory enzyme by the selective Lp-PLA2 inhibitor, darapladib, may provide 
therapeutic benefits in CV patients.
Methods: 959 coronary heart disease (CHD) or CHD-risk equivalent patients on 
atorvastatin 20 or 80mg were randomized to oral darapladib 40, 80, 160mg or placebo 
once daily for 12 weeks. Blood samples were analyzed for Lp-PLA2 activity, inflammatory 
and platelet biomarkers.
Results: At baseline, LDL-c was 68 ± 22 mg/dL. Plasma Lp-PLA2 activity was higher in 
elderly patients (≥75 years), males, those on atorvastatin 20mg, those with LDL-c ≥70 
mg/dL or HDL-c <40 mg/dL, or those with documented vascular disease (multivariate 
regression; all p<0.01). Lp-PLA2 activity correlated positively with LDL-c (r=0.459, 
p<0.0001) and inversely with HDL-c (r=−0.229, p<0.0001). Darapladib 40, 80 and 160mg 
inhibited Lp-PLA2 activity by 43, 55 and 66%, respectively, compared to placebo (p<0.001 
for all doses at weeks 4 and 12). Sustained, dose-dependent inhibition was noted overall, 
in both atorvastatin groups, and at different levels of baseline LDL-c (≥70 vs <70 mg/
dL) and HDL-c (<40 vs ≥40 mg/dL). At 12 weeks, darapladib 160mg decreased IL-6 by 
12% (95% CI: −22, −1; p=0.028) and hs-CRP by 13% (95% CI: −28, +5; NS) compared 
to placebo. When explored post-hoc by quartiles of baseline Lp-PLA2, only darapladib 
160mg significantly reduced hs-CRP by 43% (95% CI: −50, −10; p=0.013) compared to 
placebo in the highest quartile. Lp-PLA2 inhibition produced no detrimental effects on 
platelet biomarkers (P-selectin, CD40 ligand and urinary 11-dehydrothromboxane B2). 
No major safety concerns were noted.
Conclusions: Darapladib produced sustained, dose-dependent inhibition of plasma Lp-
PLA2 activity in CHD or CHD-risk equivalent patients receiving intensive atorvastatin 
therapy. Changes in IL-6 and hs-CRP after 12 weeks of darapladib 160mg suggest a 
possible reduction in systemic inflammatory burden. Further studies will determine if 
sustained inhibition of Lp-PLA2 is associated with favorable effects on CV outcomes.
10:00 a.m.
1007-169 Significant Increases in Plasma Levels of Oxidized Low 
Density Lipoprotein and Myeloperoxidase after a Single 
Session of Hemodialysis in Patients with Diabetes 
Mellitus Nephropathy
Chizuko Kitabayashi, Shoichi Ehara, Masashi Nakagawa, Nobuyuki Shirai, Hiroki Oe, 
Kenichi Sugioka, Takeshi Hozumi, Yoshihiro Ikura, Takahiko Naruko, Kazuo Haze, 
Minoru Yoshiyama, Makiko Ueda, Osaka City University Graduate school of Medicine, 
Osaka, Japan, Osaka City General Hospital, Osaka, Japan
Background: Previous studies have demonstrated that there is increased oxidative stress 
in patients undergoing hemodialysis (HD). However, little is known how mechanisms 
contribute to the oxidative stress induced by HD. Low-density lipoprotein (LDL) from 
dialysis patients has been shown to be susceptible to in vitro peroxidation, therefore, 
oxidized LDL (ox-LDL) could be generated in these patients. We previously reported that 
our ox-LDL-measuring method is a sensitive method to analyze the behavior of oxidized 
phosphatidylcholine particles as part of ox-LDL and minimally modified LDL (MM-LDL), 
which may be generated in association with the progression of inflammatory reactions. 
Moreover, myeloperoxidase (MPO) released from activated neutrophils may play a role 
in the induction of LDL oxidation. The purpose of this study is to investigate whether a 
relationship is present between plasma ox-LDL levels, plasma MPO levels, and serum 
high sensitivity C-reactive protein (hs-CRP) levels in patients with diabetes mellitus (DM) 
nephropathy during HD. Methods: Patients with DM nephropathy (n=28) undergoing HD 
had serial venous blood samples drawn before HD and after HD at initial, second, and 
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third session. Plasma ox-LDL levels were measured using a specific monoclonal antibody 
DLH3 and plasma MPO levels were measured using an enzyme-linked immunosorbent 
assay kit. Results: In each session of HD, plasma ox-LDL levels and MPO levels after a 
session of HD increased significantly (ox-LDL, p<0.005; MPO, p<0.0001) compared with 
the levels before a session of HD, whereas there was no significant difference in serum 
hs-CRP levels before and after a session of HD. However, serum hs-CRP levels at the 
third session were distinctly decreased compared with the levels at the initial session. 
Conclusions: These observations suggest that increased oxidative stress during HD with 
neutrophil activation and MPO release may induce a temporal increase in plasma levels 
of MM-LDL, detected by our ox-LDL-measuring method, after a single session of HD. 
Our present findings suggest a pivotal role for MM-LDL(ox-LDL) in the progression and 
acceleration of atherosclerosis in patients undergoing hemodialysis.
10:00 a.m.
1007-170 Vascular Endothelial Function Predicts Mortality Risk in 
Patients with Advanced Ischemic Chronic Heart Failure
Michael Shechter, Michael Arad, Shlomi Matetzky, Micha S. Feinberg, Dov Freimark, 
Heart Institute, Sheba Medical Center, Tel Hashomer, Israel
Background: Endothelial function is known to be impaired in patients with chronic heart 
failure (CHF), but the association between endothelial function and subsequent mortality 
risk in advanced CHF has not been previously reported.
Methods: We prospectively assessed endothelium-dependent flow-mediated dilation 
(FMD) in the brachial artery in 62 consecutive advanced ischemic CHF patients [New 
York Heart Association III-IV], mean age 64±12 years, 26 (43%) males and left ventricular 
ejection fraction 22±3%. Following overnight fasting and discontinuation of all medications 
for ≥ 12 hours, percent improvement in brachial artery FMD (%FMD) and nitroglycerin-
mediated vasodilation (%NTG) were assessed using high resolution (15 MHz) linear array 
ultrasound. Subjects underwent clinical follow-up for a mean of 12±2 months.
Results: Subjects were divided into two groups: below (n=31) and above (n=31) the 
median %FMD of 7.6%. The two groups were comparable regarding CAD risk factors, 
lipid panel, fasting glucose, electrolytes, hemoglobin, serum creatinine and renal function 
tests, and concomitant medications. Subjects underwent clinical follow-up every month 
up to a mean of 12±2 months (Table). Cox regression nalysis revealed that FMD was an 
independent predictor for the occurance events.
Conclusion: Endothelial dysfunction in advanced ischemic CHF patients is associated 
with increased mortality risk. Larger long-term studies are required to determine the 
clinical value of these results.
Values are expressed as mean+/-SD; Hosp.=hospitalization; MI=myocardial infarction.
%FMD≤7.6 (n=31) %FMD>7.6 (n=31) p value
%FMD 3.1±3.7 14.3±5.6 <0.001
%NTG 9.8±4.7 15.9±4.9 <0.01
Death 4 (12.9%) 0 <0.05
Hosp. for CHF exacerbation 2 (6.4%) 1 (3.2%) 0.12
Hosp. for acute MI 1 (3.2%) 0 0.23
Composite events 7 (22.5%) 1 (3.2%) <0.03
10:00 a.m.
1007-171 Diadenosine P1, P4-tetraphosphate and Its 
Tetraphosphonate Derivatives Synergistically Inhibit 
Platelet Activation via Both P2Y1 and P2Y12
Hung Chang, Ivan B. Yanachkov, Alan D. Michelson, YouFu Li, Marc R. Barnard, George 
E. Wright, Andrew L. Frelinger, III, Center for Platelet Function Studies, University of 
Massachusetts Medical School, Worcester, MA, GL Synthesis, Worcester, MA
Background: Inhibition of platelet P2Y12 receptors is the mechanism of action of 
clopidogrel and some antithrombotic drugs in development. Diadenosine P1,P4-
tetraphosphate (Ap4A) and its derivatives block ADP-induced platelet activation but 
their selectivity for platelet ADP receptors P2Y1 and P2Y12 is unknown. Methods: Ap4A 
and its P1,P4-dithio (ApSp2pSA), chloromethyl (Ap2CHClp2A), and dithio-chloromethyl 
(ApSpCHClppSA) derivatives were synthesized by a novel method. The ADP-stimulated 
P2Y1-mediated increase in platelet cytosolic calcium and P2Y12-mediated decrease in 
phosphorylated vasodilator stimulated phosphoprotein (VASP) were measured by whole 
blood flow cytometry. ADP-stimulated platelet aggregation, mediated by P2Y1 and P2Y12, 
was measured optically. Results: Ap4A inhibited P2Y1 function and this was enhanced with 
ApSp2pSA, and reduced with Ap2CHClp2A (Table). Ap4A and ApSp2pSA weakly inhibited 
P2Y12 but Ap2CHClp2A and ApSpCHClppSA were potent inhibitors. IC50s for inhibition of 
platelet aggregation by Ap4A and its derivatives were much lower than IC50s for inhibition 
of the ADP-induced increase in cytosolic calcium or decrease in VASP phosphorylation. 
Inhibition of platelet aggregation was greatest with ApSpCHClppSA. Conclusions: Ap4A 
and its derivatives inhibit ADP-induced platelet activation via both P2Y1 and P2Y12 and 
this dual inhibition may be synergistic. These compounds, especially ApSpCHClppSA, 
may have utility as antithrombotic agents. 
IC50 (µM)
Calcium 
Flux
VASP 
Phosphorylation
Platelet 
Aggregation
Ap4A 40.8±12.3 >250 9.8±2.8
ApSp2pSA 2.8±0.9 154.7±86.1 3.3±1.2
Ap2CHClp2A 88.5±49 24.3±10.0 1.2±0.3
ApSpCHClppSA 11.4±3.1 8.8±2.8 0.2±0.04
Compounds were added simultaneously with 3 µM ADP. 
Data are mean ± SEM, n=3.
10:00 a.m.
1007-172 Simvastatin Improves Flow-Mediated Dilation, but 
Reduces Adiponectin Levels and Insulin Sensitivity In 
Hypercholesterolemic Patients Independent of Doses
Kwang K. Koh, Michael J. Quon, Seung H. Han, Wook-Jin Chung, Byung C. Oh, Eak K. 
Shin, Gachon University Gil Medical Center, Incheon, South Korea, Diabetes Unit, NIH, 
Bethesda, MD, South Korea
Background: Lipophilic statins particularly high dose may cause exacerbation of insulin 
resistance. We investigated vascular and metabolic responses to different doses of 
simvastatin in hypercholesterolemic patients.
Methods: This was a randomized, double-blind, placebo-controlled, and paralleled study. 
Age, sex, and body mass index were matched. All patients were recommended low fat 
diet. Thirty-two patients were given placebo and 30, 32, 31, and 31 patients were given 
simvastatin 10, 20, 40, and 80 mg, respectively once during 2 month treatment period.
Results: When baseline values were compared among each treatment arm, no significant 
differences were noted in any of the parameters. Placebo significantly reduced total and 
LDL cholesterol levels, however, did significantly neither improve flow-mediated dilator 
response to hyperemia (FMD) nor decrease plasma adiponectin levels and insulin 
sensitivity (determined by QUICKI) relative to baseline measurements. Simvastatin 10, 
20, 40, and 80 mg significantly reduced total cholesterol (mean % changes; by 27%, 
25%, 37%, and 38%), LDL cholesterol (by 39%, 38%, 52%, and 54%) and apolipoprotein 
B levels (24%, 30%, 36%, and 42%) and improved FMD (68%, 40%, 49%, and 63%) after 
2 months administration compared with baseline (all P<0.001 by paired t-test). And these 
effects of four different doses of simvastatins were significant compared with placebo (all 
P<0.001 by ANOVA). Simvastatin 10, 20, 40, and 80 mg significantly decreased plasma 
adiponectin levels (by 4%, 12%, 5%, and 10%) and insulin sensitivity (5%, 8%, 6%, and 
6%) compared with baseline (all P<0.05 by paired t-test). And these effects of four different 
doses of simvastatins were significant compared with placebo (P=0.011 for adiponectin 
and P=0.034 for QUICKI by ANOVA). However, the magnitude of these changes (FMD, 
adiponectin, and QUICKI) were not significantly different among four different doses of 
simvastatin therapies despite of different extents of LDL cholesterol reduction.
Conclusions: Simvastatin improves endothelium-dependent dilation, but reduces adiponectin 
levels and insulin sensitivity in hypercholesterolemic patients independent of doses.
10:00 a.m.
1007-173 Additional Novel Advantage of Carvedilol as a 
Prevention of Nitrate Tolerance via Attenuating 
Depletion of Cytochrome P450
Atsushi Nakahira, Yukiko Minamiyama, Shigekazu Takemura, Yoshihiko Funae, Shigeru 
Okada, Shigefumi Suehiro, Osaka City University Graduate School of Medicine, 
Department of Cardiovascular Surgery, Osaka, Japan, Okayama University Graduate 
School of Medicine, Department of Anti-Aging Food Sciences, Okayama, Japan
Background: A randomized clinical study suggested that carvedilol may prevent the 
development of nitrate tolerance, but the protective mechanism is still unknown. We 
have already proposed that decreased expression of cytochrome P450 is responsible 
for nitrate tolerance. Therefore, we precisely elucidated the protective mechanism of how 
carvedilol attenuated nitrate tolerance.
Methods: Male Wistar rats were assigned to the following 4 groups (n=5 in each group). 
Nitroglycerin (0.5 mg/hr infusion, group NTG) or vehicle were continuously administered 
at the flow rate of 1 ml/hr for 48 hours through the femoral vein and, in other two groups, 
carvedilol (20 or 100 µg/hr, group Carv) was simultaneously administered with NTG 
infusion. At the end of the infusion, induction of the nitrate tolerance in each group was 
evaluated by injecting various doses of additional bolus NTG and animals were sacrificed. 
Cardiac P450 (CYP1A1) expression was assessed by immunoblotting and vascular 
superoxide production in the heart and aortic tissue was examined. We also studied the 
vasodilator-stimulated phosphoprotein (VASP) serine 239 phosphorylation (pVASP) to 
evaluate the NO-cGMP pathway.
Results: Although the nitrate tolerance was induced in group NTG, the tolerance was 
significantly prevented in group Carv in a dose-dependent manner of the simultaneously 
administered carvedilol. Cardiac P450 (CYP1A1) expression markedly decreased in 
group NTG, but the decrease was significantly attenuated in group Carv in the dose 
dependent manner. Vascular superoxide production in the heart and aortic tissue, which 
was enhanced in group NTG, was significantly decreased in group Carv. Furthermore, 
NTG markedly reduced the pVASP in aorta, but in groups Carv the depletion of pVASP 
was significantly inhibited in the dose dependent manner.
Conclusions: Carvedilol was demonstrated to have an additional novel advantage as a 
cardiovascular medicine other than β-blocker. The concomitant administration of carvedilol 
with an organic nitrate prevented nitrate tolerance, through the maintenance of NO/cGMP 
pathway by preserving P450 expression and by checking free radical generation.
10:00 a.m.
1007-174 Urine Proteome Patterns can Identify Coronary Artery 
Disease
Constantin von zur Muehlen, Eric Schiffer, Markus Kellmann, Petra Zuerbig, Mario 
Brasse, Harald Mischak, Christoph Bode, Karlheinz Peter, University Hospital Freiburg, 
Freiburg, Germany
Background: Coronary artery disease (CAD) is a major cause of mortality and morbidity. 
Non-invasive screening methods using proteome analysis could guide clinical evaluation 
and early/preventive treatment.
Methods and Results: Urine and plasma of 67 patients presenting with symptoms 
suspicious for unstable CAD were obtained, analyzed by capillary electrophoresis and 
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coupled to mass spectrometry (CE-MS). CAD status of all patients was determined by 
coronary angiography and patients either assigned to a CAD or non-CAD group. A training 
set of 29 patients was used to establish a CAD and non-CAD specific proteome pattern, 
which was then applied to a test set of 38 patients. Whereas plasma polypeptide patterns 
were dependent upon storage time and procedure, for the urine samples a combination of 
only 17 polypeptides allowed a separation of both groups in the test set with a sensitivity 
of 81.0 % [95 % CI 60 to 93], a specificity of 92 % [95 % CI 62 to 99] and an accuracy of 
classification with 84 %. Sequencing of marker peptides identified fragments of collagen 
α1 (I and III), which are typical constituents of atherosclerotic plaques. Furthermore, in 
independent patient sets without CAD-suspicious symptoms and coronary angiography, 
the pattern scored positive for CAD in diabetic patients corresponding to the prevalence 
of CAD in this group, and similarly for non-CAD in another independent set of patients 
with malignant diseases.
Conclusions: CE-MS allowed the identification of CAD-associated polypeptide patterns in 
urine and allowed non-invasive detection of CAD in patients presenting with symptoms 
suspicious for CAD. Peptides constituting these patterns may be used to identify 
functionally important proteins in atherosclerosis. This promising data encourages the 
further development of a urine-based screening method with the potential of improving 
the diagnostic approaches for CAD.
10:00 a.m.
1007-175 Comparison of a Chromogenic Factor X Assay to 
International Normalized Ratio for Monitoring Oral 
Anticoagulation Therapy
Benjamin G. Romick, David L. McGlasson, Bernard J. Rubal, Wilford Hall U.S. Air Force 
Medical Center, Lackland Air Force Base, TX, Brooke Army Medical Center, Fort Sam 
Houston, TX
Background: The chromogenic Factor X (CFX) assay for measurement of factor X levels 
is unaffected by the presence of lupus anticoagulant (LA), which may falsely elevate 
values for International Normalized Ratio (INR). Several investigations have evaluated the 
performance of CFX for monitoring anticoagulation in patients with LA, however, the range 
of values that define subtherapeutic, supratherapeutic, and therapeutic anticoagulation 
with this assay have not been universally defined.
Methods: The purpose of this investigation was to compare the INR to a CFX assay for 
monitoring subjects on oral anticoagulant therapy (OAT) not known to have LA using the 
DiaPharma® Chromogenic Factor X method. INR values were correlated with the CFX 
method for determining normal, subtherapeutic, therapeutic and supratherapeutic ranges 
for subjects on OAT. Specimens were analyzed and grouped as normal or subjects on 
OAT with INR <2.0; INR 2.0-3.0; INR >3.0.
Results: 309 randomly selected OAT subjects were tested. 30 normal subjects not 
receiving any anticoagulants were also tested for comparison. Range of INR and CFX in 
anticoagulated subjects were 0.92 - 12.76 and 9 - 132%, respectively. CFX was inversely 
related to INR: R = 0.964 with p< 0.0001 (CFX = 13.2+ (5.3/INR) + (81.3/INR2). Results 
by group were as follows: Normal (n=30) CFX range 72-131%, mean CFX 96%; INR < 2.0 
(n=70) CFX range 32-132%, mean CFX 53%; INR 2.0-3.0 (n=135) CFX Range 18-48%, 
mean CFX 28%; INR > 3.0 (n=104) CFX range 9-46%, mean CFX 21%. Sensitivity and 
specificity crossed at a CFX of 35.5%, which yielded sensitivity of 91.7% and specificity 
of 91.9% for discriminating INR ≥ 2.0. Area under the curve on receiver-operator curve 
(ROC) using INR was 0.984 (p<0.001).
Conclusion: In a randomly selected group of OAT subjects and normal subjects at varying 
levels of anticoagulation, CFX correlated well with INR as determined by R = 0.964. 
Current data suggests that CFX, where available, can be a useful tool for monitoring 
oral anticoagulation in patient populations where confounders to INR such as LA may be 
present. Further investigation is warranted in large OAT patient populations with use of 
CFX for monitoring, including follow-up for clinical outcomes.
10:00 a.m.
1007-176 Prognostic Implications of Platelet Function Parameters 
Assessed Using Standard Optical Aggregometry In 
Patients with Type 2 Diabetes Mellitus
Dominick J. Angiolillo, Esther Bernardo, Manel Sabaté, Pilar Jimenez-Quevedo, 
Marco A. Costa, Jorge Palazuelos, Rosana Hernández-Antolin, Raul Moreno, Javier 
Escaned, Fernando Alfonso, Camino Bañuelos, Luis A. Guzman, Theodore A. Bass, 
Carlos Macaya, Antonio Fernandez-Ortiz, University of Florida-Shands Jacksonville, 
Jacksonville, FL, San Carlos University Hospital, Madrid, Spain
Background: Enhanced platelet reactivity is associated with major adverse cardiovascular 
events (MACE) despite the use of antiplatelet therapy. Light transmittance aggregometry 
(LTA) is the gold standard assay to measure platelet function. Although several LTA 
parameters have been associated with MACE, how these parameters compare and which 
is the best prognostic determinant has yet to be explored.
Methods: LTA using 20 µmol/L ADP stimuli was assessed in 173 type 2 diabetes mellitus 
(T2DM) patients on aspirin and clopidogrel therapy. LTA parameters included aggregation 
measured at peak (Aggmax), at 5 minutes (Agglate), and platelet disaggregation (D). 
Patients were followed for 2-years and MACE, defined as cardiac death, acute coronary 
syndrome and stroke, were recorded. Receiver-operating characteristics (ROC) analyses 
were performed to define sensitivity and specificity of each LTA parameter and to identify 
the best predicitive cut-off values. Positive (PPV) and negative predictive values (NPV) 
were also derived. Comparisons of areas under the curve (AUC) were made using C-
statistics to determine differences between parameters.
Results: A total of 41 MACE occurred in 34 patients (19.7%) during the 2-year follow-up. 
All LTA parameters were associated with MACE (Table). 
LTA 
parameter
Optimal 
Cut-off 
value
Odds Ratio & Confidence 
Intervals
Sensitivity Specificity NPV PPV AUC
Agg-max 62% 3.96 (1.8-8.7); p<0.001 48% 84% 86% 41% 0.633
Agg-late 51% 4.53 (2.05-10.03) p<0.001 65% 71% 89% 32% 0.662
D 11% 3.37 (1.54-7.4) p=0.002 68% 65% 89% 35% 0.664
There were no differences between AUC for all LTA parameters (>.0.2 for all 
comparisons).
Conclusions: In T2DM patients on dual antiplatelet therapy, LTA parameters, including 
Aggmax, Agglate, and D, similarly predict MACE.
10:00 a.m.
1007-177 HMG-CoA reductase inhibitors potently promote 
endothelial progenitor cell recruitment in CAD patients
Thomas Soullie, Marcel A. Beijk, Robert J. de Winter, Jeroen Vos, Patrick Serruys, 
Henricus J. Duckers, Thoraxcenter - Erasmus Medical University Center, Rotterdam, 
The Netherlands, dep.Cardiology - Academic Medical Center Amsterdam, Amsterdam, 
The Netherlands
Background: Various animal and human studies have shown mobilization of circulating 
endothelial progenitor cells (EPCs, CD45+/CD34+/KDR+) with endothelial damage, 
vascular trauma and acute myocardial infarction, reflecting ongoing vascular repair. 
Stimulation of EPC levels in various animal models by exercise, EPC infusion or either 
pharmacotherapy may result in accelerated reendothelialization and improved endothelial 
function, thereby stimulating vascular repair, improve vasomotor function, as well as 
promote neoangiogenesis. In addition, EPC cell count have been shown to be a significant 
independent predictor of MACE in CAD patients during a one year follow-up. HMG CoA 
reductase inhibitors (statins) have been shown to improve EPC recruitment and function 
in vitro and in vivo in different animal models.
Methods: 81 patients with recently diagnosed CAD were treated with either 40 mg (n=18) 
or 80 mg (n=63) atorvastatin qd for at least 6 weeks. Blood was collected at baseline, and 
weekly following initiation of the statin therapy for analysis of EPC titer by flow cytometry.
Results: As early as 2 weeks following initiation of therapy, both 40 and 80 mg atorvastatin 
significantly stimulated circulating EPC titers by 296 and 401%, respectively (P<0.001; 
CD34+/KDR+), but did not affect the CD34+ hematopoietic sub population (respectively 
+7%,+19%), suggestive of enhanced differentiation towards the endothelial progenitor 
cell, or stimulated recruitment.
Conclusion: Statin therapy dose-dependently enhances EPC titers in CAD patients within 
2 weeks after initiation, but does not affect CD34+ cell count, suggestive of stimulated 
differentiation towards an endothelial progenitor cell.
10:00 a.m.
1007-178 Effects of Prolonged Intensive Lipid Therapy on Carotid 
Intima-Media Thickness (CIMT): A Case-Control Study 
of the 20-year Familial Atherosclerosis Treatment - 
Observational Study (FATS-OS) 
Binh An P. Phan, Andrew B. Moore, Chunhua Zheng, Joseph Davis, Laura J. Pollan, 
Blazej Neradilek, B. Greg Brown, Xue-Qiao Zhao, University of Washington, Seattle
Background: Though studies have documented the short-term clinical and vascular 
benefits of aggressively lowering LDL-C<100 mg/dL, the long-term effects of intensive 
lipid therapy on atherosclerosis have not been reported.
Methods: We compared carotid IMT in two risk-matched groups of CAD patients who had 
finished FATS between 1984 and 1990 and are participating in the 20-year FATS-OS. At 
the conclusion of FATS, 101 patients returned to the standard care of their providers with 
treatment primarily with a statin, and 75 patients received intensive therapy with lovastatin 
(40 mg/day), niacin (2-3 gm/day), and colestipol (20 gm/day) for 11 years, then continued 
with simvastatin (10-80 mg/day) or lovastatin (40-80 mg/day) plus niacin (2-4 gm/day). 
After a mean duration of 17.8±0.8 years with intensive therapy and 19.0±0.8 years with 
standard care, cholesterol levels and ultrasound measurement of bilateral CIMT were 
collected in 43 patients still active in FATS-OS and 26 patients in standard care. A patient’s 
vascular age was determined by taking the age at which the patient’s mean CIMT would 
represent the mean CIMT for an age and sex matched normal population.
Results: For the intensive therapy and standard care groups, un-treated baseline LDL-C 
(201±55 vs. 191±68 mg/dL, respectively, p=0.53) did not differ. After 20 years, the intensive 
therapy group had a lower LDL-C (85±31 vs. 103±29 mg/dL, p<0.01) as compared to 
standard care. The mean CIMT (0.902±0.164 vs. 1.056±0.169 mm, p<0.001) and mean 
vascular age (74.4±16.5 years vs. 84.6±13.5 years, p<0.05) on intensive therapy was 
significantly less compared to standard care. With adjustment for baseline characteristics, 
intensive therapy was significant predictor of CIMT (coefficient, 95% CI) (-0.12, -0. 22 
- -0.02, p=0.02). Multivariate regression analysis showed that intensive therapy (-0.13, 
-0.21 - -0.04, p=0.003) and on-therapy LDL-C (0.15, 0.02 - 0.28, p=0.03) were significant 
independent predictors of CIMT.
Conclusions: These findings support the recommendation to aggressively lower LDL-
C<100 mg/dL in patients with atherosclerotic disease and illustrate the potential vascular 
benefits of long-term intensive lipid therapy.
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10:00 a.m.
1007-179 The First Prospective Study of the Anti-inflammatory 
Effects of Statins in Hyperlipidemic South Asian 
Patients
Prakash C. Deedwania, Joseph Ycas, Michael Stein, VA Central California Health Care 
System/University of California, San Francisco, Fresno, CA, AstraZeneca, Wilmington, DE
Background: The inflammatory biomarker C-reactive protein (CRP) is considered a 
potential risk marker for cardiovascular disease. CRP is often elevated in South Asians, 
a group with a high risk of coronary events. However, little is known about the impact of 
statins on CRP in this population. Methods: Hyperlipidemic South Asians living in the USA 
or Canada (N = 740) were enrolled in this prospective study (Investigation of Rosuvastatin 
In South Asians [IRIS, 4522US/0006]) and randomized (1:1:1:1) to rosuvastatin 10 or 
20 mg/day or atorvastatin 10 or 20 mg/day. CRP and low-density lipoprotein cholesterol 
(LDL-C) were measured before statin therapy (baseline) and after 6 weeks. Results: Most 
patients were male (68%); mean age was 56 years. Most patients (66%) were at high risk 
of CHD by National Cholesterol Education Program Adult Treatment Panel III guidelines; 
44% had diabetes. Statin therapy decreased median CRP from baseline (Table).
Therapy N*
Baseline 
median CRP 
(mg/L)
% Change
Rosuvastatin 10 mg 174 1.50 -17.2
Rosuvastatin 20 mg 162 1.65 -30.6
Atorvastatin 10 mg 173 1.80 -20.9
Atorvastatin 20 mg 166 1.60 -25.0
*Patients with available CRP values
Differences between statins and doses were not detectable (P = .206, Kruskall-Wallace 
test). Median CRP changes in patients with and without CHD risk equivalents were not 
significantly different (−25.0% and −21.4%, respectively [P = .085, Wilcoxon test]). LDL-C 
reduction correlated weakly with CRP lowering (Pearson correlation coefficient = .134). 
Conclusion: This is the first study showing that lipid-lowering therapy with rosuvastatin or 
atorvastatin reduces CRP in South Asian patients at risk of coronary events.
10:00 a.m.
1007-180 In Vivo Properties of a Novel Apolipoprotein A-I Mimetic 
Peptide
Belinda A. Di Bartolo, Shisan Bao, Kerry-Anne Rye, Stephen J. Nicholls, Philip J. Barter, 
The Heart Research Institute, Sydney, Australia, Cleveland Clinic, Cleveland, OH
Background: Novel mimetic peptides of apolipoprotein (apoA-I) represent a new strategy 
for promoting the biological activity of HDL. The in vivo functional properties of mimetic 
peptides have not been characterised.
Methods: Non-occlusive collars were placed around the carotid arteries of 42 chow-fed, 
normocholesterolemic, New Zealand White rabbits. Animals received daily infusions of 
saline or discoidal complexes of an amphipathic peptide, 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine and sphingomyelin (ETC-642) at doses of 1, 3, 10 or 30 mg/kg daily, 
commenced prior to collar insertion. Animals were sacrificed 48 hours following collar 
insertion for assessment of inflammatory activity within the vessel wall.
Results: ETC-642 resulted in a rapid increase in plasma cholesterol levels, most 
of which was unesterified and present in the HDL fraction, with the HDL-C being 
increased by 222% (p<0.001)) at 1 hour following infusion of the 30mg/kg dose. The 
early accumulation of unesterified cholesterol within HDL is consistent with mobilization 
of lipid to HDL particles. Collar insertion resulted substantial expression of intercellular 
adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) in the 
carotid endothelium and neutrophil infiltration within the artery wall. Infusion of ETC-642 
resulted in dose-dependent reductions in expression of ICAM-1 expression by up to 93% 
(p<0.004), VCAM-1 expression by up to 87% (p<0.05) and the neutrophil marker CD18 
by up to 50% (p=0.02). Infusing ETC-642 did not reduce arterial wall levels of oxidant 
products of either arachidonic acid (HETEs, HODEs) or myeloperoxidase (nitrotyrosine, 
chlorotyrosine) pathways.
Conclusions: Administration of an apoA-I mimetic peptide is associated with cholesterol 
mobilization to HDL and reduction of vascular inflammation. The effect of this mimetic 
peptide on formation of atherosclerotic plaque remains to be established.
10:00 a.m.
1007-181 The Haptoglobin 2 Genotype is Associated with 
Increased Redox Active Hemoglobin Derived Iron in the 
Atherosclerotic Plaque
Shiri Kalet-Litman, Rabea Asleh, Rachel Miller-Lotan, Andrew P. Levy, Technion-Isreal 
Institute of Technology, Haifa, Israel
Background. The haptoglobin (Hp) gene is polymorphic with two classes of alleles, 1 
and 2. In multiple longitudinal studies the Hp 2-2 genotype has been demonstrated 
to be associated with a 3-5 fold increase in the risk of MI in individuals with diabetes 
mellitus (DM). In mice we have shown that the atherosclerotic plaques of Hp 2 mice 
are associated with increased inflammation and markers of oxidation. In vitro we have 
demonstrated that the Hp 2 protein is inferior to the Hp 1 protein in preventing oxidation by 
hemoglobin derived iron. In this study we set out to demonstrate that the Hp 2 genotype 
was associated with increased extravasation of Hb into the atherosclerotic plaque and 
that the increased oxidation in Hp 2 plaques was due to hemoglobin derived iron induced 
oxidation.
Methods. We injected via the tail vein 125I labeled Hp-Hb complexes into Apo E -/- mice 
to assess the ability of the complex to extravasate into the plaque. Immunohistochemical 
analysis was used to assess the relative amount of hemoglobin in plaques of C57Bl/6J 
Apo E-/- Hp 1-1 or ApoE-/- Hp 2-2 mice. Oxidation in the plaque was monitored without 
disrupting plaque architecture by assessing the in situ oxidation of Dihydrorhodamine 
(DHR) which becomes fluorescent when oxidized.
Results. We found markedly greater extravasation of the Hp 2-Hb complex into the plaque 
as compared to the Hp 1-Hb complex. Immunohistochemistry demonstrated a significantly 
greater amount of Hb in the plaque of Hp 2 mice as compared to Hp 1 mice. DHR 
fluorescence was significantly increased in Hp 2 plaques as compared to Hp 1 plaques 
and was found to tightly correlate and colocalize with plaque iron and hemoglobin. The 
in situ oxidation of DHR in the plaque was markedly inhibited by desferroxamine (DFO) 
a potent chelator of iron.
Conclusions. The increased oxidation present in Hp 2 plaques appears to be due to 
hemoglobin iron induced oxidation derived at least in part by increased extravasation of 
Hp 2-Hb complexes. Agents which prevent iron induced oxidation may have considerable 
value in decreasing oxidation and inflammation in Hp 2 plaques thereby reducing the risk 
of plaque rupture and atherothrombosis in Hp 2 DM individuals.
10:00 a.m.
1007-182 High Glucose and Advanced Glycation End Products 
Potentiate IL-17-Mediated Human Coronary Artery 
Smooth Muscle Cell Proliferation, and Is Reversed by 
Resveratrol
Miguel R. Zabalgoitia, Robert Chilton, Joe M. Moody, Jr., Steven R. Bailey, Bysani 
Chandrasekar, Department of Veterans Affairs, South Texas Veterans Health Care 
System, San Antonio, TX, University of Texas Health Science Center, San Antonio, TX
Background: We investigated whether the novel cytokine Interleukin-17A stimulates SMC 
proliferation, and whether high glucose or AGE potentiates its pro-mitogenic effects. We 
also investigated whether resveratrol blunts this response.
Methods: Human coronary artery SMC were treated with rhIL-17. Expressions of IL-
17R and receptor for AGE (RAGE) were analyzed by RT-PCR and FACS analysis; and 
proliferation by MTT and 3H-leucine incorporation. Possible signal transduction pathways 
involved in IL-17 and AGE were investigated using pathway-specific pharmacological 
inhibitors, siRNA-mediated knockdown and adenoviral transduction of wild type and 
mutant expression vectors.
Results: rhIL-17A induced SMC proliferation (blocked by anti-IL-17A or IL-17RA neutralizing 
antibodies). IL-17A induced PI3K-mediated PI3P formation (blocked by Ly294002, 
Ad.dnPI3Kp85), Akt phosphorylation and activity (blocked by SH-1 or Ad-dnAkt1), Akt-
dependent tuberin phosphorylation (blocked by hamartin), mTOR activation (inhibited by 
rapamycin), S6 kinase, 4EBP-1, and enhanced protein (3H-leucine incorporation) and 
DNA synthesis (3H-thymidine incorporation) resulting in increased proliferation (MTT 
assay). While addition of high glucose (25 mM) had minimal effect on SMC proliferation, 
it significantly potentaited IL-17A-mediated SMC proliferation. Moreover, AGE increased 
SMC proliferation (72 h, 1.8-fold, p<0.01), an effect blunted by anti-RAGE/Fc chimera or 
sRAGE. Importantly, IL-17A enhanced RAGE mRNA and protein expression (3.1-fold, 
p<0.001) in an NF-ÎºB dependent mechanism (blocked by Ad.dnIÎºB-Î± or Ad-dnp65), and 
AGE potentiated IL-17A-mediated SMC proliferation (72 h, 3.71-fold, p<0.001). Notably, 
resveratrol blunted IL-17A or IL-17A+glucose/AGE-dependent SMC proliferation.
Conclusions: Together our results demonstrate that IL-17A potently induces SMC 
proliferation, and high glucose and AGE potentiate IL-17A pro-mitogenic effects. Since 
resveratrol blunted the pro-mitogenic effects of IL-17A, our results also indicate that 
resveratrol may have therapeutic effects in atherosclerosis and restenosis.
10:00 a.m.
1007-183 Inter-relationships of Arterial Stiffness With Asymmetric 
Dimethylarginine, Endothelin-1 and Adiponectin in 
Essential Hypertension
Kyriakos Dimitriadis, Costas Tsioufis, Costas Thomopoulos, Dimitris Tsiachris, Aliki 
Gennadi, Dimitris Chatzis, Christodoulos Stefanadis, Ioannis Kallikazaros, Department 
of Cardiology, Hippokration Hospital, Athens, Greece
Background: Arterial stiffening is a marker of atherosclerosis progression and it is 
associated with enhanced cardiovascular risk. In this study we examined the relationships 
of arterial stiffness with adiponectin, endothelin-1 (ET-1) and asymmetric dimethylarginine 
(ADMA) levels in essential hypertensives.
Methods: 165 newly diagnosed untreated non-diabetic patients with stage I to II essential 
hypertension [110 men, mean age=49 years, office blood pressure (BP)=151/97 mmHg] 
were divided into three groups according to carotid to femoral pulse wave velocity (PWV) 
values, assessed by means of a computerized method (Complior SP): Group A (PWV<7.4 
m/sec), group B (PWV=7.4-8.7 m/sec) and group C (PWV>8.7 m/sec). Additionally, 
venous blood samples were drawn for estimation of lipid profile, adiponectin, ET-1 and 
ADMA concentrations.
Results: Patients in group A (n=61) compared to subjects in group B (n=53) and C (n=51) 
had lower office systolic BP (147±12 vs 150±14 vs 158±13 mmHg, respectively; p<0.05 
for all cases) and left ventricular mass index (101.4±13 vs 115.2±15 vs 121.2±12 g/m2, 
respectively; p<0.05 for all), while did not differ regarding metabolic profile (p=NS). In 
the entire population, ADMA levels were positively associated with waist to hip ratio 
(r=0.209, p<0.05), office systolic BP (r=0.430, p<0.0001), and PWV (r=0.193, p<0.05), 
while negatively correlated with adiponectin (r=-0.222, p<0.0001). Patients in group C 
compared to group B and A, exhibited higher levels of ADMA (0.63±0.04 vs 0.57±0.04 vs 
0.52±0.03 µmol/l, respectively; p<0.05 for all), ET-1 (1.13±0.28 vs 0.65±0.17 vs 0.45±0.19 
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fmol/ml, respectively; p<0.05 for all) and lower adiponectin concentrations (7.1±1.5 vs 
8.7±2.6 vs 10.1±2.5 µg/ml, respectively; p<0.05 for all). Analysis of covariance revealed 
that ADMA, ET-1 and adiponectin values remained significantly different between groups 
after adjustment for confounders
Conclusion: In essential hypertension arterial stiffness, as reflected by PWV, is gradually 
related to adiponectin, ET-1 and ADMA levels. These findings underscore the integrative 
nature of diffuse pro-atherosclerotic and vascular dysfunction processes in this setting.
10:00 a.m.
1007-184 Intra-Arterial Nitrite Causes an Enduring Vasodilation 
in Man
Abdul R. Maher, Philip Thomas, Simon Anderson, Khalid Abozguia, Ibrar Ahmed, 
Rebekah Weaver, Philip James, Michael Frenneaux, Birmingham University, 
Birmingham, United Kingdom
Background: We present the important observation that the vascular effects of nitrite 
following an intra-arterial infusion persist long after the intravascular concentration of 
nitrite has returned to levels close to baseline.
Methods: 17 Healthy volunteers were studied while either breathing room air or 12% 
oxygen. Following saline, sodium-nitrite was infused intra-arterially at 7.84µmol/min 
followed by an hour-long saline infusion. At each stage Forearm Blood Flow (FBF), 
Forearm Venous Volume/Pressure relation (an index of venous tone) and plasma levels 
of NO metabolites were assessed.
Results: Following cessation of nitrite infusion venodilation persisted for up top 30 minutes 
whereas venous nitrite levels had decreased from a peak of 48.9 microM to 4.4microM by 
15minutes. Arterial blood flow expressed as FBF-ratio (FBFR), increased from baseline 
to 1.50±0.16 (P<0.05) and 1.99±0.17 (P<0.01) in normoxia and hypoxia respectively and 
returned to baseline only at 45 minutes and 15 minutes respectively.
Conclusions: We demonstrate a persisting effect of nitrite long after the intravascular 
levels have decreased suggesting a significant degree of protein binding. We propose 
that protein binding of NO in vessels (possibly by myoglobin) may be responsible. Our 
data may provide new insights into the role of nitrite in vascular physiology. 
10:00 a.m.
1007-185 EPIgenetic Mechanisms May Play a Role in the 
Susceptibility of Diabetic Patients to Restenosis After 
a Percutaneous Coronary Intervention: A Study in 
Diabetic and Nondiabetic Patients
Douwe Pons, Moniek P.M. de Maat, Aeilko H. Zwinderman, Robbert J. de Winter, Rene 
A. Tio, Pieter A.F.M. Doevendans, J. Wouter Jukema, Leiden University Medical Center, 
Leiden, The Netherlands
Background: EPIgenetic processes modulate gene expression patterns without modifying 
the actual DNA sequence. NFkB-mediated inflammation, which is under EPIgenetic 
control, has been implicated in the increased susceptibility of diabetic patients to aspects 
of cardiovascular diseases, including restenosis. Diabetic conditions have been shown 
to increase in vivo recruitment of NFkB and histone acetyltransferases (HATs), leading 
to excessive histone acetylation at the promoters of inflammatory genes. Histone 
deacetylase 3 (HDAC3) is known to deacetylate NFkB, thereby reducing NFkB-mediated 
inflammatory gene expression. In search for an explanation for the excessive restenosis 
risk in diabetics we examined the impact of polymorphisms in the HDAC3 gene on the risk 
of target vessel revascularization (TVR) in diabetic and non-diabetic patients undergoing 
percutaneous coronary intervention (PCI).
Methods: The GENetic DEterminants of Restenosis (GENDER) project is a multicenter 
prospective study design that enrolled 3104 consecutive patients after successful PCI. Of 
these patients 453 had diabetes, as defined by the use of either insulin or anti-diabetic 
medication. All 3104 patients were genotyped for 3 polymorphisms in the HDAC3 gene 
using the Sequenom massarray genotyping platform. TVR was the primary endpoint.
Results: The rs2530223 C/T polymorphism, located +1863 from the HDAC3 promoter, 
was associated with a highly elevated TVR risk in diabetic patients (HR: 1.6, 95%CI: 1.1-
2.3) when compared to the non-diabetic group, in which we observed a low risk for TVR 
regardless of genotype (HR: 1.0, 95%CI: 0.8-1.2). When compared to CC homozygous 
diabetic patients, heterozygous patients were at higher risk for TVR (HR: 1.8, 95%CI: 
1.0-3.3), whereas patients with the TT genotype had an even further increased risk (HR: 
2.5, 95%CI: 1.2-5.2).
Conclusions: We hypothesize that carriers of the 1863T allele may be more susceptible 
to the metabolic alterations present in patients with diabetes. This allele could lead to a 
reduced capability to suppress NFkB-induced inflammation, thereby increasing the risk 
for restenosis after PCI. Further research is needed to confirm this hypothesis.
10:00 a.m.
1007-186 Associations Between Methods of Measurement of 
Aspirin Resistance and Their Temporal Variations in 
Patients With Ischaemic Heart Disease
Alison R. Muir, Mary-Frances McMullin, Christopher Patterson, Pascal P. McKeown, 
Queen’s University, Belfast, Belfast, United Kingdom, Royal Victoria Hospital, Belfast, 
United Kingdom
Background: The Antiplatelet Trialists’ Collaboration highlighted a 25% reduction of cardiac 
events in patients treated with aspirin. Aspirin’s antiplatelet effects are variable as events 
still occur despite therapy (“clinical aspirin resistance”). There is no agreed laboratory 
definition of aspirin resistance; various tests, including optical platelet aggregometry 
(OPA), Platelet Function Analyser (PFA-100TM) and serum / urine levels of thromboxane 
B2 (TXB2) metabolites have been used.
This study aimed to characterize the prevalence of aspirin resistance in a Northern 
Irish cohort, to investigate the associations between various methods of assessment of 
response to aspirin and to evaluate their variability on a temporal basis.
Methods: Patients with stable ischaemic heart disease, taking 150mg aspirin daily, had 
platelet function assessment (by OPA and PFA-100TM) and quantitative analysis of 
serum and urine TXB2, at two visits, 2 weeks apart. The prevalences of resistance by 
each method and associations between methods and time points were assessed.
Results: 175 patients (62.7 ± 8.7 years, 82.9% male) were enrolled. The prevalence of 
aspirin resistance by OPA was 1.7% and 4.6% at the first and second visits respectively, 
while 63.4% and 68.0% were aspirin semi-responders. By PFA-100TM, 21.7% and 20.0% 
were aspirin non-responders at each visit. There were poor associations between PFA-
100TM and OPA, and between TXB2 metabolites and both PFA-100TM and OPA. There 
were no associations between visits in OPA resistance or TXB2 metabolites, but there 
was significant weak association for PFA-100TM response.
Conclusion: The prevalence of aspirin resistance is highly dependent on the method of 
platelet function testing used. The gold standard method of OPA cannot be reliably predicted 
by PFA-100TM testing or measurement of TXB2 metabolites. Aspirin response varies on a 
temporal basis, indicating that one method of testing on a single occasion is not adequate to 
reliably diagnose aspirin resistance or guide antiplatelet therapy in a clinical setting.
10:00 a.m.
1007-187 Prostaglandin D2 Synthase Isoforms and Diabetic 
Vasculopathy
Anthony F. Tramontano, Christopher Hall, Visali Kodali, Joshua R. DeLeon, Louis 
Ragolia, Winthrop-University Hospital, Mineola, NY, SUNY Stony Brook University 
Medical School, Stony Brook, NY
Background: Elevated levels of urinary lipocalin-type prostaglandin D2 synthase 
(L-PGDS) have been associated with Diabetes Mellitus type 2 (DM).We recently 
demonstrated accelerated atherosclerosis and glucose intolerance in L-PGDS knockout 
mice. Furthermore, we proved that post-translational modification of L-PGDS altered its 
apoptotic activity and inhibited vascular smooth muscle cell (VSMC) hyperproliferation. 
The aim of this study was to analyze the urine of diabetic individuals for the presence of 
these L-PDGS isoforms.
Methods: We prospectively studied the urine from a cohort of patients with DM and age-
matched controls. L-PGDS was purified by affinity chromatography and separated into 
its isoforms by two-dimensional gel electrophoresis. The effect of L-PGDS on VSMC 
apoptosis was measured by TUNEL and caspase3 assay.
Results: L-PGDS isolated from diabetic urine was unable to induce apoptosis and 
control hyperproliferation of VSMCs. L-PGDS concentration was higher in the urine of 
patients with DM than in the control subjects. In addition, two-Dimensional PAGE of L-
PGDS demonstrated an absence of an isoform at a pI of approximately 6.0 and a 5-fold 
decrease of an isoform at a pI of approximately 7.3 in the urine of DM subjects when 
compared to controls.
Conclusions: We conclude that urinary L-PGDS isoforms may represent a novel biomarker 
of vascular disease and VSMC hyperproliferation in the DM population. Further work is 
needed to clarify the role of L-PGDS isoforms in the vascular pathology of DM.
10:00 a.m.
1007-188 Anti-Apoptotic Effects of Erythropoietin in Human 
Vascular Endothelial Cells
Valentina O. Puntmann, Manvinder S. Dhillon, John Wharton, Richard G. Bogle, Imperial 
College, London, United Kingdom
Background. Recent studies have shown that endothelial cell apoptosis occurs in acute 
coronary syndromes (ACS) and correlates with the instability and complexity of coronary 
lesions. Sera of patients with ACS contain pro-apoptotic factors, such as tumor necrosis 
factor-α (TNF-α), which may trigger apoptosis and contribute to increased plaque 
vulnerability. Erythropoietin (EPO) promotes proliferation and differentiation of erythroid 
progenitor cells in bone marrow by preventing apoptosis. Recently, EPO receptors 
have also been identified on vascular endothelial cells however their biological function 
remains unknown. In the present study we investigated whether EPO alters endothelial 
cell proliferation and modulates TNF-α stimulated apoptosis.
Methods. Human umbilical vein endothelial cells (HUVEC; passage 1-8) were cultured in 
large vessel basal endothelial cell medium containing 2% serum. Cell proliferation was 
determined by measuring cellular ATP content using CellGlow assay. Apoptosis was 
assessed using both DNA fragmentation (Cell Death Detection ELISA plus®) and nuclear 
staining with Hoechst 33342 dye.
Results. EPO (1-300 U/ml) resulted in a concentration-dependent increase in endothelial 
cell number with maximum effect seen at 10 U/ml. EPO (10 U/ml) reduced the basal rate 
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of apoptosis in HUVECs from (OD450, AU) 0.035±0.012 to 0.029±0.007 (n=3). Addition 
of TNF-α (1ng/ml) resulted in a marked increase in apoptosis (0.060±0.003) which was 
significant inhibited by co-incubation with EPO (10 U/ml; 0.044±0.009). Similar results were 
obtained when staurosporine, an inhibitor of protein kinase C, was used to induce apoptosis.
Conclusions. These data indicate that EPO induces proliferation of HUVECs and prevents 
apoptosis induced by TNF-α or staurosporine. The proliferative and anti-apoptotic effects 
of EPO in vascular endothelial cells may provide an explanation for beneficial effects 
observed with EPO in myocardial ischemia-reperfusion injury and support the idea that 
EPO might be a useful agent for vascular protection and lesion stabilisation.
10:00 a.m.
1007-189 Framingham Risk Score Is Associated With Femoral 
Artery Intima-Media Thickness in Asymptomatic Young 
Adults: The Bogalusa Heart Study
Timir Paul, Wei Chen, Sathanur Srinivasan, Janet Rice, Jiang He, Ahmet Toprak, Gerald 
Berenson, Tulane Center for Cardiovascular Health, New Orleans, LA
Background: The Framingham Risk Score (FRS) is increasingly being used in the clinical 
prediction of coronary artery disease. Femoral artery intima-media thickness (IMT), like 
carotid IMT, is a surrogate indicator of atherosclerotic coronary and peripheral vascular 
diseases in middle-aged and older adults. However, the association between FRS and 
femoral artery IMT has not been studied in asymptomatic young adults. This study 
examined the relationship between FRS and femoral artery IMT in a bi-racial (black-
white) population.
Methods: IMT was assessed by B-mode ultrasonography in 1080 black and white 
subjects aged 24-43 years, average age 36 years, (71% white, 43% male) enrolled in 
the Bogalusa Heart Study. Age, gender, systolic blood pressure, diastolic blood pressure, 
LDL cholesterol, HDL cholesterol, cigarette smoking (yes/no) and diabetes were used to 
calculate participants’ FRS.
Results: Age-adjusted femoral IMT showed a gender difference (males > females, p = 
0.001) among whites only but no race difference in both genders. FRS was lower in 
females vs males (p = 0.001); males vs females displayed significantly higher systolic 
and diastolic blood pressure, LDL cholesterol and prevalence of diabetes, and lower HDL 
cholesterol (whites only); blacks vs whites showed higher systolic and diastolic blood 
pressure, HDL cholesterol (males only) and prevalence of diabetes. BMI was higher in 
black females vs white females. A significant positive linear relationship between tertiles of 
FRS and IMT of femoral artery was noted in both whites and blacks (p for trend < 0.001). 
In a multiple regression analysis, FRS, insulin and BMI were independently associated 
with femoral IMT (total R2 = 0.09), with the FRS as a major contributor of the variance in 
IMT (partial R2 = 0.085).
Conclusions: These observations support the use of FRS in both white and black young 
adults. The observed trend of increasing femoral IMT with higher tertiles of FRS in 
asymptomatic young individuals underscores the need for multiple risk factors profiling in 
early life for prevention and control of cardiovascular disease.
10:00 a.m.
1007-190 Can We Speculate Thin Fibrous Cap Only by Virtual 
Histology Intravascular Ultrasound In Vivo?
Takahiro Sawada, Junya Shite, Toshiro Shinke, Yusuke Tanino, Daisuke Ogasawara, 
Hiroyuki Kawamori, Hiroki Kato, Naoki Miyoshi, Ken-ichi Hirata, Division of 
Cardiovascular Medicine, Depatment of Internal Medicine, Kobe University Graduate 
School, kobe, Japan
Background:Virtual histology intravascular ultrasound (VH-IVUS) may be useful in 
detecting necrotic core (NC), however it is difficult to visualize thin fibrous-cap in vivo.
Methods:We examined 56 patients with angina (126 plaques identified by IVUS). IVUS-
derived thin-cap fibroatheroma (TCFA) was defined as NC of >10% of the cross-sectional 
area (CSA) in contact with the lumen (NCCL) and %plaque volume >40%. After diagnosing 
IVUS-derived-TCFA, fibrous-cap thickness was measured by optical coherence tomography. 
If its fibrous-cap thickness was of <65µm, we defined it as a definite-TCFA. In addition, the 
vessel remodeling-index, the degree of angle occupied by NCCL in lumen circumference 
(angle-NCCL) and the area of NCCL (area-NCCL) were measured.
Results:Sixty-one plaques were diagnosed as IVUS-derived-TCFA. Among these, 28 
plaques had thin fibrous-cap and were diagnosed as definite-TCFA. The remaining 33 
plaques didn’t have a thin fibrous cap (average cap thickness 99.0±13.3µm) and were 
diagnosed as non-thin-cap IVUS-derived-TCFA. Definite-TCFA showed larger remodeling-
index, greater angle-NCCL and larger area-NCCL than non-thin-cap IVUS-derived-TCFA 
(remodeling-index; 1.20±0.13 vs 1.10±0.11, P=0.0013, angle-NCCL; 89.4±31.3 vs 
54.7±24.1°, P=0.0003, area-NCCL; 1.15±0.54 vs 0.67±0.34mm2, P=0.0007).
Conclusions:Only 45.9% of IVUS-derived-TCFA had thin fibrous-cap. VH-IVUS may speculate 
thin fibrous cap by larger remodeling-index, greater angle-NCCL and larger area-NCCL. 
10:00 a.m.
1007-191 A Highly Purified Omega-3 Fatty Acid Derivative 
Improves Endothelial Function in Patients With Stable 
Coronary Artery Disease
Mahmoud I. Traina, Sheba K. Meymandi, Mohamed R. Labedi, Atef H. El Gassier, Tarik 
A. Ngab, Robin Y. Wachsner, Olive View-UCLA Medical Center, Sylmar, CA
Background: Fish oil has been shown to improve mortality and reduce cardiovascular 
events in patients with coronary artery disease (CAD). CAD has been associated with 
impaired endothelial function as determined by ultrasound of the brachial artery. Fish oil 
has been found to improve flow-mediated vasodilation by brachial artery ultrasound in 
healthy volunteers but has not been previously studied in patients with established CAD.
Methods: In a randomized, double-blinded, placebo-controlled trial, 71 patients with 
established stable coronary artery disease and normal or near-normal ejection fraction 
received either 1 gram twice a day of a highly purified omega-3 fatty acid derivative, Lovaza, 
(n=37) or placebo (n=34) for 2 months. At day 0 and day 60, brachial artery endothelium-
dependent flow-mediated vasodilation (EDV) and endothelium-independent nitroglycerin-
mediated vasodilation (EIDV) were assessed with high-resolution ultrasound.
Results: Fish oil supplementation resulted in a significant increase in EDV 
(5.3%±4.0% in fish oil, -1.8% ±4.5%,P=0.001) and EIDV (3.72%±6.86% in fish oil, -
1.73%±8.40%,P=0.004).
Conclusions: Fish oil supplementation in patients with coronary artery disease is 
associated with improved endothelial function. 
10:00 a.m.
1007-192 Possible Role of Somatic Mitochondrial Mutations in 
the Development of Atherosclerotic Lesion of Human 
Aorta
Margarita A. Sazonova, Yegor Yu Budnikov, Zukhra B. Khazanova, Anton Yu 
Postnov, Igor A. Sobenin, Alexander N. Orekhov, Institute of General Pathology and 
Pathophysiology, Moscow, Russian Federation, Institute for Atherosclerosis Research, 
Moscow, Russian Federation
Background: Somatic mutations in human genome may be one of the causes of local 
development of atherosclerotic lesions in arteries. The aim of our research was to reveal 
the average percent of mutations in mitochondrial genome in affected and normal intima 
from human aorta.
Methods: Ten aortas were taken at autopsy from subjects who had died in a result of 
accident or sudden death. The samples were taken from fibrous plaques, lipofibrous 
plaques, and fatty streaks in comparison to atherosclerosis-free regions. Samples of 
liver tissue and skeletal muscle were taken as control. Assayed fragments of mDNA 
were amplified with PCR. Relative quantity of mutant allele was determined with 
pyrosequencing method.
Results: We adopted pyrosequencing method for conditions where both mutant and normal 
allele were present in the same specimen. So it became possible to determine a quantity 
of mutant allele. To find mutations associated with atherosclerotic lesions of aorta, we 
analyzed 40 mitochondrial mutations previously revealed at such pathologies as coronary 
stenosis, diabetes mellitus, deafness, myocardial infarction, cardiomyopathy, and stroke. Ten 
mitochondrial mutations in 8 genes (rRNA 12S, 2 genes tRNA-Leu (codons recognized UUR 
and CUN), cytochrome B, and subunits 1, 2, 5, and 6 NADH dehydrogenase) were shown 
to have higher frequency in plaques as compared to normal intima. The frequencies of these 
mutations in liver and muscular tissues were significantly less than in normal intima.
Conclusions: At least three somatic mitochondrial mutations G12315A (tRNA-Leu gene 
(CUN)), G14459A (subunit 6 of NADH dehydrogenase gene), and C5178A (subunit 2 of 
NADH dehydrogenase gene) are associated with the atherosclerotic lesions in human aorta.
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10:00 a.m.
1007-193 Interrelationships of Urinary Albumin Excretion 
With Endothelin-1 and Arterial Stiffness in Essential 
Hypertension: An Integrative Approach to Vascular 
Dysfunction
Kyriakos Dimitriadis, Costas Tsioufis, Costas Thomopoulos, Dimitris Syrseloudis, 
Dimitris Tsiachris, Efstathios Taxiarchou, Christodoulos Stefanadis, Ioannis Kallikazaros, 
Department of Cardiology, Hippokration Hospital, Athens, Greece
Background: Endothelin-1 (ET-1), a powerful vasoconstrictor, is linked to vascular 
dysfunction, while urinary albumin excretion is an index of atherosclerosis progression 
beyond the glomerulus. We investigated the interrelationships between albumin to 
creatinine ratio (ACR), ET-1 and arterial stiffness in essential hypertensives.
Methods: Our population consisted of 210 newly diagnosed untreated non-diabetic 
patients with stage I to II essential hypertension [130 men, mean age=50 years, office 
blood pressure (BP)=148/95 mmHg]. According to the ACR values determined as the 
mean of two non-consecutive morning spot urine samples, the study population was 
divided into microalbuminurics (n=35) (mean ACR=30-300 mg/g) and normoalbuminurics 
(n=175) (mean ACR<30 mg/g). In all subjects arterial stiffness was evaluated on the basis 
of carotid to femoral pulse wave velocity (PWV), by means of a computerized method 
(Complior SP) and venous blood samples were drawn for estimation of metabolic profile 
and ET-1 concentrations.
Results: Microalbuminurics compared to normoalbuminurics were older (52±7 vs 49±7 years, 
p<0.05) and had higher 24-h systolic BP (141±15 vs 130±12 mmHg, p<0.0001). Groups did 
not differ regarding sex, body mass index and metabolic profile (p=NS), microalbuminurics 
compared to normoalbuminurics exhibited increased ET-1 (1.25±0.37 vs 0.53±0.17 fmol/ml, 
p<0.0001) and PWV values (9±1.8 vs 7.8±1.1 m/sec, p<0.0001). In the entire population, ET-
1 was related to 24-h systolic/diastolic BP (r=0.184 and r=0.240, p<0.05 for both), and PWV 
(r=0.270, p<0.0001). In multiple regression analysis, 24-h systolic BP (b=0.36, p<0.0001, ET-
1 (b=0.33, p<0.0001) and PWV (b=0.423, p<0.0001) were independent predictors of ACR. 
Analysis of covariance revealed that ET-1 and PWV values remained significantly different 
between groups after adjustment for confounders (p<0.05 for all).
Conclusion: Microalbuminuric hypertensives are characterized by a state of diffuse 
vascular dysfunction, as reflected by increased ET-1 and PWV. These findings suggest 
that ACR determination is a useful clinical tool to identify subjects at high cardiovascular 
risk in this setting.
10:00 a.m.
1007-194 HDL-Cholesterol as a Predictor of the Flow-Mediated 
Dilatation of the Coronary Artery in Postmenopausal 
Women
Akiko Yoshikawa, Shuichi Hamasaki, Sanemasa Ishida, Tetsuro Kataoka, Msakazu 
Ogawa, Keishi Saihara, Hideki Okui, Takuro Shinsato, Kouji Orihara, Takuro Kubozono, 
Etsuko Mizoguchi, So Kuwahata, Shoji Fujita, Yuichi Ninomiya, Chuwa Tei, Kagoshima 
University, Kagoshima, Japan
Background: There are a number of reports about gender-specific differences regarding 
the development and prognosis of coronary heart disease (CHD). In woman, risks of 
CHD drastically increase after menopause. Although, it remains unclear what is a major 
contributor to the flow-mediated dilation of the coronary artery in postmenopausal 
women. Methods: The flow-mediated dilation of the coronary artery was determined 
in 50 consecutive postmenopausal women (68±8 yrs) with normal or mildly diseased 
coronary artery. Ninety-three age-matched men (66±8 yrs) served as control subjects. 
Using quantitative coronary angiography, we measured coronary artery diameter of the 
left anterior descending coronary artery at rest and in response to reactive hyperemia (with 
increased flow causing an endothelium-dependent vasodilation) induced by papaverine 
(12.5mg/20sec) (%FMD). Endothelium-independent vasodilation of the coronary artery 
was also assessed by administration of nitroglycerin (%NTG). Vascular responses were 
compared between men and women. Body mass index, C-reactive protein, LDL-cholesterol, 
HDL-cholesterol, triglyceride, fasting blood sugar, and insulin resistane (HOMA-R), and 
systolic blood pressure were also measured. Results:When only subjects of women were 
considered, in a univariate analysis, %FMD had an inverse correlation with triglycerides (r=-
0.30, p<0.05) and a positive correlation with HDL-cholesterol (r=0.38, p<0.01). A Logistic 
regression analysis revealed that HDL-cholesterol was associated with %FMD (odds ratio 
1.08, 95% confidence interval 1.01 to 1.16, p=0.02). In age-matched men, no significant 
correlation existed between %FMD and any parameters. Conclusion: These data suggest 
that HDL-cholesterol is highly associated with endothelium-dependent vasodilation of the 
epicardial coronary artery in postmenopausal women.
10:00 a.m.
1007-195 High Toll-Like Receptor 2 Expression Level on 
Monocytes as an Important Risk Factor for 
Arteriosclerotic Diseases
So Kuwahata, Koji Orihara, Shuichi Hamasaki, Sanemasa Ishida, Tetsuro Kataoka, 
Akiko Yoshikawa, Masakazu Ogawa, Naoya Oketani, Keishi Saihara, Hideki Okui, Takuro 
Shinsato, Takahiro Shirasawa, Takuro Kubozono, Etsuko Mizoguchi, Hitoshi Ichiki, 
Yuichi Ninomiya, Shoji Fujita, Takuro Takumi, Ryutaro Oba, Hiroyuki Hirai, Kinya Nagata, 
Chuwa Tei, Graduate School of Medicine, Kagoshima University, Kagoshima, Japan, 
Department of Advanced Medicine and Development, BML, INC., Saitama, Japan
Background: Toll-like receptors (TLRs) on antigen-presenting cells recognize pathogen-
associated molecular patterns and initiate an innate immune response. We previously 
reported that Toll-like receptor 2 (TLR2) expression level on monocytes in patients with 
significant coronary artery disease (CAD) were significantly up-regulated than those 
in patients without CAD. Therefore, our purpose is to test whether high level of TLR2 
is regarded as a risk factor of arteriosclerotic diseases, independent of well-known 
arteriosclerosis risk factors.
Methods: Consecutive patients with arteriosclerotic diseases (arteriosclerotic group n = 
134) and age- and sex-matched patients without arteriosclerotic diseases (control group, 
n = 70) were enrolled. The patients classified into arteriosclerotic group had significant 
CAD (angiographic diameter >/= 50%), abdominal aortic aneurysm, thoracic aortic 
aneurysm, or arteriosclerosis obliterans. TLR2 level on monocytes was assayed by using 
our developed flow-cytometric analysis system, and represented by the number of anti-
TLR2 monoclonal antibody binding sites on monocyte.
Results: TLR2 levels between arteriosclerotic group and control group was compared. 
TLR2 levels in arteriosclerotic group was higher than that in control group (median, 4909 
[95% CI, 4413 to 4804] vs. 5238 [95% CI, 5205 to 5596] sites/cell; p < 0.001). Multivariate 
ordinal logistic regression analysis showed that diabetes mellitus (Wald 8.206, p < 0.01), 
hypertension (Wald 15.308, p < 0.001), hypercholesterolemia (Wald 15.485, p < 0.001) and 
TLR2 level (Wald 12.095, p < 0.001) were independent risk factors for arteriosclerosis. On 
the basis of TLR2 level distribution in control group, cutoff points were 5429 sites/cell (mean 
+ SD) and 6249 sites/cell (mean + 2SD). The multivariate-adjusted odds ratios of TLR2 level 
for arteriosclerotic disease were 3.764 (95% confidence interval [CI], 1.783 to 7.943).
Conclusions: We indicated that patients with high level of TLR2 (> 5429 sites/cell) had 
a significant increase in arteriosclerotic disease prevalence, independent of well-known 
arteriosclerosis risk factors.
10:00 a.m.
1007-196 Arterial Stiffness and Endothelial Dysfunction as 
Consequences of Hypertension Disease Lead to 
Impaired Microcirculation of the Brain Represented as 
Cognitive Dysfunction
Helen Triantafyllidi, Chrysa Arvaniti, John Lekakis, Ignatios Ikonomidis, Stavros Tzortzis, 
Konstantinos Tsitlakidis, Konstantinos Papadopoulos, Dimitrios Kremastinos, Medical 
School, University of Athens, ATTIKON Hospital, Athens, Greece, Department of 
Neurology, Thriasion Hospital, Athens, Greece
Background: It is known that essential hypertension may be implicated in the development 
of cognitive dysfunction which may be due to microvascular disease of the brain. It has 
been hypothesized that increased arterial stiffness of the large arteries may lead to 
microvascular changes due to increased pulsatile flow to microcirculation. Our study tests 
the hypothesis that large artery stiffness and endothelial dysfunction are related to brain 
microcirculation changes represented as impaired cognitive function.
Methods: We studied 103 non-diabetic patients aged 40-80 years (mean age 53.8 + 11.2 
years, 54 men) with recently diagnosed stage I-II essential hypertension using Mini Mental 
State Examination (MMSE) as a screening test for global cognitive dysfunction. We performed 
2-D echocardiography in order to evaluate aortic stiffness and carotid IMT. Pulse wave velocity 
(PWV) was used for carotid-femoral arterial stiffness estimation while microalbumin levels 
(MAU) as an index of endothelial dysfunction were measured in 24h urine collection.
Results: In the entire population, MMSE was negatively correlated with age (r=-0.42, 
p<0.001), 24h pulse pressure (r=-0.18, p<0.05) and PWV (r= -0.3, p=0.003). However, 
when a cut-off of 65 years was used regarding age, MMSE was negatively correlated with 
MAU (r=-0.58, p=0.003). No correlation was observed between MMSE and IMT or arterial 
stiffness derived by echocardiography.
Conclusions: In the early stages of essential hypertension, impaired cognitive function 
correlates with large artery stiffness and microalbumin excretion. The latter support the 
hypothesis regarding cognitive dysfunction due to impaired microcirculation linked to 
large artery stiffness and endothelial dysfunction.
10:00 a.m.
1007-197 LOX-1 Deletion Decreases Collagen Accumulation in 
Atherosclerotic Plaque in LDLR Knockout Mice Fed 
High Cholesterol Diet
Changping Hu, Abhijit Dandapat, Muhammad R. Marwali, Jawahar L. Mehta, University 
of Arkansas for Medical Science, Little Rock, AR
Background: Collagen, as a component of the extracellular matrix, has been linked to 
atherosclerotic plaque formation and stability. Activation of LOX-1, a lectin-like oxidized-LDL 
receptor-1, exerts a significant role in collagen formation. We postulated that LOX-1 deletion 
may inhibit collagen accumulation in atherosclerotic arteries in LDLR knockout mice.
Methods and Results: We generated LOX-1 KO and LOX-1/LDLR double KO mice on 
C57BL/6 (wild-type mice) background, and fed 4% cholesterol/10% cocoa butter diet for 
18 weeks. Vessel wall collagen accumulation (Masson’s trichrome and Picro-sirius red 
staining) was increased in association with atherogenesis in the LDLR KO mice (P<0.01 
vs. wild-type mice), but much less so in the double KO mice. Collagen accumulation 
data were corroborated with pro-collagen I measurements. Expression of osteopontin, 
fibronectin and matrix metalloproteinases (MMP-2 and MMP-9) was also increased in the 
LDLR KO mice (P<0.01 vs. wild-type mice), but not in the mice with LOX-1 deletion. The 
expression of NADPH oxidase (p47phox and p22phox) was increased in the LDLR KO 
mice (P<0.01 vs. wild-type mice), and not in mice with LOX-1 deletion. Phosphorylation 
of Akt-1 and endothelial nitric oxide synthase and expression of heme-oxygenase-1 were 
found to be reduced in the LDLR KO mice (P<0.01 vs. wild-type mice), but not in the mice 
with LOX-1 deletion. 
Conclusions: This study demonstrates that LOX-1 deletion reduces enhanced collagen 
deposition and MMP expression in atherosclerotic regions via inhibition of pro-oxidant 
signals.
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1007-198 Potential of Carotid Intima Media Thickness to Identify 
Patients With Diabetes Mellitus at Risk for Coronary 
Heart Disease
Roxana Djaberi, Joanne D. Schuijf, Eelco J. de Koning, Alberto M. Pereira, Ton J. 
Rabelink, Jos op ‘t Roodt, Jan W. Smit, Martin Spaans, J. Wouter Jukema, Jeroen J. 
Bax, Leiden University Medical Center, Leiden, The Netherlands
Background: In diabetes mellitus (DM), methods of risk stratification and selection of 
patients at risk for coronary heart disease (CHD) remain a controversial issue. We aimed 
to evaluate the role of carotid intima media thickness (CIMT) as a predictor of CHD in 
this population group.
Methods: In a prospective study, CIMT of the left and right common carotid artery was 
assessed by B-mode ultrasound in 92 patients (mean age 49 yrs, male 56) with DM (mean 
duration 12.7 yrs). In all patients, classical risk factors of CHD were registered to evaluate 
potential predictors of CIMT. In addition, non-invasive multi-slice computed tomography 
(MSCT) coronary angiography was performed to relate CIMT to the presence and severity 
of CHD. For this purpose, patients were classified as having 1. no atherosclerosis, 2. non-
obstructive atherosclerosis or 3. obstructive stenosis with ≥ 50% luminal narrowing.
Results: Mean CIMT was 0.65 ± 1.4 mm. Linear regression analysis of baseline 
characteristics showed age to be the only significant predictor of CIMT (p=0.001), 
whereas no relationship was found between the CIMT and the duration of DM, LDL- and 
total cholesterol levels, smoking or gender.
Importantly, mean CIMT increased significantly from 0.54 mm in patients with normal 
coronary arteries on MSCT (n=21, 23%) to 0.64 mm in patients with non-obstructive 
atherosclerosis (n=44, 48%). Highest mean CIMT (0.75 mm) was observed in patients 
with obstructive stenosis (n=27, 29%, P<0.01). Finally, ROC analysis yielded a sensitivity 
and specificity of respectively 79% and 74% using a CIMT cut-off value of 0.65 mm, for 
predicting obstructive coronary atherosclerosis.
Conclusions: A significant relation was shown between CIMT and the presence and 
severity of coronary atherosclerosis in patients with DM. Assessment of CIMT in this 
population may be a useful technique to identify patients at a higher risk for CHD.
10:00 a.m.
1007-199 Increased Urinary 11-Dehydro Thromboxane B2 in 
Diabetes Mellitus: An Atherothrombotic Risk Factor?
F. Jon Geske, Ivana J. Muncy, Aldo A. Oregon-Miranda, Ignacio Garcia-Valladares, 
Ignacio Garcia-De La Torre, Luis R. Lopez, Corgenix Medical Company, Broomfield, CO, 
Hospital General de Occidente de la Secretaria de Salud, Guadalajara, Mexico
Background: Atherothrombotic cardiovascular disease (CVD) is a significant cause 
of morbidity and mortality in patients with diabetes mellitus (DM). Urinary 11-dehydro 
thromboxane B2 (11dhTxB2) levels reflect circulating thromboxane A2 and platelet 
activation. High levels of 11dhTxB2 have been correlated with increased risk of CVD 
events. We postulated that DM patients have increased urinary 11dhTxB2 levels 
compared to healthy individuals.
Methods: 53 consecutive DM patients (mean age 56 years) attending the diabetes clinic 
of the Hospital General de Occidente of Guadalajara, Mexico, and 47 age-matched 
healthy controls were studied. Patients and controls taking aspirin were excluded. Urinary 
11dhTxB2 levels were measured with the AspirinWorks Test Kit. Urinary creatinine levels 
were determined for normalization, and final results were expressed as picograms of 
11dhTxB2/milligrams of creatinine.
Results: DM patients had significantly higher average 11dhTxB2 values than controls 
(5656 vs. 3337 pg/mg; p = 0.005). Males and females showed wide ranges of 11dhTxB2, 
both in DM and control populations (male DM ranged from 594-7333 pg/mg, while male 
controls ranged from 200-5676 pg/mg; female DM ranged from 524-27661 pg/mg and 
female controls ranged from 1561-11323 pg/mg). Female DM had significantly higher 
average 11dhTxB2 levels than control females (6975 vs. 4078 pg/mg; p = 0.04). In 
addition, female DM had higher average levels than male DM (6975 vs. 3298 pg/mg; p = 
0.01). Female controls had higher average 11dhTxB2 levels than male controls (4078 vs. 
2788 pg/mg; p = 0.02), while male DM and control subjects were not statistically different 
(3298 in DM vs. 2788 pg/mg in controls; p = 0.36).
Conclusions: The increased urinary 11dhTxB2 levels observed in this DM population 
indicate platelet activation as a potential contributor to CVD events. Females with 
DM demonstrate a significantly higher degree of platelet activation and thromboxane 
production than males, which may have therapeutic implications. Future outcome studies 
will determine the clinical significance of these findings.
10:00 a.m.
1007-200 Longitudinal Changes in Cardiac Parameters and 
Biomarkers Associated With Rapid Half-Marathon 
Training in Previously Sedentary Subjects
Gordon L. Chen, Mark Stoutenberg, Jochen Kressler, Kevin A. Jacobs, Arlette C. Perry, 
Robert J. Myerburg, University of Miami Miller School of Medicine, Miami, FL
Background: Physical training appears to provide cardiovascular risk modification, but 
the underlying mechanisms for the benefits of training are unclear. There is also recent 
evidence of potentially adverse cardiac biomarker changes associated with marathon 
performance.
Methods: Nineteen previously sedentary subjects, age 22-37 years, were enrolled in a 
17-week half-marathon (H-M) training program. Serial measurements of resting heart 
rate (rHR), blood pressure (BP), VO2 max, lipid profile, C-reactive protein (CRP), and 
echocardiograms (ECHO) were obtained from baseline to peak training. The observations 
were compared to sedentary controls.
Results: Among the study group, VO2 max increased from 37.1 to 42.0 ml•kg-1•min-1 
(p<0.001). There was no change in the control group. Significant decreases in rHR 
and BP were observed in the study group. ECHO revealed increased septum and left 
ventricular posterior wall dimensions among the study group, as well as increase in stroke 
volume and left ventricular mass (Table). There were no significant changes in rHR, BP, 
V02 max, or ECHO parameters in the control group. CRP and lipid profiles did not change 
significantly in either group. 
Study Group (n=19) Baseline 
(±SD)
Peak (±SD) Abs Change p value 
(2-tailed)
rHR (beats/min) 76.7±12.4 67.6±11.8 -9.1 0.002
Systolic BP (mmHg) 121.6 114.3 -7.3 0.0001
Diastolic BP (mmHg) 80.1±9.7 73.2±8.2 -6.9 0.007
Septal thickness-diastole (cm) 0.925±0.102 1.003±0.128 0.078 0.028
LV internal diameter-diastole (cm) 4.803±0.490 4.818±0.490 0.015 0.864
LV posterior wall-diastole (cm) 0.961±0.092 1.075±0.123 0.114 0.003
LV Mass(g) 186.6±37.4 209.2±30.0 22.6 0.009
LV Mass Index (g/m2) 91.4±16.8 102.8±12.8 11.4 0.008
LV End Diastolic Volume (ml) 118.4±23.8 144.1±29.6 25.7 0.002
LV End Systolic Volume (ml) 45.8±16.4 52.4±16.7 6.6 0.195
Ejection Fraction (%) 61.9±7.9 63.8±7.8 1.9 0.461
Stroke Volume (ml) 72.6±14.0 91.6±20.9 19.0 0.001
E to A ratio 1.59±0.37 1.38±0.40 -0.21 0.030
Conclusions: Intensive training for H-M over 17 weeks leads to increased cardiac and 
hemodynamic performance that is not associated with changes in longitudinal cardiac 
risk biomarkers linked to inflammation. Expression of any training-induced changes in 
such biomarkers likely requires a longer training period.
10:00 a.m.
1007-201 Genetic Variation in the Galectin 3 Gene Associates 
With Angiographic Restenosis After Percutaneous 
Coronary Interventions
Douwe Pons, Moniek P.M. de Maat, Aeilko H. Zwinderman, Robbert J. de Winter, René 
A. Tio, Pieter A.F.M. Doevendans, J. Wouter Jukema, Leiden University Medical Center, 
Leiden, The Netherlands
Background: Galectin 3 has a diverse functional profile. It has been shown to inhibit 
apoptosis, to stimulate cell-cycle progression and it has been implicated in re-
epithelialization of wounds and malignant transformation of cancer cells. As Galectin 3 is 
also known to be involved in the differentiation of monocytes to macrophages and in the 
proliferation of smooth muscle cells, it is likely to play a role in cardiovascular diseases 
such as atherosclerosis and restenosis. Furthermore, it has been shown to be expressed 
in human atherosclerotic lesions. Therefore, we examined the impact of polymorphisms 
in the LGALS3 gene on the risk of restenosis in a large population of patients undergoing 
percutaneous coronary intervention (PCI).
Methods: The GENetic DEterminants of Restenosis (GENDER) project is a multicenter 
prospective study design that enrolled 3104 consecutive patients after successful PCI. 
Follow-up angiography was performed in a predefined subpopulation of 478 patients six 
months after PCI. Clinical restenosis was defined as target vessel revascularization (TVR), 
and binary angiographic restenosis was defined as a stenosis diameter >50% within the 
stent or in the 5-mm segments proximal or distal to the stent. All 3104 patients were 
genotyped for 2 polymorphisms in the LGALS3 gene using the Sequenom massarray 
genotyping platform.
Results: The -1090 G/T and 843 A/C (Pro64His) polymorphisms in the LGALS3 gene were 
significantly associated with angiographic restenosis (OR: 2.0, 95%CI: 1.1-3.7, p=0.027 
and OR: 1.9, 95%CI: 1.1-3.5, p=0.028, respectively). However, despite a small trend 
towards increased TVR rates in groups carrying the variant alleles, these polymorphisms 
were not significantly associated with TVR.
Conclusions: Patients carrying one or two copies of either the -1090T or the 843C 
alleles in the LGALS3 gene showed significantly more in-stent restenosis, as measured 
angiographically at 6 months after PCI. The lack of association with TVR suggests that the 
increase in neointima formation does not necessarily result in symptoms.
10:00 a.m.
1007-202 Mechanism of Thrombin Mediated Phosphorylation 
of Endothelial NO-Synthase in Endothelial Cells Is 
Dependent on ATP-Fluctuations
Brynhildur Thors, Haraldur Halldórsson, Gudmundur Thorgeirsson, Institute of 
Pharmacy, Pharmacology and Toxicology, University of Iceland, Reykjavik, Iceland, 
Department of Medicine, Landspitali-University Hospital, Reykjavik, Iceland
Background: Conflicting results have been reported concerning the role of AMP-activated 
protein kinase (AMPK) in mediating thrombin stimulation of endothelial NO-synthase 
(eNOS) in endothelial cells. In the present study we examined the involvement of two 
upstream kinases in AMPK activation, LKB1 stimulated by a rise in intracellular AMP/ATP 
ratio, and Ca+2/CaM kinase kinase (CaMKK) responding to elevation of intracellular Ca+2. 
Also studied were the effects of AMPK activation on the downstream target eNOS.
Methods: Endothelial cells were obtained from human umbilical veins with collagenase 
treatment and cultured to confluence. Liquid chromatography or luceferace assay were 
used for AMP and/or ATP measurements. Western blotting was used for the quantification 
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of cellular proteins and for the detection and quantification of phosphorylated proteins.
Results: After treatment with thrombin, STO-609 which is an inhibitor of CaMKK prevented 
to a variable degree the phosphorylation of AMPK, acetyl coenzyme A carboxylase (ACC) 
and eNOS, dependent on the culture conditions. In medium 1640, STO-609 totally inhibited 
the phosphorylation of AMPK and ACC but not eNOS. The level of intracellular ATP was 
not changed in this medium after thrombin stimulation. In Morgan´s medium 199, STO-609 
partially inhibited the phosphorylation of AMPK, ACC and eNOS and under these conditions 
thrombin caused a significant lowering of intracellular ATP, suggesting the involvement of 
LKB1. Also, the AMPK inhibitor compound C partially inhibited the phosphorylation of eNOS 
in medium 199 but not in 1640, demonstrating a clear difference in the pathways mediating 
thrombin stimulated eNOS phosphorylation in different culture media.
Conclusions: Conditions that subject endothelial cells to a fall in ATP when stimulated with 
thrombin facilitate activation of signal transduction pathways that are partly dependent on 
AMPK and cause downstream phosphorylation of eNOS. In contrast, under culture conditions 
that do not allow or facilitate a fall in ATP after stimulation AMPK activation is exclusively 
mediated by CaMKK and does not contribute to the phosphorylation and activation eNOS.
10:00 a.m.
1007-203 Vascular Function, Endothelial Precursors Cells and 
Angiogenic Factors in Morbid Obesity
Luigi M. Biasucci, Francesca Graziani, Giovanna Liuzzo, Vittoria Rizzello, Salvatore 
Brugaletta, Caterina Guidone, Andrea Piccioni, Grazia Alecce, Gertrude Mingrone, 
Filippo Crea, Catholic University, Rome, Italy
Background: Obesity (O) and overweight (OW) are associated with endothelial dysfunction 
and with an increased risk to develop atherosclerosis and consequent acute coronary 
syndrome. Morbid obesity (MO) is a growing condition defined by a BMI>40, largely due to 
abnormally expanded subcutaneous adipose tissue; the metabolic profile in this condition 
differs from obesity, but little is known about coronary risk in this population. Interestingly, 
post-mortem studies have shown a striking limited severity of coronary atherosclerosis in 
morbid obesity. Therefore , aim of our study was to assess endothelial function in O and 
OW subjects (OOW) compared to subjects with MO.
Methods: We enrolled 38 consecutive healthy normoglycaemic subjects, divided in two 
classes by BMI: 23 obese and overweight subjects (OOW; BMI 25-39.9) and 15 morbidly 
obese subjects (MO;BMI>40). Flow-mediated dilation (FMD) was measured by brachial 
artery ultrasound. Circulating levels of endothelial progenitor cells CD34+CD45-CD133+ 
(EPCs) were assessed by flow-citometry and serum levels of angiogenic factors, 
Hepatocyte Growth Factor (HGF) and Platelet Derived Growth Factor (PDGF), as well as 
leptin, were measured by ELISA.
Results: FMD was higher in MO than in OOW (21% vs 13%; p 0.009). Similarly, EPCs were 
higher in MO (0.50% vs 0.14%; p 0.027). Also PDGF and HGF levels were significantly 
higher in MO than in OOW (mean 4066 pg/ml vs 2134 pg/ml and 4794 pg/ml vs 3489 pg/
ml ; p 0.034 and p 0.018). Finally, a positive correlation was observed between FMD and 
EPC (r=0.29 p 0.041); also HGF levels positively correlated with EPC (r=0.60 p=0.001), 
with BMI (r=0.36 p 0.031) and with leptin levels (r= 0.39 p=0.021).
Conclusions: Our study demonstrates that vascular function is improved in MO vs 
OOW and this is associated with higher levels of EPCs and angiogenic factors. These 
observations suggest that in MO abnormally expanded subcutaneous adipose tissue 
might contribute to protect vascular function possibly through enhanced EPCs mobilization 
and HGF levels, with beneficial effects on the endothelium.
10:00 a.m.
1007-204 Repression of PAI-1 Expression by Quercetin Involves 
Upstream Stimulatory Factor-2
Nelida C. Olave, Priscilla I. Correa-Jaque, Maximiliano H. Grenett, Paul E. Wolkowicz, 
Hernan E. Grenett, University of Alabama at Birmingham, Birmingham, AL
Background: The intake of dietary flavonoids lowers risk for cardiovascular disease. We 
demonstrated that the flavonoid quercetin (Quer) represses PAI-1 expression in cultured 
human coronary artery endothelial cells (ECs). Here we test whether Quer represses PAI-
1 though the upstream stimulatory factor-2 (USF2) transcription factor (TF).
Methods: ECs were transfected with (i) 5’ deletion constructs of the PAI-1 promoter and 
(ii) a 251-bp fragment of the PAI-1 promoter, both cloned into appropriate reporter vectors. 
Transfected ECs were incubated in the absence or presence of 10µM Quer for 5hr and 
luciferase was measured. ECs also were co-transfected with the 251-bp fragment and 
with a plasmid encoding USF2. Electrophoretic mobility shift assays (EMSA) were carried 
out with nuclear extract (NE) from Quer-treated ECs using appropriate 32P-labeled 
double-stranded oligonucleotides. Supershift identification of DNA binding proteins was 
performed using antibodies specific for USF2 and c-Myc. Western blot analysis measured 
PAI-1 expression in ECs transiently transfected with USF2.
Results: Deletion constructs identified a 251-bp promoter fragment localized between 
nucleotide -800 and -549 of the PAI-1 gene as a molecular mediator of the repressive 
effect of Quer on PAI-1 expression. This PAI-1 promoter fragment contains two E-Box 
motifs at position -691 (E-Box1) and -575 (E-Box2). These motifs recognize TFs containing 
basic helix-loop-helix domains such as USF and cMyc/Max. ECs co-transfected with the 
p251/luc and pUSF-2.cDNA3.1 show reduced luciferase activity driven by the 251-bp PAI-
1 promoter construct when compared with vector alone (pcDNA). Incubation of NE from 
Quer-treated ECs with labeled E-Box1 or E-Box2 show increased specific DNA-protein 
complex formation compared with untreated ECs. EMSA supershift analyses with USF2 
antibodies confirm the presence of the USF2 DNA-binding protein in this complex.
Conclusion: Quer represses PAI-1 gene expression by activating USF2 which occupies 
the inhibitory E-Boxes in the PAI-1 gene promoter. Suppression of pro-thrombotic PAI-
1 gene expression may contribute to the cardioprotective benefit of dietary flavonoid 
consumption.
10:00 a.m.
1007-205 Soluble Receptor for Advanced Glycation End Products 
(sRAGE): A Novel Biomarker and Potential Inhibitor of 
Atherosclerosis. Observations from the Dallas Heart 
Study
Jason B. Lindsey, James A. de Lemos, Colby R. Ayers, Anand Rohatgi, Sandeep Das, 
Amit Khera, David A. Morrow, Francesco Cipollone, Darren K. McGuire, University of Texas 
Southwestern Medical Center, Dallas, TX, Gene Design and Development Ltd., Chieti, Italy
Background: Interaction between the receptor for advanced glycation end products 
(RAGE) and its ligands has been implicated in the development and progression of 
atherosclerosis. A circulating, soluble form of RAGE (sRAGE) has anti-atherogenic effects 
in animal models; its association with human atherosclerosis remains unclear.
Methods: Plasma levels of sRAGE were measured in 3300 subjects from the Dallas Heart 
Study, a multiethnic population-based study; of these 2571 had electron beam computed 
tomography measurements of coronary artery calcium (CAC), with prevalent CAC defined 
by Agatston score >10.
Results: Mean age was 44, including 56% women; 69% non-White; and 12% with diabetes 
mellitus (DM). Older age, black race, hypertension, smoking, BMI, insulin levels and 
HOMA-IR were independently associated with lower sRAGE levels. An inverse, graded 
association was observed between sRAGE quartiles and CAC prevalence (figure). After 
multivariable adjustment sRAGE levels in the 1st and 2nd quartiles (vs 4th quartile) 
remained associated with CAC > 10 (adjusted OR 1.76, 95% CI 1.24 to 2.51 and 1.51, 
95% CI 1.07 to 2.13 respectively; adjusted ptrend <0.0001 across quartiles). All results 
were qualitatively similar in the analyses stratified by DM status.
Conclusions: sRAGE is a novel biomarker that is independently associated with coronary 
atherosclerosis. The possible role of sRAGE in the pathobiology of atherosclerosis and its 
potential therapeutic implications warrant further investigation.
10:00 a.m.
1007-206 Candidate Genetic Variants in Fibrinogen, 
Methylenetetrahydrofolate Reductase and Intercellular 
Adhesion Molecule-1 Associated With Atherosclerosis 
and Their Baseline Plasma levels Among Various Race/
Ethnic Groups
Michelle Albert, Alanna Morris, Julie Buring, Paul M. Ridker, Robert Zee, Brigham and 
Women’s Hospital/Harvard Medical School, Boston, MA
Background: Genetic polymorphisms of fibrinogen (FGB), methylenetetrahydrofolate 
reductase (MTHFR - homocysteine), and intercellular adhesion molecule-1 (ICAM-1) are 
implicated in atherosclerosis. However, little data are available about their relationship 
with corresponding plasma biomarker levels in different race/ethnic (r/e) groups.
Methods: We genotyped specific polymorphisms in FGB (-455G>A/rs1800790), MTHFR 
(677C>T/rs1801133) and ICAM-1 (Lys56Met/rs5491 and Gly241Arg/rs1799969) at 
baseline, and evaluated their relationship with respective inflammatory biomarker levels 
in 24,926 white, 474 African-American (black), 267 Hispanic and 356 Asian women 
participating in the Women’s Health Study.
Results: The allele frequencies for -455G>A were similar in white, Hispanic and Asian 
women. While, the minor allele was associated with elevated FGB levels in whites and 
Asians, no association was observed for blacks or Hispanics. Black women had the 
highest FBG levels [GA: 412.2 Umol/L (interquartile range (IQR), 356.9, 457.5)], although 
the minor allele frequency was lowest (6.7 %) in this group. Asian women had the lowest 
homocysteine levels [CT: 9.3 umol/L (IQR 8.0, 11.7)], whereas the minor allele frequency 
of the MTHFR 677C>T polymorphism was lowest in blacks (blacks:12.4%, whites 
33.1%, Hispanics 39.0%, Asians 24.0%) and was only significantly associated with 
homocysteine levels in white women. Among whites, Hispanics and Asians, the Lys56Met 
polymorphism was rare compared to the frequency in blacks. Neither the Lys56Met nor 
Gly241Arg polymorphisms were common in Asians. Nonetheless, both polymorphisms 
were associated with significantly lower ICAM-1 levels in all r/e groups; the lowest levels 
were observed in black women.
Conclusions: We found significant associations between certain candidate genetic 
polymorphisms and baseline plasma levels of fibrinogen, homocysteine and intercellular 
adhesion molecule-1 in women from various race/ethnic groups. This investigation is 
hypothesis generating and suggests genetic determination of differential concentrations of 
these atherosclerosis-related inflammatory biomarkers among various race/ethnic groups.
10:00 a.m.
1007-207 Bifunctional Targeting of Echogenic Immunoliposomes 
for Directed Stem Cell Delivery
Melvin E. Klegerman, Yuejiao Zou, Shaoling Huang, Harnath S. Shelat, Yong-Jian Geng, 
David D. McPherson, University of Texas Health Science Center, Houston, TX
Background: The development of bifunctional targeted molecular contrast agents may 
provide directed delivery of large molecules/cells to target sites. We hypothesized that 
liposomes conjugated to antibodies to both ICAM-1 and CD34 protein will allow targeting 
and selective migration of mesenchymal stem cells to inflamed atheroma to modulate 
atheroma formation.
Methods: Human umbilical vascular endothelial cells (HUVEC) were cultured in collagen-
coated 96-well microplates. Human peripheral mononuclear cells (HMNC) from healthy 
donors were transfected with an adenovirus vector incorporating the green fluorescent protein 
(GFP) gene. Echogenic liposomes were prepared and conjugated to monoclonal antibodies 
specific for human/mouse ICAM-1 and CD34 via a thioether linkage to produce bifunctional 
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echogenic immunoliposomes (BF-ELIP). ICAM-1 binding of the BF-ELIP was verified by a 
sandwich ICAM-1 ELISA. Bifunctionality of the preparation was demonstrated by: 1) counting 
of cells adsorbed to BF-ELIP in the ICAM-1 ELISA protocol, and 2) successive incubation 
of adherent HUVEC with BF-ELIP, HMNC and a phycoerythrin-labeled anti-CD34 antibody. 
Characteristic phycoerythrin and GFP fluorescent emission intensities were measured.
Results: We successfully achieved double antibody conjugation of liposomes (22.2µg IgG/
mg lipid), while fully retaining echogenicity (retained air entrapment). After demonstrating 
nM-range ICAM-1 affinity of the targeted formulation, we verified the ability of BF-ELIP 
to promote net HMNC binding to an ICAM-1 matrix (5.07 x 103 vs. 3.51 x 103 cells per 
well). Finally, to confirm effective BF-ELIP bridging of HUVEC and HMNC, we showed 
significant enhancement of both phycoerythrin and GFP fluorescence relative to a 
control lacking BF-ELIP (p<0.05; phycoerythrin n = 3; GFP n = 10).Conclusions: We have 
demonstrated the ability to produce bifunctional targeted molecular imaging agents that 
are able to bind stem cells, while actively directing them to inflammatory components of 
atheroma. The retained echogenicity allows BF-ELIP to be tracked to the site of interest, 
as well as to be used as a bioactive vehicle for delivery of stem cells into atheroma.
10:00 a.m.
1007-208 Acute effects of passive smoking on peripheral 
vascular function
Jean-François Argacha, Dionysis Adamopoulos, Marko Gujic, David Fontaine, Nadia 
Amai, Guy Berkenboom, Philippe van de Borne, Erasme Hospital, Anderlecht, Belgium
Background: Environmental tobacco smoke (ETS) acutely affects peripheral and coronary 
vascular tone.
Aim of the study: To test the hypothesis that 1) ETS exerts specific deleterious effects 
on aortic wave reflection above those of non-tobacco smoke, 2) these effects are related 
to a rise in plasma nicotine levels, 3) they persist after ETS cessation and 4) ETS alters 
NO-dependent mechanisms in skin blood flow.
Materials and methods: We examined the vascular effects of one hour exposure to ETS, 
compared to exposure to a non-tobacco smoke and normal-air, in 11 healthy male non-
smokers, using a randomized, single blinded, cross over study design. Augmentation 
index (AIx), and wave transit time (Tr) were assessed non-invasively with a validated 
system, and NO-dependent skin microvascular hyperemia to local heating was measured 
with a laser Doppler flowmeter.
Results: Air particle densities did not differ during the ETS and non-tobacco smoke sessions. 
Compared to normal air, ETS and non-tobacco smoke did not affect central or peripheral 
blood pressure. AIx increased both during (p=0·01) and after (p<0·01) the ETS session, 
but remained unchanged in the non tobacco smoke session when compared to normal 
air. The largest increases in serum nicotine levels (n=10) were accompanied by the most 
pronounced rises in AIx (r=+0·84, p<0·01). Tr decreased both during (p=0·02) and after 
(p<0·01) ETS, but remained unchanged in the non-tobacco smoke session when compared 
to normal air. ETS reduced the late rise in skin blood flow in response to heating (p=0·03). 
This did not occur during the non tobacco smoke and the normal air sessions.
Conclusions: Passive smoking of tobacco, compared to passive inhalation of non 
tobacco smoke, increases aortic wave reflection and impairs endothelium-dependent 
microvascular function. The increase in wave reflection is associated with the rise in 
plasma nicotine levels. These acute deleterious effects persist after ETS cessation.
10:00 a.m.
1007-209 Circulating Progenitor Cells and Endothelial 
Dysfunction in Patients With Coronary Heart Disease 
and Concomitant Abnormal Glucose Metabolism
Maria M. Ruda, Alexey V. Mazurov, Olga A. Antonova, Valery P. Masenko, Tatyana 
V. Kuznetsova, German A. Tkachev, Oleg N. Vyborov, Tatiana I. Arefieva, Tatyana 
V. Balakhonova, Maria I. Tripoten, Yuriy A. Karpov, Yelena V. Parfyonova, Russian 
Cardiology Research Center, Moscow, Russian Federation
Background: Bone marrow-derived circulating progenitor cells (CPCs) (CD34+) are 
capable of endothelial maturation and play an important role in endothelial repair. We 
studied whether number of CPCs is associated with endothelial dysfunction in patients 
with coronary heart disease (CHD) with or without concomitant abnormal glucose 
metabolism (AGM here: type 2 diabetes mellitus, impaired fasting glycemia and impaired 
glucose tolerance).
Methods: Numbers of CPCs, plasma von Willebrand factor and endothelin levels, serum 
nitric oxide metabolites level, brachial artery flow-mediated dilatation and carotid intima-
media thickness were examined in 76 persons (40-69 years old, mean age 55.6±0.9): 32 
patients with stable angina (SA) (50% with AGM, 50% without), 26 - with non-ST elevation 
acute coronary syndromes (ACS) (27% with AGM, 73% without) in 24h after onset of 
symptoms and 18 control subjects without CHD and AGM. CPCs were quantified by the 
expression of surface cell marker CD34 by flow cytometry.
Results: Numbers of CD34+ cells in ACS group decreased by 39.3% (p<0.01) vs. control 
and by 20.8% (p<0.05) vs. SA group; in SA group vs. control - by 18.5% (p=ns). Numbers 
of CPCs were lower in SA group with AGM vs. control (p<0.05), whereas in non-AGM SA 
group there was no significant difference. In patients compared to control: brachial artery 
flow-mediated dilatation was impaired (ACS, p<0.05, SA, p=ns); carotid intima-media 
thickness was increased (ACS and SA, p<0.05) as well as von Willebrand factor (ACS, 
p=ns, SA, p<0.05) and endothelin (ACS, p=ns) levels, nitric oxide metabolites level was 
decreased (ACS, p<0,05, SA, p=0,057).
Conclusions: Patients with CHD (especially with ACS) had impaired endothelial function 
and reduced number of CPCs, more prominent in subgroups with AGM. Thus, the reduced 
number of CPCs might be an indicator of endothelial dysfunction. We suggest, that CPCs 
may become an important new diagnostic and therapeutic target for endothelial function 
improvement and coronary heart disease treatment.
10:00 a.m.
1007-210 Expression Profiling of Peripheral Blood Cells Identifies 
Genes That Distinguish Patients With and Without 
Coronary Artery Stenosis
James A. Wingrove, Amy J. Sehnert, Whittemore G. Tingley, Michael Elashoff, Susan E. 
Daniels, Nicholas F. Paoni, Lori Littleford, Rachel L. Nuttall, Michael Doctolero, Steven 
Rosenberg, Lutz Buellesfeld, Eberhard Grube, L. Kristin Newby, William E. Kraus, Duke 
University, Durham, NC, CardioDx, Inc, Palo Alto, CA
Background: Coronary artery disease (CAD) is characterized by vessel wall inflammation 
and cytokine release; how this relates to gene expression in circulating cells is unknown. 
To address this, we compared global gene expression of blood cells between patients 
with and without angiographic evidence of CAD.
Methods: Total peripheral blood mononuclear cell (PBMC) RNA was isolated from 
patients undergoing coronary angiography. Cases had 70% stenosis in >1 vessel or 
50% stenosis in >2 vessels; controls had 0% luminal stenosis. We performed whole 
genome microarrays on 41 subjects (27 cases, 14 controls), then performed RT-PCR on 
two independent cohorts comprising 214 subjects (160 cases, 54 controls), using either 
PBMC or total blood RNA.
Results: Array analysis yielded 520 genes with >1.3 fold differential expression (p 
<0.05). Of these, 110 genes, including the most significant genes from microarrays and 
additional literature genes, were tested by RT-PCR on the two independent cohorts. 
52 genes (p <0.05) discriminated patients with and without CAD; 16 were significant 
in both cohorts. These included S100 family members, CSF, cytokine and scavenger 
receptors, and complement and proteoglycan components. The figure shows the 
relationship between gene expression and CAD severity.
Conclusion: Peripheral blood gene expression can reflect the presence or absence 
of CAD and represents a possible tool for development of a diagnostic classifier to 
distinguish these patients. 
10:00 a.m.
1007-211 Depletion of CD133/KDR Endothelial Progenitor 
Cell Correlates With the Presence of Coronary 
Atherosclerosis in Patients With Rheumatoid Arthritis
Kai Hang Yiu, Si Lun Wang, Hon Wah Chan, Wai Luen Lee, Clara Ooi, Chu Pak Lau, 
Yok Lam Kwong, Chak Sing Lau, Hung Fat Tse, Division of Cardiology, Department of 
Medicine, Queen Mary Hospital, Univeristy of Hong Knog, Hong Kong, Hong Kong
Background: Rheumatoid arthritis (RA) is associated with increased atherosclerosis that 
is not contributable by convention risk factors. We hypothesized that the depletion of 
circulating endothelial progenitor cells (EPC) related to chronic inflammation increase the 
risk of developing coronary atherosclerosis.
Methods: We measured the levels of circulating CD34/KDR+ and CD133/KDR+ EPCs, 
C-reactive protein (CRP) and coronary calcium score (CCS) with computer tomography 
of thorax in 60 female RA patients (pts) and 78 age matched healthy controls. All subjects 
had no documented coronary artery disease.
Results: The prevalence of asymptomatic coronary atherosclerosis (defined as 
CCS>100) was significantly higher in RA pts than controls (13 vs. 0%, p<0.01). There 
were no significant differences in EPC counts between RA pts and controls (all p>0.05). 
However, RA pts with chronic active disease (> 2 years) had significantly lower CD34/
KDR+ (2.7±2.9 vs.1.6±1.1%, p=0.05) and CD133/KDR+ (1.0±0.9vs. 0.6±0.3%, p<0.01) 
EPC compared to those with early RA. RA pts with coronary atherosclerosis were older 
(68±5vs 52±10 yrs, p<0.01), had a higher urea level (6.2±1.1 vs 4.8±1.6 mmol/L, p=0.01) 
and a lower CD133/KDR (0.4±0.3 vs. 0.9±0.7%, p=0.01) compared to those without. After 
adjusting for age, a lower CD133/KDR+ EPC, but not the duration of RA, serum CRP and 
urea levels, was an independent predictor for the presence of coronary atherosclerosis 
(OR 8.0 C.I. 1.05-26.1, p=0.02).
Conclusions: Our results confirm that the prevalence of asymptomatic coronary 
atherosclerosis was significantly higher in RA pts than age-matched controls. The 
presence of chronic active RA was associated with depletion of circulating EPC, and 
a lower CD133/KDR+ EPC independently predicted the occurrence of coronary 
atherosclerosis.
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1007-212 Obesity, Metabolic Syndrome and Progression of 
Coronary Atherosclerosis: Insights From ILLUSTRATE
Kellan E. Ashley, John M. Galla, E. Murat Tuzcu, Amy Hsu, Steven E. Nissen, Stephen J. 
Nicholls, Cleveland Clinic Foundation, Cleveland, OH
Background: The metabolic syndrome (MS) portends adverse outcomes in patients with 
coronary artery disease, but its impact on disease progression is unknown. This analysis 
evaluated the impact of MS on atheroma progression in patients stratified according to 
the prevalence of obesity.
Methods: Patients (n=910) with angiographic disease treated with torcetrapib or placebo 
with background atorvastatin in the ILLUSTRATE trial were stratified according to the 
prevalence of obesity (BMI >30 kg/m2) and MS. Groups were compared with regard to 
demographics, changes in plaque burden measured by intravascular ultrasound, and 
clinical events.
Results: 385 patients had MS and 419 were obese. MS was associated with a greater 
prevalence of diabetes, hypertension and use of ACE inhibitors in both obese and non-
obese patients. MS was associated with lower levels of HDL cholesterol and higher levels 
of triglyceride and CRP in both obese and non-obese patients. The presence of MS 
was associated with a greater rate of progression of percent atheroma volume (PAV), 
reductions in external elastic membrane (EEM) and lumen volumes, and greater rates 
of cardiovascular events (death, MI, stroke, revascularization, hospitalization for unstable 
angina) in the obese patients only. (Table) 
Parameter
BMI </= 30 BMI > 30
No MS MS P Value No MS MS P Value
Revascularization (%) 19 16 0.61 13 21 0.03
Cardiovascular events (%) 21 18 0.58 15 23 0.06
Change PAV (%) 0.1±2.9 0±2.6 0.97 -0.1±2.8 0.5±3.1 0.02
Change EEM Volume (mm3) -21±53 -20±38 0.73 -17±52 -28±51 0.04
Change Lumen Volume (mm3) -14±43 -11±28 0.48 -11±38 -20±42 0.05
Conclusions: MS is more likely to promote an adverse effect on plaque progression, 
arterial remodeling and clinical outcome in obese patients. This has important implications 
given the global rise in incidence of both of these conditions.
10:00 a.m.
1007-213 Does Tissue Characteristics Differ Between Proximal 
and Distal Segment of Left Anterior Descending 
Coronary Artery in Angina Pectoris? An Integrated 
Backscatter Intravascular Ultrasound (IB-IVUS) Study
Naohiro Komura, Kiyoshi Hibi, Ikuyoshi Kusama, Fumiyuki Ootsuka, Takayuki 
Mitsuhashi, Mitsuaki Endou, Satoshi Umemura, Kazuo Kimura, Yokohama City 
University Medical Center, Yokohama, Japan
Background: Recent studies have shown that plaque ruptures and culprit lesions for acute 
myocardial infarction cluster mainly in the proximal segment of left anterior descending 
coronary artery (LAD) within 30 mm from the ostium. However, the precise mechanism 
remains unknown. The aim of this study was to investigate whether coronary plaque 
tissue characteristics of non culprit intermediate lesion in the proximal LAD differ from 
those in the distal LAD as assessed by Integrated Backscatter Intravascular Ultrasound 
(IB-IVUS).
Methods: IVUS interrogation was performed in 70 non-culprit intermediate plaques in 47 
patients (42 men; mean age 68 years) with angina pectoris (57% with unstable angina) 
who underwent percutaneous coronary intervention (PCI) to the culprit lesions in the LAD. 
The target plaque had to be a minor lesion (less than 50% diameter stenosis by coronary 
angiography) and had to be at least 5 mm apart from any PCI site. Proximal and distal 
segment was defined as < 30 mm and ≥ 30 mm from the ostium of LAD, respectively. IB-
IVUS images were recorded using 40-MHz intravascular catheter at an interval of 0.5 mm 
in each plaque and radiofrequency signal was acquired. Measurements of IB-IVUS were 
made through whole length of each plaque (mean length 10 mm) and average value of 
each plaque component (lipid, fibrosis, dense fibrosis, and calcification) was compared 
between proximal and distal segment.
Results: Plaques in the proximal segment (n = 30) had higher %lipid content (37 vs. 
18%, p < 0.01) and lower %fibrosis content (56 vs. 64%, p < 0.01) as well as lower 
%calcification content (2.0 vs. 5.5%, p < 0.01) than those in the distal segment (n = 40). 
By multiple linear regression analysis, proximal plaque was associated with higher %lipid, 
lower %fibrosis, and lower %calcification content independent of age, gender, unstable 
presentation, and other coronary risk factors (all p < 0.05).
Conclusions: The vulnerable plaque characteristics in the proximal coronary artery as 
assessed by IB-IVUS may partly explain higher prevalence of cardiac events in the 
proximal coronary artery.
10:00 a.m.
1007-214 Clopidogrel pretreatment abolishes increase of PAI-1 
after coronary stent implantation
Katharina M. Katsaros, Walter S. Speidl, Stefan P. Kastl, Gerlinde Zorn, Kurt Huber, 
Gerald Maurer, Dietmar Glogar, Johann Wojta, Guenter Christ, Medical University of 
Vienna, Vienna, Austria
Background: An increase of PAI-1 after percutaneous coronary intervention (PCI) with 
stent implantation may favour the development of stent thrombosis and instent restenosis 
due to inhibition of the fibrinolytic system. Clopidogrel pretreatment before (PCI) may 
reduce major adverse cardiovascular events at 1 month. Therefore, we studied whether 
pretreatment with clopidogrel may reduce the increase of PAI-1 after coronary stent 
implantation.
Methods: We included 51 patients with stable angina who underwent elective PCI with 
stent implantation. At the time when the study was performed, routine use of clopidogrel 
before PCI was not advised and treatment was at the discretion of the referring cardiologist. 
We matched 17 patients with stable angina that were not pretreated with clopidogrel but 
received a loading dose of 300mg immediately after stent implantation according age, 
sex and smoking with 34 patients that received clopidogrel at least 12 to 24 hours before 
PCI. Blood samples for measurement of PAI-1 and t-PA were taken directly before and 24 
hours after the procedure.
Results: PAI-1 and t-PA active antigen plasma levels before PCI were not different in 
patients with and without clopidogrel pretreatment. PCI induced a significant increase of 
PAI-1 levels in patients without pretreatment (+7.4±3.1ng/mL; p<0.05). In contrast, the 
procedure had no effect on PAI-1 active antigen in patients that were pretreated with 
clopidogrel (-3.2±2.0ng/mL; p=NS) resulting in significant lower plasma levels of PAI-1 
compared to patients without pretreatment 24 hours after PCI (15.2±2.0 vs 29.6±6.0 ng/
mL; p<0.05). t-PA levels did not change in both groups.
Conclusion: Clopidogrel pretreatment completely abolishes the increase of PAI-1 active 
antigen after coronary stent implantation. This may explain in part the beneficial effects 
of this treatment regimen.
10:00 a.m.
1007-215 Genetic Polymorphisms Are Associated With the 
Response of Arterial Function to Acute Inflammation
Ioanna Dima, Charalambos Vlachopoulos, Carmen Vasiliadou, Panagiotis Xaplanteris, 
Nikolaos Alexopoulos, Konstantinos Aznaouridis, Katerina Baou, Christodoulos 
Stefanadis, 1st Department of cardiology,Athens Medical School, Athens, Greece
Background: Arterial stiffness is an independent prognosticator of cardiovascular 
risk. ID polymorphism of angiotensin-converting enzyme (ACE) gene and -174G>C 
promoter polymorphism of IL-6, have been linked with increased cardiovascular risk. 
Acute inflammation has been associated with an increase of aortic stiffness. However, 
the relationship between these polymorphisms and arterial stiffness has not been 
investigated yet.
Methods: Nineteen healthy adults (mean age 34.7±2.2 years old, 11 men) participated in 
the study (randomised, double-blind design). Salmonella Typhi vaccine was used as an 
inflammatory stimulus. RLFPs were performed by standard methods for IL-6 and three 
genotypes were determined, GG, GC and CC. For the ACE polymorphism three genotypes 
were determined II, ID and DD. Carotid-femoral pulse wave velocity (PWV) was measured 
as an index of aortic stiffness using a non-invasive device (Complior®). Augmentation 
index (AIx) was measured as an index of wave reflection and arterial stiffness using a 
validated system (SphygmoCor©). Arterial stiffness was assessed before and 8 hours 
after vaccination as well as in 11 non-vaccinated matched volunteers.
Results: In the vaccine group, pulse wave velocity increased 8 hours after vaccination 
In the GG genotype group there was a more prominent change of aortic stiffness (5.59 
to 5.82m/sec for GG group, p<0.01, 5.88 to 6.07m/sec for GC and CC group, p=NS). 
Moreover, there was a significant decrease in AIx eight hours after the vaccine in G allele 
genotype group (GG and GC, 18.31% to 12.22%, p<0.05 and CC 23% to 14.7%, p=NS), 
indicating decreased wave reflection. For the DD polymorphism, there was a significant 
fall in AIx in the vaccine group in the D allele carriers (19.57% to 13.18%, p<0.05) but not 
in the II subgroup (6.65% to 1%, p=NS). There were no changes in the control group.
Conclusions: Acute inflammation results in an increase of aortic stiffness depending on 
IL-6 genotype, while the decrease in wave reflection seems to be influenced by both 
polymorphisms. These findings underscore the genetic significance of IL-6 and ACE 
genes on the pathophysiology of cardiovascular system and highlight the need for further 
investigation.
10:00 a.m.
1007-216 Atorvastatin-Ezetimibe combination improves Pulse 
Wave Velocities in patients with established coronary 
artery disease
Niteen Vijay Deshpande, Dhananjay V. Deo, Shriram A. Lokare, Harshwardhan M. 
Mardikar, Spandan Heart Institute and Research Center, Nagpur, India
Background: Pulse wave velocity (PWV) is a simple non-invasive measure of vascular 
damage. We conducted a trial of Atorvastatin-Ezetimibe (A+E, 10 mg each) versus 
Atorvastatin-Niacin (A+N, 10 mg + 500 mg SR) in patients with established CAD and low 
HDL (≤40 mg/dl) for modulation of HDL and PWV.
Methods: 100 patients were enrolled for the study. Following a statin washout phase of 
1 week and Atorvastatin therapy (10 mg) for 3 weeks, patients were randomized to fixed 
dose combinations either of A+E (Group A) or A+N (Group B) for two months. Fasting 
lipid profile and PWV were measured at randomization and at completion of the study. A 
validated computerized oscillometric device was used to measure PWV. Of the various 
indices available, carotid femoral (PWVcf), heart brachial (PWVhb), and brachial ankle 
(PWVba) PWV were compared.
Results: Ninety-six patients completed the study. Six patients were excluded due to 
peripheral vascular disease.Lipid parameters TC, TG and LDL decreased insignificantly 
in both groups, HDL increased significantly in both groups (from 36.4 ± 5.2 to 43.6 ± 7.9 in 
Gr A vs from 36.19 ± 4.4 to 40.02 for Gr B). HDL increment in Gr A was significantly more 
as compared to Gr.B (7.1 vs 3.8 mg p <0.041). PWVcf and PWVba improved significantly 
in Gr A. Patients in Gr B demonstrated only marginal change in all of them (Table)
Conclusions: A+E combination significantly increased HDL and improved PWV in patients 
with CAD reflecting improvement in vascular health.
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Changes in PWV
Gr A(n=45) Gr B(n=45)
Baseline Follow-up p value Baseline Follow-up p value
PWVcf 981±239 949±180 0.02 977±240 986±208 0.14
PWVhb 312±63 307±50 0.34 320±48 314±44 0.68
PWVba 1434±278 1384±210 0.01 1395±228 1422±203 0.17
10:00 a.m.
1007-217 Circulating Endothelial Cells and Circulating Progenitor 
Cells in hypertension in pregnancy: A balance between 
endothelial damage and repair?
Vellore J. Karthikeyan, Timothy Watson, Deirdre A. Lane, Sabah Baghdadi, D. 
Gareth Beevers, Gregory YH Lip, University Department of Medicine, City Hospital, 
Birmingham, United Kingdom
Background Endothelial damage has been implicated in the pathogenesis of hypertension in 
pregnancy. Circulating endothelial cells (CECs) reflect endothelial damage whilst progenitor 
cells (CPCs) regulate and maintain the vasculature. We hypothesized that CPC:CEC ratio is 
altered in (hypertensive) pregnant women compared to non-pregnant healthy controls.
Methods Hypertensive pregnant (HBP, n=30) women, >20 weeks gestation attending the 
ante-natal clinic [blood pressures (BP) >140/90 untreated or ≤ 140/90 mmHg treated) 
were recruited. CECs were measured by immunomagnetic separation using anti-CD146 
monoclonal antibody coated beads. CPCs were defined using flow cytometry as CD133+/
CD34+/CD45- lymphocytes. Controls included normotensive pregnant (NBP, n=39) and 
non-pregnant healthy women (HC, n=43); CPC:CEC ratio was determined.
Results We recruited 112 women [mean (SD) age 30 (7) years]. CECs were markedly 
raised in the HBP women (p<0.001). CPCs were raised in NBP group compared to HC 
(p<0.05); the CPC:CEC ratio was lower in HBP women compared to HC (p<0.05). A 
strong negative correlation was noted between CPC:CEC ratio and BP (table).
Conclusion Whilst our findings confirm the association of endothelial damage in 
hypertensive compared with normotensive pregnancies, low CPC:CEC ratios in the 
former and high CPCs in the latter suggest a complex patho-physiological relationship 
involving endothelial damage and regeneration attempts by CPC mobilization to restore 
vascular haemostasis. 
Levels of Blood Pressure, vWF and CECs in hypertensive, normotensive pregnant women and 
non-pregnant healthy controls
Mean (SD) Hypertensive 
Pregnant (n=30)
Normotensive 
Pregnant (n=39)
Non-pregnant healthy 
controls (n=43) p-value
Age(years) 32 (6) 29 (6) 31(8) 0.146
Median (IQR) Parity 2 (0-3) 1 (0-2) 0 (0-0) < 
0.0001
SBP (mm Hg) 132(13) 112 (10) 118 (10) < 
0.0001
DBP (mm Hg) 88 (9) 66 (6) 75 (8) < 
0.0001
Median (IQR) CEC levels 
(/ ml) 4 (2-5)
 * 2 (1-2) 1 (0-2) < 
0.0001
Median (IQR) CPC levels 
(/ ml)
148 296 
(72-274145-548)
185 370 
(125250-247494) *
127 254 
(72144-189378) < 0.05
CPC:CEC ratio 39 78 (2041-86172) † 97 194 (51-185101-370)
60 120 
(3978-115230) < 0.05
CPC:CEC ratio correlates to SBP and DBP (Spearman r = -0.30, p<0.005 & r = -0.26, p<0.05, 
respectively) overall.
CEC: Circulating Endothelial Cells; CPC: Circulating Progenitor Cells; DBP: Diastolic Blood Pressure; 
SBP: Systolic Blood Pressure 
Between group analyses by ANOVA with Tukey post hoc test and Kruskal Wallis test with Dunn’s post 
hoc test, as appropriate 
*Significantly higher than healthy controls 
† Significantly lower than healthy controls
10:00 a.m.
1007-218 B-type Natriuretic Peptide Enhances Vasculogenesis by 
Promoting The Number and Functional Properties of 
Endothelial Progenitor Cells
Jacob George, Haim Shmilovich, Jeremy Ben Shoshan, Gad Keren, Tel Aviv Medical 
Center, Tel Aviv, Israel
Background: B-type natriuretic peptide (BNP) is a neurohormonal agent that predicts 
outcome and used for treatment in CHF patients. It has been shown to promote 
angiogenesis in experimental animals. EPC have been demonstrated to contribute to 
post natal angiogenesis and vasculogenesis. We tested the hypothesis that BNP acts as 
a vasculogenic agent by enhancing the number and functional properties of endothelial 
progenitor cells (EPC).
Methods: The number of EPC colony forming units (CFU) and levels of NT-ProBNP were 
assayed in patients with severe controlled NYHA II-IV heart failure. The in vitro effects of 
BNP on EPC-CFU numbers, adhesive and vascular tube formation capacity, were studied 
in human and murine systems. The effects of in vivo BNP administration on mouse Sca-1/
Flk-1 progenitors and on vasculogenesis in the hindlib ischemia model were then assayed 
in wild type mice.
Results: A significant correlation was found between circulating NT-ProBNP and EPC-
CFU numbers in 38 heart failure patients. We observed a dose dependent effect of BNP 
on the numbers of CFU from human EPC as well as on their adhesive and tube formation 
capacity, in vitro. Systemic BNP administration to mice led to a significant increase in 
bone marrow Sca-1/Flk-1 EPCs and improvement in blood flow and capillary density in 
the ischemic limbs of mice.
Conclusions: BNP promotes vessel growth by increasing the number of endothelial 
progenitors and enhancing their functional properties. These pro-vasculogenic properties 
of BNP could account for some its beneficial effects in CHF patients and may be 
harnessed for the purpose of improving collateral formation in ischemic subjects.
10:00 a.m.
1007-219 Effect of Chronic Carbon Monoxide Exposure on 
Carotid Intima-Media Thickness and C-Reactive Protein 
Levels
Ibrahim SARI, Suat ZENGIN, Orhan OZER, Cuma YILDIRIM, Vedat DAVUTOGLU, 
Murat SUCU, Mehmet AKSOY, Gaziantep University, School of Medicine, Department of 
Cardiology, Gaziantep, Turkey, Gaziantep University, School of Medicine, Department of 
Emergency Medicine, Gaziantep, Turkey
Background: Being the most common cause of death from poisoning worldwide, 
cardiovascular manifestations of acute carbon monoxide (CO) poisoning have been 
subject of various studies but current evidence about the effects of chronic CO exposure 
on the cardiovascular system and atherosclerosis is limited. We aimed to investigate 
association of chronic CO exposure with atherosclerosis by means of carotid intima-
media thickness (CIMT) and high sensitivity C-reactive protein (hs-CRP) measurement.
Methods: Apparently healthy 40 male non-smoker indoor barbecue workers (mean age; 
33.0±9.1) working in restaurants for at least three years and 48 age matched healthy men 
(mean age; 34.7±6.5) were enrolled into the study. CIMT, total cholesterol, high density 
lipoprotein, low density lipoproten, triglyceride, carboxyhemoglobin (COHb) and hs-CRP 
levels were measured.
Results: Clinical characteristics of indoor barbecue workers and control group were 
comparable in terms of body mass index, blood pressure and lipid profile. However 
COHb (6.4±1.5% vs. 2.0±1.1%), hs-CRP (2.7±2.0mg/L vs. 1.1±0.8mg/L) and CIMT 
(1.10±0.31mm vs. 0.91±0.11mm) were higher in indoor barbecue workers (p<0.001 
for all). In Pearson correlation analysis there were significant correlations between age 
and COHb (r=0.577, p<0.001), age and hs-CRP (r=0737, p<0.001), COHb and hs-CRP 
(r=0.610, p<0.001), COHb and CIMT (r=0.387, p=0.014), COHb and years worked (years 
exposed to CO, r=0.575, p<0.001), hs-CRP and CIMT (r=0.359, p=0.025), hs-CRP and 
years worked (r=0.687, p<0.001) and CIMT and years worked (r=0.335, p=0.035) among 
indoor barbecue workers. However, there was significant correlation only between COHb 
and hs-CRP (r=0.427, p=0.002) in the control group.
Conclusions: In conclusion, the present study is the first demonstrating the association 
of chronic CO exposure with atherosclerosis in terms of increased CIMT and hs-CRP in 
subjects exposed to moderate doses of CO on average of 15.6 ± 7.1 years.
10:00 a.m.
1007-220 The Platelet P2Y12 Receptor Influences the Vessel Wall 
Response to Arterial Injury and Thrombosis
David JW Evans, Daniel J. Crosdale, Heather M. Judge, Janet Chamberlain, Karim 
Jetha, Keith E. Norman, Sheila E. Francis, Robert F. Storey, Cardiovascular Research 
Unit, The University of Sheffield, Sheffield, United Kingdom
Background: Platelets are believed to play an important role in atherogenesis and the 
vessel response to vascular injury. The P2Y12 receptor (P2Y12) plays a central role in 
amplifying platelet aggregation, dense granule and alpha-granule secretion, P-selectin 
expression, microparticle formation and pro-coagulant membrane changes, regardless of 
the activating stimulus. We hypothesised that P2Y12 deficiency might reduce the vessel 
wall response to vascular injury as well as thrombosis in murine vascular injury models.
Methods: P2Y12 deficient (-/-) mice and littermate controls (+/+) were bred on a C57 
BL/6 background. In vivo murine models of arterial injury were employed alone and in 
combination with bone marrow transplantation to investigate the role of P2Y12 in the 
vessel wall response to arterial injury and thrombosis.
Results: At 21 days post ferric chloride injury, neointima formation in P2Y12 -/- arteries 
was significantly less than that observed in control strain arteries (p<0.001). Clopidogrel 
fed P2Y12 +/+ animals exhibited similar neointimal areas to arteries from P2Y12 -/- 
animals but significantly less neointima than arteries from P2Y12 +/+ animals (p<0.001).
To confirm these findings, femoral wire injury or sham operation of P2Y12-/- and P2Y12+/+ 
animals was employed. The intima:media ratio was significantly greater in injured arteries 
from P2Y12+/+ as compared to P2Y12-/- animals (p<0.05).
Bone marrow transplantation was used to examine the importance of vessel wall P2Y12 versus 
platelet P2Y12. Two types of chimeric mice; P2Y12+/+ mice with P2Y12-/- bone marrow (-/- to 
+/+), and P2Y12-/- mice with P2Y12+/+ bone marrow (+/+ to -/-) were generated. Control 
P2Y12+/+ to P2Y12+/+, and P2Y12-/- to P2Y12-/- transfers were also performed. Analysis of 
arterial sections from these animals 21 days post-injury revealed a smaller intima:media ratio 
in -/- to +/+ animals as compared to positive (+/+ to +/+) control group (p<0.05).
Conclusion: These data demonstrate a role for platelet (not vascular smooth muscle cell) 
P2Y12 in the vessel wall response to arterial injury and thrombosis. This illustrates how 
platelets may contribute to atherogenesis and restenosis.
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10:00 a.m.
1007-221 Dissecting the role of p22phox genetic variation in 
coronary artery disease through the use of different 
clinical and in vitro cardiovascular phenotypes
Alexandre Costa Pereira, Neuza H. Lopes, Ayumi A. Miyakawa, Jose G. Mill, Pedro 
Lemos, Eulógio Martinez, Whady Hueb, Jose E. Krieger, Heart Institute, University of 
Sao Paulo Medical School, Sao Paulo, Brazil
Background:We have studied the power of genetic variation of the p22phox gene to 
predict the occurrence of cardiovascular events in patients with CAD and the potential 
modulation of genetic variation at this locus on different cardiovascular phenotypes 
assayed in several large, independent, epidemiological and experimental designs.
Methods:We genotyped 10 different p22phox SNPs in 611 patients with multivessel-
disease CAD followed for 5 years in the MASS II Trial. A replication study was conducted 
in an independent sample of 359 individuals with CAD followed for 4 years. The potential 
causes for the effect of genetic variability in the studied locus and CAD were explored 
using a sample of 1576 individuals from the general population, a sample of 871 
individuals submitted to coronary angiography for CAD diagnosis and an in vitro system 
of human vascular tissue designed to explore the association between p22phox genetic 
markers and different expression patterns of inflammatory genes.
Results:Linkage disequilibrium structure of the studied locus was defined. A significantly 
higher all-cause mortality was associated with SNP rs4673 (p=0.01). In a Cox multivariate 
analysis model adjusting for covariates presence of the T allele of rs4673 was 
independently associated with higher mortality (p=0.007, OR 1,98). This association was 
confirmed in an independent sample of individuals with CAD. No association between 
p22phox genetic variability and cardiovascular risk factors in the general population was 
observed, but a significant interaction between p22phox genetic markers and traditional 
cardiovascular risk factors for the occurrence of coronary atherosclerosis was observed 
in another independent population. Vascular gene expression levels of 10 inflammatory 
related genes were assayed and a genotype-specific expression pattern was observed 
for p22phox SNPs and assayed genes.
Conclusions:Our data support the role of p22phox rs4673 polymorphism on the incidence 
of cardiovascular events in CAD patients, a direct modulation of the effect of traditional 
cardiovascular risk factors in CAD development, and a genotype-specific modulation of 
inflammatory gene expression in the vascular tissue.
10:00 a.m.
1007-222 Catch up Growth is Associated With Increased Blood 
Pressure and Arterial Stiffness in Childhood
Marietta Charakida, Ann Donald, Atul Singhal, Julian Halcox, George Davey-Smith, 
John Deanfield, Institute of Child Health, University College London, London, United 
Kingdom, Unit of Paediatric and Perinatal Epidemiology, Department of Community 
Based Medicine, University of, Bristol, United Kingdom
Background: Low birthweight, a surrogate of events that occur in the intrauterine life has 
been reported as a risk factor for adverse cardiovascular health. Promotion of postnatal 
growth has been thought as a good alternative to ameliorate these effects, but evidence 
is lacking. We have assessed the impact of early postnatal growth rate on blood pressure 
and arterial distensibility in childhood.
Methods: We studied 6167 children aged 10 years nested within the Avon Longitudinal 
Study of Parents and Children (ALSPAC). Blood pressure was measured and BMI was 
calculated as weight (kg)/ height (m)2. Weight was recorded at birth and within a period of 
2 months. All values were converted to z scores. Change in growth in the first two months 
was assessed as the change in weight z score between birth and the first two months 
of life. Arterial distensibility was measured in the brachial artery using high resolution 
ultrasound. The distension of the artery was determined by measuring the luminal 
diameter excursion from diastole to systole.
Results: Faster weight gain in the first two months was associated with increased systolic 
blood pressure (SBP) at 10 years later (0.5 [0.2, 0.9]; B [95%CI]; p<0.01). This association 
remained after adjusting for birthweight z score, sex, heart rate, BMI at 10 years and 
lipoprotein profile. In addition, faster weight gain was also associated with decreased 
arterial distensibility (-0.29[0.5,-0.13]; B [95%CI]; p<0.0001). This association remained 
after multivariable analysis. Birthweight z score was not independently associated with 
SBP or arterial distensibility. When children were assessed in quartiles of weight change 
the highest quartile had 1.69mmHg increase in blood pressure and 0.56 Pascal-1 
decrease in distensibility compared to the lowest weight gain quartile.
Conclusions: We have demonstrated that more rapid weight gain during the first two 
months of life is associated with increased SBP and increased arterial stiffness as early 
as 10 years of age in a healthy, prospectively followed, contemporary cohort. Further 
studies are needed to assess the implications of these abnormalities for cardiovascular 
risk in adulthood.
10:00 a.m.
1007-223 Characterization of the expression of CB1 and CB2 in 
human atherosclerotic plaques
Maria Luigia Fazia, Andrea Di Francesco, Domenico De Cesare, Marco Bucci, 
Francesco Spigonardo, Sante Ucchino, Andrea Mezzetti, G. d’Annunzio University of 
Chieti, Chieti, Italy
Background: Although some pharmacological approaches are able to limit atherosclerosis 
progression, ischemic syndromes due to atherosclerotic plaque rupture remain the main 
cause leading to cardiovascular mortality. Recently, it has been shown that blockade of 
CB1, one of the two receptors of endocannabinoids, is able to improve the cardiovascular 
risk profile. However, it is not known whether endocannabinoids receptors are present in 
human atherosclerotic plaques and may play a role in atherosclerosis progression. Thus, 
the aim of this study was to characterize CB expression in atherosclerotic plaques and to 
correlate it with the extent of inflammatory infiltration and with enzymes involved in plaque 
instability, such as metalloproteinases (MMPs).
Methods:Plaques were collected from 67 patients who underwent carotid endarterectomy. 
Patients were subdivided according to the clinical evidence of hypertension, diabetes, 
dyslipidemia, smoke. Plaque expression of CB1, CB2, MMP-2 and MMP-9 was evaluated 
through immunohistochemistry, immunofluorescence and western blot.
Results: Immunohistochemical analysis showed that plaques from 46 (69%) patients 
contained detectable levels of both CB1 and CB2, while the other 21 (31%) plaques 
did not show any immunoreactivity for these enzymes. Double immunofluorescence 
showed that CB1 and CB2 were mainly associated with CD68 macrophages and smooth 
muscle cells. Interestingly, the analysis of the association between CB expression and the 
individual cardiovascular risk factors showed that CB1 levels were significantly correlated 
with both diabetes (P<0.05) and glycaemic levels > 126 mg/dL (P=0.005). Furthermore, 
in diabetic patients, CB1 expression was associated to the expression of MMP-2 and 
MMP-9 (Spearman rho=0.53).
Conclusions:This study showed for the first time: a) the presence of CB1 receptors in 
human atherosclerotic plaque; b) the higher expression of CB receptors in plaques from 
diabetic patients than in plaques from nondiabetic subjects. Finally, the association of 
CB1 receptors with MMP expression suggests a potential role of CB1 in atherosclerotic 
plaque instability.
10:00 a.m.
1007-224 Erythropoietin stimulates normal endothelial progenitor 
cell-mediated endothelial turnover, but attributes 
to neovascularization only in the presence of local 
ischemia
B. Daan Westenbrink, Hisko Oeseburg, Pim Van der Harst, Rudolf de Boer, Adriaan 
A. Voors, Regien G. Schoemaker, Dirk J. van Veldhuisen, Wiek H. van Gilst, University 
Medical Center Groningen, Groningen, The Netherlands
Background: We aimed to compare the effects of erythropoietin (EPO) on incorporation 
of EPCs in the endothelium and their related effects on endothelial and cardiac function, 
in the presence and absence of ischemia.
Methods: Bone marrow of rats was replaced by transgenic cells to allow tracking of EPCs. 
Ischemic heart failure was induced by left coronary artery ligation to induce myocardial 
infarction (MI) and control rats received a sham procedure. Three weeks after surgery, 
rats were randomized to receive erythropoietin (darbepoetin alfa 40µg/kg/3weeks; EPO) 
or vehicle and were sacrificed 9 weeks after surgery.
Results: In all treated groups, EPO significantly increased circulating EPCs and their 
incorporation into the endothelium of the heart, kidney, and liver, and significantly improved 
endothelial dependent relaxation. Improvement of endothelial function was strongly 
correlated with circulating EPCs (R=0.7, p<0.01), and was abrogated by the NOS blocker 
LNMMA. However, EPCs preferentially homed to the ischemic MI borderzone (p<0.01) and 
EPO significantly improved cardiac microvascularization and performance only in ischemic 
hearts (all p<0.05). The differential stimulation of neovascularization by EPO was associated 
with increased EPO-receptor and VEGF expression in ischemic hearts only.
Conclusions: EPO regulates normal endothelial progenitor cell-mediated endothelial 
turnover, irrespective of the presence of ischemia. However, EPO attributes to 
neovascularization and improves cardiac function only in the presence of local ischemia.
10:00 a.m.
1007-225 Effects of Acarbose on in Vivo Markers of Oxidative 
Stress and Platelet Activation in Early Type 2 Diabetes
Francesca Santilli, Gloria Formoso, Paolo Sbraccia, Maurizio Averna, Roberto Miccoli, 
Patrizia Di Fulvio, Antonella Ganci, NicolÃ² Pulizzi, Giovanni Ciabattoni, Agostino 
Consoli, Renato Lauro, Carlo Patrono, Giovanni DavÃ¬, Center of Excellence on Aging, 
â€œG. dâ€™Annunzioâ€  University Foundation, Chieti, Italy, Department of Internal 
Medicine, University of Rome â€œTor Vergataâ€ 
Background. Chronic hyperglycemia is a major determinant of in vivo platelet activation in 
diabetes mellitus (DM). Acarbose, an α-glucosidase inhibitor, is associated with a significant 
reduction in the risk of cardiovascular events in patients with impaired glucose tolerance.
We tested the hypothesis that acarbose may exert a cardioprotective effect by 
downregulating the enhanced lipid peroxidation and platelet activation that characterizes 
type 2 DM.
Methods. Forty-eight subjects (26 M, 22 F, aged 61±8 yr), with early type 2 DM (baseline 
HbA1c <7% and no previous hypoglycemic treatment), selected for being free of vascular 
complications and non-smokers, were randomly assigned to acarbose up to 100 mg tid 
or placebo in addition to dietary counselling and evaluated every 4 weeks for 20 weeks 
with blood and urine sampling.
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Results. Statistically significant reductions in 2-hour postprandial glycemia (PPG) after 
a test meal, fasting blood glucose (FBG), HbA1c and other biochemical variables were 
detected as early as 8 weeks on acarbose. At 20 weeks, acarbose but not placebo was 
associated with a significant reduction in FBG (7.0±0.8 to 6.5±1.2 mmol/L, p=0.01), PPG 
(9.5±2.9 to 7.7±2.0 mmol/L, p<0.001), HbA1c (6.7±0.5 to 6.3±0.5%, p<0.0001), urinary 
11-dehydro-thromboxane (TX)B2, a marker of platelet activation, (1699±1000 to 987±584 
pg/mg creatinine, p<0.0001) and 8-iso-prostaglandin (PG)F2α, a marker of oxidant stress, 
(515±182 to 346±142 pg/mg creatinine, p<0.0001).
PPG but not FPG was significantly related to both 11-dehydro-TXB2 (Rho 0.30, p=0.034) 
and 8-iso-PGF2α (Rho 0.45, p=0.001) during acarbose, but not placebo.
In the whole group, the % change in HbA1c at the end of the treatment period correlated 
with that in urinary 11-dehydro-TXB2 (Rho 0.36, p=0.01) and 8-iso-PGF2α (Rho 0.35, 
p=0.02). The % change in 8-iso-PGF2α was related to that in 11-dehydro-TXB2 (Rho 
0.61, p<0.0001).
Conclusion. We conclude that a moderate decrease in PPG achieved with acarbose is 
associated with downregulation of abnormal oxidative stress and platelet activation in 
early type 2 DM and may contribute to cardioprotection in this setting.
10:00 a.m.
1007-226 Hypoxia up-regulated cholesterol synthesis and 
angiogenesis-related genes in porcine mesenchymal 
stem cells
Yifu Zhou, Eric M. Billings, Suna Wang, Zuxi Yu, Timothy Hunter, Shawn Kozlov, Keith A. 
Horvath, National Institutes of Health, Bethesda, MD
Background:Adult stem cell transplantation has been used as an alternative therapeutic 
strategy in many applications including regenerative therapy for cardiovascular diseases. 
To determine whether hypoxia mediates porcine bone marrow-derived stem cell’s (MSC) 
gene expression, we performed expressional profiling using Affymetrix gene chips. 
Methods:Adult porcine bone marrow-derived MSCs were cultured using previously 
reported methods for 4 wks, and then incubated in either a hypoxic chamber (1% O2) 
or normal culture condition for 24 hours. Twelve paired RNA samples, 6 hypoxic and 
6 non-hypoxic treated from three animals, were hybridized to Affymetrix Porcine arrays 
(Affymetrix, CA).Results:All samples met initial QC requirement. The probes presented 
in less than 50% (6/6) samples were excluded. Differential gene expression patterns were 
determined using the R package 2.4 (Significance Analysis of Microarrays, Hierarchical 
Clustering and Prediction Analysis of Microarrays). Genes were grouped into functional 
classifications and pathway analysis based on the DAVID Bioinformatics Resources 
2007. Of 14, 638 probes presented >50%, 1,571(672 up- and 899 down-regulation) were 
differentially expressed between control and hypoxic samples. However, only 149 of them 
are known genes, 143 of these genes were mapped into human gene set with a minimum 
similarity of 90%. We found that in PPAR signaling, FABP was 18.5 fold and Acyl-CoA 
synthestase was 2.8 fold up-regulated. The highly up-regulated genes also include 
VEGFA, TGFBR1, TLR4, HSPA1A and SLC2A1, all of which enhance cell response to 
stress, proliferation, vasculogenesis and angiogenesis, as well as carbohadrate transport 
activity. Pathway analysis shows the top hit pathways are focal adhesion, calcium 
signaling, MAPK signaling and JAK-STAT signaling. Conclusions: The transcriptional 
profile results indicate that MSCs’ cholesterol synthesis activities were dramatically up-
regulated, in addition to the increased cellular angiogenesis processes under hypoxic 
condition. Our data suggests that MSCs may involve the process of atherosclerosis and 
angiogenesis as a consequence of the stimulation by hypoxia or ischemia.
10:00 a.m.
1007-227 Phagocytosis of activated platelets by circulating 
neutrophils in acute myocardial infarction
Norma Maugeri, Patrizia Rovere-Querini, Virgilio Evangelista, Cosmo Godino, Marco 
Mussardo, Filippo Figini, Giovanni Coppi, Massimo Slavich, Monica De Metrio, 
Giancarlo Marenzi, Domenico Cianflone, Antonio Bartorelli, Angelo A. Manfredi, Attilio 
Maseri, Univ San Raffaele, Milan, Italy
Background: Activated platelets express P-selectin (Psel) as well as phagocytic tags 
triggering their recognition and clearance. Neutrophils with intracellular platelets were 
observed in patients with high expression of Psel. In preliminary studies we observed that 
activation of circulating neutrophils in patients with myocardial infarction (AMI) correlates 
with the expression of Psel on circulating platelets.
Purpose: Aim of this study was to determine whether platelet-neutrophil interaction may 
regulates neutrophil activation and/or platelet clearance in the blood-stream.
Methods: Psel and myeloperoxidase (MPO) expression and neutrophils containing 
internalized platelets were assessed by flow cytometry, confocal and electron microscopy 
in 20 AMI patients, 16 patients with chronic stable angina (CSA) and 34 healthy controls 
(C). In parallel, normal isolated platelet were activated and exposed to autologous 
neutrophils for 5 min. As inhibitors anti Psel, anti Psel receptor (PSGL-1), anti-CD11b/
CD18 antibodies, EDTA (to block the effect of divalent cations), annexin V, to block the 
effect of phosphatidylserine (PhSer) were used.
Results: Neutrophils do phagocytose platelets in vivo thus in AMI patients, 16.5±3.4% 
of neutrophils contained intracellular platelets (CSA: 1.1±0.5 and C: 0.92±0.3, P<0.001). 
The presence of intra-neutrophil platelets correlates with platelet Psel expression (r=0.63, 
P<0.0001) and platelet-neutrophil aggregates (r=0.48, P<0.0003). In vivo phagocytosis 
of whole platelet was confirmed by electron microscopy. In vitro experiments showed 
that blockade of the key adhesive molecules and PhSer on platelet surface revealed that 
the phagocytic process includes two events: adhesion (which requires divalent cations 
and depends on Psel , on PSGL-1 and on CD11b/CD18) and internalisation (which 
requires PhSer). Adhesion of activated platelets, induce MPO release, and is blocked by 
antibodies specific for Psel and PSGL-1.
Conclusions: These data suggest that the interaction between circulating platelets 
and neutrophils regulates innate functions, and induce release the neutrophil content 
contributing to tissue damage during vascular inflammation.
10:00 a.m.
1007-228 Different Pathways of Innate and Adaptative Immunity 
in Type 1 and Type 2 Diabetes Mellitus Might Influence 
the Cardiovascular Risk
Simona Giubilato, Salvatore Brugaletta, Dario Pitocco, Valeria Colafrancesco, Michela 
Narducci, Costantino Smaldone, Luigi M. Biasucci, Giovanni Ghirlanda, Giovanna 
Liuzzo, Filippo Crea, Catholic University of the Holy Heart, Rome, Italy
Background: Diabetes is associated with an increased cardiovascular (CV) risk. Immune 
system has a prominent role in type 1 diabetes (T1DM) pathogenesis, but remains ill-
defined in type 2 diabetes (T2DM). CD4+CD25+ regulatory T cells (Treg) mantain self-
tolerance and suppress aberrant or excessive immune responses. A defective Treg 
compartment induces diabetes and accelerated atherosclerosis in animal models, and 
reduced number and altered function of Treg have been observed in acute coronary 
syndromes. Furthermore, expansion of an aggressive population of effector T cells, 
CD4+CD28null, able to induce proinflammatory and tissue-destructive immune pathways, 
occurs in chronic autoimmune disorders. We investigated the role of CD4+CD28null T 
cells and Treg in the immune system disorders associated with diabetes.
Methods: Peripheral blood T cells from 33 patients with T1DM and 47 patients with T2DM 
were analyzed for the distribution of T cell subsets by flow cytometry. No patients had 
clinical evidence of micro- or macro-vascular complications. High sensitivity C-reactive 
protein (CRP), glyco-haemoglobin A1c (HbA1c), lipid status and body mass index (BMI) 
were also assessed.
Results: No differences were found in lymphocyte count and total CD4+ T cell frequency. 
CD4+CD28null cell frequency (median, range) (normal value <1%) was significantly 
higher in T1DM (8.0, 0.6-26.1%) than in T2DM (5.3, 0.5-22.5%; P=0.045). In contrast, 
Treg cell population (normal value >5%) was significantly lower in T1DM (1.5, 0.4-3.3%) 
than in T2DM (2.3, 0.3-6.2%; P=0.012), and also CRP levels were lower in T1DM (2.6, 
0.3-6.5 mg/L) than in T2DM (4.9, 0.4-21.9 mg/L; P=0.023). T1DM patients were younger 
than T2DM patients (51±14 versus 63±11 yrs; P=0.006), and had lower BMI (25.2±5 
versus 29.2±4.9 kg/m2; P=0.026). In T2DM, CRP levels were associated with BMI 
(r=0.52, P=0.001).
Conclusions: Immune system might influence the pathogenesis of T1DM and T2DM 
throughout different pathways. Innate immunity might have a predominant role in T2DM, 
as shown by high levels of CRP correlating with abdominal obesity. In contrast, a profund 
perturbation of T-cell repertoire might play a key role in T1DM.
10:00 a.m.
1007-229 Brachial-Ankle Pulse Wave Velocity is Associated with 
Walking Distance in Patients Referred for Evaluation of 
Peripheral Arterial Disease
Comfort Amoh-Tonto, A. Rauoof Malik, Venkateswarlu Kondragunta, Iftikhar J. Kullo, 
Mayo Clinic, Rochester, MN
Background: We hypothesized that brachial-ankle pulse wave velocity (baPWV), a 
measure of arterial stiffness, is associated with functional capacity in patients undergoing 
non-invasive evaluation for peripheral arterial disease (PAD).
Methods: We studied 114 patients (age 68±10 years, 58.7% men) referred for PAD 
evaluation to the non-invasive vascular laboratory. Functional capacity was estimated in 
terms of distance walked over 5 min on a treadmill at a speed of 1.0-2.0 mph. Ankle-
brachial index (ABI, a marker of PAD) was obtained with Doppler method before and after 
the treadmill walking test. baPWV was estimated non-invasively using an oscillometric 
device with ECG-gating. The association of baPWV with walking distance was tested in 
accelerated failure time and Cox proportional-hazards models.
Results: In univariable analyses, greater age (P = 0.04), higher pulse pressure (P = 0.01), 
history of smoking (P = 0.047), hypertension medication use (P = 0.032), and higher 
baPWV (P =0.0004) were associated with a shorter walking distance. In multivariable 
analyses, higher baPWV (P = 0.029) was associated with a lower walking distance, even 
after adjustment for age, sex, body mass index, hypertension medication and statin use, 
smoking history, ABI, heart rate, and pulse pressure. ABI was not associated with walking 
distance in either univariable or multivariable analyses. After adjustment for covariates, 
higher baPWV (P = 0.033), but not ABI, was associated with a greater probability of failure 
to complete the 5-minute treadmill walk test.
Conclusion: Arterial stiffness, as assessed by baPWV, is associated with impaired 
functional capacity in patients undergoing evaluation for PAD.
10:00 a.m.
1007-230 Sex-Based Differences in Bone Marrow Progenitor Cell 
Depletion and Immune Response of Atherosclerosis: 
Viewing Atherosclerosis as a Disease of Failed 
Endogenous Repair
Andrey G. Zenovich, Wendy D. Nelson, Angela Panoskaltsis-Mortari, Gabriel J. Caron, 
Harald Ott, Doris A. Taylor, University of Minnesota, Minneapolis, MN, Massachussetts 
General Hospital, Boston, MA
Background: Recent studies have shown clinically-relevant differences in symptoms, risk 
stratification and efficacy of therapies between men and women with coronary artery 
disease (CAD). Whether these reflect the differences in bone marrow progenitor cells 
(BMPCs) and immune response (components of endogenous repair) is unknown.
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Methods: At 4 wks, 22 male (M) and 30 female (F) ApoE-/- mice were placed on a high-fat 
diet. At 14, 21 and 32 wks, aortic (Ao) plaque burden, CD34+ BMPCs, CD31+/CD45low 
vascular progenitor cells (VPCs), and AC133+/CD34+ endothelial progenitor cells (EPCs) 
and 22 cytokines (plasma) quantified endogenous repair. Regression, curve fitting and 
hierarchical clustering were used to elucidate sex-based differences with p≤0.05.
Results: Ao plaque in M rose fast and plateaued in parallel to CD34+ BMPCs and VPCs 
depletion. In F, Ao plaque climbed (J-shaped) later (21-32 wks) vs M; CD34+ BMPCs fell 
7 wks prior and VPCs fell when plaque rose. EPCs increased at disease midpoint in M 
and F and fell; EPC % were always higher in F vs M.
Table 1. Atherosclerosis and Endogenous Repair in M and F ApoE-/- Mice
14 wks 21 wks 32 wks Curve Fit R2 p-value
M Ao plaque, % 3.8±0.1 18.2±1.4 27.7±2.5 Exponential rise to max 0.80 <0.001
F Ao plaque, % 5.5±0.3 14.4±0.7* 43.4±4.7* Exponential rise 0.85 <0.001
M VPC, % 14.3±0.7 11.0±0.8 7.9±1.2 Linear regression 0.40 0.002
F VPC, % 11.2±0.9* 11.8±0.8 7.9±0.6 Cubic regression 0.26 0.05
M EPC,% 3.3±0.2 3.7±0.6 2.9±0.9 Log-normal regression 0.24 0.03
F EPC, % 4.7±0.2* 7.0±0.5 6.4±0.4* Log-normal regression 0.32 0.01
*p<0.05 F vs. M. At 21 wks in F ApoE-/- mice, Th2 anti-inflammatory cytokines 
counteracted every Th1-driven atherogenic cluster (not seen in M).
Conclusions: Atherosclerotic male and female ApoE-/- mice exhibited differences in 
plaque burden, in bone marrow progenitor cell composition and in Th1/Th2 balance 
reflecting gender differences in endogenous repair. Modulation of endogenous repair with 
cell therapy in CAD may require different approaches based on gender.
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1014-157 A second generation antisense oligonucleotide directed 
to human apolipoprotein B-100 reduces lipoprotein(a) 
levels and oxidized phospholipids on apolipoprotein B-
100 particles in lipoprotein(a)-transgenic mice
Esther Merki, Mark J. Graham, Adam Mullick, Elizabeth R. Miller, Roseanne M. Crooke, 
Robert Pitas, Joseph L. Witztum, Sotirios Tsimikas, University of California San Diego, 
La Jolla, CA
Background: Lipoprotein (a) [Lp(a)] is a genetic cardiovascular risk factor that preferentially 
binds oxidized phospholipids in plasma. There is a lack of therapeutic agents that reduce 
plasma Lp(a) levels.
Methods:Transgenic mice overexpressing either human apolipoprotein B-100 (apoB-
100, “h-ApoB-mice”) or both human apoB-100 and human apolipoprotein (a) to generate 
genuine Lp(a) particles (“Lp(a)-mice”) were treated via intraperitoneal injection with a 
second generation antisense oligonucleotide (ASO) against human apo B (ISIS 301012) 
or a control ASO for 11 weeks. Therapy was then withdrawn and mice were followed for 
an additional 10 weeks.
Results: Administration of ISIS 301012 significantly decreased plasma apoB-100 in both 
groups of mice to near undetectable levels by 5 weeks. In Lp(a)-mice, Lp(a) levels were 
also reduced by ~75% in a similar timeframe (p<0.0001 for trend). Concomitant with the 
reduction of plasma human apoB-100 levels, apo(a) was noted to accumulate on mouse 
apoB-100 particles in Lp(a) mice. The content of oxidized phospholipids per apoB-100 
particle (OxPL/apoB) was significantly higher at baseline in the Lp(a)-mice compared 
to the h-ApoB-mice (p<0.0001), but decreased in a time-dependent fashion with ISIS 
301012 therapy in the Lp(a)-mice and returned to baseline on withdrawal of therapy. The 
proportion of OxPL epitopes on apo(a) particles remained unchanged despite lower Lp(a) 
levels. All lipid and biochemical variables reached their maximal effect by 3-5 weeks, 
remained unchanged up to 11 weeks of treatment and then returned to baseline by 10 
weeks post treatment. There was no effect of the control ASO on any lipid or oxidative 
parameters.
Conclusions: ISIS 301012, a human apoB-100 antisense drug currently in Phase 2 
development, significantly reduces plasma Lp(a) and OxPL/apoB levels in Lp(a)-mice. 
This study suggests a novel therapeutic approach to reduce plasma levels of Lp(a) levels 
and associated oxidized phospholipids.
2:00 p.m.
1014-158 Lipoic Acid Prevents Insulin Resistance and Adipocyte 
Inflammation
Qinghua Sun, Theodore Chang, Thomas Kampfrath, Carey N. Lumeng, Peibin Yue, 
Srikanth Vedamoorthy, Raju Desikan, Sampath Parthasarathy, Bobby Khan, Sanjay 
Rajagopalan, The Ohio State University, Columbus, OH, InVasc Therapeutics, Inc., 
Atlanta, GA
Background: There is increasing evidence implicating oxidative stress mediated by pro-
inflammatory signals such as tumor necrosis factor-alpha (TNF-α) in the pathogenesis 
of disorders such as insulin resistance and metabolic syndrome. The thiol antioxidant 
α-lipoic acid (LA) has shown to prevent inflammation. We hypothesized that LA attenuates 
inflammation and vascular dysfunction in diet-induced obesity.
Methods: Male C57BL/6 mice (n=16), fed with high fat chow for 3 months, were treated 
with LA (50 mg/kg) or placebo intraperitoneally for 8 weeks. Mice were sacrificed at the 
end of the experiments. In acute experiments, C57/BL6 mice (n=12) fed with regular 
chow were treated with a single dose of LA or placebo for 24 hours, followed by injection 
of TNF-α (1µg/kg) or placebo to assess LA effects in the cremasteric endothelium via 
intravital microscopy. NF€B translocation and monocyte adhesion were examined in 
cultured human endothelial and THP-1 cells.
Results: Chronic LA treatment corrected hyperglycemia and hyperinsulinemia (250 ± 15 
vs. 291 ± 40 mg/dl and 0.3 ± 0.1 vs. 0.6 ± 0.1 ng/ml, p<0.05) in response to intraperitoneal 
glucose loading and improved endothelial response to acetylcholine in aorta (90% vs 
45%). LA prevented increases in circulating TNF-α, IL-6, ICAM-1, E-selectin, and PAI-
1, decreased adipocyte size and prevented macrophage infiltration in epididymal fat 
associated with high fat chow feeding. Acute administration of LA restored increased 
leukocyte adhesion in response to TNF-α to levels seen in placebo treated mice. NF€B 
translocation increased with TNF-α while LA prevented translocation to levels seen prior 
TNF-α exposure and prevented THP-1 adhesion to endothelial cells.
Conclusions: LA prevents insulin resistance, adipocyte inflammation and vascular 
dysfunction through early effects on leukocyte adhesion and migration mediated through 
NFkB activation.
2:00 p.m.
1014-159 Short-Term Air Pollution Exposure Potentiates Insulin 
Resistance
Peibin Yue, Qinghua Sun, Aixia Wang, Ximei Jin, Qiang Li, Mianhua Zhong, Morton 
Lippmann, Sampath Parthasarathy, Lung Chi Chen, Sanjay Rajagopalan, Dorothy M. 
Davis Heart Lung Research Institute, the Ohio State University, Columbus, OH, New 
York University School of Medicine, Tuxedo, NY
Background: Although there is no direct link between air pollution and diabetes, there is a 
strong correlation between the latter and urbanization. We hypothesized that short-term 
exposure to fine particulate matter <2.5µm (PM2.5) impairs insulin signaling pathways 
and potentiates insulin resistance.
Methods: Male C57BL/6 mice were fed with high fat diet for 5 months, then randomly 
exposed to concentrated ambient PM2.5 (n=20) or filtered air (FA, n=20) in a wholebody 
exposure chamber for 10 weeks (6 hour/day, 5 day/week). Mice were euthanized at the 
end of this period for performance of studies.
Results: PM2.5 exposed mice exhibited fasting hyperglycemia (168 ± 6 vs. 126 ± 7 mg/dl, 
p < 0.01) and hyperinsulinemia (0.6 ± 0.1 vs. 0.2 ± 0.1 ng/ml, p < 0.05) compared with 
the FA group. Glucose levels in response to a glucose loading was significant higher in 
PM2.5 compared with FA group (430 ± 28 vs. 315 ± 25 mg/dl at 30 minutes, p < 0.05). 
Maximal aortic vasodilation in response to insulin was attenuated in PM2.5 group (51 ± 
6% vs. 75 ± 4%, p < 0.05). Basal nitric oxide bioavailability assessed by the increase in 
constriction of aortic rings to NG-monomethyl-L-arginine (10-4 M) was reduced in PM2.5 
group (86 ± 4% vs. 133 ± 8%, p < 0.01). Phosphorylation of Akt and endothelial nitric 
oxide synthase (eNOS) were significantly downregulated in PM2.5 group compared with 
FA group (49 ± 11% vs. 100 ± 19%; 51 ± 3% vs. 100 ± 16%, p < 0.05, respectively). 
PM2.5 exposure attenuated insulin induced Akt phosphorylation at 30 minutes in aortic 
ring segments. PM2.5 exposure markedly decreased tyrosine phosphorylation of insulin 
receptor substrate-1 (IRS-1) and the recruitment of PI3-kinase p85 subunit to IRS-1.
Conclusions: PM2.5 exposure aggravates insulin resistance, attenuates nitric oxide 
release and impairs vasorelaxation through downregulation of IRS-1/PI3-Kinase/Akt/
eNOS pathway, suggesting an important new link between air pollution and insulin 
resistance.
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1014-160 Noninvasive Estimation of Left Ventricular Filling 
Pressure by E/e’ Is a Powerful Predictor of Major 
Adverse Cardiac and Cerebrovascular Events in 
Patients With A First ST Elevation Acute Myocardial 
Infarction
Noriaki Iwahashi, Kazuo Kimura, Jun Okuda, Kengo Tsukahara, Yoshio Tahara, Kiyoshi 
Hibi, Masami Kosuge, Toshiaki Ebina, Shinnichi Sumita, Toshiyuki Ishikawa, Kazuaki 
Uchino, Satoshi Umemura, Yokohama City University Medical Center, Yokohama, Japan, 
Yokohama City University Hospital, Yokohohama, Japan
Background: The early diastolic velocity of mitral valve annulus (e’) combined with 
measurement of early transmitral flow velocity(E), the resultant ratio (E/e’) correlates 
well with mean left ventricular filling pressure. Echocardiographical parameters(including 
E/e’>15, left atrial volume index≥32ml/m2, ejection fraction<40%) and BNP>180pg/ml 
at 3-4weeks after onset have been reported as a powerful prognostic marker of acute 
myocardial infarction(AMI). However, there is no study in which patients with first ST 
elevation(STE)MI were exclusively involved. We examined which is a most reliable 
prognostic marker for a first STEMI.
Methods: Echocardiography and blood sampling were obtained in consecutive 
235 patients 3 weeks after onset of first STEMI(age=64.0y.o., male=187, 
LMT=4•LAD=108•RCA=101•LCx=22). All patients underwent PCI and were followed 
for 12months. Primary end point was major adverse cardiac and cerebrovascular 
events(MACCE: death from cardiovascular disease, re-infarction and ACS, readmission 
because of heart failure, and cerebral infarction). Exclusion criteria were non-STEMI, A-C 
bypass, atrial fibrillation and renal failure on dialysis.
Results: MACCE was occurred in 22 patients (2patients died of heart failure and 6patients 
had non-fatalMI or ACS, 12 with readmission because of heart failure, 1 with arrhythmia, 
3 with stroke). E/e’>15 was a most powerful predictor of MACCE.
Conclusion: E/e’ >15 is a powerful predictor of MACCE within 12 months after a first 
STEMI.
2:00 p.m.
1014-161 Atorvastatin Inhibits Hypercholesterolemia-Induced 
Glomerular Proliferation and Matrix Production via the 
Lrp5/Wnt Pathway
Tullio Manca, Frank C. Caira, Amy L. Flores, Nalini M. Rajamannan, Northwestern 
University, Chicago, IL
Background: Recent studies link early renal insufficiency with cardiovascular risk 
factors. Chronic renal nephrosclerosis is a common cause for end stage renal disease, 
the cellular mechanisms are not well known. We studied a model of hypercholesterolemic 
with and without atorvastatin to determine the Wnt/Lrp5 activation of nephrosclerosis 
which is regulated by Notch Signaling. Methods: 48 rabbits were assigned to one of 
3 groups: chol (0.25%) diet, chole (0.25%) plus atorvastatin (2.5 mg/kg), and control 
diet for six months, and serum creatnine levels were measured. Immunohistologic 
staining, RTPCR and Western Blots were performed. Atherosclerosis was tested by 
immunohistochemistry: macrophage, α -actin smooth muscle, and Proliferating Cell 
Nuclear Antigen. Bone formation were determined by osteopontin, osteocalcin, p42/44, 
Lrp5, and Wnt. Results: Serum creatnine, macrophage, αbone matrix marker, Lrp5, Wnt, 
β-catenin, Sox 9, Notch 1 and PCNA, were increased in the vascular glomeruli from the 
chol treated rabbits. *p value ≤ 0,001 compared to cnt.°p value ≤ 0,001 compared to 
chol treated.’’ p value ≤ 0,005,† p value ≤ 0,05 compared to cnt Atorvastatin decreased 
the amount of atherosclerosis, proliferation and bone matrix expression in the glomeruli. 
Conclusion: Glomerular atherosclerosis is regulated by the Lrp5/Wnt that is modified 
with the use of a lipid-lowering agent. These results may have implications in the slowing 
of progression of glomerular disease in patients who have hyperlipidemia.
Cnt Chol Chol+Lip
Notch1 1.06+/- 0.00 0.24+/- 0.00* 1.04+/- 0.00°
Cbfa1 0.37+/- 0.00 0.54+/- 0.00* 0.34+/- 0.00°
Sox9 0.52+/- 0.00 0.96+/- 0.00’’ 0.65+/- 0.00°
Wnt3 0.52+/- 0.00 0.96+/- 0.00’’ 0.65+/- 0.00°
OP 0.55+/- 0.00 0.99+/- 0.00* 0.75+/- 0.00°
OCN 0.13+/- 0.00 0.26+/- 0.00 0.16+/- 0.00
Creatnine 0.9+/-0.03 1.3+/-0.43† 1.12 +/-0.25
2:00 p.m.
1014-162 Endothelial Progenitor Cells Exist in Abundance in 
Adipose Tissue but not in Peripheral Blood
BARRY A. BOILSON, Harald Froehlich, Adriana Harbuzariu, Allan B. Dietz, Tyra A. Witt, 
Laurel S. Kleppe, Rajiv Gulati, Robert D. Simari, Mayo Clinic, Rochester, MN
Background: The localization and quantification of endothelial progenitor cells (EPCs) is 
controversial. EPCs are believed to exist in circulating blood and have been defined as 
cells co-expressing CD34 and VEGFR2. Cells of alleged endothelial phenotype have been 
grown in culture from both blood-derived and adipose tissue (AT) cells, but recently the 
true endothelial nature of cells grown from blood has been questioned. We hypothesized 
that CD34+ cells in blood and AT are distinct in phenotype and differentiation potential.
Methods: Human omental fat samples from consenting patients undergoing bariatric 
surgery were obtained and were minced, digested with collagenase and cells were 
extracted. Human mononuclear blood cells were extracted by density gradient 
centrifugation from leukopheresis cones derived from healthy platelet donors. CD34+ cells 
were isolated with >90% purity using magnetic beads and analyzed by flow cytometry for 
CD34, CD45 and VEGFR2 expression. The CD34+ and negative fractions were cultured 
in endothelial growth medium (EGM) and hematopoietic progenitor cell (HPC) growth 
medium. Cells were counted every 48 hours and analyzed by flow cytometry at 7 days.
Results: CD34+ cells isolated from blood were CD45(dim)+ and VEGFR2(-). CD34+ 
cells from blood did not demonstrate attachment or growth in EGM but grew rapidly in 
HPC culture medium. At 7 days cells remained CD45+ but VEGFR2(-) and lost CD34 
expression. In contrast, CD34+ cells isolated from AT were CD45(-) but VEGFR2+. With 
culture in EGM they attached and proliferated rapidly. At 7 days cells remained CD34+ 
and VEGFR2+, but CD45(-). Only a minority of AT cells from the more numerous negative 
fraction attached and no endothelial colonies were formed.
Conclusions: CD34+ cells in blood and in AT are different in antigenic profile and behavior 
in culture. Purified CD34+ cells from blood have the antigenic profile of HPCs and do 
not grow in EGM. In contrast, CD34+ cells from AT fit the antigenic profile of EPCs 
and proliferate rapidly in EGM producing cells of endothelial phenotype. We conclude 
therefore that EPCs can be readily identified and extracted from AT in contrast to whole 
blood where HPCs are the predominant CD34+ cell type.
2:00 p.m.
1014-163 Differentiation of Bone Marrow-derived Lineage 
negative cells into Insulin-producing β cells in vitro and 
in vivo
shoukang zhu, Yongjun Li, Brian H. Annex, Pascal J. Goldschmidt-Clermont, Chunming 
Dong, Duke University Medical Center, Chapel Hill, NC
Background: Type I Diabetes results from autoimmune destruction of pancreatic insulin-
secreting β cells. Regeneration of β cells could provide a cure for diabetes. Bone marrow 
harbors precursor cells that have the capacity to differentiate into cells of multi-lineages, 
including β cells. The Aim of this study was to evaluate the potential capability of lineage 
negative bone marrow (Lin-BM) cells to differentiate into β cells in vitro and in vivo, 
restoring islet function after injury and reducing hyperglycemia using a mouse model of 
chemically induced type I diabetes.
Methods: Lin-BM cells were cultured in DMEM in the presence of glucose, IGF-1 and 
EGF. Eight week-old female C57BL/6 mice were injected intravenously with Alloxan 
monohydrate. Animals with blood glucose levels >300 mg/dl were considered diabetic. 
5x105 fresh or cultured Lin- BM cells isolated from 5 week-old GFP+ male mice or 
saline was injected via tail vein at 4 weeks after alloxan treatment, and the injection was 
repeated every two weeks for 12 weeks. Immunostaining of mouse GFP, CD31, insulin-
1 and Glucose transport-2 (Glut-2) was performed on serial sections to determine the 
engraftment and identity of mouse GFP+ cells and islet regeneration in the mice.
Results: Lin-BM cells efficiently differentiated into insulin-producing β cells in vitro. Mice 
received cell injection had higher survival rate (100%) as compared with control mice 
(50%). Cells expressing mouse GFP were detected in the pancreatic ducts and islets with 
no evidence of cell fusion. Colocalization of GFP and CD31 were found in the ductal and 
islet regions. Importantly, colocalization of GFP and insulin-1/or Glut-2 were found in 31-
42 % cells in the islets. The number of islets was increased in cell treated groups. Mean 
blood glucose levels in fresh cell treated mice were decreased by 34% at the end point 
relative to saline injection. Fresh cells were 22% more effective than cultured cells.
Conclusions: Lin-BM cells contain precursors capable of homing, engraftment, and 
differentiation into ductal epithelial cells, endothelial cells and islet β cells, restoring islet 
function. These data implicate a potential therapeutic role for bone marrow transplantation 
in diabetes
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1014-164 Myeloperoxidase, Subclinical Atherosclerosis, and 
Cardiovascular Disease Events
Nathan D. Wong, Heidi Gransar, Jagat Narula, Leslee J. Shaw, Donna Polk, Johanna 
Moon, Lisa Miranda-Peats, Daniel S. Berman, University of California, Irvine, Irvine, CA, 
Cedars-Sinai Medical Center, Los Angeles, CA
Background: Myeloperoxidase (MPO) is a leukocyte-derived enzyme generating 
reactive oxidant species which may be atherogenic. We evaluated if MPO predicts future 
cardiovascular disease (CVD) events in asymptomatic adults, and whether pre-existing 
atherosclerosis may affect this relation.
Methods: We studied 1,212 adults (mean age 59 years, 47% female) without known CVD 
followed for an average of 3.2 years. MPO was measured using an immunoassay (Biosite, 
Inc.); elevated levels were defined as the highest quartile (>356 pM). Coronary artery 
calcium (CAC), a measure of subclinical atherosclerosis, was measured by computed 
tomography and categorized as none/minimal (0-9), mild (10-99), and moderate/significant 
(>100). Cox regression, adjusted for age, gender, and other risk factors, examined the 
relation of CAC and/or MPO with incident CVD events.
Results: Incident CVD events were more likely in those with (4.5%) vs. without (2.4%) 
elevated MPO levels (unadjusted hazard ratio [HR] = 1.89, p=0.053), although this was 
attenuated after adjustment (HR=1.65, p=0.14). CAC was strongly related to CVD events 
(HR=11.4, p<0.0001 for those with scores of >100 vs. 0-9). Combining CAC and MPO 
categories, CVD incidence ranged from <1% in those with CAC 0-9 (w/low or high MPO) 
to 13.3% in those with CAC >100 and high MPO (adjusted HR=16.4, p<0.0001). 
CAC 
Score
MPO 
Level
Incidence (%) of CVD 
Events
Adjusted HR (95% 
confidence interval) p-value
0-9 <356 pM 3/483 (0.62%) 1.0 (reference)
0-9 >356 pM 1/145 (0.69%) 1.02 (0.11-9.8) 0.99
10-99 <356 pM 6/214 (2.8%) 3.9 (0.9-16.0) 0.06
10-99 >356 pM 2/70 (2.9%) 4.0 (0.6-24.3) 0.14
>100 <356 pM 15/204 (7.4%) 9.5 (2.6-35.0) 0.0007
>100 >356 pM 12/90 (13.3%) 16.4 (4.2-63.4) <0.0001
Conclusions: Our study suggests increased levels of MPO appear to confer added risk of 
CVD events, especially in the presence of pre-existing subclinical atherosclerosis.
2:00 p.m.
1014-165 The metabolic syndrome is more strongly associated 
with cell adhesion than inflammation
Tora Leong, Catherine McGorrian, Anthony Fitzgerald, Jane Fogarty, Peter Gaffney, 
Gerard Boran, David Moore, Niall Mulvihill, Ian Graham, Adelaide & Meath Hospital, 
Dublin, Ireland, St James’s Hospital, Dublin, Ireland
Introduction: The metabolic syndrome (MS) has been associated individually with 
markers of inflammation and coagulation. This study examined the association of the 
MS with these risk markers (CD40 ligand, VCAM, P-selectin, fibrinogen, hsCRP and 
homocysteine) both individually and in combination.
Methods: We recruited 730 consecutive patients in 2 centres undergoing elective day case 
coronary angiography excluding patients who had a recent acute coronary syndrome (1 
month), acute infection, chronic inflammatory and malignant disease, renal impairment 
and hypothyroidism. The AHA 2005 definition of the MS was used.
Results: The prevalence of the MS was 42%. The table compares median levels of the 
markers in patients with and without the MS. 
CD40 ligand 
(pg/ml)
VCAM 
(ng/ml)
P-selectin 
(ng/ml)
Fibrinogen 
(g/L)
hsCRP 
(mg/L)
Homocysteine 
(µmol/L)
Without MS 170 631 50 2.9 1.7 9.9
With MS 186 654 54 3.0 2.3 9.9
P value 0.047 0.47 0.0007 0.06 0.0001 0.9
There was a graded association between median levels of the risk markers with the number 
of MS components (0 to 5): CD40 ligand (171, 171, 170, 179, 190, 208, p=0.01), hsCRP 
(0.9, 1.5, 1.8, 2.0, 2.9, 4.1, p<0.001) and P-selectin (50, 47, 53, 54, 54, 60, p<0.001). In 
a multivariable logistic regression with age, sex, creatinine, smoking, statin use and the 
above risk markers in combination, only P-selectin (OR 1.4, p<0.001 for a 1 SD or 16 ng/ml 
increase) and statin use (OR 1.5, p=0.03) independently predicted the MS.
Conclusions: The MS is associated individually with markers of inflammation (CD40 
ligand and CRP) and cell adhesion (P-selectin). In combination however, only P-selectin 
is independently associated with the MS.
2:00 p.m.
1014-166 Disruption of a Hepatocyte Growth Factor / c-Met 
Receptor Axis Severely Impairs the Potency of 
Pluripotent Adipose Stromal Cells
Brian H. Johnstone, Liying Cai, Todd G. Cook, Dongni Feng, Dmitry O. Traktuev, 
Liang Zhong, Elliot D. Rosen, Keith L. March, Indiana University School of Medicine, 
Indianapolis, IN
Background Paracrine stimulation of repair, rather than direct tissue regeneration, is 
increasingly accepted as a major mode of therapeutic stem and progenitor cell action. 
Adipose-derived stem cells (ASCs) secrete many factors, promote reperfusion and 
facilitate tissue repair in ischemia models. We have recently provided the first direct 
demonstration in vivo that secretion of a factor by ASCs is essential for promoting 
this effect. In that study RNA interference silencing of hepatocyte growth factor (HGF) 
expression resulted in significant attenuation of ASCs ability to promote repair of ischemic 
tissues. In the present study we determined the exact mechanisms leading to this effect.
Methods and Results Dual-cassette lentiviral vectors, expressing GFP and either a small 
hairpin RNA (shRNA) specific for HGF mRNA (shHGF) or a control sequence (shCtrl), were 
used to stably transduce ASCs (ASC-shHGF or ASC-shCtrl). ASC-shHGF, which secreted 
5-fold less HGF, were less able to withstand serum withdrawal compared to ASC-shCtrl 
(p<0.05). Activation through the HGF receptor (c-Met) of downstream survival pathways, 
such as PI3K/Akt, was significantly reduced in ASC-shHGF. Both cells types were 
systemically infused into mice after inducing unilateral hindlimb ischemia. Gastrocnemius 
muscles from normal and ischemic limbs were analyzed for total GFP-labeled ASCs as 
well as apoptosis by TUNEL assay. While there was no difference in total GFP+ cells in 
ischemic limbs at 1 and 5 d after infusion, indicating similar homing potentials, 3-fold fewer 
ASC-shHGF were present in ischemic tissues by 20 d compared to ASC-shCtrl (p<0.01). 
Increased TUNEL-positive ASC-shHGF cells (61 + 0.1%) compared to ASC-Ctrl (41% 
+ 3.2%) were observed in ischemic tissues at 5 d (p<0.01); suggesting that attenuated 
potency of ASC-shHGF was related to reduced survival in ischemic tissues.
Conclusions These results indicate that secretion of HGF is critically important for ASC 
potency. In addition to promoting endogenous repair, the data suggest that a HGF/c-Met 
axis is critical for promoting ASC survival in ischemic tissue. Enhanced donor cell survival 
is an important goal for increasing the efficacy of cell therapy.
2:00 p.m.
2:00 p.m.
1014-168 Circulating Levels of Soluble Form of LR11, A Novel 
Migration Regulator of Intimal SMC, Are Increased in 
Subjects with Coronary Stenosis
Mao Takahashi, Hideaki Bujo, Meiji Jiang, Kenji Ohwaki, Hirofumi Noike, Wolfagang 
J. Schneider, Yasushi Saito, Kohji Shirai, Toho University School of Medicine Sakura 
Hospital, Sakura, Japan, Chiba University Graduate Scool of Medicine, Chiba, Japan
Background: Soluble form of LR11 (sLR11), a member of LDL receptor gene family, is 
specifically produced by intimal smooth muscle cells (SMCs) and enhance migration of 
intimal SMCs via activation of signal pathways initiated by urokinase-type plasminogen 
activator receptor. Targeted disruption of the LR11 gene drastically reduces intimal 
thickness of femoral arteries after cuff placement in mice. Here, we show that elevated 
circulating level of sLR11 is a novel predictor for the development of coronary stenosis. 
Methods: Ninety-six subjects (mean age, 65 years, 69% men) were divided to two groups 
based on their angiographycal findings: coronary stenosis (CS) and normal coronary 
arteries (NCA). Plasma sLR11 level was immunologically determined using a specific 
polyclonal antibody against human sLR11. RESULTS: There were no significant difference 
between the CS and NCA groups in age, BMI, and plasma levels of LDL-cholesterol 
and triglycerides. The plasma sLR11 levels were significantly increased in the CS group 
compared with the NCA group (5.0 + 2.8 vs 3.8 + 1.6 U, P<0.05), and moreover, gradually 
increased in relation to the number (0, 1 and 2) of stenotic vessels in the CS group. The 
sLR11 levels were positively correlated with high-sensitivity CRP levels (r=0.25, P<0.05). 
Multiple regression analysis revealed that the association of plasma LR11 levels with the 
development of CS remained significant (β=0.22, P<0.01) when controlling for traditional 
atherosclerotic risk factors including sex, HDL-cholesterol, hypertension and diabetes 
mellitus. Conclusion: Circulating sLR11 level is a novel biomarker for the development of 
coronary stenosis and/or atherosclerosis.
2:00 p.m.
1014-169 Fas and Fas-Ligand as Indices of Apoptosis in Patients 
With Impaired Glucose Tolerance Following Acute 
Myocardial Infarction
Shahirose S. Jessani, Vellore J. Karthikeyan, Teri Millane, Gregory YH Lip, University 
Department of Medicine, City hospital, Birmingham, United Kingdom, Basildon and 
Thurrock University Hospital, Basildon, United Kingdom
Background: Impaired glucose tolerance (IGT) post acute myocardial infarction (AMI) 
is largely ignored despite evidence of poorer clinical outcome. We hypothesized that 
apoptotic cell death following AMI measured by an increase in soluble Fas (sFas) and Fas 
ligand (sFas-L), two transmembrane glycoproteins involved in apoptosis, would be more 
pronounced in IGT patients compared to those with normal glucose tolerance (NGT).
Method: Non-diabetic patients presenting with AMI underwent oral glucose tolerance 
testing 3-5 days after admission. Apoptosis was assessed by measuring sFas and sFas-
L levels in the fasting state, and after 75 g glucose load. sFas and sFas-L levels were 
measured by enzyme linked immunosorbent assay.
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Results: 125 patients [mean (SD) age 59 (12.5) yrs; 107 (86%) male] were studied. 
Baseline levels of sFas were higher in IGT patients versus NGT patients (p < 0.01), with 
a significant increase in sFas levels in response to glucose challenge in the IGT and DM 
groups (Table 1). There was no significant difference in sFas-L levels between the groups 
both pre and post glucose challenge.
Conclusion: IGT post AMI is associated with significantly higher levels of sFas when 
compared with NGT. Further increase in sFas appears to occur in response to a rise in 
plasma glucose levels. The increase in sFas may play a role in the pathophysiological 
mechanisms of IGT and its associated adverse cardiac events post AMI.
Table 1: sFas and sFasLigand levels by baseline glycaemic status post acute myocardial 
infarction 
sFas levels 
median (IQR)
Normal glucose 
tolerance 
(n = 52)
Impaired glucose 
tolerance 
(n= 48)
Diabetes 
mellitus 
(n = 25)
Fasting 4 (3-6) 6 (4-9) * 6 (5 - 8)*
2-h post glucose 
challenge 4 (3 -6) 7 (4 - 10)*a b 6.5 ( 4 - 10)*a b
Between group analyses by Kruskal-Wallis with Dunn’s post hoc test. 
Pre and post glucose challenge analysis by Wilcoxon signed ranks test. 
* Significantly higher (p < 0.01) compared to NGT 
a Significantly higher sFas levels at 2-hour post glucose challenge (p < 0.01) 
b Significantly higher sFas levels compared to NGT group (p < 0.05).
2:00 p.m.
1014-170 Myocardial Regeneration Therapy With Adeno-
Thioredoxin Gene Delivery Attenuates Ischemic 
Cardiomyopathy in Diabetic Rats
Ramesh Vidavalur, Mahesh Thirunavukkarasu, Srikanth Koneru, Suresh Varma 
Penumathsa, Lijun Zhan, Nilanjana Maulik, University of Connecticut Medical Center, 
Farmington, CT
Objective: Diabetic patients manifest an increase in morbidity and mortality with higher 
incidence of heart failure after myocardial infarction (MI). Decreased collateral vessel 
formation and impaired functional recovery play a significant role in diabetes induced 
ischemic cardiomyopathy. Our prior studies have demonstrated cardioprotective role 
of redox regulator, thioredoxin (Trx1), in transgenic mouse hearts, showing improved 
post-ischemic ventricular recovery and reduction in infarct size. In the present study, we 
examined the ability to augment angiogenesis and to prevent heart failure by inducing 
over expression of Trx1 in diabetic rat MI model. Methods: Streptozotocin induced 
diabetic rats in experimental group underwent left anterior descending coronary artery 
ligation followed by either intramyocardial delivery of Trx-1 adenoviral vector (Ad-Trx-1) 
or LacZ adeno vector (Ad-LacZ). Hearts were explanted for infarct size, measurement 
of apoptosis, immunohistochemistry, arteriolar and capillary density. In vivo myocardial 
function was analyzed by echocardiography after 4 weeks. Results: Trx-1 hearts exhibited 
reduced infarct size (42% vs 53% P < .05) as compared with Lac Z controls along with 
increased capillary and arteriolar density (2.68 vs 1.69 P < .05) and significant reduction 
in apoptosis (1.33 vs 2.73 P < .05) . Immunohistochemical analysis demonstrated local 
myocardial overexpression of VEGF, heme oxygenase and thioredoxin in Trx treated 
animals. Echocardiographic analysis revealed significant increase in ejection fraction (58% 
vs 52% P < .05), improved fractional shortening (35% vs 30% P < .05), decreased E/A 
ratio (2.72 vs. 4.26 P < .05) in the group that received Trx1. Conclusions: In failing hearts, 
targeted delivery of Trx1 decreases infarct size, induces angiogenesis and improves 
hemodynamic function, as measured by echocardiography. Altogether, our results indicate 
dual effectiveness of Trx-1 in diabetic animals in promoting neovascularization and 
augmenting protective as well as regenerative response in ischemic rat myocardium.
2:00 p.m.
1014-171 Enhancement of Collagen Expression by Over-
Expression of TGFβ1 in Mouse Cardiac Fibroblasts: 
Involvement of LOX-1 Dependent Redox-Sensitive 
Pathway
Changping Hu, Abhijit Dandapat, Liuqin Sun, Junaid A. Khan, Yong Liu, Paul L. 
Hermonat, Jawahar L. Mehta, University of Arkansas for Medical Science, Little Rock, 
AR, VA Medical Center, Little Rock, AR
Background: Both angiotensin II (Ang II) and transforming growth factor β1 (TGFβ1) are 
thought to relate to cardiac fibrosis. Interactions between Ang II and TGFβ1 have been 
well documented. We have earlier shown that Ang II via type 1 receptor (AT1R) activation 
upregulates the expression of LOX-1, a lectin-like receptor for oxidized LDL, and activation 
of LOX-1 in turn upregulates AT1R expression. Whether LOX-1 mediates TGFβ1-mediated 
cardiac remodeling remains unclear. This study was designed to examine the postulate 
that LOX-1 mediates Ang II- TGFβ1 interaction with regard to cardiac fibrosis.
Methods and Results: TGFβ1 was over-expressed in cultured cardiac fibroblasts from wild-
type and LOX-1 knockout mice by transfection with adeno-associated virus type 2 vector 
carrying the TGFβ1ACT (active TGFβ1) gene (thereafter refer to as AAV/TGFβ1ACT). 
Transfection with AAV/TGFβ1ACT for 3 days in cardiac fibroblasts markedly enhanced 
the expression of collagen type I and III and soluble collagen level concomitant with 
an increase in LOX-1 expression. The TGFβ1-mediated increase in collagen synthesis 
was much less pronounced in cardiac fibroblasts from LOX-1 knockout mice (P<0.01 vs. 
wild-type mice fibroblasts). Further, collagen synthesis in cardiac fibroblasts in response 
to TGFβ1 over-expression was found to be markedly reduced by pretreatment with 
angiotensin converting enzyme inhibitor lisinopril, AT1R blocker losartan, NADPH oxidase 
inhibitor apocynin, anti-LOX-1 antibody, p38 MAPK inhibitor SB203580 and p44/42 MAPK 
inhibitor U0126. Activation of p38 and p44/42 MAPKs by TGFβ1 over-expression was 
also blocked by lisinopril, losartan, apocynin and anti-LOX-1 antibody. Importantly, LOX-1 
expression induced by TGFβ1 over-expression was also inhibited by lisinopril, losartan, 
apocynin and anti-LOX-1 antibody, but not by SB203580 and U0126.
Conclusions: These findings suggest that Ang II-TGFβ1 -induced collagen synthesis in 
cardiac fibroblasts involves activation of NADPH oxidase-MAPKs pathway, and LOX-1 
plays a key role in this process.
2:00 p.m.
1014-172 Liposome Based Vascular Endothelial Growth Factor-
165 Transfection With Skeletal Myoblast for Cardiac 
Angiomyogenesis
Lei Ye, Husnain Kh Haider, RuSan Tan, WeeChi Toh, LiPing Su, Peter K. Law, Wei 
Zhang, YeanTeng Lim, Eugene KW Sim, National University of Singapore, Singapore, 
Singapore
Background: We investigated the feasibility and efficacy of cholesterol+ DOTAP liposome 
(CD liposome) based human vascular endothelial growth factor-165 (hVEGF165) gene 
transfer into human skeletal myoblasts (hSkM) for cardiac repair.
Methods: The feasibility and efficacy of CD liposome for gene transfer with hSkM was 
characterized using plasmid carrying enhanced green fluorescent protein (pEGFP). 
The gene transfection efficiency was determined by flow cytometry. Based on 
optimized transfection procedure, hSkM were transfected with CD lipoplexes carrying 
plasmid-hVEGF165 (CD-phVEGF165). The gene expression mode of hVEGF165 was 
characterized. The genetically modified hSkM was transplanted into rat heart model of 
acute myocardial infarction: group-1 = DMEM injection, group-2 = CD transfected hSkM 
transplantation, group-3 = CD-phVEGF165 transfected hSkM (CD-phVEGF myoblast) 
transplantation. All animals received cyclosporine injection from 3 days before and until 4 
weeks after treatment. Then, animals were sacrificed for immunohistochemcial studies.
Results: Flow cytometry revealed that about 7% hSkM was successfully transfected with 
pEGFP. Based on the optimized transfection condition, transfected hSkM expressed 
hVEGF165 up to day-18 (0.825± 0.08 ng/ml) with peak at day-2 (8.98± 0.55 ng/ml) 
with >90% cell viability. Animal studies revealed reduced apoptosis was found in group-
2 and group-3 animal’s heart as compared to group-1. Blood vessel density (x400) by 
immunostaining for PECAM-1 in group-3 was 19.67± 0.37 (p<0.05) as compared to 
group-1 (9.64± 0.28) and group-2 (11.86± 0.48) at 4 weeks. Significantly improved blood 
flow (ml/min/g) of left ventricular anterior wall was achieved by group-3 (1.87± 0.04, 
p<0.05) as compared with group-1 (0.77± 0.03) and group-2 (1.28± 0.08) at 4 weeks. 
Improved ejection fraction was achieved in group-3 (56.37± 2.5 %) and group-2 (51.02± 
3.44%) as compared with group-1 (39.84± 1.0 % p<0.05).
Conclusions: Though gene transfection efficiency using CD liposome mediated hVEGF165 
gene transfer with hSkM is low; hVEGF165 gene expression efficiency is sufficient to 
induce neovascularization, improve blood flow and injured heart function.
2:00 p.m.
1014-173 Oncostatin M-enhanced Vascular Endothelial Growth 
Factor Production by Human Vascular Smooth Muscle 
Cells is Attenuated by Interferon-gamma
Svitlana Demyanets, Christoph Kaun, Gersina Rega, Philipp Hohensinner, Kathrin 
Rychli, Stefan Pfaffenberger, Gerald Maurer, Kurt Huber, Johann Wojta, Medical 
University of Vienna, Vienna, Austria, Wilhelminenhospital, Vienna, Austria
Background. Vascular endothelial growth factor (VEGF) is present in atherosclerotic 
lesions and involved in blood vessel growth and in the regulation of the expression of 
prothrombotic and proinflammatory mediators in monocytes and endothelial cells at these 
sites. Oncostatin M (OSM) is a member of the glycoprotein 130 (gp130) receptor cytokine 
family. It is controversial whether interferon-γ (IFN-γ), which is expressed at high levels in 
atherosclerotic lesions, promotes or attenuates vascular remodeling in hyperproliferative 
vascular disorders, such as neointima formation after balloon injury. Methods. Human 
coronary artery smooth muscle cells (HCASMC) and human aortic SMC (HASMC) 
were treated with the gp130 ligands OSM, cardiotrophin-1, cardiotrophin-like cytokine, 
ciliary neurotrophic factor, IL-6, IL-11 or leukemia inhibitory factor. VEGF-A protein was 
determined by a specific ELISA and mRNA specific for VEGF-A, gp130, OSM receptor 
(OSMR), IL-6 receptor (IL-6R) and LIF receptor (LIFR) was detected by RT-PCR. Results. 
Only OSM increased VEGF production significantly in both HCASMC and HASMC up to 
7-fold in a dose- and time-dependent manner. The effect of OSM on VEGF production was 
reproducible in the preparation of HCASMC and HASMC derived from different donors 
(n=7 for HCASMC, n=4 for HASMC). OSM upregulated mRNA specific for VEGF up to 16-
fold in these cells. PI3K inhibitor and p38 MAPK inhibitor, but not JAK/STAT inhibitor, MEK 
inhibitor or JNK I inhibitor abolished OSM-induced VEGF upregulation. HCASMC and 
HASMC were shown to express gp130, OSMR, IL-6R and LIFR. IFN-γ dose-dependently 
reduced OSM-induced VEGF production on protein and mRNA levels in both HCASMC 
and HASMC. Conclusion. We show here that proinflammatory cytokine OSM induces 
VEGF production in vascular SMC. Since activated T-cells and macrophages have been 
found in atherosclerotic lesions we hypothesize that OSM produced by these cells could 
induce VEGF production thereby contributing to plaque angiogenesis and destabilization. 
IFN-γ attenuates OSM-induced VEGF production by vascular SMC. A possible role of 
IFN-γ in attenuating remodeling and neointima formation should be further investigated 
in vivo.
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2:00 p.m.
1014-174 Interferon-beta signaling is enhanced in patients with 
insufficient coronary collateral artery development and 
inhibits arteriogenesis in mice
Stephan H. Schirmer, Imo E. Hoefer, Joost O. Fledderus, Perry D. Moerland, Pieter T. 
Bot, Jan Baan, Jr., José P. Henriques, René J. van der Schaaf, Marije M. Vis, Anton J. 
Horrevoets, Jan J. Piek, Niels van Royen, Academic Medical Center, Amsterdam, The 
Netherlands
Background: Attempts to enhance collateral artery growth in patients were hitherto 
unsuccessful, in contrast to promising data from experimental studies. Arteriogenesis is 
orchestrated by circulating cells. In patients, a large heterogeneity exists in the arteriogenic 
response upon arterial occlusion. We analyzed the transcriptome of circulating cells from 
patients with differing coronary collateralization in order to disclose novel targets to 
stimulate arteriogenesis.
Methods and Results: Collateral flow index (CFI) was measured in 45 non-diabetic 
Caucasian patients with single-vessel coronary artery disease. Patients were grouped 
into collateral responders (CFI>0.21) and non-responders (CFI≤0.21). CD34+ stem 
cells and monocytes were isolated from peripheral blood. Monocytes were stimulated 
with LPS or taken into macrophage culture for 20 hours to mimic their phenotype 
during arteriogenesis. Genome-wide mRNA expression analysis revealed strongly 
increased expression of interferon(IFN)-beta and several IFN-related genes in stimulated 
monocytes from non-responders. Microarray data were verified using RT-PCR and 
ELISA of cell culture supernatants. These data suggest an inhibitory effect of IFNbeta on 
arteriogenesis. Therefore, we analyzed the effect of the IFN-pathway on arteriogenesis 
in a well-established murine hindlimb model of arteriogenesis. Hindlimb perfusion was 
measured 7 days after unilateral femoral artery ligation using fluorescent microsphere 
infusion. Perfusion restoration was attenuated in mice treated systemically with IFNbeta 
compared with controls (31.5±4.1% vs. 41.9±8.2%, p=0.001) and increased in mice 
lacking the IFNalpha/beta receptor (54.3±6.6%, p<0.001 compared to control).
In conclusion, circulating monocytes of patients with differing arteriogenic response 
display differential transcriptomes upon stimulation. Non-responders show increased 
gene expression of IFN-beta and its downstream targets. Exogenous IFN-beta 
application attenuates arteriogenesis in mice, while inhibition of IFN-signaling enhances 
arteriogenesis, providing a novel target for the therapeutic stimulation of arteriogenesis.
2:00 p.m.
1014-175 The impact of plasma pentraxin 3 level for arterial 
stiffness in patients with obstructive sleep apnea
Takatoshi Kasai, Kenji Inoue, Mina Sagara, Takiko Kumagai, Mitsue Kato, Fusae 
Kawana, Tomotaka Dohi, Hisashi Takaya, Kenichi Maeno, Sugao Ishiwata, Minoru Ohno, 
Tetsu Yamaguchi, Koji Narui, Toranomon Hospital, Tokyo, Japan
Background: Obstructive sleep apnea (OSA) is associated with increased risk of 
atherosclerosis. Patients with OSA revealed increased inflammatory makers. Pentraxin 
3 (PTX3) is recently recognized as specific inflammatory marker of vasculature. However 
there are no data investigated PTX3 level in OSA patients.
Methods: Seventy one patients who complaint about habitual snoring were examined 
with polysomnography and classified into 3 groups according to the apnea-hypopnea 
index (AHI); no/mild OSA (AHI<15/h), moderate OSA (15≤AHI<30/h) and severe OSA 
(AHI≥30/h). To measure PTX3, blood samples were obtained and recently established 
high sensitive plasma ELISA assay system was used. For evaluation of atherosclerosis, 
a novel blood pressure-independent arterial stiffness parameter: Cardio-Ankle Vascular 
Index (CAVI) based on the pulse wave velocity was also measured.
Results: There were no significant differences in age, gender, body mass index across 3 
groups. PTX3 was significantly increased in patients with severe OSA than in patients with 
no/mild OSA (Figure). In addition, patients with severe OSA revealed significantly advanced 
atherosclerosis (7.8±1.4, P=0.02 versus no/mild OSA). Multiple regression analysis 
which included CAVI as a dependent variable and PTX3, severity of OSA and others as 
independent variables showed that PTX3 was significantly associated with CAVI (P=0.02).
Conclusions: PTX3 might be a useful maker for the detection of atherosclerosis among 
patients with OSA. 
2:00 p.m.
1014-176 Adiponectin Blocks IL-18-Mediated Endothelial Cell 
Death Through Activation of Akt and Suppression of 
NF-ÎºB-PTEN Signaling
Devang N. Patel, John M. Erikson, Steven R. Bailey, Anthony J. Valente, Bysani 
Chandrasekar, Department of Veterans Affairs, South Texas Veterans Health Care 
System, San Antonio, TX, University of Texas Health Science Center, San Antonio, TX
Background: An inverse relationship between plasma levels of interleukin (IL)-18 and 
adiponectin is thought to be important in the pathophysiology of chronic inflammatory 
diseases such as type II diabetes, coronary artery disease, and metabolic syndrome. 
Endothelial cell death plays an early role in the development and progression of these 
diseases. Previously, we demonstrated that IL-18 is a potent inducer of endothelial 
cell death. Since adiponectin exerts anti-inflammatory and anti-apoptotic effects, we 
investigated whether it blocks IL-18-induced endothelial cell apoptosis.
Methods: Human cardiac microvascular endothelial cells (HCEC) were treated with 
IL-18 (100 ng/ml for 24 h). Cells were incubated with adiponectin (10 µg/ml for 24 h) 
prior to IL-18 addition. Expression of adiponectin receptors 1 and 2 was confirmed by 
RT-PCR; NF-€B activation by ELISA; PTEN by Western blotting; Akt by Western blotting 
with activation-specific antibodies and immunecomplex kinase assays; Bax and Bcl-xL 
by Western blotting; and cell death by MTT assay and ELISA for cytoplasmic mono- and 
oligonucleosomal fragmented DNA.
Results: IL-18 induces (1) NF-€B activation, (ii) PTEN and Bax expression, (iii) suppresses 
Akt activation and Bcl-xL expression, and (iv) stimulates significant cell death in HCEC. 
Further investigation revealed that (v) HCEC express adiponectin receptors 1 and 2, 
and (vi) treatment with adiponectin inhibits IL-18-mediated HCEC death by reversing IL-
18-mediated NF-€B-dependent PTEN expression and restoring phospho-Akt levels. (vii) 
Adiponectin also enhances the expression of Bcl-xL, and suppresses expression of Bax.
Conclusions: Our results indicate that adiponectin blocks IL-18-mediated endothelial cell 
death by activation of pro-survival Akt and Bcl-xL expression, and suppression of pro-
apoptotic NF-€B-PTEN signaling and Bax expression. Since various chronic inflammatory 
conditions including coronary artery disease are characterized by enhanced IL-18 and 
reduced adiponectin expression, enhancing adiponectin expression may have therapeutic 
potential for blocking the pro-apoptotic and pro-inflammatory effects of IL-18.
2:00 p.m.
1014-177 Genetic Polymorphism T45G On Adiponectin Gene As 
A Risk Factor For Coronary Atherosclerosis: Effects On 
Adipokines Expression
Alexios S. Antonopoulos, Dimitris Tousoulis, Charalambos Antoniades, Nikolas 
Koumallos, Carmen Vasiliadou, George Hatzis, Nikos Papageorgiou, Elli Stefanadi, 
Costas Tentolouris, Christodoulos Stefanadis, 1st Cardiology Department, Hippokration 
Hospital, Athens Medical School, Athens, Greece
Background: Evidence suggests that adiponectin, an adipokine facilitating insulin action, 
has antiatherogenic effects. We examined the impact of T45G polymorphism on adiponectin 
gene, on the risk for coronary artery disease (CAD) and we evaluated its impact on the 
expression of adiponectin and other adipokines such as resistin and leptin.
Methods: The study population consisted of 253 subjects: 141 patients with CAD and 
112 healthy controls, matched for age and gender. Genetic polymorphism T45G was 
determined by PCR, while circulating levels of adiponectin, resistin and leptin were 
determined by ELISA, under stable clinical conditions.
Results: The genotype distribution was significantly different between CAD (GG:3(2.1%) 
GT: 37(26.3%) and TT:101(71.6%)) and controls (GG:1(0.9%) GT: 19(17.0%) 
and TT:92(82.1%), p<0.05). The adjusted risk for CAD in this population was 
OR[95%CI]:0.516[0.279-0.954], p=0.035 for 45TT vs 45GT+GG. The 45TT genotype 
was associated with higher levels of adiponectin (10.83±0.93pg/ml) compared to 
45GT+GG genotypes (5.98±2.16pg/ml, p<0.001) among healthy individuals, while 
there was no significant difference between genotypes in the CAD group (14.98±1.59 
vs 14.61±1.18pg/ml respectively, p=NS). Circulating levels of resistin and leptin were 
not significantly different between genotypes in the control group (45TT: 7.1±0.4 and 
13.9±0.8 vs 6.4±0.8 pg/ml and 12.1±1.8 pg/ml, p=NS for both). In the CAD group, leptin 
levels were also similar between 45TT (15.1±2.0pg/ml) and 45GT+GG (13.1±3.5pg/ml, 
p=NS). However, the 45TT genotype was associated with lower resistin (5.6±0.3pg/ml) 
compared to 45GT+GG (7.7±0.8pg/ml, p<0.01), in the CAD group.
Conclusions: The presence of the 45TT genotype in adiponectin gene is associated 
with decreased risk for coronary artery disease. This genotype exerts a striking effect 
on adiponectin expression in healthy individuals, but not in CAD patients. These findings 
suggest that homozygosity for the 45T allele in the adiponectin gene decreases the risk 
for CAD by increasing circulating levels of adiponectin in healthy individuals, while its 
functional effect is masked after the establishment of coronary atherosclerosis.
2:00 p.m.
1014-178 CD4+ CD28null lymphocytes and accelerated 
atherosclerosis in patients with Systemic Lupus 
Erythematosus
Alejandro Recio-Mayoral, Silvia Affinito, Marinela Chaparro-Muñoz, Behnam Zal, John 
Axford, Christina Baboonian, Juan C. Kaski, St George’s Hospital, University of London, 
London, United Kingdom
Background:Patients with systemic lupus erythematosus (SLE) have increased cardiovascular 
morbidity and mortality secondary to accelerated atherosclerosis. An expansion of CD4+ T 
cells lacking the costimulatory molecule CD28 (CD4+CD28null) has been reported in patients 
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with acute coronary syndrome. We sought to assess whether this subset of T lymphocytes are 
associated with early atherosclerotic changes in patients with SLE.
Methods:We assessed circulating CD4+CD28null cell number in 17 SLE patients 
(age 41±11 years; disease duration 11±6 years) without cardiovascular disease or 
conventional coronary risk factors and 15 age and gender matched apparently healthy 
subjects (controls). In SLE patients, global damage and disease activity scores, and 
global and daily mean dose steroids were assessed. In both patients and controls, carotid 
artery intima-media thickness (IMT) and systemic endothelial function via brachial artery 
flow mediated dilation (FMD) were assessed.
Results:Patients and controls showed a similar cholesterol profile (total cholesterol 5.1±1.5 
versus 5.1±1.1 mmol/L, p=0.85; LDL 3.2±1.1 versus 3.1±0.9 mmol/L, p=0.89) and IMT 
(0.55±0.11 mm versus 0.57±0.10, p=0.6). FMD was significantly lower in SLE patients 
compared to controls (2.84±2.25 versus. 6.14 ±2.10, p<0.0001). Circulating CD4+CD28null 
cells were absent in the control group but present in 12 out of 17 patients. The number 
of CD4+CD28null cells showed a significant positive correlation with IMT values (r=0.71, 
p<0.0001) and a significant negative correlation with FMD responses (r=-0.54, p=0.017) in 
SLE patients. Eight patients with persistent expansion of CD4+CD28null T cells, constituting 
over 15% of the total CD4+ compartment, had a stronger reduction in FMD and increased 
IMT compared to SLE patients with <15% CD28 null population (1.38±1.89 versus 
3.88±1.95, p=0.02 and 0.65±0.05 versus 0.52±0.09, p<0.002, respectively ).
Conclusions:Circulating CD4+CD28null lymphocyte numbers are increased in SLE 
patients. These T cells may contribute to cardiovascular disease in these patients.
2:00 p.m.
1014-179 Increased Expression of Oxidation-Specific Epitopes 
and Lp(a) Reflect Unstable Plaques in Human Coronary 
Arteries
Allen Burke, Nathaniel Cresswell, Frank Kolodgie, Renu Virmani, Sotirios Tsimikas, 
CVPath Institute, Inc, Gaithersburg, MD, University of California, San Diego, CA
Background: The distribution of oxidation-specific epitopes (OSE) in coronary 
atherosclerotic lesions has important implications regarding potential imaging and 
therapeutic targets, as well as furthering the understanding of the mechanisms of 
atherosclerotic plaque progression.
Methods: We studied 48 coronary artery sections obtained from 11 autopsies of sudden 
coronary death victims. The lesions were sampled to represent progressing plaque types: 
adaptive intimal thickening without lipid pools (n=2), pathologic intimal thickening (PIT) 
with lipid pools in areas of smooth muscle cell death (n=16), early fibroatheroma (FA), 
with diffuse macrophage infiltration of lipid core, but without intralesional fibrin (n=6), late 
FA, with central core necrosis and fibrin (n=9), thin cap FA, with fibrous cap <65 microns 
overlying late core (n=9), and acute plaque rupture (n=4). Morphometric measurements 
were performed on immunohistochemical staining of apoB100, Lp(a) and OSE by 
antibodies E06. The extent of OSE and Lp(a), as well as fraction of apoB100 and Lp(a) 
area with OSE positivity, was quantitated using serial sections.
Results: Expression of apoB100 was strongest in lipid pools, with lesser expression 
in macrophages and late necrotic cores. In contrast, Lp(a) and OSE were localized 
preferentially within foamy macrophages and late cores. Mean % intimal area with OSE 
was 0 in intimal thickening, 13% in PIT, 24% in early FA, 31% in late FA, 34% in thin cap 
atheroma, and 40% in plaque rupture (p<.0001). Similarly, % area Lp(a) increased from 
16% in PIT to 38% in late cores and acute ruptures (p<.0001). The overall % oxidized area 
was 52% for Lp(a) vs. 26% for apoB100. Although there was no significant difference in % 
area apoB100 by plaque type, % oxidized area for apoB100 increased from 0 in adaptive 
intimal thickening to 100% in acute ruptures (p<.0001).
Conclusion: Coronary atherosclerotic lesions begin as PIT, rich in apoB100. With 
progressive plaque types, the proportion of oxidized lipids and Lp(a) increases, while 
intact apoB100 decreases. The increase of OSE and Lp(a) in advanced and unstable 
plaques provides a strong rationale for use of these targets in imaging and treatment of 
vulnerable plaques.
2:00 p.m.
1014-180 Soluble CD40-ligand Levels Are Associated With 
Vascular Superoxide Production And eNOS Coupling In 
Human Vessels: Interrelationships With Homocysteine 
Biosynthetic Pathway
Charalambos A. Antoniades, Cheerag Shirodaria, Paul Leeson, Otto Baarholm, Alexis 
Antonopoulos, Ravi Pillai, Chandi Ratnatunga, Dimitris Tousoulis, Helga Refsum, 
Christodoulos Stefanadis, Keith M. Channon, University of Oxford, Oxford, United 
Kingdom
Background: Soluble CD40 ligand (sCD40L) a proinflammatory molecule of the tumor 
necrosis factor alpha family released by activated platelets, has a prognostic role in 
atherosclerosis. However, it is unclear whether it has an effect on vascular redox and 
endothelial nitric oxide synthase (eNOS) “coupling”. sCD40L release is affected by 
plasma total homocysteine (tHCy), but it is unclear whether this effect is due to tHCy itself 
or to other aminoacids of tHCy metabolic pathway. We searched for interrelationships 
between plasma sCD40L and aminoacids in the homocysteine biosynthetic pathway, and 
we examined the impact of sCD40L on vascular superoxide production in patients with 
atherosclerosis.
Methods: The study population consisted of 138 patients undergoing CABG (66.6±0.6 yrs). 
Preoperative sCD40L were determined by ELISA while plasma tHCy, total cystathione, 
cysteine, methionine, glutathione and 5-methyl-tetrahydrofolate (5-MTHF) were 
determined by HPLC. Vascular superoxide (O2-) generation was determined in saphenous 
veins (SV) obtained during CABG, by lucigenine enhanced chemiluminescence +/- NOS 
inhibitor LNAME (to determine NOS-derived O2-) and after adding NADPH (to determine 
NADPH-oxidase activity).
Results: sCD40L was significantly associated with total vascular O2- (rho=0.349, 
p=0.009) and LNAME-inhibitable O2- (rho=-0.319, p=0.029), but not with NADPH-
induced O2- (rho=-0.112, p=0.423). In bivariate analysis, sCD40L was associated with 
tHCy (rho=0.317, p=0.0001), cystathione (rho=0.251, p=0.034) and cysteine (rho=0.260, 
p=0.027), but not with methionine (rho=0.082, p=0.498), glutathione (rho=-0.050, 
p=0.679) or 5-MTHF (rho=-0.008, p=0.927). In multiple linear regression, plasma tHCy 
was a predictor of sCD40L (stand.Beta=0.178, p=0.04) independently of 5-MTHF (stand.
Beta=0.003, p=0.970).
Conclusions: Plasma total homocysteine, cysteine and cystathione (but not 5-MTHF) are 
associated with sCD40L levels in patients with atherosclerosis. Importantly, sCD40L is 
significantly associated with vascular superoxide radical production and eNOS coupling 
in humans, suggesting that this molecule may be directly implicated in atherogenesis.
2:00 p.m.
1014-181 Relationships Between Vascular/Plasma Biopterins 
and Endothelial Nitric Oxide Synthase Coupling, 
Endothelial Function And Inflammation, In Human 
Atherosclerosis
Charalambos A. Antoniades, Christodoulos Shirodaria, Paul Leeson, Mark Crabtree, 
Ravi Pillai, Chandi Ratnatunga, Dimitris Tousoulis, Alexis Antonopoulos, Christodoulos 
Stefanadis, Keith M. Channon, University of Oxford, Oxford, United Kingdom
Background: Tetrahydrobiopterin (BH4) is a regulator of endothelial nitric oxide synthase 
(eNOS) coupling but its synthesis is stimulated by inflammation in experimental models. 
We defined for the first time, the relationships between plasma and vascular biopterins 
in patients with coronary artery disease, and we determined the impact of BH4 on 
endothelial function, eNOS coupling, and O2- production in human vessels.
Methods: Paired samples of saphenous veins (SV) and internal mammary arteries 
(IMA) were obtained from 219 patients undergoing CABG. Vasorelaxations of SV to 
acetylcholine (Ach) were determined ex-vivo, and vascular O2- (±LNAME) was measured 
by chemiluminescence. Biopterins were measured by HPLC.
Results: Vascular BH4 was associated with better vasorelaxations to Ach, whereas 
plasma BH4 was associated with worse vasorelaxations (Fig. a-b). There was an inverse 
association between plasma and vascular biopterins (Fig c). High vascular (but not plasma) 
BH4 was associated with lower O2- and less L-NAME inhibitable O2- (suggesting better 
eNOS coupling) in both SV and IMA (Fig c). Serum C-reactive protein was correlated with 
plasma (r=0.268, p=0.001) but not with vascular biopterins.
Conclusions: There is an inverse association between plasma and vascular biopterins 
in patients with atherosclerosis. Vascular but not plasma BH4 is a modulator of eNOS 
coupling in human vessels, while plasma biopterins reflect systemic inflammation, rather 
than vascular function in vivo. 
2:00 p.m.
1014-182 Essential Hypertensive Subjects With Exaggerated 
Blood Pressure Response During Treadmill Test Are 
Characterized by Accelerated Arterial Stiffening and 
Augmented Asymmetric Dimethylarginine Levels
Costas Tsioufis, Kyriakos Dimitriadis, Costas Thomopoulos, Karmen Vasiliadou, 
Dimitris Tousoulis, Dimitris Tsiachris, Christodoulos Stefanadis, Ioannis Kallikazaros, 
Department of Cardiology, Hippokration Hospital, Athens, Greece
Background: A hypertensive response to exercise (HRE) is associated with high risk 
for worsening hypertension, while arterial stiffening and elevations of asymmetric 
dimethylarginine (ADMA) levels are related to atherosclerosis progression. In this study 
we sought to determine the relationships of HRE with ADMA and arterial stiffness in 
essential hypertensives.
Methods: 109 newly diagnosed untreated non-diabetics with stage I to II essential 
hypertension [76 men, mean age=52 years, office blood pressure (BP)=146/94 mmHg] 
with a negative treadmill exercise test (Bruce protocol) were divided into those with HRE 
(n=34) (peak exercise systolic BP ≥210mmHg in men and ≥190 mmHg in women) and 
those without HRE (n=75). In all subjects arterial stiffness was evaluated on the basis of 
carotid to femoral pulse wave velocity (PWV) values, by means of a computerized method 
(Complior SP).
Results: Patients with HRE compared to those without HRE were older (55±9 vs 51±9 
years, p<0.05), had greater 24-h systolic BP (141±13 vs 132±12 mmHg, p<0.05), while 
did not differ regarding metabolic profile and left ventricular mass index (p=NS). Patients 
with HRE as compared to those without HRE exhibited greater levels of ADMA (0.62±0.05 
vs 0.54±0.04 µmol/l, p<0.0001) and PWV (8.9±1.7 vs 7.8±1.2 m/sec, p<0.0001). In the 
total population, ADMA was associated with waist to hip ratio (r=0.216, p<0.05), 24-h 
pulse pressure (r=0.477, p<0.0001) and PWV (r=0.282, p=0.003). Multiple regression 
analysis revealed that 24-h systolic BP (b=0.225, p=0.004), male sex (b=0.290, p=0.01) 
and ADMA (b=0.219, p=0.008) were independent predictors of peak exercise systolic 
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BP. Furthermore, analysis of covariance revealed that ADMA and PWV values remained 
significantly different between groups after adjustment for confounders (p<0.05).
Conclusion: In essential hypertensives, a HRE is accompanied by a state of increased 
arterial stiffening and endothelial dysregulation, as reflected by PWV and ADMA values. 
The association of ADMA with exercise BP response and stiffness suggests that 
endothelium-mediated vascular dysfunction is a mediator of atherosclerosis progression 
and contributes to HRE-related risk in hypertension.
2:00 p.m.
1014-183 Improvement in pulse wave velocity by 2-year-treatment 
of continuous positive airway pressure for patients 
with obstructive sleep apnea complicated by obesity 
and hypertension
Tsunenori Saito, Tsunehiro Saito, Shigeyuki Sugiyama, Kyoichi Mizuno, Toranomon 
Hospital, Tokyo, Japan, Good Sleep Clinic, Tokyo, Japan
Background: Obstructive sleep apnea (OSA) induces atherosclerosis and is associated 
with cardiovascular complications. Brachial-ankle pulse wave velocity (PWV) reflects 
arterial stiffness that indicates degree of atherosclerosis. Continuous positive airway 
pressure (CPAP) for OSA patients contributes to prevent the progression of atherosclerosis 
in short-term observation. However, long-term effect of CPAP for atherosclerosis is still 
unclear.
Methods: Eighty-eight severe OSA patients who were treated with CPAP for 2 years were 
admitted to this study. All patients were male and 4 had diabetes, 35 had hypertension, 
7 had hyperlipidemia and 10 had hyperuricemia. PWV and percent body fat (PBF) were 
measured at the beginning, after 6, 12 and 24 months of CPAP therapy. Patients were 
divided into two groups by PWV changes on 24 months. One whose PWV decreased and 
the other increased; former had 47 patients and the latter 41. Clinical features including 
apnea-hypopnea index (AHI), Epworth sleepiness scale (ESS), basal metabolism, body 
mass index (BMI), PBF, systolic and diastolic pressure and minimal oxygen saturation 
and blood chemistry data were compared between 2 groups.
Results: PWV on all patients decreased in 6 and 12 months (p < 0.005 and 0.025, 
respectively), but no significant changes were seen on 24 months. PBF decreased in all 
patients at 6, 12 and 24 months (p < 0.05, 0.01 and 0.025, respectively). Systolic blood 
pressure and basal metabolism improved in 2-year-observation (p < 0.05 and 0.005, 
respectively). Group of patients whose PWV decreased had higher AHI (70.2 ± 25.2 vs 
60.6 ± 24.5; p < 0.05), ESS (11.6 ± 4.4 vs 9.9 ± 3.7; p < 0.01), basal metabolism (1733 ± 
286 vs 1630 ± 188 kcal; p < 0.05), BMI (30.4 ± 5.4 vs 27.5 ± 3.0; p < 0.005), PBF (30.7 
± 6.2 vs 27.8 ± 6.1%; p < 0.025) and systolic and diastolic pressure (140.5 ± 17 vs 131.4 
± 15 and 89.6 ± 12 vs 83.6 ± 11 mmHg; p < 0.005 and 0.005, respectively) at the point 
of treatment.
Conclusions: PWV decreased after 6 and 12 months using CPAP. Patients whose PWV 
were improved had higher AHI, ESS, basal metabolism, BMI, PBF and blood pressure. 
This suggests that CPAP therapy is effective for the patients with severe OSA who had 
complications such as hypertension and obesity.
2:00 p.m.
1014-184 Role of Shear Stress in Predicting Neointima Distribution: 
Drug-eluting Stents Versus Bare Metal Stents
Michail I. Papafaklis, Christos V. Bourantas, Panagiotis E. Theodorakis, Christos S. 
Katsouras, Dimitrios I. Fotiadis, Lampros K. Michalis, Medical School, University of 
Ioannina, Ioannina, Greece
Background: In-stent restenosis (ISR) after bare metal stenting has been associated with 
shear stress (SS). Drug-eluting stents (DES) diminish neointimal growth, but also can 
cause tissue regression and lead to incomplete stent apposition. We investigated the role 
of SS in predicting neointima thickness (NT) following DES implantation against a control 
group with bare metal stents (BMS).
Methods: By using coronary angiography and intravascular ultrasound, we performed 
three-dimensional (3D) artery and stent reconstruction in 24 patients at 6-month follow-
up following implantation of sirolimus-eluting stents (SES; 8 patients), paclitaxel-eluting 
stents (PES; 8 patients) and BMS (8 patients). In-stent SS was calculated by applying 
computational fluid dynamics to the stent reconstruction and NT was determined in 3D 
space. Positive NT represented ISR, while negative NT represented tissue regression 
outside the stent surface and lumen enlargement. SS values were normalized using the 
mean for each patient, and linear regression analysis was performed.
Results: Baseline demographic and procedural characteristics were similar in all groups. 
The mean NT was -0.005 ± 0.06mm (range -1.1 to 0.46mm) in DES [SES: -0.02 ± 
0.09mm (range -0.61 to 0.44mm); PES: 0.03 ± 0.12mm (range -1.1 to 0.46mm)] and 0.2 
± 0.16mm (range -0.1 to 0.83mm) in BMS. Tissue regression was frequently observed in 
DES (48% of all measured in-stent locations; 57% for SES and 37% for PES), while it was 
minimal in BMS (7%). Incomplete stent apposition occurred only in one case with PES. 
In both the DES (r = -0.1, p<0.001) and the BMS (r = -0.29, p<0.001) group a significant 
negative correlation between NT and normalized SS was observed. Separate analysis 
for positive (ISR) and negative (tissue regression) NT in the DES group demonstrated 
a significant negative correlation between ISR and normalized SS (r = -0.28, p<0.001) 
and a very weak positive correlation between tissue regression and normalized SS (r = 
0.06, p<0.001).
Conclusions: ISR is inversely correlated to SS in both DES and BMS, while SS has a 
limited role in tissue regression. These findings support the value of in vivo measuring SS 
during percutaneous coronary interventions.
2:00 p.m.
1014-185 Visceral fat Related Adverse Effects on Arterial Elastic 
Properties Beyond Body Mass Index Levels: Insights from 
the Hippokration Hellenic Hypertension Study (3H Study)
Dimitris Chatzis, Costas Tsioufis, Dimitris Tsiachris, Efstathios Taxiarchou, Costas 
Thomopoulos, Pavlos Pavlidis, Christodoulos Stefanadis, Ioannis Kallikazaros, 
Department of Cardiology, Hippokration Hospital, Athens, Greece
Background: Arterial stiffening and obesity are established risk factors related to adverse 
cardiovascular outcomes. We sought to investigate the plausible associations between 
visceral obesity and arterial stiffness in a large population of overweight essential 
hypertensives.
Methods: From 1344 hypertensives included in the H Study, an ongoing registry of 
hypertension related target organ damage, we separated the overweight ones (n=596, 
341 males, aged 56±12 years, BMI= 25-30 kg/m2). Among overweight subjects 279 
had abdominal obesity according to the ATP III criteria (waist circumference >102cm for 
men and >88cm for women). Arterial stiffness was evaluated in all participants on the 
basis of carotid to femoral pulse wave velocity (PWV), by means of an established non-
invasive method (Complior SP). All participants underwent venous blood sampling for the 
determination of their metabolic profile.
Results: Among overweight hypertensives, those with abdominal obesity compared 
to those without, were older (57.5±11.5 vs. 54.5±13 years, p=0.001), more frequently 
females (59% vs.30%, p<0.001, had increased office systolic blood pressure (148±18 vs. 
144±17 mmHg, p=0.008), office pulse pressure (57.1±16 vs. 53.7±14 mmHg, p=0.002) 
as well as plasma glucose levels (106±12 vs. 100±10 mg/dL, p=0.013) and triglycerides 
levels (135±76 vs. 122±70 mg/dl, p=0.048). Aortic elastic properties were more impaired in 
subjects with abdominal obesity based on increased PWV values (8.35±1.6 vs. 7.95±1.7 
m/sec, p=0.006) even after adjustment for age and sex (adjusted p=0.004). In the total 
population, PWV was related to age (r=0.526, p<0.001), office systolic blood pressure 
(r=0.284, p<0.001), office pulse pressure (r=0.336, p<0.001), waist circumference 
(r=0.147, p<0.001) and plasma glucose levels (r=0.157, p<0.001) but not BMI.
Conclusions: For the same BMI in the overweight range, abdominal obesity is 
accompanied by pronounced arterial stiffening closely related to waist circumference. Our 
findings demonstrate the adverse prognostic role of visceral fat on vascular adaptations 
and partially explain the increased cardiovascular risk in this setting.
2:00 p.m.
1014-186 Diabetes Reduces EPCs in the Bone Marrow and in 
Circulation and Improves with Statin Treatment
Emile R. Mohler, III, Yuquan Shi, Jonni Moore, Drew Bantly, Damir Hamamdzic, Daniel J. 
Rader, Mervin Yoder, Robert L. Wilensky, University of Pennsylvania, Philadelphia, PA
Background: Endothelial progenitor cells (EPCs) are early precursors of mature 
endothelial cells made in the bone marrow that presumably replenish aging and damaged 
endothelial cells that line blood vessels. Patients with DM have endothelial dysfunction 
and accelerated atherosclerosis although the pathological mechanism(s) are poorly 
understood. We studied a diabetic swine model to determine if induction of DM adversely 
affects both bone marrow and circulating EPCs and see if a HMG-CoA reductase inhibitor 
(statin) rescues this deleterious effect.
Methods: One month after induction of DM using streptotozocin, diabetic pigs were given 
atorvastatin (statin, n=10), ezetamibe (inhibits intestinal cholesterol absorption, n=10) or 
no drug (n=10) and evaluated for number of bone marrow and circulating EPCs as well as 
femoral artery endothelial function.
Results: One month after induction and before administration of drugs, the number of bone 
marrow and circulating EPCs decreased dramatically (P<0.001) compared to baseline. 
Three months after DM induction, the number of circulating EPCs was increased with 
atorvastatin compared to ezetamibe (p<0.05, Figure) and untreated animals. The control 
group showed progressive reduction in percentage of flow mediated vasodilatation (no 
dilatation at 3 months) whereas the statin group and ezetamibe had vasodilation, 6% 
and 4% respectively.
Conclusions: DM results in significant impairment of bone marrow and circulating EPCs 
as well as endothelial function. This deleterious effect was improved with statin treatment. 
The effect was ameliorated, in part, by statin treatment. The accelerated atherosclerosis 
seen with DM may be due in part from bone marrow dysfunction.
2:00 p.m.
1014-187 Relationship Between Endothelial, Inflammatory, 
Thrombotic Markers and Large and Small Artery 
Elasticity - Results of the Multi-Ethnic Study of 
Atherosclerosis (MESA) Cohort Study
Daniel A. Duprez, David R. Jacobs, Jr., Pamela L. Lutsey, David M. Herrington, Darryl 
D. Prime, Pamela Ouyang, Graham R. Barr, David A. Bluemke, University of Minnesota, 
Minneapolis, MN
Background: Arterial stiffness is a marker for cardiovascular disease (CVD) morbidity 
and mortality. Endothelial dysfunction, vascular inflammation and arterial thrombosis 
are conditions that could potentially affect large and small arteries. We examined the 
relationship between these biomarkers and large (LAE) and small (SAE) arterial elasticity 
at baseline in blacks, whites, Hispanic and Chinese.
Methods: Pulse wave contour registration at the radial artery was performed using radial 
tonometry in 3,293 women and 3,000 men aged 45-84 years free of overt CVD. LAE 
and SAE were derived from diastolic pulse contour analysis. At baseline, a venous blood 
sample was analyzed for markers in subsets of the sample: endothelial dysfunction, 
(soluble ICAM-1 and E-selectin) , vascular inflammation (hs-CRP, Il-6, soluble interleukin-
2 receptor and CD40 ligand) and thrombotic markers (fibrinogen, also involved in 
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inflammation, and PAI1). Urinary albumin/creatinine ratio (UAC) was determined from a 
morning urine sample and indicates general vascular damage.
Results: Mean LAE was 13.9 ± 4.5 ml/mmHgx10 and SAE was 4.8 ± 2.4 ml/mmHgx100. 
Table 1 presents slope of LAE and SAE (dependent variables) per standard deviation 
(SD) of each biomarker, adjusting for age, race/ethnicity, sex, clinic, height, body mass 
index, heart rate and blood pressure.
Conclusions: These biomarker associations suggest pathways which may mediate an 
association of arterial stiffness with clinical CVD.
Table 1
Biomarker N
LAE 
Slope per biomarker 
SD
LAE 
P trend
SAE 
Slope per biomarker 
SD
SAE 
P trend
sICAM1 2,437 - 0.094 0.33 - 0.240 <0.001
E-Selectin 994 0.085 0.60 - 0.168 0.03
ln (UAC) 6,268 - 0.467 <0.001 - 0.130 <0.001
ln (CRP+1) 6,258 - 0.131 0.04 - 0.223 <0.001
ln (IL6+1) 6,135 - 0.148 0.02 - 0.185 <0.001
sIL-2receptor 994 - 0.433 0.01 - 0.160 0.04
CD40 ligand 994 - 0.428 0.01 0.019 0.81
ln (PAI1) 968 0.298 0.09 - 0.100 0.24
Fibrinogen 6,263 - 0.044 0.48 - 0.136 <0.001
2:00 p.m.
1014-188 Role of the C1236T (rs1128503) polymorphism of the 
MDR-1 Gene on Clopidogrel Responsiveness
Dominick J. Angiolillo, Esther Bernardo, Elisabetta Trabetti, Martina Zanoni, Fernando 
Alfonso, Rosana Hernandez-Antolin, Piera Capranzano, Marco A. Costa, Theodore A. 
Bass, Pier F. Pignatti, Carlos Macaya, Antonio Fernandez-Ortiz, University of Florida-
Shands Jacksonville, Jacksonville, FL, San Carlos University Hospital, Madrid, Spain
Background: Clopidogrel intestinal absorption and active metabolite formation are 
influenced by P-glycoprotein-mediated efflux. The functional activity of P-glycoprotein is 
under genetic control by the Multi Drug Resistance-1 (MDR-1) gene. If genetic variations 
of MDR-1 contribute to variability in clopidogrel response in patients with coronary artery 
disease remains poorly explored.
Methods: The C1236T (rs1128503) polymorphism of the MDR-1 gene was assessed 
in a total of 62 patients. Patients who were homozygous for the wild-type allele were 
compared with those carrying ≥1 variant T allele (dominant model); thus, patients were 
divided into 2 groups: carriers and non-carriers of the T allele. Platelet aggregation was 
performed before and 24 hours after clopidogrel loading dose administration. Standard 
(300mg; n=45) and high (600mg: n=17) loading dose regimens were used. All patients 
were on treatment with aspirin (100mg/day). Peak platelet aggregation was assessed 
by light transmittance aggregometry using 6 µmol/L ADP stimuli. Post-treatment platelet 
reactivity and percentage inhibition of platelet aggregation (IPA) were determined.
Results: The C1236T polymorphism of the MDR-1 gene was in Hardy-Weinberg 
equilibrium; 71% and 29% of the study population were T and non-T allele carriers, 
respectively. At baseline, there were no differences in platelet aggregation between T and 
non-T allele carriers (300mg: 53±17% vs 60±20%; p=0.3; 600mg: 65±10% vs 60±9%, 
p=0.4). At 24 hours there were no differences in post-treatment platelet reactivity between 
groups following a 300mg loading dose administration (35±19% vs 33±15%; p=0.7). 
However, following a 600mg loading dose administration, post-treatment platelet reactivity 
was significantly higher in T allele carriers (35±11% vs 16±3%; p=0.006). Accordingly, 
there were no differences in IPA following a 300mg dose (31±44% vs 43±26%, p=0.3) 
and IPA was significantly lower in T allele carriers following a 600mg dose (44±18% vs 
73±5%, p=0.001).
Conclusions: The C1236T polymorphism of the MDR-1 gene modulates clopidogrel 
responsiveness in the acute phase of treatment when using high, but not standard, 
loading dose regimens.
2:00 p.m.
1014-189 Balance between Pro-oxidants and Anti-oxidants 
Biomarkers in Patients after Percutaneous Coronary 
Intervention; Myeloperoxidase, Oxidized Low Density 
Lipoprotein, and Paraoxonase
Masashi Nakagawa, Shoichi Ehara, Takahiko Naruko, Chizuko Kitabayashi, Yoshihiro 
Ikura, Nobuyuki Shirai, Hiroki Oe, Kenichi Sugioka, Takeshi Hozumi, Akira Itoh, Kazuo 
Haze, Minoyu Yoshiyama, Makiko Ueda, Osaka City University Graduate School of 
Medicine, Osaka, Japan, Osaka City General Hospital, Osaka, Japan
Background: Many lines of evidence support the hypothesis that oxidized low density 
lipoprotein (ox-LDL) plays a critical role in the genesis of the inflammatory process 
in atherosclerotic lesions. Recently, methods have been developed to measure ox-
LDL in blood, using different antibodies and assay procedures. We have previously 
demonstrated that our ox-LDL-measuring method is a sensitive method to detect oxidized 
phosphatidylcholine particles as part of ox-LDL and minimally modified LDL (MM-LDL) 
in circulating plasma. Moreover, there are another two key components for pro-oxidant 
and anti-oxidant: myeloperoxidase (MPO) and paraoxonase (PON). The purpose of 
this study is to investigate the balance between pro-oxidants and anti-oxidants by the 
measurements of ox-LDL, MPO, and PON in the blood in patients with stable angina 
pectoris (SAP) after percutaneous coronary intervention (PCI).
Methods and Results: The study population contained 101 SAP patients who underwent 
elective PCI (PCI group), and 22 patients who underwent coronary angiography (CAG) 
because of chest pain and did not undergo PCI because of angiographically normal 
coronary arteries (control group). Both groups showed a significant increase in plasma 
ox-LDL and MPO levels immediately after procedure (P < 0.0001) compared with those 
at the baseline, and a subsequent decrease from first post-procedural day (PPD) onward 
(P < 0.0001). Interestingly, there was a significant difference in changes of plasma ox-
LDL and MPO levels between the PCI and control groups (P < 0.0001). In contrast, 
serum PON levels immediately after PCI or CAG had decreased significantly (P< 0.0001) 
compared with those at the baseline, and from first PPD a subsequent recovery was 
found in both groups.
Conclusions: Our results suggest that a temporal imbalance between pro-oxidants and 
anti-oxidants may play an important role to determine the extent of LDL oxidation in the 
blood, and that PCI-related plaque injuries with neutrophil activation and MPO release 
may induce excessive generation of pro-oxidants and could cause a temporal increase in 
plasma levels of MM-LDL, detected by our ox-LDL-measuring method.
2:00 p.m.
1014-190 Suppression of Markers of Thrombin Generation and 
Inflammation in Patients Receiving Low Molecular 
Weight Heparin Compared to Unfractionated Heparin 
for TEE-Guided Cardioversion of Atrial Fibrillation: 
Results from the Assessment of Cardioversion Using 
Transesophageal Echocardiography (ACUTE II) 
Randomized Study
Debra A. Hoppensteadt, Jawed Fareed, Allan Klein, Susan Jasper, Carolyn Apperson-
Hansen, Elizabeth Lieber, William Katz, Joseph Malouf, Marcus Stoddard, Loyola 
University Medical Center, Maywood, IL
Background: Atrial fibrillation (AF) represents a cardiovascular syndrome which can lead 
to embolic stroke. Several AF clinical trials have shown a decrease risk of stroke with 
anticoagulation using warfarin. Currently, there are two approaches for anticoagulation 
in AF patients. For outpatients, warfarin therapy is used with the goal of therapeutic 
anticoagulation (INR=2-3). For inpatients requiring cardioversion, unfractionated heparin 
(UFH, IV) is used as a bridge to therapeutic warfarin. More recently, anticoagulation with 
a low molecular weight heparin, enoxaparin has been reported to give a more predictable 
anticoagulant response than UFH in TEE guided cardioversion. The present study 
compares the markers of inflammation and thrombin generation in patients included in 
the ACUTE II study.
Methods: This was a randomized multicenter trial of 155 patients from 17 clinical sites, the 
anticoagulant activity of LMWH (enoxaparin, 1 mg/kg sc bid, Sanofi-Aventis, n=76) was 
compared to that of UFH (APTT 1.5 - 2.5 x control, n=79). Blood samples were drawn 
at enrollment (baseline), day 2 (peri cardioversion) and day 4 in both groups. Day 2 and 
day 4 samples were taken 3-4 hours after the injection of LMWH in patients in the LMWH 
group. Blood samples were evaluated for CRP, CD 40L, MCP-1, Thrombin antithrombin 
complex (TAT) and prothrombin fragment (F 1.2).
Results: The APTT and anti-Xa levels indicated therapeutic anticoagulation was achieved 
(previously reported). In addition both TAT and F1.2 levels were increased at baseline and 
were significantly decreased with LMWH in comparison to UFH. The CRP was decreased 
after treatment in both groups of patients.
Conclusions: These results suggest that AF patients treated with LMWH demonstrate a 
stronger anticoagulant effect as measured by a significant reduction in the markers of 
thrombin generation. Anticoagulation with LMWH in AF patients may be a better alternate 
during TEE cardioversion.
2:00 p.m.
1014-191 Endothelial Serum Markers, Serum Uric Acid and 
Lipoprotein (a), Correlate with Activity of Vasospasm
Masami Nishino, Shinpei Nakatani, Masahiko Hara, Akihito Hashimoto, Kiyoshi 
Yamagami, Ken Matsuoka, Hiroyasu Kato, Yasuyuki Egami, Ryu Shutta, Hitoshi 
Yamaguchi, Kenjiro Tanaka, Jun Tanouchi, Yoshio Yamada, Osaka Rosai Hospital, Sakai, 
Osaka, Japan
Background: It has been reported that cause of vasospastic angina (VSA) is endothelial 
dysfunction of coronary artery and VSA shows variation of activities including circadian 
variation. On the other hands, some studies showed that serum uric acid (UA) and 
lipoprotein (a) correlate with endothelial dysfunction. In this study we examined whether 
these two endothelial serum markers, UA and lipoprotein (a), correlate with VSA activity.
Methods: Consecutive 441 patients with suspected VSA who underwent coronary 
angiogram with acetylcholine provocation (Ach test) for 8 years in our hospital were 
enrolled. We divided our patients into two groups: active VSA group who showed 
coronary spasm by Ach test and non-active VSA group who did not show. We compared 
the following serum markers between the two groups: LDL cholesterol , HDL cholesterol, 
high sensitive C-reactive protein, lipoprotein (a), fibrinogen, total PAI-1, and UA.
Results: UA, hs-CRP, and lipoprotein (a) were significantly higher in active VSA group 
than in non active VSA group (6.1±1.7 vs. 5.5±1.4,0.32±0.90 vs. 0.23±0.29,28.9±29.5 vs. 
21.8±16.4,all p<0.05), while there were no significant differences of the other parameters. 
Multivariate analyses using these three parameters revealed UA and lipoprotein (a) 
reveled significant markers for active VSA (table).
Conclusions: UA and lipoprotein (a) correlate with activity of VSA, and the medical 
intervention to decrease UA and lipoprotein (a) may be effective to control activity of VSA. 
SEE Exp(β) P valve
UA 0.09 1.25 0.01
hs-CRP 0.27 1.42 0.19
lipoprotein(a) 0.01 1.01 0.02
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2:00 p.m.
1014-192 Adipocytokines in the Relationship between Adiposity 
and Arterial Stiffness
B. Gwen Windham, Luigi Ferrucci, Michael E. Griswold, S. Morteza Farasat, Josephine 
Egan, Olga Carlson, Samer S. Najjar, National Institute on Aging, Baltimore, MD, Johns 
Hopkins Bloomberg School of Public Health, Baltimore, MD
Background: Although arterial stiffness, a risk factor for cardiovascular disease, renal 
disease, and mortality, has been associated with obesity, the mechanism linking arterial 
stiffness and obesity is unknown. We hypothesized that the production of adipokines from 
adipose tissue may explain the link between obesity and arterial stiffness.
Methods: We examined the relationships between carotid-femoral pulse wave velocity 
(PWV) and fasting serum levels of three adipokines, leptin, adiponectin, and resistin in 
605 participants (aged 26-99 years, 49% women) of the Baltimore Longitudinal Study of 
Aging using linear regression analyses and a mediation causal steps analysis.
Results: Truncal fat, assessed by dual x-ray absorptiometry, was moderately correlated 
with leptin (β=0.494, p<.0001), adiponectin (β=0.192, p<.001), and HDL (β=0.333, 
p<.0001) but not resistin (β=0.046, p=.23). Truncal fat was positively associated with 
PWV in unadjusted analysis (β=0.033, p=.002). The relationship between truncal fat and 
PWV was attenuated in a partially adjusted model that included age, race, sex, mean 
arterial pressure, heart rate, LDL, triglycerides, smoking, fasting glucose and blood 
pressure medications (β=0.020, p=.08). Individually, HDL and adiponectin reduced the 
β -coefficient for truncal fat to similar degrees (β=0.013, p=.26; and β=0.013, p=.29, 
respectively) when added to the partially-adjusted model; resistin did not alter the truncal 
fat coefficient (β=0.021, p=.08). Leptin, however, had the greatest attenuating effect 
(β=0.005, p=.70). No relationship between PWV and truncal fat was observed when either 
leptin, adiponectin, or HDL was added to the model. In a fully adjusted model (partially 
adjusted model plus leptin, adiponectin, resistin and HDL), greater PWV was associated 
with increasing leptin (β=0.006, p=.02) and decreasing adiponectin (β=-0.017, p<.01) and 
resistin (β=-0.036, p<.01) but not truncal fat (β=-0.004, p=.78) or HDL (β=-0.006, p=.17).
Conclusion: Leptin, adiponectin and HDL, or a pathway common to HDL and adipokines, 
such as inflammation, may mediate the relationship between truncal fat and arterial 
stiffness.
2:00 p.m.
1014-193 CYP4A polymorphism but no other vasomotor 
or inflammatory genes correlates with coronary 
endothelial function in patients with coronary artery 
disease - the ENCORE trials
Matthias Hermann, Kurt Quitzau, Thomas Munzel, Thomas Meinertz, Michael M. 
Hoffmann, Jens Hellermann, Thomas F. Luscher, University Hospital, Cardiology, Zurich, 
Switzerland
Background: Cytochrome P450 (CYP) is expressed in the human endothelium and 
metabolizes arachidonic acid into vasoactive epoxyeicosatrienoic acids (EETs) and 20-
hydroxyeicosatetraenoic acid (20-HETE). Endothelial dysfunction and plaque formation 
are important features of atherosclerosis. Thus, we investigated the impact of several 
CYP polymorphisms as well as vasomotor and inflammatory gene polymorphisms on 
coronary endothelial function in patients with coronary artery disease (CAD).
Methods: We investigated CYP 4A11F434, CYP 2C9 I359L-3, CYP 2J2 Promotor G-50T, 
and several other polymorphisms of inflammation and endothelial mediator genes in 758 
patients undergoing PCI enroled in the ENCORE 1 and 2 trials. Acetylcholine (10-6 to 10-
4 M) was infused in a coronary segment without angiographically significant CAD and the 
coronary artery vasomotor response was measured by quantitative angiography.
Results: Patients with substitution of phenylalanine 434 by serine (434SS, n=15, 2.04%) 
in CYP 4A11F434 demonstrated significantly augmented endothelium-dependent 
vasoconstriction compared to patients with the 434FS (n=193, 26.29%) and 434FF 
genotype (n=526, 71.66%). In addition, patients with the 434SS genotype had higher 
systolic blood pressure levels (p=0.039). Plasma creatinine and creatinine clearance 
were comparable in all groups. All other polymorphisms did not show any correlation 
with coronary vasoconstriction, hypertension, diabetes mellitus, blood pressure or 
cholesterol.
Conclusions: The 434SS variant of CYP 4A11F434 is associated with increased coronary 
vasoconstriction and higher blood pressure levels in patients with established coronary 
artery disease.
2:00 p.m.
1014-194 Prevalence and Predictors of Carotid Versus Femoral 
Plaque by Screening Vascular Ultrasound in 
Asymptomatic Adults
John Postley, Julius M. Gardin, Alejandro Perez, Maria Chan, Nathan D. Wong, 
Columbia University, New York, NY
OBJECTIVE: Ultrasound assessment of carotid (CP) and femoral (FP) artery plaque 
has shown great predictive sensitivity for CVD in outcome studies; but risk factor (RF) 
predictors for CP and FP are not well described. We compared predictors of CP and FP in 
low and intermediate risk individuals without prior evidence of prior CVD.
METHODS: Asymptomatic patients without CVD (n=486) were screened for CP and FP 
by ultrasound. Age range was 32 to 85 years (46% female). The presence of plaque 
was defined as a 1.5 mm projection into the lumen. In multivariable logistic regression, 
we examined mutliple RFs in relation to the likelihood of demonstrating CP, FP, or either 
CP or FP. Dyslipidemia was defined as a total cholesterol >=240 mg/dl, HDL-C <40 mg/
dl, triglycerides >200 mg/dl, or on medication and hypertension as blood pressure of 
>=140/90 mmHg or on medication.
RESULTS: Among 486 subjects, 194 had either CP or FP. Overall, 29% of subjects had 
CP, 25% had FP, and 40% had either CP or FP or both. The following table shows the 
odds ratios (OR) and 95% confidence intervals for each RF in relation to the likelihood of 
CP, FP, and either or both: 
CP Only FP Only CP and/or FP
Age (per 10 years) 2.83 (2.17-3.67)*** 2.42 (1.87-3.14)*** 2.77 (2.16-3.56)***
Male vs. Female 1.92 (1.12-3.31)* 1.83 (1.05-3.19)* 2.14 (1.28-3.58)**
Hypertension (yes vs. no) 0.75 (0.46-1.22) 1.26 (0.78-2.04) 0.81 (0.51-1.27)
Diabetes (yes vs. no) 1.70 (0.44-6.56) 0.94 (0.23-3.76) 1.59 (0.39-6.47)
Waist Circumference (per cm) 1.02 (0.95-1.09) 1.00 (0.93-1.07) 0.99 (0.93-1.06)
Dyslipidemia (yes vs. no) 1.50 (0.96-2.34) 1.68 (1.09-2.67)* 1.94 (1.27-2.96)**
Smoking 
Current vs. none 
Past vs. none
4.79 (1.82-
12.63)** 
1.56 (0.96-2.54)
3.03 (1.11-8.25)* 
1.81 (1.10-2.96)*
3.20 (1.23-8.34)* 
1.75 (1.09-2.80)*
* p< 0.05, **p<0.01, ***p<0.001
CONCLUSIONS: Our study demonstrates that besides advancing age and male gender, 
dyslipidemia and cigarette smoking (particularly current smoking) appear to be most 
consistently related to likelihood of carotid and femoral artery subclinical atherosclerosis 
in asymptomatic individuals without known CVD.
2:00 p.m.
1014-195 Correlation of Endothelial Progenitor Cells With 
Carbohydrate Metabolism in Prediabetic and Diabetic 
Patients
Maria Chiara Barsotti, Rossella Di Stefano, Laura Pucci, Daniela Lucchesi, Giuseppe 
Penno, Renato Vanacore, Mariacarla Iorio, Stefano Del Prato, Alberto Balbarini, 
University of Pisa, Pisa, Italy
Background: Diabetes has been associated with decreased number and impaired function 
of endothelial progenitor cells. Our purpose was to evaluate the levels of circulating and 
endothelial progenitor cells (CPCs and EPCs) in pre-diabetic subjects.
Methods: 34 patients with pre-diabetes (impaired fasting glucose and/or impaired 
glucose tolerance), 18 newly diagnosed Type 2 diabetic patients, and 26 age-matched 
healthy controls were recruited. No subject was on any pharmacological treatment. 
Anthropometric parameters, HbA1c, blood pressure, lipid profile and inflammatory 
parameters were determined. Metabolic syndrome was diagnosed based on the National 
Cholesterol Education Program Adult Treatment Panel III criteria. Blood samples were 
obtained to determine CPCs (CD34+ cells) and EPCs (CD34+KDR+ cells) by flow 
cytometry analysis. Data are expressed as cells number per ml of blood according to the 
International Society of Hematotherapy and Graft Engineering protocol; the EPCs/CPCs 
ratio was also calculated.
Results: In subjects with pre-diabetes both EPCs and EPCs/CPCs were comparable 
with healthy controls (EPCs: 533±355 vs. 479±378/ml, p=n.s.; EPCs/CPCs: 24.9±18.8 
vs. 25.0±14.7%, p=n.s.). On the contrary, diabetic patients had lower EPCs (254±217/
ml) and EPCs/CPCs ratio (16.6±9.6%) in comparison with both pre-diabetic (p<0.01 and 
p<0.05, respectively) and control subjects (p<0.005). No correlations were found among 
EPCs and EPCs/CPCs ratio and clinical as well as laboratory parameters. Even after 
stratification for presence or absence of metabolic syndrome, no apparent reduction in 
EPCs and EPCs/CPCs was found. EPCs were negatively correlated with both fasting 
(p<0.05) and post-challenge (p<0.05) glucose in the whole population.
Conclusions: These preliminary results suggest that minor impairments of glucose 
regulation (pre-diabetes) do not affect the levels of circulating EPCs. On the contrary, 
overt diabetes even at the time of diagnosis is associated with a significant reduction of 
EPCs. However, carbohydrate metabolism is a determinant of EPCs levels.
2:00 p.m.
1014-196 Factor Analysis of Risk Variables Associated With Low-
Grade Inflammation
Doron Aronson, Ophir Avizohar, Giris Jacob, Walter Markiewicz€, Rambam Medical 
center, Haifa, Israel
Background: Chronic subclinical inflammation, manifesting as elevated levels of 
inflammatory markers such as C-reactive protein (CRP), predicts future atherothrombotic 
events. Elevated CRP is associated with various intercorrelated conditions including 
characteristics of the metabolic syndrome, reduced cardiorespiratory fitness, elevated 
uric acid, fatty infiltration of the liver, and reduced pulmonary function.
Methods: Principal factor analysis was used to investigate clustering of 10 variables 
associated with elevated CRP using data from 1077 subjects without known coronary 
disease. Components of the metabolic syndrome, uric acid, liver enzymes, pulmonary 
function tests, smoking status, cardiorespiratory fitness (measured by maximal treadmill 
test), and high-sensitivity C-reactive protein were determined in each subject. 
Results: Factor analysis identified 3 factors, which explained 54.2% of the total variance in 
the dataset (24.6% factor 1, 17.8% factor 2, and 11.8% factor 3). Based on factor loadings of 
≥ 0.5, These factors were interpreted as 1) “Metabolic factor” including BMI, fasting glucose, 
HDL cholesterol, triglycerides, systolic blood pressure, uric acid and elevated liver enzymes; 2) 
“Cardio-respiratory” factor that included fitness level and forced expiratory volume in 1 second 
(FEV1); and 3) “Smoking” factor that included cigarette smoking alone. In a multivariable 
logistic regression model, each of these factors was significantly associated with the presence 
of high-risk CRP (≥ 3 mg/L) in the study population (P = 0.01 to 0.0001). The ability of a 
multivariable logistic regression model that included the scores of these 3 factors to predict 
high-risk CRP was comparable to a model containing the original 10 variables (area under the 
receiver-operator characteristics curve 0.70 vs. 0.72, respectively).
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Conclusions: These results suggest that metabolic perturbations, cardio-respiratory 
fitness, and smoking are separate and largely non-overlapping factors in the 
pathophysiology of chronic, low-grade inflammation. Importantly, all of these factors are 
amenable to behavioral interventions.
2:00 p.m.
1014-197 The Direct Toxic Effect of Ultrafine Particles on 
Coronary Flow: The Importance of the Hydroxyl Radical
Hyosook Hwang, Boris Z. Simkhovich, Michael T. Kleinman, Robert A. Kloner, Good 
Samaritan Hospital, Los Angeles
Background: Data from the epidemiology literature suggest that particulate air pollutants 
are associated with a marked increase in cardiovascular events, but the mechanism for 
this effect remains unknown. Studies suggest that ultrafine particles (UFP) associated 
with inhalation exposure may directly enter the vasculature. We have developed a 
model to investigate the direct effects of UFP on the coronary vasculature and heart, 
without involving the lung. Isolated Langendorff-perfused hearts directly exposed to UFP 
consistently showed reductions in coronary artery flow in normal adult hearts (by 40.0 ± 
5.8%), in hearts of spontaneously hypertensive rats (by 30.3 ± 4.7%), and in hearts with 
previous myocardial infarctions (by 24.8 ± 4.0%). Methods: To determine whether the effect 
of UFP on coronary flow involves an oxidative stress mechanism, we exposed Langendorff 
perfused hearts obtained from normal adult Sprague Dawley rats to a 30-minute infusion 
of UFP (from 12.5 mg/L of standard particulate matter, National Institute of Standards 
and Technology). Hearts were either untreated or received the potent hydroxyl radical 
scavenger, N  (2  mercaptopropionyl)  glycine (MPG; lmM). Results: Thirty minutes of UFP 
perfusion significantly decreased coronary flow from 7.8 ± 0.5 ml/min to 5.4 ± 0.7 ml/min; 
a 32% reduction from baseline (p < 0.05); whereas coronary flow in hearts co-treated with 
MPG was fully preserved (8.8 ± 0.5 ml/min at baseline to 8.7 ± 0.8 ml/min at 30 minutes; 
only a 2% reduction from baseline; p = NS). There was a trend toward attenuated response 
to diminished contractile function of the UFP in the MPG treated hearts (developed 
pressure was reduced by 23.5 ± 5.5% in UFP  treated versus 15.9 ± 3.6% in UFP with 
MPG treatment; dP/dt
max
 was reduced by 22.5 ± 6.1% in UFP  treated versus 13.8 ± 4.0% in 
UFP with MPG treatment). Conclusion: To the best of our knowledge this is the first study 
showing that the direct toxic effects of UFP on coronary flow can be treated with an oxygen 
radical scavenger and that the hydroxyl radical may play a role in the mechanism of the 
direct and acute toxic effect of UFP on the coronary vasculature.
2:00 p.m.
1014-198 Racial Variations in Abnormal Metabolic Profiles 
Associated With Cardiovascular Risk
Suresh R. Mulukutla, Oscar C. Marroquin, Kevin E. Kip, Aryan Aiyer, Daniel 
Edmundowicz, Steven E. Reis, University of Pittsburgh, Pittsburgh, PA
Background: South Asians and blacks are at higher cardiovascular (CV) risk than whites. 
Insulin resistance and hypoadiponectinemia are factors associated with adverse metabolic 
profile and CV risk and have been shown to correlate with body mass index (BMI) in 
whites. However, the relationship between BMI and metabolism among different races 
is not well described. Accordingly, we evaluated the association of BMI with metabolic 
parameters in 3 races.
Methods: The study included whites (n=278), blacks (n=211), and South Asians (n=239). 
BMI, insulin, glucose, adiponectin, and leptin were measured, and insulin resistance was 
assessed with Homeostasis model assessment (HOMA).
Results: Although BMI was lowest among South Asians and highest among blacks, 
insulin resistance by HOMA was most prevalent among South Asians and least 
prevalent among whites (table). Adiponectin was lowest among South Asians despite 
having a lower BMI. Leptin correlated with BMI across the races. In multivariate analysis, 
hypoadiponectinemia was independent of BMI in South Asians, and this group had the 
highest inverse correlation between HOMA and adiponectin.
Conclusions: BMI does not predict either insulin resistance by HOMA or 
hypoadiponectinemia in South Asians. Therefore, BMI may significantly misclassify a 
significant proportion of South Asians, and possibly blacks, who are at high risk for having 
or developing the metabolic syndrome. This may be an important factor that may help 
explain racial differences in CV risk.
Metabolic Parameters in Three Distinct Racial Groups
Parameter
Caucasians 
(CA)
African-
Americans (AA)
South 
Asians (SA)
N=278 N=211 N=239
p-value (CA 
vs AA)
p-value (CA 
vs SA)
p-value (AA 
vs SA)
Body Mass Index 
(kg/m2) 28.3±5.1 31.9±6.9 23.7±4.1 p<0.00001 p<0.00001 p<0.00001
HOMA - Insulin 
Resistance
2.21±1.77 2.98±2.79 4.83±5.07 p<0.0005 p<0.00001 p<0.00001
Adiponectin 
(ug/ml) 11.6±5.9 9.4±6.6 8.2±4.2 p<0.00001 p<0.00001 p<0.02
Leptin (ng/ml) 19.4±17.7 25.2±21.6 14.8±13.9 p=0.001 p=0.001 p<0.00001
2:00 p.m.
1014-199 Bone Marrow Progenitor Cell Stores Impact Circulating 
EPC Levels and are Depleted in Elderly Subjects
Thomas J. Povsic, Madhav Swaminathan, Francine Kelly, Katherine L. Zavodni, Stacie D. 
Adams, Carmelo A. Milano, Mark F. Newman, Joseph P. Mathew, Pascal J. Goldschmidt-
Clermont, Eric D. Peterson, Duke University Medical Center, Durham, NC, Duke Clinical 
Research Institute, Durham, NC
Background: Depletion of circulating endothelial progenitor cells (EPCs) by aging 
presages the development of cardiovascular disease and predicts cardiovascular events. 
Cardiac surgery offers a unique opportunity to sample circulating EPCs and bone marrow 
progenitors (BMPCs) as well as evaluate EPC mobilization after vascular injury
Methods: We assessed EPCs in 63 patients before, immediately after, 24 and 48 hours 
after open cardiac surgery and BMPCs in samples curetted at time of median sternotomy. 
We assessed effect of age on BMPC content, and the relationship between BMPC 
content and circulating EPCs.
Results: EPCs (aldehyde dehydrogenase bright [ALDHbr] and CD133+CD34+) are 
mobilized hours after open cardiac surgery and return to baseline levels within 48 hours 
(ANOVA p<0001). Aging results in depletion of both CD34+ (Pearson r=0.28, p<05) and 
ALDHbr cells (Pearson r=0.35, p<0.005), with significant differences observed between 
patients <75 vs. >75 years old (mean CD34+ cells 7.087 ± 0.61% vs. 4.263 ± 0.62%, 
p<0.01; mean ALDHbr cells 5.072 ± 0.48% vs. 2.119 ± 0.29%, p<0.0001). BMPC numbers 
were associated with baseline and 48 hour EPC levels (Pearson r=0.44, p<0.005) but not 
extent of EPC mobilization, which was affected by procedural variables.
Conclusion: Aging results in depletion of BMPC stores, which may underlie loss of 
circulating EPCs. These findings have implications for the use of autologous bone marrow 
sources for cellular therapy in diseases which predominantly effect the elderly. 
2:00 p.m.
1014-200 Flow Augmentation Index as a Risk Factor for Silent 
Lacunar Infarction
Kozo Hirata, Michael O’Rourke, Shin-ichi Momomura, Omiya Medical Center, Jichi 
Medical University, Saitama, Japan
Background: Silent lacunar infarction (SLI) has been regarded as a strong predictor 
and thus an early stage of symptomatic lacunar infarction. We have reported that high 
flow pulsation extending from common carotid artery into the microvasculature of the 
brain may be a primary cause of lacunar infarction (1). High flow pulsation is caused 
by wave reflection and can be quantified as flow augmentation index (FAIx). However, 
the relation between FAIx and the presence of SLI has not been investigated so far. (1) 
Stroke. 2006;37:2552-2556.
Methods: We studied consecutive 113 subjects without medication, and no history of 
stroke (24 to 84 years old) who visited brain health screening unit at Saitama Medical 
Center. All subjects underwent carotid duplex scanning and cerebral MRI / MRA. Thirteen 
subjects were excluded because of carotid stenosis (5 subjects) and cortical infarction 
(8 subjects). Thirty two subjects had SLI and the values of cardiovascular risk factors, 
including blood pressure (BP), heart rate, total cholesterol, triglyceride, fasting glucose, 
HgA1c, uric acid, current Tobacco consumption, gender, and body mass index, and 
pressure augmentation index (PAIx) and FAIx were compared between SLI group and 68 
normals. FAIx was defined as (Vsr-Ved) / (Vs-Ved); Vs; peak flow velocity (FV), Vsr; peak 
FV of the secondary rise, Ved; end diastolic FV.
Results: FAIx (SLI group; 71.2% vs. normal group; 50.2%, p<0.0001), age (65.3 yo vs. 
50.4 yo, p< 0.0001), PAIx (33.6% vs.17.0%, p<0.0001), systolic BP (140.6 mmHg vs. 
127.8mmHg, p=0.0006), and pulse pressure (60.2mmHg vs. 49.8 mmHg, p=0.0001) were 
significantly higher in SLI group. Multiple logistic regression analysis revealed that only 
age (Odds Ratio [OR] 2.24 [by 10 y]; CI: 1.12-4.50, p=0.023) and FAIx (OR 1.78 [10%]; 
CI 1.17-2.71, p=0.0073 ) (model 1), or age (OR 2.40 [10 y]; CI: 1.19-4.83, p=0.014) and 
PAIx (OR 2.20 [10%]; CI 1.23-3.93, p=0.008)(model 2) were independent predictors of 
SLI. FAIx closely correlated with PAIx (r=0.87, p<0.0001)
Conclusions: FAIx was a strong independent risk factor for SLI. These results confirm the 
pivotal role of high flow pulsation in the pathogenesis of lacunar infarction and suggest a 
new strategy to prevent stroke.
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1014-201 Increased Augmentation Index of Radial Pulse Wave in 
Patients With Paroxysmal Atrial Fibrillation
Toru Miyoshi, Masayuki Doi, Youko Kaji, Satoshi Hirohata, Shigeshi Kamikawa, Shozo 
Kusachi, Tohru Ohe, Okayama University, Okayama, Japan
Background: Recent studies have shown that increased aortic stiffness may increase 
the risk of atrial fibrillation. We examined relationship between augmentation index (rAI), 
a marker of arterial stiffness, and paroxysmal atrial fibrillation (PAF). Methods: A total of 
one hundred twenty outpatients were investigated and divided into PAF group (n=60) and 
normal sinus rhythm (SR) group (n=60). Radial AI (rAI) was obtained from radial artery 
applanation tonometry and pulse wave analysis during sinus rhythm. Comprehensive 
transthoracic echocardiography was concurrently performed. Results: The rAI in PAF group 
showed significantly higher than those in SR group (91+/-12 % vs. 81+/-8 %, p<0.001). In 
all subjects, univariate analysis demonstrated rAI was correlated with left atrial dimension 
(r=0.33, p<0.01), age (r=0.23, p=0.01), and height (r=-0.24, p<0.01). In multivariate analysis, 
rAI and left atrial dimension independently correlated with PAF. The patients were classified 
on the basis of the quartiles of rAI to identify the characteristics of patients with a high 
rAI. The occurrence of PAF was significantly greater in patients classified into the highest 
quartile of rAI than in those classified into the other quartiles. Logistic regression analysis 
demonstrated that a higher rAI was associated with an increased risk of PAF (crude OR 
9.33, CI 2.8-30.6, p<0.01). This association remained significant after adjustment for age, 
gender and risk factors of atrial fibrillation (OR 10.4, CI 2.8-45.2, p<0.05). Conclusion: This 
study revealed for the first time that the significant association of increased augmentation 
index with PAF. These findings may be important with regard to the potential role of arterial 
stiffness and wave reflections in the pathogenesis of PAF.
2:00 p.m.
1014-202 Pre-Operative Flow Mediated Dilatation in Patients 
Undergoing Coronary Artery Bypass Surgery: 
Prediction Of NO-Bioavailability and Vascular 
Superoxide Production in Arterial and Vein Grafts
Charalambos A. Antoniades, Shafi Mussa, Cheerag Shirodaria, Justin Lee, Tim Van-
Assche, Jonathan Diesch, David Taggart, Keith M. Channon, Paul Leeson, University of 
Oxford, Oxford, United Kingdom
Background: Variations in endothelial biology of arterial (left internal mammary artery 
(LIMA) and left radial artery (LRA)) and saphenous vein (SV) grafts used in CABG, may 
be relevant to long- term patency of the grafts. We hypothesised that pre-operative flow 
mediated dilatation in the right brachial (FMD-RBA) and left radial artery (FMD-LRA) 
predicts nitric oxide bioavailability and vascular superoxide production in arterial and SV 
CABG grafts.
Methods: We studied 126 patients undergoing CABG, using LIMA plus SV or LRA grafts. 
FMD-LRA and FMD-RBA were determined preoperatively. Vasomotor responses of LRA 
or SV grafts to acetylcholine (ACh) were determined ex-vivo, while vascular superoxide 
(O2-) generation was estimated in SV and LIMA grafts by chemiluminescence.
Results: FMD-LRA and FMD-RBA predicted the ex-vivo vasorelaxations of LRA grafts 
to ACh (Fig. A and B). FMD-RBA was associated with vascular superoxide generation in 
LIMA (Fig c) but not in SV grafts. In multivariate analysis including cardiac risk factors, 
FMD was the main independent predictor of vasorelaxations of arterial grafts to ACh 
(β=0.020(SE:0.009), p=0.030 for FMD-RBA and β=0.024(SE:0.011), p=0.05 for FMD-LRA) 
and vascular superoxide generation in LIMA (β(SE):-0.343(0.114), p=0.004) but not in SV.
Conclusions: FMD in LRA or RBA, provides robust information about nitric oxide 
bioavailability and superoxide production in arterial CABG-grafts and can predict variation 
in graft endothelial biology pre-operatively. 
2:00 p.m.
1014-203 Association of a Single Nucleotide Polymorphism 
(SNP) (rs3798220) in the Apolipoprotein(a) (LPA) Gene 
With Lipoprotein(a) (lp(a)) Levels, Carotid Intima Media 
Thickness (CIMT) and Peripheral Arterial Disease (PAD) in 
the Atherosclerosis Risk In Communities (ARIC) Study
Vijay Nambi, Alanna Morrison, Josef Coresh, Ron C. Hoogeveen, Lance Bare, Hanyu 
Ni, Eric Boerwinkle, Christie Ballantyne, Baylor College of Medicine, Houston, TX, 
University of Texas, School of Public Health, Houston, TX
Background: Lp(a) levels, which are largely genetically determined, are associated with 
coronary artery disease (CHD) and stroke. We examined the association of a putative 
functional SNP (rs3798220) in the protease-like domain of apolipoprotein a (encoded by 
the apolipoprotein a gene (LPA)) with Lp (a) levels, CIMT and peripheral artery disease 
(PAD) in the ARIC study.
Methods: Mean Lp(a) levels and rs3798220 were available in 13,019/14,215 individuals. 
Outcomes of abnormal CIMT (age and gender stratified CIMT >75th percentile; n=3314) 
and PAD (ankle brachial index of ≤ 0.9 in men and ≤ 0.85 in women; n=326) were also 
analyzed. Logistic regression models, adjusted for age and gender, performed separately 
in each race, analyzed the relationship between the additive effect of the C-allele and 
CIMT and PAD.
Results: The C allele was present in 3% of the Whites and 2% of the African Americans 
and the mean Lp(a) levels for those with the C allele were significantly higher in both 
races (table). The SNP was significantly associated with abnormal IMT (OR = 1.38, 95% 
CI 1.07 - 1.78) only in whites. No association with PAD was noted in either race.
Conclusions: Heterozygous carriers of the C allele for rs3798220 in the LPA gene have 
elevated Lp(a) levels in the ARIC study and White carriers of the mutation have abnormal 
CIMT. This supports a causal role of Lp(a) in atherogenesis and will need to be interpreted 
in the context of the complex genetic architecture of the LPA gene.
Mean Lp(a) levels by race and genotype classes in the ARIC study
N (Frequency) Mean (mg/dl) SD (mg/dl)
Whites
TT (wild-type) 9382 (96.8%) 7.48 8.32
CT (heterozygote) 307 (3.1%) 23.84* 16.28
Total 9689 7.99 9.14
African Americans
TT (wild-type) 3264 (98.01%) 15.81 12.06
CT (heterozygote) 66 (1.99%) 19.91* 17.98
Total 3330 15.89 12.22
*P value <0.01 for differences in mean Lp(a) levels between the CT heterozygotes and 
TT homozygotes.
2:00 p.m.
1014-204 Preeclampsia Susceptibility Genes are Associated With 
Risk of Cardiovascular Disease, Especially in Younger 
Women
Svati H. Shah, Jessica Johnson, Sarah Nelson, Carol Haynes, Mimi Biswas, Duke 
University Medical Center, Durham, NC
Background: Preeclampsia has a hereditary component, and genes have been shown 
to be associated with preeclampsia risk. We have previously shown that women with 
preeclampsia have higher all-cause and cardiac mortality, and increased risk of early-
onset myocardial infarction (MI). Therefore, we hypothesized that preeclampsia genes are 
also associated with cardiovascular disease risk.
Methods: From a cohort of patients undergoing cardiac catheterization, cases with 
coronary artery disease (CAD, N=809) with a CAD index ≥32 (at least one vessel with 
≥95% stenosis) were identified, and were further stratified by age-of-onset (≤55 and >55). 
Controls age >60 with no history of cardiovascular disease were also identified (N=167). 
A haplotype-tagging approach was used to identify single nucleotide polymorphisms 
(SNPs) within preeclampsia genes identified from the literature and were genotyped 
using Taqman. Logistic regression models adjusted for race and sex were used to test for 
genetic association. Given that preeclampsia is a disease of women, to evaluate potential 
sex-specific effects, analyses were also stratified by sex.
Results: Ninety-three SNPs within 17 genes were analyzed. Two genes were strongly 
associated with CAD: NOS2A (p-values 0.0004 - 0.003) and STOX1. NOS2A is known to 
be associated with CAD. However, STOX1, identified from a linkage peak for preeclampsia, 
has never before been shown to be associated with CAD. Three SNPs within STOX1 were 
significantly associated with CAD (OR 0.66-0.75, p-values 0.03 - 0.05). Sex-stratified 
analyses confirmed a sex-specific effect, with stronger association for CAD in women 
with early-onset CAD (OR 0.45-0.59, p-values 0.006 - 0.02). Hence, the minor allele of 
the STOX1 SNPs is protective against early-onset CAD, or alternatively the major allele is 
a susceptibility gene for early-onset CAD, particularly in women.
Conclusions: To our knowledge, this is the first systematic study of preeclampsia 
genes as susceptibility genes for CAD. Our results suggest the presence of common 
pathophysiologic mechanisms underlying preeclampsia and early-onset CAD in women. 
Validation and further functional studies are necessary.
JACC March 11, 2008  ABSTRACTS - Vascular Disease, Hypertension and Prevention  A305 
Vascular D
isease, H
ypertension and P
revention
2:00 p.m.
1014-205 Gender-Related Difference in Arterial Elastance During 
Exercise in Patients With Diabetes Mellitus
Jong-Won Ha, Hyun-Chul Lee, Sungha Park, Chi-Young Shim, Eui-Young Choi, Donghoon 
Choi, Namsik Chung, Yonsei University College of Medicine, Seoul, South Korea
Background: Diabetes mellitus is an important cause of heart failure (HF). Interestingly, 
the risk of HF in diabetic patients is higher in women when compared with men even 
after adjusting for other risk factors and women with HF more often have a preserved left 
ventricular (LV) systolic function. Recently, arterial stiffness has been suggested as an 
important contributor for the development of HF. How the gender difference affects the 
arterial stiffening and its response to exercise is not well known. We hypothesized that 
arterial elastance (Ea) during exercise would be more abnormal in women compared with 
that of men in patients with type 2 diabetes.
Methods: Ea was estimated as the arterial systolic pressure/stroke volume and was 
measured at rest and during graded supine bicycle exercise (25W, 3 minutes increments) 
in 96 patients with type 2 diabetes (51 male, 45 female, mean age 55).
Results: The subjects were divided into 2 groups by gender. Age was similar between the 
groups. However, exercise duration was significantly shorter in women compared with 
that of men (605+203 vs 376+138 secs, p<0.0001). Ea was not significantly different 
at rest and during 25 W of exercise between the groups (rest, 1.86+0.41 vs 1.94+0.48 
mmHg/ml, p=0.46; 25 W, 1.98+0.43 vs 2.22+0.61 mmHg/ml, p=0.074). However, Ea 
became significantly higher during 50 W of exercise in women compared with those of 
men (2.13+0.38 vs 2.42+0.60 mmHg/ml, p=0.043).
Conclusions: In patients with type 2 diabetes, female gender was associated with 
increase in arterial stiffness with exercise and poor exercise tolerance. These data 
suggest gender-related difference in dynamic change of arterial stiffness may contribute 
exercise intolerance in patients with type 2 diabetes.
2:00 p.m.
1014-206 Circulating Endothelial Progenitor Cell Activity as a 
Predictor of Cardiovascular Outcomes
Kreton Mavromatis, Konstantinos Aznaouridis, Nima Ghasemzadeh, Zohreh Forghani, 
Emir Veledar, Diane Sutcliffe, Taffere Mihretu, Tanuj Kamineni, Muhammad R. Ishaque, 
Padi K. Reddy, Jacob Green, W. Robert Taylor, Arshed A. Quyyumi, Emory University, 
Atlanta, GA, Atlanta VA Medical Center, Decatur, GA
Background: Circulating endothelial progenitor cells (EPC) contribute to vascular repair. 
Studies have shown that patients with reduced numbers of circulating EPC, as estimated 
by flow cytometry, have increased cardiovascular risk. Using an “intermediate” term 
colony formation unit (EPC-CFU) assay as a measure of circulating EPC activity, we have 
shown increased levels in patients with risk factors and those with vascular disease. We 
hypothesized that this increased EPC activity is potentially in response to greater vascular 
injury, and will be associated with increased cardiovascular risk.
Methods: A 7-day culture of peripheral blood mononuclear cells (PBMCs) in endothelial 
specific medium that yields colonies with mixed morphology cells in the center and 
endothelial-type cells at their periphery was used. It was performed in 191 subjects (age 
62+/-10) with stable coronary artery disease and on stable statin therapy before (baseline) 
and 1 week after undergoing elective percutaneous coronary angioplasty (PCI). Patients 
were followed for non-procedural death, myocardial infarction (MI) and repeat PCI for an 
average of 23 months (range 13-43 months).
Results: PCI induced an acute increase in circulating EPC-CFUs (median baseline = 
96/106 PBMCs; median delta = 17/106 PBMCs; p=0.02). During follow-up, more death 
and MIs occurred in patients with high (> median) vs. low (< median) baseline EPC-CFU 
levels (death: 6.3% vs. 2.2%, p=0.14; MI: 7.4% vs. 2.2%, p=0.18; death + MI: 12.5% vs. 
4.4%, p=0.05). In addition, more repeat PCIs occurred in patients with high (> median) vs. 
low (< median) delta EPC-CFU levels (23% vs. 9.5%; p=0.02).
Conclusion: Increased baseline EPC activity in stable CAD patients is associated with an 
increased risk of death + MI, while increased PCI-induced EPC activity is associated with 
an increased risk of repeat PCI. As such, increased circulating EPC activity, as measured 
by the “intermediate” term EPC-CFU assay, may reflect increased levels of ongoing 
chronic and acute vascular injury.
2:00 p.m.
1014-207 Iron Content and Heme Metabolism Are Increased in 
Diabetic Atherosclerotic Plaques From Individuals With 
the Hp 2-2 Genotype
Pedro R. Moreno, Purushothaman K-Raman, Meerarani Purushothaman, Luis Astudillo, 
Elias Zias, Patrick Lento, John T. Fallon, Valentin Fuster, Nina Levy, Andrew P. Levy, 
Mount Sinai School of Medicine, New York, NY
Background: Haptoglobin (Hp) genotype is a major susceptibility gene for the development 
of atherosclerosis in diabetes mellitus (DM). The Hp gene is polymorphic in man with 
two classes of alleles, 1 and 2. The function of the Hp protein is to prevent damage 
and promote the clearance of extracorpuscular hemoglobin. We hypothesized that 
atherosclerotic lesions from Hp 2-2 DM patients will have increased plaque iron due to a 
decreased ability to clear hemoglobin in these patients.
Methods: Plaques from 24 formalin fixed cadaveric aortas were characterized. A novel 
method was adapted to Hp genotype the specimens by assessing Hp protein. Iron was 
assessed with Perl’s stain and HO-1 by immunohistochemistry. Plaque Iron and HO-1 
were scored 0 (none), 1+ (mild), 2+ (moderate).
Results: Diabetic Hp2-2 plaques expressed striking increase in iron and HO-1 protein 
expression when compared to Hp1-1 or Hp2-1 (p<0.0001, n=50), as seen in Figure. 
A significant correlation between iron and HO-1 expression was observed in Hp 1-1 
(R=0.68, p=0.005), while no correlation exists in Hp 2-1 DM individuals (R=0.35, p=0.35). 
Finally, non-DM plaques observed very little iron and found no relationship between Hp 
genotype and iron staining.
Conclusions: Iron is increased in plaques of Hp 2-2 DM patients, most probably due to 
impairment in clearance of hemoglobin from the Hp 2-2 DM plaque. Agents that prevent 
iron-induced injury may have considerable value in reducing the risk of plaque rupture 
and atherothrombosis in Hp 2-2 DM patients. 
2:00 p.m.
1014-208 Plasma Bone Morphogenic Protein 4 as a Predictor of 
Coronary Artery Calcification in Patients With Coronary 
Artery Disease
Sung-Won Jang, Sang Hong Baek, Hun-Jun Park, Chan-Suk Park, Dong-Bin Kim, Pum 
Joon Kim, Hae-Ok Jung, Ki-Bae Seung, Jae-Hyung Kim, Kyu-Bo Choi, The Catholic 
University of Korea, Seoul, South Korea
Background: Calcification is a common finding in human coronary artery disease (CAD) 
and clinically significant in atherosclerosis. It has been demonstrated that coronary artery 
calcification (CAC) correlates with severity of CAD and is highly predictive of future 
coronary events. The bone morphogenic proteins (BMPs) have important developmental 
roles in osteogenesis in a variety of tissue. The aim of this study was to evaluate whether 
plasma BMP-4 is predictive of CAC
Methods: We studied 161 patients (males, 66.5%; mean age, 63.42±9.77) who had 
ischemic chest symptoms and coronary artery stenosis > 50% of the luminal diameter, 
confirmed by coronary angiography. Presence of CAC and number of diseased coronary 
vessel were evaluated by visual analysis of coronary angiography. Biochemical markers 
such as high sensitivity C-reactive protein, lipid profiles, and BMP-4 were analyzed. 
Aortic stiffness was evaluated by non-invasive carotid-femoral pulse wave velocity (PWV) 
measurement using applanation tonometry method.
Results: CAC was detected in 31 patients. Univariate analysis revealed that significant 
variables associated with CAC were age (p=0.004), pulse pressure (p=0.044), PWV 
(p<0.001), BMP-4 (p=0.023), and multi-vessel disease (p<0.001). Stepwise multiple 
logistic regression analysis showed that the independent predictors of CAC were PWV 
(p<0.001), BMP-4 (p=0.013), and multi-vessel disease (p<0.001).
Conclusions: The present study demonstrated that increment of BMP-4 is associated 
with CAC in patients with CAD. BMP-4 may have significant role in pathogenesis of CAC 
in patients with CAD.
2:00 p.m.
1014-209 Dose Response Effect Of Atorvastatin On Biomarkers 
of Oxidative Stress And Inflammation In Subjects With 
Metabolic Syndrome
Ishwarlal Jialal, Uma Singh, Sridevi Devaraj, David Siegel, UC Davis Medical Center, 
Sacramento, CA, Medical Center at Mather, Mather, CA
Background: Metabolic syndrome (MetS) is characterized by low-grade inflammation and 
confers an increased risk for cardiovascular disease. Although previous studies have 
demonstrated that various statins decrease levels of high-sensitivity C-reactive protein 
(hs-CRP), the dose response effect of atorvastatin on lowering hs-CRP has not been 
investigated. Furthermore, oxidative burden also is an underlying feature in MetS. In 
the present study, we tested the dose response effect of atorvastatin on biomarkers of 
inflammation and oxidative stress.
Methods: A randomized, double-blind clinical trial was performed in subjects with MetS 
characterized by NCEP ATP III. The subjects were randomized to placebo (0 mg), 10 mg 
and 80 mg atorvastatin per day for 12 weeks. A total of 70 (n=23/24 per group) subjects 
completed the study. Various biomarkers of inflammation (hs-CRP and MMP-9) and 
oxidative stress (oxidized-LDL and urinary F2-isoprostanes) were assayed in the present 
study in addition to the lipid profile.
Results: A strong dose response was observed for changes in total and low density 
lipoprotein-cholesterol (LDL-C) (32 and 44% reduction at 10 and 80 mg atorvastatin 
respectively from baseline). Additionally, as a marker of oxidative stress, atorvastatin 
significantly reduced oxidized-LDL in a dose-dependent manner (24 and 39% reduction at 
10 and 80 mg atorvastatin respectively from baseline). However, there was no significant 
effect on urinary F2-isoprostanes in any group. Furthermore, as a marker of inflammation, 
hs-CRP was significantly decreased (35%, p=0.006) in 80 mg atorvastatin group only 
compared to baseline. Also, MMP-9 and NFkB activity were significantly (p<0.05) 
decreased in 80 mg atorvastatin group only compared to baseline.
Conclusion: In conclusion, this randomized trial in subjects with MetS shows the 
superiority of atorvastatin at 80 mg dose in reducing oxidized-LDL, hsCRP, MMP-9 and 
NFkB activity.
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2:00 p.m.
1014-210 Measures of Cardiovascular Risk in Retired National 
Football League Players
Erik Wissner, Robert F. Burke, Arthur Roberts, Chris Kendall, Robert T. Hurst, Bijoy 
Khandheria, Mayo Clinic Arizona, Scottsdale, AZ
Background: National Football League (NFL) players have a higher prevalence of obesity 
and obstructive sleep apnea. In retired NFL players an increased rate of metabolic 
syndrome and a higher mortality in linemen has been reported. We sought to define 
vascular health and, by association, cardiovascular risk in retired NFL players.
Methods: Carotid intima-media thickness (CIMT) (or just a plaque screen when CIMT not 
obtainable) and echocardiographic determined left ventricular (LV) mass index and left 
atrial volume index (LAVI) as established markers of cardiovascular risk were obtained in 
retired NFL players at multi-site health screening events.
Results: 233 retired NFL players between the ages of 35 to 65 years participated in the 
health screening program and were included in the study. Mean weight and body mass 
index were 110.3±17.7 kg and 31.6±4.4 kg/m2. Echocardiographic data was available in 
98/233 patients. LV mass (103.6±23.3 g/m2) and LAV indices (25.7±8.4 ml/m2) were not 
outside of the general population normal range. In the 109 players with complete CIMT 
examinations, 77% had either carotid artery plaque or a CIMT thickness greater than the 
75th percentile adjusted for age, sex and race. Carotid artery plaque was noted in 79 of 
233 (34%) players. Of those less than 50 years of age, 45 of 55 (82%) had either plaque 
or CIMT thickness greater than 75th percentile adjusted for age, sex and race.
Conclusion: CIMT as a measure of subclinical atherosclerosis and a surrogate marker for 
adverse cardiovascular event risk is abnormal in retired NFL players when compared to 
the general population. The high incidence of plaque suggests that the increased CIMT 
is not solely due to increased BMI. Other parameters of risk such as LAV and LV mass 
adjusted for body surface area were not different from the general population.
2:00 p.m.
1014-211 Genetic Variability of Polymorphism C242T on the P22 
Phox Subunit of NAD(P)H Oxidase Is Associated With 
Aortic Stiffness and Levels of Inflammatory Markers
Carmen Vasiliadou, Charalambos Vlachopoulos, Ioanna Dima, Despoina Kardara, 
Panagiotis Xaplanteris, Katerina Baou, Christos Pitsavos, Dimitrios Tousoulis, 
Christodoulos Stefanadis, 1st Department of Cardiology, Athens, Greece
Background: NAD(P)H oxidase is a major source of superoxide anion in all vessel 
wall cells. C242T polymorphism of p22phox subunit seems to influence significantly 
the enzyme activity. The correlation of this polymorphism with arterial stiffness and 
inflammation markers such as interleukin-6 (IL-6) and C-reactive protein(CRP) has not 
been studied yet.
Methods: The study included 219 apparently healthy individuals aged 40.5±8.3 years 
old (144 males). CC, CT, and TT genotypes at 242 position of NAD(P)H oxidase gene, 
as well as the levels of IL-6 and CRP, were determined by standard methods. Central 
(aortic) blood pressure was calculated with applanation tonometry by using a validated 
system (SphygmoCor ®). Carotid-femoral pulse wave velocity (PWV) was measured as 
an index of aortic stiffness using a non-invasive device (Complior ®). Higher values of 
PWV indicate increased aortic stiffness.
Results: The prevalence of CC, CT and TT genotypes was 31.1%, 53.4% and 15.5%, 
respectively. Regression analysis showed that absence of the T allele was associated with 
higher value of both peripheral systolic (117.8±14.0 vs. 115.6±14.0 mmHg, P=0.089) and 
aortic systolic pressure (107.0±13.9 vs. 104.8±13.1 mmHg, P=0.04). Our data suggest 
a higher pulse wave velocity in CC individuals (6.46±1.24 vs. 6.25±1.19 m/sec, P=0.08) 
compared with T allele carriers. However, analysis of covariance, showed there was a 
significant association of p22 phox genotype with level of IL-6 (1.53pg/ml vs.1.31pg/ml vs 
2.03 pg/ml in CC, CT and TT genotypes respectively, p=0.003). Post-hoc analysis showed 
that TT subjects had higher levels of IL-6 compared to CC (P=0.043) and CT subjects 
(P=0.002). There was no correlation between the polymorphism and CRP (P=NS).
Conclusions: Our findings indicate that, in healthy individuals, p22phox C242T polymorphism 
is associated with arterial stiffness and levels of inflammatory mediators in an controversial 
way, possibly because of down-regulation of oxidative stress status in TT subjects. These 
preliminary data provide new insights into the possible links between the p22 phox subunit 
gene and the cardiovascular system and highlight the need for further investigation.
2:00 p.m.
1014-212 ACE-Inhibitors may efficiently prevent aortic dilatation 
after Acute Type A Aortic Dissection
Eva S. KrÃ¤henbÃ¼hl, Florian Schoenhoff, Mario Stalder, Lars Englberger, Friedrich 
S. Eckstein, Thierry P. Carrel, Franz F. Immer, Department of Cardiovascular Surgery, 
Berne, Switzerland
Background: Secondary dilatation of the downstream aorta after repair of acute type A 
aortic dissection (AADA) is a major concern. In animal models ACE-Inhibitors have been 
shown to have a beneficial effect on aortic wall remodelling. The aim of the present study 
is to assess the effect of ACE-Inhibitors on secondary dilatation after surgical treatment 
of AADA.
Methods: 160 consecutive patients after repair of AADA were followed in our outpatient 
clinic. All in-hospital data were assessed and a clinical follow-up with CT-Angio and/or 
MRI was performed. 32 patients (Group 1, 20%) showing an increase in diameter of 
the descending thoracic aorta were compared to 128 patients (Group 2) with stable 
dimensions of their aorta.
Results: The two groups were comparable regarding age (61.0Â±10yrs vs. 61.0Â±11yrs; 
p=ns), gender and cardiovascular risk factors. Mean systolic blood pressure at the time 
of follow-up was also similar in bothgroups.All patients were discharged on beta-blocking 
agents and remained on this regimen through-out follow-up. ACE-inhibitors was indicated 
in patients in whom hypertension coul not be controlled by beta-blocking agents only.
Only 3 patients (9.3%) in group 1 were treated with ACE inhibitors, whereas 51 (40%) in 
group 2 were under this therapy (p<0.05).
Conclusion:Although ACE-Inhibitors are known to have stabilizing effects on the aortic 
wall, this is, to our knowledge, the first clinical study showing a protective effect on 
secondary dilatation in patients with AADA.
2:00 p.m.
1014-213 The Role Of Systemic Oxidative Stress In The 
Regulation Of Asymmetrical Dimethyl-Arginine (ADMA) 
Synthesis In Homocysteinemia
Charalambos Antoniades, Dimitris Tousoulis, Kyriakoula Marinou, Carmen Vasiliadou, 
George Bouras, George Latsios, Elli Stefanadi, Charalambos Vlachopoulos, Gerasimos 
Siasos, Costas Tentolouris, Christodoulos Stefanadis, 1st Cardiology Department, 
Hippokration Hospital, Athens Medical School, Athens, Greece
Background: Endothelial nitric oxide synthase endogenous inhibitor, asymmetical-dimethyl 
arginine (ADMA), is associated with endothelial dysfunction. Although methionine-induce 
homocysteinemia is associated with increased oxidative stress which results to impaired 
endothelial function, the role of ADMA remains unclear. We investigated the role of ADMA 
and oxidative stress in endothelial dysfunction observed during methionine-induced 
homocysteinemia.
Methods: Thirty healthy subjects (24±2 yrs old) underwent methionine loading (100 
mg methionine/Kg body weight). Fifteen of them also received vitamin C (2gr) and E 
(800IU) before methionine loading and 15 placebo. Forearm blood flow was measured 
by plethysmography at baseline and 4 hours post methionine loading (4h-PML), and 
endothelium dependent dilation (EDD) was determined. Plasma homocysteine (Hcy), 
ADMA and oxidized-LDL (ox-LDL) were determined at baseline and 4h-PML.
Results: Plasma Hcy was increased in both vitamins and placebo groups (12.05(6.6-26.2) 
and 11.3(6.8-15.5) to 34.6(22.7-54.4) and 31.4(23.7-47.6) µM p<0.01 for both at 4h-PML. 
Ox-LDL was increased only in the placebo group (56.3±8.26 to 107.6±8.9 IU/L p<0.01) but 
remained unchanged in the vitamins group (61.57±5.31 to 61.78±9.76 IU/L p=NS). EDD 
was decreased in both vitamins and placebo groups (86.6±10.5 and 96.7±9.6 to 41.1±6.3 
and 52.2±6.5% respectively, p<0.01 for both). Plasma ADMA was also increased in both 
vitamin-treated and placebo (0.59±0.03 and 0.61±0.041 to 0.78±0.048 and 0.82±0.038 
µM respectively, p<0.01 for both) at 4h-PML.
Conclusions: Both oxidative stress and ADMA are implicated in endothelial dysfunction 
during methionine-induced homocysteinemia. Although antioxidants prevent the increase 
of oxidative stress in acute homocysteiemia, they do not affect the increase of ADMA and 
the development of endothelial dysfunction. These findings suggest that the release of 
ADMA during methionine-induced homocysteinemia is not regulated by oxidative stress, 
and it is partly responsible for the rapid development of endothelial dysfunction in this 
disease model, independently from free radicals production.
2:00 p.m.
1014-215 Direct blood-sampling from the coronary collateral 
circulation provides new insights in human collateral 
artery growth
Stephan H. Schirmer, Niels van Royen, Joost O. Fledderus, René J. van der Schaaf, 
Jan Baan, Jr., José P. Henriques, Marije M. Vis, Jan J. Piek, Academic Medical Center, 
Amsterdam, The Netherlands
Background: Analyses of blood samples derived locally from the coronary collateral 
circulation can reveal new insights into the mechanisms of collateral artery development 
in humans. However, limitations in collateral-specific blood sampling in patients hamper 
such specific analyses. Proximal embolic protection devices have a wide inner lumen 
and can potentially also be used to perform direct blood sampling from the collateral 
circulation.
Methods and Results: We used a Proxis® proximal embolic protection device (St. Jude 
Medical) to perform blood sampling directly from the collateral circulation in 50 patients 
undergoing percutaneous coronary intervention. Patients also underwent invasive 
measurement of the coronary collateral flow index (CFI). Arterial blood specifically 
sampled from the collateral circulation demonstrated decreased myocardial oxygen 
extraction in patients with adequate collateral supply (CFI>0.21) as opposed to patients 
with inadequate collateral supply (10.10% vs. 19.73%, p<0.01). Partial oxygen pressure 
(pO2) ratios of collateral/coronary blood correlated clearly with CFI (correlation coefficient 
0.67, R²=0.45, p<0.001). Collateral blood plasma showed significantly increased levels 
of bFGF, Eotaxin, HGF, MCP-1 and TGFbeta as compared to coronary blood plasma. 
Conversely, collateral-specific concentrations of b-NGF, SCF, SCGF and TNFbeta 
were significantly decreased. Concentrations of the majority of cytokines were lower in 
collateral samples of patients with adequate collateral supply.
Conclusion: This study demonstrates for the first time that oxygen partial pressure as 
measured directly in the collateral circulation correlates with the degree of collateral 
maturation. Well developed collateral arteries are capable to supply the myocardium 
with sufficiently oxygenized blood. In addition, collateral blood plasma shows distinct 
cytokine expression profiles compared to non-collateral coronary blood. Lower cytokine 
concentrations in more mature collateral arteries suggest decreased inflammatory activity 
in these vessels.
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1014-216 Linear relation between plaque vulnerability and 
the balance of n6/n3 polyunsaturated fatty acids: a 
study of stable angina pectoris with radiofrequency 
intravascular ultrasound
Yoichi Takaya, Masayuki Ueeda, Takenori Domei, Nobuhiko Ohnishi, Atsushi Takaishi, 
Atsushi Hirohata, Shozo Kusachi, Mitoyo General Hospital, Kanonji, Japan
Background: We have reported that the balances of n6/n3 PUFAs, particularly arachidonic 
acid (AA) to eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA), are important 
determinant factors not only of the amount of coronary plaque volume quantified by 
computed tomography, but also of the prognosis of acute myocardial infarction (AMI). 
Recently developed radiofrequency intravascular ultrasound (VH-IVUS®) could elucidate 
plaque composition in vivo. Thus, we conducted this study to examine whether the amount 
and balance of PUFAs relate to the plaque components assessed by VH-IVUS.
Methods: A total of 33 patients of stable angina pectoris, averaged age of 70+-8 years, 
were enrolled into this study. All of them received successful percutaneous coronary 
intervention with an assistance of VH-IVUS. Their lesions were all de novo. We analyzed 
four components of plaque that is fibrous (F), fibrolipidic (FL), necrotic core (NC) and 
calcified area (C), at the culprit lesion (11 frames and a total of 10mm length). The means 
of four components were compared with the classical coronary risk factors (T.Cho, HDL-
C, LDL-C, TG, blood sugar and HbA1c) and PUFAs. We used Pearson’s correlation 
analysis and one-way regression analysis for statistics.
Results: The total plaque volume at culprit lesion was positively related to LDL-C (r=0.39, 
p=0.023) and negatively to HDL-C (r=-0.46, p=0.007). However, the percent necrotic core 
in the plaque was not related to LDL-C or HDL-C, but to the balance of AA/EPA (r=0.41, 
p=0.017) and HbA1c (r=0.43, p=0.012). A higher percentage of the necrotic core was 
reported to be related to plaque vulnerability. These result suggested that the volume of 
coronary plaque at culprit lesion is related to cholesterol, but instability of the plaque is 
influenced by the balance of n6/n3 PUFAs and diabetic condition. No significant correlation 
could be found between the balances of PUFAs and other coronary risk factors, indicating 
they are independent factors.
Conclusions: The balances of n6/n3 PUFAs, particularly AA/EPA, are significantly related 
the vulnerability of coronary plaque.
2:00 p.m.
1014-217 Overlapping Traits in carriers of Mutations of the 
TGFBR1 and TGFBR2 genes associated with Marfan 
Syndrome Type II, Loeys-Dietz Syndrome and Familial 
Thoracic Aortic Dilation/Dissection
Nicola Marziliano, Maurizia Grasso, Michele Pasotti, Eliana Disabella, Savina 
Mannarino, Daniela Larizza, Mario Viganò, Luigi Tavazzi, Eloisa Arbustini, Fondazione 
IRCCS Policlinico San Matteo, Center for Inherited Cardiovascular Diseases, Pavia, Italy
Background. Mutations of Transforming growth factor-beta receptor 1 (TGFBR1) gene 
cause Loeys-Dietz Syndrome (LDS) and Marfan Syndrome type II (MFS2). TGFBR2 
mutations cause LDS, MFS2 and Familial Thoracic Aortic Aneurysm and Dissection 
(TAAD). We describe the phenotypes and quantitative TGFBR1&2 expression associated 
with mutations of the two genes.
Methods and results. Twenty-eight members of eight unrelated families, whose probands 
have been diagnosed previously with MFS [n=7 with negative Fibrillin 1 (FBN1) gene 
screening] and TAAD [n=1], underwent multidisciplinary clinical evaluation and sequencing 
of the TGFBR1&2 genes. Quantitative expression of TGFBR1&2 and FBN1 genes was 
measured in peripheral blood RNA. Ten live patients of seven families carried TGFBR2 
mutations [novel: G417E, W504R, R537P; known: M425V (two unrelated probands) 
R460H, D446N]. Three relatives from one family carried the novel R487W TGFBR1 
mutation. Five of 13 patients fulfilled Ghent criteria for MFS: three showed additional traits 
typical of LDS. A 5-year-old girl showed typical LDS. A 4-year-old girl showed incomplete 
MFS traits. In six affected members from two unrelated families we diagnosed TAAD: one 
proband (TGFBR1-R487W) also showed broad implant of the uvula and arterial tortuosity. 
In TGFBR1&2 mutation carriers, both mutated and FBN1 genes showed wide expression 
variability, according to type of mutation, age and severity of the disease.
Conclusions. Patients diagnosed with MFS2 and TAAD may show traits reported in LDS. 
This partial phenotype overlapping makes difficult the diagnosis and calls for definition 
of minimal diagnostic criteria for the different syndromes associated with TGFBR1&2 
mutations.
2:00 p.m.
1014-218 Identification of the Patient Requiring Revascularization 
by Multianalyte Profiling Analysis: A Blueprint 
Characterized by Heightened Inflammation and 
Endothelial Dysfunction
Kevin Bliden, Udaya Tantry, Lookman Lawal, Oscar V. Bailon, Anand Singla, Miruais 
Hamed, Paul A. Gurbel, Sinai enter for Thrombosis Research, Baltimore, MD
Background: Inflammation is important in the pathogenesis and progression of coronary 
artery disease. Elevated levels of inflammation markers are found in patients with acute 
coronary syndromes. It is unknown whether heightened inflammation can identify patients 
who will require revasularization.
Methods: We studied 84 subjects with stable angina undergoing PCI and 71 subjects 
with stable coronary artery disease who had undergone PCI more than 6 months earlier. 
Blood samples were drawn pre-procedure for fluorokine multianalyte profiling (MAP) 
assays. Patients in both groups were evenly matched for age, sex, and risk factors. All 
patients were on aspirin therapy prior to blood draws.
Results: PCI patients had significantly higher levels of C-reactive protein (CRP), 
B2-microglobulin, complement C3, RANTES, ENA-78, lymphotactin, IL-10, IL-15, 
Macrophage inflammatory protein-1 (MIP-1) alpha and beta, and Endothelin-1and IL-
1alpha, IL-13 and IL-16 were lower in PCI patients (Table).
Conclusion: The biomarker profile of stable patients undergoing PCI is markedly 
different from patients with stable CAD after remote PCI; and is highlighted by marked 
inflammation and endothelial dysfunction. These findings suggest that a state of high 
risk marked by inflammation distinctly identifies the patient requiring revascularization. 
Early identification of heightened inflammation and endothelial dysfunction may identify 
the patients at risk and facilitate diagnosis and therapy. 
SA-PCI (n=84) S-CAD (n=71) p value
B2-Microglobulin (ug/ml) 2.5± 2.4 2 ± 0.7 p<0.05
CRP (mg/l) 9.3 ± 14.6 4 ± 8.1 P<0.01
Complement C3 (mg/ml) 1.17 ± 0.3 1 ± 0.2 p<0.001
RANTES (ng/ml) 11.5 ± 10 4.2 ± 3 P<0.00001
ENA-78 (ng/ml) 0.57 ± 0.9 0.19 ± 0.3 P<0.001
Lymphotactin (ng/ml) 0.22 ± 0.17 0.14 ± 0.11 P<0.001
IL-1 alpha (ng/ml) 0.31 ± 0.15 0.43 ± 0.24 P<0.001
IL-13 (pg/ml) 52.8 ± 35 87.7 ± 46 P<0.0001
IL-15 (ng/ml) 1.8 ± 0.8 1.5 ± 0.5 P<0.01
IL-16 (pg/ml) 653 ± 248 752 ± 225 P<0.05
IL-10 (pg/ml) 13.8 ± 8 9.4 ± 5 p<0.0001
Endothelin-1 (pg/ml) 4.9 ± 6.4 1.15 ± 1 P<0.00001
MIP-1alpha (pg/ml) 28.3 ± 24 19.3 ± 9 P<0.01
MIP-1beta (pg/ml) 203 ± 302 90 ± 43 P<0.01
2:00 p.m.
1014-219 Does a sirolimus-eluting stent affect endothelial 
function?-Comparison with bare-metal stent
Hiroki Teragawa, Kenji Nishioka, Noritaka Fujimura, Yuko Makita, Naoya Mitsuba, Yuichi 
Fujii, Junko Soga, Yuichiro Watari, Koichiro Okuhara, Yukihito Higashi, Tetsuya Oshima, 
Kazuaki Chayama, Graduate School of Biomedical Sciences, Hiroshima Univesity, 
Hiroshima, Japan
Background:Sirolimus-eluting stents (SESs) reduce restenosis in patients with coronary 
artery disease (CAD). However, it has recently been reported that SESs do not always 
improve the long-term prognosis of patients with CAD, as compared with bare-metal stents 
(BMSs). It is unknown whether deterioration of endothelial function after the implantation 
of SESs contributes to this discrepancy. Therefore, we investigated endothelial function of 
the brachial artery before and after the implantation of SESs, and compared it with that 
before and after the implantation of BMSs.
Methods: The subjects were 129 patients with CAD who underwent successful stenting. 
The patients were distributed into a Group I of 54 patients who bore SESs and a Group 
II of 75 patients who bore BMSs. Changes in the diameter of the brachial artery in 
response to hyperemic flow (FMD) and nitroglycerin spray (NTG) were measured using 
high resolution ultrasonography just before stenting and 6 months after it. The changes 
in FMD and NTG-induced dilation were expressed as differences between the two 
measurements.
Results:The characteristics of the patients did not differ between the 2 groups except 
for the concentration of high-density lipoprotein cholesterol (p<0.05) and the presence 
of diabetic mellitus (p<0.05). The restenosis rate was significantly lower in Group I (4%) 
than in Group II (43%, p<0.0001). Before stenting, FMD (Group I: 3.8±0.5%, Group II: 
3.7±0.5%) and NTG-induced dilation (Group I: 11.9±0.8%, Group II: 13.7±0.7%) did 
not differ significantly between the 2 groups. Six months after stenting, the change in 
FMD was smaller in Group I (-1.5±0.6%, p<0.001) than in Group II (1.0±0.5%) while the 
change in NTG-induced dilation did not differ significantly between the 2 groups (Group I: 
1.7±1.0%, Group II: 2.1±0.9%). Multivariate analysis demonstrated that the implantation 
of SESs (p<0.001) was one of the factors affecting FMD after stenting.
Conclusions: These results suggest that endothelial function deteriorated 6 months after 
the implantation of SESs, compared with BMSs, although SESs reduced restenosis. 
This finding may confirm the need for a careful follow-up of patients with CAD after the 
implantation of SESs.
2:00 p.m.
1014-220 Association of Endothelial Progenitor Cell Colonies 
With Cardiovascular Risk Factors
Konstantinos Aznaouridis, Muhiddin Ozkor, Jonathan R. Murrow, Kreton Mavromatis, 
Salman Sher, Jesse Jorgensen, Diane J. Sutcliffe, Seema Hameed, Wayne AC Harris, 
W Robert Taylor, R Wayne Alexander, Arshed A. Quyyumi, Emory University School of 
Medicine, Atlanta, GA
Background: Cardiovascular risk factors (RFs) modulate the level of endothelial progenitor 
cells (EPCs) and their capacity to form colonies. In contrast to culture assays of late 
outgrowth “proliferative” EPC colonies (EPC-cfu), the number of early “angiogenic” EPC-
cfu correlate inversely with RFs. We explored the relationship of RFs with EPCs using an 
“intermediate” duration assay for EPC-cfu and flow cytometry for circulating EPCs.
Methods: 7-day culture of mononuclear cells that yield colonies with endothelial-type 
cells at their periphery were performed in 426 subjects (age 58±12) with or without 
cardiovascular RFs or disease. Circulating EPC-enriched populations were quantified as 
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CD34+/CD133+ and CD34+/VEGFR2+ dual positive cells in 114 subjects (age 62±10).
Results: Age correlated positively with the number of EPC-cfu (r=0.41, P<0.001), but 
inversely with the CD34+/CD133+ count (r= -0.31, P=0.001). There was a correlation 
between EPC-cfu and the number of RFs, even after adjusting for age, gender and 
atherosclerotic disease (P<0.001, figure A). In contrast, we observed a progressive 
decrease in CD34+/CD133+ (P=0.017) and CD34+/VEGFR2+ cell counts (P=0.001, 
figure B) with increasing number of RFs.
Conclusions: Although a higher burden of cardiovascular RFs is related to lower level of 
circulating EPC-enriched populations, their proliferative capacity assessed in culture is 
greater. This is the first illustration of the divergence in impact of RFs on the number and 
function of EPCs. 
2:00 p.m.
1014-221 Angioscopic Evaluation of Overlapping Paclitaxel-
Eluting Stents: Correlation to Histopathologic 
Observations in Swine Coronary Arteries
Toshiro Shinke, Lakshmana Pendyala, Sara Geva, Traci Goodchild, Refat Jabara, 
Jinsheng Li, Nicolas Chronos, Keith Robinson, Dongming Hou, Saint Joseph’s Research 
Institute, Atlanta, GA
Background: Human autopsy studies on paclitaxel-eluting stents (PES) correlated 
late stent thrombosis (LST) to incomplete re-endothelialization, persistent intramural 
thrombus/hemorrhage, and inflammation; however there is a shortage of data regarding 
the relation of late clinical outcomes and PES responses in animal models, and no 
pulished information on overlapping PES in a coronary model. We correlated in vivo 
fiberoptic angioscopy of overlapping PES (TAXUS®) to histology in a swine coronary 
model.
Methods: Pigs (n=8) received PES and BMS with 3-6mm target overlap. Angiography 
(n=8), angiosopy (n=4) and histology (n=4) were studied at one month. Angiographic late 
lumen loss (LL); angioscopic grading for neointimal coverage (NC, from grade 0; stent strut 
visible to 3; non-visible) and mural thrombus (MT; from grade 0; none to 3; severe); and 
histopathologic scoring for intramural thrombi (IT) and endothelialization (EN) were done.
Results: LL was greater in BMS vs PES (1.11±0.42 versus 0.25±0.14, P<0.01), especially 
in overlapped segment (P<0.001). PES showed lower NC score (P<0.05) and higher MT 
score compared to BMS (P<0.05). Histologically, although full EN existed in both groups, 
IT score was higher in PES (P<0.05).
Conclusions: Overlapping PES markedly increases the incidence of mural thrombus compared 
to BMS. Persistent neointimal thrombus which is likely related to late adverse events, is 
detectable by angioscopy and so is a useful clinical evaluation in patients with PES. 
2:00 p.m.
1014-222 Myocardial capillary density is severely reduced 
in patients with end-stage congestive heart failure 
secondary to idiopathic dilated cardiomyopathy
E. Tsagalou, E. Agapitos, J. Kanakakis, G. Alexopoulos, A. Ntalianis, N. Lazaris, C. 
Pantsios, J. Nanas, University of Athens Medical School, Athens, Greece
Background: Decreased myocardial capillary density (MCD) has been reported in 
patients with idiopathic dilated cardiomyopathy (IDC). The aim of the present study was 
to to examine the possible correlation between MCD and disease severity in patients 
with IDC.
Methods: Myocardial tissue samples were obtained from right ventricular septal 
endomyocardial biopsies in 14 patients, or from left ventricular apical myectomies, 
performed during left ventricular assist device implantation in 4 patients. Autopsied 
samples from 5 non-failing hearts were used as controls. The tissue was histochemically 
stained with CD-34 for morphometric measurements of MCD.
Results: The patients were in a mean age of 48±10 years, in mean New York Heart 
Association functional class 2.9±1.3, mean left ventricular ejection fraction 22±8 percent, 
and mean pulmonary capillary wedge pressure 34±12 mmHg .We observed a close 
correlation between NYHA functional class and MCD (r=0.839, P=0.0001). The MCD in 7 
patients in NYHA class 1 or 2 (73.2±17) was similar to that measured in normal controls, 
(85±11, P=ns). In contrast, the MCD in 11 patients in a NYHA class 3 or 4 despite maximal 
drug therapy was 33.2±14, significantly lower than in patients with CHF and preserved 
clinical condition (73.2±16, P=0.001) or in controls (85±11, P < 0.0001).
Conclusion: MCD is severely depressed in patients with end stage CHF due to IDC
2:00 p.m.
1014-223 Is Insulin Resistance or Obesity a Hypercoagulable 
State?
Haruka Itakura, Gerald M. Reaven, Philip S. Tsao, Stanford University, Stanford, CA
Background: Insulin resistance (IR), the cardinal feature of type 2 diabetes mellitus, is 
associated with cardiovascular disease. Although the underlying mechanism is not well 
understood, it is hypothesized that IR promotes a pro-thrombotic milieu, predisposing an 
individual with impaired insulin utilization to vascular occlusive events. However, individuals 
with IR are frequently obese, and it is unclear whether obesity or the impaired insulin 
utilization itself is the significant contributor in predisposing to coagulation. This study 
quantifies and compares the integrative coagulation activity between individuals with and 
without IR, and of varying levels of body mass index (BMI), using a novel functional thrombin 
generation assay. Methods: The modified insulin suppression test was used to characterize 
the degree of insulin sensitivity in non-diabetic participants with no significant organ 
dysfunction. In a case-control study design, individuals with IR (defined as steady-state 
plasma glucose [SSPG] >152 mg/dL; n= 30) and insulin sensitivity (IS; SSPG <100 mg/dL; 
n=25) were compared their degree of overall coagulability using the thrombin generation 
assay. Levels were compared in both univariate and multivariate analyses, adjusting for age, 
sex, and BMI. Results: Subjects with IR had higher thrombin generation (p<0.05) compared 
with those with IS. However, after adjustment for sex, age, and BMI, the association was 
no longer present. In contrast, thrombin generation was significantly associated with BMI 
both in the univariate analysis (p<0.00001) and even after adjustment for age, sex, and 
SSPG (p<0.001). Mean BMI was 27.4 kg/m2 (range 16.6-33.5 kg/m2) in the IS, and 30.8 
kg/m2 (range 25.7-37.7 kg/m2) in the IR group. Male:female ratios were 0.48 in the IS, and 
0.43 in the IR group. Mean ages were 52.4 and 49.2 in the IS and IR groups, respectively 
(p=0.1674). Conclusion: We were able to observe a difference in thrombin generation 
that was significantly associated with BMI. This finding suggests that hypercoagulability 
may be associated more with obesity than IR per se. Ongoing investigations are aimed at 
elucidating the specific mechanisms underlying this association.
2:00 p.m.
1014-224 Adult Bone Marrow Cells Differentiate Into Multiple 
Structures and Trigger Angiogenesis Expression in 
ApoE Knockout Mice
Qi Liu, Zhiqiang Chen, Toya Terry, Janice McNatt, James T. Willerson, Pierre Zoldhelyi, 
Texas Heart Institute at St. Luke’s Episcopal Hospital and University of Texas Health 
Science Center, Houston, TX
Background: Cell therapy promotes angiogenesis in animal models of ischemia, but it 
is unclear to what extent new blood vessels originate, respectively, from transplanted 
and endogenous precursor cells. We addressed this issue in a mouse model of 
hindlimb ischemia. Methods: The proximal femoral artery of apoE-/- mice was occluded 
by 2 adjacent ligatures followed by intrafemoral injection of 2.5 x 106 GFP positive 
unfractionated mononuclear bone marrow cells (BMC) or PBS. Hindlimb blood flow of 
ischemic and normal limbs was monitored up to 30 days post-surgery by Laser Doppler 
imager at 3-day intervals. At 24 hours, 3, 7, 14, 21 and 28 days, the ishemic hindlimbs 
were analyzed histochemically and immunohistochemically. Angiogenesis array was 
also performed. Results: Compared to PBS treated mice legs (N=13), mice injected 
with GFP BMC (N=15) showed significant flow recovery at 21 days after surgery, with 
further improvement by day 28 (41.9%± 13.9% vs. 61.8% ± 15%, P<0.05). Under dual 
band pass filter fluorescence microscope, cross sections from decalcified ischemic legs 
showed GFP positive cells formed cord-like structures as early as 7 days, which stained 
positive for CD34, negative for CD31 and CD105. At 14 days, a larger cord-like structure 
was found with an increased number of CD34 positive cells, again negative for CD31 
and CD105. At 21 days, small arteries, originating from GFP BMC, in the subcutaneous 
layer were stained positive for α-SMC actin and vWF. At 28 days, GFP BMC regenerated 
skeletal muscle fibers, which stained positive for laminin. Angiogenesis array indicated 
TGFβ, VEGF, IL-4 and TNFα were up regulated at 3 days and further at 14 days, post 
BMC delivery. Conclusions: Adult bone marrow cells contributed to restoration of blood 
flow, formation of vascular and skeletal structures after induced hindlimb ischemia and 
triggered early up-regulation of several angiogenesis activators and inhibitors. Such 
findings suggest that bone marrow cells exhibit plural effects in treating peripheral arterial 
occlusive disease. 
2:00 p.m.
1014-225 Peripheral arterial disease panel
John P. Cooke, Stanford University, Stanford, CA
Background: Peripheral arterial disease (PAD) is common, but often not diagnosed. A 
biomarker index would be useful to raise suspicion of PAD, so as to trigger appropriate 
vascular testing and management.
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Methods: The study comprised 549 subjects, 197 subjects with both coronary artery 
disease and peripheral arterial disease (CAD+PAD); 81 subjects with CAD only; and 
262 subjects with no hemodynamically significant disease (NHSD) of the coronary or 
peripheral arteries. Multiple linear regression was performed to generate a biomarker 
panel score that could predict ABI. Logistic regression was used to investigate the 
relationship between disease status and the panel score as well as other risk factors (e.g. 
age, diabetes status, smoking status). ROC analysis was performed to test the prediction 
power of the biomarker panel score.
Results: Among the plasma markers tested, β2M and cystatin C had the highest 
correlation with ankle-brachial index, and higher than any of the conventional risk factors 
of age, smoking status, and diabetes status. A biomarker panel score derived from β2M, 
cystatin C, hsCRP, and glucose had an increased association with PAD status (OR=12.4, 
for highest vs lowest quartile) which was still significant after adjusting for known risk 
factors (OR=7.3, 95% confidence interval 3.6-14.9 for highest vs lowest quartile).
Conclusions: After taking into account the traditional risk factors for PAD, a biomarker 
panel comprising β2M, cystatin C, hsCRP, and glucose adds useful information to assess 
the risk of disease.
2:00 p.m.
1014-226 Clinical Implications of Aortic Atherosclerosis 
Evaluated by Transesophageal Echocardiography in 
Surgery of Patients with Valvular Heart Diseases
Won-Jang Kim, Jong-Min Song, Jong-Young Lee, Yun-Jeong Kim, Jeong-Woo Lee, Jae 
Won Lee, Duk-Hyun Kang, Jae-Kwan Song, Asan Medical Center, Seoul, South Korea
Background: Clinical significance of aortic atherosclerosis (AA) in patients with 
valvular heart disease (VHD) who undergo open heart surgery has not been clearly 
demonstrated.
Methods: Transesophageal echocardiography was performed to evaluate AA and 
VHD in 364 patients before cardiac surgery. The grade of AA was classified into none, 
mild, moderate and severe according to the maximal AA thickness in aortic arch and 
proximal descending aorta. Brain magnetic resonance image (MRI) and angiography, and 
coronary angiography were performed before surgery. Clinical outcomes were evaluated 
after surgery.
Results: The prevalence of significant coronary artery disease was 9%, 17%, 31% and 
44% in patients with none, mild, moderate and severe AA, respectively (p<0.005). Stroke 
was developed immediate after surgery in 4 patients (1.1%). The stroke incidence was 
not significantly associated with age, sex, body mass index, atrial fibrillation, smoking, 
hypertension, hypercholesterolemia, diabetes, and coronary artery or carotid artery 
diseases. The perioperative stroke incidence was higher in patients with moderate to 
severe AA than in those with none to mild AA (5.2 vs 0.3%, p<0.05), and higher in patients 
with old cerebral infarct in MRI performed before surgery than in those without (6.3 vs 
0.3%, p<0.05). Perioperative mortality (1.1%) was not related with the severity of AA. 
Significant AA increased the risk of perioperative stroke with odds ratio of 16.6 (95% 
confidence interval, 1.7 - 162.9).
Conclusion: AA evaluated by transesophageal echocardiography is associated with 
coronary artery disease. Although stroke incidence is low in VHD surgery, significant AA 
is the risk of stroke in this clinical situation.
2:00 p.m.
1014-227 Chemokine Upregulation in the Aortic Vasa Vasorum 
is Associated With Inflammatory Cell infiltration and 
Aneurysmal Dilation of the Aorta
Oliver Dewald, Pankaj Madan, Thorsten Leucker, Haug Loriz, Hyuk-Jung Kweon, Armin 
Welz, Nikolaos G. Frangogiannis, University of Bonn, Bonn, Germany, Baylor College of 
Medicine, Houston, TX
Background: Leukocytes infiltrating the aortic wall may be involved in aortic aneurysm 
formation by releasing cytokines and proteases that induce extracellular matrix degradation 
mediating dilative remodeling of the aorta. Local upregulation of the chemokines, a family 
of chemotactic cytokines, may regulate leukocyte recruitment in the aneurysmal aorta 
playing an important role in the pathogenesis of aortic dilation.
Objective: To examine the involvement of chemokine-induced inflammation in aneurysmal 
dilation of the aorta.
Methods: Samples from abdominal aortic aneurysms (A, n=30) and control aortic samples 
from patients without aortic dilation undergoing bypass surgery (C, n=15) were studied. 
Macrophage, mast cell and microvascular density in the aortic media and adventitia was 
compared. Inflammatory activity was assessed using staining for Mac387, a marker that 
identifies newly-recruited leukocytes, but not mature macrophages. Chemokine mRNA 
expression was assessed using an RPA.
Results: Aneurysmal aortas had decreased adventitial collagen and medial elastin 
content in comparison with non-aneurysmal aortas. Aneurysmal aortas exhibited intense 
infiltration of the adventitia with newly-recruited Mac387-positive leukocytes (A: 31.1±5.5 
vs. C: 12.7±4.7 cells/mm2, p<0.01). Furthermore, aneurysmal dilation was associated 
with increased density of adventitial mast cells (A: 10.5±0.9 vs. C: 4.9±1.5 cells/mm2, 
p<0.01), enhanced infiltration of the adventitia and media with macrophages and 
increased adventitial vascular density. mRNA expression of the chemokines MCP-1, IL-
8 and I-309 was significantly higher in aneurysmal samples. MCP-1 expression in the 
aneurysmal aorta was localized in the endothelium of the vasa vasorum.
Conclusions: Aneurysmal dilation of the aorta is associated with active inflammation in 
the aortic adventitia. Activated endothelial cells of the vasa vasorum express chemokines 
and induce leukocyte recruitment in the aortic wall. Mononuclear cells and mast cells 
infiltrating the aortic adventitia and outer media are capable of secreting proteases that 
degrade the extracellular matrix network, inducing dilative remodeling of the aorta.
2:00 p.m.
1014-228 Ankle Brachial Index Does Not Predict Health Status in 
Peripheral Arterial Disease
Kelly R. O’Neal, III, David M. Safley, John A. House, John A. Spertus, Steven P. Marso, 
Mid America Heart Institute, Kansas City, MO
Background: The Peripheral Artery Questionnaire (PAQ) is a useful, disease-specific 
measure of quality of life for patients with peripheral arterial disease (PAD). The PAQ 
correlates with walking times but has not been examined in correlation with ankle-brachial 
indices (ABI’s), a reproducible, easy-to-obtain measure of PAD disease severity that is 
commonly reported as an outcome of studies of lower extremity revascularization.
Methods: All patients included in the ALEVE study who underwent baseline rest and/
or exercise ABI measurement were included in this subanalysis. There was no protocol 
mandate for ABI measurement in ALEVE. Pearson correlation coefficients were performed 
for resting and exercise ABI’s with PAQ scores at the time of enrollment in ALEVE, before 
attempted revascularization.
Results: There were 117 patients included in this analysis. All 117 had baseline resting 
ABI’s, and 85 had exercise ABI’s. Correlation coefficients were not significant at rest (r = 
0.057, p = 0.49) or exercise (r = 0.135, p = 0.93) between ABI’s and PAD-specific health 
status as quantified by Peripheral Artery Questionnaire Summary score.
Conclusions: There was no correlation between ABI’s and health status in PAD patients 
as measured by the PAQ. ABI measurement is useful in the diagnosis of PAD and is 
often reported as an outcome measure in studies of lower extremity revascularization. 
However, the lack of a correlation between ABI and health status calls into question the 
utility of ABI as an endpoint for studies of a procedure that is overwhelmingly performed 
specifically to improve health status. The PAQ (or another health status measure) may be 
a more useful study endpoint, and should be included in future studies of lower extremity 
revascularization.
2:00 p.m.
1014-229 Low Ejection Fraction and Poor Performance 
Status Negates the Beneficial Effects of Complete 
Revascularization in Patients with Critical Limb 
Ischemia
Osamu Iida, Shinsuke Nanto, Masaaki Uematsu, Takakazu Morozumi, Tetsuya 
Watanabe, Masaki Awata, Toshinari Onishi, Fusako Sera, Hitoshi Minamiguchi, Hirokuni 
Akahori, Masamichi Yano, Kuniyasu Ikeoka, Shin Okamoto, Nobuaki Tanaka, Haruyo 
Yasui, Seiki Nagata, Kansai Rosai Hospital, Amagasaki, Japan
Background: We have previously demonstrated the complete revascularization to the 
pedal arch in patients with critical limb ischemia (CLI) not only improves the limb salvage, 
but also improves the survival. Nonetheless, not every patient benefits from complete 
revascularization. We sought to elucidate the factors influencing the mortality of patients 
with CLI underwent complete revascularization.
Method: Among consecutive 167 patients with CLI (Rutherford 4 to 6), those in whom 
the complete revascularization to the pedal arch was achieved were enrolled (male = 
77, age ranged 29-93 years). Patients were followed up for 14 months. Single regression 
analysis and subsequent multivariate analysis were performed to explore the independent 
determinants of mortality.
Results: Death occurred in 12 patients during the follow up. Eastern Cooperative 
Oncology Group Performance Status as defined by Oken MM et al. ≥3, dialysis treatment, 
ejection fraction (EF) <35% as measured by echocardiography, cholinesterase (ChE), 
C reactive protein, and cerebral vascular disease (CVD) with sequelae were chosen as 
independent variables related to mortality by single regression analysis (P<0.05). Results 
of the multivariate analysis were shown in the Table.
Conclusion: Low ejection fraction and poor performance status negates the beneficial 
effects of complete revascularization in patients with critical limb ischemia. 
2:00 p.m.
1014-230 Divergent Trends in Stroke and Myocardial Infarction 
Incidence and Case-Fatality (A New Jersey Statewide 
Study)
Yu-Hsuan Shao, William J. Kostis, Abel E. Moreyra, Alan C. Wilson, Nora M. Cosgrove, 
John B. Kostis, For the Myocardial Infarction Data Acquisition System (MIDAS) Study 
Group, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ
Background: Mortality due to stroke and coronary heart disease has declined during 
the last two decades. However, patterns of in incidence and case fatality of these two 
conditions have not been examined closely.
Methods: We examined the crude and age-adjusted incidence and case fatality of first 
hospitalized stroke (N=239,898) in New Jersey during 1994 to 2006 using the Myocardial 
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Infarction Data Acquisition System (MIDAS) and contrasted these trends to those with 
AMI in the same database during the same study period. Incidence was adjusted to the 
1994 New Jersey population age distribution.
Results: Crude stroke incidence decreased by 30% from 445 in 1994 to 306 per 100,000 
in 2006. Age- and sex-adjusted incidence also decreased by 31% from 445 to 296 per 
100,000. The magnitude of the decline in incidence was positively associated with age. 
The decrease was largest among persons aged 85 and older (44.6%), with smaller 
declines in other age groups (75-84: 41.0%, 65-74:38.0%, 55-64:23.7%). However, the 
stroke incidence increased in the youngest (30-54) age group by 22.8%. In-hospital case 
fatality due to stroke declined from 11.1% in 1994 to 6.2% in 2006. This decline was 
observed in all age and gender groups. In contrast, during the same study period, the 
incidence of acute myocardial infarction increased only among persons aged 85 and 
older (+12%) and decreased in the youngest age group (-14%).
Conclusions: While there has been an overall decrease in the incidence of hospitalized 
stroke, a disturbing increase was observed in younger individuals (below age 55). This 
age-specific increase was not observed in AMI. The reason for these divergent trends is 
not yet known.
ACC.ORAL CONTRIBUTIONS
803 
Venous Thrombosis and Pulmonary 
Hypertension
Monday, March 31, 2008, 8:00 a.m.-9:30 a.m.
McCormick Place, Room E353
8:00 a.m.
803-4 SR123781A, a New Synthetic Anticoagulant for the 
Prevention of Venous Thromboembolism in Total Hip 
Replacement Surgery - DRIVE: a Dose Ranging Study
Michael R. Lassen, Ola Dahl, Patrick Mismetti, Dirk Zielske, Hørsholm Hospital, 
Hørsholm, Denmark
Background: SR123781A is a novel synthetic hexadecasaccharide, which is a highly 
potent antithrombin III-dependent inhibitor of coagulation factors Xa and IIa. DRIVE (a 
multicenter, randomized, double-blind, double-dummy, parallel group, dose response 
study of subcutaneous SR123781A with an enoxaparin calibrator arm in the prevention of 
venous thromboembolism in patients undergoing elective total hip replacement surgery) 
evaluated the efficacy and safety of SR123781A for primary prophylaxis of venous 
thromboembolism (VTE).
Methods: Patients were randomized to receive subcutaneously and once daily SR123781A 
(0.25, 0.5, 1.0, 2.0 or 4.0 mg) or enoxaparin 40 mg for up to 10 days after surgery. The 
pre-operative injection of SR123781A was placebo, whereas the first dose of enoxaparin, 
depending of the investigator’s judgment, was administered either 12±1 h before or 8±1 h 
after surgery. The primary efficacy endpoint was the composite outcome of (1) any deep 
vein thrombosis (DVT) identified on mandatory venography identified 5 - 11 days after 
surgery; (2) confirmed symptomatic VTE and (3) VTE-related deaths. The primary safety 
endpoint was major bleeding defined according to a CPMP modification.
Results: Of 1009 treated patients, 736 were eligible for the primary efficacy analysis. 
The primary efficacy outcome rates were at 21.2%, 17.7%, 13.5%, 7.0% and 4.4% for 
the SR123781A doses of 0.25, 0.5, 1.0, 2.0 and 4.0 mg, respectively demonstrating a 
highly statistically significant dose response (p<0.0001). The rate in the enoxaparin group 
was 8.7%. A significant dose response was also observed for proximal DVT with rates 
decreasing from 6.7% to 0% (p<0.0001). A statistically significant dose response was 
found for major bleeding with rates increasing from 1.2% to 5.8% (p=0.0037) and any 
bleeding ranging from 4.1 % to 24.6% (p< 0.0001) for the SR123781A dosing arms, 
compared with 0.6% and 3.6%, respectively, in the enoxaparin group.
Conclusions: In DRIVE, SR123781A, a novel anticoagulant, showed a significant dose 
response in prevention of venous thromboembolic events and a inverse dose-response 
for bleeding.
8:15 a.m.
803-5 Incidence and Management of Acquired 
Thrombocytopenia Among Patients Receiving 
Prolonged Heparin Venous Thromboembolism 
Prophylaxis: Insights From the Complications After 
Thrombocytopenia Caused by Heparin (CATCH) 
Registry
Tracy Y. Wang, Emily F. Honeycutt, E. Magnus Ohman, Stephan Moll, Christopher B. 
Granger, Victor F. Tapson, Duke Clinical Research Institute, Duke University Medical 
Center, Durham, NC
Background: Heparin is commonly used for venous thromboembolism (VTE) prophylaxis, 
however, the incidence of acquired thrombocytopenia in this setting has not been well 
described.
Methods: CATCH was designed to evaluate the risk of thrombocytopenia among 
patients (pts) receiving heparin in diverse clinical settings. We examined the incidence, 
management, and outcomes of acquired thrombocytopenia (defined as platelet count 
drop >=50% or to nadir <150 x109/L) among pts with normal admission platelet counts 
(>=150x109/L) who received >=72 hours of heparin VTE prophylaxis.
Results: Among 1017 pts receiving heparin VTE prophylaxis, 190 (19%) developed 
thrombocytopenia. Factors significantly associated with the development of 
thrombocytopenia are shown below (Table). For thrombocytopenic pts, heparin-induced 
thrombocytopenia (HIT) serologies were obtained in 5%, and a hematology consult 
was obtained in 3%, but none were switched to a direct thrombin inhibitor. Heparin was 
continued in 170 pts (89.5%) for a median of 162 hours (interquartile range 99-276) 
after the nadir platelet count. Acquired thrombocytopenia was associated with increased 
mortality (3.7 vs. 0.7%, P=0.004) and both thrombotic and bleeding complications (11.1 
vs. 7.1, P=0.07; 16.5 vs. 4.9, P<0.0001).
Conclusion: Thrombocytopenia occurs frequently in pts on heparin VTE prophylaxis and 
is associated with worse outcomes. Careful platelet count monitoring and prompt heparin 
discontinuation in these pts may improve outcomes. 
Table. Factors significantly associated with the development of thrombocytopenia 
(c-index 0.76).
Chi-square Adjusted  OR 95% CI P
Admission platelet count 65.8 <0.0001
Platelet count <330x109/L 0.86 0.83-0.89
Platelet count >330x109/L 1.06 1.03-1.09
Ventilator 22.0 2.43 1.68-3.53 <0.0001
Days on heparin (per day) 20.6 1.09 1.05-1.12 <0.0001
Unfractionated heparin use (vs. low 
molecular weight heparin) 5.5 1.52 1.07-2.16 0.02
Systolic BP (per 10 mm Hg decrease) 4.9 1.10 1.01-1.19 0.03
Cardiac surgery 4.6 2.36 1.08-5.17 0.03
Candidate variables used to create the model included: age, sex, diabetes, prior 
MI, former vs. current smoker, systolic blood pressure, heart rate, body mass index, 
admission creatinine clearance, admission platelet count, cardiac surgery during 
hospitalization, other surgery during hospitalization, ventilator dependence during 
hospitalization, unfractionated vs. low molecular weight heparin use, heparin duration, 
use of other antiplatelet medications (aspirin, clopidogrel, GP IIb/IIIa inhibitors), and 
non-steroidal anti-inflammatory drug use.
8:30 a.m.
803-6 Deep Vein Thrombosis in Heart Failure Patients: 
Venous Thromboembolism Risk Factors Common and 
Prophylaxis Frequently Omitted
Gregory Piazza, Ali Seddighzadeh, Samuel Z. Goldhaber, Beth Israel Deaconess 
Medical Center, Boston, MA, Brigham and Women’s Hospital, Boston, MA
BACKGROUND: Heart failure patients are particularly vulnerable to the development of 
venous thromboembolism (VTE) and its related complications of pulmonary embolism 
and right ventricular failure.
METHODS: We studied heart failure patients in a prospective registry of 5,451 consecutive 
ultrasound-confirmed deep vein thrombosis (DVT) patients.
RESULTS: Of the 5,451 registry patients, 685 had a history of clinical heart failure, 3,890 
were non-heart failure patients and 876 had uncertain heart failure status. Heart failure 
patients had a high frequency of comorbid conditions contributing to a high medical acuity 
(Table). Furthermore, heart failure patients were more likely to have VTE risk factors of 
immobilization (52.6% versus 42.4%, p<0.0001), acute infection (33.3% versus 27%, 
p=0.01) and chronic obstructive pulmonary disease (28.8% versus 12.1%, p<0.0001). 
Heart failure patients also had a high frequency of recent hospitalization (47.5%). 
However, only 46% of heart failure patients who subsequently developed DVT received 
any VTE prophylaxis.
CONCLUSION: Heart failure patients are particularly vulnerable to developing VTE due 
to their high medical acuity and an increased frequency of VTE risk factors. Despite this 
elevated risk and a high frequency of recent hospitalization, fewer than half of heart failure 
patients received any VTE prophylaxis prior to developing DVT. Further studies should 
focus on improving implementation of VTE prophylaxis in this vulnerable population. 
Comorbid conditions and VTE risk factors among heart failure and non-heart failure 
patients with DVT
Heart Failure Patients Non-Heart Failure Patients p-value
Hypertension, n (%) 493 (72.0) 2,214 (56.9) < 0.0001
Immobilization within 
30 days, n (%) 281 (52.6) 1,346 (42.4) < 0.0001
Diabetes, n (%) 246 (35.9) 859 (22.1) < 0.0001
Acute infection, n (%) 132 (33.3) 528 (27.0) 0.01
Neurological disease 
including stroke, n (%) 224 (32.7) 1,010 (26.0) 0.0002
Acute lung disease 
including pneumonia, 
n (%)
122 (30.8) 289 (14.8) < 0.0001
Chronic obstructive 
pulmonary disease, 
n (%)
197 (28.8) 471 (12.1) < 0.0001
Acute coronary 
syndrome, n (%) 44 (11.1) 69 (3.5) < 0.0001
Chronic kidney 
disease, n (%) 56 (8.2) 212 (5.5) 0.005
Chronic venous 
disease, n (%) 51 (7.5) 148 (3.8) < 0.0001
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803-7 The REVEAL Registry: Hemodynamic Characterization 
of the First 1226 Patients Enrolled
Michael D. McGoon, Raymond L. Benza, Dave P. Miller, David B. Badesch, Mayo Clinic, 
Rochester, MN, University of Colorado at Denver and Health Sciences Center, Denver, CO
Background: The Registry to EValuate Early And Long-term PAH Disease Management 
(REVEAL) is a multicenter, observational, U.S.-based study designed to provide current 
information about the demographics, clinical course and management of patients 
diagnosed with pulmonary arterial hypertension (PAH).
Methods: Consecutive consenting patients with PAH diagnosed according to specific 
hemodynamic criteria are being enrolled at 50 sites in the U.S. Demographic data gathered 
at the time of enrollment include the results of diagnostic right heart catheterization (RHC) 
and echocardiographic measures of chamber enlargement.
Results: Among the 1226 total patients enrolled during the first 9 months, including 855 
with functional class (FC) available at the time of RHC, 706 (82.5%) were classified as 
New York Heart Association (NYHA) FC II or III. NYHA FC III patients, compared with 
FC II patients, have significantly higher median right atrial pressure (n=477, 9 mmHg 
versus n=165, 8 mmHg, respectively; p=0.001), significantly lower median Cardiac 
Index (n=260, 2.3 L/min/m2 versus n=103, 2.7 L/min/m2, respectively; p<0.001), and 
significantly shorter median 6 minute walk distances (6MWD; n=162, 311 m versus n=62, 
403 m, respectively; p<0.001). NYHA FC II and III patients do not differ significantly with 
respect to mean pulmonary arterial pressure (p=0.12), mean pulmonary capillary wedge 
pressure (p=0.32), or pulmonary vascular resistance index (p=0.51). At the time of the 
most recent NYHA assessment, patients who have had an echocardiogram performed 
within 12 months of that assessment (n=730) are more likely to have right atrial and right 
ventricular enlargement if they are NYHA FC III versus FC II (p<0.001 for both).
Conclusions: Our results show that FC, though subjective, is significantly associated with 
quantitative measures from RHC, echocardiography, and 6MWD. Substantial overlap 
exists between FC II and FC III patients, suggesting that risk assessment may require 
a multifactorial approach. Longitudinal data from the REVEAL study will help determine 
which measures are most strongly related to outcomes.
9:00 a.m.
803-8 Impact of Changes in Brain Natriuretic Peptide Levels on 
Survival in Outpatients with Pulmonary Hypertension
Richard A. Krasuski, Stephen Hart, Joseph Parambil, Venu Menon, Raed A. Dweik, The 
Cleveland Clinic, Cleveland, OH
Background: Serial brain natriuretic peptide (BNP) monitoring is common in heart failure. 
Whether changes are predictive in pulmonary artery hypertension (PAH) is uncertain.
Methods: We examined a prospective registry of patients referred to an academic PAH 
center. Demographic and clinical data was recorded at initial office visit and subsequently 
updated. All patients underwent initial diagnostic catheterization and BNP level was 
measured using the BioSite assay. Follow-up level was measured at the last routine visit. 
Vital status was confirmed with the SSDI.
Results: 161 patients underwent cardiac catheterization between 2/03 and 4/07 prior to 
therapy initiation for PAH. By Venice Classification 74% were category I (43% idopathic, 
24% connective tissue and 13% shunts), 15% category III, 7% category IV and 4% 
category V. Mean age was 53±15 years and 66% were women. Baseline WHO class was 
2.8±0.7, mean PA pressure was 50±15 mm Hg and cardiac index was 2.4±0.8. During 
follow-up 46% received an endothelin blocker, 57% a PDE5 inhibitor, 55% a prostaglandin 
and 47% received combination therapy. 8.1% of patients died over a median of 18 
months. No baseline characteristics or hemodynamics predicted mortality including BNP. 
In contrast, change in BNP was strongly predictive, with a ≥20% increase associated with 
a 7.6 fold increase in deaths (p<0.001)
Conclusions: With modern therapy outcomes in PAH have greatly improved. Changes in 
BNP levels appear to identify patients at highest mortality risk. 
9:15 a.m.
803-9 Survival With and Without Transplantation in Advanced 
Idiopathic Pulmonary Arterial Hypertension
Michael Dandel, Sead Mulahasanovic, Hans B. Lehmkuhl, Yuguo Weng, Onnen Grauhan, 
Christoph Knosalla, Roland Hetzer, Deutsches Herzzentrum Berlin, Berlin, Germany
Background: Progress in medical therapy has increased the life expectancy with 
idiopathic pulmonary arterial hypertension (IPAH). Consequently, there is doubt as to 
whether transplantation (Tx), which is associated with relatively high mortality, is still most 
promising for survival once right heart failure (RHF) emerges or whether prostanoids 
and endothelin-receptor-antagonists can improve survival to an extent that exceeds post-
transplant survival. 
Methods: Among 62 IPAH patients listed for Tx between 9/1996-9/2007, 48 who were 
treated with iloprost and/or bosentan were evaluated. Of these, 28 received iloprost 
i.v.-infusion (7 in combination with bosentan), 16 received aerosolized iloprost (8 in 
combination with bosentan) and 4 were treated only with bosentan. Main listing criteria 
were: WHO functional class III/IV-IV with severe hemodynamic alterations (pulmonary 
vascular resistance >1200dyn·s·cm-5, CI <2.0 l/min/m², mean right atrial pressure 
>15mmHg), severe right ventricular and atrial (RA) dilation with tricuspid regurgitation 
>grade II, 6-minute walk distance <100m and RHF. Patients with rapid exercise tolerance 
reduction and/or rapid progression of right heart dilation despite iloprost treatment were 
listed before RA pressure became >15mmHg and/or the CI dropped <2.0 l/min/m².
Results: Among 48 patients treated with iloprost and/or bosentan, 30 (62.5%) showed 
worsening and only 18 patients remained stable or improved slightly. Among the patients 
with worsening despite iloprost dose increases, 15 died on waiting lists. Tx was performed 
in 23 (47.9%) patients treated with iloprost and/or bosentan. Survival calculated from 
the day of listing was better (p = 0.017) for transplanted patients than for those who 
were not transplanted during the study period. The 1-year survival rate after Tx-listing 
in patients who underwent Tx after iloprost and/or bosentan therapy was 79.8 ±9.1%. In 
those who received the same medical treatment but not Tx, the 1-year survival rate after 
listing reached only 39.8 ±10.3%.
Conclusions: Transplantation appears to be still the most promising option for long-term 
survival with IPAH, once criteria for Tx listing are fulfilled for the first time.
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1021-157 Does Pleotropism Extend to the Kidneys; Statins Role 
in Nephroprotection?
Valentyna Ivanova, Diane A. Vido, Jennifer Spotti, David Lasorda, Robert W. W. 
Biederman, Allegheny General Hospital, The Gerald McGinnis Cardiovascular Institute, 
Pittsburgh, PA
Introduction: HMG-CoA reductase inhibitors are widely used for the treatment of 
dyslipidemia and prevention of CAD. Considerable controversy exists regarding potential 
pleotropic effect of statins with many vascular and nonvascular beds seemingly benefiting 
from statin administration. However, little data exists to support possible nephroprotective 
effect with statin therapy.
Hypothesis: We hypothesize that pre-administration of statins in pts prior to undergoing 
percutaneous coronary intervention (PCI) may be beneficial in preventing contrast 
induced nephropathy (CIN).
Methods: A retrospective study of 3600 pt charts who underwent PCI for standard clinical 
reasons was performed. Pts were categorized into those who developed CIN (based on 
serum creatinine (SCr) level elevation by ≥0.5mg/dl from baseline) and those with normal 
renal function after PCI. Pts with CIN were further grouped into those who were and were 
not on statin prior to the procedure. Multivariate analysis against HTN, DM, age, sex, 
baseline SCr and the amount of contrast received was performed as related to presence 
or absence of statin therapy.
Results: SCr was measured at or within 1 week prior to PCI in 647 pts (411(64%) male, 236 
(37%) female and within 1 week post PCI in whom a complete data was available. Statin 
therapy was initiated in 387( 60%) pts ≥week prior to PCI. In those in whom did not receive 
statin (260 (40%)), there was no-significant increase in the number of pts who developed 
CIN (36 vs 26, p=0.9). However, when limited to the absolute rise in SCr, the mean rise in 
SCr was 0.272 in statin negative vs 0.035mg/dl in statin positive subgroup, representing 
an over 8-fold nephroprotective effect of statins (p<0.001). Interestingly, neither HTN, age, 
sex, baseline SCr nor contrast load were a significant variable predicting the rise in SCr; 
while only statin therapy was nephroprotective.
Conclusion: Conceptually, vascular pleotropism due to statin therapy is under intense 
debate. In this database, a strong signal supporting additional statin capability as a 
nephroprotective agent emerged. Pre-PCI use of statins therapy was independently 
protective despite the strong presence of otherwise high risk comorbidities.
10:00 a.m.
1021-158 Prognastic Value of Functional Performance for 
Mortality in Patients With Peripheral Arterial Disease
Mary M. McDermott, Lu Tian, Kiang Liu, Jack M. Guralnik, Luigi Ferrucci, Jin Tan, 
William H. Pearce, Joseph R. Schneider, Michael H. Criqui, Northwestern University’s 
Feinberg School of Medicine, Chicago, IL
ABSTRACT: Background: The ability of office-based functional performance measures 
to predict mortality in patients with Peripheral Arterial Disease (PAD) is unknown. Among 
persons with lower extremity PAD, we determined whether objective measures of walking 
performance predict mortality, independently of the ankle brachial index (ABI).
Methods: Participants were 444 persons with PAD followed prospectively for 4.8 years. 
The six-minute walk and four-meter walks at usual and fastest pace were measured at 
baseline. Cox proportional hazard models were used to assess relations between baseline 
measures of lower extremity performance with mortality, adjusting for confounders.
Results: 127 patients (28.6%) died during follow-up. Adjusting for age, sex, race, comorbidities, 
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ABI, and other confounders, participants in the poorest baseline quartile of six-minute walk 
performance had significantly increased total mortality (hazard ratio (HR) = 2.36 (95% 
Confidence Interval (CI) = 1.33-4.18)) and cardiovascular mortality ((HR) = 5.59 (95% CI = 
1.97-15.9)) compared to the best quartile of baseline performance. Participants in the poorest 
baseline quartile of normal-paced four meter walking speed had significantly increased total 
mortality (hazard ratio (HR) = 1.86 (95% CI = 1.06-3.29)) and cardiovascular mortality ((HR) = 
2.55 (95% CI = 1.01-6.46)) compared to the best quartile of baseline performance.
Conclusions: This study demonstrates for the first time that performance based measures, 
which can be administered in an office setting, provide prognostic information regarding 
mortality beyond that provided by the ABI.
10:00 a.m.
1021-159 Effect of Low Suspicion Presentation of Type A Acute 
Aortic Dissection On Care and Outcomes: Data From 
the International Registry of Acute Aortic Dissection 
(IRAD)
Hadas Shiran, Christoph Nienaber, Eric Isselbacher, Thomas Tsai, Gabriel Meinhardt, 
Jeanna V. Cooper, Mary Grzybowski, Reed Pyeritz, Alan Braverman, Toru Suzuki, Kim 
Eagle, James B. Froehlich, University of Michigan, Ann Arbor, MI
Background: The effect of patient characteristics on presentation of type A acute aortic 
dissection (AD) on delivery of care and outcomes has not been explored.
Methods: Patients from the International Registry of Acute aortic Dissection (IRAD) with 
acute type A AD were identified as either “high suspicion” (HS) or “low suspicion” (LS) 
based on presentation. HS was defined as severe back or chest pain, with or without 
aortic insufficiency, pulse deficits, or both. LS was defined as no or mild pain, CHF, 
neurological changes (CVA, syncope, deficit), AI, or pulse deficit without pain.
Results: Of 895 type A AD, LS patients (N=191) were more likely to have a history of 
prior AD (p=.0372), diabetes mellitus (p=.0205), and to have MRI as the initial imaging 
study (p=.0381). LS patients had increased time delays from symptom onset (p<.0001), 
initial hospital arrival (p<.0001), and suspected dissection (p=.0022) to diagnosis, as well 
as hospital arrival to surgery (p<.0001). Therapeutic management was similar between 
groups. HS patients (N=704) had more pre-operative myocardial ischemia (p=.0044), 
hypotension (p=.0323), limb ischemia (p=.0001), and post-operative limb ischemia 
(p=.0419). Mortality rates were equivalent between the two groups.
Conclusion: Low suspicion presentation was associated with delays in diagnosis and 
treatment, but mortality was equivalent to patients with more classic presentations. 
Factors other than diagnosis delay likely contribute to mortality rates. 
Statistically Significant Variables in Patients with Type A Dissection (n=895)
Type of Presentation
Characteristic
High 
Suspicion 
N=704 
N (%)
Low 
Suspicion 
N=191 
N (%)
OR 
(95% CI) p-value
Patient History: Prior AD 17 (2.5) 10 (5.5) 2.29 (1.03-5.09) 0.0372
Diabetes mellitus 20 (3.0) 12 (6.7) 2.33 (1.12-4.87) 0.0205
1st Diagnostic Imaging: MRI 3 (0.5) 4 (2.3) 5.14 (1.14-23.18) 0.0381
Time Intervals: median 
(IQR), h 
Symptom onset to diagnosis
8 (3.3, 26.1) 24 (5.8, 72.0) X <.0001
Initial hospital arrival to 
diagnosis
3.67 (1.5, 
24.0)
23.88 (2.9, 
72.0) X <.0001
Suspected dissection to 
diagnosis 1 (0.5, 3.2) 2 (1.0, 6.2) X 0.0022
Initial hospital arrival to surgery 8.25 (4.5, 28.8) 24 (7.9, 72.0) X <.0001
Outcomes: In-hospital 
mortality 226 (32.1) 51 (26.7) 0.77 (0.54-1.10) 0.1522
Abbreviations: OR: odds ratio; CI, confidence interval
10:00 a.m.
1021-160 The Prevalence of Ischemic Heart Disease in Patients 
with Aortic Aneurysms and Peripheral Artery Disease
Kenichi Hirose, Taishiro Chikamori, Satoshi Hida, Hirokazu Tanaka, Yuko Igarashi, 
Chie Shiba, Yuka Otaki, Yoshiko Watanabe, Satoshi Kawaguchi, Yukio Obitsu, Hiroshi 
Shigematsu, Akira Yamashina, Tokyo Medical University, Tokyo, Japan
Background:Although the presence of ischemic heart disease (IHD) is the major 
determinant of perioperative mortality and long-term prognosis in patients with aortic 
aneurysms (AA) and peripheral artery disease (PAD), the prevalence and severity of IHD 
in individual vascular diseases is unknown.
Methods:Adenosine triphosphate (ATP) loading myocardial SPECT was performed in 787 
patients with vascular diseases of aorta and peripheral arteries. They were aged 71±9 
years: 649 men and 138 women. Four hundred ninety-nine patients with AA consisted of 
two hundred patients with thoracic AA, two hundred twenty-seven with abdominal AA and 
seventy-two with chronic aortic dissection. PAD was localized in the lower limb arteries 
in 186 patients; the remaining 102 had both AA and PAD. Patients with known IHD such 
as those with prior MI or revascularization procedures were excluded. Myocardial SPECT 
was analyzed using a 20-segment model, and summed stress score (SSS) and summed 
difference score (SDS) were calculated. Abnormal SPECT was defined as SSS≥4 and/or 
SDS≥2, and stress-induced myocardial ischemia as SDS≥2.
Results:The presence of abnormal SPECT and myocardial ischemia were the highest in 
combined PAD and AA (77.5% and 71.6%), followed by PAD (62.9% and 55.4%; p<0.05 
and p=0.02, respectively) and the lowest in AA (41.5% and 37.1%; p<0.0001 for all). 
An SSS was also the greatest in combined PAD and AA (11.5±1.0), followed by PAD 
(7.9±0.6; p<0.0001) and the least in AA (4.0±0.3; p<0.0001 for both). Similarly, an SDS 
was the greatest in combined PAD and AA (6.3±0.6), followed by PAD (4.5±0.4; p=0.002), 
and AA (2.3±0.2; p<0.0001 for both).
Conclusions:The prevalence of IHD in PAD was >50%, and higher than in AA. Although 
myocardial ischemia was observed only in a third of patients with AA, its prevalence not 
only doubled but also showed the sign of extensive myocardial ischemia when combined 
with PAD. Thus, cardiac evaluation is particularly important in patients with combined AA 
and PAD.
10:00 a.m.
1021-161 Incidence and Clinical Impact of Stent Fractures after 
Femoropopliteal Stenting
Yoshimitsu Soga, Hiroyoshi Yokoi, Tomoko Urakawa, Kenji Ando, Shinichi Shirai, 
Masashi Iwabuchi, Hitoshi Yasumoto, Hideyuki Nosaka, Masakiyo Nobuyoshi, 
Department of Cadiology,Kokura memorial hospital, Kitakyushu, Japan
Background: It has recently been reported that stent fractures of nitinol stent were 
associated with poor outcomes after femoropopliteal stenting. But a little is known about 
the frequency and the clinical impact of stent fractures after stent implantation.Objectives: 
In this study, we investigated its incidence and the clinical impact of stent fractures after 
femoropopliteal stenting.Method: We prospectively enrolled 40 patients 44 limbs (32 
male gender, aged 71 ± 8 years) who were treated by implantation of self-expandable 
nitinol stents. We evaluated clinical sonographic and angiographic follow-up information 
at 3, 6 12 and 18 months after stenting. Stent fracture was defined as more than single 
strut fracture. Fractures were classified as mild fracture (single strut), moderate fracture 
(more than 2 strut) and severe fracture (complete separation).RESULTS: All procedures 
were considered to be technically successful and all patients were treated with dual-
antiplatelet therapy. Of all patients, 1 patient dropped out of this study. A total of 39 
patients (43 legs and 71 stents) constituted the study population for this trials. In a stent 
bases analysis, the rate of stent fractures was 1.9% (at 3 months), 3.8% (at 6 months), 
18.9% (at 12 months) and 18.9% (at 18 months). The mean period up to fracture after 
stenting was 182 ± 24 days . The stent fracture did not occur between 12 and 18 month. 
The classification of fractures was mild in 5 stents, moderate in 7 stents (44%) and severe 
in 1 stent (12%). There was a total stent reocclusion in a severe fracture case. Overall, 14 
of all stents (36%) showed restenosis of more than 50% diameter reduction. Resenosis at 
the stent fracture site was 6 in 9 stents (67%). Kaplan-Meyer survival curve showed that 
the restenosis rate at 18 months was significant higher for patients with stent fractures 
(18% vs. 67%, p = 0.0034). Using univariate analysis of various factors that may have 
affected in-stent restenosis, stent fracture (Hazard ratio 4.6, 95% confidence interval 
1.5 to 16, p=0.003) was identified as only predictors.Conclusions: Stent fractures after 
femoropopliteal stenting were considered to occur within 12 months and to be associated 
with in-stent renstenosis.
10:00 a.m.
1021-162 A Novel Therapeutic Angiogenesis With Sustained 
Delivery Form Of Platelet-Rich Plasma In Mouse Hind 
limb Ischemia Model
Shyamal Bir, Jiro Esaki, Akira Marui, Hisashi Sakaguchi, Yoshio Arai, Keiichi Hirose, 
Tadashi Ikeda, Yasuhiko Tabata, Masatoshi Fujita, Masashi Komeda, Kyoto University, 
Kyoto, Japan
Background: Platelet-rich plasma (PRP) contains several angiogenic growth factors 
derived from platelets and may be promising in the treatment of hind limb ischemia.
Methods: PRP and platelet-poor plasma (PPP, plasma supernatant) were processed from 
whole blood of 6 weeks old C57BL/6 mice by centrifugation. Concentrations of growth 
factors in PRP and PPP were measured by ELISA. We induced hind limb ischemia by 
excising right femoral artery. Gelatin hydrogel microspheres were used as a sustained 
release carrier for growth factors in PPP and PRP. After surgery, mice were randomly 
assigned to 4 experimental groups (each, n=10): control (no treatment), 100µl of PRP 
solution and 100µl of PPP or PRP solution mixed with microspheres (sustained release 
(Sr) PPP or PRP); applied by single intramuscular injection and observed for 4 weeks. 
Tissue blood perfusion was evaluated by laser Doppler perfusion image index (LDPII). 
Capillary density and mature vessel density were also evaluated.
Results: The concentration (pg/ml) of stromal cell derived factor-1 (3372 ± 55 vs. 585 
± 38), PDGF (2571 ± 24 vs. 833 ± 10), VEGF (63 ± 11 vs. 26 ± 4), bFGF (50 ± 6 vs. 
15 ± 3), IGF-1 (7304 ± 595 vs. 2709 ± 104, mean ± S.D.) were higher in PRP than in 
PPP respectively, all p<0.05). LDPII, capillary density and mature vessel density were 
significantly higher in SrPRP than in other groups (table).
Conclusions: SrPRP containing potent growth factors restores blood perfusion, as a result 
of effective neovascularization in mouse hind limb ischemia.
Data of blood perfusion, capillary density and mature vessel density
Parameters Control SrPPP PRP solution SrPRP
Tissue blood perfusion (LDPII, %) 57 ± 12 56 ± 9 75 ± 7 * † 98 ± 4 * † ‡
Capillary density / mm2 151 ± 16 158 ± 12 189 ± 39 * † 276 ± 39 * † ‡
Mature vessel density / mm2 28 ± 2 31 ± 3 52 ± 10 * † 85 ± 13 * † ‡
P<0.05 by ANOVA (* vs. control, † vs. SrPPP, ‡ vs. PRP solution).
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1021-163 Real Time/Live Three-Dimensional Transthoracic 
Echocardiography is A Clinically Useful Diagnostic Tool 
for Acute Aortic Dissection
Noriaki Iwahashi, Kazuo Kimura, Jun Okuda, Kengo Tsukahara, Yoshio Tahara, Kiyoshi 
Hibi, Masami Kosuge, Toshiaki Ebina, Shinichi Sumita, Toshiyuki Ishikawa, Kazuaki 
Uchino, Satoshi Umemura, Yokohama City University, Medical Center, Yokohama, 
Japan, Yokohama City University Hospital, Yokohama, Japan
Background: Because transthoracic echocardiography (TTE) visualizes only a limited area 
of aorta and has commonly instrument artifact, only a minority of acute aortic dissection 
(AAD) could be detected from transthoracic window (Feigenbaum’s echocardiography). 
Real-time 3D TTE (RT3DE) has been found more useful in diagnosis of cardiovascular 
disease compared with 2DTTE (2DE). The aim of this study was to explore the utility of 
RT3DE in diagnosis of AAD.
Methods: 15 patients admitted due to chest pain (ACS=8,AAD=7) were enrolled our study on 
their chronic stable state. Conventional 2DE and RT3DE were examined by 2 sonographers 
blinded to all patient data with a Philips iE33 system (S5,4X matrix transducer) scanned 
from transthoracic (Th), subcostal (Sc) and abdominal (Ab) windows.
Results: RT3DE with angle correction has made a definitive diagnosis of AAD in 6 patients 
(83%) without 1 case of thrombosed false lumen type. Furthermore, RT3DE was able to rule 
out AAD in ACS. On the other hand, 2DE was able to make definitive diagnosis only in 2 cases 
(29%) with false lumen, because dissection flap appears as a linear structure by 2DE. There 
was no interobserver variability for diagnosis regardless of windows (χ2 test, p<0.001). We 
spent a minimum time to switch to RT3DE mode from 2DE (within 5seconds per patient).
Conclusion: RT3DE is a valuable tool for real-time noninvasive diagnosis of AAD. 
Furthermore, it might be an adjunctive tool to CT scan for AAD even at emergency room, 
because of their quick and accurate scan. 
10:00 a.m.
1021-164 Distal Aortic Growth in Marfan’s Syndrome: 
Comparison Between Patients With and Without 
Elective Surgery of the Aortic Root Using Magnetic 
Resonance Imaging
Freek W. A. Verheugt, Michelle M.W.P. Schrauwen, Janneke Timmermans, Lya E. van 
Die, Rudi Hoekema, Radboud University Nijmegen, Medical Centre, Nijmegen, The 
Netherlands
Background In Marfan’s syndrome the leading cause of premature death is dissection of 
a dilating aortic root, which can be prevented by elective surgery. Although dissection can 
also occur in the distal aorta little is known about growth in that area. As pts with elective 
root surgery represent the group with more growth in the aortic root, growth in the distal 
aorta in these pts may be faster than in pts without elective surgery.
Methods Marfan pts (>16 yr) who first visited our outpatient clinic between 1985-2007, 
with at least two MRI scans and without prior dissection were analyzed. MRI scans were 
made at 1-3 year intervals. Growth of the distal aorta was calculated at four levels (1. distal 
arch, 2. descending thoracic aorta, 3. diaphragm, 4. abdominal aorta). We compared pts 
who had elective surgery of the aortic root with pts without.
Results Of the 115 pts 32 (28%) had elective root surgery after 9.5 (IQR 5.8-13.8) yrs. 
Age at first visit did not differ between the two groups with and without surgery (30.1 vs 
30.0 yr, p=0.99). At first MRI pts with surgery had larger diameters at level 1 (24 vs 22 
mm, p=0.03), and at level 2 (27 vs 24 mm, p=0.01). However, growth of the distal aorta did 
not differ between groups (table). During follow-up one pt in the surgery group (3%) and 
one pt in the group without (1%) suffered from type B dissection (p=0.93).
Conclusion Despite a larger initial diameter of the thoracic aorta, growth of the distal 
aorta in Marfan pts who underwent elective aortic root surgery did not differ from pts 
without surgery.
No elective root surgery (n=83) Elective root surgery (n=32)
Aortic 
level
Slope mm/y 
(95% CI)
Intercept mm 
(95% CI)
Slope mm/y 
(95% CI)
Intercept mm 
(95% CI)
P 
value
1 0.146 (0.057-0.236)
15.90 (13.08-
18.72)
0.066 (-0.047-
0.178)
23.50 (16.58-
30.42) 0.263
2 0.264 (0.154-0.374)
18.80 (15.30-
22.30)
0.271 (0.139-
0.404)
17.49 (9.32-
25.65) 0.934
3 0.106 (0.001-0.211)
15.84 (12.52-
19.16)
0.024 (-0.100-
0.149)
24.92 (17.27-
32.58) 0.318
4 0.311 (0.066-0.557)
11.36 (4.12-
18.52)
0.450 (0.235-
0.666)
-1.99 (-14.93-
10.95) 0.429
10:00 a.m.
1021-165 Gender, Clinical, and Diagnostic Contributors to 
Delayed Recognition and Treatment of Acute Aortic 
Dissection: The International Registry of Acute Aortic 
Dissection (IRAD)
Kevin M. Harris, Alan T. Hirsch, Eric M. Isselbacher, Thomas Tsai, James Froehlich, 
Jeanna V. Cooper, Rossella Fattori, Craig Strauss, Arturo Evangelista, Kim Eagle, 
Alfredo Llovet, Christoph A. Nienaber, Minneapolis Heart Institute Foundation at 
Abbott Northwestern Hospital, Minneapolis, MN, University Hospital Rostock, Rostock, 
Germany
Background: In acute aortic dissection (AAD) a wide time spectrum exists between patient 
arrival at an emergency department and diagnosis, and definitive treatment. No prior data 
elucidate the factors that contribute to diagnostic and therapeutic delays.
Methods: We analyzed 1024 type A AAD patients enrolled in International Registry of 
Acute Aortic Dissection (IRAD) to evaluate the factors that contributed to diagnostic and 
therapeutic delays for all type A AAD patients, with a focus on the time from: (a) hospital 
presentation to definitive diagnosis, and (b) from diagnosis to surgery. Time data was 
available for 894 and 751 patients respectively.
Results: Significant delays in AAD diagnosis occur in patients who are female or have a 
history of previous cardiac surgery; whose symptoms were not abrupt, or did not include 
chest, back or any pain; who lacked a pulse deficit or hypotension; had initial testing other 
than CT and who initially presented to a non-tertiary care hospital. Delay in operative 
repair was associated with history of previous cardiac surgery; presentation with atypical 
AAD symptoms; initial testing other than CT or TEE, with initial presentation to a non-
tertiary care hospital.
Conclusions: These data suggest that improved physician awareness of atypical AAD 
presentations, earlier use of CTA or TEE diagnostic testing, and prompt transport of AAD 
patients from primary to tertiary care hospitals may reduce the time to diagnosis and 
operative intervention.
Contributors to diagnostic and therapeutic delays for patient with AAD
Characteristic
Median hours: 
Presentation to 
diagnosis
P-
value*
Median hours: 
Diagnosis to 
surgery
P-
value*
Yes No Yes No
Female gender 6.40 3.94 0.001 4.65 4.22 0.11
Previous cardiac surgery 13.09 4.00 0.001 17.58 4.00 <0.001
Abrupt onset of pain 3.50 24.00 <0.001 4.00 20.52 <0.001
Chest pain 4.01 7.07 0.017 4.12 5.17 0.015
CHF 23.28 4.07 0.005 8.12 4.25 0.06
Pulse deficit 3.00 4.65 <0.001 3.46 4.65 0.007
Hypotension/shock/
tamponade 2.50 5.16 <0.001 3.04 4.75 <0.001
Normal CXR 7.42 4.08 0.009 4.82 4.54 0.74
*Wilcoxon
10:00 a.m.
1021-166 Prevalence and Predictor of Silent Atherosclerotic 
Vascular Disease in Patients With Asymptomatic 
Abdominal Aortic Aneurysm
Masateru Takigawa, Naoyuki Yokoyama, Shingo Sakamoto, Yuiichi Tamori, Satoshi 
Kasai, Tsuyoshi Yoshimuta, Koichi Akutsu, Toshiya Okajima, Hiroshi Nonogi, Satoshi 
Takeshita, National Cardiovascular Center, Osaka, Japan
Background: Patients with AAA have a high prevalence of atherosclerotic vascular 
disease including CAD, CVD, PAD, and TAA/IAA. Although these diseases eventually 
result in poor outcome, the exact prevalence remains unclear when they progress silently. 
The aim of this study is to clarify the prevalence and predictors of silent atherosclerotic 
vascular disease in patients with asymptomatic AAA. Methods: From 2001 to 2006, 516 
consecutive patients underwent elective graft replacement of AAA in our institution. In 
157 patients (128 men [82%]; mean age 73±8 years) who had no history or treatment of 
symptomatic vascular disease, clinical characteristics including age, gender, size of AAA, 
BMI, diabetes, smoking, CCr, BP, ABI, lipid profile (TC, LDL, TG, and HDL), medication 
were evaluated and CT, US, scintigraphy, and CAG were performed. The data was 
analyzed multivariately. Results: Asymptomatic CVD, CAD, PAD, and TAA/IAA accounted 
for 39 (25%), 46 (29%), 25 (16%), and 55 (35%), respectively. Increased LDL significantly 
predicted asymptomatic CVD or TAA/IAA. Male sex and diabetes significantly predicted 
asymptomatic CAD. Patients under statin therapy at hospitalization had a significantly low 
prevalence of asymptomatic PAD or TAA/IAA. Conclusion: This study confirmed a high 
prevalence and specific predictors of coexistent silent atherosclerotic vascular disease in 
patients with asymptomatic AAA. Statin may have preventative efficacy against PAD or 
TAA/IAA progression. 
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Multivariate analysis for silent atherosclerotic cardiovascular disease
Odds ratio 95% CI P value
Asymptomatic CVD
LDL, per 10mg/dl increase 1.2 1.0-1.4 0.015
Asymptomatic CAD
Gender, male 6.2 1.6-32.2 0.018
Diabetes 4.1 1.2-14.3 0.024
Asymptomatic PAD
Antihyperlipidemic agent (Statin) 0.23 0.04-0.79 0.033
Asymptomatic TAA/IAA
LDL, per 10mg/dl increase 1.1 1.0-1.3 0.050
Antihyperlipidemic agent (Statin) 0.37 0.14-0.85 0.025
AAA= abdominal aortic aneurysm, ABI = ankle-brachial index, BMI = body mass index, 
BP = blood pressure, CAD = coronary artery disease, CCr = creatinine clearance, CT = 
computed tomography, CVD = cerebrovascular disease, HDL = high density lipoprotein 
cholesterol, IAA = iliac artery aneurysm, LDL = low density lipoprotein cholesterol, PAD 
= peripheral artery disease, TAA = thoracic aortic aneurysm, TC = total cholesterol, TG 
= triglycerides, US = ultrasound
10:00 a.m.
1021-167 Subclavian and Innominate Artery Stent Placement for 
Symptomatic Patients: Three-Year Follow-Up
Samir N. Patel, Stephen R. Ramee, Tyrone J. Collins, Gary A. Daniel, J. Stephen 
Jenkins, J. P. Reilly, Rachael F. Morris, Christopher J. White, Ochsner Clinic Foundation, 
New Orleans, LA
Background: Subclavian and innominate artery (S/IA) stenosis represent about 20% of 
symptomatic extracranial cerebrovascular disease. Symptoms include vertebrobasilar 
insufficiency, claudication, and angina (due to “steal” if an internal mammary graft 
is present). Surgery is effective, however it is associated with stroke or death in 5%. 
Endovascular revascularization may offer a better alternative to surgery.
Methods: Between 1993-2006, 170 patients (mean age 65.2 years, 44% male) underwent 
stent placement in 177 arteries. Indications included arm claudication (57%), subclavian 
steal syndrome (37%), coronary steal syndrome (21%), or prior to coronary bypass using 
the internal mammary artery (8%).
Results: Stent success was achieved in 174 (98.3%) arteries, including 99.4% for stenotic 
lesions (155/156) and 90.5% for occlusions (19/21). There were no procedure related 
deaths and only one stroke (0.6%, 1/170). Minor complications included 1 (0.6%) TIA, 3 
(1.8%) flow-limiting dissections, and 1 (0.6%) embolus. 151 (89%) patients were followed 
at a mean of 35.2 months, 138 of whom had ≥ 6 month follow-up and a TVR of 17% 
(23/138). At last follow-up, 82% (124/151) remained asymptomatic. Primary (unassisted) 
and secondary (assisted) patency is shown below: 
Conclusion: Endovascular revascularization with stents for symptomatic S/IA lesions can 
be performed successfully in 98% of patients with symptom resolution in > 80% at almost 
3 years of follow-up and offers an excellent alternative to surgery.
10:00 a.m.
1021-168 Role of Age in Acute Type A Aortic Dissection 
Outcome: Report From the International Registry of 
Acute Aortic Dissection (IRAD)
Santi Trimarchi, Christoph A. Nienaber, Kim A. Eagle, Vincenzo Rampoldi, Thomas 
Tsai, James Froehlich, Arturo Evangelista, Jeanna V. Cooper, Jin Li, Gabriel Meinhardt, 
Thoralf Sundt, III, Eduardo Bossone, Eric M. Isselbacher, Istituto Policlinico S. Donato, 
San Donato, Italy, University of Michigan Health System, Ann Arbor, MI
BACKGROUND: The increasing life expectancy will likely be accompanied by a rise in 
the incidence of acute type A aortic dissection (AAD) associated with age. However, it 
is important to define when, if at all, the risks of aortic repair outweigh the risk of death 
from AAD.
METHODS: We analyzed 936 patients enrolled in the International Registry of Acute 
Aortic Dissection (IRAD), categorized according to patient age by decade and surgical 
vs. medical management.
RESULTS: The rate of surgical aortic repair decreased progressively with age, whereas 
surgical mortality increased with age (figure). Age greater than 70 was an independent 
predictor for mortality (OR 1.73). Other significant predictors of mortality included coma 
and/or cerebrovascular accident (OR 2.93), preoperative acute renal failure (OR 2.46), 
hypotension/shock at presentation (OR 3.21), abrupt onset of symptoms (OR 2.10), 
ischemic peripheral neuropathy (OR 3.34), prior cardiac surgery (OR 1.84) and history 
of hypertension (OR 0.55).
CONCLUSIONS: Although ascending aortic repair is traditionally considered the standard 
of care for managing AAD, the mortality rises sharply after the age of 85, and equals 
or exceeds the mortality of medical beyond the age of 90. The data suggest that AAD 
surgery may still be appropriate for patients up to age of 85, but may not be preferable in 
the nonagenarian population. 
10:00 a.m.
1021-169 Inhibition of the Chemokine Monocyte Chemoattractant 
Protein-1 Decreases Recruitment of Circulating 
Fibrocytes to the Stenotic Porcine Kidney in 
Renovascular Hypertension
Xiang-Yang Zhu, Alejandro Chade, James D. Krier, Elena Daghini, Ronit Lavi, Amir 
Lerman, Lilach O. Lerman, Mayo Clinic, Rochester, MN
Background: Renal artery stenosis (RAS) often accompanies peripheral vascular disease 
and causes renal inflammation, fibrosis, and functional deterioration, but the mechanisms 
remain obscure. This study is to test the hypothesis that the chemokine monocyte 
chemoattractant protein (MCP-1) is involved in recruitment of circulating fibrocytes and 
thereby renal fibrosis and dysfunction in RAS. Methods: After 6 wks of experimental 
RAS (n=7), RAS supplemented with the specific MCP-1 inhibitor bindarit (50mg/kg/day 
PO, n=6), and normal controls (n=8), renal blood flow (RBF) and glomerular filtration 
rate (GFR) were quantified in the stenotic porcine kidney using 64-slice multidetector 
CT. Renal fibrosis was evaluated by trichrome staining and transforming growth factor 
(TGF)-β expression, MCP-1 expression by immunostaining, and recruited fibrocytes 
using CD34/collagen I double staining. Results Compared to normal, stenotic RAS 
kidneys had increased MCP-1 and TGF-β expression, fibrosis, and fibrocyte recruitment, 
accompanied by decreased RBF and GFR (Table). Remarkably, all were improved in 
bindarit-treated RAS. Conclusion: A novel mechanism of MCP-1-mediated stenotic 
kidney fibrosis involves recruitment of circulating fibrocytes, which may contribute to renal 
scarring and dysfunction.
Table. Single-kidney characteristics (mean ± SEM) in normal, RAS, and RAS pigs treated 
with bindarit. 
Normal 
n=8
RAS 
n=7
RAS+bindarit 
n=6
Mean arterial pressure (mmHg) 98.7±3.8 122.6±9.6* 125.4±8.3*
Degree of stenosis (%) 0.0±0.0 71.4±7.4* 68.7±3.6*
Trichrome 1.1±0.1 6.3±0.5* 3.2±0.2*†
MCP-1 0.9±0.1 4.8±0.6* 0.6±0.1
CD34+/Collagen I+ 0.2±0.0 0.8±0.1* 0.1±0.0
RBF (mL/min) 469.8±37.2 302.1±91.5* 448.9±44.1†
GFR (mL/min) 62.3±3.83 36.8±11.2* 77.4±7.0†
*p<0.05 vs. normal; † p<0.05 vs. RAS (staining units: % surface area)
10:00 a.m.
1021-170 Graded Association Between Carotid Intima 
Media Thickness, Aortic Stiffness and Duration of 
Vasculogenic Erectile Dysfunction: Linking Erectile 
Dysfunction With Generalized Vascular Disease
Charalambos Vlachopoulos, Nikolaos Ioakeimidis, Alexios Samentzas, Konstantinos 
Rokkas, Athanasios Tsokanis, Athanasios Bratsas, Thanos Askitis, Christodoulos 
Stefanadis, 1st Department of Cardiology, Athens Medical School, Hippokration 
Hospital, Athens, Greece
Background: Carotid intima media thickness (cIMT) and aortic stiffness are markers 
and prognosticators of cardiovascular risk. Erectile dysfunction (ED) may be the early 
manifestation of a generalized vascular disease. We investigated the association between 
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cIMT, aortic stiffness and duration of ED.
Methods: 187 consecutive men with ED (detected with a validated questionnaire) were 
studied: 52 men (61±8 yrs, mean time interval of ED= 3 yrs) with coronary artery disease 
(ED-CAD) and 135 men (58±10 yrs) without CAD, divided into three groups, according to 
ED duration: Group A (<2 yrs, n=53), group B (2-3 yrs, n=42) and group C (>3 yrs, n=40). 
Ultrasound cIMT and carotid-femoral pulse wave velocity (PWV) as an index of aortic 
stiffness were used to assess subclinical atherosclerosis.
Results: PWV and cIMT values were comparable among ED-CAD patients and patients 
of group C and higher of those in men of groups A and B (P<0.01, for both, figure). In men 
without CAD, there was a stepwise augmentation in cIMT and PWV throughout increasing 
duration of ED. This last relationship remained significant in multivariate analysis (P<0.05 
by ANCOVA after adjusting for age, mean pressure, smoking, metabolic profile and C-
reactive protein).
Conclusions: In men with ED, the longer duration of ED, the greater progression of cIMT 
and the greater impairment of aortic elastic properties. These findings may partially 
elucidate the complex mechanisms linking ED with generalized vascular disease and 
increased cardiovascular risk. 
10:00 a.m.
1021-171 X-Ray Visible Stem Cell Therapy Enhances Angiogenesis 
in a Rabbit Model of Peripheral Arterial Disease
Dara L. Kraitchman, Dorota A. Kedziorek, Kenyatta Cosby, Wesley D. Gilson, Gary 
Huang, Trey Kohl, III, Brad P. Barnett, Jeff WM Bulte, Lawrence V. Hofmann, Johns 
Hopkins University, Baltimore, MD, Stanford University, Stanford, CA
Background: Stem cell therapies suffer from the inability to visualize their delivery. 
Furthermore, early rapid destruction often results in poor engraftment. We sought to 
develop a method to enhance cell survival in concert with X-ray visualization of stem 
cells. This therapy was tested in a rabbit model of peripheral arterial disease.
Methods: Bone marrow-derived stem cells (MSCs) were expanded from male New Zealand 
White rabbits. A non-surgical left superficial femoral artery occlusion was created using 
percutaneous delivery of platinum coils in female rabbits (n=22). To enhance engraftment, 
microencapsulation of the allogeneic MSCs was performed using the classical alginate 
encapsulation method with the addition of barium sulfate to enable X-ray visualization, 
e.g., “XCaps.” One day post-occlusion, rabbits were randomized to receive 6 intramuscular 
injections in the medial thigh of 13x106 naked MSCs (n=6), 5000 XCaps with MSCs 
(n=5), 5000 XCaps without MSCs (n=5), or sham injections (n=6). XCap visibility was 
determined on a clinical angiography system. Two weeks post-injection, angiogenesis 
was assessed angiographically using a modified TIMI frame count, i.e., comparing the 
difference in time to filling of the popliteal bifurcation between the right non-ischemic and 
left ischemic limb, followed by histopathological analysis.
Results: No acute immunological rejection was observed in any animal receiving XCaps 
based on gross, hematological, or histological analysis. As few as 10 XCaps were easily 
visible angiographically in vitro. XCaps with and without MSCs had similar radiopacity 
and were equally visible at 1 and 14 days post-occlusion. At 2 weeks, TIMI frame counts 
showed the greatest angiogenesis in the XCap with MSCs-treated rabbits (4.2 ± 0.8 s) 
and the least in the XCaps without MSCs (11.8 ± 5 s, ANOVA P<0.002). Naked MSCs and 
sham injections had an intermediate response and similar therapeutic effect (7.7 ± 3 s vs. 
7.3 ± 3 s, P=NS). Histopathology of endothelial vessels mirrored angiographic results.
Conclusions: XCaps with MSCs offer an X-ray targeting method for cellular delivery 
with enhanced angiogenesis using allogeneic cells, potentially through decreased 
destruction.
10:00 a.m.
1021-172 Low Suspicion Presentation of Type B Acute Aortic 
Dissection Leads to Increased Mortality: Data From 
the International Registry of Acute Aortic Dissection 
(IRAD)
Hadas Shiran, Eric Isselbacher, Christoph Nienaber, Kim Eagle, Thomas Tsai, Rossella 
Fattori, Joshua Beckman, Patrick O’Gara, Linda Pape, Jeanna V. Cooper, Mary 
Grzybowski, Marek Ehrlich, James Froehlich, University of Michigan, Ann Arbor, MI
Background: Acute aortic dissection (AD) has high morbidity and mortality. Classic 
findings on presentation and their association with diagnosis, treatment or outcomes in 
type B acute AD, have not been explored.
Methods: Patients from the International Registry of Acute Aortic Dissection (IRAD) with 
acute type B AD were identified as either “high suspicion” or “low suspicion” based on 
presentation. High suspicion was defined as severe back or chest pain, with or without 
aortic insufficiency, pulse deficits, or both. Low suspicion was defined as no or mild pain, 
CHF, neurological changes (CVA, syncope, deficit), AI, or pulse deficit without pain.
Results: Of 521 patients with type B dissection, low suspicion patients (N=96) were 
more likely to have a history of known aortic aneurysm (p=.0008), prior aortic dissection 
(p=.0016), diabetes mellitus (p=.0004), and to have MRI as the initial imaging study 
(p=.0048). Times from symptom onset to diagnosis (p=.0001) and from hospital arrival to 
diagnosis (p=.0013) were longer in low suspicion patients. Therapeutic management was 
similar between groups. Low suspicion patients were less likely to suffer post-operative 
mesenteric ischemia (p=.0351), but were more likely to die in hospital (p=.0049).
Conclusions: Low clinical suspicion presentation of type B acute aortic dissections is 
associated with a delay to diagnosis and increased in-hospital mortality. Evaluation of 
methods leading to earlier recognition of type B AD is warranted. 
Statistically Significant Variables in Patients with Type B Dissection (n=521)
Type of Presentation
Characteristic
HIgh 
Suspicion 
N=425 
N (%)
Low 
Suspicion 
N=96 
N (%)
OR 
(95% CI) p-value
Patient History: Known aortic 
aneurysm 62 (15.0) 28 (29.5)
2.37 (1.42-
4.00) 0.0008
Prior aortic dissection 26 (6.3) 15 (16.1) 2.88 (1.46-5.69) 0.0016
Diabetes mellitus 18 (4.3) 13 (14.1) 3.63 (1.71-7.71) 0.0004
Time Intervals: median (IQR), h 
Symptom onset to diagnosis
9 (3.8, 
48.0)
48 (9.3, 
168.0) X 0.0001
Initial hospital arrival to diagnosis 4.4 (1.5, 24.0)
10.15 (3.8, 
50.0) X 0.0013
Post-Operative Complications: 
Mesenteric ischemia/infarct 5 (3.1) 5 (11.6) X 0.0351
Outcomes: In-hospital mortality 41 (9.7) 19 (19.8) 2.31 (1.27-4.20) 0.0049
Abbreviations: OR: odds ratio; CI, confidence interval
10:00 a.m.
1021-173 Asymmetric Dimethylarginine Predicts Mortality and 
Major Adverse Cardiovascular Events in Patients With 
Peripheral Arterial Disease
David S. Shin, Carlton W. Weatherby, Andrew M. Wilson, John P. Cooke, Stanford 
University School of Medicine, Stanford, CA
Background: Patients with peripheral arterial disease (PAD) are at high risk for future 
cardiovascular disease events. Several parameters of vascular function are abnormal in 
PAD patients, including ankle-brachial index, claudication time, flow-mediated vasodilation 
and vascular compliance. In addition, PAD patients have elevated plasma levels of 
asymmetric dimethylarginine (ADMA), the endogenous inhibitor of nitric oxide synthase, 
which is associated with impaired endothelial vasodilator function. We hypothesized that 
one or more of these vascular tests would add predictive value to the traditional predictors 
of major adverse cardiovascular events (MACE).
Methods: We acquired baseline measurements of the above vascular tests as well as 
traditional cardiovascular risk markers in 133 PAD patients enrolled in the NO-PAIN study 
(mean age 73 years, 101 males), which was a randomized, placebo-controlled trial of 
long-term L-arginine supplementation. MACE was predefined as myocardial infarction, 
stroke, revascularization and all-cause mortality. Detailed telephone follow-up was 
obtained in 125 subjects (mean follow-up 35 months) using a structured questionnaire.
Results: At least 1 MACE was observed in 49 of 125 patients (39%). Cox regression 
analysis showed that age (P=0.023) and ADMA (P=0.028) were the only significant 
predictors of death, independent of vascular function measures and traditional 
cardiovascular risk factors such as lipids, glucose, blood pressure and smoking history. 
In addition, subjects with ADMA levels in the highest quartile (>0.84 µmol/L) showed 
significantly greater occurrence of MACE compared to those with their ADMA levels in the 
lower 3 quartiles (P=0.001, log-rank test).
Conclusion: Our investigation indicates that the plasma ADMA concentration is an 
independent marker of cardiovascular risk in patients with PAD. Indeed, in this population 
of patients, it is a more powerful predictor of MACE than traditional cardiovascular risk 
factors and other non-invasive vascular tests. More studies are warranted to confirm that 
ADMA is a useful prognostic indicator in PAD.
10:00 a.m.
1021-174 Do Obesity and Body-Mass-Index Differentially Predict 
an Abnormal Carotid-Intima Media Thickness Over 
Coronary Calcium?
Fernando Mendoza, Farhad Rafii, Prediman K. Shah, Heidi Gransar, Asim Rafique, 
Maria Guerra, Shah Azmoon, Norman E. Lepor, Daniel S. Berman, Tasneem Z. Naqvi, 
Cedars-Sinai Medical Center, Los Angeles, CA
Background: Coronary artery calcification (CAC) as measured by computed tomography 
and carotid intima-media thickness (CIMT) using B-mode ultrasound can quantify 
atherosclerosis and predict both incident and prevalent atherosclerotic vascular disease. 
However, each test measures different aspects of vascular disease and little is known 
about the variables that differentially predict CAC versus CIMT.
Methods: CIMT and CAC were measured in 136 patients with no history of coronary 
disease (mean age 57 years, 56% females). Patients were identified as abnormal CIMT or 
CAC if they were over the 75%ile for each respective test. Obesity was defined as a BMI 
≥ 30. Oneway ANOVA and Pearson chi-square tests were performed to identify potential 
predictors of abnormal CAC or CIMT.
Results: BMI as a continuous variable and obesity were independent predictors of 
abnormal CIMT but not abnormal CAC (p<0.007 and p=0.4). Age, gender, diabetes, 
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total cholesterol, LDL, HDL, hypertension, smoking and family history of cardiovascular 
disease were not significantly different between the two groups. After multivariate 
adjustment for Framingham risk, obesity remained differentially predictive of an abnormal 
CIMT (OR 6.3, 1.7-23.4).
Conclusion: Increasing BMI and obesity are independent predictors of abnormal CIMT, 
but not abnormal CAC and thus may help explain discordant test results. Further research 
into the mechanisms obesity differentially accelerates carotid atherosclerosis is needed.
Obesity and BMI Differentially Predict Abnormal CIMT over CAC
% w/ CIMT >75%ile (n) % w/ CAC >75%ile (n)
BMI 20-25 (n=48) 20.8% (10) 20.8% (10)
BMI 25-30 (n=61) 31.1%(19) 11.5%(7)
BMI > 30 (n=27) 51.9%(14) 27.2%(9)
10:00 a.m.
1021-175 Arterial Stiffness Is Increased in Patients With Hepatitis 
C Virus Seropositivity, but not in Patients With Hepatitis 
B Virus Seropositivity; the Role of Leptin
Charalambos Vlachopoulos, Katerina Baou, Emmanuel Manesis, Panagiotis 
Xaplanteris, Ioanna Dima, Nikolaos Ioakeimidis, Georgios Antoniou, Athanasios 
Archimandritis, Christodoulos Stefanadis, 1st Department of Cardiology, Athens, 
Greece, 2nd Department of Internal Medicine, Athens, Greece
Background: Recent data suggest that chronic systemic inflammation impairs vascular 
function and plays a critical role in cardiovascular disease. There is also increasing 
evidence that hepatic steatosis and morbid rates of adipocytokines, i.e. adipose tissue 
secreted molecules, are associated with atherosclerosis. Patients with hepatitis C 
virus (HCV) may reveal a secondary steatosis. Aortic stiffness and wave reflections 
are independent predictors of cardiovascular risk. The present study was undertaken 
to assess whether chronic infection with hepatitis B virus (HBV) or HCV affects aortic 
stiffness and wave reflections and the role of leptin in patients with hepatitis.
Methods: We determined aortic stiffness and wave reflections in 36 patients (mean 
age: 49±15yrs, 16M/20F) positive for HCV chronic infection and 28 patients (mean 
age: 56±11yrs, 19M/9F) with HBV chronic infection, who had never been treated with 
interferon. 40 subjects matched for age, gender, body-mass index and risk factors 
were used as controls. Aortic stiffness was evaluated with carotid-femoral pulse wave 
velocity (PWV) and wave reflections with augmentation index (AIx) of the aortic pressure 
waveform. Leptin levels were measured by ELISA kit.
Results: Patients with HCV infection had higher carotid-femoral PWV than controls, 
indicating increased aortic stiffness (7.6±1.4 vs. 6.7±1.3 m/s, P<0.05), whereas AIx did 
not differ (27.5±15 vs. 27.1±14%, P=NS). Carotid-femoral PWV and AIx in the subjects 
with HBV infection were similar to those in the control subjects. There were not differences 
as regard systolic, diastolic pressures and heart rate between patients with hepatitis 
and controls. Furthermore, after adjustment for confounding factors, leptin levels were 
independently associated with an increase in PWV in patients with HCV (p<0.05, t=4.5, 
stand. coefficient = 1).
Conclusions: Patients with HCV have impaired aortic elastic properties, whereas HBV 
does not influence aortic stiffness. These findings are important to further characterize 
the increase of cardiovascular risk in patients with hepatitis C virus seropositivity and to 
specify the linking role of the adipocytokines.
10:00 a.m.
1021-176 The Cirrhotic Alterations in Systemic Hemodynamics 
Ameliorate the Arterial Stiffness in Patients with Non-
Alcoholic Steatohepatitis
Katerina Baou, Charalambos Vlachopoulos, Emmanuel Manesis, Panagiotis 
Xaplanteris, Ioanna Dima, Nikolaos Alexopoulos, Nikolaos Ioakeimidis, Georgios 
Antoniou, Athanasios Archimandritis, Christodoulos Stefanadis, 1st Department of 
Cardiology, Athens, Greece, 2nd Department of Internal Medicine, Athens, Greece
Background: Non-alcoholic steatohepatitis (NASH) represents a component of the 
metabolic syndrome and is associated with increased cardiovascular risk. NASH is 
characterized by steatosis, inflammation, and fibrosis and may progress to cirrhosis. We 
investigated the arterial stiffness in NASH patients with or without cirrhosis.
Methods: The study population consisted of 34 subjects (mean age: 62.2 ± 10.2 yrs, 
9M/25F). In particular, 19 had bioptical evidence of NASH, cirrhosis was present in 7 of 
them and none of the 14 control subjects showed ultrasound evidence of liver steatosis. 
The three groups did not differ in classical risk factors. Aortic stiffness was evaluated with 
carotid-femoral pulse wave velocity (PWV) and wave reflections with augmentation index 
(AIx) of the aortic pressure waveform.
Results: PWV was significantly increased in NASH patients without cirrhosis compared 
to controls (9.3 ± 1.6 vs 7.7 ± 1.3 m/s, p<0.05), but cirrhotic patients had significantly 
reduced PWV compared to NASH patients without cirrhosis (7.2 ±1.2 vs 9.3 ± 1.6 m/s, 
p<0.05), while AIx did not differ. Systolic, diastolic and pulse pressure were not different 
among the three groups.
Conclusion: The transition of NASH to cirrhosis is followed by the paradoxical improvement 
of the stiffened arteries, which may be explained from the changes in neurohormonal 
regulatory systems, kidney function and cardiovascular system.
10:00 a.m.
1021-177 The Efficacy of Stenting at Aorta in Takayasu Arteritis
Jaedeok Kim, Cheol Ryong Ku, Eui Im, Jung-Sun Kim, Young-Guk Ko, Donghoon Choi, 
Yangsoo Jang, Won Heum Shim, Yonsei Cardiovascular Center, Seoul, South Korea
Background: Takayasu arteritis (TA) is a chronic vasculitis of unknown etiology involving the 
aorta and its main branches and it is related to arterial hypertension, congestive heart failure, 
and disabling claudication. But, the efficacy and safety of endovascular stent implantation at 
the aorta have not been investigated clearly. Therefore, we evaluated the usefulness of stent 
implantation at the aorta in Takayasu arteritis patients in our single center registry.
Methods: Eleven patients were treated with percutaneous transluminal angioplasty 
(PTA) with stent implantation at the aorta from January 2001 to May 2007. All of the 
enrolled patients were female (mean age: 48 years, range : 33-65 years). The indication 
was disabling claudication or uncontrolled hypertension. The patency of the stent during 
follow-up period was evaluated with ankle-brachial index (ABI) and aorta computed 
tomography (CT) scan.
Results: The mean clinical follow-up duration was 43 months (range: 3-214 months). The 
stent implantation was done in 10 patients. Although PTA without stent implantation was 
performed in only one patient, the patient underwent stent implantation 2 month after the 
procedure due to aortic dissection. The 9 of 11 patients with the stent were evaluated with 
aorta CT scan at mean 12 months after the procedure and none of them developed in-
stent restenosis. All the patients have not shown clinical evidence of stent restenosis such 
as uncontrolled hypertension or claudication during follow-up period.
Conclusions: PTA with stent implantation is safe and feasible in the aortic lesion of 
patients with TA.
10:00 a.m.
1021-178 Carotid Intima-media Thickness is Associated With an 
Index of Central Arterial Stiffness but not Peripheral 
Arterial Stiffness in Hypertensive Patients
Chi Young Shim, Sungha Park, Jung-Sun Kim, Young-Guk Ko, Seokmin Kang, 
Donghoon Choi, Jong-Won Ha, Se-Joong Rim, Yangsoo Jang, Namsik Chung, 
Cardilogy Division, Yonsei Cardiovascular Center, Seoul, South Korea
Background: Central arterial stiffening and early atherosclerosis are common features 
in hypertensive patients. We sought to determine the differing association between 
the indices of regional arterial stiffness and carotid intima-media thickness (CIMT) in 
hypertensive patients. Methods: In 285 (156 males, age: 55.4 ± 9.7) treated hypertensive 
patients, pulse-wave velocity (PWV) and carotid ultrasound examination were performed 
at the same time. Heart to femoral PWV (hfPWV) and brachial to ankle PWV (baPWV) 
were used as indices of central and peripheral arterial stiffness. Mean CIMT and 
maximum CIMT were measured at the common carotid arteries. Results: Mean and 
maximum CIMT were well correlated with log hfPWV (r = 0.287, p < 0.001, r = 0.268, 
p < 0.001) and log baPWV (r = 0.193, p = 0.001, r = 0.189, p = 0.001). Multiple linear 
regression analysis, controlled for variables demonstrating significant association with 
PWV in univariate analysis such as age, body mass index, fasting glucose and lipid 
profiles, revealed that mean and maximum CIMT were independently associated with 
hfPWV, an index of central arterial stiffness (β = 0.192, p = 0.004, β = 0.185, p = 0.006). 
However, the mean and maximum CIMT were not independently associated with baPWV 
(β = 0.070, p = 0.258, β = 0.081, p = 0.198). These associations were consistent after 
control for antihypertensive medications.Conclusions: The CIMT was associated with 
central arterial stiffness, but not peripheral arterial stiffness, independent of age, body 
mass index, fasting glucose, lipid profiles and antihypertensive medications in treated 
hypertensive patients.
10:00 a.m.
1021-179 L-arginine Exerts its Beneficial Effects on Arterial 
Stifness through the Improvement of Endothelial 
Function and the Reduction of Inflammatory Process in 
Chronic Smokers
Gerasimos Siasos, Dimitris Tousoulis, Charalambos Vlachopoulos, Charalambos 
Antoniades, Nikos Ioakeimidis, Kostas Zisimos, A. Papavasiliou, Elli Stefanadi, 
Emmanuel Vavuranakis, Nikos Papageorgiou, Christodoulos Stefanadis, 1st Cardiology 
Department, Hippokration Hospital, Athens Medical School, Athens, Greece
Background: Endothelial dysfunction is accompanied by increased arterial stiffness. 
The effect of short term L-arginine (the substrate for endothelial nitric oxide synthase) 
administration on vascular function in chronic healthly smokers is unknown. We 
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investigated the effects of a L-arginine on endothelial function inflammatory process and 
arterial stifness in healthy smokers
Methods: We administered 3-day oral administration of L-arginine in 12 healthy smokers 
(aged 24±3yrs) on 3 occasions (day0: baseline measurements, day1 and day3). The 
study was carried out on two separate arms, one with L-arginine (7gr tid) and one 
with placebo according to a randomized, placebo-controlled, double-blind, cross-over 
design. All measurements were performed one hour after L-arginine or placebo intake. 
Endothelial function was evaluated with flow-mediated dilatation (FMD) of the brachial 
artery. Carotid-femoral pulse wave velocity (PWV) was measured as an index of aortic 
stiffness and augmentation index (AIx) as a measure of arterial wave reflections. Plasma 
levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and soluble intercellular 
adhesion molecule (sICAM-1) were measured with ELISA.
Results: Compared to placebo, L-arginine led to a progressive increase of FMD (by 
1.74%, p=NS at day 1 and by 1.96%, p<0.05 at day 3), indicating a favorable effect on 
endothelial function. Moreover, L-arginine intake led to a progressive decrease of PWV 
(by 0.32 m/s at day1 and by 0.36 m/s at day 3, both p<0.01) and of AIx (by 5.1%, p<0.01 
at day 1 and by 9.3%, p<0.001 at day3), indicating a decrease in aortic stiffness and wave 
reflections. Finally, 3-day oral administration of L-arginine decreased the level of sICAM 
(p<0.05), whereas, there was no effect on the expression of pro-inflammatory cytokines, 
IL-6 and TNF-α.
Conclusions: Short-term daily administration of L-arginine, a precursor of nitric oxide 
synthesis in vascular endothelium, improves endothelial function, arterial performance 
and decreases soluble intercellular adhesion molecule in healthy smokers. Therefore, L-
arginine exerts its beneficial effects on arterial stifness by improving endothelial function 
and reducing inflammation.
10:00 a.m.
1021-180 Validation of Renal Duplex Ultrasound in Detecting 
Renal Artery Stenosis Post Stenting
Ira Galin, Biana Trost, Jeanwan Kang, Robert Lookstein, Michael R. Jaff, Thomas A. 
Abbruzzese, Susan Gustavson, Jeffrey W. Olin, Mount Sinai Medical Center, New York, 
NY, Massachusetts General Hospital, Boston, MA
Background: The restenosis rate after renal artery stenting ranges between 10% - 20%. 
While there are well defined duplex ultrasound criteria for native renal artery stenosis, 
there are no ultrasound derived velocity criteria that have been validated in stented renal 
arteries. Most investigators believe that the velocities in stented renal arteries are higher 
than that seen in native renal arteries.
Methods: Vascular laboratory databases from two academic medical centers were 
retrospectively reviewed for patients who underwent duplex ultrasound evaluation of 
previously stented renal arteries arteries and had a Multidetector CT angiogram or 
conventional digital subtraction angiogram as a gold standard for comparison within 
6 months of the of the ultrasound. All ultrasound examinations were performed in an 
accredited vascular laboratory. Each renal artery was evaluated by ultrasound and 
compared to the gold standard angiogram
Results: There were a total of 134 renal arteries that had angiographic comparisons. The 
results are shown on Table I. The velocity criteria that are associated with these results 
will be discussed.
Conclusion: Duplex ultrasound of the renal arteries is an accurate technique to identify 
significant restenosis in stented renal arteries. In addition, a normal duplex ultrasound 
after renal artery stenting virtually rules out significant restenosis. 
Correlation Between Renal Artery Ultrasound and Angiography
Degree of Stenosis by Angiography
Degree of Stenosis by Ultrasound 0 - 59% 60 - 99% 100% Total
0 - 59% 85 4 0 89
60 - 99% 3 41 0 44
100% 0 0 1 1
Total 88 45 1 134
Sensitivity 
Specificity 
Positive Predictive Value 
Negative Predictive Value 
Accuracy
91% 
97% 
91% 
96% 
95%
10:00 a.m.
1021-181 Optimizing Platelet Inhibition And Anticoagulation In 
Treating Critical Limb Ischemia: High-Dose Single-
Bolus Short-Infusion IIb/IIIa Inhibition With Tirofiban 
And Direct Thrombin Inhibition During Peripheral 
Interventions
David E. Allie, Chris J. Hebert, Raghotham R. Patlola, Craig M. Walker, Cardiovascular 
Institute of the South, Lafayette, LA
Background: Glycoprotein (GP) IIb/IIIa and direct thrombin inhibition (DTI) have shown 
ischemic and vascular access hemostasis outcomes benefits during percutaneous 
coronary (PCI) and safety and feasibility during peripheral vascular interventions (PVI). 
Recent PCI reports suggest benefit with high-dose single bolus (HDSB) GP IIb/IIIa 
inhibition with limited infusions. Critical limb ischemia (CLI) patients have a high incidence 
of diabetes, small vessel disease, hypercoagulability, platelet dysfunction, thrombus, 
distal macro-/microembolization and overall complications.
Methods: Between October 2005 and June 2007, a CLI treatment group of 98 patients 
underwent PVI utilizing a single high dose tirofiban (Aggrastat, Medicure, Inc., Winnipeg, 
Manitoba) (25 mcq/kg/min) bolus with a limited 6-hr infusion (0.1 mcq/kg/min) and 
bivalirudin (Angiomax, The Medicines Company, Parsippany, NJ) (0.75 mg/kg/min) bolus 
with 1.75 mg/kg/min periprocedural infusion (group A). A matched CLI control group B 
used unfractionated heparin (UFH) without GP IIb/IIIa inhibition.
Results: Table.
Conclusion: A high dose single GP IIb/IIIa bolus of tirofiban with a limited 6-hour infusion 
and DTI combination is safe and feasible during PVI in CLI. 
Variables Group A  (N= 98)
Group B  
(N=98) P-Value
Procedural Success 96 (97.9%) 95 (96.9%) N/A
VAC (Major)* 0 (0.0%) 2 (2.0%) 0.196
VAC (Minor)** 6 (6.1%) 12 (12.2%) 0.133
Clinical Distal Embolization 0 (0.0%) 2 (2.0%) 0.196
Acute Thrombosis (<48 hours) 1 (1.0%) 3 (3.1%) 0.367
Subacute Thrombosis (30 day) 2 (2.0%) 5 (5.1%) 0.283
Secondary re-intervention (6-mo) 9 (9.18%) 16 (16.3%) 0.140
Limb salvage (6-mo) 97 (98.9%) 95 (96.9%) 0.622
VAC = vascular access complications 
*Any surgery, intracranial bleed, stroke, > 5 cm hematoma, pseudoaneurysm, 
retroperitoneal hematoma, or > 2u procedural related transfusion 
**Any other bleeding or hematoma < 5 cm
10:00 a.m.
1021-182 Inflammatory Markers Predicts Future Cardiovascular 
and Neurological Events In Patient Undergoing Carotid 
Stent Implantation
Francesco Versaci, Costantino Del Giudice, Achille Gaspardone, Gian Luigi Condorelli, 
Antonio Pellegrino, Alessandro Mauriello, Laura Liberatoscioli, Igino Proietti, Giovanni 
Simonetti, Claudio Cortese, Luigi Chiariello, Tor Vergata University, Rome, Italy
Background. C-Reactive protein predicts cardiovascular events after coronary stenting 
implantation. The aim of this study was to assess whether baseline inflammatory markers 
predicts future neurological and cardiovascular events after carotid stenting and to 
correlate systemic inflammation and histomorphometric analysis of the carotid plaque 
evaluated from the filters utilized as protective devices during the procedure.
Methods. Eighty consecutive patients (mean age 70,8±8,32, 55 men) with stable severe 
carotid stenosis were treated with stent implantation with distal filter devices. Levels of 
high-sensivity C-reactive protein (hs-CRP) and Interleukin-6 (IL-6) levels were measured 
before the procedure. Histomorphometric analysis of the debris from the filters was 
performed in all patients. All patients were followed-up for 5 years and major cardiovascular 
events (death, myocardial infarction and stroke) were recorded.
Results. Procedural success was 98.75%. The incidence of cumulative disabling stroke, 
myocardial infarction and death at the follow-up was 19%. Higher pre-procedural levels 
of hs-PCR and IL-6 were associated with clinical events at follow-up (p=0.0044 and 0.04 
respectively). Furthermore, a significant correlation was found between preprocedural 
hs-CRP and IL-6 and both the total number of particles (respectively p=0.03; r=0.3 and 
p = 0.02 , r= 0,3) and the mean debris area per filter (respectively p=0.04; R=0.3 and 
p=0.02, r=0,3). Finally mean debris area per filter was significantly associated with a 
higher incidence of events at follow-up (p=0,048).
Conclusions. Preprocedural levels of hs-CRP and IL-6 are predictive of neurological and 
cardiovascular events at follow-up. Patients with higher levels of hs-CRP and IL-6 presents 
a greater number of debris embolizing particles suggesting that systemic inflammation is 
associated with a higher plaque instability
10:00 a.m.
1021-183 The P22phox -930A/G Polymorphism of NADPH 
Oxidase: An Independent Genetic Determinant of 
Arterial Wave Reflections
Panagiotis Xaplanteris, Charalambos Vlachopoulos, Katerina Baou, Carmen Vasiliadou, 
Ioanna Dima, Nikolaos Ioakeimidis, Despina Kardara, Christodoulos Stefanadis, 1st 
Department of Cardiology, Athens Medical School, Hippokration Hospital, Athens, Greece
Introduction: Oxidative stress impairs wave reflections, which are independent markers 
and prognosticators of cardiovascular risk.The NADPH oxidase system maintains 
the redox state in the vessel wall. Recent studies have reported that the presence of 
allele G in the -930 polymorphic site of the p22phox NADPH subunit is associated with 
increased enzyme activity, while the presence of allele A accounts for reduced activity. We 
investigated the relation between the -930A/G polymorphism and wave reflections.
Methods: The study included 154 healthy individuals (102 males, mean age 40 years). The 
A-to-G substitution at position -930 in the p22phox promoter was typed by BbvI digestion 
of specific polymerase chain reaction products amplified from genomic DNA. The AA, AG 
and GG genotypes were determined. Augmentation index (AIx) was measured as index 
of wave reflections, using a validated device (SphygmoCor).
Results: In our population, the prevalence of AA, AG and GG genotypes was 24%, 45.5% 
and 30.5% respectively. Multiple linear regression analysis revealed that after adjustment 
for age, systolic blood pressure, heart rate, gender, BMI and HDL cholesterol, subjects 
with GG genotype had significantly lower values of AIx by 5.89% compared to subjects 
with AA genotype (p<0.01), while subjects with AG genotype had significantly lower 
values of AIx by 4.77% compared to subjects with AA genotype (p<0.01).
Conclusion: Our findings suggest that the -930A/G polymorphism of the p22phox 
promoter of NADPH oxidase is an independent determinant of wave reflections in healthy 
individuals. Presence of the G allele is associated with lower values of AIx.
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10:00 a.m.
1021-184 Quantitative Contrast Enhanced Ultrasound Imaging of 
the Carotid Artery Vasa Vasorum. Calibration and Initial 
Results
Dan Adam, Alex Soqulin, Blai Coll, Shelly Anne Miller, Paul Espinosa, Jonathan Steer, 
William Zang, Anne Hall, Cindy Owen, Kai Thomenius, Pete Meyer, Steven Feinstein, 
Rush University Medical Center, Chicago, IL, Technion, Haifa, Israel
Background: Adventitial Vasa Vasorum (VV), a surrogate marker of atherosclerosis, can 
be effectively imaged using contrast enhanced ultrasound imaging. We performed in vitro 
and in vivo validation of the VV.
Methods: For the in vitro studies, we designed a phantom using a tissue mimicking matrix 
in which varying concentrations of a contrast agent filled two distinct compartments: lumen 
and adventitial VV. The resultant gray-scale intensity within the regions of interest was 
quantified with a modified software. Subsequently, we performed an in vivo assessment 
of the vasa vasorum in 4 patients, following the same image-acquisition protocol 
(different contrast concentrations). Following these validation studies, we analyzed the 
vasa vasorum of 324 patients. For quantification we used the AutoIMT software (GE 
Haifa, Israel). The VV to lumen intensity was normalized as follows: VV ratio = VV/lumen 
intensity. Descriptive statistics and intraclass correlation coefficient were applied.
Results: In vitro and in vivo experiments calibration studies revealed a monotonic 
response based on ultrasound contrast concentration and the signal response for lumen 
and adventitial VV (Figure 1). In the clinical setting, the intraclass correlation coefficient 
was 97% for the common and 93% for the bulb.
Conclusions: Quantification of adventitial VV using standardized acquisition protocols can 
be validated permitting future clinical applications, using contrast enhanced ultrasound 
and automated software. 
10:00 a.m.
1021-185 Aortic Arch Plaques and Risk of Recurrent Ischemic 
Stroke and Death in Medically Treated Stroke Patients
Cesare Russo, Marco R. Di Tullio, Zhezhen Jin, Bruce Levin, J.L.P. Thompson, Ralph 
L. Sacco, J.P. Mohr, Shunichi Homma, Columbia University, New York, NY, University of 
Miami, Miami, FL
Background: Aortic arch plaques (AP) are a risk factor for ischemic stroke (IS). The best 
treatment to prevent stroke recurrence in patients with AP has not been established. 
Antiplatelet treatment is often prescribed, and oral anticoagulation has been advocated, 
especially for AP with mobile components (thrombi). The IS recurrence rates in patients 
on these treatments are not known.
Methods: As part of the Patent Foramen Ovale in Cryptogenic Stroke Study (PICSS), we 
performed transesophageal echocardiograms (TEE) in 630 patients who had experienced 
non-cardioembolic IS within the previous 30 days. AP were classified as none, small 
(1mm to 3.9mm thick) or large (>=4 mm). Plaques complexity was defined as presence of 
ulceration or mobile components on the plaque. Patients were randomized to aspirin 325 
mg/die or warfarin (target INR 1.4-2.8), and were followed for 2 years.
Results: Optimal visualization of the aortic arch was obtained in 82% of subjects (516; 291 
M, 225 F). AP of any degree were present in 337 (65.3%), whereas large and complex 
AP were present in 19.6% and 8.9%, respectively (8.5% had both large and complex AP). 
Patients with large AP were older than those with small AP or those without AP (66±9 vs. 
63±10 vs. 52±12 years, respectively; p<0.0001), and were more frequently white (50% vs. 
43% vs. 43%, p=0.003), hypertensive (79% vs. 61% vs. 59%, p=0.002), diabetic (46.5% 
vs. 28.9% vs. 21.8, p<0.0001), sedentary (50% vs. 33% vs. 25%, p<0.0002). In multivariate 
analysis adjusting for the above variables, large AP were associated with increased risk of 
recurrent IS or death in the overall population (hazard ratio [HR] 2.1, 95% CI 1.0 to 4.3), 
especially when complex AP morphology was present (HR 2.5, 95% CI 1.1 to 5.9). The 
risk of recurrent IS or death was higher in the cryptogenic stroke subgroup (large AP: HR 
3.6, 95% CI 1.0 to 13.0; large complex AP: HR 4.7, 95% CI 1.0 to 21.8).
Conclusions: In stroke patients treated with aspirin or warfarin, large aortic arch plaques, 
especially those with complex morphology, remain significantly associated with recurrent 
stroke and death over a follow-up of 2 years. The risk may be especially high in subjects 
with cryptogenic stroke.
10:00 a.m.
1021-186 Warfarin Versus Aspirin for Prevention of Recurrent 
Stroke and Death in Patients With Large Aortic Arch 
Plaques
Cesare Russo, Marco R. Di Tullio, Zhezhen Jin, Ralph L. Sacco, Bruce Levin, J.L.P. 
Thompson, J.P. Mohr, Shunichi Homma, Columbia University, New York, NY, University 
of Miami, Miami, FL
Background: The presence of aortic arch atherosclerotic plaques (AP) is a risk factor 
for ischemic stroke (IS). Treatment strategies for prevention of IS recurrence in patients 
with AP are not well defined. While systemic anticoagulation is recommended in AP with 
superimposed mobile thrombus, the treatment for large (>=4mm) but non-mobile AP, 
which also carry an increased IS risk, is uncertain. In particular, the efficacy of warfarin 
(W) and aspirin (A) in patients with large AP is unestablished.
Methods: 630 patients who had experienced non-cardioembolic IS within the previous 30 
days underwent transesophageal echocardiograms (TEE) as part of the Patent Foramen 
Ovale in Cryptogenic Stroke Study (PICSS). AP were classified as none, small (1mm to 
3.9mm thick) or large (>=4 mm). Patients were randomized to A 325 mg/die or W (target 
INR 1.4-2.8) and followed for 2 years. Primary endpoint was recurrent ischemic stroke 
or death.
Results: Diagnostically adequate TEE images of the aortic arch were obtained in 516 
patients (82%, 291M, 225 F). There were no significant differences between W and A 
groups regarding age (W 59±11 vs. A 60±11 years), female sex (W 41% vs. A 46%) 
and frequencies of traditional cardiovascular risk factors (hypertension 64% vs. 63%; 
diabetes 31% vs. 29%, smoking 28% vs. 30%; prior IS: 16.0% vs. 14.2%; W and A groups, 
respectively, all p-values=NS). Primary endpoint rates in patients with large AP after 2 
years follow-up were 22.9% in W group and 30.2% in A group (p=0.21). In the subgroup 
with cryptogenic stroke, event rates were not significantly different between the W and A 
groups (17.7% vs. 30.0%, respectively; p=0.19).
Conclusions: In stroke patients with large aortic plaques, rates of recurrent stroke or death 
at two years are high despite treatment with warfarin or aspirin. Although event rates were 
lower in the warfarin group, no significant difference from the event rates in the aspirin 
group was observed.
10:00 a.m.
1021-187 Aspirin Prevents Cholesterol Crystallization: A Potential 
Mechanism of Plaque Stabilization
Ameeth Vedre, Kusai Aziz, Ruiping Huang, George S. Abela, Michigan State University, 
East Lansing, MI, Edward Sparrow Hospital, Lansing, MI
Background: Recently it was demonstrated that cholesterol expands rapidly during 
crystallization forming crystals that rupture fibrous membranes. However, direct effects of 
ASA on cholesterol crystallization and plaque stabilization are unknown.
Method: To evaluate effects of ASA on cholesterol crystallization, cholesterol powder was 
melted in graduated cylinders then allowed to crystallize at 22°C with and without ASA 
and volume changes measured. ASA was mixed with cholesterol (1,2,3 g) at various 
doses (5 - 50 mg) prior to crystallization. A fibrous membrane (rabbit pericardium) was 
placed in the path of growing crystals to simulate plaque rupture. Also, human carotid 
plaques from endarterectomy were cut and equal halves incubated with ASA (25mg/
ml saline; 48hr) or saline. Tissue and crystal morphology were examined by light and 
electron microscopy.
Results: In vitro, ASA markedly reduced cholesterol volume expansion by 34% (p<0.001, 
r=0.9; graph). Microscopy demonstrated severe membrane damage by cholesterol 
crystallization while ASA prevented damage by reducing expansion and altering crystal 
morphology. In carotid plaques, ASA treated samples had blunt tipped crystals compared 
to pointed forms in matched controls.
Conclusions: ASA reduced or eliminated volume expansion during cholesterol 
crystallization and altered crystal morphology preventing fibrous membrane damage. 
Similar findings were noted in human carotid plaques suggesting a direct effect of ASA 
on plaque stabilization. 
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10:00 a.m.
1021-188 Relationship of hemodynamic parameters, pulse wave 
velocity and ankle-brachial index in heterozygous 
familial hypercholesterolemic patients undergoing LDL-
apheresis
Nicholas A. Haglund, Da Chang, Leonard M. Keilson, Maine Center for Lipids and 
Cardiovascular Health, Scarborough, ME
Background: Elevated plasma LDL levels in patients with heterozygous familial 
hypercholesterolemia (heFH) are associated with premature vascular disease. LDL-
apheresis (LDL-A) achieves > 50% reductions in LDL and apoB containing atherogenic 
lipoproteins. LDL-A is utilized for heFH patients on maximal medical therapy with coronary 
artery disease and LDL levels > 200mg/dl. Two properties responsible for the development 
of arterial disease include atherosclerosis and arteriosclerosis. These properties can be 
measured using non-invasive, oscillometric methods including ankle-brachial index (ABI), 
a proxy for atherosclerosis and pulse wave velocity (PWV), a proxy for arteriosclerosis. 
This study will explore the relationship between hemodynamic parameters, ABI, and 
PWV in patients with heFH undergoing long term LDL-A.
Methods: This is a prospective, self-matched case control study. Supine ABI and PWV 
were measured before and after each LDL-A treatment, using the Omron VP-1000 device 
and a standard protocol. All LDL-A was performed by the Kaneka Liposorber system 
utilizing dextran sulfate adsorption.
Results: 13 heFH patients (9 males, 4 females) with coronary artery disease were studied 
(median age 54, range 39-78). The median number of LDL-A treatments per patient prior 
to this study was 22 (range 7-170). Systolic blood pressure (SBP) and PWV change 
before and after LDL-A treatment demonstrated a linear relationship (R2 = .73). The 
average pre and post LDL-A treatment measurements were: ABI (1.08 +/- 0.11 and 1.09 
+/- 0.10, p 0.94, N.S.); SBP (143.3 +/- 15.8 and 156.8 +/- 7.5, p<0.011); PWV (1475.44 
+/- 284.1 and 1477.1 +/- 205.9, p 0.99, N.S.).
Conclusions: Our prevalence of peripheral vascular disease (ABI<0.9) was unexpectedly 
low (8%) compared to the reported prevalence (35%) in non-heFH populations with 
coronary artery disease. Although no difference was found between ABI and PWV before 
and after LDL-A, there was a significant difference in pre and post treatment SBP. A 
significant positive relationship was also observed between changes in SBP and PWV 
before and after LDL-A. 
10:00 a.m.
1021-189 Angina, Open Arteries and Endothelial Dysfunction in 
Women with Suspected Ischemia
Donna Polk, Chrisandra Shufelt, Yuching Yang, Joan Kirschner, Maura Paul-Labrador, 
Jana Williams, Saibal Kar, Kristen Tolstrup, C. Noel Bairey Merz, Cedars-Sinai Medical 
Center, Los Angeles, CA
Background: Evidence suggests that more women than men have angina with open or 
non-obstructive coronary artery disease. Women with angina and non-obstructive disease 
have evidence of microvascular coronary dysfunction by coronary reactivity testing (CRT). 
CRT requires intra-coronary acetylcholine to evaluate endothelial dependent macro and 
microvascular function. Peripheral arterial tonometry (PAT) is a non-invasive method to 
measure peripheral endothelial function and has been shown to correlate with coronary 
endothelial function.
Methods: Fourteen women with clinical and stress testing evidence of myocardial ischemia, 
and no obstructive CAD underwent CRT and PAT testing. Measurements made during CRT 
included intra-coronary artery adenosine coronary flow reserve (CFR) (non-endothelial 
microvascular function), changes in coronary blood flow (CBF) and coronary artery diameter 
with intra-coronary acetylcholine (micro- and macrovascular function, respectively). 
Macrovascular endothelial abnormality is defined as no vasodilation to acetylcholine. CBF 
measures microvascular endothelial abnormality with an abnormal response less than 50% 
change from baseline. Coronary PAT testing was assessed using digital volume changes in 
flow (Itamar Medical Ltd) and abnormal as an index less than 1.67.
Results: The mean age was 53.7 + 6.4 years, 21.4% were non-white, 50% had 
dyslipidemia, 43% were hypertensive and 43% were former smokers. None were 
current smokers and there were no diabetics. Abnormal PAT response was present in 
7%. Macrovascular endothelial dysfunction measured by acetylcholine percent diameter 
response was present in 64%. The correlation between acetylcholine response and PAT 
was r = -0.24, (p=0.40). Microvascular endothelial dysfunction measured by CBF was 
present in 50% and the correlation of CBF and PAT testing was r = -0.49, p=0.075.
Conclusions: The noninvasive peripheral PAT correlates with CBF but not percent 
diameter response to acetylcholine measured during invasive CRT. These results suggest 
that peripheral endothelial function measurements are better estimates of microvascular 
than macrovascular endothelial coronary function.
10:00 a.m.
1021-190 Can We Predict Right Ventricular Dysfunction by 
Serologic Tests Before Echocardiography in Patients 
With Acute Pulmonary Thromboembolism?
Kye Hun Kim, Hyun Ju Yoon, Nam Sik Yoon, Jae Youn Moon, Young Joon Hong, Hyung 
Wook Park, Ju Han Kim, Youngkeun Ahn, Myung Ho Jeong, Jeong Gwan Cho, Jong 
Chun Park, Jung Chaee Kang, Chonnam National University Hospital, Gwangju, South 
Korea
Background: Right ventricular (RV) dysfunction by echocardiography is a critical finding 
in the risk stratification of acute pulmonary thromboembolism (PTE). The aim of this study 
was to investigate the serologic predictors of RV dysfunction in patients with acute PTE. 
Methods: A total of 86 patients with acute PTE were divided into two groups; the patients 
with RV dysfunction (group I, n=54, 65.3±14.2 years, 35 females) versus the patients 
without RV dysfunction (group II, n=32, 61.0±16.3 years, 16 females). Various laboratory 
parameters were analyzed between the groups. Results: The results were summarized in 
table. The levels of N-terminal pro B type natriuretic peptide (NT-proBNP), cardiac specific 
troponin T (cTnT), and I (cTnI) were significantly elevated, but the level of fibrinogen was 
significantly decreased in group I than in group II. By receiver operation curve analysis, 
the area under the curve was 0.917 in NT-proBNP, 0.865 in cTnT, 0.897 in cTnI, and 0.346 
in fibrinogen. The optimal cut-off value to predict RV dysfunction by echocardiography was 
922.5 pg/mL in NT-proBNP (sensitivity: 94.7%, specificity: 85.7%), 0.014 ng/mL in cTnT 
(sensitivity: 84.2%, specificity: 92.9%), 0.065 ng/mL in cTnI (sensitivity: 89.5%, specificity: 
92.9%). Conclusions: NT-proBNP, cTnT, and cTnI are significant serologic predictors of 
RV dysfunction. Measurements of NT-proBNP, cTnT, and cTnI are simple and useful test 
in the risk stratification or treatment of acute PTE before echocardiography.
Group I Group II P value
NT-proBNP (pg/mL) 5760.0±1227.2 1227.2±4117.3 0.002
cTnT (ng/mL) 0.15±0.22 0.03±0.05 0.009
cTnI (ng/mL) 0.77±1.77 0.04±0.07 0.022
High sensitivity C-reactive protein (mg/dL) 5.47±5.60 3.03±3.02 0.173
D-dimer (mg/L) 2.03±2.99 0.87±0.87 0.095
Fibrinogen (mg/dL) 243.45±114.76 338.44±128.54 0.008
Fibrin degradation product (ug/mL) 28.79±62.15 12.44±10.56 0.148
10:00 a.m.
1021-191 Atrial Septal Ablation Using High Intensity Focused 
Ultrasound
Yasuyoshi Takei, Kazue Okajima, Kohei Fujimoto, Takuya Haseagwa, Kotaro Arai, Yukiko 
Sashida, Yelena Rekhtman, Marco R. Di Tullio, Shunichi Homma, Andrew Kalisz, Robert 
Muratore, Columbia University Medical Center, New York, NY, Riverside Research 
Institute, New York, NY
Background: High intensity focused ultrasound (HIFU) has been successfully applied 
clinically as a non-invasive therapeutic tool for conditions such as prostate cancer, uterine 
fibrosis, and atrial fibrillation. Atrial septostomy (AS) is a palliative treatment for refractory 
primary pulmonary hypertension (PPH). AS involves the creation of a right-to-left shunt, 
producing a pathway that reduces right atrial and ventricular pressure and increases 
cardiac output. The purpose of this study was to assess the feasibility of atrial septal 
ablation in vitro using HIFU.
Methods: Fourteen specimens of atrial septum from freshly excised pig hearts were 
treated in vitro with HIFU pulses. Focused ultrasound energy was applied with an 
operating frequency of 5.25MHz at the nominal focal point intensity of 4.0 kW/cm2 for 0.4 
seconds at 1 second intervals.
Results: Thirty-five lesions were created with ultrasonic exposures ranging from 40 pulses 
to 120 pulses successfully. There was a significant dose-response relationship between 
the applied HIFU exposure times, lesion area (r=0.54, p=0.0009), and lesion volume 
(r=0.69, p<0.0001). Patho-histological analysis revealed coagulation of collagen tissue 
and the presence of many small vacuoles around the perforation.
Conclusions: HIFU is a novel method of creating focal atrial septum perforation without 
direct tissue contact. This method may prove useful for non-invasive atrial septostomy in 
patients with PPH. 
10:00 a.m.
1021-192 Normalization of Lung Aquaporin-1 Expression by 
Simvastatin in Monocrotaline-Induced Pulmonary 
Hypertension in Rats
Dongseok Lee, Yungkyu Kim, Yongwook Jung, Dookwon Kim, Aesuk Kim, Sungmin 
Choi, Dongguk University Hospital, Kyungju, South Korea
Background: Pulmonary hypertension is characterized by abnormal proliferation of 
vascular endothelial and smooth muscle cells, and progressive pulmonary microvascular 
leak leading to pulmonary edema. The mechanisms of pulmonary edema formation remain 
uncertain. This study was designed to investigate the role of lung and renal aquaporin 
(AQP) water channel, and the therapeutic effect of simvastatin in monocrotaline (MCT)-
induced pulmonary hypertension.
Methods: Twenty one 8-week-old rats were randomized to control, MCT (60 mg/kg, sc) 
and MCT plus simvastatin (5 mg/kg/day, po) groups. Four weeks later, systolic right 
ventricular pressure, right ventricular hypertrophy (right ventricular/left ventricle+septum 
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ratio), pulmonary artery morphometric analysis and renal function were measured. 
Western blot for lung AQP-1 and renal AQP-2 were performed.
Results: Simvastatin treatment reduced right ventricular pressure (32.3±2.1 vs. 52.4±3.9 
mmHg; p<0.01), right ventricular hypertrophy (0.32±0.03 vs. 0.48±0.07; p<0.01), medial 
wall thickness of peribrochiolar artery (0.14±0.02 vs. 0.28±0.02; p<0.01) and pulmonary 
arterioles (0.15±0.04 vs. 0.29±0.11; p<0.01) compared with MCT groups. Expression of 
lung AQP-1 and renal AQP-2 were significantly diminished in MCT-induced pulmonary 
hypertension rats (p<0.01). Lung AQP-1 and renal AQP-2 protein expression were 
normalized by the simvastatin treatment. Additionally, simvastatin treatment significantly 
reduced perivascular and interstitial edema in lung. Serum osmolarity and sodium levels 
were slightly increased in MCT group (p<0.01), but normalized after simvastatin treatment 
(p<0.01). Other parameters of renal function were not altered.
Conclusions: Simvastatin attenuates the development of MCT-induced pulmonary 
hypertension and reduces pulmonary edema by upregulation of lung AQP-1. Normalization 
of AQP may be an important mechanism of statin effect.
10:00 a.m.
1021-193 Prevalence of Free-Floating Thrombi in the Right Heart 
Complicating Acute Pulmonary Embolism
Imad Abi-Nasr, NIcolas Mansencal, Vincent Caille, Roland N’Guetta, Antoine Vieillard-
Baron, Pascal Lacombe, François Jardin, Olivier Dubourg, AP-HP, Hôpital universitaire 
Ambroise Paré, Boulogne, France
Background: Free-floating thrombi in the right heart is considered as exceptional in acute 
pulmonary embolism (PE). Studies evaluating such complications are rare. The aim of 
this study was to estimate the prevalence of free-floating thrombi in the right heart in a 
population of patients presenting with acute PE.
Methods: We studied 340 consecutive patients with confirmed PE (by CT-scan or lung 
scintigraphy) and all these patients underwent transthoracic echocardiography. We 
systematically assessed: 1) right to left ventricular end-diastolic area ratio using 2D echo 
in apical 4-chamber view and a right ventricular dilation was defined as a ratio > 0.6; 2) 
systolic pulmonary arterial pressure (SPAP) using CW Doppler and 3) the presence of 
free-floating thrombi in the right heart using 2D echo and we separated thrombi prolapsing 
into the tricuspid valve from those less mobile in the right atrium.
Results: Mean age was 65 ± 18 yo (range: 16-95), 141 men and 199 women. Using 
transthoracic echocardiography, 141 patients (41%) presented with right ventricular 
dilation and mean SPAP was 43 ± 13 mmHg. Twelve patients had free-floating thrombi in 
the right heart. The prevalence of free-floating thrombi in the right heart in our population 
was 3.5 %. The characteristics of free-floating thrombi in the right heart were as follows: 
the thrombus was serpentine, very mobile and prolapsing into the tricuspid valve in 
10 patients and was less mobile and spherical in 2 patients; all patients had also right 
ventricular dilation and mean SPAP was 50 ± 8 mmHg and was significantly higher as 
compared to patients without free-floating thrombus (p=0.03).
Conclusion: Our study suggests that the prevalence of free-floating thrombi in the right 
heart in acute PE is 3.5 %. This complication is not so unusual in acute PE and should be 
systematically assessed using transthoracic echocardiography.
10:00 a.m.
1021-194 Percutaneous Rheolytic Thrombectomy with AngioJet 
for Pulmonary Embolism: the Experience of a High 
Volume Center
Gaia Spaziani, Sabine Vecchio, Guido Vittori, Tania Chechi, Elena Falchetti, Gabriele 
Giuliani, Alessio Lilli, Massimo Margheri, Careggi Hospital, Florence, Italy
Background: Pulmonary embolism (PE) is a common disease with significant mortality. 
Anticoagulant and thrombolytic therapies are a mainstay in the management of acute 
PE, especially with hemodynamic compromise. However, systemic drugs cannot 
achieve timely and effective treatment of acute PE in all patients. Percutaneous rheolytic 
thrombectomy might be a safe and efficacious therapeutical strategy and the use of a 
rheolytic thrombectomy catheter during pulmonary angiography represents a promising 
therapeutical tool. Our aim was to evaluate the efficacy of thrombus removal using the 
AngioJet catheter in patients with acute massive and submassive PE.
Methods: Pulmonary angiography was performed in 54 consecutive patients (28 men; 
mean age 66.8±13.5 years) with massive or submassive PE from September 2001 to 
March 2007. Rheolytic thrombectomy (RT) was not performed in 8 patients because 6 
of them showed involvement of small vessels (<3mm) and 2 died in the cath lab before 
RT due to cardiogenic shock. Forty-six patients were treated with RT: the Miller index (an 
angiographic index of severity as the sum of obstruction and perfusion indexes) and the 
systolic pulmonary pressure were evaluated pre and post RT.
Results: In all patients treated an efficacious removal of thromboembolic material was 
obtained, as showed by the significant improvement in the obstruction, perfusion and 
Miller indexes and in the systolic pulmonary pressure observed after RT (p<0.0001). 
The achievement of a larger experience by the operators was associated with a less 
procedural complications rate (i.e. post-procedural increase in creatinine, cardiac arrest 
during the procedure and post-procedural hemoptysis). In-hospital mortality occurred in 8 
patients (17.4%), 75% of them presented with cardiogenic shock. All patients were alive 
at follow-up (mean 28.8 months, range 6-62 months), except one patient who died after 3 
months for acute myocardial infarction.
Conclusions: Percutaneous rheolytic thrombectomy using the AngioJet catheter may be a 
valid treatment option for patients with massive or submassive PE with rapid and significant 
hemodynamic improvement and encouraging results at early and long-term follow-up.
10:00 a.m.
1021-195 Activation of Protein Kinase A by Pioglitazone and 
Atorvastatin Determines if 5-Lipoxygenase Interacts 
with Cyclooxygenase-2 to Produce 15-Epilipoxin A4 or 
Cytosolic Phospholipase A2 to Produce Leukotrienes
Yochai Birnbaum, Yumei Ye, Yu Lin, Regino J. Perez-Polo, University Of Texas Medical 
Branch, Galveston, TX
Background: 5-lipoxygenase (5LO) produces 15-epilipoxin-A4 (15ELX), an anti-
inflammatory mediator, and leukotriene-B4 (LTB4). Phosphorylation at Ser523 by protein 
kinase A (PKA) prevents 5LO translocation to the perinuclear membrane. Atorvastatin 
(ATV) and pioglitazone (PIO) upregulate 15ELX production. We assessed whether 5LO 
phosphorylation (P5LO) by PKA determines whether 5LO interacts with the membranous 
cPLA2 to produce LTB4 or with COX2 to produce 15ELX. Methods: Rats received 3-day 
pretreatment with oral PIO (10 mg/kg/d) or ATV (10 mg/kg/d) with or without oral H89 (a 
PKA inhibitor, 20 mg/kg/d). Results: PIO and ATV did not affect total 5LO levelsexpression. 
However, both treatments increased 5LO levels in the cytosolic fraction. H89 alone had 
no effect, but in combination with both PIO and ATV, caused a decrease in 5LO levels 
in the cytosolic fraction. PIO and ATV did not affect 5LO levels in the membranous 
fraction; however;, H89 in combination with PIO and ATV caused a significant increase 
in the membranous 5LO levels. PIO and ATV increased P-5LO levels. H89 attenuated 
this increase. Both PIO and ATV increased COX2 levels in the cytosolic fraction and 
the membranous fraction. H89 prevented this increase. PIO and ATV increased cPLA2 
expression in the membranous fraction. This effect was not attenuated by H89. Co-
immunoprecipitation showed an interaction between COX2 and 5LO in the PIO and ATV 
groups. This was prevented by H89. On the other hand, cPLA2 interacted with 5LO in the 
PIO+H89 and ATV+H89 groups, but not in the other groups. Co-immunoprecipitation of 
COX2 with 5LO occurred in the cytosolic fraction, but not in the membranous fraction. 
Myocardial cells incubated with PIO and ATV showed enhanced production of 15ELX. 
H89 attenuated this effect. PIO, ATV and H89 had no effect on LTB4 production. However 
PIO+H89 and ATV+H89 markedly increased LTB4 levels. Conclusions: PKA-mediated 
phosphorylation of 5LO prevents migration of 5LO into the membranous fraction and 
interaction with cPLA2 to produce LTB4. Instead, P-5LO interacts with COX2 in the 
cytosolic fraction to produce 15ELX. Inability to prevent 5LO-cPLA2 interaction may 
explain myalgia and elevated enzymes seen with statins.
10:00 a.m.
1021-196 Cardiorenal Properties of a Novel Designer Natriuretic 
Peptide Fusing Urodilatin and C-Type Natriuretic 
Peptide
Candace Y.W. Lee, Sharon M. Sandberg, Denise M. Heublein, John C. Burnett, Jr., Mayo 
Clinic and Mayo Clinic College of Medicine, Rochester, MN
Background: Urodilatin (URO) activates the natriuretic peptide receptor (NPR)-A and 
cGMP and mediates cardiac-unloading, arteriodilating and renal-enhancing actions but 
may lower blood pressure (BP). C-type NP (CNP) in contrast activates NPR-B and has 
limited renal actions and is venodilating with less effect on BP. We hypothesized that 
fusion of the N- and C-termini of URO to the ring structure of CNP would result in a novel 
designer NP with the cardiorenal actions of URO but without lowering BP.
Methods: URO (n=5) or CU-NP (n=6) 14.14 pmol/kg/min iv was infused into normal anesthetized 
dogs for 75 min. Clearances are reported for pre-infusion (pre-I), 30 min and 60 min of I. 
Plasma renin activity (PRA) and angiotensin II (Ang II) were measured by radioimmunoassays. 
Mean±SE, P<0.05*, <0.01† vs pre-I; P<0.05‡, <0.01§, <0.001¶ CU-NP vs CNP.
Results: URO (n = 5) vs CU-NP (n = 6) increased urine flow (0.16±.06 to 1.7±.3† to 
1.7±.2† vs 0.13±.02 to 1.3±.2† to 1.3±.2† mL/min), urinary Na+ excretion (9±7 to 242±30† 
to 242±30† vs 8±3 to 216±42† to 238±36† µEq/min) and GFR (36±4 to 42±1 to 52±7* 
vs 38±4 to 51±3* to 54±3† mL/min). Pulmonary capillary wedge pressure (mmHg) was 
reduced by URO (4±.8 to 3.1±.8† to 2.7±.7†) and CU-NP (5.6±.9 to 3.9±.6* to 2.9±.9†). 
Right atrial pressure (mmHg) was reduced by URO (1±.3 to 0.4±.3† to 0.04±.3†) and 
CU-NP (1±.6 to 0.3±.5* to -0.1±.5†). Importantly, MAP (mmHg) decreased with URO 
(128±4 to 123±5* to 119±4†‡) but not CU-NP (136±4 to 136±3 to 134±4). Both URO and 
CU-NP increased plasma cGMP (6±1 to 39±3†¶ to 43±4†¶ vs 8±1 to 26±1† to 30±1† 
pmol/mL) and urinary cGMP excretion (865±56 to 7229±1015†§ to 9145±1187†¶ vs 
770±48 to 3508±574† to 4591±664† pmol/min); and decreased PRA (8.9±1.9 to 2.3±.5† 
to 1.42±.3† vs 8.8±2 to 2.5±.8† to 1.5±.4† ng/mL/hr) and Ang II (14±2 to 4±.5† to 4±.9† 
vs 14±2 to 7±.7† to 4±.3† pg/mL).
Conclusion: We report the successful transformation of URO to a URO-like designer 
peptide with similar natriuretic, diuretic, GFR-enhancing and cardiac-unloading actions 
and comparable suppression of the renin-angiotensin system to URO, but without 
lowering BP. Further studies are needed to assess the mechanisms of actions of CU-NP 
and its therapeutic potential in heart failure.
10:00 a.m.
1021-197 Enhanced Cholesterol Efflux With Adiponectin and its 
Receptors in HEK293T Cells
Ken Kitajima, Shin-Ichiro Miura, Toshimasa Yamauchi, Yoshinari Uehara, Takashi 
Kadowaki, Keijiro Saku, Fukuoka University School of Medicine Depatment of Cardiology, 
Fukuoka, Japan, Graduate School of Medicine University of Tokyo, Tokyo, Japan
Background: Low plasma adiponectin levels were associated with the progression of 
coronary artery calcification and found in patients with coronary artery disease (CAD) or 
metabolic syndrome (MetS). We hypothesized that adiponectin and its receptors enhance 
the cholesterol efflux for the high-density lipoprotein (HDL) takes up cholesterol through 
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ATP binding cassette A1 (ABCA1) as reverse cholesterol transport (RCT).
Methods: We transfected adiponectin receptor 1 and 2 (AdipoR1 and AdipoR2) cDNA to 
human kidney cells (HEK293T), which endogenously expressed ABCA1. The AdipoR1 
and AdipoR2-transfected HEK293T cells were labeled with tritium labeled cholesterol 
following cholesterol loading for 24 hours with or without adiponectin or reconstituted 
(r)HDL, a new therapeutic strategy which enhances RCT. The levels of cholesterol efflux 
were analyzed using a liquid scintillation counter. The AdipoR1 and AdipoR2 transfected 
HEK293T cells were also determined for the ABCA1 mRNA expression using quantitative 
reverse transcription- PCR.
Results: The efflux of AdipoR1- and AdipoR2-transfected HEK293T cells (2.4±0.2 and 
3.3±0.4 %, respectively) showed higher efflux significantly in AdipoR2-transfected cells 
compared to mock-transfected cells (2.4±0.4%). Treatment with adiponectin at 25µg/ml 
had additional effects on efflux (mock, 3.3±0.4; AdipoR1, 3.4±0.1; AdipoR2, 5.2±0.5 %) 
in transfected cells. In addition, rHDL at 0.4µg/ml also increased efflux in significantly 
compared to mock-transfected cells (mock, 2.6±0.1; AdipoR1, 5.0±0.6; AdipoR2 5.4±0.9 
%). Interestingly, 0.4µg/ml rHDL-induced cholesterol uptake increased significantly in the 
presence of adiponectin at 25µg/ml (mock, 6.8±1.6; AdipoR1, 7.3±0.7; AdipoR2 7.9±0.8 
%). The mRNA levels of ABCA1 were increased significantly in AdipoR2-transfected 
cells.
Conclusion:
Adiponectin and overexpression of its receptors increased cholesterol efflux and also 
enhanced rHDL-induced cholesterol efflux in HEK293T cells. These results suggest that 
adiponectin and its receptors may enhance the RCT system through ABCA1 pathway and 
are expected to induce an anti-atherogenic effect for the patients with CAD or MetS.
10:00 a.m.
1021-198 Ranolazine increases glucose stimulated insulin 
secretion in rats
Arvinder K. Dhalla, Dongmin Liu, Melissa Santikul, Luiz Belardinelli, CV Therapeutics 
Inc., Palo Alto, CA, Virginia Polytechnic Institute and State University, Blacksburg, VA
Introduction: Diabetes is an independent risk factor for coronary artery disease (CAD). 
Conversely myocardial infarction increases the risk of developing impaired glucose 
tolerance. Ranolazine, an inhibitor of the late sodium current, is a novel antianginal agent 
that also lowers HbA1c (CARISA and MERLIN TIMI-36). The mechanism of the HbA1c 
lowering effect of ranolazine remains to be elucidated. In the present study, we determined 
the effect of ranolazine on glucose-stimulated insulin secretion (GSIS).
Methods: The effect of ranolazine on GSIS in-vitro was determined in rat isolated 
pancreatic islets while the in-vivo effect was determined in normal awake rats using an 
intravenous glucose tolerance test (IVGTT).
Results: Ranolazine increased GSIS by ~2-fold at concentrations between 100 nM to 1 µM 
in pancreatic islets in the presence (Figure A), but not in the absence of 20 mM glucose. In 
awake rats, pretreatment with ranolazine (15 mg/kg, PO) increased insulin levels following 
IV glucose load by 1.5 fold compared to vehicle (Figure B). Peak increase in insulin levels 
by ranolazine was similar to that seen with glibenclamide used as a positive control. But 
unlike glibenclamide, ranolazine did not increase insulin levels prior to administration of 
glucose load. Conclusion: Ranolazine increases GSIS in pancreatic islets and in whole 
animals when challenged with high glucose, and this may be responsible for improved 
glucose homeostasis and the decrease in HbA1c observed in clinical trials.
10:00 a.m.
1021-199 The Defect in HDL Function and Reverse Cholesterol 
Transport Found in Diabetic Mice With the Hp 2-
2 Genotype Can Be Corrected With High Dose 
Antioxidant Therapy
Rabea Asleh, Rachel Miller-Lotan, Zaid Abassi, Andrew P. Levy, Technion-Israel Institute 
of Technology, Haifa, Israel
Background: The primary function of the Haptoglobin (Hp) protein is to clear free 
hemoglobin (Hb). Two common alleles exist at the Hp locus (1 and 2). We recently 
demonstrated that reverse cholesterol transport is impaired in individuals with Diabetes 
Mellitus (DM) and the Hp 2-2 genotype which may explain the increased incidence of 
CVD in this population. We sought to (1) test the hypothesis that clearance of the Hp 
2-Hb complex is slower in DM allowing more complex to bind to HDL thereby resulting 
in increased oxidative modification of HDL and inhibition of reverse cholesterol transport 
and (2) determine if antioxidant therapy could restore normal HDL function in Hp 2-2 
DM mice.
Methods and Results: Injection of I125- Hp 1 or Hp 2-Hb complexes into non-DM 
mice demonstrated that the half-life of the Hp 2-Hb complex was 2-3 fold longer 
than the Hp 1-Hb complex (57.8±2.8 vs. 20.4±1.7 min). Moreover, in DM the half-life 
of the Hp 2-Hb complex was doubled while the half-life of the Hp 1-Hb complex was 
unchanged (103±3.9 vs. 18.6±1.8 min). Coimmunoprecipitation studies demonstrated 
that over 25% of the injected Hp 2-Hb complex was associated with HDL in DM mice 
representing a greater than 10 fold increase compared to Hp 1-Hb complex in non-DM 
mice. Coimmunoprecipitation studies in Hp 0 (knockout) mice demonstrated that the Hp 
protein was absolutely necessary for the interaction of Hb with HDL. Reverse cholesterol 
transport was impaired by DM in Hp 2 mice but this impairment was prevented by high 
dose antioxidant supplementation to these mice.
Conclusions: These data may explain why the Hp 2 genotype promotes less efficient 
reverse cholesterol transport in DM and suggests that strategies targeted to decrease 
oxidation of HDL by the Hp 2-Hb complex may improve HDL function.
10:00 a.m.
1021-200 A Novel Porcine Model of Diet-Induced Obesity Causes 
Deranged Myocardial Insulin Signaling
Jenny Lee, Ya Xu, Li Lu, Wayne Leitner, Clifford Greyson, Bryan Bergman, Boris 
Draznin, Gregory Schwartz, VA Medical Center and University of Colorado Health 
Sciences Center, Denver, CO
Background: Pre-diabetic systemic insulin resistance confers increased cardiovascular 
risk independent of its effects on atherosclerosis. However, it is uncertain whether 
derangements in myocardial glucose metabolism and insulin signaling occur in the setting 
of pre-diabetic systemic insulin resistance. We developed a porcine model of diet-induced 
obesity to test the hypothesis that myocardial insulin resistance develops in parallel with 
systemic insulin resistance, and is characterized by impaired phosphatidylinositol-3-
kinase (PI3K) and Akt signaling.
Methods: Yucatan micropigs (n=16) were assigned to intervention diet (17% w/w simple 
sugars, 25% fat from coconut oil) or control diet (2% simple sugars, 4% fat). IV glucose 
tolerance tests (IVGTT) were performed at 0, 3, and 6 mo of assigned diet. At 7 mo, under 
euglycemic clamp, myocardial glucose uptake in response to graded infusion of insulin 
was determined by Fick method; 3 h after these measurements, myocardial and skeletal 
muscle biopsies were obtained prior to and 5 min after a 10 U/kg IV insulin bolus. In these 
samples, PI3K activity and Akt phosphorylation pre- and post-insulin were determined by 
thin layer chromatography and Western blotting, respectively. 
Results: Pigs in the intervention diet group developed obesity (final weight 73±4 vs 
40±4 kg, p<.001), mildly elevated fasting blood glucose (54±3 vs 44±2 mg/dl, p<.001) 
and free fatty acids (p=.01), hypertension and dyslipidemia, thus recapitulating several 
features of clinical “metabolic syndrome.” Systemic insulin resistance was demonstrated 
by IVGTT, and by blunted insulin stimulation of skeletal muscle PI3K activity and Akt 
phosphorylation (each p<.05). In parallel, myocardial insulin resistance was manifest by 
blunted insulin-stimulation of myocardial glucose uptake, PI3K activation (p<.05), and Akt 
phosphorylation (p<.05).
Conclusions: Myocardial insulin resistance develops in parallel with systemic insulin 
resistance in pigs fed a diet high in simple sugars and saturated fat. This abnormality 
could potentially impair cardiac responses to ischemia/reperfusion or other physiologic 
stresses where insulin signaling is believed to be important.
10:00 a.m.
1021-201 B-Type Natriuretic Peptide 8-32 (BNP 8-32), 
Which Is Produced From Mature BNP 1-32 by the 
Metalloprotease Meprin A, Has Reduced Bioactivity
Guido Boerrigter, Lisa C. Costello-Boerrigter, John C. Burnett, Jr., Mayo Clinic, 
Rochester, MN
Background: 32-amino acid B-type natriuretic peptide (BNP 1-32) plays an important 
compensatory role in cardiovascular diseases. Recently, it has been reported that BNP 1-
32 is cleaved in plasma by the metalloprotease meprin A and inhibitors of meprin A are in 
development. To date, the bioactivity of BNP 8-32 in cardiorenal regulation as compared 
to mature biologically active BNP 1-32 is unknown. We hypothesized that BNP 8-32 has 
reduced vasodilating and natriuretic bioactivity as compared to BNP 1-32 in vivo.
Methods: We investigated the cardiorenal actions of intravenous synthetic human BNP 8-32 and 
BNP 1-32 in a crossover study in four anesthetized normal canines. After a baseline clearance, 
BNP 1-32 was infused at 30 ng/kg/min. After a 15’ lead-in a 30’ clearance was done. This was 
followed by a 60’ washout and a 30’ post-infusion clearance. Subsequently, an equimolar dose 
of BNP 8-32 was infused with a 30’ clearance after a 15’ lead-in. In half the studies the sequence 
of BNP 1-32 and BNP 8-32 infusion was reversed. Peptides were compared by analyzing the 
changes from the respective preinfusion clearance to the respective infusion clearance with 
paired t-test or Wilcoxon signed rank test. *p<0.05 between peptides.
Results: Mean arterial pressure was reduced by both BNP 1-32 and BNP 8-32 (-10±4 
vs -9±5 mmHg, p=0.83). Changes in right atrial pressure, pulmonary capillary wedge 
pressure, heart rate, cardiac output, renal blood flow, and glomerular filtration rate were 
similar with BNP 1-32 and BNP 8-32. In contrast, urinary sodium excretion increased 
more with BNP 1-32 than with BNP 8-32 (+390±64 vs +181±25* uEq/min), as did urinary 
potassium excretion. Similarly, urine flow increased more with BNP 1-32 than with BNP 
8-32 (+2.6±0.5 vs +1.1±0.1* mL/min).
Conclusions: While BNP 8-32 has similar vasodilating actions as compared to BNP 1-
32, its diuretic and natriuretic actions are reduced. These findings suggest that inhbition 
of meprin A may have an important role in the regulation of BNP 1-32 bioactivity in the 
kidney and that meprin A inhibition could be a potential strategy to increase the bioactivity 
of endogenous and exogenous BNP 1-32 in cardiovascular disease states such as heart 
failure and hypertension.
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1021-202 Intravascular Stents Electroplated with 117mSn Reduce 
Arterial Wall Inflammation in Hyperlipidemic Rabbits
Jinsheng Li, Keith A. Robinson, David W. Mueller, Lakshmana Pendyala, Gilbert 
Gonzales, Radoslav Adzic, Suresh C. Srivastava, Nicolas A.F. Chronos, Saint Joseph’s 
Research Institute, Atlanta, GA
Background: Inflammatory cells play a key role in atherogenesis. Anti-inflammatory 
therapies can suppress inflammatory cell activity in atherosclerotic lesions and thereby 
stabilize plaques vulnerable to rupture. Low-energy conversion electrons generated by the 
radioisotope 117mSn have been shown to be effective in suppressing the inflammation 
and emit 159 KeV photons amenable to gamma camera imaging. The objective of this 
study is to evaluate the effect of a novel radioactive stent electroplated with 117mSn on 
atherosclerotic plaque in hyperlipidemic rabbits.
Methods: NZW rabbits were fed 1% cholesterol and 5% peanut oil for 2 mo. Eleven radioactive 
stents [cold (0-), low (30-), medium (60-) and high (150-µCi) 117mSn] were implanted in the 
abdominal aorta 3 days prior to termination; BrdU was injected 24 hours prior. Segments 
of thoracic aorta (as control) and stented regions of abdominal aorta were examined using 
histological, immunohistochemical, and histomorphometric techniques to assess inflammatory 
and smooth muscle cell localization, area density, cell proliferation, lipid content in the intima, 
and overall histopathology. Total cholesterol was measured at baseline and termination.
Results: Total cholesterol was <100mg/dl in all rabbits at baseline and increased to 391± 
8.9 mg/dl at termination. Oil Red O staining showed atherosclerotic plaque involved 
60.8±4.7% of aortic surface. In control aorta, intimal lesions consisted of RAM-11-positive 
macrophage-foam cells with a cap of α-smooth muscle actin-positive spindle-shaped 
cells present near the luminal surface. Inflammatory cells in the stented segments were 
no different between cold and low groups (66.4±6.9% and 61.8±3.4%). It was dramatically 
reduced in medium group (26.8±3.6%; p<0.05 than cold and low) and there was no 
inflammatory cell in high group (0±0%; p<0.01 than cold and low).
Conclusions: 117mSn-electroplated stents reduced inflammation in the aortic vessel 
wall 3 days post-implant, in a roughly dose-dependent fashion. This novel radioisotope 
shows promise as a possible therapeutic strategy to reduce inflammatory events in 
atherosclerosis, and may therefore provide a means to limit plaque vulnerability.
10:00 a.m.
1021-203 EP3 Receptors - A New Target For Antithrombotic 
Agents
Stan Heptinstall, Dan Hartman, University of Nottingham, Nottingham, United Kingdom, 
deCODE Genetics Inc, Brighton, MI
Background: Platelets respond to PGE2 produced by atherosclerotic plaques and 
in a complex way. PGE2 promotes platelet aggregation through EP3 receptors via a 
mechanism involving Gi and inhibition of adenylate cyclase. PGE2 also inhibits platelet 
aggregation through IP receptors, Gs and stimulation of adenylate cyclase. Genetic 
studies have linked EP3 receptors to MI, stroke and the severest forms of peripheral 
arterial disease; therefore blocking the effects of PGE2 on the EP3 receptor might provide 
successful antithrombotic therapy. We have examined the contribution of EP3 receptors to 
platelet function using the selective agonist sulprostone and the antagonist DG-041. We 
have also determined the effects of PGE2 and DG-041 on platelet function. DG-041 is an 
oral EP3 antagonist that is currently being evaluated in clinical trials.
Methods: Studies were performed in vitro in plateler-rich plasma (PRP) or whole blood 
from human subjects. Studies were performed by aggregometry (light absorbance, 
platelet counting and impedance [Multiplate]) and/or flow cytometry.
Results: Sulprostone alone did not induce platelet aggregation but enhanced aggregation 
induced by collagen, TRAP, PAF, U46619, serotonin and ADP. Sulprostone enhanced 
P-selectin expression induced and also increased platelet-monocyte and platelet-
neutrophil conjugate formation. Sulprostone inhibited adenylate cyclase (measured by 
VASP phosphorylation and enhanced Ca2+ mobilization. Sulprostone potentiated platelet 
function even in the presence of aspirin (an inhibitor of TXA2 synthesis) and AR-C69931 
(a P2Y12 antagonist). DG-041 antagonised the effects of sulprostone on platelet function 
both in vitro and ex vivo. PGE2 alone either potentiated or inhibited platelet function 
depending on the nature and concentration of the primary agonist and the concentration 
of PGE2 used. DG-041 potentiated the protective effects of PGE2.
Conclusions: EP3 receptors on platelets contribute to platelet function and EP3 receptor 
blockade by DG-041 potentiates the protective effects of PGE2. These data suggest that 
DG-041 may provide useful atherosclerotic lesion specific anti-thrombotic therapy.
10:00 a.m.
1021-204 Absence of Effect of R1658/JTT-705 on Blood Pressure 
and Tissue Expression of Renin-Angiotensin System-
related Genes in Rats
Erik S. Stroes, John J. Kastelein, Agnes Benardeau, Denise Blum, Roger G. Clerc, 
Luciana Campos, Eric J. Niesor, University of Amsterdam, Amsterdam, The Netherlands
Background: The cholesteryl ester transfer protein (CETP) inhibitor torcetrapib 
has previously been associated with blood pressure (BP) increases and increased 
cardiovascular events in humans. It remains to be established whether this is a compound 
or a class effect. In order to better characterize the mechanism of BP increase, we 
evaluated the hemodynamic effects of different CETP inhibitors in normotensive Wistar 
and spontaneously hypertensive (SH) rats. Since rats do not express CETP, this enables 
direct comparison of off-target toxicity by CETP inhibitors.
Methods: Mean arterial pressure (AP), systolic AP, diastolic AP, and heart rate were 
measured by telemetry in normotensive and SH rats during 5 days of treatment with 
torcetrapib 10, 40 or 80 mg/kg/day; R1658/JTT-705 100, 300 or 500 mg/kg/day; or vehicle. 
The mechanism of BP increase was investigated by analyzing expression genes involved 
in BP regulation i.e. renin-angiotensin system (RAS) genes. Quantitative PCR was used 
to measure RAS genes mRNA levels in tissue samples (adrenal glands, kidneys, aorta, 
lung) collected from normotensive rats on day 5.
Results: Following torcetrapib administration to normotensive rats, there was a transient 
increase in BP (+5 mmHg). In SH rats, torcetrapib dose-dependently increased mean, 
systolic and diastolic APs. The mean AP increases (+7 to +11 mmHg with torcetrapib 40 
mg/kg/day [p<0.05 versus placebo]) were maintained over the treatment period. Heart 
rate did not change. R1658/JTT-705 did not change BP or heart rate. Torcetrapib dose-
dependently increased angiotensinogen, angiotensin-1 receptor and endothelin-1 mRNA 
in adrenal glands as well as endothelin-1 mRNA in aortas. No changes in RAS-related 
gene expression were observed in tissues from rats administered R1658/JTT-705.
Conclusions: In rats, torcetrapib increased BP with a concomitant increase in gene 
expression of RAS and endothelin-1, whereas R1658/JTT-705 had no impact on BP or 
RAS gene expression. These findings illustrate the off-target toxicity of torcetrapib which 
does not apply to R1658/JTT-705. Further studies are needed with other CETP inhibitors 
to evaluate their impact on BP and gene expression.
10:00 a.m.
1021-205 Telmisartan Prevents in vitro the Adverse Effects of 
Protease Inhibitors on Adipocyte Functions
Franck Boccara, Martine Caron, Martine Auclair, Ariel Cohen, Chloé Legrand, 
Jacqueline Capeau, INSERM U680, UPMC, Paris, France, St Antoine University 
Hospital, paris, France
Background: HIV antiretroviral therapy and particularly protease inhibitors (PIs) can 
lead to insulin resistance through direct toxicity on the adipose tissue and increased 
cardiovascular risk. The renin-angiotensin system (RAS) is present and functional in 
adipocytes and is a major contributor to insulin resistance and oxidative stress. Whether 
the adipocyte RAS is involved in the PI-induce adipocyte dysfunction and the potential 
beneficial effects of an AT1R blocker are unknown.
Methods: 3T3-F442A murine adipocytes and primary human adipocytes were incubated 
with two frequently prescribed PIs in HIV-infected patients: lopinavir [LPVr] (10 µM) and 
atazanavir [ATVr] (5 µM) associated with ritonavir (2 µM), in the presence or absence 
of Telmisartan (10 µM). AT1R, AT2R protein expression and AT1R cellular localization, 
adipocyte differentiation, insulin resistance, oxidative stress and IL-6 and PAI-1 production 
were evaluated.
Results: PI combinations deregulated the protein expression of AT1R and AT2R (up 
and down-regulation, respectively), accumulated AT1R at the plasma membrane, 
inhibited insulin signaling and increased oxidative stress (> 2-fold) in murine and human 
adipocytes. LPVr and ATVr increased by 3-fold IL-6 and 2-fold PAI-1 production in the 
milieu of the murine adipocytes cultures. All these abnormalities were prevented by co-
incubation with Telmisartan.
Conclusions: This study demonstrates for the first time that PIs-induced deregulation of 
AT1R and AT2R, increased insulin resistance, oxidative stress and inflammation were 
reversed by an AT1R blocker in cultured adipocytes. Telmisartan may have promising 
potential benefits in preventing PI-induced metabolic complications in HIV-infected 
patients.
10:00 a.m.
1021-206 The KATP Channel as a Target to Improve the 
Senescent Heart’s Response to Stress
Sandeep Sagar, Danielle C. Hoehn, Ranjini R. Roy, Viqar Maria, Syed Ahmad, Anu 
Gupta, Arshad Jahangir, Mayo Clinic Graduate School Of Medicine, Rochester, MN
Background: Stress-induced myocardial calcium overload in senescence may result from 
altered cardiac KATP channel function.
Methods: The effect of isoproterenol stress (1 µM) on cellular calcium (Flou4 fluorescence) 
was determined in cardiomyocytes (DAM treated; paced at 3 Hz) isolated from adult (6 
month) and aged (24 month) rats in the presence and absence of the KATP channel 
antagonist, glyburide (5 µM), and agonist, diazoxide (100 µM).
Results: Unlike adult that tolerated isoproterenol challenge well (A-B), with temporary 
increase in the amplitude of calcium fluorescence and preserved systolic/diastolic 
ratio without contractures (J), the aged cardiac myocytes exhibited diastolic calcium 
accumulation (D), spontaneous calcium waves (I) and developed contracture (J). KATP 
channel blockade (E-J) reproduced the aging phenotype in adult with decompensated 
calcium handling during stress, diastolic calcium buildup and cell death (F-J). KATP 
channel activation in aged restored adult response with improved calcium handling 
following catecholamine stress (G).
Conclusions: The KATP channel may serve as a pharmacological target to improve 
senescent heart’s response to stress and calcium handling and prevent calcium-overload-
mediated cardiac dysfunction. 
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1021-207 A Novel Vasopressin Antagonist-like Peptide With 
Potent Aquaretic Natriuretic, Cardiac Unloading 
Properties and Preservation of Blood Pressure
Horng H. Chen, John A. Schirger, Alessandro Cataliotti, Fernando L. Martin, John C. 
Burnett, Jr., Mayo Clinic, Rochester, MN
BACKGROUND: Vasopressin (AVP) is a neurohormone activated in heart failure with 
potent water retaining properties. Antagonism of AVP is currently investigated for the 
management of heart failure. C-type natriuretic peptide (CNP) is a 22-amino-acid peptide 
produced mainly in the endothelium and is a ligand for a guanylyl cyclase-coupled 
receptor, the NPR-B receptor and also the NPR-C, the latter which may suppress 
adenylyl cyclase thus antagonizing the actions of AVP as well as inhibiting AVP release. 
CNP has hypotensive and cardiac unloading effects with minimal renal actions. Based on 
our previous knowledge, we altered the amino acid (aa) sequence in the ring structure 
of CNP and fused a 5 aa sequence from ANP to the N-terminus and a 6 aa sequence 
from BNP to the C-terminus of CNP. We hypothesized that this novel peptide ABC-NP 
would maintain CNP’s inherent cardiac unloading characteristics plus gaining aquaretic 
properties without hypotensive effects.
METHODS: We determined the cardiorenal and humoral actions of intravenous bolus 
administration of ABC-NP at 25 microgram/Kg in 5 normal anaesthetized dogs. * p<0.05
RESULTS: IV bolus administration of ABC-NP resulted in a sustained aquaresis (from 
0.4±0.2 to 2.6±0.5 ml/min for up to 210 minutes*) with an increase in free water clearance 
(from -0.3±0.4 to +0.9±0.1 ml/min*) and decrease in urine osmolarity (from 709±120 
to 201±6 mOsm/L*). In addition, urinary sodium excretion increased (37±25 to 221±54 
microEq/min*) with reduction of cardiac filling pressures but no change in blood pressure. 
These actions were associated with increases in plasma cGMP*, urinary cGMP*, urinary 
AVP* excretion and suppression of plasma renin activity.
CONCLUSION: We report for the first time that ABC-NP has potent AVP antagonist-like 
actions in addition to natriuretic and cardiac unloading properties without blood pressure 
lowering effects. The combination of both the properties of AVP antagonism and of the 
natriuretic peptides in the absence of hypotension may have potential therapeutic benefit 
in states of cardiorenal dysfunction with volume overload to enhance salt and water 
excretion and unload the heart without the detrimental side effect of hypotension.
10:00 a.m.
1021-208 ATP-binding Cassette Transporter G1 Promoter -257T>G 
Polymorphism Provides a Characterization of High-
density Lipoprotein
Keisuke Okamura, Yoshinari Uehara, Bo Zhang, Shin-ichiro Miura, Hidenori Urata, 
Keijiro Saku, Department of Cardiology, Fukuoka University, Fukuoka, Japan
Background:ATP-binding cassette transporter G1 (ABCG1) is membrane cholesterol 
transporter and has been implicated to mediate cholesterol efflux from cells in the 
presence of high-density lipoprotein (HDL). We have reported that an activity of ABCG1 
gene transcription was significantly low in -257T>G missense mutation in vitro reporter 
assay. HDL-mediated cholesterol efflux was significantly increased by an overexpression 
of ABCG1 gene in HEK293 cell.
Methods:Therefore, we investigated 107 patients without taking anti-atherosclerotic agents 
and analyzed -257T>G polymorphism assessed by MS-PCR methods. We classified into T/
T genotype and G allele in -257T>G on ABCG1 gene and compared the polymorphism with 
lipid profile characterized by analytical capillary isotachophoresis, total platelet-activating 
factor-acetylhydrolase (T-PAF-AH), HDL-PAF-AH, low-density lipoprotein (LDL)-PAF-AH, 
Lyso-phosphatidylcholine (Lyso-PC) and paraoxonase 1 (PON1).
Results:In G allele group, fast migrating-HDL (fHDL) and fHDL ratio to slow migrating-
HDL assessed by cITP were significantly lower than those in T/T genotype (p<0.001 
and p<0.05, respectively). However, there was no significant difference in serum total 
cholesterol and HDL cholesterol level. The ratio of HDL-PAF-AH to LDL-PAF-AH and ratio 
of Lyso-PC to PAF-AH were significantly low in G allele group (p<0.01).
Conclusions:The characterization and activation of HDL particles might be modified by 
ABCG1 transporter. ABCG1 transporter activity may contribute to lipid metabolism and 
vascular inflammation.
10:00 a.m.
1021-209 Value of Biomarkers to Identify Women at Risk for 
Coronary Events with Postmenopausal Hormones
Judith Hsia, Jacques Rossouw, Mary Pettinger, Philip Greenland, Charles Kooperberg, 
Jennifer Robinson, Donald M. Lloyd-Jones, Susan L. Hendrix, Paul Bray, Mary 
Cushman, George Washington University, Washington, DC, National Heart, Lung and 
Blood Institute, NIH, Bethesda, MD
Background: In the Women’s Health Initiative, postmenopausal hormones increased 
early coronary events. We assessed biomarkers’ ability to predict this early risk in a case:
control substudy.
Methods: We randomized 16,608 women with an intact uterus to estrogen/progestin or 
placebo, and 10,739 women with prior hysterectomy to estrogen or placebo. Biomarkers 
were measured at baseline and year 1 in 359 women experiencing myocardial infarction/
CHD death within 4 years and 820 matched controls. Associations with CHD were 
evaluated by multivariable logistic regression.
Results: Baseline interleukin (IL)-6, matrix metalloproteinase (MMP)-9, insulin (all p=.04), 
total, high (HDL) and low density lipoprotein (LDL) cholesterol (all p<.005), D-dimer, 
factor VIII (both p<.001), von Willebrand factor and homocysteine (p=.002) levels were 
independently associated with CHD. Table shows interactions of baseline levels with 
randomized treatment. On treatment, C-reactive protein, MMP-9, HDL, triglycerides and 
plasmin-antiplasmin complex rose (all p<.001); LDL, total cholesterol, E-selectin, insulin, 
plasminogen activator inhibitor (all p<.001), glucose (p=.002), homocysteine (p=.01) and 
fibrinogen (p=.02) fell. No significant treatment interactions with biomarker changes were 
identified.
Conclusion: Postmenopausal hormones had both favorable and unfavorable effects on 
inflammatory, thrombotic and metabolic biomarkers. No biomarker predicted early CHD 
risk with either hormone regimen.
Baseline Levels of Biomarkers and Adjusted CHD Risk by Treatment Assignment
E+P Placebo E+P E Placebo E p value for interaction 
(active vs placebo)
OR (95% CI Q4 v Q1)
MMP-9 3.12(1.46-6.64)
1.29(0.56-
2.99)
1.16(1.49-
2.74)
1.25(0.49-
3.17) 0.32
E-selectin 1.08(0.52-2.22)
0.84(0.33-
2.11)
0.44(0.18-
1.08)
1.01(0.40-
2.55) 0.09
HDL 0.29(0.14-0.61)
0.78(0.34-
1.78)
0.44(0.17-
1.10)
0.56(0.20-
1.59) 0.08
LDL 4.12(1.93-8.80)
1.03(0.42-
2.54)
2.93(1.23-
6.97)
2.28(0.88-
5.88) 0.03
D-dimer 2.14(1.04-4.39)
2.51(1.02-
6.16)
3.74(1.33-
10.48)
2.54(1.03-
6.28) 0.19
Factor VIII 2.14(1.05-4.38)
2.37(1.02-
5.48)
2.00(0.87-
4.60)
2.20(0.90-
5.35) 0.86
Homocysteine 2.39(1.16-4.92)
0.96(0.42-
2.18)
2.25(0.93-
5.42)
1.22(0.49-
3.02) 0.12
Insulin 2.75(1.21-6.23)
1.50(0.58-
3.87)
2.07(0.72-
5.99)
0.93(0.34-
2.58) 0.21
10:00 a.m.
1021-210 Do Lipoprotein Subpopulations Predict Coronary 
Events with Postmenopausal Hormone Therapy in the 
Women’s Health Initiative Randomized Trials
Judith Hsia, James Otvos, Jacques Rossouw, Lieling Wu, Sylvia Wassertheil-Smoller, 
Susan Hendrix, Jennifer G. Robinson, Bernadine Lund, Lewis H. Kuller, George 
Washington University, Washington, DC
Background: The Women’s Health Initiative (WHI) randomized trials unexpectedly 
demonstrated increased myocardial infarction/coronary death (CHD) after initiating 
estrogen alone (E) or with progestin (E+P). We sought predictors of CHD risk with 
hormones in a case:control study.
Methods: We measured lipoproteins at baseline and year 1 by NMR spectroscopy in 
354 WHI participants with early CHD, and matched controls. Odds ratios (OR) and 95% 
confidence intervals (CI) were calculated from conditional logistic regression of 4th vs 
1st quartile of each log-transformed biomarker after adjustment for multiple variables 
including treatment group.
Results: Several baseline lipoproteins independently predicted CHD (Table). Year 1 
predictors of CHD with E+P included high density lipoprotein-cholesterol (HDL) mass 
(p=.039) and very low density lipoprotein-cholesterol (VLDL) particle concentration 
(p=.028). Changes in lipoprotein levels did not independently predict CHD in either trial. 
Interactions for CHD were identified between hormones and baseline HDL particles 
(p for interaction=0.05) and low density lipoprotein-cholesterol (LDL) mass (p for 
interaction=0.02). No significant hormone interaction was identifed for on-treatment or 
change in lipoprotein level.
Conclusions: Of 36 lipoprotein variables tested, potentially meaningful interactions for 
CHD were identified between active hormone therapy and two baseline lipoprotein 
variables: HDL particle concentration and LDL mass. 
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Baseline lipoproteins and adjusted CHD risk
E+P (n=202) 
OR (95% CI) p value
E (n=152) 
OR (95% CI) p value
HDL mass, mg/dL 0.48 (0.19-1.21) 0.044 0.63 (0.23-1.73) 0.169
Total HDL particles nmol/L 0.81 (0.3601.81) 0.605 0.08 (0.02-0.20) 0.006
Large HDL particles, nmol/L 0.42 (0.18-1.00) 0.048 0.74 (0.30-1.81) 0.550
LDL mass, mg/dL 1.16 (0.46-2.93) 0.236 4.09 (1.33-12.57) 0.017
Total LDL particles, nmol/L 1.95 (0.82-4.62) 0.030 1.85 (0.68-5.03) 0.182
Large LDL particles, nmol/L 0.71 (0.31-1.62) 0.938 1.42 (0.59-3.43) 0.555
Small LDL particles, nmol/L 1.65 (0.72-3.77) 0.248 1.22 (0.49-3.00) 0.461
VLDL particles, nmol/L 2.76 (1.05-7.27) 0.044 0.78 (0.29-2.12) 0.826
Triglyceride mass, mg/dl 1.56 (0.66-3.69) 0.072 0.78 (0.30-2.04) 0.790
10:00 a.m.
1021-211 A Novel Inhibitory Effect of Antrodia Camphorata 
on Smooth Muscle Cell Proliferation, Migration and 
Neointima Formation After Arterial Injury
Yi-Heng Li, Hsing-Chun Chung, Shu-Lin Liu, Ting-Hsing Chao, Jian-Chyi Chen, 
National Cheng Kung University Medical Center, Tainan, Taiwan,ROC, Southern Taiwan 
University of Technology, Tainan, Taiwan,ROC
Background: Antrodia camphorata (AC) is a traditional Chinese medicine. It has been 
shown to inhibit cancer cells migration. We examined its effect on rat aortic smooth 
muscle cell (RASMC) behavior and neointima formation after arterial injury.
Methods: In MTT cell proliferation assay, RASMCs were pretreated with AC or saline 
and stimulated with 10 ng/mL platelet-derived growth factor (PDGF). The proliferation 
was expressed as absorbance ratio of AC- to saline-treated cells. In Transwell migration 
assay, RASMCs were treated with AC or saline. PDGF (10 ng/mL) was added to the lower 
compartment. Migrated cells on the lower side were fixed and counted. The migration 
ability was expressed by the cell number ratio of AC- to saline-treated cells. In wound 
scratch assay, RASMCs were treated with AC or saline. They were wounded with pipette 
tips and stimulated with PDGF. The migration ability was expressed by the migration 
distance ratio of AC- to saline-treated cells. The left common carotid arteries of C57BL/6 
mice were ligated near the carotid bifurcation. The mice were fed with water or AC for 4 
weeks. Neointima formation was measured and expressed as intima/media (I/M) ratio.
Results: AC treatment reduced the PDGF-induced RASMCs proliferation (saline vs 50 
vs 100 vs 500 µg/mL AC, 100% vs 43±8% vs 31±7% vs 15±2%, p<0.05). In Transwell 
migration chamber assay, AC treatment inhibited PDGF-induced RASMC migration in 
a dose dependent fashion (saline vs 50 vs 100 vs 500 µg/mL AC, 100% vs 66±17% vs 
52±10% vs 35±10%, p<0.05). The inhibitory effect of AC on RASMC migration was also 
proved in wound scratch assay (saline vs 50 vs 100 vs 500 µg/mL AC, 100% vs 98±5% 
vs 85±3% vs 69±12%, p<0.05). The AC-treated mice showed less neointima formation 
at 4 weeks after carotid ligation (I/M ratio, water, n=14 vs 250, n=15 vs 1250 mg/kg AC, 
n=15; 1.51±0.26 vs 0.48±0.15 vs 0.41±0.12, p<0.05). AC treatment also reduced the 
PDGF-induced RASMC matrix metalloproteinase-2 expression.
Conclusions: AC is an effective inhibitor of RASMC proliferation and migration. AC 
treatment significantly reduced neointima formation in a mouse carotid ligation model.
10:00 a.m.
1021-212 A Phase I Clinical Trial on a Novel Chimeric Natriuretic 
Peptide, CD-NP
Candace Y.W. Lee, Horng H. Chen, Ondrej Lisy, Sharon M. Sandberg, Denise M. 
Heublein, John C. Burnett, Jr., Mayo Clinic and Mayo Clinic College of Medicine, 
Rochester, MN
Background: CD-NP is a Mayo-designed chimeric natriuretic peptide (NP) which was 
synthesized by fusion of the 22 amino acids (AA) of human C-type NP (CNP) with the 15-
AA C-terminus of Dendroaspis NP (DNP). This novel peptide was designed to transform 
CNP, a venodilating peptide with minimal hypotensive effects but limited renal actions, 
into a CNP-like peptide with enhanced natriuretic and diuretic actions without lowering 
systemic blood pressure. Preclinical studies have demonstrated the augmented renal 
effects of CD-NP and the absence of significant hypotension. The aim of this study is to 
evaluate CD-NP for the first time in humans for its safety and pharmacologic effects.
Methods: This phase I clinical trial in healthy subjects consists of an open-label sequential 
dose-escalation study (stage 1) and a randomized, double-blind, placebo (PLB)-controlled 
study (stage 2). Three cohorts of 4 subjects were enrolled in stage 1 and 10 subjects (6:4 
for CD-NP vs PLB) in stage 2. In stage 1, CD-NP 10, 17.5, or 25 ng/kg/min was infused i.v. 
for 4 hours. In stage 2, CD-NP at the maximum tolerated dose (MTD) or PLB was infused 
for 4 hours. Mean±SE, CD-NP vs PLB P<0.001¶.
Results: CD-NP was well tolerated. There were no serious adverse events. In stage 1, 
significant increases in plasma cGMP were observed. Two subjects who received CD-NP 
25 ng/kg/min experienced symptomatic orthostatic hypotension. The MTD was selected 
to be 17.5 ng/kg/min and was confirmed. In stage 2, CD-NP vs PLB increased plasma 
cGMP (1.4±.1 to 7.2±1¶ vs 1.7±.4 to 1.7±.3 pmol/mL), urinary cGMP excretion (449±68 to 
858±116¶ vs 420±45 to 271±41 pmol/min) and urinary Na+ excretion (0.05±.006 to 0.1± 
.01¶ vs 0.05±.006 to 0.05±.01 mmol/min) and preserved GFR (82±7 to 84±8 vs 76±4 to 
77±3 mL/min/1.73m2) without significant effects on mean arterial pressure (85±2 to 82±3 
vs 87±1 to 84±3 mmHg). Preliminary pharmacokinetic parameters were also defined.
Conclusion: This first-in-human clinical trial on CD-NP demonstrates its safety in healthy 
subjects and its favorable cGMP-activating, natriuretic and diuretic actions. Future clinical 
trials are needed to evaluate its therapeutic potential in heart failure.
10:00 a.m.
1021-213 Rosiglitazone and Edema without Heart Failure
Amanda R. Stream, Sumiko Armstead, Shuaib M. Abdullah, Jonathan McGavok, Lidia 
S. Szczepaniak, Colby Ayers, Amit Khera, James A. De Lemos, Peter Snell, Darren K. 
McGuire, Raphael See, University of Texas South Western, Dallas, TX
Background: Thiazolidinedione (TZD) medications for type 2 diabetes mellitus (T2DM) 
increase risk of peripheral edema (5-15%), with a smaller but important increment in 
risk of heart failure (HF; ~0.5%). The etiology of these adverse effects remains poorly 
understood.
Methods: In a sub-group analysis of data from a trial comparing 6-months of treatment 
with Rosiglitazone (Rsg) v. placebo, we evaluated patients in the Rsg arm who developed 
new/worse peripheral edema. Patients had T2DM and diagnosed cardiovascular disease 
(CVD) or ≥1 additional CVD risk factor without HF or prior TZD use. Using non-parametric 
paired-sample analyses, we analyzed changes from baseline to 6 months in selected 
measures of plasma volume status, peak oxygen consumption (VO2peak) during maximal 
exercise, and cardiac MRI measures.
RESULTS: Out of 71 patients evaluated for edema, 36 (51%) had new/worse edema 
v. 32% on placebo. Selected results for those with complete exercise (n=29) and MRI 
(n=24) data are in the Table. A small but significant decline in VO2peak occurred with no 
significant worsening in MRI parameters of cardiac structure/function, with stroke volume 
increasing. However, measures reflecting plasma volume expansion all significantly 
worsened.
Conclusions: These observations support the hypothesis that TZD edema is attributable 
at least in part to plasma volume expansion, with no evident pernicious effects on cardiac 
structure/function, and a small decline in cardiovascular performance.
Table 1
Characteristic Baseline 6-months p-value
Weight (kg) 97.07 [85.5, 113.4] 104.33 [84.37, 114.53] 0.000
Hematocrit (%) 40.3 [37.5, 44.3] 37.6 [32.9, 40.3] 0.000
BNP (pg/mL) 9.62 [3.64, 23.39] 25.6 [3.23, 83.79] 0.015
LV End Diastolic volume (mL) 115.63 [97.74, 142.67] 126.09 [115.29, 151.22] 0.000
VO2peak/fat free mass 24.49 [20.48, 30.14] 24.13 [21.34, 27.85] 0.003
Ejection Fraction (%) 65.89 [59.22, 69.95] 66.42 [56.99, 70.44] 0.424
Stroke Volume (mL) 73.31 [62.22, 88.07] 83.26 [73.88, 89.13] 0.008
Peak Flow Reserve (mL/sec) 59.45 [39.54, 93.57] 77.54 [46.59, 127.34] 0.118
LV mass (gm/m^2) 76.86 [65.82, 89.26] 77.38 [64.18, 86.92] 0.419
10:00 a.m.
1021-214 Flushing Profile of Extended Release Niacin/
Laropiprant Versus Gradually Titrated NiaspanTM in 
Patients With Dyslipidemia
Michael J. Koren, Darbie Maccubbin, Michael Davidson, Geraldine Macdonell, Madhuja 
Mallick, Christine McCrary Sisk, Christie Ballantyne, John F. Paolini, Jacksonville Center 
for Clinical Research, Jacksonville, FL, Merck Research Laboratories, Rahway, NJ
Background: Laropiprant (LRPT), a selective prostaglandin D2 receptor (DP1) antagonist, 
reduces flushing symptoms that frequently limit the clinical utility of extended release 
niacin (ERN). We compared flushing symptoms using ERN/LRPT dosed according to a 
simplified 1 g→2 g regimen vs. gradually titrated NiaspanTM (NSP) over 16 weeks (wks) 
in patients (pts) with dyslipidemia.
Methods: 1455 dyslipidemic pts were randomized 1:1 to ERN/LRPT (1 g for 4 wks 
advanced to 2 g for 12 wks) or NSP (0.5g for 4 wks titrated in 0.5 g increments every 4 
wks to 2 g for the last 4 wks). NSAIDS and aspirin were allowed for mitigation of flushing 
symptoms. Flushing severity was assessed using the validated Global Flushing Severity 
Score (GFSS; none/mild [0-3], moderate [4-6], severe [7-9], extreme [10]) captured in 
pt-reported electronic diaries.
Results: ERN/LRPT pts experienced less flushing than NSP pts as measured by days/wk 
with moderate or greater flushing across the treatment period (p<0.001), despite having 
received higher doses of niacin advanced more quickly. Overall, the flushing signal 
(shown as days/wk or % of pts with moderate or greater flushing) was lower with ERN/
LRPT (Figure). Fewer pts discontinued due to flushing in the ERN/LRPT vs. the NSP arm 
(7.4% vs. 12.4%; p=0.002). ERN/LRPT was generally well tolerated.
Conclusions: Improvement in flushing observed with ERN/LRPT vs. gradually titrated 
NSP supports a rapidly advanced 1 g→2 g dosing regimen, allowing pts to quickly reach 
and tolerate a 2 g dose of ERN. 
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1021-215 Efficacy and Safety of Ezetimibe/Simvastatin 
Coadministered With Extended Release Niacin in 
Patients With Type IIa or IIb Hyperlipidemia
Sergio Fazio, B. Greg Brown, John R. Guyton, Adam Polis, Joanne E. Tomassini, 
Andrew M. Tershakovec, Merck/Schering-Plough Pharmaceuticals, North Wales, PA
Background: Guidelines recommend consideration of combination drug therapy to achieve 
optimal LDL-C lowering and broader lipid-altering effects in high risk CHD patients. The 
safety and efficacy of ezetimibe/simvastatin (E/S) coadministered with extended release 
niacin was assessed in Type IIa or IIb hyperlipidemia (HL) patients.
Methods: Part 1 of a multicenter, randomized, double-blind, 64 wk study in which 1220 
patients were randomized to 1X/day E/S (10/20 mg) + niacin (titrated to 2g), niacin 
(titrated to 2g) or E/S (10/20 mg) for 24 wk. Change from baseline in LDL-C (primary) 
and other lipoproteins was assessed in completers (n=769) and modified ITT (n=1112) 
populations. Safety was assessed in all patients
Results: At 24 wks E/S + niacin induced significantly greater reductions in LDL-C and other 
lipid/lipoproteins than niacin and E/S alone (p<0.001) (Table). Increases in HDL-C were 
significantly greater for E/S + niacin than E/S (p<0.001). A significantly greater % of patients 
discontinued the study due primarily to flushing on E/S + niacin (9.9%) and niacin (12.1%) 
than E/S (0.4%; p<0.001). Incidences of other clinical and laboratory AEs were similar.
Conclusions: Triple combination, E/S + niacin therapy demonstrated superior lipid-altering 
efficacy compared to niacin or E/S in type IIa or IIb HL patients and was generally well 
tolerated aside from niacin-associated flushing. E/S + niacin provides an optional therapy 
with improvements in lipid effects beyond LDL-C in HL patients.
Efficacy 
Variable
% Change from Baseline (24 wk) 
Completers†‡ Treatment Difference (%)
Niacin 
(n=166)
E/S 
(n=212)
E/S + Niacin  
(n=391)
E/S + 
Niacin 
vs Niacin
E/S + Niacin 
vs E/S
LDL-C
baseline mean 157.1 155.4 156.9
-38.4*** -4.9***
% change§ -20.1 -53.5 -58.5
Non-HDL-C
baseline mean 191.0 190.8 190.9
-33.5*** -7.7***
% change§ -22.0 -47.9 -55.6
HDL-C
baseline mean 50.5 49.9 50.5
2.1 22.1***
% change§ 28.1 8.1 30.2
TG (median)
baseline median 148.0 158.0 159.0
-11.7*** -18.7***
% change -30.1 -23.7 -42.5
LDL-C:HDL-C 
baseline mean 3.3 3.3 3.3
-30.3*** -9.9***
% change§ -35.8 -56.2 -66.1
Apo B
baseline mean 149.9 151.2 151.5
-28.6*** -8.1***
% change§ -19.5 -40.1 -48.1
Apo A-I
baseline mean 163.9 166.1 165.8
0.3 7.4***
% change§ 10.7 3.6 11.0
hsCRP 
baseline mean¶ 2.0 2.1 2.3
-21.7** 1.6
% change§¶# -6.7 -30.0 -28.4
E/S = ezetimibe/simvastatin (10/20 mg); niacin = niacin (ER) (starting dose of 500 
mg/day titrated to 2 g) 
Treatment difference = E/S + niacin minus niacin and E/S + niacin minus E/S 
†Completers include all patients with a baseline value who received at least 24 wk of 
active study therapy and who had an on-treatment value at the maximum titrated dose 
[i.e. 2 g of niacin (ER) for both E/S + Niacin and Niacin treatment groups]; n’s represent 
the number of patients in the analysis of the primary endpoint (percent change from 
baseline to wk 24 in LDL-C). 
‡Similar results were attained in an analysis of the modified ITT population (all 
randomized patients who had a baseline value and at least one post baseline value 
with A Last Observation Carried Forward [LOCF] approach to impute any missing data 
for the Week 24 assessment), performed as a secondary and supportive approach to 
the Completers analysis. 
§LS means; ¶geometric mean based upon back transformation via exponentiation of 
log transformation; #Treatment differences are differences in geometric mean percent 
changes from baseline calculated using the delta method. 
**p=0.005; ***p<0.001
10:00 a.m.
1021-216 Blood Pressure-Lowering Effect of ER Niacin and ER 
Niacin/Laropiprant in Dyslipidemic Patients
Harold Bays, Darbie Maccubbin, Alan Meehan, Olga Kuznetsova, Yale Mitchel, John F. 
Paolini, Louisville Metabolic and Athersclerosis Research Center, Louisville, KY, Merck 
Research Laboratories, Rahway, NJ
Background: Niacin is the most efficacious agent approved for raising high-density 
lipoprotein cholesterol levels and has been shown to reduce coronary heart disease 
(CHD). Laropiprant (LRPT) is a PGD2 receptor antagonist that reduces extended-release 
niacin (ERN)-induced flushing without affecting ERN’s beneficial lipid effects. In a post-
hoc evaluation, the effect of ERN and ERN/LRPT on systolic (SBP) and diastolic (DBP) 
blood pressure were assessed in a 24-week placebo (Pbo)-controlled Phase III study in 
dyslipidemic patients.
Methods: Dyslipidemic patients (N=1613) were randomized 3:2:1 to ERN/LRPT 1 g/20 
mg, ERN 1 g, or PBO, taken in the evening with food. After 4 weeks, doses were doubled 
(ERN/LRPT = 2 g/40 mg as 2 1g /20 mg tablets) for 20 additional weeks. SBP and DBP 
were measured in the morning, following an overnight fast.
Results: In addition to the beneficial lipid-altering effects produced by ERN and ERN/
LRPT compared to placebo, ERN, alone or in combination with LRPT, significantly 
reduced SBP and DBP (table). Overall, ERN and ERN/LRPT were well tolerated. The 
incidence of hypotension and orthostatic hypotension was similar across the treatment 
groups (table).
Conclusion: ERN, alone or in combination with LRPT, significantly reduced SBP and 
DBP in dyslipidemic patients. Since LRPT decreases ERN-induced flushing, and both 
ERN and ERN/LRPT produced similar decreases in BP, the data suggest that the ERN-
induced reductions in BP were not related to niacin’s PGD2-mediated flushing effect. 
Placebo 
(N=270)
ERN 
(N=541)
ERN/LRPT 
(N=798)
Study Week 4 24 4 24 4 24
Niacin Dosage (g) 1 2 1 2
Mean Baseline SBP/DBP (mmHg) 125/78 125/77 126/78 126/78 126/78 126/78
Least Squares Mean (95% CI) 
Change from Baseline in SBP 
(mmHg)†
0.4 
(-1.2, 
1.9)
-0.3 
(-2.0, 
1.4)
-1.7* 
(-3.0, 
-0.4)
-2.5* 
(-3.8, 
-1.2)
-1.5* 
(-2.2, 
-0.8)
-3.4*** 
(-4.6, 
-2.3)
Least Squares Mean (95% CI) 
Change from Baseline in DBP 
(mmHg)†
-0.1 
(-1.1, 
0.9)
0.4 
(-0.7, 
1.5))
-1.9* 
(-2.7, 
-1.0)
-2.3*** 
(-3.1, 
-1.4)
-1.6* 
(-2.7, 
-0.5)
-2.1*** 
(-2.8, 
-1.3)
No. (%) of patients with 
hypotension 2 (0.7) 0 2 (0.3)
No. (%) of patients with orthostatic 
hypotension 0 1 (0.2) 1 (0.1)
*p<0.05 vs. placebo, ***p<0.001 vs. placebo 
†Based on analysis of variance model in all-patients-as-treated study population (last 
observation carried forward) 
SBP=systolic blood pressure; DBP=diastolic blood pressure
10:00 a.m.
1021-217 Effects of Co-Administered Extended Release 
Niacin/Laropiprant and Simvastatin on Lipoprotein 
Subclasses in Patients With Dyslipidemia
Christie Ballantyne, Gilbert Gleim, Yale Mitchel, Sally Thompson-Bell, Nancy Liu, Amy O. 
Johnson-Levonas, John F. Paolini, Methodist DeBakey Heart Center and Baylor College 
of Medicine, Houston, TX, Merck Research Laboratories, Rahway, NJ
Background: Extended-release niacin and the DP-1 selective antagonist laropiprant 
(ERN/LRPT) reduce ERN-induced flushing while preserving ERN’s lipid-modifying effects. 
This secondary analysis examined the individual and combined effects of ERN/LRPT and 
simvastatin (SIM) on lipoprotein subclasses.
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Methods: This double-blind study randomized 1398 dyslipidemic pts equally to ERN/
LRPT 1g/20mg, SIM (10, 20, or 40 mg), or ERN/LRPT 1g/20 mg+SIM (10, 20, or 40 
mg) once/day for 4 wks. At Wk 5, doses were doubled except SIM 40 mg (unchanged) 
and ERN/LRPT 1g/20mg+SIM 40 mg (switched to ERN/LRPT 2g/40mg+SIM 40 mg). 
Cholesterol in subclasses was quantified by VAP-II. Primary analysis was % change for 
ERN/LRPT+SIM (pooled) vs. ERN/LRPT and SIM alone (pooled) at Wk 12.
Results: ERN/LRPT+SIM was more effective than ERN/LRPT and SIM at reducing LDL-
C (-48, -17 and -37%), triglycerides (TG) (-33, -22 and -15%), and non-HDL-C (-46, -18 
and -33%), and raising HDL-C (28, 23 and 6%). ERN/LRPT+SIM produced substantial 
reductions in IDL-C which appeared additive compared to each monotherapy. ERN/
LRPT+SIM and ERN/LRPT raised both HDL-C2 and 3 with the relative % changes higher 
for HDL2 than HDL3. ERN/LRPT+SIM and SIM lowered both LDL-C1 and LDL-C3 while 
the effects were more variable for ERN/LRPT; all 3 treatments raised LDL-C4.
Conclusion: Coadministered ERN/LRPT+SIMVA led to marked reductions in atherogenic 
lipoproteins with the greatest effect on IDL-C (-82%) and increases in protective HDL 
subclasses (+38% for HDL-C2). 
Table. Baseline and median % change (95% CI) from baseline in cholesterol content 
associated with lipoprotein subclasses at Week 12.
Median 
values
ERN/LRPT 
(N = 155-156)
Pooled SIMVA 
(N = 549-551)
Pooled ERN/LRPT + 
SIMVA 
(N = 504-507)
B 
(mg/
dL)
Change 
(% [95% CI])1
B 
(mg/
dL)
Change 
(% [95% CI])1
B 
(mg/
dL)
Change 
(% [95% CI])1
IDL-C 20.0 -38.5 (-46.4, 
-30.5) 20.0
-52.6 (-55.4, 
-49.9) 20.0
-81.8 (-85.5, 
-78.1)*†
VLDL-C1+2 10.5
-19.1 (-23.7, 
-14.4) 10.6
-18.3 (-20.4, 
-16.3) 10.6
-31.3 (-33.6, 
-29.0)*†
VLDL-C3 14.0
-22.2 (-26.4, 
-18.0) 14.0
-22.2 (-24.1, 
-20.3) 14.0
-38.5 (-40.7, 
-36.2)*†
LDL-C1 24.7 -10.7 (-16.6, 
-4.9) 26.4
-39.4 (-41.3, 
-37.4) 27.0
-52.6 (-55.3, 
-49.9)*†
LDL-C2 42.8 7.9 (0.4, 15.4) 42.9 -37.2 (-37.9, 
-34.6) 45.0
-37.2 (-41.5, 
-32.8)*
LDL-C3 54.3 -18.8 (-24.8, 
-12.8) 55.5
-31.7 (-33.8, 
-29.5) 53.7
-48.5 (-51.4, 
-45.7)*†
LDL-C4 4.9 9.5 (-14.8, 33.8) 4.9 21.6 (7.6, 35.7) 5.1
26.3 (4.1, 
48.6)**
HDL-C2 11.0 25.0 (17.6, 32.4) 12.0 0.0 (-2.0, 2.0) 12.0
37.5 (33.2, 
41.8)*†
HDL-C3 39.0 15.0 (12.2, 17.8) 39.0 3.2 (2.2, 4.2) 40.0
14.0 (12.4, 
15.6)†
B= baseline value; IDL-C = intermediate-density lipoprotein cholesterol; VLDL-C = very 
low-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; HDL-C= 
high-density lipoprotein cholesterol 
1Expressed as median % change from baseline to Wk 12 (95 % confidence interval) 
*p<0.001 vs. ERN/LRPT; **p<0.050 vs. ERN/LRPT 
†p<0.001 vs. Pooled SIMVA
10:00 a.m.
1021-218 Muscle Characteristics In Statin-induced 
Rhabdomyolysis
Tam H. Truong, Ryan Moran, Brian A. Schick, Georgirene D. Vladutiu, Reijo Laaksonen, 
Matej Oresic, Raymond J. Hohl, Helene CF Côté, Paul S. Phillips, Scripps-Mercy 
Hospital, San Diego, CA
Background: Statin-induced rhabdomyolysis (SIR) is a worrisome clinical event whose 
etiology remains unclear. Proposed mechanisms involve depletion of the three main 
products of the HMG-CoA reductase pathway: cholesterol which affects membrane integrity, 
coenzyme Q10 which interferes with mitochondrial respiration, and prenylated proteins 
which disturbs cellular signaling cascade. These hypotheses have been studied mostly in 
animal models and human myocyte cell culture experiments. We tested these hypotheses 
by analyzing muscle samples from SIR patients and comparing them to controls.
Methods: Skeletal muscle specimens were obtained sequentially from 10 SIR patients and 
8 age-matched statin-naïve patients (CONTROL) who underwent total knee replacement. 
SIR was defined as patient on statin with muscle symptoms and creatine kinase level 
greater than 10 times the upper limit of normal. The specimens were analyzed using 
standard techniques to measure sterol levels, mitochondrial content including coenzyme 
Q10, and RAS (a cell signaling molecule).
Results: See table.
Patient Population and Muscle Characteristics
SIR (n=10) CONTROL (n=8) p-value
Median age 63.5 64.0 0.24
Number of females 2 6 0.06
Mitochondrial/nuclear DNA 1942 1752 0.96
Coenzyme Q10 (µg/g tissue) 28 36 0.4
Choesterol(µmol/g) 1.4 1.3 0.89
RAS (density indexed to a reference protein) 0.47 0.64 0.008
Conclusions: There was no significant difference in the muscle cholesterol concentration 
or mitochondrial content between the SIR patients and CONTROL. However, SIR patients 
had significantly lower (p=0.008) intramuscular RAS levels than CONTROL. These 
findings suggest that the mechanism of statin myotoxicity in human may reside in the 
disruption of cellular signaling pathways.
10:00 a.m.
1021-219 Dramatic Fall in Transcript Levels of Muscle Fatty Acid 
Metabolism Signals a Reversal of Leptin Resistance in 
Clinically Severe Obesity
Joshua G. Leichman, Erik B. Wilson, Terry Scarborough, Sherman Yu, Carol Wolin-
Riklin, Heinrich Taegtmeyer, University of Texas, Houston Medical School, Houston, TX
Background: Obesity is characterized by fatty atrophy of non-adipose tissues, including 
heart and skeletal muscle. Significantly increased concentrations of leptin may signal 
another aspect of the maladaptive process effecting lipid partitioning. We sought to 
characterize leptin regulated skeletal muscle metabolic gene expression in clinically 
severe obese patients after bariatric surgery.
Methods: In a prospective longitudinal cohort study, we enrolled 25 clinically severe 
obese participants [mean BMI (+/- SEM): 50.3 kg/m2 (2.54)] who subsequently 
underwent bariatric surgery. The mean age was 42 (2.7) years, and 92% were women. 
Each patient had fasting blood chemistries before, three months, and nine months after 
bariatric surgery. At the same time points a percutaneous biopsy of the vastus lateralis 
was performed for quantitative analysis of metabolic gene expression. Outcomes were 
analyzed using repeated measures ANOVA.
Results: BMI and total body fat mass decreased significantly at three and nine months 
(mean percent change: BMI - 16% and 14%, respectively, p<0.0001 for both; fat mass 
- 23% and 24%, p<0.0001 for both). Leptin concentrations decreased 45% and 24% 
at three nine months (p<0.0001 and 0.01, respectively). Plasma free fatty acids (FFA) 
decreased 20% at nine months (p=0.02). Expression of Stearoyl CoA Desaturase (SCD) 
decreased 84% (p=0.003) at three months with no significant change at nine months. 
Three months after surgery peroxisome proliferation activated receptor alpha (PPAR-α) 
regulated genes remained unchanged, however significantly decreasing at nine months 
after surgery when leptin levels were normalized.
Conclusions: Non-pharmacological weight loss is associated with decreases in leptin 
levels and a beneficial effect on FFA partitioning and beta-oxidation mediated by SCD 
and PPAR-α regulation. This indicates a positive adaptive change and suggest a reversal 
in leptin resistance in skeletal and heart muscle.
10:00 a.m.
1021-220 A Two-Year Study to Assess the Efficacy, Safety, and 
Tolerability of Taranabant in Obese Patients: 52 Week 
Results
Ira Gantz, Ngozi Erondu, Shailaja Suryawanshi, Bret Musser, Jagriti Nayee, Amy O. 
Johnson-Levonas, Steven Heymsfield, John Amatruda, Merck Research Laboratories, 
Rahway, NJ
Objectives: Assess the long-term efficacy and safety of taranabant, a selective CB1R 
inverse agonist.
Methods: After a 2-wk single-blind placebo (Pbo) plus 25% caloric deficit diet/exercise run-
in, 2,502 obese patients (40% male; 50% metabolic syndrome [MS]‡) were randomized to 
Pbo or taranabant 2-, 4-, or 6- mg plus continued diet/exercise. BW, WC, HDL-C, LDL-C, 
TG were analyzed at Wk 52 in the all-patients treated population using ANCOVA. Based 
on its minimal increase in efficacy over 4-mg and trend toward a higher incidence of AEs, 
an external Data Safety Monitoring Committee recommended discontinuing the 6- mg 
dose. Patients on 6-mg were re-randomized to 2 mg or Pbo and the 6-mg group was not 
included in the analysis at Wk 52.
Results: Compared to Pbo, taranabant 2- and 4-mg improved BW, WC, HDL-C, TG, and 
MS status at Wk 52 (Table 1). The most commonly reported AEs were gastrointestinal 
(GI)-related, which occurred in 28.5%, 41.8%, 46.7% of Pbo, 2- and 4-mg groups, 
respectively (p<0.001 vs. Pbo). Psychiatric AEs occurred in 20.4%, 28.3%, 40.2% of the 
Pbo, 2-, and 4-mg groups, respectively (p<0.010 vs. placebo). Discontinuations due to GI- 
and psychiatric-related AEs were 0.7%, 1.7%, 2.7% and 4.6%, 8.9%, 12.5%, respectively, 
for Pbo, 2- and 4- mg groups. Most AEs were mild to moderate in intensity.
Conclusions: Treatment with taranabant for 52 wks led to clinically meaningful weight loss 
and improvements in metabolic parameters with a favorable risk/benefit profile.
Table. Key efficacy analyses at Wk 52 
Pbo 
N= 417
Taranabant 2 mg 
N= 414
Taranabant 4 mg 
N= 415
B (SD) Wk 52
§
 
(95% CI) B (SD)
Wk 52§ 
(95% CI) B (SD)
Wk 52§ 
(95% CI)
BW; kg 100.0 (16.1)
-2.6 (-3.3, 
-1.8)
99.7 
(16.2)
-6.6 (-7.4, 
-5.9)*
99.3 
(15.3)
-8.1 (-8.9, 
-7.4)*
5% 
Responders†;n/
N(%)
113/416 (27.2%) 231/409 (56.5%)* 264/411 (64.2%)*
10% 
Responders†;n/
N(%)
35/416 (8.4%) 114/409 (27.9%)* 148/411 (36.0%)*
WC; cm 110.6 (11.7)
-3.1 (-3.9, 
-2.3)
110.6 
(11.7)
-7.0 (-7.8, 
-6.1)*
110.9 
(11.1)
-7.5 (-8.3, 
-6.7)*
HDL-C; mg/dL 47.0 (12.0)
7.0 (5.0, 
9.1)
48.6 
(14.8)
13.2 
(11.2,15.2)*
48.5 
(12.7)
14.1 (12.1, 
16.1)*
LDL-C; mg/dL 118.8 (33.7)
3.6 (1.0, 
6.3)
115.8 
(34.0)
2.0 (-0.7, 
4.6)
118.5 
(34.1)
0.3 (-2.3, 
2.9)**
TG††; mg/dL 139.0 (76.3)
4.0 (-0.4, 
8.3)
132.0 
(69.8)
-3.1 (-7.2, 
0.9)*
134.0 
(75.3)
-6.2 (-9.9, 
-2.5)*
MS‡; n/N (%) 197/389 (50.6%)
184/389 
(47.3%)
178/378 
(47.1%)
136/378 
(36.0%)¤¤
201/391 
(51.4%)
120/391 
(30.7%)¤
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B= mean baseline value or proportion; SD= standard deviation; Pbo= placebo; BW= 
body weight; WC=waist circumference; HDL-C= high-density lipoprotein cholesterol; 
LDL-C= low-density lipoprotein cholesterol; TG= triglycerides; MS= metabolic syndrome 
§
 Expressed as least squares mean change from baseline for BW and WC, mean or 
median % change from baseline for lipids, or proportion for MS. 
†Defined as proportion (n/N; %) of pts who lost >5% or 10% of their baseline BW. 
††Expressed as median baseline (standard deviation of median) and median % change 
from baseline (95% CI for median) 
‡Pts were classified as having MS if they met 3 of the following criteria: HDL-C <40 mg/
dL for men or <50 mg/dL for women; TG >150 mg/dL; systolic >130 mm Hg or diastolic 
>85 mm Hg; fasting plasma glucose >100 mg/dL ; and/or WC >102 cm for men and >88 
cm for women. 
*p<0.001 and **p<0.050 vs. Pbo; ¤p<0.001 and ¤¤p<0.050 vs. Pbo based on logistic 
regression without adjusting for multiplicity
10:00 a.m.
1021-221 The Role Of Losartan In Prevention Of Exercise-
Induced Myocardial Ischemia
Giancarlo Longobardi, Graziamaria Corbi, Francesco Cacciatore, Pasquale Abete, Giuseppe 
Furgi, Dino Franco Vitale, Franco Rengo, Nicola Ferrara, Cardiology Division, Fondazione 
“Salvatore Maugeri,” IRCCS, Scientific Institute of Telese Terme, Telese Terme, Italy, 
Department of Health Sciences, School of Medicine, University of Molise, Campobasso, Italy
Background: Because no controlled clinical studies are available about the possible role 
of angiotensin II receptor blockers in preventing effort myocardial ischemia, we evaluated 
the effect of angiotensin II receptor blocker/losartan in preventing exercise-induced 
myocardial ischemia in patients with coronary artery disease.
Methods: Twenty-four sedentary patients with chronic stable ischemia were 
prospectively randomized to 28 days (double blind) of losartan 100 mg or losartan 
placebo in 2 divided doses. In each patient the treatment was crossed over to the 
alternative regimen (28 days, double blind) after a 1-week placebo period (single 
blind). At the end of each phase a new exercise stress test was performed.
Results: At baseline, systolic blood pressure was significantly decreased after losartan 100 mg 
compared with losartan placebo (p<0.05). At submaximal exercise systolic blood pressure and 
rate-pressure product were lower after losartan 100 mg administration (p<0.005) compared with 
losartan placebo, and these findings remained significant at 1-mm ST depression (p<0.001) and 
at peak exercise (p<0.02). Losartan 100 mg administration versus losartan placebo significantly 
delayed the time to 1-mm ST-depression onset (p<0.01) and decreased ST-segment depression 
at peak exercise (p<0.05) and time to recovery of ST-segment depression (p<0.01). Losartan 
100 mg administration compared with losartan placebo was able to significantly increase 
exercise duration (p<0.001) and maximal work load (p<0.001) during exercise stress testing.
Conclusions: In conclusion, in our study losartan deceased electrocardiographic 
parameters of myocardial ischemia in patients with coronary artery disease, suggesting a 
possible role of this drug in treatment of patients with effort myocardial ischemia.
10:00 a.m.
1021-222 Efficacy and Safety of a Novel Fibrate, ABT-335, in 
Combination with Atorvastatin in Patients with Mixed 
Dyslipidemia: a 12-week Phase 3 Study
Anne C. Goldberg, Harold E. Bays, Christie M. Ballantyne, Maureen T. Kelly, Susan M. 
Buttler, Carolyn M. Setze, Darryl J. Sleep, James C. Stolzenbach, Washington University 
School of Medicine, St. Louis, MO, Abbott Laboratories, Abbott Park, IL
Background: Monotherapy with lipid-altering drugs, including statins, does not always 
achieve all lipid goals in dyslipidemic patients with the triad of elevated LDL-C, TG and low 
HDL-C levels. Hence, this multicenter, double-blind, controlled study evaluated ABT-335 
in combination with two doses of atorvastatin (A) in patients with mixed dyslipidemia.
Methods: A total of 613 patients with LDL-C > 130 mg/dL, TG > 150 mg/dL and HDL-C 
< 40 mg/dL (< 50 mg/dL for females) were randomized to either ABT-335 (135 mg), A 
(20, 40 or 80 mg), or the combination of ABT-335 with A 20 or 40 mg, and treated for 12 
weeks. The primary efficacy comparisons were mean percent change in HDL-C and TG 
(ABT-335/A v. A), and LDL-C (ABT-335/A v. ABT-335).
Results: Both ABT-335/A combinations resulted in significantly greater increases in HDL-C and 
decreases in TG and LDL-C compared to the corresponding monotherapy doses and also 
improved multiple secondary endpoints including non-HDL-C, ApoB, TC and VLDL-C. Combination 
therapy was well tolerated with a safety profile consistent with ABT-335 and A monotherapies. No 
rhabdomyolysis or unexpected hepatic, renal or muscle safety signals were identified.
Conclusion: ABT-335 in combination with A 20 or 40 mg significantly improved HDL-C 
and TG (compared to A 20 or 40 mg), as well as LDL-C (compared to ABT-335), without 
additional safety findings. Combination therapy resulted in the most comprehensive 
improvement in the overall atherogenic lipid profile of patients with mixed dyslipidemia. 
Mean percent change from baseline to final value in primary efficacy comparisons: 
HDL, TG and LDL.
ABT-335 A 20 mga ABT-335/ A 20 mg P-value
HDL-C 
mg/dL
(N) 
Baseline mean 
Final mean 
% Change (SE)
(N=93) 
38.3 
45.5 
19.9% (2.04)
(N=101) 
38.7 
40.5 
6.3% (1.96)
(N=95) 
38.7 
43.8 
14.0% (2.02)
0.005b
TG 
mg/dL
(N) 
Baseline mean 
Final mean 
% Change (SE)
(N=104) 
289.8 
187.1 
-29.6% (3.35)
(N=108) 
268.4 
208.9 
-16.5% (3.31)
(N=105) 
264.5 
132.3 
-45.6% (3.36)
<0.001b
LDL-C 
mg/dL
(N) 
Baseline mean 
Final mean 
% Change (SE)
(N=97) 
166.0 
153.3 
-3.4% (1.90)
(N=103) 
157.3 
97.4 
-37.1% (1.85)
(N=97) 
159.9 
102.2 
-33.7% (1.91)
<0.001c
ABT-335 A 40 mg ABT-335/ A 40 mg P-value
HDL-C 
mg/dL
(N) 
Baseline mean 
Final mean 
% Change (SE)
(N=93) 
38.3 
45.5 
19.9% (2.04)
(N=92) 
38.4 
39.9 
5.3% (2.05)
(N=91) 
38.0 
42.3 
12.6% (2.08)
0.010b
TG 
mg/dL
(N) 
Baseline mean 
Final mean 
% Change (SE)
(N=104) 
289.8 
187.1 
-29.6% (3.35)
(N=105) 
278.9 
211.7 
-23.2% (3.35)
(N=102) 
282.6 
143.9 
-42.1% (3.40)
<0.001b
LDL-C 
mg/dL
(N) 
Baseline mean 
Final mean 
% Change (SE)
(N=97) 
166.0 
153.3 
-3.4% (1.90)
(N=95) 
160.3 
94.1 
-39.7% (1.92)
(N=96) 
158.4 
99.8 
-35.4% (1.93)
<0.001c
a
 One outlier was excluded. 
b ABT-335/A vs. corresponding A monotherapy. 
c ABT-335/A vs. ABT-335 monotherapy.
10:00 a.m.
1021-223 Efficacy and Safety of a Novel Fibrate, ABT-335, in 
Combination with Simvastatin in Patients with Mixed 
Dyslipidemia: a Phase 3 Study
Syed M. Mohiuddin, Carl J. Pepine, Maureen T. Kelly, Susan M. Buttler, Carolyn M. 
Setze, Darryl J. Sleep, James C. Stolzenbach, The Cardiac Center of Creighton 
University, Omaha, NE, Abbott Laboratories, Abbott Park, IL
Background: Single agent lipid therapy, particularly statins, cannot simultaneously 
normalize LDL-C, TG and HDL-C levels in most patients with atherogenic dyslipidemia. 
Accordingly, this multicenter, double-blind, controlled study evaluated ABT-335 in 
combination with two doses of simvastatin (S) in patients with mixed dyslipidemia.
Methods: A total of 657 patients with LDL-C > 130 mg/dL, TG > 150 mg/dL and HDL-C 
< 40 mg/dL (< 50 mg/dL for females) were randomized to either ABT-335 (135 mg), S 
(20, 40 or 80 mg), or the combination of ABT-335 with S 20 or 40 mg, and treated for 12 
weeks. The primary efficacy comparisons were mean percent change in HDL-C and TG 
(ABT-335/S v. S), and LDL-C (ABT-335/S v. ABT-335).
Results: Both ABT-335/S combinations resulted in significantly greater increases in HDL-
C and decreases in TG and LDL-C compared to prespecified corresponding monotherapy 
doses and also improved multiple secondary endpoints including non-HDL-C, ApoB, TC 
and VLDL-C. Combination therapy was well tolerated with a safety profile consistent 
with ABT-335 and S monotherapies. No rhabdomyolysis or unexpected hepatic, renal or 
muscle safety signals were identified.
Conclusion: ABT-335 in combination with S 20 or 40 mg significantly improved HDL-C 
and TG (compared to S 20 or 40 mg), as well as LDL-C (compared to ABT-335), without 
additional safety findings. Combination therapy resulted in the most comprehensive 
improvement in the overall atherogenic lipid profile of patients with mixed dyslipidemia. 
Mean percent change from baseline to final value in primary efficacy comparisons: 
HDL, TG and LDL.
ABT-335 S 20 mg ABT-335/ S 20 mg P-value
HDL-C 
mg/dL
(N) 
Baseline mean 
Final mean 
% Change (SE)
(N=107) 
38.2 
44.1 
16.2% (1.85)
(N=114) 
38.4 
40.8 
7.2% (1.80)
(N=105) 
37.2 
43.9 
17.8% (1.86)
<0.001a
TG 
mg/dL
(N) 
Baseline mean 
Final mean 
% Change (SE)
(N=113) 
300.9 
181.4 
-31.7% (2.74)
(N=116) 
281.2 
223.1 
-14.2% (2.71)
(N=113) 
295.6 
164.4 
-37.4% (2.75)
<0.001a
LDL-C 
mg/dL
(N) 
Baseline mean 
Final mean 
% Change (SE)
(N=107) 
156.5 
147.1 
-4.0% (1.96)
(N=116) 
153.2 
117.5 
-22.4% (1.90)
(N=109) 
157.9 
116.6 
-24.0% (1.94)
<0.001b
ABT-335 S 40 mg ABT-335/ S 40 mg P-value
HDL-C 
mg/dL
(N) 
Baseline mean 
Final mean 
% Change (SE)
(N=107) 
38.2 
44.1 
16.2% (1.85)
(N=102) 
38.5 
41.3 
8.5% (1.89)
(N=106) 
38.5 
45.0 
18.9% (1.86)
<0.001a
TG 
mg/dL
(N) 
Baseline mean 
Final mean 
% Change (SE)
(N=113) 
300.9 
181.4 
-31.7% (2.74)
(N=112) 
284.4 
202.3 
-22.4% (2.76)
(N=111) 
274.1 
147.0 
-42.7% (2.77)
<0.001a
LDL-C 
mg/dL
(N) 
Baseline mean 
Final mean 
% Change (SE)
(N=107) 
156.5 
147.1 
-4.0% (1.96)
(N=106) 
163.3 
108.1 
-31.7% (1.98)
(N=108) 
155.9 
113.3 
-25.3% (1.96)
<0.001b
a ABT-335/S vs. corresponding S monotherapy. 
b ABT-335/S vs. ABT-335 monotherapy.
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1021-225 Improvement of HDL and LDL functional characteristics 
without quantitative alterations after short-term 
exercise training in patients with metabolic syndrome
Antonio Casella-Filho, Ivani C. Trombetta, Caio B. Casella, Bruno C G Nascimento, 
Maria Urbana P B Rondon, Fernando Y. Cesena, Desiderio Favarato, Carlos E. Negrao, 
Protasio L. DaLuz, Antonio Carlos P. Chagas, Heart Institute (InCor) HCFMUSP, Sao 
Paulo, Brazil
Background: Long-term exercise training increases blood lipoprotein level, but the effects 
of short-term exercising are not well known.
We hypothesized that short-term aerobic exercise training (ST) improves functional 
characteristics of low density lipoprotein (LDL) and high density lipoprotein (HDL) in 
patients with MetS.
Methods: Thirty sedentary persons were studied, 20 with MetS and 10 controls. Those 
with MetS were subjected to a 3 times/week controlled training load (45 min/day) for 
3 months on a bicycle ergometer. LDL and HDL (subfractions 2a and 3b) from MetS 
patients (before and after ST) and LDL from the controls were obtained by plasma 
ultracentrifugation. In vitro LDL resistance to oxidation with CuSO4 was analyzed. LDL 
from control subjects was incubated with HDL2a, HDL3b from MetS patients (before and 
after ST) and the resistance to oxidation was verified. Serum samples from MetS group, 
before and after ST, were assayed for TBAR and Paraoxonase 1 (PON1) activity and 
compared with controls.
Results: Baseline plasma levels of HDL-cholesterol were significantly lower in the MetS 
group compared to the controls, while LDL-cholesterol concentration was similar between 
groups. ST did not change plasma HDL-, LDL-cholesterol levels, but significantly increased 
LDL resistance to oxidation in the MetS group (+ 91.4%), reaching values similar to those 
verified in the controls. ST reduced TBAR levels (8.34±2.35 before vs 6.21±1.30 nmol/mL 
after ST, p<0.05). LDL resistance to oxidation increased when mixed with HDL2a or 3b 
from patients with MetS after ST, compared to co-incubation with HDL2a or 3b from these 
patients before ST (+22.6% for HDL2a, +17.6% for HDL3b).ST increased PON1 activity in 
MetS group (58.31 ± 36.20 before vs 70.78 ± 38.44 ng/ml/min after ST, p<0.05). However, 
PON1 activity in the MetS group after ST was lower than in controls.
Conclusions: ST reduces in vitro LDL oxidability, TBAR levels and enhances anti-oxidative 
properties of HDL2a, HDL3b with PON1 activity increasing, without modifying plasma 
HDL-, LDL-cholesterol levels, in patients with MetS.
These findings suggest that lipoprotein functional improvement conferred by exercise in 
MetS precedes quantitative changes.
10:00 a.m.
1021-226 Dual Therapy with Statins and Antioxidants are Superior 
to Statins Alone in Decreasing the Cardiovascular 
Disease Risk of Individuals with Diabetes Mellitus and 
the Haptoglobin 2-2 Genotype
Shany Blum, Uzi Milman, Chen Shapira, Rachel Miller-Lotan, Yefim Anbinder, Junia 
Alshiek, Lawrence Bennett, Maria Kostenko, Michele Landau, Shlomo Keidar, Yishai 
Levy, Alexander Khemlin, Arman Radan, Andrew P. Levy, Technion-Israel Institute of 
Technology, Haifa, Israel
Background. Oxidative stress is an important mediator of DM atherosclerosis. 
Paradoxically, antioxidants have not been found to provide CVD benefit to DM individuals. 
However, the inability to demonstrate benefit may have been due to inadequate patient 
selection as antioxidants may only benefit those with particularly high levels of oxidative 
stress. A polymorphism in the Haptoglobin (Hp) gene, an antioxidant protein, appears to 
permit identification of individuals with high oxidative stress and who may benefit from 
antioxidant therapy. There exists two classes of alleles at the Hp locus, 1 and 2, and the 
antioxidant capacity of the Hp 2 protein is inferior to the Hp 1 protein. Robust clinical data 
has shown that individuals homozygous for the Hp 2 allele (Hp 2-2 genotype), 40% of 
DM individuals, have an up to 500% increased risk of CVD. We have previously reported 
that vitamin E therapy results in a 50% reduction in CVD events in Hp 2-2 DM individuals. 
However, only about half of the Hp 2-2 DM participants in these studies received statin 
therapy. Because statin therapy is currently recommended for all DM individuals we 
sought to determine if antioxidant therapy could still be demonstrated to provide benefit to 
Hp 2-2 DM individuals also taking statins.
Methods. We previously presented and reported results for ICARE, a double blind 
prospective study in 1434 DM individuals with the Hp 2-2 genotype randomized to 
vitamin E or placebo. The major study outcomes (MI, stroke, CVD death) were identified 
prospectively in this population. We present here a secondary analysis of the CVD event 
rate in ICARE stratified by vitamin E and statin use.
Results. The event rate among individuals who did not receive antioxidants or statins 
was 6.1%. As expected we found that statins reduced the event rate in this population 
compared to individuals who did not take statins. However, unexpectedly we found that 
the addition of vitamins to statin treatment dramatically reduced the event rate (4.1% vs. 
1.3%, p<0.01), significantly more than statin or vitamin E treatment alone.
Conclusions. Dual therapy with antioxidants and statins appears to provide superior 
cardiovascular protection to Hp 2-2 DM individuals as compared to statins alone.
10:00 a.m.
1021-227 Effect of Lipid Lowering Therapy on Progression 
of Intermediate Coronary Atherosclerotic Plaque 
Evaluated by Virtual Histology Intravascular Ultrasound
Kenya Nasu, Etsuo Tsuchikane, Osamu Katoh, Hiroshi Fujita, Masashi Kimura, Mariko 
Ehara, Yoshihisa Kinoshita, Keiko Asakura, Yasushi Asakura, Tetsuo Matsubara, 
Mitsuyasu Terashima, Takahiko Suzuki, Toyohashi Heart Center, Toyohashi, Japan
Background: The aim of this study is to asses the effect of 12 month treatment with 
Fluvastatin (60 mg daily) on progression of intermediate coronary atherosclerotic plaques 
of a non-culprit vessel.
Methods: This prospective study was performed at 2 centers and designed to enroll 
80 patients. Patients were randomized to receive lipid-lowering therapy by Fluvastatin 
or a lipid lowering diet. All patients with high low-density lipoprotein-cholesterol level 
(> 140 mg/dl) were included in the Fluvastatin group. Non-culprit vessel’s were imaged 
with a 20 MHz phased-array intravascular ultrasound (IVUS) catheter with motorized 
pull-back system at 0.5 mm/s. In vivo Virtual Histology images were reconstructed by 
radiofrequency data analysis. Radiofrequency signals were classified into four component 
types: Dense Calcium; Fibrous; Fibro-fatty; and Necrotic Core. For each image, the area 
of vessel and each plaque component, as well as the volume of vessel and each plaque 
component was calculated using the Simpson‘s method. At 12-month follow-up repeat 
IVUS measurements were performed.
Results: In the Fluvastatin group, fibrous and fibro-fatty volumes significantly decreased, 
necrotic core did not increase, and there was a significant reduction in atherogenic 
lipoproteins. In the control group, fibrous, necrotic core and dense calcium volumes 
significantly increased (table).
Conclusion:
Lipid-lowering therapy with Fluvastatin prevented progression of coronary atherosclerotic 
plaque.
Laboratory data and IVUS measurements
Fluvastatin 
Baseline
Fluvastatin 
after 12 mo p value
Control 
Baseline
Control after 
12 mo p value
Low-density lipoprotein-
cholesterol, mg/dl 134±37 101±34 0.0008 122±22 126±39 0.69
Vessel volume, mm³ 795±358 748±389 0.36 880±429 880±371 0.99
Lumen volume, mm³ 342±153 367±180 0.34 450±243 403±191 0.07
Plaque volume, mm³ 275±161 234±151 0.14 228±132 372±142 0.05
Fibrous volume, mm³ 161±89 133±90 0.03 137±91 170±100 0.04
Fibro-fatty volume, mm³ 71±58 40±31 0.01 59±30 60±35 0.89
Necrotic core volume, 
mm³
30±33 28±22 0.70 20±16 33±30 0.04
Dense calcium volume, 
mm³
12±12 16±18 0.06 12±12 19±16 0.005
JACC March 11, 2008  ABSTRACTS - Vascular Disease, Hypertension and Prevention  A329 
Vascular D
isease, H
ypertension and P
revention
10:00 a.m.
1021-228 Pioglitazone Further Raises High-Density Lipoprotein 
Cholesterol in Metabolic Syndrome Patients Treated 
With Niacin
Richard L. Dunbar, Ramprassad Gadi, LeAnne Bloedon, Wolfe L. Megan, Baer 
L. Amanda, Daniel J. Rader, Frederick F. Samaha, University of Pennsylvania, 
Philadelphia, PA
Background: Low high-density lipoprotein (HDL) cholesterol is a major risk factor for 
cardiovascular events, and is improved by niacin, and to a lesser extent, pioglitazone 
(PIO). Combined use may be complementary, since the drugs are thought to raise HDL by 
different mechanisms, and because PIO may attenuate insulin resistance from niacin.
Methods: We conducted a randomized clinical trial of double-blinded PIO or placebo added to 
open-label extended-release niacin in non-diabetics with low HDL and metabolic syndrome. 
Over 4 weeks, subjects titrated niacin to 2 grams daily, the maintenance dose. One group was 
randomized to add PIO 30 mg daily, which was raised to 45 mg at 10 weeks; the other group 
added a matching PIO placebo. We assessed lipoproteins at 0, 4, 10, and 16 weeks.
Results: At baseline, mean (SD) HDL was 34.2 (5.3) mg/dL in 53 men vs 40.5 (7.6) mg/dL 
in 19 women. After niacin titration, 38 subjects were randomized to niacin+PIO and 34 
to niacin+placebo. By week 16 niacin+PIO raised HDL 27% over baseline vs 12% with 
niacin+placebo (p=0.0007). The HDL increase was greatest at 4-10 weeks, peaking at 
41% on niacin+PIO vs 28% on niacin+placebo (p=0.025). At week 16 apoAI rose 11% 
on niacin+PIO vs 5% on niacin+placebo (p=0.0172). The atherogenic lipoproteins fell 
significantly from baseline: NonHDL= -15%, apoB= -18%, LDL= -11%, LP(a)= -17%, 
VLDL= -32%, and TG= -31% (all p<0.0005). None of the latter varied by treatment group, 
suggesting these benefits resulted from niacin.
Conclusion: Pioglitazone may be useful to further raise HDL in patients with persistently 
low HDL-C. This combination appears to preserve the other known benefits of niacin on 
atherogenic lipoproteins.
10:00 a.m.
1021-229 Safety and Tolerability of the Triple Combination 
Ezetimibe/Simvastatin + Extended Release Niacin in 
Hyperlipidemia Patients
John R. Guyton, B. Greg Brown, Sergio Fazio, Adam Polis, Joanne E. Tomassini, 
Andrew M. Tershakovec, Merck/Schering-Plough Pharmaceuticals, North Wales, PA
Background: To achieve optimal LDL-C lowering and broader lipid-altering effects in high 
risk CHD patients, combination drug therapy can be considered. This study assessed the 
safety and tolerability of coadministered ezetimibe/simvastatin (E/S) + extended release 
niacin in hyperlipidemia (HL) patients. 
Methods: Part 1 (24 wk) of a 64 wk, multicenter, randomized, double-blind study which 
evaluated the efficacy and safety of 1X/day E/S (10/20 mg) coadministered with niacin 
(2g) vs niacin (2g) vs E/S (10/20 mg) in type IIa or IIb HL patients. Clinical and laboratory 
AEs were monitored including prespecified AEs (muscle, GI, hepatic, flushing, FSG, new 
onset of diabetes).
Results: Study discontinuations were significantly greater in both niacin groups compared 
to E/S alone (p<0.001) due to clinical AEs (primarily flushing) (Table). Rates of serious AEs 
were similar for all treatments. There were no significant differences in muscle, hepatic or GI 
AEs. FSG levels increased during the first 12 wks to a maximum of ~7.0% above baseline 
in both niacin groups and 2.4% in the E/S group. At 24 wks, FSG levels were 3.6%, 2.6% 
and -0.1% above baseline for niacin, E/S + niacin and E/S respectively. The onset of new 
diabetes was 11.8% for niacin, 9.6% for E/S + niacin and 7.0% for E/S.
Conclusion: Combination therapy with E/S + niacin was generally well-tolerated except 
for flushing, and exhibited a safety profile similar to that of either agent alone. E/S + niacin 
offers a safe, lipid-altering option for treatment of HL patients. 
Prespecified 
Laboratory AEs
Niacin 
N=272
E/S 
N=272
E/S+Niacin 
N =670
E/S+Niacin 
vs Niacin
E/S+Niacin 
vs E/S
m/n % m/n % m/n % Difference (95% CI)
Difference 
(95% CI)
ALT ≥3xULN† 1/252 0.4 1/260 0.4 3/605 0.5 0.1 (-1.7, 1.1)
0.1 
(-1.7, 1.1)
AST ≥3xULN† 1/252 0.4 1/260 0.4 2/605 0.3 -0.1 (-1.9, 0.9)
-0.1 
(-1.8, 0.9)
ALT and/or AST 
≥3xULN‡ 1/252 0.4 1/260 0.4 4/605 0.7
0.3 
( -1.6, 1.3)
0.3 
(-1.5, 1.4)
CK ≥10xULN 0/252 0.0 1/260 0.4 4/605 0.7 0.7 (-0.9, 1.7)
0.3 
(-1.5, 1.4)
CK ≥10xULN with 
muscle symptoms 0/252 0.0 0/260 0.0 1/605 0.2
0.2 
(-1.3, 0.9)
0.2 
(-1.3, 0.9)
CK ≥10xULN 
with muscle 
symptoms‡
0/252 0.0 0/260 0.0 0/605 0.0 - -
Discontinuation 
due to flushing 33/272 12.1 1/272 0.4 66/670 9.9
-2.3 
(-7.1, 1.9)
9.5 
(6.8, 
12.0)***
Gallbladder-
related AEs 0/272 0.0 1/272 0.4 1/670 0.1
0.1 
(-1.2, 0.8)
-0.2 
(-1.9, 0.5)
Cholecystectomy 0/272 0.0 1/272 0.4 0/670 0.0 - -0.4 (-2.1, 0.3)
New onset of 
diabetes§ 32/272 11.8 19/272 7.0 64/670 9.6
-2.2 
(-7.0, 1.9)
2.6 
(-1.6, 6.1)
E/S = ezetimibe/simvastatin (10/20 mg); niacin = niacin (ER) (starting dose of 500 
mg/day titrated to 2 g) 
N = number of patients randomized and treated 
m/n = number of patients with adverse experience category / number of treated patients 
> laboratory tests postbaseline 
†Includes those patients with (a) two consecutive measurements >3xULN, (b) a single, 
last measurement >3ULN, or (c) a measurement >3xULN followed by a measurement 
<3xULN that was taken more than 2 days after the last dose of study medication. 
‡considered to be drug-related 
§Patients who had an adverse event related to a diagnosis of diabetes, who started 
taking an anti-diabetic medication during the study, or whose fasting glucose increased 
to >126 mg/dL 
- Not estimable 
***p <0.001
10:00 a.m.
1021-230 Effect of Dehydroepiandrosterone (DHEA) Replacement 
on Lipoprotein Profile in Hypoadrenal Women
Manivannan Srinivasan, Brian Irving, Ketan Dhatariya, Kate Klaus, Stacey J. Hartman, 
Joseph P. McConnell, Sreekumaran Nair, Mayo Clinic, Rochester, MN
Background: Levels of DHEA and its sulfate form (DHEAS) are inversely associated with 
cardiovascular mortality in men but not in women. Very little evidence is available on the 
impact of DHEA administration on lipoprotein profile in women. LDL particle size has 
been accepted as an important predictor of cardiovascular events. Since DHEAS levels 
are very low/ undetectable in hypoadrenal women we determined the effect of DHEA 
replacement on Lipoprotein profile in hypoadrenal women.
Methods: In this double-blind, randomized, placebo controlled, crossover design study, 
33 hypoadrenal women (mean± SD: Age: 50.3+15.2 yrs., BMI: 26.6+4.4 kg/m2) were 
assigned to receive either a placebo or 50 mg/day of DHEA for three months each. 
DHEA period had higher plasma DHEAS levels than during placebo (< 0.3 ±0.0 vs. 3.5 
±1.3 nmol/L, p< 0.001). Lipid levels and Lipoprotein profile was analyzed using the Lipo 
Science Lipoprotein NMR system .
Results: DHEA replacement significantly reduced total cholesterol and HDL levels, and 
tends to reduce triglyceride, and total LDL levels (Table). Although, DHEA replacement 
had no effect on LDL particle size, it significantly reduced large HDL particles size.
Conclusion: Our study findings suggest that exogenous DHEA administration resulted in 
unfavorable lipoprotein profile by reducing both HDL levels and large HDL particle size 
and warrants long-term outcome measures to determine the impact of DHEA replacement 
on cardio vascular risk. 
Placebo 
Median Change 
(Interquartile Range)
DHEA 
Median Change 
(Interquartile Range)
p value
Total Cholesterol (mg/dL) 20.0 (-3, 36) -22.0 (-34, 6) 0.021
Triglycerides (mg/dL) 2.0 (-4, 35) -5.0 (-26, 06) 0.076
LDL Cholesterol (mg/dL) 6.0(-2, 22) -4.0 (-25.5, 7) 0.084
LDL mean particle size(nm) -0.1 (-0.2, 0.0) -0.1 (-0.2, 0.0) 0.888
Small LDL particles (µmol/L) 73.0 (-24, 179) -14.0 (-208, 121) 0.1467
HDL Cholesterol (mg/dL) 2.0(-1, 16) -6.0(-10, -2) 0.0061
HDL mean particle size (nm) 0.0(-0.1, 0.1) -0.1 (-0.2, -0.1) 0.128
Large HDL particles (µmol/L) 0.5 (0.2, 2.6) -1.0 (-2.7, -0.4) 0.0057
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805-3 Greater Regression of Electrocardiographic Left 
Ventricular Hypertrophy During Hydrochlorothiazide 
Therapy in Hypertensive Patients and the Interaction 
With Losartan vs Atenolol Therapy: The LIFE Study
Peter M. Okin, Richard B. Devereux, Darcy A. Hille, Sverre E. Kjeldsen, Lars H. Lindholm, 
Jonathan M. Edelman, Björn Dahlöf, Weill Cornell Medical College, New York, NY
Background: Although treatment of hypertensive patients with losartan- vs atenolol-based 
therapy was associated with greater regression of ECG left ventricular hypertrophy (LVH) 
in the LIFE study, whether concomitant hydrochlorothiazide (HCTZ) therapy in >70% of 
LIFE patients was associated with greater regression of LVH and whether this effect was 
different between treatment groups has not been examined.
Methods: Changes in Cornell product (CP) and Sokolow-Lyon (SL) LVH were assessed 
yearly in 9,193 hypertensive patients during randomized losartan vs atenolol use and 
additional HCTZ as needed according to study protocol. An interaction term between 
randomized and HCTZ treatment was used in analysis of covariance to assess whether 
the effect of HCTZ on regression of LVH differed significantly between treatment arms.
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Results: Baseline CP and SL were similar but baseline systolic and diastolic pressure 
were higher in patients taking HCTZ at year 1. After controlling for baseline and change in 
systolic and diastolic pressure, sex, race and baseline LVH by CP or SL, HCTZ use was 
associated with greater decreases in SL and, less strongly, CP LVH and with consistently 
greater regression of SL LVH in patients on losartan-based therapy (table). 
Change 
in ECG 
LVH from 
Baseline 
to Year
Atenolol Therapy Losartan Therapy P Values
No HCTZ HCTZ No HCTZ HCTZ
HCTZ 
vs 
no 
HCTZ
Losartan 
vs 
Atenolol
Interaction 
of HCTZ 
with 
Losartan vs 
Atenolol
CP Year 1 
(mm•ms) -64±769 -106±675 -193±704 -262±632 0.019 <0.001 0.347
CP Year 2 
(mm•ms) -147±732 -164±735 -232±674 -339±693 0.040 <0.001 0.024
CP Year 3 
(mm•ms) -119±825 -176±765 -214±702 -343±680 <0.001 <0.001 0.191
CP Year 4 
(mm•ms) -158±765 -142±822 -189±775 -341±743 0.014 <0.001 <0.001
SL Year 1 
(mm) -0.9±6.2 -1.3±5.9 -1.9±5.8 -3.4±5.6 <0.001 <0.001 <0.001
SL Year 2 
(mm) -1.8±6.4 -2.2±6.4 -2.4±6.2 -4.3±6.0 <0.001 <0.001 <0.001
SL Year 3 
(mm) -2.4±6.8 -2.6±6.6 -2.8±6.3 -4.8±6.3 <0.001 <0.001 <0.001
SL Year 4 
(mm) -2.7±7.4 -3.1±6.6 -3.3±6.6 -5.2±6.6 <0.001 <0.001 <0.001
Conclusion: HCTZ use was associated with greater regression of ECG LVH, especially by 
SL criteria. This effect was greater in patients on losartan- than atenolol-based therapy, 
independent of baseline severity of LVH and blood pressure at baseline and during 
treatment.
1:15 p.m.
805-4 Left ventricular concentric remodeling and cardiac 
function in Patients with Hypertension and Diastolic 
Dysfunction: the VALIDD Trial
Anil Verma, Michael R. Zile, Gerard P. Aurigemma, J. Malcolm Arnold, William Daley, 
Yves LaCourcier, Scott D. Solomon, Brigham and Women’s Hospital/harvard Medical 
School, Boston, MA
Background: Left ventricular (LV) concentric remodeling (CR) and hypertrophy portend 
increased cardiovascular risk. However, the relationship between LV CR and diastolic 
function, an early measure of myocardial end-organ damage in hypertension, has not 
been well defined.
Methods: Echocardiographic measures of LV structure and function were assessed 
in 384 patients from the VALsartan in Diastolic Dysfunction (VALIDD) trial with mild 
hypertension and evidence of diastolic dysfunction based on Doppler assessment of 
myocardial diastolic relaxation velocities (E’).
Results: LV hypertrophy was present in < 3%, CR (relative wall thickness>0.42 and normal 
LV mass index) in 71 (19%) and normal geometry in 301 (80%) subjects. Mean blood 
pressure in the cohort was 143.8 ± 16.1/86.2 ± 10.3 mmHg. When compared to normal 
geometry, CR was associated with lower E’, higher E/E’, higher NT-ProBNP [figure], 
higher isovolumic relaxation time (0.11 sec ±0.02 vs 0.10 sec ±0.02 s) and increased 
vascular stiffness (2.8±0.5 vs 2.6±0.5) (all p<0.05), even after adjusting for age, diabetes, 
gender, systolic BP, and eGFR. LV ejection fraction, LA volume and systolic longitudinal 
velocity were similar in both groups.
Conclusion: LV concentric remodeling is associated with impaired relaxation and worse 
diastolic function in patients with hypertension, and both measures may represent 
important and modifiable markers of early myocardial end-organ damage even in patients 
with mild blood pressure elevation.
1:30 p.m.
805-5 Cardiotrophin-I Plasma Levels Are Increased in 
Hypertensive Patients With Cardiac Hypertrophy and 
Diastolic Dysfunction
Luigi Gabrielli, María Ocaranza, Iván Godoy, Silvana Llevaneras, Jorge Jalil, Pontificia 
Universidad Católica, Santiago, Chile
Background: Cardiotrophin-1 (CT-1) is an interleukin-6-related cytokine with known 
hypertrophic actions on cardiac myocytes. Plasma CT-1 levels are increased in patients 
with hypertension (HT) and left ventricular hypertrophy (LVH). Whether CT-1 could be 
a marker of diastolic dysfunction (DD) associated with LVH and left atrial enlargement 
(LAE) in hypertensive patients remains unknown.
Methods: Thirty six consecutive hypertensive patients without treatment (mean age 52 ± 
9 years, 58% men) and a normotensive control group matched by age and gender were 
included. All patients had normal systolic function. Plasma CT-1 levels were measured 
by ELISA. LV mass index (LVMI) and atrial size were determined by transthoracic 
echocardiography (LVH was defined as a LVMI > 115 grs/m2 in men and 95 > grs/m2 
in women). Diastolic LV function was determined by the E/E´ relationship (mitral annulus 
tissue Doppler).
Results (mean ± SEM) were: 
Controls (n = 20) HT without LVH (n = 13)
HT with LVH 
(n = 23)
CT-1 (fmol/ml) 8.9 ± 0,6 9.8 ± 0,6 22.2 ± 8.6*
MAP (mm Hg) 82 ± 2 127± 3.2† 126 ± 3.2†
Left atrial area (cm2 ) 14.9 ± 1.5 15.8 ± 1.9 22.8 ± 2.4†
E/E’ 8.5 ± 0.7 8.9 ± 0.8 12.9 ± 1.1*
Symbols: * = p < 0.03 and † = p < 0.01 (after significant ANOVA). Abbreviations: MAP = 
mean arterial pressure.
In hypertensive patients a significant positive correlation between plasma CT-1 levels and 
LVMI (r = 0.51, p< 0.01), E/E´ ratio (r = 0.61 p = 0.04) and left atrial area (r = 0.68 p = 
0.02) was found. No correlation was observed between plasma CT-1 levels and arterial 
blood pressure
Conclusion: Plasma CT-1 levels are elevated in hypertensive patients with LVH, LAE and 
DD and could be a marker of progressive cardiac damage in this population.
1:45 p.m.
805-6 Pulse Pressure is a Predictor of Vascular Endothelial 
Function in Healthy Volunteers
Michael Shechter, Yaron Arbel, Roy Beigel, Micha S. Feinberg, Danny Dvir, Heart 
Institute, Sheba Medical Center, Tel Hashomer, Israel
Background: Elevated pulse pressure is a new cardiovascular risk factor.
Methods: To investigate whether pulse pressure is associated with endothelial function in 
healthy subjects we prospectively assessed brachial artery flow-mediated dilation (FMD) 
in 335 consecutive healthy subjects [206 (61%) men, mean age 52±11 years] without 
known coronary artery disease. Following an overnight fast and the discontinuation 
of all medications for ≥ 12 hours, percent improvement in brachial FMD (%FMD) and 
nitroglycerin-mediated vasodilation (%NTG) were assessed using high resolution (15 
MHz) linear array ultrasound.
Results: Linear regression analysis revealed a significant inverse association between 
%FMD and pulse pressure (r=-0.65, p<0.01), systolic blood pressure (r=0.52, p<0.01) and 
age (r=-0.21, p<0.05). Multivariate analysis showed that pulse pressure was the stongest 
independent predictor of %FMD. We therefore divided the study population into 2 groups: 
Group A (n=185) ≤ and Group B (n=150) > the median pulse pressure of 50 mmHg (Table). 
Both groups were comparable with regard to age, gender, body mass index, concomitant 
medications, lipids, homocysteine, C-reactive protein and fastig blood glucose.
Conclusion: Pulse pressure is inversely associated with FMD in healthy subjects, 
suggesting a potential mechanism whereby elevated pulse pressure contributes to 
cardiovascular disease. Long-term follow-up is warranted to elucidate the incidence of 
CAD in both study groups given our results.
Values are expressed as mean+/-SD
Glroup A (n=185) Group B (n=150) p value
Systolic blood pressure (mmHg) 123±9 152±18 <0.001
Diastolic blood pressure (mmHg) 79±7 82±9 <0.001
Pulse pressure (mmHg) 44±6 69±14 <0.001
Mean arterial pressure (mmHg) 93±7 106±12 <0.001
Resting heart rate (bpm) 65±10 68±10 <0.01
Brachial artery diameter (mm) 5.79±0.93 5.43±0.98 <0.01
%FMD 14.9±5.0 10.8±5.0 <0.001
%NTG 16.1±4.8 14.8±4.9 0.38
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805-7 Progression of Preclinical Diastolic Dysfunction to the 
Development of Symptoms
Correa De Sa D. Daniel, Magaret M. Redfield, David O. Hodge, Joshua P. Slusser, John 
C. Burnett, Jr., Horng H. Chen, Mayo Clinic, Rochester, MN
Background: Preclinical diastolic dysfunction (PDD) has been defined as subjects with 
normal systolic function, diastolic dysfunction but no symptoms of heart failure (HF) . 
The clinical phenotype and natural history of the syndrome remains poorly defined. Our 
objective was to determine the clinical phenotype and progression to the development 
of symptoms in a group of patients with moderate or severe diastolic dysfunction as 
determined by Doppler criteria without any symptoms of HF (dyspnea or edema or 
fatigue) at the time of echocardiography.
Methods: Using the resources of the Mayo Clinic echo database, between January to 
December 2005, 3367 patients with moderate or severe diastolic dysfunction by Doppler 
criteria and EF equal or greater than 50% were identified. Medical records were reviewed 
and those with symptoms of HF at the time of the echo were excluded leaving a cohort 
of 99 PDD subjects. The medical records of these subjects were reviewed to determinate 
clinical characteristics and outcome. Primary end point was the time to the development 
of symptoms of HF.
Results: The mean age of the cohort of PDD subjects was 70 ± 10 yrs with a female (66%) 
predominance. Prevalence of hypertension was 77%, coronary artery disease (CAD) was 
40%, previous myocardial infarction was 20%, atrial fibrillation was 30%, renal dysfunction 
as defined by calculated creatine clearance of < 60 ml/min was 50%, hypercholestrolemia 
was 55% and type II Diabetes was10%. 71% had a chest x-ray (CXR) within 6 months 
of echo and 21% had abnormal cardiac findings on CXR (cardiomegaly or pulmonary 
venous congestion or pleural effusion). Mean follow up was 520 days. The 2-year rate of 
developing symptoms of HF was 23 %. Significant mitral valve regurgitation (MR) on echo 
and abnormal cardiac findings on CXR were independently associated with increased 
likelihood for the development of the symptoms of HF. Conclusion: This retrospective 
review suggests that hypertension, CAD, hyperlipidemia and renal dysfunction are 
prevalent in patients with PDD. More importantly, there was a moderate degree (23%) of 
progression to symptoms of HF over 2 years. Further prospective studies are needed to 
confirm these observations in PDD.
2:15 p.m.
805-8 Early Impairment of Myocardial Function and Large 
Artery Remodeling Are Associated With an Enhanced 
Left Ventricular Inotropic Function in Pre-Hypertensive 
Subjects
Vitantonio Di Bello, Michaela Kozakova, Enrica Talini, Maria Laura Canale, Maria 
Grazia Delle Donne, Caterina Palagi, Silvia Affinito, Giulia Dell’Omo, Roberto Pedrinelli, 
Carmela Morizzo, Mario Mariani, Carlo Palombo, Marzilli Mario, Pisa, Italy
Background: Aim of study was to simultaneously evaluate left ventricular function and 
vascular structure and function in pre-hypertension (PH)
Methods: we studied 24 asymptomatic, uncomplicated pre- hypertensive patients (PH) 
and 10 sex- and age-matched healthy volunteers (C group: age 45±12, BP 118±12/73±7 
mmHg). All patients were analysed by conventional and new echocardiographic techniques 
(2D-Strain) with a GE echograph (Vivid 7). Carotid artery intima-media thickness (IMT) 
was assessed by high resolution vascular US (Aloka SSD-5500) bilaterally. On digitized 
zoomed images, IMT was averaged through 12 segments.
Results : PH patients showed an higher mean arterial pressure (PH: 98.3±9.68 vs. C: 86.5 
± 7 mmHg, p<0.001); furthermore PH showed: an higher left ventricle mass values indexed 
for body surface (PH 98.5±23.9 vs C 70.6±16.1 g/m2, p<0.001); a normal left ventricular 
function evaluated by conventional echocardiography;in PH systolic longitudinal and 
radial 2D strain was significantly higher then in controls; a reduced left ventricular diastolic 
function compared with C, evidenced by a lower peak E longitudinal strain rate (SR) (PH 
1.2±0.3 vs C 1.5±0.5 sec-1, p<0.05) and an higher peak A longitudinal strain rate (PH 
1.1±0.2 vs C 0.8±0.3 sec-1, p<0.0001) at septum level. We found a similar behavior of SR 
at lateral wall level. 2D-Strain analysis revealed a late diastolic alteration in left ventricular 
circumferential strain rate evidenced by an higher peak A SR in many segments.
Compared to controls, PH had significantly higher mean IMT (786±107 vs 666±106 µ p< 
0.05). Some significant relationships were found between cardiac and vascular findings 
: such as between longitudinal systolic strain and IMT (r=0.64; p<0.01) and longitudinal 
diastolic strain (E/A) and IMT (r=-0.56;p<0.05).
Conclusions: otherwise normal subjects with “pre-hypertension” show an enhanced 
myocardial systolic performance, subclinical impairment of LV diastolic function and 
increased IMT. This cluster is in keeping with the hypothesis of a sustained adrenergic 
activation preceding the development of established hypertension.
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2:00 p.m.
1028-157 Influence of the XbaI Polymorphism in the APOB 
Gene on Lipids, Statin Response, and Recurrent 
Cardiovascular Events
Jessica L. Mega, Christopher P. Cannon, Marc S. Sabatine, Brigham & Women’s 
Hospital, Boston, MA
Background: Rare mutations in APOB are associated with profound changes in lipid levels 
and atherogenicity. Several studies have examined the more common XbaI polymorphism 
(7673 C→T) in APOB and found paradoxical associations with higher LDL levels but 
lower risk of incident CV disease.
Methods: In 2022 Caucasian post-ACS patients randomized to atorvastatin 80 mg or 
pravastatin 40 mg in PROVE IT - TIMI 22, we investigated whether the XbaI variant was 
associated with lipid levels, statin response, and recurrent CV events over 2 yrs.
Results: Baseline characteristics were similar among the 3 genotypes. The TT genotype 
was associated with significantly higher baseline levels of apolipoprotein B (apoB) and 
LDL (Fig) but did not impact the LDL/apoB ratio (a measure of small, dense LDL), P=0.80. 
There was no significant interaction between genotype and the effect of either statin on 
apoB, LDL, or the LDL/apoB ratio. TT homozygotes had the lowest rates of CV death, MI, 
or UA (Fig) after adjusting for traditional CV risk factors.
Conclusion: The XbaI polymorphism is associated with higher baseline levels of apoB 
and LDL, but paradoxically lower rates of CV events. Our observations support prior 
studies and demonstrate that the protective influence of the T allele extends to recurrent 
CV events post-ACS. Additionally, our data suggest that the protective effect of the XbaI 
polymorphism on CV events is mediated through a molecular mechanism other than 
response to statin therapy or levels of apoB, LDL, or the LDL/apoB ratio.
2:00 p.m.
1028-158 Fast-Migrating Low-Density Lipoprotein as Analyzed by 
Capillary Isotachophoresis Is Related to Inflammatory 
Markers and Reduced by Pravastatin and Simvastatin: 
The SPECIAL Study
Bo Zhang, Shin-ichiro Miura, Keita Noda, Hiroaki Nishikawa, Akira Matsunaga, Kazuyuki 
Shirai, Atsushi Iwata, Keijiro Saku, Fukuoka University, Fukuoka, Japan
Background: Atherogenic modified low-density lipoprotein (LDL) including oxidized 
LDL and small, dense LDL (sdLDL) is characterized with increased negative charge. 
Electronegative LDL as separated by ion-exchange chromatography has been consistently 
shown to be inflammatory. Electronegative LDL in plasma is analyzed as fast-migrating 
LDL (fLDL) by capillary isotachophoresis (cITP). We examined the relation between cITP 
fLDL and inflammatory markers and the effects of pravastatin and simvastatin.
Methods: Hypercholesterolemic (HC) patients with risk factors of coronary heart disease 
(n=73) were analyzed for cITP lipoprotein subfractions at baseline and after treatment 
with pravastatin 10 mg or simvastatin 5 mg daily for 6 months.
Results: HC patients had markedly increased cITP fLDL as compared with normal subjects 
(Figure). At baseline, cITP fLDL was significantly correlated with inflammatory markers, 
high-sensitive C-reactive protein (r=0.36) and LDL-associated platelet-activating factor 
acetylhydrolase (r=0.37), and atherogenic lipoproteins, remnant-like particle cholesterol 
(r=0.44) and sdLDL cholesterol (r=0.50). Treatment with pravastatin and simvastatin 
reduced cITP fLDL levels by 21% and 31%, respectively.
Conclusions: cITP fLDL was related to inflammatory markers and atherogenic lipoproteins 
and was effectively reduced by low-dose of pravastatin and simvastatin. Charge-modified 
LDL subfraction could be a novel marker for atherosclerosis and a target for therapy. 
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2:00 p.m.
1028-159 Impact of Hyperinsulinemia on Tissue Characteristics 
of Non-culprit Plaque in Non-diabetic Patients With 
Acute Coronary Syndrome
Takayuki Mitsuhashi, Kiyoshi Hibi, Masami Kosuge, Toshiaki Ebina, Shingo Tsukahara, 
Jun Okuda, Noriaki Iwahashi, Mitsuaki Endo, Fumiyuki Otsuka, Ikuyoshi Kusama, 
Naohiro Komura, Satoshi Umemura, Kazuo Kimura, Yokohama City University Medical 
Center, Yokohama, Japan
Background: Hyperinsulinemia is associated with elevated risk of acute coronary events 
even before the onset of diabetes, indicating increased plaque vulnerability. However, 
the precise mechanism remains to be elucidated. The aim of this integrated backscatter 
intravascular ultrasound (IB-IVUS) study was to clarify the association between 
hyperinslinemia and the tissue characteristics of coronary plaques in non-diabetic 
patients (pts) with acute coronary syndrome (ACS).
Methods: Non-culprit coronary lesions with mild to moderate stenosis in 64 non-
diabetic pts with ACS were examined by IB-IVUS using 40-MHz intravascular catheter. 
Radiofrequency data were captured and IB-IVUS images were constructed. The target 
plaque had to be an intermediate lesion with angiographically no more than 50% luminal 
narrowing and had to be at least 5mm apart from the culprit lesion. Measurements of IB-
IVUS were made every 1mm for 10mm length in each plaque, and average value of each 
plaque component (lipid, fibrosis, dense fibrosis, and calcification) was calculated. All pts 
underwent 75-g oral glucose tolerance test (OGTT). Plasma glucose and immunoreactive 
insulin (IRI) levels were measured at baseline, 30, 60, and 120 minutes after the glucose 
load. Area under the curve (AUC) insulin during OGTT was used as composite variable 
reflecting IRI levels. Pts with previously treated diabetes or newly diagnosed diabetes by 
75-g OGTT were excluded. Results: No significant association was observed between 
the traditional coronary risk factors and tissue characteristics in this population. Higher 
AUC insulin were correlated with greater %lipid area (R=0.30, p=0.02) and lower %fibrous 
area (R=-0.27, p=0.03). Multiple linear regression analysis revealed that AUC insulin was 
associated with %lipid area independent of age, gender, and other coronary risk factors 
including LDL and HDL cholesterol levels (p<0.05).
Conclusions: Hyperinsulinemia was associated with elevated lipid content in the non-
culprit intermediate lesion in non-diabetic patients with ACS. Pharmacological strategy to 
ameliorate hyperinsulinemia may contribute to the stabilization of vulnerable plaque even 
in patients without diabetes.
2:00 p.m.
1028-160 Tumor Necrosis Factor Antagonists and Methotrexate 
Improve Disease Activity and Decrease Aortic Stiffness 
in Patients With Rheumatoid Arthritis
Athanasios Gravos, Charalambos Vlachopoulos, Dimitrios Vassilopoulos, Anna 
Kandili, Nikolaos Ioakeimidis, Konstantinos Aznaouridis, Athanasios Archimandritis, 
Christodoulos Stefanadis, 1st Department of Cardiology, Athens Medical School, 
Hippokration Hospital, Athens, Greece
Background: Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease, 
which is associated with increased cardiovascular mortality. Aim of the present study 
was to investigate whether there is a differential chronic effect of treatment with TNF 
antagonists or methotrexate in aortic stiffness in RA patients with active disease.
Methods: We randomized 18 RA patients (age 58.7 ± 12.7 yrs, disease duration 7.3 ± 8.4 
yrs) to receive adalimumab or matching methotrexate in combination with prednizolone 
for 12 weeks. Patients underwent evaluation of aortic stiffness, clinical status and 
inflammatory markers such as CRP and ESR, at baseline, 6 weeks and at the end of 
treatment period. DAS 28 questionnaire was used as an instrument of physical function. 
Aortic stiffness was evaluated with carotid-femoral pulse wave velocity (PWV).
Results: At 6 weeks PWV was significantly reduced in both adalimumab (from 8.07±2.68 
to 6.88±2.27 m/s, P<0.05) and methotrexate (from 8.43±1.49 to 7.56±1.43 m/s, P<0.05) 
treatment subgroups. At 12 weeks the benefit in aortic stiffness was sustained in patients 
that received adalimumab (6.8±2.23 m/s vs. 8.07±2.68, P<0.05 vs. baseline; 6.80±2.23 
m/s vs. 6.88±2.27 m/s, vs. 6 weeks, P=NS) while no significant changes in PWV were 
observed in patients randomized to methotrexate (8.10±2.27 vs. 8.43±1.49 m/s, P=NS, 
vs. baseline; 8.1±2.27 vs 7.56±1.43 m/s, vs. 6 weeks, P= NS). Finally, compared to 
baseline, a net decrease in DAS 28, CRP and ESR was found both at 6 and 12 weeks 
after treatment with adalimumab and methotrexate.
Conclusions: This is a first study to show that a 12-week treatment with methotrexate or 
TNF antagonists lead to improvement in aortic stiffness and to a significant reduction 
in inflammatory state, however the benefit of therapy with TNF antagonists on aortic 
elastic properties seems to be more sustained, compared to therapy with methotrexate. 
This finding may have important implications in RA patients who are considered to be at 
increased cardiovascular risk.
2:00 p.m.
1028-161 Statin Treatment Improves 18-Months Survival In 
Patients With End-Stage Heart Failure
Dimitris Tousoulis, Apostolis Drolias, Charalambos Antoniades, Kiriakoula Marinou, 
Nikos Papageorgiou, Penny Gounari, Alexios S. Antonopoulos, Elli Stefanadi, Christos 
Pitsavos, Christodoulos Stefanadis, 1st Cardiology Department, Hippokration Hospital, 
Athens Medical School, Athens, Greece
Background: Statin treatment has a major impact on clinical outcome in patients with 
atherosclerosis, but its role in end-stage heart failure is controversial. We examined the 
effect of statins on the long-term clinical outcome of patients with end-stage heart failure.
Methods: The study population consisted of 250 patients (57.9±1.1 yrs) with end-stage 
heart failure (NYHA IV, ejection fraction 34±0.2%). At baseline, 127 patients were treated 
with statins while 123 patients not receiving any hypolipidemic agent were selected to be 
matched to the treated group according to age, gender and risk factors for atherosclerosis. 
Participants were followed-up prospectively for 18 months, and cardiovascular death was 
the main end-point. Cox-regression was performed to determine the impact of statin 
treatment of survival in these patients.
Results: During the follow-up, 167 cardiovascular deaths were reported. The hazard 
ratio[95%CI] for cardiovascular death, was 1.494[1.028-2.173], p=0.036 for those not 
receiving statins vs those treated with statins (Figure). This effect was comparable to that 
of angiotensin converting enzyme inhibitors (HR[95%CI]:1.464[1.019-2.103], p=0.039].
Conclusions: Treatment with statins significantly decreases the hazard ratio for 
cardiovascular death in patients with end-stage severe heart failure. This finding suggests 
that statin treatment on top of standard medication, may be beneficial in this group of 
patients, since it improves their long-term survival. 
2:00 p.m.
1028-162 The Antiplatelet Effect of Higher Loading and 
Maintenance Dose Regimens of Clopidogrel: The Plavix 
Response in Coronary Intervention (PRINC) Trial
Patrick A. Gladding, Mark WI Webster, Irene SL Zeng, Helen Farrell, James Stewart, 
Peter Ruygrok, John Ormiston, Seif El-Jack, Guy Armstrong, Douglas Scott, Patrick 
Kay, Marja-Liisa Dahl, Arzu Gunes, Green Lane Cardiovascular Service, Auckland, New 
Zealand, Dept of Medical Sciences, Uppsala University, Uppsala, Sweden
Background: Clopidogrel loading doses above 600mg have not resulted in more rapid 
or complete platelet inhibition, perhaps because intestinal absorption is saturable. It is 
also uncertain whether maintenance doses of more than 75mg/day provide a greater 
antiplatelet effect.
Methods: A double-blind, randomised, controlled trial was undertaken in 60 patients 
undergoing percutaneous coronary intervention. All patients received clopidogrel 600mg 
at the start of the procedure. Using a 2x2 factorial design, patients were randomised to 
a second dose of clopidogrel 600mg given 2 hours later or matching placebo, and to 
verapamil 5mg intra-arterial or placebo given at the time of PCI. Platelet inhibition was 
measured using the Accumetrics VerifyNow® P2Y12 platelet function analyzer at 2, 4, 
and 7 hrs from the first loading dose. The next day patients were further randomised to 
receive a clopidogrel maintenance dose of either 75mg or 150mg once daily, with platelet 
function assessed after one week.
Results: Two hours after the second dose of clopidogrel or placebo, platelet inhibition 
was 42+/-27% with clopidogrel, compared with 24+/-22% with placebo, p=0.0006. By 5 
hours after the second dose, platelet inhibition was 49+/-30% with clopidogrel, compared 
with 29+/-22% with placebo, p=0.006. Verapamil given at the time of the first clopidogrel 
dose had no effect on clopidogrel pharmacodynamics. A clopidogrel maintenance dose of 
150mg daily for one week resulted in greater platelet inhibition than 75mg daily (50+/-28 
versus 29+/-19%, p=0.01). The troponin levels at seven hours were significantly higher 
in patients identified as non-responders to clopidogrel compared to responsive patients 
(0.05; 95% confidence interval [CI] 0.01 to 0.29, versus 0.01; 95% CI 0.01 to 0.03).
Conclusions: A clopidogrel 1200mg loading dose, given as two 600mg doses two hours 
apart, results in more rapid and complete platelet inhibition than a single 600mg dose. 
A clopidogrel maintenance dose of 150mg daily produces greater platelet inhibition 
than 75mg daily. Non-response to clopidogrel is associated with a higher incidence of 
periprocedural myonecrosis.
JACC March 11, 2008  ABSTRACTS - Vascular Disease, Hypertension and Prevention  A333 
Vascular D
isease, H
ypertension and P
revention
2:00 p.m.
1028-163 The Pharmacogenetics and Pharmacodynamics of 
Clopidogrel Response: An Analysis From the PRINC 
(Plavix Response in Coronary Intervention) Trial
Patrick A. Gladding, Mark WI Webster, Irene SL Zeng, James Stewart, Peter Ruygrok, 
John Ormiston, Helen Farrell, Seif El-Jack, Guy Armstrong, Patrick Kay, Jo Perry, Marja-
Liisa Dahl, Arzu Gunes, Green Lane Cardiovascular Service, Auckland, New Zealand, 
Dept of Medical Sciences, Uppsala University, Uppsala, Sweden
Background: Pharmacogenetics may predict drug response prior to drug administration. 
Inter-individual variability in clopidogrel drug response appears in part mediated by 
polymorphisms in the cytochrome enzyme genes (e.g. CYP2C19) and p-glycoprotein 
efflux pump (e.g. MDR1).
Methods: 60 patients undergoing elective percutaneous coronary intervention enrolled in the 
randomised PRINC trial had platelet function measured using the VerifyNow P2Y12 analyzer. 
There was greater platelet inhibition with a split 1200mg compared with a standard 600mg 
clopidogrel loading dose, and with a 150mg compared with a 75mg daily maintenance dose. 
Pharmacogenetic analysis of the P2Y12, P-glycoprotein, CYP2C19 and CYP3A5 genes 
used iPlex® assays on the Sequenom® Mass spectrometer and validated Taqman® assays.
Results: Platelet inhibition 2 hours after a clopidogrel 600mg loading dose predicted 
response at 7 hours (r=0.65, p=0.0001); a cutoff of <2% identified nonresponders 
(inhibition <10%) with sensitivity 100% and specificity 88%. CYP2C19 *2, *4, *17 carriers 
had reduced platelet inhibition 2 hours after a 600mg dose (13+/-20%), compared with 
CYP2C19 *1*1 carriers (26+/-20%, p=0.02). CYP2C19*1*1 carriers had similar platelet 
inhibition after a 1200 and 600mg loading dose at four hours (51+/-28% and 35+/-27% 
p=0.2) and after a 150 and 75mg daily maintenance dose (51+/-25% and 40+/-18%, 
p=0.3). In contrast, CYP2C19*2 or *4 carriers had increased platelet inhibition with the 
higher loading (36+/-24% and 16+/-13%, p=0.008), and maintenance dose regimens 
(49+/-31% and 24+/-18%, p=0.02).
Conclusions: Clopidogrel poor-responders can be identified by phenotyping and by 
pharmacogenetic analysis. Carriers of the CYP2C19 *2, *4 loss of function alleles show a 
reduced early antiplatelet response to a clopidogrel 600mg loading dose, but respond to 
increased loading and maintenance dose regimens. Point-of-care rapid platelet function 
analysis and genotyping may allow individualised treatment regimens.
2:00 p.m.
1028-164 The effects of valsartan and spironolactone on collagen 
metabolism and heart function in patients after acute 
myocardial infarction with aneurysm
Xianghua Fu, Shaodong Hu, Xinshun Gu, Weize Fan, Yunfa Jiang, Ling Xue, Guozhen 
Hao, Weili Wu, Shiqiang Li, 2nd Hospital of Hebei Medical University, Shijiazhuang, 
People’s Republic of China
Backgroud:To evaluate the effects of valsartan and spironolactone on collagen 
metabolism and heart function in patients after acute myocardial infarction by measuring 
serum N-terminal procollagenIIIpropeptide(PIIINp) and Carboxyterminal propeptide of 
typeIprocollagen (PICp)level as well as echocardiaography.
Methods: Patients of first anterior AMI with left ventricular aneurysm proved by left 
ventriculography were divided into Valsartan-and- Spironolactone group (VS group, 36 
cases, male 31,54.36±6.42 years), Valsartan group(n=34, male 30, 53.16±5.54 yrs). 
Serum PIII Np and PICP were measured at 1st ,2nd ,12th week after onset of AMI. 
At 2nd ,12th week after onset of AMI, the parameters of left ventricular end diastolic 
volume index(LVEDVI), left ventricular end systolic volume index(LVESVI), left ventricular 
ejection fraction(LVEF) and regional wall movement index(RWMI) were measured with 
echocardiaography.
Results: There was no significant difference between the two groups in clinical 
characteristicssuch as age, sex, risk factors (include history of smoking,hypertension, 
diabetes, hyperlipidemia), heart function and the time from onset to reperfusion.
. Serum PIIINP and PI CP, which were no difference between the two groups at 1st , 2nd 
week, were lower significantly in VS group than those in Valsartan group At 12th weeks 
(VS group PIIINP, PICP was 4.38±1.39 vs. 5.28±1.62,98.41±16.24 vs.106.36±18.29; 
P<0.05). At 12th week, LVEF in VS group was significantly increased by 4.81%(P<0.05), 
while other parameters were decreased significantly (P<0.05) as compared with those 
in Valsartan group. At 12 week, LVEF and VE/VA in both groups was significantly higher 
while other parameters were decreased significantly (P<0.05) as compared with those at 
2nd week. PIIINP and PICP were positively correlated with LVEDVI in VS group(r= 0.57, 
r= 0.69;P<0.05); PIIINP and PICP were correlated negatively with LVEF and VE/VA inVS 
group (r= -0.49, r= -0.42;P<0.05).
Conclusion:Valsartan helps to reverse the formation of collagen and improve the 
systolic and diastolic function in post-myocardial infarction; Combining Valsartan with 
spironolactone were more effective than monotherapy.
2:00 p.m.
1028-165 Non-Alcoholic Fatty Liver Disease and Adipose Tissue-
Related Hormones: a Possible Link With Cardiovascular 
Disease
Katerina Baou, Charalambos Vlachopoulos, Emmanuel Manesis, Nikolaos Ioakeimidis, 
Ioanna Dima, Panagiotis Xaplanteris, Georgios Papatheodoridis, Athanasios 
Archimandritis, Christodoulos Stefanadis, 1st Department of Cardiology, Athens, 
Greece, 2nd Department of Internal Medicine, Athens, Greece
Background: The pathophysiology of hepatic steatosis, a prerequisite of non-alcoholic 
fatty liver disease (NAFLD), is poorly understood. This entity has received increasing 
attention because of the possible role of NAFLD in the development of atherosclerosis. 
Morbid rates of adipocytokines may provide a link between metabolic syndrome, 
inflammation and cardiovascular disorder in NAFLD patients. We investigated whether 
NAFLD is associated with fat produced hormones and if this relation can affect the 
impaired endothelial structure and function.
Methods: We studied 34 patients (mean age 55±13 years, 20M/14F) with biopsy evidence 
of NAFLD, and 34 control subjects adjusted for classical risk factors. The changes in the 
diameter of the brachial artery were measured in response to reactive hyperemia and 
also in response to nitroglycerin. Mean IMT of common carotid arteries was determined 
as a marker of atherosclerosis using B-mode ultrasound imaging. Carotid-femoral pulse 
wave velocity (PWV) was measured as index of aortic stiffness. Adiponectin, resistin and 
leptin were measured by ELISA kit.
Results: NAFLD subjects had significantly reduced flow-mediated vasodilation (1.1±1.9% 
vs 4.3± 3%, p<0.05), while nitroglycerin-mediated vasodilation did not differ among the 
two groups. Mean value of carotid IMT (0.98±0.3 vs 0.77±0.2 mm, p<0.05) and PWV 
(8.4±1.6 vs 7.3±1.7 m/s, p<0.01) were significantly increased compared to controls. 
NAFLD subjects had significantly increased levels of leptin (21.81± ng/ml vs 12.12±10 ng/
ml, p<0.01), and resistin (5.174±1.6 ng/ml vs 3.5±1.28 ng/ml, p<0.01) and reduced levels 
of adiponectin (7.96±5.19 µg/ml vs 13.17±12.4 µg/ml, p<0.05) compared to controls. 
After adjustment for confounding factors, resistin levels were independently associated 
with impaired endothelial function (p<0.05, t=7.53, coefficient st=0.883) and leptin levels 
were independently associated with the increased mean IMT (p<0.01, t=6.92, coefficient 
st=0.888), and PWV (p< 0.05, t=2.258, coefficient st=0.32) in NAFLD patients.
Conclusion: NAFLD is associated with surrogate markers of cardiovascular function, and 
this relation is influenced by adipose tissue hormones.
2:00 p.m.
1028-166 Cardiovascular Safety of the Cholesteryl Ester Transfer 
Protein Inhibitor R1658/JTT-705: Results from Phase 2 
Trials
George Steiner, John J. Kastelein, David Kallend, Erik S. Stroes, Toronto General 
Hospital, Toronto, Canada
Background: R1658/JTT-705 is under investigation as a cholesteryl ester transfer protein 
(CETP) inhibitor to improve high-density lipoprotein cholesterol levels with the potential 
to slow progression of atherosclerosis and decrease cardiovascular (CV) risk. CV safety 
data from several phase 2 trials were assessed following concerns over the withdrawal of 
the CETP inhibitor torcetrapib due to hypertension and increased CV events.
Methods: Adverse events (AEs) and other safety data were pooled from phase 2a 4-
week studies. Patients with type II hyperlipidemia received 300, 600 or 900 mg R1658/
JTT-705 (n=144) or placebo (n=49). In three combination studies, patients with type II 
hyperlipidemia or coronary heart disease (CHD) or CHD risk equivalents received 300 or 
600 mg R1658/JTT-705 (n=199) or placebo (n=154) in combination with pravastatin (300 
mg only), atorvastatin or simvastatin. Data from a phase 2b 12-week combination study with 
pravastatin where patients were exposed to 300, 600 or 900 mg of R1658/JTT-705 (n=218) 
or placebo (n=74) were analyzed separately. Blood pressure and heart rate were recorded 
at each study visit. ECGs were recorded at the beginning and end of treatment.
Results: Data from the 4-week studies revealed the incidence of AEs and CV AEs was 
similar across treatment groups with no dose trends with respect to severity or causality 
of CV AEs. There were no other clinically significant changes. Data from the 12-week 
study showed similar findings. No changes were observed in mean and median systolic 
or diastolic blood pressure across the dose range in any of the studies compared with 
placebo. There were no clinically significant changes in heart rate or in mean QTcB 
interval in the R1658/JTT-705 or placebo treatment groups.
Conclusions: R1658/JTT-705 alone or in combination with pravastatin, atorvastatin or 
simvastatin is well tolerated and did not demonstrate any drug-related trends in CV AEs, 
changes in blood pressure or ECGs in phase 2 trials of patients with type II hyperlipidemia 
including subjects with CHD and other CHD risk equivalents. Further large-scale studies 
are required to assess the effect of CETP inhibition with R1658/JTT-705 on CV mortality 
and morbidity.
2:00 p.m.
1028-167 Safety Profile of the Cholesteryl Ester Transfer Protein 
Inhibitor R1658/JTT-705 in Patients with Type II 
Hyperlipidemia or Coronary Heart Disease
Evan A. Stein, David Kallend, Brendan Buckley, Metabolic & Atherosclerosis Research 
Center, Cincinnati, OH
Background: While cholesteryl ester transfer protein (CETP) inhibitors are effective agents 
to raise high-density lipoprotein cholesterol levels, their development has come under 
intense scrutiny since the discontinuation of torcetrapib. New CETP inhibitors without the 
apparent toxicity of torcetrapib are in development. This analysis reports safety data for 
R1658/JTT-705.
Methods: A pooled analysis to evaluate all adverse events (AEs) from four phase 2a 
clinical trials in 546 patients with type II hyperlipidemia or coronary heart disease (CHD) 
or CHD risk equivalents receiving R1658/JTT-705 (n=343) or placebo (PL; n=203) was 
conducted. Patients received doses of 300, 600 or 900 mg of R1658/JTT-705 per day for 
4 weeks either as monotherapy (1 study) or 300 or 600 mg in combination with a statin 
(3 studies). Safety data from a phase 2b 12-week combination study with pravastatin 
where patients received 300, 600 or 900 mg of R1658/JTT-705 (n=218) or PL (n=74) were 
analyzed separately. Vital signs including blood pressure (BP) were also analyzed.
Results: Pooled data from the 4-week studies showed the incidence of AEs was similar 
between PL (86 patients, 42.4%) and R1658/JTT-705 dose groups, and there were no 
dose trends with respect to the incidence of AEs (300 mg: 50 patients, 49.5%; 600 mg: 
80 patients, 41.7%; 900 mg: 29 patients, 58%). All AEs were mild or moderate in intensity, 
with gastrointestinal disorders, headache and dizziness being the most frequent. There 
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was no increased incidence of CHD AEs in R1658/JTT-705 groups compared with PL. 
Six serious AEs were reported (PL: 3; 300 mg: 1; 600 mg: 2); all were considered by 
the investigator to be unlikely to be related or unrelated to treatment. There was one 
withdrawal due to an AE (headache) considered by the investigator to be possibly related 
to the study drug. There were no deaths. BP remained stable over the study period, and 
there were no clinically significant findings from laboratory tests. Data from the 12-week 
study showed similar findings.
Conclusions: R1658/JTT-705 (at doses of up to 900 mg/day), either alone or in 
combination with statins, was safe and well-tolerated and showed no increase or trend 
towards increase in BP in phase 2 trials.
2:00 p.m.
1028-168 Safety Profile of Extended-Release Niacin/Laropiprant 
in Patients With Dyslipidemia
James McKenney, Harold Bays, Michael J. Koren, Christie Ballantyne, Darbie 
Maccubbin, Yale Mitchel, Abigaile Betteridge, Olga Kuznetsova, Aditi Sapre, Christine 
McCrary Sisk, John F. Paolini, Virginia Commonwealth University, Richmond, VA, Merck 
Research Laboratories, Rahway, NJ
Background: Niacin has proven lipid-modifying efficacy and cardiovascular benefit but is 
underutilized, mainly due to flushing. Laropiprant, a selective prostaglandin D2 receptor 
(DP1) antagonist, reduces niacin-induced flushing. We evaluated the safety profile of 
extended-release niacin/laropiprant (ERN/LRPT). 
Methods: Data were pooled from 3 active- or placebo-controlled Phase III studies and 
3 Phase II 1-year safety extensions, comprising 4747 patients exposed to ERN/LRPT 
(n=2548), ERN (n=1268), or simvastatin/placebo (n=931). The studies ranged from 12 
to 52 weeks.
Results: ERN/LRPT had a safety profile similar to that of ERN (Table). There were fewer 
adverse events and discontinuations due to flushing with ERN/LRPT vs. ERN. The 
incidence of consecutive ≥3 x ULN increases in ALT and/or AST was low and similar 
across the groups; elevations were reversible with therapy discontinuation and not 
associated with clinical hepatotoxicity. There was no evidence that ERN/LRPT had an 
adverse effect on muscle. Two cases of myopathy occurred (one each in the ERN and 
ERN/LRPT groups); both were associated with unusually high levels of physical activity. 
ERN/LRPT and ERN produced small increases in fasting blood glucose levels (~4 mg/
dL), consistent with known effects of niacin.
Conclusions: The favorable safety and tolerability profile of ERN/LRPT for up to 12 months 
supports the use of LRPT to achieve the optimal therapeutic dosing of niacin, an agent 
shown to reduce cardiovascular risk. 
Safety Parameter
SIMVA/
Pbo 
N=931
ERN 
N=1268
ERN/LRPT 
N=2548
Drug-related* AEs (n [%]) 156 (16.8) 501 (39.5) 901 (35.4)1,2
Drug-related* serious AEs (n [%]) 1 (0.1) 1 (0.1) 8 (0.3)3,4
Discontinuations due to drug-related* AEs (n [%]) 28 (3.0) 204 (16.1) 328 (12.9)1,2
Pre-specified parameters of interest:
Confirmed adjudicated cardiovascular events (n/N 
[%])
3/931 
(0.3)
5/1268 
(0.4)
8/2548 
(0.3)5,6
Consecutive or presumed consecutive ALT/AST 
elevations >3 x ULN (n/N [%])
8/920 
(0.9)
6/1221 
(0.5)
25/2465 
(1.0)5,6
Drug-related hepatitis (n) 0 0 0
Myopathy** (n/N [%]) 0 1/1221 (0.08)
1/2465 
(0.04)5,6
CK elevations >10 x ULN (n/N [%]) 2/920 (0.2)
2/1221 
(0.2)
7/2465 
(0.3)5,6
New onset diabetes§ (n/N [%]) 1/888 (0.1)
3/1094 
(0.3)
12/2276 
(0.5)5,6
AE=adverse events; SIMVA=simvastatin; Pbo=placebo; ERN=extended-release niacin; 
ERN/LRPT=extended-release niacin/laropiprant; ALT/AST=alanine aminotransferase 
and/or aspartate aminotransferase; ULN=upper limit of normal; CK=creatine kinase 
*Determined to be possibly, probably, or definitely drug-related by the investigator. 
**Defined as CK ≥10 x ULN with muscle symptoms and considered drug-related by the 
investigator. 
§Based on clinical AEs and/or change in medication. 
195% CI for difference with ERN does not include 0. 
295% CI for difference with SIMVA/Pbo does not include 0. 
395% CI for difference with ERN includes 0. 
495% CI for difference with SIMVA/Pbo includes 0. 
5Not significantly different from ERN based on exposure-adjusted analysis. 
6Not significantly different from SIMVA/Pbo based on exposure-adjusted analysis.
2:00 p.m.
1028-169 Influence of the Menstrual Cycle on the Circulating 
Level of Endothelial Progenitor Cells in Women - 
Possible Regulation by Estrogens
Caroline Lemieux, Isabelle Cloutier, Jean-François Tanguay, Montreal Heart Institute, 
Montreal, QC, Canada, University of Montreal, Montreal, QC, Canada
Background: Estrogen benefits on women’s cardiovascular health have been studied for 
decades and recently, the implication of endothelial progenitor cells (EPCs) in estrogen-
induced cardiac repair has generated great interest. Still, it remains unknown if estrogen 
naturally modulates level of circulating EPCs (cEPCs) in women. Therefore, we evaluated 
level of cEPCs in women during phases of the menstrual cycle. Methods: For this study, 
10 women (30,8 ± 2,3 years) and 10 men (28,9 ± 1,9 years), as reference subjects, 
have been enrolled. In women, peripheral blood samples were collected at the following 
menstrual cycle phases: 1) menstrual, day 1-5 2) follicular, day 6-14 and, 3) luteal, day 
15-28 corresponding to low, high and intermediate blood level of 17β-estradiol (17βE) 
respectively. In men, peripheral blood samples were collected three times within a month 
period. The level of cEPCs was evaluated by flow cytometry. Data are expressed as mean 
± SEM. Results: Analysis shows that in women, level of CD133+/CD34+ progenitor cells/
ml of blood is significantly modulated during the menstrual cycle. It is low during menses 
(32 ± 8) and markedly increased during the follicular (66 ± 17) and luteal phase (56 
± 9) (P = 0.0163). Accordingly, levels of CD133+/CD34+/VEGFR-2+ cEPCs were also 
significantly modulated during the menstrual cycle going from 27 ± 6 during menses 
to 45 ± 12 and 44 ± 7 cells/ml of blood (P = 0.0221) during the follicular and the luteal 
phases respectively. Those increases correlate with the raise in 17βE blood levels which 
were 195 ± 50 pmol/L during menses, 655 ± 176 during the follicular phase and 584 ± 48 
during the luteal phase. The mean global levels of circulating CD133+/CD34+ progenitor 
cells and CD133+/CD34+/VEGFR-2+ cEPCs are 72% and 110% higher in women than in 
men respectively. Conclusion: Our results clearly demonstrate that cEPCs level fluctuate 
during the menstrual cycle in a predictable pattern. Since the number of cEPCs increases 
with 17βE blood level, it can be proposed that 17βE strongly regulates level of cEPCs in 
women during their reproductive years. Such regulation by 17βE in women may partially 
explain the lower prevalence of cardiovascular events at middle age compared with men.
2:00 p.m.
1028-170 Progression of Coronary Atherosclerosis in Statin 
Treated Patients with Hypertriglyceridemia
John M. Galla, Kellan E. Ashley, E. Murat Tuzcu, Danielle Brennan, Steven E. Nissen, 
Stephen J. Nicholls, Cleveland Clinic, Cleveland, OH
Background: The role of hypertriglyceridemia (HTG) in cardiovascular disease is 
uncertain. Triglycerides promote a number of events implicated in atherogenesis. This 
analysis investigated the progression of coronary atherosclerosis in patients with HTG.
Methods: 1897 statin-treated patients with angiographic coronary artery disease in 
clinical trials that evaluated changes in atheroma burden by intravascular ultrasound 
(REVERSAL, ASTEROID, NORMALISE, ACTIVATE, ILLUSTRATE) were investigated. 
Patients stratified according to the prevalence of HTG at baseline (TG ≥ 150 mg/dL) were 
compared with regard to clinical characteristics and changes in atheroma burden.
Results: HTG patients (n=913) were younger (57±9 v 59±10 years, p<0.001), had a higher 
body mass index (31±6 v 29±5 kg/m2, p<0.001), a greater history of diabetes (23 v 16%, 
p<0.001), hyperlipidemia (83 v 69%, p<0.001) and coronary intervention (59 v 50%, 
p<0.001) and were more likely to be treated with a beta-blocker (79 v 73%, p=0.007). On-
treatment levels of LDL-C (89±28 v 85±24 mg/dL, p=0.007), CRP (2.2 v 1.6 mg/dL, p<0.001) 
and systolic blood pressure (130±14 v 128±14 mmHg, p<0.001) were greater and HDL-C 
levels less (42±10 v 48±11 mg/dL, p<0.001) in HTG patients. Baseline values of percent 
atheroma volume (PAV, 39.0±9.7 v 39.2±9.5%, p=0.63) and total atheroma volume (TAV, 
193±83 v 192±83 mm3, p=0.79) were not greater in HTG patients. However, HTG patients 
demonstrated a greater increase in PAV (0.7±4.2 v 0.1±3.6%, p=0.001) and less reduction 
in TAV (-1.9±27 v -5.4±24 mm3, p=0.008) in comparison with non-HTG patients. A greater 
proportion of HTG patients underwent substantial plaque progression (>5% increase in PAV, 
35 v 25%, p<0.001). After adjusting for differences in clinical characteristics on multivariate 
analysis, the presence of HTG at baseline was not found to be an independent predictor of 
increased progression of either PAV (p=0.19) or TAV (p=0.10).
Conclusions: Increased plaque progression in patients with HTG is likely to reflect the 
prevalence of an atherogenic risk factor profile. These results support the need for more 
intensive modification of global risk in patients with coronary artery disease and HTG.
2:00 p.m.
1028-171 Adiponectin, E-Selectin, and Risk of Type 2 Diabetes in 
Patients with Stable Coronary Disease
Jessica L. Mega, David A. Morrow, Madeline M. Rice, Kathleen A. Jablonski, Eugene 
Braunwald, Marc S. Sabatine, Brigham & Women’s Hospital, Boston, MA
Introduction: The link between inflammation, including hs-CRP, and diabetes mellitus 
(DM) has been described. However, the independent ability of multiple inflammatory 
markers to predict the development of DM has not been well-characterized.
Methods: We examined adiponectin, E-selectin, and hs-CRP in a case-cohort design 
that included 341 cases of incident DM and a sub-cohort of 673 patients, within PEACE, 
a randomized trial of trandolapril vs placebo in stable CAD patients followed for a 
median of 4.8 y.
Results: Adiponectin (median 8.83, IQR 8.45-9.23 mg/L) and E-selectin (median 3.43, 
IQR 3.13-3.68 ng/L) correlated only weakly with each other and BMI (|r|<0.25 for each). 
Patients with lower adiponectin and those with higher E-selectin were younger and more 
likely to be male and have a higher BMI (P<0.001 for each). After adjusting for clinical 
characteristics, individually both adiponectin (P<0.001; Fig, left) and E-selectin (P<0.001; 
Fig, middle) remained significant predictors of DM. In a multivariable model, including 
adjustment for hs-CRP, adiponectin <median (adj HR 2.16, P<0.001) and E-selectin 
>median (adj HR 1.71, P<0.001) remained significant predictors of DM (Fig, right). 
Conclusion: Adiponectin and E-selectin, biomarkers of specific inflammatory pathways, 
are significant predictors of incident DM in patients with stable CAD, independent of each 
other and hs-CRP. These data further support the role of inflammation in DM and provide 
insight into potentially relevant pathobiology.
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2:00 p.m.
1028-172 Measurement of clopidogrel resistance by ADP-
inhibition does not reflect the benefit of clopidogrel on 
overall thrombotic status
Diana A. Gorog, Smriti Saraf, Imen Ben Salha, Sumeet Sharma, Waqar Saleem, 
Imperial College, London, United Kingdom, East & North Hertfordshire NHS Trust, 
Welwyn Garden City, United Kingdom
Background: Clopidogrel [C], an ADP (P2Y12) receptor inhibitor, is used to prevent arterial 
thrombotic events. Clopidogrel resistance has been reported in up to 40% of patients, yet 
the laboratory phenomenon of [C] resistance has not been shown to translate directly into 
an increase in thrombotic events.
Clopidogrel resistance has traditionally been measured by antagonism to ADP-induced 
platelet activation. However, [C] also affects other important contributors to thrombosis 
such as thrombin generation and fibrin formation.
We aimed to assess the specific inhibitory effect of [C] on ADP-induced platelet activation 
and compare this to the effect of [C] on overall thrombotic status.
Methods: To assess the effect of clopidogrel in normal volunteers, we used a novel 
technique (GTT, Montrose Diagnostics Ltd, UK), which quantifies shear-induced occlusive 
thrombus formation from native blood (occlusion time, OT) and also detects thrombolysis. 
Thrombin generation by platelets plays an important part in this technique. To assess the 
effect on ADP-induced platelet activation, in another channel of the instrument, a small 
volume of water was added downstream of the shear site to expose activated platelets to 
ADP released by haemolysis (accelerated occlusion time, aOT).
Results: GTT sensitively detected the effect of [C] by significantly prolonging OT in all 
subjects (352 vs. 453 s, p=.001).
The aOT was markedly shorter than the native OT (142 vs. 352 s, p=.0007). Clopidogrel 
also prolonged aOT (142 vs. 354 s, p=.01). However, the effect of [C] on ADP-induced 
platelet activation (aOT) was variable and did not correlate with the overall improvement 
in thrombotic status (OT).
Conclusions: The beneficial effect of [C] on global thrombotic status cannot be inferred merely 
from its specific effect on ADP-induced platelet activation. Thus, measurement of global 
thrombotic status may provide a more clinically meaningful assessment of [C] therapy.
2:00 p.m.
1028-173  Transmural Myocardial Strain Profile is A Useful 
Method to Estimate the Regional Myocardial Damage 
after Reperfused ST Elevation Acute Myocardial 
Infarction: A Comparison with Tc-99m Sestamibi Single 
Photon Emission Computed Tomography
Noriaki Iwahashi, Kazuo Kimura, Jun Okuda, Kengo Tsukahara, Yoshio Tahara, Kiyoshi 
Hibi, Masami Kosuge, Toshiaki Ebina, Shinichi Sumita, Toshiyuki Ishikawa, Kazuaki 
Uchino, Satoshi Umemura, Yokohama City University Medical Center, yokohama, Japan
Background: Evaluation of myocardial damage after acute myocardial infarction(AMI) is 
important. Angle corrected short-axis tissue Doppler echocardiography(TDI-Q, Toshiba) 
can assess tissue strain imaging (TSI) including its profile(TMSP). It was reported 
as new tool to estimate transmural distribution of viable myocardium in AMI (Am J 
Physiol.2007;292,921). The aim of this study was to evaluate the relationship between TSI 
parameters and myocardial perfusion by Tc-99m sestamibi(MIBI) single photon emission 
computed tomography in case of reperfused AMI.
Methods: 30 inferior ST elevation AMI with successful reperfusion within 12 hours 
were enrolled(CPK2071±1085). Conventional Doppler echocardiography including 
TSI and Tc-99m MIBI were performed 2weeks after onset. Peak systolic radial strain 
of subendocardium(SRendo) and subepicardium(SRepi) and location of peak 
strain(SR%:%distance of wall thickness from endocardium) were obtained. Perfusion was 
estimated by “cardio Bull (Fuji film)”. Regional severity score was a measure of reduction 
in tracer uptake within defined defect area, expressed as the number of standard 
deviations(SDs) of mean value of corresponding area in the normal database.
Results : %SR and SRendo had a significant correlation with SDs of severity score 
(r=0.50, r=0.27, p<0.05). Thus, %SR and SRendo reflected the degree of regional 
perfusion abnormality.
Conclusions: Strain M-mode imaging might be useful to predict the regional myocardial 
damage in reperfused AMI.
2:00 p.m.
1028-174 Can Pioglitazone Reduce In-stent Neointimal 
Proliferation? Prevention Of In-stent Neointimal 
Proliferation By Pioglitazone Study (POPPS)
Tsutomu Takagi, Hiroyuki Okura, Yoshiki Kobayashi, Toru Kataoka, Haruyuki Taguchi, 
Iku Toda, Koichi Tamita, Atsushi Yamamuro, Yuji Sakanoue, Akira Ito, Shiro Yanagi, Kenji 
Shimeno, Katsuhisa Waseda, Masao Yamasaki, Peter J. Fitzgerald, Fumiaki Ikeno, 
Yasuhiro Honda, Minoru Yoshiyama, Junichi Yoshikawa, Takagi Cardiology Clinic, Kyoto, 
Japan, Bell Land General Hospital, Sakai, Japan
Background: Previous single center studies have suggested possible anti-restenotic 
effect of a PPARgamma agonsit, pioglitazone following coronary intervention.The aim 
of this multicenter study was to clarify whether pioglitazone supress in-stent neointimal 
proliferation and reduce in-stent restenosis and target lesion revascularization following 
stent implantation.
Methods: A total of 97 patients with type 2 diabetes mellitus undergoing coronary stent 
implantation were enrolled. After successful stent implantation, patients were randomly 
assigned to either pioglitazone group (group P, n=48) or control group (group C, n=49). 
Angiographical and intravascular ultrasound (IVUS) imaging were performed at baseline 
and repeated at 6 months follow-up. Primary endpoint includes in-stent restenosis and 
target lesion revascularization at 6 months follow-up. Secondary endpoint includes in-
stent neointimal volume by IVUS at 6 months. Angiographical and IVUS analysis was 
performed at an independent core laboratory.
Results: Baseline glucose level and HbA1c level were similar between group P and group C. 
Clinical follow-up data are available in 87 patients (90%). Target lesion revascularization rate 
showed a trend toward lower in group P than in group C (14% vs. 27 %, p=0.13), although the 
difference did not reach statistical significance.By IVUS (n=56), in-stent neointimal volume at 6 
months showed a trend toward smaller in group P than in group C (48.0+-30.2 vs. 62.7+-29.0 
mm3, p=0.07). %neointimal volume (neointimal volume / stent volume x 100) was significantly 
smaller in group P than in group C (31.1+-14.3 vs. 40.5+-12.9 %, p=0.01).
Conclusions: Pioglitazone treatment may supress in-stent neointimal proliferation and 
possibly reduce incidence of target lesion revaszularization after stent implantation.
2:00 p.m.
1028-175 Short-term Treatment with Dextromethorphan 
Attenuated Endothelial Dysfunction, Inflammation, and 
Oxidative Stress in Healthy Male Smokers
Ping-Yen Liu, Chih-Chan Lin, Wei-Chaun Tsai, Yi-Heng Li, Li-Jen Lin, Jyh-Hong Chen, 
Jau-Shyong Hong, Hua-Lin Wu, National Cheng-Kung University Medical Center, 
Tainan, Taiwan,ROC
Objective: This study examined the effects of dextromethorphan (DM) on the vascular 
markers of inflammation and endothelial functions in healthy smokers.
Background: DM, an ingredient widely used in antitussive remedies, is reported to reduce 
the inflammation-mediated degeneration of dopaminergic neurons by inhibiting microglial 
activation. Higher serum inflammatory levels and endothelial dysfunction were found in 
smokers and high-risk cardiovascular patients. Thus, we hypothesized that DM has an 
anti-inflammatory effect that provides cardiovascular protection in healthy smokers.
Methods: Forty healthy male volunteers (mean age, 31.5 ± 1.4 years) who were habitual 
smokers were randomly given either DM (120 mg/day) or a placebo in a double-blinded 
6-month study. We determined endothelial function using the changes in flow-mediated 
diameter (FMD). Inflammatory and oxidative markers presented in serum, plasma and 
urine were also measured.
Results: During the 6-month clinical trial, FMD increased significantly (from 6.2 ± 1.8 to 8.2 
± 2.4%, p < 0.01) in the DM-treated smokers group, whereas no significant change was 
observed in the placebo-treated smokers group (from 6.3 ± 2.1 to 6.1 ± 1.9%, p > 0.05). Levels 
of plasma glutathione peroxidase, an antioxidant enzyme, significantly increased (from 25.6 
± 10.8 to 27.4 ± 12.5 mg/ml, p = 0.01), and the urinary excretion of 8-epi-prostaglandin 
F2a, a free radical-catalyzed product from the oxidative modification of arachidonic acid, 
significantly decreased (from 1300 ± 658 to 1247 ± 523 pg/mg of creatinine, p = 0.01). 
Significant reductions in serum levels of high-sensitivity C-reactive protein, phospholipase 
A2, matrix metalloproteinase-3, interleukin 6, and tumor necrosis factor-α receptor II (all p 
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< 0.01) were observed only in those 6-month DM-treated smokers.
Conclusion: Using DM for 6 months significantly improved endothelial function and 
attenuated oxidative stress and inflammation in healthy smokers.
2:00 p.m.
1028-176 Safety of Alternate-day Plavix in Dual Antiplatelet 
Therapy After Drug-Eluting Stent Implantation in 
Patients on Long-Term Anticoagulation
Mohammed W. Akhter, Sharad Kothari, Prabhakara B. Kunamneni, Pramod 
Krishnamurthy, Pedro R. Moreno, Michael C. Kim, Prakash Krishnan, Samin K. Sharma, 
Annapoorna S. Kini, Cardiovascular Institute, Mount Sinai Medical Center, New York, NY
Background: Dual antiplatelet therapy with daily Aspirin (ASA) and Plavix after drug-eluting 
stent (DES) implantation in patients who require long-term warfarin for clinical indications 
is associated with increased bleeding. Currently there is no consensus regarding an 
optimal strategy for combination antiplatelet therapy in chronically anticoagulated patients. 
Since Plavix has a long half-life (>24hrs) we propose a modified regimen with ASA 81mg 
daily and Plavix 75mg on alternate days plus warfarin adjusted to the target INR.
Methods: In a single-center retrospective analysis 550 consecutive patients on chronic 
warfarin undergoing DES implantation from May 2003 to May 2007 were studied. We 
compared 1-year incidence of vascular complications, bleeding, stent thrombosis and 
MACE (coronary revascularization, non-fatal myocardial infarction and death) in patients 
given ASA and Plavix daily versus those receiving ASA daily and Plavix on alternate days.
Results: At one year the vascular complications, TIMI minor bleeding, myocardial infarction 
(MI) and MACE were significantly lower in the alternate-day Plavix group. There was no 
difference between the groups with regards to incidence of stent thrombosis, target lesion 
revascularization and death.
Conclusions: In patients on chronic anticoagulation with warfarin, dual antiplatelet 
therapy with low dose daily ASA and alternate-day Plavix is superior to daily combination 
antiplatelet therapy, with reduced risk of bleeding, MI and MACE. 
Variables
Coumadin + ASA 
daily and Plavix 
alternate days 
(n=355)
Coumadin + ASA & Plavix daily 
(n=195) P
TIMI major bleeding % 1.1 1.0 NS
TIMI minor bleeding % 3.4 9.2 <0.01
Stent thrombosis % 1.4 2.7 0.34
Myocardial infarction % 1.1 5.6 <0.01
TLR % 7.0 9.2 0.41
Death % 4.5 5.6 0.54
MACE % 12.1 21.0 <0.01
MACE + Bleeding % 16.6 31.3 <0.001
2:00 p.m.
1028-177 In Type 2 Diabetes, an Incremental Rise in Big 
Endothelin-1 is Associated with the Metabolic 
Syndrome Independently of Coronary Artery Disease
Michel P. Hermans, Sylvie A. Ahn, Michel F. Rousseau, University of Louvain, Brussels, 
Belgium
Background: Key vascular tone modulators, including Big Endothelin-1 (Big ET-1), are 
regulated by insulin, and therefore insulin resistance (IR) and/or hyperinsulinemia may 
be involved in the pathogenesis of cardiovascular diseases. Imbalance in ET-1/nitric oxide 
may link IR to coronary artery disease (CAD). The relation between Big ET-1, metabolic 
syndrome (MetS) categories (1-5/5) and type 2 diabetes (T2DM) is poorly documented. 
We therefore investigated the relationship between Big ET-1, HOMA-insulin sensitivity 
(HOMA-S), MetS and CAD in a large T2DM cohort.
Methods: We assessed MetS categories, HOMA-S, circulating Big ET-1 and CAD 
[CAD(+)/(-)] in 458 consecutive T2DM patients with or without MetS [MetS (+)/(-)] defined 
according to AHA/NHLBI.
Results: CAD prevalence was 52% (MetS (+)) and 45% (MetS(-)). Big ET-1 was higher by 
29% in MetS (+) (median [IQ range]): 5.2 [4.3-6.0] in MetS (-) (n=75) vs. 6.7 [5.2-9.1] pg/
mL in MetS (+) (n=383; p<0.0001). There was an incremental rise in Big ET-1 across MetS 
scores: 6.3 [5.2-8.5] in MetS (+) 3/5; 6.9 [5.1-9.4] in MetS (+) 4/5 and 7.3 [5.6-9.5] pg/mL 
in MetS (+) 5/5 (NS). The stepwise difference in Big ET-1 between MetS (+) and MetS (-) 
was observed both in the absence or presence of CAD: 4.7 [4.5-5.5] in MetS (-) CAD (-) 
vs. 6.0 [4.8-7.8] in MetS (+) CAD (-) (p<0.0001), and 5.8 [5.2-7.6] in MetS (-) CAD (+) vs. 
7.7 [5.8-10.3] pg/mL in MetS (+) CAD (+) (p<0.007), respectively. Comparison between 
MetS (+) CAD (-) vs. MetS (-) CAD (+) confirmed that such incremental differences were 
not ascribable to parallel shifts in HOMA-S and/or compensatory hyperinsulinaemia.
Conclusions: Big ET-1 levels are raised in T2DM patients with MetS, and these levels 
proceed stepwise to MetS categories. Elevated Big ET-1 is present in all categories of 
MetS patients, with or without CAD. Elevated Big ET-1 levels found in MetS patients 
without CAD were of the same magnitude as those conferred by the presence of CAD in 
the absence of MetS. Therefore, Big Et-1 is destined to become a simple emerging risk 
marker for assessing cardiovascular status in patients with MetS.
2:00 p.m.
1028-178 Antihypertensive effect of Angiotensin Receptor 
Blockers vs. other classes of antihypertensives in 
United Kingdom primary care
Peter Sharplin, George Chamberlain, Clodagh Beckham, Nicolas Wisniacki, Cardiff 
Research Consortium Ltd, Cardiff, United Kingdom, sanofi-aventis / Bristol Myers 
Squibb, Guildford, United Kingdom
Background: To explore the use of Angiotensin Receptor Blockers (ARBs) in BP reductions 
compared to other antihypertensive classes in UK primary care.
Methods: We analysed the records of 158,995 patients, greater than 18 years of age, with 
hypertension who were initiated on anti-hypertensive therapy between 1998 and 2006 using 
the UK THIN general practice database. Antihypertensive agents were identified by class: 
ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), Calcium Channel Blockers, Beta 
Blockers, and Diuretics. Hypertension was defined as a SBP reading >=140 mmHg or DBP 
>=90 mmHg. Two analytical comparisons were made: 1) for patients on ARB monotherapy 
over the first sixteen quarters of treatment vs. all other monotherapies, and 2) for patients 
receiving ARBs at any stage of their treatment pathway vs. those that don’t.
Results: In monotherapy, patients’ mean SBP reductions reached 18.5 mmHg for ARB 
monotherapy vs. 10-15.5 mmHg for the alternative classes. This difference is statistically 
significant (p<0.0001) in a multivariate analysis after adjusting for baseline blood pressure 
levels, age, sex, weight, and type of and number of co-therapies prescribed. Furthermore, 
the probability of patients achieving BP target was 21.1% greater in those patients taking 
ARBs vs. other agents (p=0.006).
Across all treatment pathways, patients’ mean SBP reductions reached 17mmHg for 
ARB inclusive pathways vs. 14mmHg for non ARB pathways. Multivariate analysis was 
conducted as per above and the probability of patients reaching target in the first year of 
treatment was 23.6% higher in the ARB containing pathways than in non ARB pathways 
(P<0.0001 in both cases).
Conclusions: In a real world setting, ARBs were shown greater blood pressure lowering 
compared to other antihypertensive classes, whether as a single agent or when 
considered in the context of ARB vs. non ARB containing treatment pathways.
2:00 p.m.
1028-179 Reappraisal of the Role of Uric Acid in Essential 
Hypertension: Cross-Sectional Relationships With 
Subclinical Inflammation, Adiponectin and Arterial 
Stiffness
Kyriakos Dimitriadis, Costas Tsioufis, Maria Selima, Dimitris Tsiachris, Dimitris 
Soulis, Aliki Gennadi, Christodoulos Stefanadis, Ioannis Kallikazaros, Department of 
Cardiology, Hippokration Hospital, Athens, Greece
Background: Elevated uric acid (UA) levels are associated with enhanced cardiovascular 
risk. In this study, we investigated the relationships between serum UA levels, high-
sensitivity C-reactive protein (hs-CRP), adiponectin and arterial stiffness in essential 
hypertensives.
Methods: In our population of 292 newly diagnosed untreated non-diabetics with stage I 
to II essential hypertension [190 men, aged 50 years, office blood pressure (BP)=148/95 
mmHg], the distribution of UA was split by the median (5.3 mg/dl) and accordingly subjects 
were classified into those with high and low values. In all subjects, arterial stiffness was 
evaluated on the basis of carotid to femoral pulse wave velocity (PWV), by means of a 
computerized method (Complior SP).
Results: Patients with high UA (n=143) compared to those with low UA (n=149) exhibited 
higher 24-h systolic BP (139±12 vs 132±11 mmHg, p<0.0001) and left ventricular 
mass index (112.5±11 vs 104.3±14 g/m2, p<0.05), while did not differ regarding age, 
body mass index and lipid profile (p=NS). Those with high UA compared to those with 
low UA had increased levels of hs-CRP (3.1±1.4 vs 2.3±1.2 mg/l, p<0.05) and PWV 
(8.7±1.2 vs 7.9±1.2 m/sec, p<0.05), whereas exhibited lower adiponectin (8.1±2.4 vs 
9.7±2.8 µg/ml, p<0.05). In the total population, UA was associated with 24-h systolic 
BP (r=0.297, p<0.0001), triglycerides (r=0.236, p<0.0001), hs-CRP (r=0.204, p=0.001), 
PWV (r=0.165, p=0.009) and adiponectin (r=-0.218, p<0.0001). Furthermore, hs-CRP 
was correlated with PWV (r=0.233, p<0.0001), and adiponectin (r=-0.193, p=0.001). In 
multiple regression analysis, 24-h systolic BP (b=0.246, p=0.001), hs-CRP (b=0.142, 
p<0.05) and adiponectin (b=-0.154, p<0.05) were independent predictors of UA. Analysis 
of covariance revealed that hs-CRP, PWV and adiponectin values were significantly 
different between groups after adjustment for confounders (p<0.05).
Conclusion: Increased UA levels in essential hypertension are paralleled by a state of 
pronounced inflammatory activation, hypoadiponectinemia and arterial stiffening. These 
findings underscore the pluripotent nature of UA in the progression of the hypertensive 
atherosclerotic disease.
2:00 p.m.
1028-180 Parallel Abnormalities in Circadian Blood Pressure 
Variation, Erectile Function and Left Ventricular 
Adaptations in Male Hypertensives
Apostolis Kakkavas, Costas Tsioufis, Dimitris Tsiachris, Kyriakos Dimitriadis, Maria 
Selima, Efstathios Taxiarchou, Christodoulos Stefanadis, Ioannis Kallikazaros, 
Department of Cardiology, Hippokration Hospital, Athens, Greece
Background: Ambulatory blood pressure (ABP) exhibits strong correlation with target 
organ damage while erectile dysfunction (ED) reflects diffuse vascular damage. Our aim 
was to investigate the association between circadian blood pressure (BP) variation, ED 
and cardiac adaptations in hypertensive males.
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Methods: 129 consecutive, newly diagnosed, stage I-II hypertension, males (aged 50.6 
years, office BP=151/98mmHg) underwent ABP monitoring and classified into dippers 
(n=71) and non-dippers (n=58). All subjects were non-diabetics and without clinical 
evidence of atherosclerotic disease. By means of International Index of Erectile Function 
score (IIEF score) hypertensives were divided into those with ED (IIEF score<26, n=40, 
31%) and those without ED (IIEF score≥26, n=89, 69%). Left ventricular hypertrophy 
(LVH) was defined as left ventricular mass index ≥116g/m2 and diastolic function was 
evaluated by means of conventional Doppler and tissue Doppler imaging (TDI).
Results: Among hypertensive men, non-dippers compared with dippers were older (52±9 
vs 49±7 years, p<0.05), whereas there was no difference in smoking status and body 
mass index. Regarding haemodynamic load, non-dippers had significantly greater night 
systolic and diastolic BP (128 vs 116 mmHg, and 79 vs 72, respectively, both p<0.001) 
and night pulse pressure (49 vs 44 mmHg, p=0.001). Non dippers compared with dippers 
exhibited lower IIEF score (25 vs 27.3, p=0.008), a higher prevalence of ED (40.8% 
vs 20%, p=0.008), a higher prevalence of LV hypertrophy (19.7% vs 7%, p<0.05) and 
significantly decreased TDI-derived Em and Em/Am ratio (7.1 vs 8 cm/s, and 0.69 vs 0.8, 
respectively, both p<0.05). Non-dipping status was positively correlated with ED (r=0.235, 
p=0.007), night pulse pressure (r=0.331, p<0.001) and negatively correlated with Em and 
Em/Am (r=-0.218 and r=-0.207, both p<0.05).
Conclusions: In newly diagnosed hypertensive males, abnormalities in circadian BP 
variation are closely interrelated with erectile function and LV structure and function. 
Increased haemodynamic load associated with non-dipping status seems to be an 
important factor in the interpretation of cardiovascular risk in hypertensives with ED.
2:00 p.m.
1028-181 Assessment Of Angiopoietin 1 and Angiopoietin 2 gene 
expression in peripheral monocytes After angiotensin-
converting enzyme inhibition treatment in hypertensive 
patients
Maria Marketou, Joanna Kontaraki, Evangelos Zacharis, Evangelos Zacharis, George 
Kochiadakis, Elias Saloustros, Dimitris Arfanakis, Panos Vardas, Heraklion University 
Hospital, Heraklion, Greece
Background: Angiopoietins (Ang) are significant angiogenic and endothelial cell growth 
factors and are related with an increased risk of atherogenesis and target organ damage 
in hypertension. We investigated the effect of perindopril - a long-acting angiotensin-
converting enzyme inhibitor (ACE-i) - on Ang1 and Ang2 gene expression in peripheral 
monocytes in patients with essential hypertension.
Methods: We recruited 32 previously untreated patients with essential hypertension 
(22 male, aged 65±10 years) who were randomly assigned to receive treatment with 
either perindopril (n= 17) or atenolol (n= 15), achieving a mean blood pressure below 
140/80 mmHg. Blood samples were taken before and 3 months after therapy initiation. 
Mononuclear cells were isolated using anti-CD14+ antibodies and mRNAs were estimated 
by real-time quantitative reverse transcription-PCR and expressed as fold induction.
Results: Both treatments reduced all blood pressure components significantly (p < 0.001). 
In contrast with atenolol group, Ang1 gene expression was significantly downregulated 
after treatment with perindopril (fold induction in perindopril group 0.8±0.69 versus 
1.50±1.67 in the atenolol group, p= 0.01). Ang2 gene expression did not show any 
significant difference between the two groups (fold induction in perindopril group 
10.6±13.1 versus 12.2±15.4 in the atenolol group, p= 0.18).
Conclusions: Treatment with perindopril results in a significant attenuation in Ang1 
expression in hypertension patients. Our findings may provide new insights into the 
benefits and cardiovascular protection of ACE-i in hypertensive patients.
2:00 p.m.
1028-182 Clinical Outcomes in Patients with Advanced Limb 
Ischemia
Scott J. Haugen, Judith G. Regensteiner, William R. Hiatt, Mark Nehler, Marvin Eng, 
Carlos Rueda, Pamela Strecker, Becki Bucher-Bartelson, Ivan P. Casserly, Denver VA 
Medical Center, Denver, CO
Background: Estimates of limb and cardiovascular outcomes in patients with advanced 
limb ischemia without evidence of critical limb ischemia (CLI) are poorly defined, and 
based on older data from small series of patients.
Methods: A retrospective review of patients referred to the vascular lab at the Denver 
VA Medical Center from January 1999 to September 2006 was performed. Patients with 
advanced limb ischemia were identified using the following criteria: a) ABI </=0.60 and/or 
toe pressure </=50 mmHg, b) absence of current or prior diagnosis of CLI in either lower 
extremity, c) absence of terminal illness, d) age </=85 years-old. Review of the electronic 
medical record was used to assess clinical outcomes.
Results: A total of 114 patients with 153 affected limbs were identified. Follow-up was 
available in all patients with mean follow-up duration of 2.8 years. Kaplan-Meier analysis 
of event-free survival from (A) major adverse cardiovascular events (MACE) and (B) CLI 
are shown in the Figure. The 5-year freedom from MACE and CLI were 54.2% (95% CI 
39.6-68.8%) and 65.1% (95% CI 47.6-82.6%), respectively. Diabetes mellitus was not 
significantly associated with development of CLI in this cohort.
Conclusions: This large contemporary analysis demonstrates that the diagnosis of 
advanced limb ischemia is associated with significant cardiovascular morbidity and a 
higher rate of progression to CLI than has been reported for the general population with 
claudication. 
2:00 p.m.
1028-183 Effect of selective serotonin reuptake inhibitors 
(SSRI) on TNFa-induced expression of cell adhesion 
molecules in endothelial cells
John Lekakis, Ignatios Ikonomidis, Zoi Papoutsi, Anastasia Moutsatsou, Dimitrios T. 
Kremastinos, University of Athens, Attikon Hospita, Athens, Greece
Background: The use of Selective serotonin reuptake inhibitors (SSRIs) improves 
endothelium- dependent vasodilation in patients with CAD and depression.We examined 
the effect of SSRIs on the endothelial cell expression of adhesion molecules , an early 
step in atherogenesis.
Methods: The effect of citalopram, fluvoxamine and fluoxetine (SSRIs) on TNF-a -induced 
expression of vascular cell adhesion molecule (VCAM-1) and intracellular adhesion 
molecule (ICAM-1) in human aorta endothelial cells(HAEC) was examined.Cells were 
incubated for 24 hours with different concentrations( 1-100µM) of SSRIs.€he last 6 hours 
of incubation TNF-a was added. A-Tocopherol ( 20µM) was used as positive control. 
Following incubation ,surface expression of adhesion molecules ICAM-1 and VCAM-1 
was quantified by cell ELISA.
Results: A-Tocopherol,as expected ,decreased the TNF-a -induced endothelial expression 
of both VCAM-1 and ICAM-1(p<0.001). Citalopram , fluoxetine and fluvoxamine 
decreased the TNF-a-induced endothelial expression of VCAM-1 at concentration range 
1-100µM (p<0.001,Fig 1). Fluvoxamine (p<0.001)and fluoxetine (p<0.01) decreased the 
TNF-a-induced endothelial expression of ICAM-1 at concentration range 1-100µM, while 
citalopram decreased ICAM-1 at concentrations 1µM and 10µM (p<0.01) .
Conclusion: SSRIs exhibit anti-inflammatory activity on human aortic endothelial cells 
and merit further investigation to identify their role in the inflammatory process of 
atherogenesis. 
2:00 p.m.
1028-184 N-terminal Pro-Natriuretic Peptide in Patients With 
Preeclampsia
Dong Heon Yang, Sang Hyuk Lee, Tae Bon Goo, Hun Sik Park, Yongkeun Cho, Shung 
Chull Chae, Jae Eun Jun, Wee Hyun Park, Jang Hoon Lee, Kyungpook National 
University Hospital, Daegu, South Korea
Background: N-terminal pro-natriuretic peptide (NT-proBNP) is well-known marker to 
reflect status of the left ventricular (LV) stress. There was rare study on NT-proBNP in 
patients with pregnancy-induced hypertension. The aim of this study is to investigate 
serum levels of NT-proBNP as an index of LV function in patients with preeclampsia. 
Methods: We measured serum levels of NT-proBNP in 35 normotensive pregnant women 
and 34 preeclamptic women. Echocardiographies were performed in 16 women (14 
severe preeclampsia, 1 mild preeclampsia, 1 normotensive). Results: The serum levels 
of NT-proBNP in normotensive, mild preeclamptics, and severe preeclamptics were 
78.7±76.1, 145.3±131.4, and 1036.9±2126.4 pg/mL, respectively, with the severe group 
being significantly higher than the mild group (p=0.015, Fig 1). The NT-proBNP levels 
were positively correlated with systolic blood pressure (r=0.408, p=0.001) and diastolic 
blood pressure (r=0.422, p<0.001). The median LV ejection fraction was 65% (44-73%). 
LogNT-proBNP was negatively correlated with LVEF (r2=0.233, p=0.034). A NT-proBNP 
cut-off of <60 pg/mL had a negative predictive values 84% in excluding preeclampsia 
(Fig 2). Conclusions: Serum levels of NT-proBNP was markedly elevated in patients with 
severe preeclampsia. This may reflect ventricular stress or subclinical cardiac dysfunction 
associated with preeclampsia.
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2:00 p.m.
1028-185 Impact of Prescription of Classes of Antihypertensive 
Medications on Blood Pressure Control in the 
Metabolic Syndrome
Oreste Arcucci, Giovanni de Simone, Raffaele Izzo, Marcello Chinali, Maria AE Rao, 
Francesco Rozza, Nicola De Luca, Bruno Trimarco, Federico II University, Naples, Italy
Background. We have recently reported that metabolic syndrome (MetS) is associated 
with insufficient blood pressure (BP) control, despite use of greater number of combined 
medications. There is no information on whether efficacy of BP control is also associated 
with the classes of prescribed antihypertensive medications in relation to the presence 
or absence of MetS. Thus, we evaluated wether uncontrolled BP in a tertiary-care 
Hypertension Center is related to classes of prescribed drugs, in relation to the presence 
or absence of MetS.
Methods. We studied 4551 hypertensive patients without prevalent cardiovascular 
disease (43.4% women; 51±12 years). MetS was defined according to modified ATPIII-
criteria (no waist girth; BMI≥30 kg/m2). At the last available visit, BP was considered 
uncontrolled when systolic BP≥140mmHg and/or diastolic BP≥90mmHg. Class of 
prescribed medications and their numbers were evaluated in relation to BP control and 
presence of MetS, by logistic regression adjusting for age and sex.
Results: MetS was found in 1444 subjects (32%; 45% women, p=ns vs without MetS). 
BP was less controlled in MetS (p<0.0001), despite the significantly more frequent 
prescription of ACE-inhibitors (ACEi), β-blockers (BB), Ca++-channel blockers (CCB) 
and diuretics (DRT) (all p<0.01). MetS was associated with 41% increased probability of 
uncontrolled BP, whatever drug class was considered (all p<0.0001). When each class of 
medications was tested separately, DRT were less likely (OR=0.83 [95%CI 0.74-0.94]) 
and CCB more likely to be prescribed (OR=1.31 [95%CI 1.15-1.50]; both p<0.005) when 
BP was uncontrolled, without differences in the other classes of drugs (ACEi, ARB, 
BB and alpha+alpha/beta blockers). These results were confirmed in a logistic model 
including all classes of medications. Conclusions: MetS is at high risk of uncontrolled BP, 
despite the use of more antihypertensive medications. Among antihypertensive drugs, 
less prescription of DRT is significantly associated with a higher probability of uncontrolled 
BP. In contrast, CCB appears to be more prescribed when BP is uncontrolled.
2:00 p.m.
1028-186 A Novel Marker, Urinary Liver-Type Fatty Acid Binding 
Protein, for the Detection of Renotubular Damage in 
Acute Decompensated Heart Failure
Naoki Sato, Masataka Kamiya, Asuka Yoshida, Takeshi Yamamoto, Yu-ki Iwasaki, 
Yasuhiro Hirasawa, Koji Kato, Yukichi Tokita, Koji Murai, Kyoichi Mizuno, Keiji Tanaka, 
Intensive and Cardiac Care Unit, Nippon Medical School, Tokyo, Japan, Internal 
Medicine, Nippon Medical School, Tokyo, Japan
Background/Goal:
In acute decompensated heart failure (ADHF), renoprotection is reportedly important, 
because worse renal function during hospitalization is associated to short-term outcome. 
Serum creatinine is the most common marker for renal damage, but it is not enough for 
the evaluation of renal function. Recently, several studies have demonstrated that urinary 
live-type fatty acid binding protein (L-FABP), which is expressed in the proximal tubules, is 
a good marker for renotubular damage in chronic renal disease and the development of its 
rapid-kit has been planned. In ADHF, it is known that hypoxia and pre-renal mechanisms 
damage not only glomerulus and also renal tubulus, especially proximal tubulus. However, 
it is not well clarified whether or not renotubular damages exist and urinary L-FABP is a 
useful maker for the detection of renotubular marker in ADHF.
Methods: Urinary L-FABP levels were measure at admission by a specific ELISA in thirty 
ADHF patients (age 73±8 years, male/female=22:8) admitted to Nippon Medical School 
hospital. Serum creatinine and urinary beta2-microglobuline (B2MG) and N-acetyl-D-
glucosamidase (NAG) were also measured.
Results: Urinary B2MG was high, 434.8±695.1 (normal: <230) µg/L . Urinary NAG and 
serum creatinine levels were 6.6±6.2 (normal <6.0) U/L , 0.81±0.24 (normal: <0.79) 
mg/dl, respectively. Urinary L-FABP levels were 110±312 ng/ml, which were higher than 
normal value, i.e., <4 ng/ml, in 90% ADHF patients, which suggested that proximal tubular 
damages were common in ADHF. Urinary L-FABP levels were significantly correlated 
to urinary B2MG levels in 93 samples (y=0.0029x + 15.427, r=0.58, p<0.001), but not 
correlated to NAG levels and serum creatinine.
Conclusions: Thus, in ADHF, renotubular damages were common and urinary L-FABP 
might be a useful marker for the detection of renotubular marker, suggesting that a rapid-
kit for L-FABP will shed a light on the management of ADHF in terms of renal protection.
2:00 p.m.
1028-187 Risk Factors for Recurrence of Sirolimus-Eluting Stent 
Restenosis: Insights From j-CYPHER Registry
Takuya Taniguchi, Mitsuru Abe, Nobuhito Yagi, Nobuaki Kokubu, Yoichiro Kasahara, 
Yu Kataoka, Yuji Yasuga, Yoritaka Otsuka, Atsushi Kawamura, Hiroshi Nonogi, Takeshi 
Morimoto, Kazuaki Mitsudo, Takeshi Kimura, on behalf of the j-CYPHER registry 
investigators, National Cardiovascular Center, Osaka, Japan
Background: Sirolimus-eluting stents (SES) have dramatically reduced restenosis in 
various lesion subsets, however, recurrence of SES restenosis has remained a critical 
issue. Because there are few reports on risk factors for recurrence of SES restenosis, 
elucidating those factors will help interventional cardiologists to take preventive measures 
for high risk patients.
Methods: Design of j-CYPHER registry was multi-center prospective enrollment of 
consecutive patients receiving SES from 41 centers in Japan. From August 2004 to April 
2006, 8752 patients (12938 lesions) were successfully treated with SES. Among 639 
restenotic lesions after SES implantation, we identified 313 lesions retreated with SES 
and investigated risk factors in initial procedures.
Results: During a median follow-up of 183 days, target lesion revascularization (TLR) 
occurred in 9.6% (30/313). After adjustment for other factors, in-stent restenotic lesion 
[odds ratio (OR), 4.00; 95% confidence interval (CI), 1.64-9.59], usage of two-stent 
strategy [OR, 3.90; 95% CI, 1.08-12.7], and lesion length >30mm [OR, 2.39; 95% CI, 
1.03-5.50] were demonstrated as independent risk factors for recurrence of SES 
restenosis (Table).
Conclusions: In our study population, recurrence of SES restenosis occurred in 9.6%. 
In-stent restenotic lesion, usage of two-stent strategy, and lesion length >30mm were 
revealed as the independent risk factors in initial procedures. 
Risk factors for Recurrence of SES restonosis
Variable Odds Ratio 95% CI
In-stent restenotic lesion 4.00 1.64-9.59
Usage of two-stent strategy 3.90 1.08-12.7
Pre-PCI lesion length>30mm 2.39 1.03-5.50
Usage of IVUS 1.96 0.84-4.81
Diabetes Mellitus 1.48 0.65-3.48
Age>75 0.50 0.15-1.38
BMI>25 0.47 0.17-1.14
2:00 p.m.
1028-188 School-Based Obesity and Related Cardiovascular 
Disease Prevention Interventions Improve Diastolic and 
Systolic Blood Pressure in Elementary-Aged Children
Danielle Hollar, Agatston Research Foundation, Miami Beach, FL
Background: Childhood onset obesity and related health consequences continue 
to be major clinical and public health issues in the US. Healthier Options for Public 
Schoolchildren (HOPS) is a school-based obesity prevention intervention with both 
nutrition and physical activity components implemented in the elementary school setting 
and targeting 6-12 year olds. The overall goal of HOPS is to reduce childhood obesity 
rates and improve overall health status using strategies that can be easily replicated and 
integrated in other public school settings.
Methods: HOPS was implemented in August, 2004 and includes approximately 3,200 
children (48% Hispanic) attending six elementary schools (4 intervention; 2 control) in 
central Florida. Demographic, anthropometric (height, weight, body mass index [BMI]) 
and clinical (systolic and diastolic blood pressure) data were collected at baseline and 
follow-up. The HOPS intervention included modified dietary offerings, nutrition and 
lifestyle educational curricula, school gardens, and other school-based wellness projects. 
We hypothesized that the HOPS intervention would improve diastolic and systolic blood 
pressure in study participants versus a control group.
Results: Over a two year study period, repeated measures analysis showed the HOPS 
intervention significantly decreased systolic blood pressure in females (P = 0.02). There 
was also a trend in females for a decrease in diastolic blood pressure (P = 0.09). No 
significant change was found for males for either systolic or diastolic blood pressure. 
Repeated measures analysis also showed that the intervention significantly decreased z 
score for weight (p<0.01) and ZBMI scores in females (P<0.01), but again, no significant 
change was noted in males when comparing the intervention and control groups.
Conclusions: School-based obesity prevention interventions that use both nutrition and 
physical activity components show promise in improving health, particularly among 
elementary-aged females. If overweight children can lower their blood pressure from an 
early age, via prevention programs such as HOPS, they will be less likely to develop 
cardiovascular disease in early adulthood.
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2:00 p.m.
1028-189 Evidence to Support the Role of the Aortic Reservoir 
via a Direct Mechanism in Determination of the 
Pressure Waveform With Ageing
Justin E. Davies, Nearchos Hadjiloizou, Charlotte H. Manisty, Zachary I. Whinnett, 
Darrel P. Francis, Kim H. Parker, Jamil Mayet, Alun D. Hughes, International Centre for 
Circulatory Health, Imperial College & St Mary’s Hospital, London, United Kingdom
Background:For over 200 years scientists have noted the change in shape of the pressure 
waveform which occurs with ageing and disease. Two main mechanisms have been 
used to account for these changes. 1. An ‘indirect’ mechanism of progressively earlier 
wave reflection from the distal aorta. 2. A ‘direct’ reservoir (or Windkessel) mechanism of 
increasing aortic stiffness (reduced compliance).
Methods:Pressure and Doppler velocity were measured in 18 subjects (aged 53±10years) 
in the proximal aorta using intra-arterial wires. Pressure was separated using a new 
technique that separates forward and backward pressure from arterial reservoir 
pressure.
Results:Mean forward pressure was 36.4±10.9 mmHg (44.3%), backward pressure 
4.8±4.1 mmHg (5.8%), and reservoir pressure 40.9±9.5 mmHg (49.9%). All components 
were increased with age (Figure). Forward pressure increased the most (8.6±1.7mmHg/
decade, r2=0.62, p<0.001) followed by the reservoir pressure (5.8±1.6 mmHg/decade, 
r2=0.45, p<0.005). However, the increase in the backward pressure was far smaller 
(2.4±0.8mmHg/decade, r2=0.35, p<0.01).
Conclusions:The change in shape of the pressure waveform with age is principally 
determined by increasing forward pressure and the aortic reservoir via a ‘direct’ reservoir 
mechanism of decreasing aortic compliance. The contribution from the backward 
(reflected) wave is far smaller than is widely considered, and cannot account for the large 
changes in shape of the pressure waveform which occur with ageing.
2:00 p.m.
1028-190 Differential Effects of Sustained, White-Coat and 
Masked Hypertension on C-Reactive Protein, 
Adiponectin and Arterial Stiffening: Linking Blood 
Pressure Status to Diffuse Atherosclerosis
Kyriakos Dimitriadis, Costas Tsioufis, Costas Thomopoulos, Dimitris Tsiachris, 
Efstathios Taxiarchou, Ioannis Skiadas, Christodoulos Stefanadis, Ioannis Kallikazaros, 
Department of Cardiology, Hippokration Hospital, Athens, Greece
Background: The clinical significance of “masked” hypertension (MHT) and “white-coat” 
hypertension (WCHT) remains controversial. In this study we investigated the relationships 
of MHT, WCHT and sustained hypertension (SHT) with high-sensitivity C-reactive protein 
(hs-CRP), adiponectin, and arterial stiffness.
Methods: 335 consecutive untreated non-diabetic subjects who referred to our outpatient 
clinic for 24-h ambulatory blood pressure (BP) monitoring, were classified as subjects 
with sustained normal BP (office BP<140/90 mmHg and daytime BP<135/85, n=44), MHT 
(office BP <140/90 mmHg and daytime BP >or=135/85 mmHg, n=32), WCHT (office BP 
>or=140/90 mmHg and daytime BP <135/85 mmHg, n=81) and SHT (office BP >or= 
140/90 mmHg and daytime BP >or= 135/85 mmHg, n=178). In all hypertensive subjects, 
arterial stiffness was evaluated on the basis of carotid to femoral pulse wave velocity 
(PWV), by means of a computerized method (Complior SP).
Results: Patients with SHT compared to WCHT and MHT had higher 24-h systolic BP 
(138±10 vs 119±7 vs 129±15 mmHg, respectively; p<0.0001) and left ventricular mass 
index (118.3±17 vs 111.2±13 vs 101.4±17 g/m2, respectively; p<0.05). Although groups 
did not differ regarding sex, body mass index and metabolic profile (p=NS), patients 
with SHT compared to those with WCHT and MHT had increased hs-CRP (2.8±0.7 vs 
2.2±0.6 vs 1.9±0.4 mg/l, respectively; p<0.05), lower adiponectin (8.4±1.5 vs 10.5±1.8 
vs 10.2±1.6 µg/ml, respectively; p<0.05) and heightened PWV levels (8.2±1.4 vs 7.8±1.2 
vs 7.3±0.9 m/sec, respectively; p<0.05). However, there was no difference between 
the MHT and WCHT group regarding hs-CRP, adiponectin and PWV values (p=NS for 
all). In hypertensives, hs-CRP was associated with PWV (r=0.232, p<0.0001), whereas 
adiponectin was negatively related to 24-h systolic BP (r=-0.203, p=0.001), hs-CRP (r=-
0.192, p=0.001) and PWV (r=-0.247 p<0.0001).
Conclusion: Patients with MHT and WCHT did not differ regarding hs-CRP, adiponectin 
and PWV levels. These findings suggest that although SHT is associated with activated 
inflammatory and proatherogenic pathways, masking and white coat effect may be 
associated with lower vascular disease burden.
2:00 p.m.
1028-191 Molecular Basis of the Stabilization of Angiotensin II 
Type 1 Receptor by Valsartan
Shin-ichiro Miura, Yoshihiro Kiya, Satoshi Imaizumi, Yoshino Matsuo, Masahiro Fujino, 
Keijiro Saku, Fukuoka University School of Medicine, Fukuoka, Japan
Background: The sartan family of Angiotensin II type 1 (AT1) receptor blockers 
(ARBs), such as valsartan and olmesartan, have a common pharmacophore structure, 
which includes a biphenyl-tetrazole group. Previous studies have suggested that this 
pharmacophore binding to the AT1 receptor consists of critical bonding with residues 
located on transmembrane (TM) helices V, VI and VII.
Methods and Results: Site-directed mutagenesis and substituted cysteine accessibility 
mapping (SCAM) studies presented here suggest that the molecular basis of valsartan 
binding differs from that of inverse agonism. First, we confirmed constitutive activity of 
the AT1-wild-type (WT) receptor using an inositol phosphate (IP) production assay in 
native vascular smooth muscle cells and in a transfected cell model system. Next, the 
affinity of valsartan for WT and mutant AT1 receptors was measured, and indicated that 
interactions between valsartan and residues Ser105, Ser109 and Lys199 were important 
for binding. Valsartan is a strong inverse agonist of constitutive IP production by the WT 
and N111G and F77A/N111G mutant receptors. SCAM indicated that valsartan and 
olmesartan behaved similarly and stabilized an inactive state of the N111G receptor 
upon binding. The most important position of AT1 receptor for inducing inverse agonism 
by valsartan was Lys199. In addition, this inverse agonism was mostly abolished with 
S105A/S109A/K199Q substitutions in the N111G background. Molecular modeling 
suggested that Ser109 and Lys199 bind to phenyl and tetrazole groups of valsartan, 
respectively. Ser105 is a candidate for binding to the carboxyl group of valsartan. Thus, 
the most critical valsartan bonding interaction for inducing inverse agonism involves TMV 
(Lys199) of AT1 receptor, although its inverse agonist potency is comparable to that of 
olmesartan, which bonds to TM III (Tyr113) and TMVI (His256).
Conclusion: These results provide new insights into the improvement of ARBs and the 
development of new G-protein coupled receptor antagonists.
2:00 p.m.
1028-192 Atrasentan, an Endothelin: A Receptors Antagonist, Is 
a Potent Antihypertensive Drug With Renoprotective 
Properties and Favorable Metabolic Effect
Eugenia Raichlin, Abhiram Prasad, Verghese Mathew, David R. Holmes, Jr., Rebecca 
E. Nelson, Lilach O. Lerman, Amir Lerman, Mayo Clinic, Division of Cardiovascular 
Diseases, Rochester, MN
Background: Endothelin plays a pivotal role in pathogenesis of atherosclerosis. We 
evaluated the safety, hemodynamic and metabolic response to 6 months treatment with 
Atrasentan, the selective endothelin-A (ETA) receptor antagonist.
Methods: Fifty patients with multiple cardiovascular risk factors and nonobstructive 
coronary artery disease (<30% diameter stenosis of any coronary artery) on coronary 
angiogram were randomized in a double-blind manner to Atrasentan (10 mg, per os) or 
placebo in addition to their standard medical therapy. Blood tests were performed and 
aortic blood pressure was assessed invasively prior to coronary angiography at baseline 
and at 6 month follow-up. Side effects were recorded. The primary end point of the study 
was the changes in mean blood pressure, in renal function and metabolic parameters 
during the 6 monts follow up.
Results: Mean arterial blood pressure (MAP) decreased from 93±10 to 80±10mmHg 
(p=0.0001) in the Atrasentan group and did not change in the placebo group (93±10, 
92±11 mmHg, p=0.09). The difference between the groups was significant (p=0.0001) and 
independent of baseline clinical characteristics. Inverse linear correlation was observed 
between baseline MAP and subsequent changes in MAP in Atrasentan group. No effect 
on heart rate was observed. Creatinine level decreased significantly in Atrasentan versus 
placebo in a subgroup of patients not treated with ACE inhibitors (p=0.011). Fasting 
glucose (p=0.026), glycosylated hemoglobin level (p=0.041), triglycerides l (p=0.013), 
lipoprotein-A (p=0.046) and uric acid levels (p=0.048) decreased significantly in the 
Atrasentan group compared to placebo. The most common side effects with Atrasentan 
were nasal stuffiness, headache and edema.
Conclusions: Six months treatment with selective ETA receptor antagonist Atrasentan 
results in significant reduction of blood pressure and improvement of renal function. The 
improvement in metabolic markers suggests the beneficial role of Atrasentan in the treatment 
of metabolic syndrome. The current study supports a role of the endogenous endothelin 
system in the regulation of vasomotor, renal and metabolic pathways in humans.
2:00 p.m.
1028-193 All-Cause and Cardiovascular Mortality in Relation 
to Changing Heart Rate During Treatment of 
Hypertension: The LIFE Study
Peter M. Okin, Sverre E. Kjeldsen, Stevo Julius, Darcy A. Hille, Jonathan M. Edelman, 
Björn Dahlöf, Richard B. Devereux, Weill Cornell Medical College, New York, NY
Background: Higher heart rate (HR) has been associated with an increased risk of 
cardiovascular (CVD) and all-cause (ACD) death. Although increasing HR over time has 
been associated with a greater risk of developing heart failure or atrial fibrillation, the 
relationship of changing HR over time to mortality has not been examined..
Methods: HR was evaluated over time in 9190 hypertensive patients with baseline HR 
data in the LIFE Study. Patients were treated with losartan- or atenolol-based regimens 
and followed with annual ECGs.
Results: During mean follow-up of 4.8±0.9 years, 814 patients (8.9%) died; 438 (4.8%) had 
a CVD. Compared with patients who survived, patients who died had smaller decreases 
A340  ABSTRACTS - Vascular Disease, Hypertension and Prevention JACC March 11, 2008 
Va
sc
ul
ar
 D
is
ea
se
, 
H
yp
er
te
ns
io
n 
an
d 
P
re
ve
nt
io
n
in HR to last ECG prior to death or last in-treatment ECG (-2.4±14.6 vs -5.3±12.7 bpm, 
p<0.001) whether on losartan- (-0.5±14.0 vs -2.4±11.9, p=0.014) or atenolol-based 
treatment (-4.1±14.9 vs -8.2±12.7, p<0.001). In univariate Cox analyses, every 10 bpm 
higher HR on in-treatment ECGs was associated with a 27% increased risk of ACD (95% 
CI 21-34%) and a 23% greater risk of CVD (95% CI 14-32%). In an alternative analysis, 
persistence or development of a HR≥84 (upper quintile of baseline HR) was associated 
with a 97% greater risk of ACD (95% CI 65-135%) and an 89% greater risk of CVD 
(95% CI49-141%). After adjusting for losartan vs atenolol-based treatment, baseline risk 
factors for death, baseline and in-treatment systolic and diastolic blood pressure, the 
known predictive value of baseline and in-treatment ECG LVH and QRS duration, and 
for new myocardial infarction, higher in-treatment HR in time-varying multivariable Cox 
models remained strongly predictive of mortality: every 10 bpm higher HR was associated 
with a 25% increased adjusted risk of ACD (95% CI 17-33%) and a 16% greater risk of 
CVD (95% CI 6-27%), with persistence or development of a HR≥84 associated with a 
79% increased adjusted risk of ACD (95% CI 46-121%) and 55% greater risk of CVD 
(95% CI 16-105%).
Conclusions: Higher in-treatment HR on serial ECGs predicts greater likelihood of 
subsequent ACD or CVD, independent of treatment modality, blood pressure lowering, 
regression of ECG LVH and changing QRS duration in patients with essential 
hypertension.
2:00 p.m.
1028-194 Regression of Electrocardiographic Left Ventricular 
Hypertrophy During Antihypertensive Therapy is 
Associated With Decreased Incidence of New-Onset 
Microalbuminuria: The LIFE Study
Peter M. Okin, Kristian Wachtell, Richard Devereux, Hans Ibsen, Michael H. Olsen, 
Knut Borch-Johnsen, Lars H. Lindholm, Sverre E. Kjeldsen, Stevo Julius, Darcy A. Hille, 
Jonathan M. Edelman, Björn Dahlöf, Weill Cornell Medical College, New York, NY
Background: Microalbuminuria (MA), a renal measure of generalized vascular dysfunction, 
and ECG left ventricular hypertrophy (LVH), each predict increased cardiovascular (CV) 
morbidity and mortality. Although MA is related to the presence and severity of ECG LVH, 
whether regression of ECG LVH in the setting of antihypertensive therapy is associated 
with a decreased incidence of new-onset MA is unclear.
Methods: ECG LVH was evaluated over time in 5784 hypertensive patients without 
MA at baseline. Patients were treated with losartan- or atenolol-based regimens and 
followed with serial ECGs at 6 months and then yearly until death or study end. ECG 
LVH was measured using gender-adjusted Cornell product (CP; (RaVL+SV3 [+6 mm in 
women])*QRS duration) >2440 mm•msec and Sokolow-Lyon voltage (SLV; SV1+RV5/6) 
>38 mm. MA was defined as urine albumin/creatinine ratio>3.50 mg/mM.
Results: During a mean follow-up of 4.1±1.3 years, new MA occurred in 1085 patients 
(18.8%). In time-dependent Cox analyses controlling for treatment effects, baseline risk 
factors for MA, baseline and in-treatment systolic and diastolic pressure, and baseline 
severity of LVH by CP and SLV, in-treatment regression or absence of LVH by CP was 
associated with a 25% lower incidence (HR 0.75, 95% CI 0.65-0.85) and regression of 
SLV LVH with a 34% lower incidence of new MA (HR 0.66, 95% CI 0.54-0.80. Because 
both CP and SLV retained predictive power in the multivariate Cox analyses, the ability 
of the combination of CP and SLV to predict MA was further examined. Compared with 
patients with in-treatment persistence or development of ECG LVH by both CP and 
SLV, in-treatment regression of CP LVH alone (HR 0.75, 95% CI 0.55-1.02), SLV LVH 
alone (HR 0.66, 95% CI 0.52-0.84) and regression of both CP and SLV LVH (HR 0.49, 
95% CI 0.39-0.63) were associated with progressively lower risk of developing MA after 
controlling for risk factors.
Conclusions: Regression or continued absence of ECG LVH by CP and/or SLV criteria 
during antihypertensive therapy are associated with decreased likelihoods of new-onset 
MA. These findings suggest that antihypertensive therapy targeted at regression or 
prevention of ECG LVH by CP and SLV criteria may reduce the incidence of MA.
2:00 p.m.
1028-195 Usefulness of the Electronic Activity Monitor During 
24-Hour Ambulatory Blood Pressure Monitoring in 
Hypertensive Patients at Real World Practices
Won-Yik Lee, Kyung-Kuk Hwang, Jang-Whan Bae, Myeong-Chan Cho, Dong-Woon 
Kim, Department of Internal Medicine, College of Medicine, Chungbuk National 
University, Cheongju, South Korea
Background: We prospectively evaluated the usefulness of activity monitoring for the 
actual physical activity and diurnal variation of 24-hour ambulatory blood pressure 
monitoring (ABPM) in hypertensive patients at real-world clinical practice. Methods: 
24-hour ABPM with an electronic activity monitor (SenseWear PRO2 Armband) was 
performed on 10 normotensive volunteers for validation, and then performed on 73 
hypertensive patients (M:F=44:29, Age: 47±13) who were initially diagnosed at the clinic 
for usefulness of activity monitoring. To interpret the ABPM results of 73 hypertensive 
patients, we obtained the actual awake/sleep periods of every patient with using an 
electronic activity monitor and the arbitrary daytime (06:00-22:00)/night time (22:00-
06:00) periods by arbitrary method. Results: The activity values from the 10 normotensive 
volunteers were obtained according to 4 activities including sleeping, sitting, walking and 
running. The values agreed with the activities, and well correlated with blood pressure 
(BP) and heart rate. Out of 73 patients who were initially diagnosed hypertension, 15 
patients turned out normotension after APBM. By arbitrary method, 58 hypertensives 
were classified with 19 non-dippers, 36 dippers, 1 extreme dipper and 2 reverse dippers. 
The nocturnal mean BP derived by the actual period was significantly lower than that 
derived by the arbitrary period (121.7±12.3/77.3±10.7 vs 117.4±11.3/74.1±10.3mmHg, 
p<0.001). The nocturnal BP fall derived by the actual period was significantly larger than 
that derived by the arbitrary period (13.1±8.0/9.9±5.9 vs 18.3±7.7/13.9±5.5 mmHg, 
p<0.001). Twelve among the 19 non-dippers determined by the arbitrary period were re-
classified as dippers when the actual period was used. One among the 58 hypertensives 
was also re-classified as a non-hypertensive. Conclusions: The electronic activity 
monitor was valuable method to determine the actual activity level at real-world practice. 
The interpretation of ABPM might be altered by the use of the electronic activity monitor. 
These results suggest that the accuracy and reproducibility of the 24-hour ABPM will be 
improved by using an electronic activity monitor.
2:00 p.m.
1028-196 Circulating Endothelial Cells and plasma von 
Willebrand factor in hypertension in pregnancy: 
evidence for endothelial damage/dysfunction
Vellore J. Karthikeyan, Shahirose Jessani, Christopher J. Boos, Deirdre A. Lane, Sabah 
Baghdadi, D. Gareth Beevers, Gregory YH Lip, University Department of Medicine, City 
Hospital, Birmingham, United Kingdom
Background Hypertension in pregnancy is a common and important cause of maternal & 
perinatal mortality. Endothelial dysfunction is implicated in the loss of vascular haemostasis 
and blood pressure (BP) control. We hypothesized that endothelial dysfunction, as 
indicated by plasma von Willebrand factor (vWF) & Circulating Endothelial Cells (CECs), 
is associated with hypertension in pregnancy.
Methods Hypertensive pregnant (HBP) women (n=38) >20 weeks gestation attending 
the ante-natal hypertension clinic (BP>140/90 mm Hg untreated or ≤140/90 mm Hg 
treated) were recruited. vWF & CECs were measured by ELISA and immunomagnetic 
separation using anti-CD146 monoclonal antibody coated beads, respectively. Levels 
were compared with those of normotensive pregnant (NBP, n=40) and non-pregnant 
healthy controls (HC, n=50).
Results We recruited 128 women [mean(SD) age 30(7) years]. HBP women had 
significantly higher CEC levels compared to NBP women and HC (all p<0.001). Pregnant 
women had higher vWF levels than HC (table). vWF correlated with CEC levels 
(Spearman r=0.39, p<0.0001); CEC levels correlated with both systolic & diastolic BP 
(Spearman r=0.28, p<0.005 & r=0.31, p<0.001, respectively). Multiple linear regression 
analysis revealed hypertensive pregnancy as an independent predictor of CEC levels 
(p<0.0001).
Conclusion Endothelial dysfunction is evident in hypertensive pregnancies. Further 
studies exploring its progression during gestation and impact on pregnancy outcomes 
are warranted.
Levels of Blood Pressure, vWF and CECs in hypertensive, normotensive 
pregnant women and non-pregnant healthy controls
Mean (SD) Hypertensive Pregnant (n=38)
Normotensive 
Pregnant (n=40)
Non-pregnant 
healthy controls 
(n=50)
p-value
Median (IQR) Parity 2 (0-3) 1 (0-2) 0 (0-1) < 0.0001
SBP (mm Hg) 133(17) 112 (9) 118 (9) < 0.0001
DBP (mm Hg) 87 (11) 66 (6) 75 (9) < 0.0001
vWF (I.U./dL) 157.3 (33.6) * 156.1 (27.3) * 139.5 (36.8) < 0.0001
Median (IQR) CEC 
levels (/ ml) 4 (2-5) * 2 (1-2) 1 (0-2) < 0.0001
CEC: Circulating Endothelial Cells; DBP: Diastolic Blood Pressure; SBP: Systolic Blood 
Pressure; vWF: von Willebrand Factor 
Between group analyses by ANOVA with Tukey post hoc test and Kruskal Wallis test 
with Dunn’s post hoc test, as appropriate 
*Significantly higher than healthy controls
2:00 p.m.
1028-197 Ion Mobility: A New Method for Fractionation and 
Quantification of Lipoproteins
Michael P. Caulfield, Shuguang Li, Kwangja Lee, Patricia Blanche, Henry Benner, 
Richard E. Reitz, Ronald M. Krauss, Quest Diagnostics Nichols Institute, San Juan 
Capistrano, CA, Childrens Hospital of Oakland Research Institute, Oakland, CA
Ion mobility (IM) spectrometry provides a way to measure the size distribution of 
nanoparticles based on gas-phase particle electrical mobility. We adapted this technology 
to measure the size distribution of lipoprotein particles. Lipoproteins are enriched from 
plasma by ultracentrifugation, diluted in a volatile buffer and electrosprayed. Charge 
neutralization in the electrospray chamber leaves a well-characterized fraction of particles 
with a single charge which are drawn through a Differential Mobility Analyzer (DMA). 
The DMA selects particles of a narrow size to pass to a particle counter. By scanning 
the voltage applied to the DMA, particle number distributions are obtained for HDL, 
LDL, IDL and VLDL. The measurements are based on first principles. Particle number 
distributions are converted into particle mass distributions. Using this method, the intra-
assay variation for LDL diameter was <0.6% and for concentration <10% for HDL and 
LDL and <15% for IDL and VLDL. The inter-assay variation for LDL diameter was <1.0% 
and for concentration <15% for HDL and LDL and < 20% for IDL and < 25% for VLDL. 
The Table shows the summary data used to generate reference ranges for the individual 
lipoprotein fractions. A total of 259 healthy individuals (191 F, 68 M) who met the current 
NCEP ATP III criteria for optimal lipid/lipoprotein levels were used in the study. The results 
show the expected difference between genders, males having higher concentrations of 
smaller LDL particles and females having increased HDL 2b. 
JACC March 11, 2008  ABSTRACTS - Vascular Disease, Hypertension and Prevention  A341 
Vascular D
isease, H
ypertension and P
revention
Lipoprotein 
Fraction
Gender Mean nmol/L SD nmol/L
P males 
vs females
Lipoprotein 
Fraction
Gender
Mean 
nmol/L
SD 
nmol/L
P males 
vs 
females
HDL 3 Female 1443 847 0.071 IDL 1 Female 16 9 0.003
Male 1646 602 Male 20 11
HDL 2b Female 834 299 <0.003 IDL 2 Female 25 10 0.007
Male 494 258 Male 29 12
HDL 2a Female 2343 719 0.850 VLDL small Female 11.2 5.7 0.506
Male 2325 655 Male 10.7 4.8
LDL IV Female 70 24 <0.003 VLDL inter Female 3.0 1.3 <0.003
Male 84 31 Male 3.7 1.6
LDL III Female 212 103 <0.003 VLDL large Female 0.9 0.4 <0.003
Male 313 125 Male 1.2 0.6
LDL II Female 336 125 <0.003
Male 407 119
LDL I Female 112 35 0.012
Male 100 29
Total LDL Female 727 227 <0.003
Male 893 193
Angstrom Angstrom
LDL Peak Female 225.7 4.48 <0.003
Diameter Male 221.7 4.19
2:00 p.m.
1028-198 A Role for RhoA/Rho-Kinase in Particulate Air Pollution 
Mediated Cardiovascular Changes
Peibin Yue, Qinghua Sun, Michael Mikolaj, Aixia Wang, Ximei Jin, Morton Lippmann, 
Robert Brook, Lung Chi Chen, Sanjay Rajagopalan, The Dorothy M. Davis Heart Lung 
Research Institute, the Ohio State University, Columbus, OH, New York University 
School of Medicine, Tuxedo, NY
Background: Recent studies have implicated fine inhaled particulate matter <2.5µm 
(PM2.5) to changes in vascular tone and blood pressure. We investigated the effects of 
short-term exposure to PM2.5 in the angiotensin II (AII) infusion model.
Methods: Male C57BL/6 mice (n = 52) were exposed to concentrated ambient PM2.5 or 
filtered air (FA) for 8 weeks (6 hour/day, 5 day/week), followed by AII infusion (0.7 mg/
kg/day) for 14 days in conjunction with intraperitoneal administration of the Rho-kinase 
inhibitor fasudil (1 mg/kg/day) or placebo for 2 or 6 weeks. Animals were sacrificed at 
the end of these periods following for studies. Cardiac remodeling indices by MRI were 
performed at the end of 6-week fasudil treatment.
Results: AII increased blood pressure (BP) with no observable difference in tail cuff BP at 
14-day following AII between PM2.5 and FA groups. Basal nitric oxide bioactivity assessed 
by constriction of aortic rings to NG-monomethyl-L-arginine (10-4 M) was reduced in 
PM2.5-AII vs. PM2.5-FA (51 ± 3 vs. 64 ± 4%, p < 0.05), which was completely restored by 
fasudil. Maximal aortic contractile response to phenylephrine (10-5 M) was exaggerated 
in PM2.5-AII vs. FA-AII (1.14 ± 0.04 vs. 0.96 ± 0.05 g, p < 0.05) with higher levels of 
RhoA activity in PM2.5-AII vs. FA-AII (0.48 ± 0.09 vs. 0.36 ± 0.05 arbitrary unit) with 
fasudil restoring levels to that seen in the FA-AII groups. Expression of a RhoA specific 
guanine nucleotide exchange factor (GEF) p115RhoGEF and the NAD(P)H oxidase 
subunit p22phox in aorta was up-regulated in PM2.5-AII group (3.7 and 2.1-fold increase 
compared with FA-AII, respectively, p < 0.05). Fasudil only partially inhibited increase 
of p115RhoGEF while not affecting NADPH oxidase expression. PM2.5 potentiated left 
ventricular (LV) fibrosis in response to AII at 6 weeks (60 ± 5 vs. 50 ± 1% of FΑ-Α€€ , p < 
0.05 ), with fasudil preventing this response. LV mass index measured by MRI in response 
to AII was not altered by PM2.5.
Conclusions: PM2.5 potentiates vasoconstriction and reparative LV fibrosis in response 
to AII through NAD(P)H oxidase and RhoA/Rho-kinase dependent mechanisms. These 
findings have implications for chronic cardiovascular health effects of air pollution.
2:00 p.m.
1028-199 Insulin-like Growth Factor-1 Receptor Expression 
Regulates Insulin Sensitivity of Vascular Smooth 
Muscle Cells
Niels Engberding, Kathy K. Griendling, Emory University, Atlanta, GA
Insulin resistance of vascular smooth muscle cells (VSMCs) may contribute to accelerated 
atherosclerosis. VSMCs express insulin holoreceptors (IRs), insulin-like growth factor-1 
holoreceptors (IGF1Rs), and hybrid insulin/IGF-1 receptors consisting of an IR alpha/
beta-hemidimer and an IGF1R alpha/beta-hemidimer. The contribution of the IGF1R to 
overall insulin sensitivity of VSMCs is unclear. We therefore determined if regulation of 
the IGF1R alters insulin responsiveness in VSMCs. Methods: Studies were conducted 
in vitro in cultured rat aortic smooth muscle cells between passages 6-15. Results: 
Immunoprecipitation of IR β-subunits from cell lysates and blotting for phosphotyrosine 
showed that short-term stimulation with insulin (100 nM) preferentially activates the IR 
beta-subunit, while stimulation with IGF-1 (20 ng/ml) phosphorylates both the IR beta-
subunit and the IGF1R beta-subunit, suggesting that insulin stimulates only the IR. When 
IGF1R levels were reduced by siRNA, Akt phosphorylation in response to insulin was 
enhanced by 250% compared to that in control cells (siIGF1R: 1.32+0.09 vs. 0.33+0.04, 
siScr: 0.79+0.07 vs. 0.36+0.03, p<0.01). Phosphorylation of ERK1/2 in response to insulin 
was also significantly improved by IGF1R knockdown (siIGF1R: 1.65+0.06 vs. 0.61+0.06, 
siScr: 0.97+0.03 vs. 0.57+0.04, p<0.01). Furthermore, IGF1R knockdown increased 
insulin-induced glucose uptake. Interestingly, more IR beta-subunits are tyrosine-
phosphorylated in response to insulin after IGF1R knockdown, while IR expression is 
unchanged. Conclusion: These results suggest that downregulation of the IGF1R leads to 
increased insulin signaling in VSMCs, possibly by increasing the fraction of IRs organized 
in holoreceptors as opposed to hybrid receptors. It is conceivable that interventions that 
restore insulin sensitivity, such as administration of recombinant-human IGF-1, do so by 
downregulating peripheral IGF1Rs. Therefore, the IGF1R may represent a novel target for 
interventions designed to restore impaired insulin signaling in the vasculature.
2:00 p.m.
1028-200 Endothelial dysfunction correlates with obesity in 
patients with essential hypertension
takasaki kunitsugu, Masaaki Miyata, Masakazu Imamura, Shiro Yoshifuku, Eiji 
Kuwahara, Takeshi Uemura, Kenichi Nakashiki, Kayoko Kubota, Mihoko Kouno, Shuichi 
Hamasaki, Akira Kisanuki, Chuwa Tei, Kagoshima University, Kagoshima, Japan
Background: It has been reported that obesity is associated with endothelial function, 
and is an independent risk factor for cardiovascular diseases. The aim of this study was 
to determine the correlation between obesity and endothelial function in patients with 
essential hypertension (HT).
Methods: 60 untreated HT patients were enrolled. To assess vascular function, high-
resolution ultrasound (12MHz) was used to measure brachial artery diameter. The 
diameter change during reactive hyperemia was designated as percent flow-mediated 
dilation (%FMD). The diameter change after sublingual nitroglycerin administration was 
designated as %NTG. Patients were divided into normal weight [body mass index (BMI) 
< 25 kg/m2, n=36] and obesity group (BMI ≥ 25 kg/m2, n=24).
Results: There was no significant difference in age, gender, blood pressure between 
normal weight and obesity groups. %FMD in obesity group was significantly lower than 
that in normal weight group (4.1 ± 2.8% vs. 6.3 ± 3.8%, p<0.05), and there was a significant 
correlation between %FMD and BMI (r=-0.42, p<0.05). The correlation between %FMD 
and BMI, age, blood pressure, triglyceride, HDL-cholesterol or fasting plasma glucose 
was determined by multiple regression analysis. %FMD independently correlated with 
BMI (p<0.005) and age (p<0.05). In contrast, there was no significant difference in %NTG 
between normal weight and obesity groups.
Conclusion: Even in patients with HT, endothelial dysfunction correlates with obesity 
represented by BMI. 
2:00 p.m.
1028-201 Multiple RAAS Inhibition Influences the Changes of 
Biohumoral Markers in Patients With Heart Failure. Data 
from Aliskiren Observation of Heart Failure Treatment 
(ALOFT) Study
Roberto Latini, Serge Masson, Aldo P. Maggioni, Scott D. Solomon, Bertram Pitt, Vipin 
Arora, Jenny O. Chung, Beverly A. Smith, Margaret F. Prescott, John J. V. McMurray, 
and the ALOFT Investigators, Istituto Mario Negri, Milan, Italy, Novartis Pharmaceuticals 
Corporation, East Hanover, NJ
Background: Renin-angiotensin-aldosterone system (RAAS) inhibitors improve mortality 
and morbidity in patients (pts) with chronic heart failure (HF). A new direct renin inhibitor, 
aliskiren, has favorable neurohormonal actions in add-on therapy in pts with HF. The 
effect of aliskiren on circulating biomarkers in pts already taking an aldosterone receptor 
antagonist (ARA) on top of ACEi/ARB and beta-blockers is not known.
Methods: BNP, high sensitive C-reactive protein (hsCRP), hsIL-6, TNF-α, plasma renin 
activity (PRA) and concentration (PRC) were measured in 302 pts with stable NYHA II-IV 
hypertensive HF randomized to aliskiren 150 mg or placebo on top of standard HF therapy. 
Treatment comparisons (12-weeks/baseline) of biomarker concentrations were done in 
ARA-untreated (n=201) and treated (n=101) pts using an ANCOVA model adjusting for 
baseline biomarker concentration, NYHA class, LVEF, and ischemic etiology.
Results: At study entry, pts (68±10 yr, 78% males, 54.6% ischemic etiology) were treated 
with ACEi (84%) or ARB (15%), beta-blockers (94.4%) and ARA (33.4%). Table shows 
changes presented as ratios in biomarkers among pts taking or not an ARA. 
A342  ABSTRACTS - Vascular Disease, Hypertension and Prevention JACC March 11, 2008 
Va
sc
ul
ar
 D
is
ea
se
, 
H
yp
er
te
ns
io
n 
an
d 
P
re
ve
nt
io
n
ARA=NO ARA=YES
Aliskiren Placebo
Aliskiren vs 
placebo
p-value Aliskiren Placebo
Aliskiren vs 
placebo
p-value
BNP 
(ng/L)
0.59[0.24-
1.43]*
0.82[0.34-
1.94]*
0.72[0.54-
0.97]** 0.030
0.56[0.26-
1.22]*
0.67[0.29-
1.53]*
0.85[0.54-
1.32]** 0.452§
PRC 
(ng/L)
2.40[0.84-
6.87]
1.12[0.40-
3.10]
2.15[1.51-
3.06] <0.0001
3.65[1.65-
8.09]
1.12[0.49-
2.59]
3.25[2.04-
5.18] <0.0001
PRA 
(ng/
mL/h)
0.19[0.06-
0.67]
0.83[0.25-
2.77]
0.23[0.15-
0.35] <0.0001
0.18[0.07-
0.46]
0.95[0.34-
2.60]
0.19[0.11-
0.33] <0.0001
hsCRP 
(mg/L)
0.59[0.22-
1.56]
0.66[0.25-
1.70]
0.89[0.63-
1.27] 0.530
1.85[1.02-
3.36]
2.27[1.20-
4.30]
0.82[0.59-
1.13] 0.223
hsIL-6 
(ng/L)
0.85[0.52-
1.38]
0.74[0.47-
1.17]
1.14[0.92-
1.41] 0.231
1.42[0.92-
2.21]
1.36[0.85-
2.18]
1.05[0.81-
1.36] 0.725
TNF-α 
(ng/L)
0.73[0.47-
1.12]
0.76[0.50-
1.16]
0.96[0.79-
1.16] 0.671
1.16[0.90-
1.50]
1.16[0.89-
1.51]
1.00[0.85-
1.18] 0.969
*Ratio:12-week/baseline, geometric mean of biomarker level and 95% CI . **aliskiren/placebo ratio and 
95% CI. §for BNP, p-value for interaction ARA*Therapy=0.876.
Conclusion: Addition of aliskiren on top of ACEi/ARB, beta-blockers and aldosterone 
antagonists decreases PRA by about 80% despite the reactive increase in PRC. This 
contrasts with the increases in both PRA and PRC observed with ACEi and ARBs. The 
beneficial effect of aliskiren on BNP is not influenced by ARA prescription.
2:00 p.m.
1028-202 Antiplatelet Therapy Facilitates Preconditioning and 
Promotes Ischemia-Induced Angiogenesis in Critical 
Limb Ischemia
Prasanna K. Venkatesh, Jay Hood, Christopher Pattillo, Rakesh Patel, Christopher G. 
Kevil, LSUHSC, Shreveport, LA, Univ Alabama, Birmingham, AL
Background: Platelets have been shown to regulate angiogenesis in tumors. Angiogenesis 
by platelet inhibition has not been studied in the ischemic model. We hypothesized that 
antiplatelet therapy promotes ischemia-induced angiogenesis in critical limb ischemia (CLI).
Methods: Mice were pretreated with dipyridamole (Dip, 200 mg/kg/d, n=9), clopidogrel 
(Clop, 30 mg/kg/d, n=9), or acid water control (n=8) orally in 2 divided doses for 3 days, 
followed by induction of CLI by femoral artery ligation and transection. Therapy was 
continued until day 7 post ligation. Laser doppler measurements of tissue blood flows on 
ligation day 0 and days 1, 3, 5 and 7 were recorded. Mice were sacrificed on day 7 and the 
tissues from ischemic and non-ischemic limbs were analyzed for vascular density.
Results: Both Dip and Clop significantly and rapidly restored blood flows in the ischemic 
limb with a significant increase in endothelial cell proliferation and vascular density. The 
phosphodiesterase inhibition with Dip and the increase in cAMP with Clop, suggest a 
potential Phosphokinase A (PKA) dependant pathway and stimulation of nitric oxide (NO) 
by these agents. Increase in adenosine (with Dip) might contribute to preconditioning 
and angiogenesis.
Conclusions: Antiplatelet therapy with Dip or Clop promotes angiogenesis and significantly 
increases blood flow in CLI. This could be mediated through a PKA pathway and potentiation 
of NO. Adenosine could contribute to preconditioning and angiogenesis (with Dip). 
2:00 p.m.
1028-203 Low-Dose Paclitaxel Elution from a Novel Bioerodible 
Sol-gel Coating on Stents Inhibits Neointima with Less 
Vascular Toxicity in Porcine Coronary Arteries
Toshiro Shinke, Sara Geva, Lakshmana Pendyala, Refat Jabara, Jinsheng Li, Anna 
Venegoni, Ken Colley, Richard Klein, Nicolas Chronos, Keith Robinson, Dongming Hou, 
Saint Joseph’s Research Institute, Atlanta, GA, Medlogics Device Corporation, Santa 
Rosa, CA
Background: Although current polymer-based paclitaxel-eluting stents (PESs) decrease 
restenosis, the permanent polymer and entrapped drug raise concerns about delayed 
vessel healing and late stent thrombosis. The present study was designed to evaluate 
a novel PES that releases a very low dose of paclitaxel (2.67 µg / stent) from a new 
bioerodible sol-gel film coating, in the porcine coronary model.
Methods: Bare metal stents (BMS, n = 14), Sol-gel film only (Sham, n = 12), polymer-
based PES (Poly PES, n = 8), or Sol-gel film coated PES, (Sol-gel PES, n = 15) were 
implanted in 17 juvenile pigs. Animals were terminated at 28 days post-implant for 
angiographic restudy and complete histopathologic and histomorphometric analyses.
Results: Angiographic late loss was equally reduced by Poly PES and Sol-gel PES in 
comparison with BMS or sham (P<0.05). Histomorphometric percent area stenosis was 
decreased for Poly PES (21.9±13.6%) and Sol-gel PES (26.3±11.3%) compared to BMS 
and Sham (P<0.05, respectively). Re-endothelialization was complete in all types of stents 
implanted. Inflammatory cell filtration and intramural thrombi were similar between Poly 
PES and Sol-gel PES, however, the Poly PES had increased medial necrosis (P<0.05 
versus all of other groups).
Conclusions: A novel bioerodible sol-gel film coated with low-dose paclitaxel demonstrates 
less toxicity to the coronary arterial tunica media, while retaining effective inhibition of 
neointimal formation at 28 days. 
2:00 p.m.
1028-204 Impact of Combined Hypertension and Dyslipidemia on 
Risk of Coronary Heart Disease Events in the Elderly: 
the Cardiovascular Health Study
Nathan D. Wong, Victor A. Lopez, Russell Tracy, David Yanez, Lewis Kuller, Gregory 
L. Burke, Craig Roberts, Henry Solomon, Bruce Psaty, University of California, Irvine, 
Irvine, CA, Pfizer Pharmaceuticals, New York, NY
Introduction: Hypertension (HTN) and dyslipidemia (DYS) are highly prevalent conditions 
in the elderly. We studied the combined impact of both conditions on coronary heart 
disease (CHD) events.
Methods: We studied 4,311 individuals aged 65-98 (61.2% female) without prior 
cardiovascular disease from the Cardiovascular Health Study, a longitudinal epidemiologic 
study. Cox regression evaluated the relation of low density lipoprotein (LDL)-cholesterol or 
high density lipoprotein (HDL)-cholesterol categories and blood pressure (BP) categories 
with CHD events, including angina, myocardial infarction, angioplasty, coronary bypass 
surgery, or atherosclerotic CHD death occurring over 15 years (mean 10.2 + 4.5 years).
Results: CHD incidence (per 1000 person years) ranged from 20.6 in persons with BP 
<120/80 mmHg and LDL-C <100 mg/dl to 51.6 in those with BP >160/100 mmHg and 
LDL-C >160 mg/dl, and from 12.7 in those with BP <120/80 mmHg and HDL >60 mg/dl to 
46.5 in those with BP >160/100 and HDL-C< 40 mg/dl. The table below shows the hazard 
ratios (and 95% confidence intervals) (adjusted for age, ethnicity, lipid and BP medication, 
HDL-C [in LDL-C analyses] or LDL-C [in HDL-C analyses], and other risk factors) for the 
relation of BP / lipid categories with incident CHD events.
Conclusion: Abnormalities in blood pressure combined with either increased LDL-
cholesterol or decreased HDL-cholesterol confer increased risks for CHD in elderly 
persons, reinforcing the importance of controlling both conditions.
Hazard Ratios for CHD Events by BP and Lipid Category (*p<0.05, **p<0.01)
LDL-C (mg/dl) <100 100-129 130-159 >160
BP<120 / 80 mmHg 1.0 (reference)
0.9 
(0.6-1.4) 1.0 (0.7-1.5) 1.5 (0.99-2.2)
BP 120-139 / 80-89 mmHg 1.2 (0.8-1.7)
1.2 
(0.9-1.7) 1.2 (0.8-1.7) 1.7 (1.2-2.4)**
BP 140-159 / 90-99 mmHg 1.5 (1.1-2.2)*
1.6 
(1.2-2.3)** 1.6 (1.1-2.2)* 1.7 (1.2-2.5)**
BP >160 / >100 mmHg 2.1 (1.4-3.2)**
1.8 
(1.2-2.6)** 2.1 (1.4-3.0)** 2.5 (1.7-3.8)**
HDL-C (mg/dl) >60 40-59 <40
BP<120/80 mmHg 1.0 (reference) 1.5 (1.1-2.1)* 1.8 (1.3-2.7)**
BP 120-139 / 80-89 mmHg 1.3 (0.9-1.8) 1.7 (1.3-2.3)** 2.2 (1.5-3.2)**
BP 140-159 / 90-99 mmHg 1.9 (1.4-2.6)** 2.0 (1.5-2.8)** 2.9 (2.0-4.2)**
BP >160 / >100 mmHg 2.9 (2.0-4.0)** 2.7 (1.9-3.7)** 2.0 (1.2-3.3)**
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1028-205 Nox1 Promoter Polymorphism is Associated With 
Coronary Artery Disease and Myocardial Infarction
Payam Mehranpour, Harland Austin, Shaoshan Wang, Bernard Lassegue, Qing Song, 
Wei Li, Craig Hooper, A. Maziar Zafari, Emory University School of Medicine, Atlanta, 
GA, Atlanta VA Medical Center, Decatur, GA
Background: The induction of Nox1 expression in vasculature by factors such as 
Angiotensin II and oxidized LDL has been linked to cardiovascular pathology, including 
hypertension and atherosclerosis. We hypothesized that single nucleotide polymorphisms 
(SNPs) in the Nox1 promoter would alter Nox1 function and consequently affect 
cardiovascular phenotype.
Methods: We searched the Nox1 gene for genetic variants by denaturing high performance 
liquid chromatography, and three SNPs in the promoter region were selected for further 
analysis: -6360C/T, -3716G/T, and -545G/T. Genomic DNA was isolated from two cohorts: 
(1) A group of 290 patients who underwent cardiac catheterization and (2) A recently 
completed case-control study with first-incident MI cases (n=589) and controls (n=930) 
with no history of MI. The catheterization cohort was divided into two groups: 1) subjects 
with normal coronary arteries, luminal irregularities of <50%, and with single vessel 
CAD (>50% diameter stenosis); and 2) subjects with multi-vessel CAD. DNA fragments 
containing the SNPs were cloned into the pGL4.10 vector and minor allele constructs were 
created by mutagenesis. Firefly to Renilla luciferase activity ratio in transfected bovine 
aortic endothelial cells expressing major and minor allele plasmids was measured.
Results: In the catheterization group, there is an excess of the Nox1 -6360T allele (p = 
0.02) among patients with multi-vessel CAD. In the case-control study, we found a similar 
excess of this allele among MI cases compared to controls (p = 0.04). Similarly, the -
6360T allele resulted in a 119% increase in relative luciferase activity (p = 0.04).
Conclusions: In our cohorts, the -6360T allele of the Nox1 promoter is associated with 
multi-vessel CAD and MI. Furthermore, mutagenesis experiments show that the -6360T 
allele has a higher promoter activity as compared to the C allele. Since Nox1 is critical for 
vascular NADPH oxidase activity, vascular oxidative stress is likely altered in individuals 
with this SNP. These results suggest that the -6360 C/T Nox1 promoter SNP may be a 
novel genetic risk marker for CAD and MI.
2:00 p.m.
1028-206 Molecular Imaging of Early Atherosclerosis with 
Targeted Echogenic Immunoliposomes
Patrick H. Kee, Melanie R. Moody, Hyunggun Kim, Melvin E. Klegerman, Yuejiao Zou, 
Shaoling Huang, David D. McPherson, The University of Texas Health Science Center at 
Houston, Houston, TX
Background: Expression of adhesion molecules in the endothelium is a marker of 
earlier stage atherosclerosis. We hypothesize that expression of vascular cell adhesion 
molecule-1 (VCAM-1) in the arterial wall can be non-invasively detected by echogenic 
immunoliposomes (ELIP) conjugated to anti-VCAM-1 antibodies.
Methods: New Zealand White rabbits were fed an atherogenic diet for 8 weeks. Saline, 
unconjugated ELIP, non-specific IgG conjugated ELIP or anti-VCAM-1 conjugated ELIP 
were injected upstream from the area of interest. The proximal ascending and abdominal 
aorta were imaged with a sector array ultrasound transducer (8 MHz and a mechanical 
index of 0.08) and a Philips Sonos 7500 ultrasound machine. Enhancement of the arterial 
wall was measured offline using ImagePro software and expressed as mean gray scale 
values (MGSV).
Results: A pilot study demonstrated the onset of aortic endothelial VCAM-1 expression was 
consistently observed after 4-8 weeks of atherogenic diet. After 8 weeks of atherogenic 
diet, plasma cholesterol was elevated at 414±71 mg/dl. Peak enhancement of the aorta 
was seen at 10-15 min after injection of anti-VCAM-1 ELIP. Percentage increases in the 
MGSV at 15 min were 34±8% and 43±8% (mean±SEM) in the proximal ascending and 
abdominal aortas, respectively (figure).
Conclusion: Early stage atherosclerosis as evident by VCAM-1 expression can be non-
invasively detected with targeted ELIP and transcutaneous ultrasound imaging. 
2:00 p.m.
1028-207 Athero-protective Effects of a Human apoB-100 Related 
Peptide Vaccine in apoE-/- Mice Are Modulated by 
Peptide Dose and Time of Initiation of High Fat Diet
Xiaoning Zhao, Kuang-Yuh Chyu, Juliana Yano, Paul C. Dimayuga, Xiaojun Li, Portia 
Trinidad, Svetlana Jovicic, Bojan Cercek, Jan Nilsson, Prediman K. Shah, Cedars-
Sinai Medical Center, Los Angeles, CA, Malmö University Hospital, Lund University, 
Malmö, Sweden
Background: We have reported athero-protective effects of immunization with human 
apoB-100 related peptide 210 (p210). Here we tested if different doses of p210 and 
timing of high fat (HF) diet exposure modulate its athero-protective effects. Methods: 
Male apoE-/- mice were immunized at 6, 9, and 11 wks of age with p210 (KTTKQ SFDLS 
VKAQY KKNKH) at doses of 25, 50 or 100 µg conjugated to cBSA with alum as adjuvant. 
Mice receiving cBSA/alum served as control. HF diet was started 1 week before (Group1) 
or 1 week after the last injection (Group2). Atherosclerosis was assessed by en face 
analysis of lipid-stained aorta at 25 wks. Results: p210 immunization at 100 µg reduced 
atherosclerosis in both groups with greater reduction in Group 2 (61%) versus Group 1 
(36%; Table 1). Lower doses had no effect. Among mice immunized with 100 µg p210, 
Group 2 mice had lower p210 IgG compared with its control group (Table 1). p210 100 
µg also significantly suppressed LPS-induced dendritic cell (DC) maturation, assessed 
by CD86 expression in vitro, suggesting altered DC function. Conclusion: (1) p210 
immunization at 100 µg reduces atherosclerosis whereas lower doses are ineffective; 
(2) delayed initiation of HF diet until after completion of immunization produced greater 
athero-protective effects. Peptide dose and timing of HF diet modulate athero-protective 
effects of p210 immunization in apoE-/- mice. 
% Aortic Atherosclerosis P210 IgG titer (O.D.)
Group 1 control 9.6±2.5, n=8 0.322±0.192
Group 1 p210 immunized 6.1±2.5,* n=15 0.311±0.170
Group 2 control 8.2±3.1, n=19 0.387±0.230
Group 2 p210 immunized 3.2±1.9,* n=14 0.257±0.128,#
Data are mean±std; *p<0.05 vs. corresponding control by t-test; #p=0.06 vs. group 2 
control by t-test
2:00 p.m.
1028-208 IgM Antibodies Against Phosphorylcholine are 
Protective Factors for Atherosclerosis in Patients With 
Hypertension and Inhibit Uptake of Oxidized LDL in 
Macrophages
Johan Frostegård, Jun Su, Anna Cederholm, Xiang Hua, Anastasia Georgiades, Ingrid 
Dahlbom, Hans Grönlund, Ulf de Faire, Karolinska Institutet, Stockholm, Sweden
Background: Atherosclerosis is characterized by T cell and monocyte/macrophage 
infiltration in the intima of large arteries. Several different auto-antigens that can elicit 
this immune reaction have been proposed, including oxidized low density lipoprotein. 
Phosphorylcholine (PC) is a major immunogenic component in OxLDL. The aim of this 
study was to determine the importance of antibodies against PC for the development of 
atherosclerosis.
Methods: Two hundred and twenty six individuals with established hypertension (diastolic 
pressure > 95mmHg) from European Lacidipine Study on Atherosclerosis were studied. 
Antibodies of IgG and IgM subclass against PC (anti-PC) were tested by ELISA and 
high-sensitivity C-reactive protein (hsCRP) by nephelometry. As a surrogate measure of 
atherosclerosis, we used the mean of the maximum intima-media thicknesses (IMT) in 
the far walls of common carotids and bifurcations were determined by ultrasonography at 
the time of enrolment, and 4 years following enrolment. IgM anti-PC was extracted from 
human IgM. THP-1 monocytic cell-line was differentiated into macrophages and uptake of 
Oxidized LDL was studied by use of FACScan.
Results: Increases in IMT at follow-up were less common in subjects which at the time 
of enrolment had high IgM anti-PC (both 75th and 90th; odds ratios: 0.46; 95% CI: 0.25-
0.85; 0.36; 95% CI: 0.15-0.87). hsCRP was unrelated to IMT-changes. The relationship 
between IgM anti-PC, and changes in IMT was independent of age, treatment with 
antihypertensive drugs, smoking and lipids. There were no or only minor changes in anti-
PC levels between baseline and the 4 year follow-up period. Women had higher levels of 
IgM antibodies tested than men (p<0.05). anti-PC extracted from IgM were determined to 
be specific in competition experiments and abolished uptake of oxLDL in macrophages.
Conclusions: High levels of IgM anti-PC predict a favourable outcome in the development 
of carotid atherosclerosis in individuals with hypertension and could be a novel risk 
marker, indicating decreased risk at high levels. Furthermore, by inhibiting uptake of 
oxLDL in macrophages, anti-PC antibodies could inhibit atherosclerosis development.
2:00 p.m.
1028-209 Canonical Wnt-Pathway is Activated in Smooth Muscle 
Cells in Human Coronary Restenosis compared to 
Primary Atherosclerosis
Randolph Hutter, Walter Speidl, Valentin Fuster, Gerhard Bauriedel, Anapoorna Kini, 
Samin Sharma, Juan Jose Badimon, Mount Sinai School of Medicine, New York, NY, 
Klinikum Meiningen, Meiningen, Germany
Background: Recent in vitro reports imply the Wnt-pathway in the regulation of vascular 
smooth muscle cell (VSMC) growth and differentiation. Pro-proliferative and anti-apoptotic 
Wnt effects are mediated by the LRP-6 receptor on VSMC. To test the hypothesis that 
Wnt-pathway activation contributes to VSMC hyperplasia in vivo we compared human 
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coronary atherectomy samples from restenotic with primary atherosclerotic lesions (n=20) 
and examined the expression of beta-catenin (marker of Wnt-pathway activation), Wnt-1 
(secreted Wnt agonist) and of LRP-6. In addition, we tested the effect of Wnt pathway 
inhibition on VSMC growth in vitro using beta-catenin siRNA.
Methods and Results: Immuno-fluorescence labeling and morphometric analysis showed 
an increase in the number of alpha-actin positive VSMC in restenotic compared to primary 
lesions (1112 ± 517 vs. 657 ± 265 cells/mm2, P<0.05). The expression of beta-catenin as 
key effector molecule of the Wnt pathway was strongly increased in VSMC in restenotic 
tissue and closely co-localized with cell-rich myxomatous areas (80% ± 18 vs. 18% ± 15 
of intimal cells, P<0.05). Intimal VSMC number positively correlated with beta-catenin 
expression (r=0.87, P<0.05). Consistently, increased membrane-bound as well as
extra-cellular expression of the secreted glycoprotein Wnt-1 was found in the restenosis 
group (P<0.05). Double-labeling studies showed a strong co-localization of membrane-
bound Wnt-1 with LRP-6 in VSMC implying Wnt-1 binding to its receptor in the increase of 
the downstream effector molecule beta-catenin in these cells. In vitro, VSMC growth was 
significantly inhibited by treatment with beta-catenin siRNA.
Conclusions: Our data indicate an important role for the Wnt pathway in human coronary 
restenosis. The Wnt signaling pathway is highly conserved and is critically involved in 
hyperplasia and tumor progression in many organ systems. The selective and increased 
presence of effector and receptor molecules as well as of agonists of the Wnt pathway 
in human restenotic tissue correlates with the degree of VSMC hyperplasia. This novel 
finding suggests Wnt inhibory strategies to better treat restenosis without inhibiting 
endothelial repair.
2:00 p.m.
1028-210 A Novel Gateway for Vascular Drug Delivery: Controlled 
Release of Nitric Oxide from Echogenic Liposomes
Shaoling Huang, Melanie R. Moody, Patrick H. Kee, Hyunggun Kim, Yong-Jian Geng, 
David D. McPherson, The University of Texas Health Science Center at Houston, 
Houston, TX
Background: Vascular endothelium forms a physical barrier for effective drug delivery to 
the arterial wall. We hypothesize that nitric oxide (NO) containing echogenic liposomes 
(EL) can enhance endothelial permeability and improve the efficiency of drug delivery 
into the arterial wall.
Methods: NO-EL composed of phospholipids and cholesterol were prepared by a 
pressurization-freezing method. To evaluate endothelial permeability, rabbit aortas were 
treated with 100 µg of NO-EL for 2 minutes and compared to controls. To determine the 
change in endothelial permeability after NO-EL treatment, fluorescein-labeled molecules 
of different sizes including FITC-dextran (MW 9,600), FITC-BSA (MW 66,000) and FITC-
liposomes (size 300 nm) were administered to aortas and incubated for 10 minutes. 
Following incubation, each aorta was washed and snap-frozen for histological sectioning 
and fluorescent microscopy.
Results: Five milligrams of NO-EL provided encapsulation of therapeutic/non-toxic 
concentration (4 µl) of NO. NO-EL were highly echogenic as assessed by in vitro 
ultrasound imaging. Treatment of the aortas with NO-EL improved endothelial permeability 
to molecules of differing sizes into the aortic wall (figure).
Conclusions: NO-EL can effectively improve endothelial permeability and facilitate drug 
delivery of differently sized compounds. This drug delivery strategy opens a new avenue 
for targeted therapeutic application of drugs into vascular walls with active atheroma. 
2:00 p.m.
1028-211 Heat Shock Protein 27 Overexpression Prevents Ox-
LDL Induced Anoikis by Inhibiting the Expression of 
Inflammatory Cytokines and Tissue-type Plasminogen 
Activator in Vascular Smooth Muscle Cells
Ji-Yeun Lee, Bok-Soo Lee, Joo Yun Kim, Jin Yong Choi, Ji Min Ban, Bonggun Song, 
Sang Yeub Lee, YoungKeun On, Jeong Euy Park, Samsung Biomedical Research 
Institute, Seoul, South Korea
Background: In our earlier study, Heat Shock Protein 27 (HSP27) was significantly less 
expressed in the atherosclerotic plaque core lesion compared with adjacent normal looking 
area in the human carotid endarterectomy specimen (Circulation,’06). As atherosclerosis 
progresses medial smooth muscle cells (SMC) disappear especially in the area where 
macrophage infiltration and inflammation is severe. We postulated that HSP27 expression 
may prevent smooth muscle cell anoikis or apoptosis induced by oxidative stress. We tried 
to investigate the possible mechanism by which HSP27 modulate oxidized LDL-induced 
anoikis and apoptosis in SMCs.
Methods and Results: We used YSMC cells which are the SMC lineages derived from 
aorta, and do not have HSP27 detected by HSP27 Antibody.When the YSMC cells were 
treated with oxidized LDL (oxLDL), it secreted inflammatory cytokines including TNF-α 
and IL-8 and chemokines such as MCP-1. When the cells were infected with adenoviral 
vector containing wild type HSP27 (Ad-HSP27), oxLDL-induced MCP-1 and IL-8 were 
dramatically inhibited (90% and 80% reduction, respectively) compared to that of vector 
control (Ad-ADR). Furthermore, Ad-HSP27 infected YSMC suppressed the production 
of tissue type plasminogen activator (tPA) by more than 5-fold. YSMC cells infected 
with Ad-HSP27mut, which has mutation in all three known phosphorylation site of the 
HSP27, showed only partial effect on the secretion of cytokines/chemokine as well as 
tPA production. These effects were mainly mediated through ERK signaling pathway and 
heme oxigenase1 is likely to be involved in the inhibitory effect. We also tested whether 
HSP27 could prevent apoptosis. As expected, only wild type HSP27 could fully prevent 
oxLDL-induced apoptosis by up-regulating bcl-2 expression, while mutant HSP27 did not 
affect bcl-2 expression but rather induced bax expression.
Conclusions: HSP27 plays an important role for the SMC survival by inhibiting the 
inflammatory cytokines/chemokines secretion as well as protease production and up-
regulating bcl-2 expression when exposed to oxidative stress.
2:00 p.m.
1028-212 Different Angiographic Characteristics of Myocardial 
Bridge is not Associated with Significant Coronary 
Artery Spasm
Zhe Jin, Seung-Woon Rha, Kang-yin Chen, Yoshiyasu Minami, Jin Oh Na, Soon Yong 
Suh, Cheol Ung Choi, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, 
Dong Joo Oh, Cardiovascular Center, Korea University Guro Hospital, Seoul, South Korea
Background The association of myocardial bridge (MB) and significant coronary artery 
spasm (CAS) was reported but whether the detailed angiographic characteristics of MB 
are associated with significant CAS remains controversial.
Methods Study population consisted of 1,151 patients (pts, age 54.73 ± 11.84 years, 
male 72%) with suspected angina pectoris, who underwent coronary angiography and 
Acetylcholine (Ach) provocation test between Nov 2004 and Feb 2007. A total of 323 
pts (28%) showed angiographic “milking effect” of MB. The demographic, angiographic 
parameters and provocation test results of pts with MB (n=323) were compared with 
those without MB (n=828). Multivariate logistic regression analysis was used to identify 
the predictors of Ach-induced CAS. In addition, the pts with MB were further divided into 
two groups according the provocation test results and the characteristics of the MB were 
compared between the two groups.
Results The percentage of positive provocation test result and of low-dose Ach induced 
coronary spasm were higher in MB group (71.5% vs. 54.6%, P<0.001 and 10.0% vs. 4.6%, 
P=0.017, respectively), whereas the fixed lesion in spasm segment was more common 
in non-MB group (9.5% vs. 3.4%, P<0.001). The multivariate logistic regression analysis 
revealed that presence of MB and current smoker were independent predictors of Ach-
induced significant CAS (MB, OR=3.261, 95% CI 2.069~5.141, P<0.00; current smoker, 
OR=2.077, 95%CI 1.313~3.287, P=0.002, respectively). In further analysis, the angiographic 
characteristics of MB such as location, length, and severity of narrowing during systolic 
period were not different between the provocation test positive and negative group.
Conclusion The presence of MB was an independent predicator of significant CAS 
and 71.5% of MB pts showed significant Ach induced CAS. However, the angiographic 
characteristics of MB such as location, length, stenosis during systole and the presence 
of fixed atherosclerotic lesion within the MB had no impact on the Ach induced CAS.
2:00 p.m.
1028-213 Interaction between Sca-1 Positive Bone Marrow 
Progenitor Cells and Resident Vascular Smooth Muscle 
Cells After Arterial Injury
Randolph Hutter, Walter Speidl, Valentin Fuster, Juan Jose Badimon, Mount Sinai 
School of Medicine, New York, NY
Background: Bone marrow progenitor cells (BMPC) contribute to endothelial repair but 
also supply vascular smooth muscle-like cells after arterial injury. The extent, however, to 
which BMPC contribute to arterial repair compared to resident non-bone marrow derived 
smooth muscle cells (SMC) remains controversial. To study the interaction between 
BMPC and resident SMC we performed arterial injury in mice reconstituted with GFP 
expressing bone marrow (BM) and used a co-culture system in vitro.
Methods and Results: C57/BL6 were reconstituted with GFP-positive BM after irradiation 
and underwent femoral arterial injury. At 3, 10 and 28 days the presence of BMPC and 
their specific marker expression were evaluated and compared to non-injured contra-lateral 
arteries (n=5 per time point). At 3 days multiple sca-1 and GFP positive cells accumulated 
in the adventitia while the endothelium was completely denuded and the neointima still 
absent. These cells displayed fibroblast-like features comprising up to 21 ± 4% of adventitial 
cells. At 10 days a cell-rich neointima has formed containing mostly Sca-1 positive BMPC 
appearing as small alpha-actin positive cells (81 ± 8% of cells). In the adventitia the infiltrate 
of Sca-1 and GFP double positive cells encroached on the media close to the EEL. At 28 
days a mature neointima has formed with a significantly decreased BMPC content (12 ± 
3 % cells) and a much higher proportion of non-bone marrow derived SMC. Of note, in 
non-injured arteries BMPC are absent in all compartments. In vitro, SMC like differentiation 
and proliferation of lineage negative sca-1 positive BMPC was enhanced up to 20 fold by 
co-culture with aortic SMC and SMC proliferation was increased by BMPC reciprocally.
Conclusions: Early after arterial injury Sca-1 positive BMPC show a strong presence in 
the neointima and take SMC-like shapes. At later time points, however, non-bone marrow 
derived SMC are predominant and are found in close proximity to SMC-like BMPC in 
the neointima. In vitro, VSMC and BMPC interact closely. Further studies are needed to 
determine the signals that control the interaction between BMPC and non-bone marrow 
derived SMC maintaining a balance during arterial repair.
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1028-214 End-organ Damage Due To Atherosclerotic Renal Artery 
Stenosis And Its Correlations To Outcome After Stent 
Placement
Luiz A. Bortolotto, Luis J. Kajita, Eduardo M. Krieger, Heart Institute (InCor), Hospital 
das Clínicas, Faculdade de Medicina Universidade de São Paulo, São Paulo, Brazil
Background: Extension of end-organ damage in renovascular hypertension (RVH) due 
renal artery stenosis (RAS) it is not well studied and could influence outcome after 
interventionist treatment. We aim to assess cardiac, renal and vascular involvement, 
blood pressure and renal function response 12 months after stent placement and the 
outcome predictors in 91 consecutive patients diagnosed RVH due atherosclerotic RAS.
Methods: We analyzed data obtained from echocardiogram, serum creatinine, 24 
hours proteinuria, coronariography, eye fundoscopy, and peripheral arteries before the 
procedure. All patients were treated with renal artery angioplasty and stent placement 
(104 arteries). After 12 months of follow-up we defined blood pressure and renal function 
responses according AHA/ACC criteria (2002).
Results: The most frequent end-organ damage observed were: a) heart - left ventricle 
hypertrophy (74%), severe systolic dysfunction (16,3%), coronary artery disease (36,6%); 
b) kidney - stage 3 to 5 chronic kidney disease (74%), 24-hs proteinuria > 150 mg (38%); 
c) vascular - grade 3 retinopathy (9%), peripheral artery disease (30%). Improvement of 
blood pressure control was observed in 65% and the renal function improved in 31%, 
remained stable in 55%, and impaired in 14% 12 months after procedure. In stepwise 
logistic regression analysis the factors related to a better blood pressure control after 
stent were diastolic blood pressure at discharge, age above 60 years and male gender, 
while the factors correlated to renal function behavior were severity of baseline renal 
failure, use of statins and a better blood pressure control. Non-fatal cardiovascular events 
occurred in 26% in the follow-up.
Conclusions: Cardiovascular and renal burden is severe in patients with atherosclerotic 
RAS. Stent placement improves blood pressure control and improves or stabilizes renal 
function in most of patients. The most important outcome predictors include age, gender 
and baseline renal function.
2:00 p.m.
1028-215 Dietary Intake of Long-Chain Omega-3 Fatty Acids 
Correlates Positively with Heart Rate Variability 
Among Patients with a History of Malignant Ventricular 
Arrhythmias
Anil Nigam, Paola A. Lanfranchi, Georgetta Sas, Elise Latour, Julie Lalonge, Martin 
Juneau, Robert Leblanc, Reginald Nadeau, Denis Roy, Montreal Heart Institute, 
Montreal, QC, Canada, Hopital du Sacre-Coeur de Montreal, Montreal, QC, Canada
Background: Dietary consumption of omega-3 fatty acids is associated with a lower risk of 
sudden cardiac death in patients with a history of myocardial infarction, and is believed to 
be partially due to beneficial effects on the autonomic regulation of cardiovascular function. 
We sought to evaluate the relationship between dietary polyunsaturated fat intake and heart 
rate variability (HRV) in a population at high risk of sudden arrhythmic death.
Methods: Dietary fat intake was assessed using a standardized 3-day food record among 
22 subjects (mean age 60.4 + 9.1 years, 2 females:20 males) with a history of malignant 
ventricular arrhythmias possessing an implantable cardioverter defibrillator. Short-
term HRV (10-minute analysis of 20-minute recordings under resting conditions) was 
measured using time-domain and spectral analyses.
Results: SDNN (standard deviation of normal-to-normal RR intervals) correlated 
with estimated daily consumption of marine-derived omega-3 fatty acids including 
ecosapentaenoic acid (EPA) (r=0.51, p=0.014), docosahexaenoic acid (DHA) (r=0.56, 
p=0.007) and total EPA + DHA (r=0.60, p=0.003). Mean NN (normal-to-normal RR 
intervals) also correlated with total EPA + DHA (r=0.47, p=0.026). Using spectral analysis, 
estimated daily consumption of linoleic acid (an omega-6 fatty acid), correlated positively 
with the normalized low-frequency band (LFn) (r=0.50, p=0.017) and the low/high 
frequency ratio (LF/HF ratio) (r=0.44, p=0.042) and negatively with the normalized high-
frequency band (HFn) (r=-0.55, p=0.013).
Conclusions: Consumption of marine-derived omega-3 fatty acids is associated with 
beneficial effects, while omega-6 fatty acids are associated with deleterious effects on 
HRV in subjects at high risk of sudden death. These data are consistent with clinical data 
showing that omega-3 fatty acids may reduce the risk of sudden cardiac death.
2:00 p.m.
1028-216 A randomized prospective study to compare the effects 
of three anti-hypertensives on plasma adiponectin and 
arterial stiffness
Young Seok Cho, Suk-Jin Lee, Kwang-Il Kim, Tae-Jin Youn, Woo-Young Chung, In-Ho 
Chae, Dong-Ju Choi, Cheol-Ho Kim, Dae-Won Sohn, Byung-Hee Oh, Young-Bae Park, 
Yun-Shik Choi, Cardiovascular Center, Seoul National University Bundang Hospital, 
Seongnam, South Korea, Department of Internal Medicine, Seoul National University 
College of Medicine, Seoul, South Korea
Background: To investigate the effects of anti-hypertensive therapies on adiponectin 
level and arterial stiffness, we performed a prospective randomized study to compare the 
effects of beta-adrenergic antagonist, calcium-channel blocker, and angiotensin receptor 
blocker on plasma adiponectin concentration and arterial pulse wave velocity(PWV). 
Methods: Seventy-six essential hypertension patients without diabetes mellitus 
were randomly administered with atenolol(50-100mg/d), amlodipine(5-10mg/d), or 
candesartan(8-16mg/d). Plasma adiponectin concentration, fasting glucose and insulin, 
lipid levels, and brachial-ankle(ba) PWV were measured before and 8 weeks after anti-
hypertensive therapy. Results: In three treatment groups (atenolol; n=28, amlodipine; 
n=24, candesartan; n=24), the mean age (years; 48±9, 49±11, 46±10, p=0.605) and 
baseline mean blood pressure(MBP) (mmHg; 119±9, 116±5, 117±5, p=0.299) were 
similar. MBP was reduced significantly after treatment in all three groups, and the post-
treatment MBP were not significantly different between groups (101±7, 103±6, 102±9, 
p=0.410). Plasma adiponectin concentration showed significant decrease only in atenolol 
group (µg/ml; 9.0±3.2 → 8.0±2.8, p=0.006), and did not show significant change in 
amlodipine (8.5±3.0 → 9.2±4.4, p=0.200) or candesartan group (9.1±4.7 → 9.3±5.1, 
p=0.855). The change in HOMA insulin resistance index was not significant in any group. 
HDL-cholesterol showed decreasing tendency only in atenolol group (mg/dl; 57.3±13.6 
→ 54.8±13.0, p=0.060). The baPWV decreased significantly in all three groups (cm/s; 
1501±213 → 1380±256, 1527±198 → 1421±162, 1577±252 → 1448±188, all p<0.01), 
and the amount of decrease were similar. Conclusions: The reduction in MBP & baPWV 
were not significantly different between three anti-hypertensives after 8 weeks of therapy. 
However, in atenolol-treated group, significant reduction in adiponectin and decreasing 
tendency in HDL-cholesterol were observed, suggesting that there should be careful 
consideration in selecting beta-adrenergic antagonist for hypertensive patients with 
obesity or low HDL-cholesterol.
2:00 p.m.
1028-217 Cutaneous Microvascular Dysfunction is Associated 
with Diabetes-Risk HLA in Youths with Type 1 Diabetes
Michal Odermarsky, Åke Lernmark, Petru Liuba, Pediatric Cardiology, Lund University 
Hospital, Lund, Sweden
Background: Functional disturbances in microcirculation in juvenile type 1 diabetes (T1D) 
are believed to underlie in part the later occurrence of cardiovascular complications 
associated with this disease. In some epidemiological studies of T1D, a greater risk 
of developing microvascular complications was observed in those with T1D high-risk 
HLA phenotypes. We investigated whether HLA-DQ 2/8, which is linked to highest T1D 
morbidity, influences the endothelium-dependent microvascular reactivity in young 
patients with T1D.
Methods: Skin forearm perfusion was measured using laser Doppler flowmetry during 
iontophoresis of acetylcholine (endothelium-dependent) and sodium nitroprusside 
(endothelium-independent) in 62 T1D children and adolescents (9-21 yrs; diabetes 
duration: 0.5-10 yrs) without overt diabetic microvascular disease. Markers of systemic 
inflammation and glycemic control were assessed in all patients. HLA genotypes were 
determined in dried blood spots by polymerase chain reaction followed by DELFIA® 
hybridization assay.
Results: HLA-DQ 2/8 was identified in 24 patients while the remaining 38 patients were 
negative for this genotype. The groups were similar with respect to age, BMI, diabetes 
duration, HbA1c and CRP. The vascular responses to acetylcholine, expressed as area 
under the curve, were decreased in the DQ 2/8 group compared to the non-DQ 2/8 group, 
and the difference remained significant after adjustment for age, diabetes duration, HbA1c 
and CRP (ANCOVA, p<0.05). In contrast, the responses to SNP were similar in both groups 
(p=0.16). Among the HLA-DQ 2/8 patients, CRP showed significant correlation with both 
systolic (r=0.76; p<0.001) and diastolic (r=0.50; p=0.01) blood pressure, while no such 
associations were observed in the non-DQ 2/8 group (r<0.2 and p>0.25 for both).
Conclusion: Diabetes high-risk HLA DQ 2/8 seems to be associated with endothelial 
microvascular dysfunction in young patients with type 1 diabetes. This might explain in 
part the previously observed association between diabetes-risk HLA and microvascular 
complications.
2:00 p.m.
1028-218 Bridging Oral Anticoagulation with Low Molecular 
Weight Heparin: Experience in 367 Patients with Renal 
Insufficiency
Heyder Omran, Kyung Mi Jeong, Giso Von der Recke, Christoph Hammerstingl, St. 
Marien Hospital, Bonn, Germany
Background: Patients with different stages of renal impairment are at elevated bleeding 
risk due to anticoagulant therapy. The safety and efficacy of bridging therapy in those 
patients using low molecular weight heparins is not determined and the exact treatment 
protocol is not stated.
Objectives: To determine the safety and feasibility of a standardized bridging regimen in 
patients with renal impairment using low molecular weight heparin (LMWH).
Setting: In hospital; after discharge, 30 day follow up by telephone call
Patients and methods: Since 2000, patients with renal insufficiency (Creatine Clearance [Cr Cl] 
<50ml/min according to Cockroft Gault Formula) undergoing invasive procedures with need for 
interruption of OAC were prospectively enrolled. Half- therapeutic enoxaparin doses (1 mg/kg 
once daily subcutaneously) were peri- procedurally administered when OAC was ineffective. 
Main outcome measures were the incidence of hemorrhagic or thromboembolic events.
Results: In total 367 patients were included, overall Cr Cl was 35.1 ± 11.8 ml/min, 
including 264 with Cr Cl 30 - 50 ml/min and 103 pts with Cr Cl 20- 30ml/min, respectively. 
53 patients were treated after mechanical valve replacement and 314 pts with atrial 
fibrillation. These patients underwent major surgery (n=34), minor surgery/ endoscopy 
(n=175), pacemaker implantation (n=82), or coronary catheterization (n=76). Bridging 
therapy was for a mean of 7.6 ± 5.2 days. 51 patients (13.9%) were treated as outpatients. 
No thromboembolic (0%; CI 0.0 - 1.0%) and three major bleeding complications occurred 
(0.8%, CI 0.2 - 2.4%); minor bleeding occurred in 24 patients (6.5%, CI 4.2 - 9.5%).
Conclusions: Bridging- therapy using reduced doses of enoxaparin in patients with renal 
impairment was safe and effective in a large cohort of patients, without need for laboratory 
monitoring of LMWH- activity. This approach did not increase thromboembolism or major 
bleeding complications.
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1028-219 Homocysteine Variations Induce Endothelial 
Dysfunction by Activating Endothelin-1 Pathway in 
Hypertensive Patients
George Bouras, Dimitris Tousoulis, Charalambos Antoniades, Kiriakoula Marinou, 
Carmen Vasiliadou, Nikos Papageorgiou, Alexios Antonopoulos, Elli Stefanadi, Costas 
Tsioufis, Kostas Toutouzas, Christodoulos Stefanadis, 1st Cardiology Department, 
Hippokration Hospital, Athens Medical School, Athens, Greece
Background: Endothelin-1 (ET-1) is a regulator of arterial blood pressure in humans. It 
is unclear whether homocysteine-induced oxidative stress is implicated in the regulation 
of ET-1 expression in hypertension. We examined the impact of acute homocysteinemia 
on endothelial function in hypertensive and healthy individuals, and the potential role of 
ET-1.
Methods: In this double-blind placebo controlled study, 35 hypertensives and 30 healthy 
volunteers underwent methionine-loading (100mg met/Kg BW) after they received vitamins 
C (2g) + E (800IU) (16 hypertensives (HTN+vit) and 15 healthy (C+vit)) or placebo (18 
hypertensives (HTN+placebo) and 15 healthy (C+placebo)). Endothelial function was 
evaluated by plethysmography (to determine endothelium dependent dilation (EDD)), at 
baseline and 4 hours post loading (4hPML). ET-1 and lipid hydroperoxides (per-ox) levels 
were measured by ELISA.
Results: Homocysteine was similarly increased in both hypertensives (by 22.2±1.26µM 
p<0.0001) and healthy controls (by 23.2±2.22 µM, p<0.0001), and was not affected 
by pre-treatment with antioxidants. EDD was decreased in HTN+placebo (75.4±11.5 
to 51.6±7.3%, p<0.05) and C+placebo (96.7±9.6 to 52.2±6.5%, p<0.0001), while 
antioxidants did not prevent this effect in either HTN+vit (76.4±8.8 to 53.7±7.8%, 
p<0.01) or C+vit(86.6±10.5 to 41.1±6.3%, p<0.001). ET-1 was increased 4hPML only in 
hypertensives (HTN+placebo: 1.09±0.3 to 1.40±0.4pg/ml, p<0.05) an effect not prevented 
by antioxidants (HTN+vit: 0.82±0.08 to 1.1±0.09pg/ml p<0.01). Per-ox were decreased 
in the HTN+vit (170[65-368] to 148[98-372]pg/ml, p<0.05) but not in the HTN-placebo 
(170[65-268] to 148[98-372]pg/ml, p=NS). No effect of methionone-loading was observed 
on ET-1 in healthy individuals (C+placebo: 1.96±0.84 to 1.87±0.77pg/ml and C+vit: 
3.59±1.35 to 2.84±1.15pg/ml, p=NS).
Conclusions: Experimental homocysteinemia rapidly blunts endothelial function in both 
hypertensive and healthy individuals. The rapid elevation of ET-1 levels observed only 
in hypertensives, suggests that ET-1 may be a key mediator of homocysteine-induced 
endothelial dysfunction, independently of oxidative stress status.
2:00 p.m.
1028-220 Prognostic Values of theTIMI Risk Index, TIMI Risk 
Score and Modified TIMI Risk Index in the Early 
Stratification of Patients with ST-Segment Elevation 
Myocardial Infarction
Simon Kouz, Rinfret Stephane, Mark Eisenberg, Erick Schampaert, Claude Lauzon, 
Bernard Cantin, Marc Afilalo, Claude Levesque, Richard Harvey, Thao Huynh, McGill 
University Health Center, Montreal, QC, Canada
Introduction: Several risks scores have been developed in order to stratify patients at 
an early stage who are presenting with ST-elevation myocardial infarction (STEMI). The 
objective of this study was to assess the predictive value of available STEMI scores risk 
scores for in-hospital mortality in patients (pts) who received reperfusion therapy in a 
non-selected population and to assess the performance of a modified TIMI risk score, 
incorporating the Killip class.
Methods: The AMI-QUEBEC study was a cohort study of pts admitted for STEMI at 17 
hospitals in 2003 in Quebec, Canada. We computed c-statistics for risk scores that can 
be calculated at pts’ arrival. We modified the TIMI risk index by multiplying this index with 
Killip class on arrival and assessed its predictive value by receiver-operating curves.
Results: There were 1,655 pts in our cohort, of whom 1,363 pts received reperfusion 
therapy. The mean age was 61.1±12.6 years and 26% were females. The TIMI risk score 
and the TIMI risk index had similar c-statistics (0.75, 95% CI: 0.69-0.80). The modified 
TIMI risk index had the highest predictive value (0.82, 95% CI: 0.78-0.87) (Figure).
Conclusions: Early STEMI risk scores performed reasonably well in this non-selected 
population. A modified TIMI risk index incorporating the Killip class may be more predictive 
of in-hospital mortality than the original TIMI risk index, and merits further evaluation. 
2:00 p.m.
1028-221 Modified TIMI Risk Index: Risk Stratification and its 
Usefulness in the Selection of a Reperfusion Modality 
in ST-Segment Elevation Myocardial Infarction
Simon Kouz, Stephane Rinfret, Erick Schampaert, Mark Eisenberg, Marc Afilalo, 
Bernard Cantin, Claude Lauzon, Claude Levesque, Michel Nguyen, Thao Huynh, McGill 
University Health Center, Montreal, QC, Canada
Background: Although the predictive values of the TIMI risk index had been shown, the 
prognostic value of the Killip class was not incorporated in this index. We hypothesized 
that a modified TIMI risk index with incorporation of Killip class may be useful to identify 
low-risk STEMI patients (pts) in whom fibrinolytic therapy (FT) provides the same benefits 
as primary percutaneous coronary intervention (PPCI).
Method: The AMI-QUEBEC study was a retrospective cohort of STEMI pts at 17 hospitals 
in Quebec, Canada, in 2003. The TIMI index was calculated as heart rate x (age/10)2/
systolic blood pressure. We modified the TIMI index by multiplying this index with the Killip 
class and assessed its predictive value with a comparison of c-statistics. We compared 
the in-hospital mortality of pts who underwent FT and PPCI in low-risk pts, based on the 
new risk score. Multivariate logistic regression was performed to identify independent 
determinants of in-hospital mortality for the low risk pts.
Results: There were 1,363 pts who received RT. The mean age was 61.1±12.6 years 
and 26% were females. In-hospital mortality for each quintile was as follows: 1st (scores 
ranging from 0 -12): 1.5%, 2nd (13 - 18): 1.5%, 3rd (19 -23): 2.3%, 4th (24-37): 14.8% 
and 5th (>37): 22.6%. The c-statistic for this new index was 0.82 (95% CI: 0.78-0.87), 
confirming good discriminative capacity, whereas the c-statistic of the TIMI risk index was 
0.75 (95% CI: 0.69-0.80).
Sixty-percent of the cohort had a modified TIMI risk index <24. In this subgroup, pts who 
received FT and PPCI had similar age, % of females, anterior STEMI and symptom 
duration. The in-hospital mortality with PPCI and FT was similar in these low-risk 
pts (1.5% vs 1.9%, p: NS). In these pts, only age ≥75 years and female gender were 
independent predictors of in-hospital mortality, OR 22.0 (95% CI : 4.8-10.3) and OR 4.1 
,(95% CI : 1.1-15.2), respectively.
Conclusions: The TIMI risk index modified by inclusion of Killip class may be useful to 
identify low-risk pts in whom PPCI and FT yield similar in-hospital survival. These results 
might help an optimal utilization of resources with a more individualized approach in 
STEMI care.
2:00 p.m.
1028-222 Predictors of Long Term Survival among Patients 
Receiving Implantable Cardioverter-Defibrillators
Sanjeev P. Bhavnani, Nitesh Sood, Craig I. Coleman, Danette Guertin, William Baker, C. 
Michael White, Ravi Yarlagadda, Christopher Clyne, Jeffrey Kluger, Hartford Hospital, 
Hartford, CT
Background: Implantable cardioverter-defibrillator (ICD) therapy improves the 2-4 year 
survival for individuals at high-risk for sudden cardiac death. We sought to identify the 
clinical predictors of greater than 5-year survival among ICD recipients.
Methods: We retrospectively identified 1,445 individuals who underwent ICD implantation 
at a single tertiary hospital. We compared the clinical characteristics of individuals with 
death within five years (N=279) with individuals with death or last known follow up greater 
than five years (N=271). Multivariable logistic regression was used to calculate adjusted 
odds ratios (AOR) with 95% confidence intervals (CI).
Results: Our population had an average age of 65.1 ± 13.0 years, ejection fraction of 
28.9 ± 14.4%. Overall, 77.8% of individuals were male and 57.6% had an ICD placed for 
primary prevention of sudden cardiac death. Factors associated with long-term survival 
are depicted in the table below.
Conclusions: We identified 8 positive and 5 negative independent predictors of long term 
survival in our ICD population. Knowledge of these variables could be used subsequently 
to identify individuals for possible adjuvant therapies and identification of comorbid 
conditions that may require more aggressive therapies. 
Positive Independent Predictors P-Value AOR 95% CI
Sotalol Therapy at Implantation <0.001 3.552 2.366 5.333
Dofetilide Therapy at Implantation 0.028 2.862 1.122 7.300
History of Hypothyroidism <0.001 2.364 1.495 3.740
Age at Implantation < 40 years <0.014 2.287 1.180 4.432
Single Chamber ICD <0.001 2.189 1.583 3.028
Male gender 0.020 1.622 1,080 2.435
History of CABG Surgery 0.009 1.540 1.116 2.125
Digoxin Therapy at Implantation 0.017 1.487 1.074 2.060
Negative Independent Predictors P-Value AOR 95% CI
History of End Stage Renal Disease 0.031 0.108 0.014 0.818
Primary Indication for ICD Implantation <0.001 0.161 0.115 0.226
History of Obesity 0.034 0.201 0.046 0.883
History of Heart Failure <0.001 0.377 0.234 0.607
Plavix Use at Implantation 0.006 0.427 0.234 0.779
Table 1. Independent Predictors of Long Term Survival 
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1028-223 Heart Rate Recovery and Doppler Echocardiography 
in Patients with Heart Failure: A Correlative and 
Prognostic Analysis
Marco Guazzi, Jonathan Myers, Mary Ann Peberdy, Daniel Bensimhon, Paul Chase, 
Sherry Pinkstaff, Ross Arena, 1University of Milano, San Paolo Hospital, Milano, Italy, 
Virginia Commonwealth University, Richmond, VA
Background: Previous research has demonstrated the prognostic value of Doppler 
echocardiography in the heart failure (HF) population. Heart rate recovery (HRR) has 
recently shown promise as a prognostic marker in patients with HF. The purpose of this 
investigation was to assess the relationship between and combined prognostic value of 
Doppler echocardiography and HRR in a HF cohort.
Methods: Two-hundred and forty-three subjects with HF (190 male/53 female, age: 62.2 
±9.7 years) underwent standard 2-dimensional and Doppler echocardiography and 
maximal exercise testing to determine: 1) the ratio between mitral early (E) to mitral 
annular (E´) velocity; 2) left ventricular ejection fraction (LVEF); 3) LVmass; 4) LV end 
systolic volume (LVESV); and 5) HRR at one minute post exercise.
Results: Heart rate recovery was significantly correlated with LVEF (r = 0.14, p=0.03), 
LVmass (r = -0.30, p<0.001) and E/E’ (r = -0.49, p<0.001). The correlation between 
LVESV and HRR was not statistically significant (r=0.13, p=0.05). There were 48 cardiac-
related deaths during the 23.2 ±21.1 month tracking period (annual mortality rate: 9.4%). 
Multivariate Cox regression analysis revealed HRR was the strongest predictor of cardiac 
mortality (Chi-square: 62.5, p<0.001). Left ventricular mass (Residual chi-square: 22.7, 
p<0.001), E/E’ (Residual chi-square: 11.9, p=0.001) and LVESV (Residual chi-square: 5.9, 
p=0.015) all added significant prognostic value and were retained in the regression while 
LVEF was removed (Residual chi-square: 0.007, p=0.94). Using the following threshold 
values for abnormal: 1) HRR < 17 beats per minute; 2) LVmass >/= 238 grams; 3) E/E’ 
>/= 10; and 4) LVESV >/=113 milliliters, Kaplan-Meier analysis revealed the percentages 
of subjects surviving in zero or one, two, three and four abnormal value subgroups were 
97.2%, 71.7%, 61.9% and 32.4%, respectively (Log-rank: 107.7, p>0.001).
Conclusion: To our knowledge, this is the first investigation demonstrating the associations 
between HRR and variables obtained from Doppler echocardiography in subjects with 
HF. Furthermore, the combination of both assessment techniques provides improved 
prognostic discrimination.
2:00 p.m.
1028-224 Does Routine Assessment of Insulin Sensitivity Identify 
Type 2 Diabetic Patients With High Cardiovascular Risk?
Michel P. Hermans, Sylvie A. Ahn, Michel F. Rousseau, University of Louvain, Brussels, 
Belgium
Background: Insulin resistance (IR) is the hallmark of the metabolic syndrome (MetS) and 
type 2 diabetes mellitus (T2DM), yet routine assessment of insulin sensitivity (IS) is not 
performed. Since it is not established whether the link between IR and cardiovascular (CV) 
disease revolves around a continuous relationship with IS, we systematically assessed 
HOMA-IS in unselected T2DM pts (HOMA calculator; normal 100%).
Methods: We measured IS in 500 consecutive T2DM pts, divided according to IS quintiles; 
the lowest quintile (QI; n=100) was compared with the 4 upper ones (QII-V; n=400). 
These cohorts were analyzed with respect to MetS and macroangiopathy [coronary and 
peripheral artery disease (CAD/PAD), transient ischemic attack (TIA)/stroke)] prevalence, 
alongside emerging CV risk factors such as hsCRP, non-HDL-C/HDL-C and adiponectin.
Results: table. QI pts had higher BMI and waist [mean (1SD) 32.8 (6.4) vs. 28.8 (4.9) 
kg/m2 and 112 (14) vs 102 (12) cm in QII-V; p<0.05]. Despite unfavourable bioclinical 
characteristics, QI had similar prevalences of CAD, PAD, TIA/stroke and overall 
macroangiopathy compared with QII-V.
Conclusions : Severe impairments in IS do no provide further CV risk stratification in 
T2DM pts, suggesting that the relationship CVD-IR is not linear in these high-risk pts. 
While our policy to routinely assess IS clearly indicates that the majority of T2DM are IR 
and have MetS, their current (and low) IS no longer behaves as a continuous, decremental 
metabolic variable.
Lower quintile 
(QI, n=100)
Four upper quintiles 
(QII-V, n=400) P
Homa-S (%) 20 (5) 60 (29) ~
MetS (NCEP ATPIII) (%) 91 76 <0.05
Adiponectin (µg/ml) 38 (24) 63 (42) <0.05
hsCRP (mg/dL) 0.58 (0.76) 0.35 (0.53) <0.05
non-HDL-C/HDL-C 3.84 (2.24) 3.26 (1.41) <0.05
CAD (%) 25 23 NS
PAD (%) 13 15 NS
TIA/Stroke (%) 6 6 NS
Data expressed as percent or mean (1SD)
2:00 p.m.
1028-225 Cardiovascular Risk in Women: The link between 
Framingham Risk Score and education inequalities
Stella M. Yala, Elaine M. Fleck, Robert Sciacca, Darlene Castro, Elsa V. Giardina, 
Columbia University, New York, NY
Background: Low education level links cardiovascular disease with individual risk factors. 
It is unknown whether the Framingham Risk Score (FRS) is related to disparities in 
education. We hypothesized that higher FRS are linked to level of education in women.
Methods:We analyzed 172 women without known CAD enrolled in a prospective study 
between 09/2005 and 05/2007. FRS was calculated using the ATP III-FRS charts. 
Estimated 10-year coronary heart disease risk was classified as low (less or equal 5%), 
intermediate (6-20%) or high risk (>20%). Education was categorized as less or equal 8th 
grade [A], 9th grade and less or equal high school graduate or GED [B], college 1 to 3 
years [C] and college more or equal 4 years [D]. Data was compared with Chi2 test and 
p <0.05 considered significant.
Results: Mean age was 58±12 years. Stratified by FRS, 41.7% were low, 4.4% 
intermediate and 49.5% high-risk. By education, 34.9% were A, 23.8% B, 9.9% C and 
31.4% D. Predicted risk for cardiovascular events was strongly related to education. In 
the high FRS group (n=94), 63.8% (n=60) belonged to education Group A, 27.6% (n=26) 
to B, 2.1% (n=2) to C and 6.3% (n=6) to D, while in the low FRS group 0% (n=0), 18.3% 
(n=13), 19.7% (n=14) and 62.0% (n=44) respectively (p=<0.001).
Conclusion: Lower education level is strongly linked to high FRS and can have a synergistic 
effect on cardiovascular risk emphasizing the importance of targeting intervention and 
prevention efforts at these populations.
2:00 p.m.
1028-226 Effects of a Long Term Lifestyle and Exercise 
Intervention on Arterial Structure, Function, and 
Compliance in Healthy Patients with Type II Diabetes
Brian A. Haluska, Leanne Jeffriess, Melodie Downey, Louise Smith, Matthew Hordern, 
Johannes Prins, Stephane G. Carlier, Thomas H. Marwick, University of Queensland 
Department of Medicine, Brisbane, Australia, The Cardiovascular Research Foundation, 
New York, NY
Background: Risk factor intervention trials in typeII diabetes (DM) have reported 
favourable (Steno-2, Look AHEAD) or limited effects (Diabetes Intervention Study). We 
sought to determine the effects of lifestyle intervention on arterial structure, function and 
compliance in addition to metabolic and functional markers.
Methods: We studied 179 DM pts (90men; age 55±8) with no known CVD. Pts were 
randomized to usual care or intervention, comprising dietary monitoring and a combination 
of monitored exercises 3X/week for 4/52, and then home exercise and monthly instruction. 
Clinical and biochemical variables, intima-media thickness (IMT), brachial artery reactivity 
(FMD) and arterial compliance (TAC) were compared at baseline and 1 year.
Results: Mean time to follow-up was 54±9weeks. Weight (90±18), BMI (31±5.5) and 
HbA1c (7.5± 1.5) were increased and FMD was impaired (4± 3%) but blood pressure 
(130±19/81±8) and TAC (1.35± .57) were normal in both groups at baseline. At 1 year 
there were sig differences in most metabolic and functional indices (Table). However, 
there were no sig differences in SBP, PP, FMD, IMT or TAC. Comparison of subgroups 
by HbA1c, BMI, IMT, HOMA or gender showed no sig differences at 1 year in any of the 
vascular parameters. 
Control Int p Control Int p
ΔFat mass 99±11% 103±12% p<.02 ΔSBP 4.7±16 2.0±19 NS
ΔBMI 99±6% 101±6% p<.01 ΔPP 6.9±15 2.8±16 NS
ΔGlucose 99±27% 112±49% p<.03 ΔFMD 2±11% 0±3% NS
ΔHOMAIR 102±64% 132±65% p<.03 ΔIMT .01± .06 .01± .07 NS
ΔVO2 111±22% 103±19% p<.02 ΔTAC .03± .69 -.02± .56 NS
Conclusions: As in previous studies, long-term lifestyle intervention improves metabolic 
and functional markers in pts with DM. However, it does not appear to have an effect on 
arterial structure, function or compliance.
A348  ABSTRACTS - Vascular Disease, Hypertension and Prevention JACC March 11, 2008 
Va
sc
ul
ar
 D
is
ea
se
, 
H
yp
er
te
ns
io
n 
an
d 
P
re
ve
nt
io
n
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1028-227 Long-Term Prognostic Factors of Young Patients 
(≤35 Years) Having Acute Myocardial Infarction: the 
Detrimental Role of Continuation of Smoking
Loukianos S. Rallidis, Christoforos Komporozos, Demosthenes Panagiotakos, 
Katerina Fountoulaki, Panagiotis Vavoulis, Ioannis Rizos, Ioannis Lekakis, Dimitrios T. 
Kremastinos, University General Hospital Attikon, Athens, Greece, General Hospital of 
Nikea, Piraeus, Greece
Background: There are few data regarding the prognostic role of continued smoking in 
young survivors of acute myocardial infraction (AMI) after the event. We evaluated the 
impact of smoking on long-term outcome in individuals with AMI ≤35 years of age.
Methods: We recruited 147 consecutive survivors of AMI ≤35 years of age. Patients were 
followed-up for up to 10 years. Clinical end points were: readmission for acute coronary 
syndrome, cardiac death or coronary revascularization due to clinical deterioration.
Results: The most prevalent risk factor at presentation was smoking (94.8%). Follow-
up data were obtained by 135 patients. During follow-up 75 (55.6%) patients reported 
continuation of smoking. Forty-four (32.6%) patients presented cardiac events (3 deaths, 
30 acute coronary syndromes, and 11 revascularizations). The figure shows the event 
free Kaplan-Meir survival curves according to smoking after AMI.
Multivariable data analysis showed that persistence of smoking (odds ratio [OR]=2.35, 
confidence interval [CI] 1.5 to 5.25, p=0.03) and ejection fraction at presentation 
(OR=0.95, CI 0.91 to 0.98, p=0.008) were the only significant predictors of cardiac events 
after adjusting for various confounding factors. Continuation of smoking was the most 
significant predictor of cardiac events (had the lowest log-likelihood ratio as compared 
to ejection fraction).
Conclusions: Persistence of smoking is the most powerful predictor for the recurrence of 
cardiac events in patients with premature AMI.
2:00 p.m.
1028-228 Carotid Plaque Morphology Correlates with Coronary 
Atherosclerotic Burden and Stenosis on 64-Slice 
Computed Tomography
Rabeea Aboufakher, Renee Bess, Howard Rosman, Mahnoud Othman, John Frank, 
Zuhair Allebban, Gerald Cohen, St. John Hospital and Medical Center, Detroit, MI
Background: Carotid plaque detected by ultrasonography is associated with coronary 
artery stenosis (CS) diagnosed by invasive coronary angiography and clinical events. 
However, the relationship between carotid disease and CS on coronary CT Angiography 
(CTA) has not been previously studied.
Methods: We performed carotid ultrasound on 150 consecutive subjects referred for CTA 
for risk-stratification. Carotid plaque was categorized as 0: no plaque, type 1: homogenous 
noncalcified, 2: heterogenous with or without calcification, and 3: complex or occlusive. 
Plaque type was correlated with CS and coronary artery calcium (CAC) score on CTA.
Results: Of the subjects (110 men, 58+10 years), 9% were diabetic, 48% hypertensive, 
54% had dyslipidemia, and 10% had known coronary disease. Carotid plaque was 
present in 71% (n = 107), whereas CS on CTA was present in 66% (n= 99), with CS 
>50% in 23% (n= 34). Carotid plaque type significantly correlated with coronary stenosis 
(r= 0.5, p= 0.001) (figure). A similar relationship with CAC score was present (r= 0.52, 
p= 0.001). Of subjects with no CS, 52% (n= 37) had carotid plaque while 21% (n = 9) of 
subjects with no carotid plaque had CS. 
Conclusions: Carotid ultrasound assessment of plaque morphology correlates with coronary 
stenosis as well as CAC score detected by CTA and represents a safe, inexpensive, and 
readily repeated method of predicting coronary disease. Therefore, carotid ultasound may 
be the desired initial imaging tool in cardiovascular risk stratification. 
2:00 p.m.
1028-229 Left Ventricular Hypertrophy Is Associated With a State 
of Pronounced Inflammatory Activation and Arterial 
Stiffening in Essential Hypertension: A Novel Approach 
to Target Organ Damage
Kyriakos Dimitriadis, Costas Tsioufis, Costas Thomopoulos, DImitris Tsiachris, Aliki 
Gennadi, Dimitris Tousoulis, Christodoulos Stefanadis, Ioannis Kallikazaros, Department 
of Cardiology, Hippokration Hospital, Athens, Greece
Background: Subclinical inflammation and arterial stiffening are markers of cardiovascular 
risk, while left ventricular (LV) hypertrophy is an independent risk factor. In this study we 
examined the interrelationship between augmented LV mass, high-sensitivity C-reactive 
protein (hs-CRP), serum amyloid-A (SAA), tumor necrosis factor-a (TNF-a) and arterial 
stiffness in essential hypertensives.
Methods: Our population consisted of 295 newly diagnosed untreated non-diabetics with 
stage I to II essential hypertension [192 men, mean age=50 years, office blood pressure 
(BP)=148/95 mmHg] that underwent echocardiographic examination and according to 
gender-specific criteria were divided into those with LV hypertrophy (n=104) and those 
with normal LV mass (n=191). Arterial stiffness was evaluated on the basis of carotid to 
femoral pulse wave velocity (PWV), by means of a computerized method (Complior SP).
Results: Patients with LV hypertrophy compared to those without LV hypertrophy were 
older (54±4 vs 45±7 years, p<0.005) and had greater 24-h systolic BP (138±10 vs 132±14 
mmHg, p<0.001). In the total population, hs-CRP was associated with 24-h systolic BP 
(r=0.144, p<0.05), SAA (r=0.425, p<0.0001), TNF-a (r=0.191, p<0.05) and PWV (r=0.233, 
p<0.0001). Moreover, PWV was associated with age (r=0.399, p<0.0001), 24-h systolic 
BP (r=0.250, p<0.0001), SAA (r=0.249, p<0.05), and TNF-a (r=0.286, p<0.0001). Although 
the two groups did not differ regarding body mass index and lipid levels (p=NS for all), 
hypertensives with LV hypertrophy as compared to those without exhibited higher levels 
of hs-CRP (2.9±0.7 vs 2.1±0.4 mg/l, p<0.05), SAA (9.0±5.3 vs 6.1±4.6 mg/dl, p<0.05), 
TNF-a (2.74±0.57 vs 1.71±0.4 pg/ml, p<0.001) and PWV (8.9±1.2 vs 7.8±1.4 m/sec, 
p<0.05). Analysis of covariance revealed that inflammatory markers levels and PWV values 
remained significantly different between groups after adjustment for confounders (p<0.05).
Conclusion: LV hypertrophy in essential hypertensives is accompanied by pronounced 
inflammatory activation and impaired arterial compliance. These findings may partially 
explain the cardiovascular risk associated with LV hypertrophy in this setting.
2:00 p.m.
1028-230 Framingham Risk Score Inadequately Predicts Patients 
at Risk of a First ST Elevation Myocardial Infarction
Bertram Mukete, Yufei Xiang, Lynn Moran, Martin E. Matsumura, Penn State College of 
Medicine/Lehigh Valley Hospital, Allentown, PA
Background: The Framingham Risk Score (FRS) and ATPIII guidelines are the standard 
tools used to assess the risk of a first cardiac event and institute primary preventive 
therapy. Because patients presenting with ST elevation myocardial infarction (STEMI) 
tend to have less signficant risk profiles vs. non-ST elevation ACS, we hypothesized that 
FRS may underestimate cardiac risk in first-time STEMI patients.
Methods: A retrospective analysis was performed on all patients presenting with a first 
STEMI and without a history of CAD or equivalent for calender years 2004-2006 at a single 
teaching community hospital. FRS was calculated for each patient based on admission 
demographics and fasting lipid profiles. Patients were divided based on whether or not 
they were treated with statins prior to STEMI; the non-statin group was further subdivided 
into Framingham 10 year risk categories.
Results: Of 238 patients who met study criteria, 45 (18.9%) were on a statin at the time 
of STEMI. Of the remaining 193, 46 had FRS and lipid profiles meeting ATPIII criteria for 
statin therapy: 14 (7.3%) with 10yr event risk>20%, 28 (14.6%) with 10yr risk 10-19%, 2+ 
risk factors, and LDL>130; and 4 (2.1%) with 10yr risk <9, 2+ risk factors, and LDL>160. 
Thus, only 91/238 (38.2%) first-time STEMI patients were either treated with statins pre-
event or had FRS meeting ATPIII criteria for statin therapy. Of those with high-risk FRS, a 
minority of patients (45/91, 49.5%) were appropriately treated with statins.
Conclusions: FRS underestimated the cardiac event risk in the majority of patients who 
presented with a first STEMI. Furthermore, a large proportion of first STEMI patients who 
met ATPIII criteria for statin treatment were not been identified and treated pre-event. 
Methods for better identifying patients at risk of STEMI and institution of appropriate 
primary preventive therapy are needed.
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Heart in Hypertension - Part II
Monday, March 31, 2008, 3:30 p.m.-5:00 p.m.
McCormick Place, Room E353
3:30 p.m.
809-3 Genome-Wide Linkage Analysis of Electrocardiographic 
and Echocardiographic Left Ventricular Hypertrophy in 
Families with Hypertension
Bongani M. Mayosi, Peter A. Avery, Martin Farrall, Bernard Keavney, Hugh Watkins, 
University of Newcastle, Newcastle, United Kingdom, University of Cape Town, Cape 
Town, South Africa
Background: Electrocardiographic and echocardiographic measures of left ventricular 
hypertrophy (LVH) are known to be heritable traits. However, candidate gene studies have 
produced conflicting results concerning the genetic factors that influence LVH. Further, 
most published studies have only studied echocardiographic LVH.
Objectives: We sought to localize chromosomal regions (or quantitative trait loci) that 
harbour genetic variants influencing electrocardiographic and echocardiographic LVH.
Methods: We evaluated genetic linkage to electrocardiographic (ECG) Sokolow Lyon 
voltage, ECG Cornell voltage product, ECG left ventricular mass; and to echocardiographic 
septal wall thickness, left ventricular cavity size, and left ventricular mass in 955 
participants from 224 white British families. A genome-wide scan was performed with 
microsatellite markers that covered the genome at 10-cM intervals and linkage was 
assessed by variance components analysis.
Results: We identified chromosomal regions of suggestive of linkage for Sokolow Lyon 
voltage on chromosome 10 at 10q23.1 (LOD=2.21), for ECG Cornell voltage product 
on chromosome 17 at 17p13.3 (LOD=2.67), and for ECG LV mass on chromosome 
12 marker at 12q14.1 (LOD=2.19). There was a single region of possible linkage for 
echocardiographic left ventricular mass on chromosome 5 at 5p14.1 (LOD=1.6).
Conclusion: Stronger genetic signals for LVH were found using electrocardiographic than 
echocardiographic measurements, and the genetic determinants of each of these appear 
to be distinct. Chromosomes 10, 12 and 17 may harbour loci that exert a major influence 
on electrocardiographic LVH.
3:45 p.m.
809-4 Comparison of Endomyocardial and Epimyocardial 
Radial Strain Between Hypertensive Patients With and 
Without Electrocardiographic Strain Pattern
Nobuo Nakamura, Kumiko Hirata, Toshio Imanishi, Masato Mizukoshi, Satoshi 
Ueno, Akio Kuroi, Yu Arita, Hideyuki Ikejima, Keishi Okochi, Hiroto Tsujioka, Manabu 
Kashiwagi, Hiroki Matsumoto, Hideaki Kataiwa, Kazushi Takemoto, Takashi Tanimoto, 
Hironori Kitabata, Shigeho Takarada, Takashi Kubo, Atsushi Tanaka, Mikio Arita, Takashi 
Akasaka, Wakayama Medical University, Wakayama, Japan
Background: Endomyocardial layer contributes more than epimyocardial layer to 
systolic myocardial wall thickening (ie, radial strain (RS)) in normal subjects. However, 
it remains unclear whether the ratio of endomyocardial to epimyocardial RS alters 
in hypertensive patients, especially in those with electrocardiographic strain pattern 
(ECGS). We hypothesized that the presence of ECGS might influence the relationship of 
endomyocardial and epimyocardial RSs in hypertensive patients.
Methods: Echocardiography was performed in 17 patients with hypertension (aged 
60.3±12.9 years). Patients were divided into two groups: 9 patients with ECGS (Strain G) 
and 8 patients without ECGS (No-Strain G). Endomyocardial RS and epimyocardial RS 
were calculated in the posterior segment of left ventricular short-axis view by using an 
EUB-8500 (Hitachi Medical Co, Tokyo, Japan) and compared between 2 groups.
Results: Thickness of interventricular septum in Strain G was greater than that in 
No-Strain G although there was no significant difference (12.4±2.3 vs. 10.4±1.7 mm, 
p=0.054). Thickness of the left ventricular posterior wall and left ventricular mass index 
in Strain G were significantly greater than those in No-Strain G (13.1±2.4 vs. 10.1±1.0 
mm, 136.0±31.5 vs. 99.6±22.1 g/m2, p<0.05, respectively). Furthermore, within No-
Strain G, endomyocardial RS was significantly greater than epimyocardial RS (51.6±18.9 
vs. 23.3±18.8%, p<0.05). However, there was no significant difference between 
endomyocardial and epimypcardial RSs within Strain G (33.9±17.2 vs. 26.8±13.9%, 
p=0.45). No significant difference in epimyocardial RS was shown between 2 groups 
(p=0.21) and endomyocardial RS of Strain G showed the tendency to be smaller than 
that of No-Strain G (p=0.08). Endomyocardial RS/epimypcardial RS in Strain G was 
significantly lower than that in No-Strain G (1.38±0.78 vs. 3.14±1.73, p<0.05).
Conclusions: In hypertensive patients with ECGS, the predominance of endomyocardial 
RS compared with epimyocardial RS is attenuated with the progression of left ventricular 
hypertrophy.
4:00 p.m.
809-5 N -Terminal Pro B-type Natriuretic Peptide Predicts 
Mortality in Patients With Left Ventricular Hypertrophy
Santiago Garcia, Shoaib Akbar, Sohail Ali, Forum Kamdar, Mike Tsai, Daniel Duprez, 
Univerisity of Minnesota, Minneapolis, MN
Background: The use of natriuretic peptides has been advocated to stratify risk in patients 
with congestive heart failure and acute coronary syndromes. Left ventricular hypertrophy 
adversely affects outcomes in patients with hypertension. Whether N-terminal pro B-type 
natriuretic peptide (NT-proBNP) adds incremental prognostic information in patients with 
hypertension and left ventricular hypertrophy is not well established.
Methods: Echocardiography was performed in 232 patients (mean age 61 ± 15, 102 
males, 130 females) for the diagnosis of left ventricular hypertrophy. Left ventricular mass 
was measured according to The American Society of Echocardiography guidelines. A 
blood sample was taken for NT-proBNP determination. NT-proBNP levels were analyzed 
in quartiles after log transformation. Long term survival was established by review of 
electronic medical records.
Results: Arterial hypertension was present in 130 patients (56%) and left ventricular hypertrophy 
was present in 108 patients (46%). In patients with left ventricular hypertrophy, NT-proBNP levels 
predicted long term survival (Chi-square=10, p=0.01) (Figure). After adjusting by age, presence 
of coronary artery disease, ejection fraction, diabetes status, and hypertension, NT pro-BNP 
was the only predictor of survival (OR=2.1, 95% CI=1.0-4.6, p=0.04).
Conclusions: NT-proBNP is an independent predictor of survival in patients with arterial 
hypertension and increased left ventricular mass.
4:15 p.m.
809-6 Subclinical Inflammation Accelerates the Age-Related 
Arterial Stiffening Processes in Essential Hypertensive 
Subjects
Kyriakos Dimitriadis, Costas Tsioufis, Dimitris Tsiachris, Pavlos Pavlidis, Michalis 
Apostolakis, Maria Selima, Christodoulos Stefanadis, Ioannis Kallikazaros, Department 
of Cardiology, Hippokration Hospital, Athens, Greece
Background: A direct association exists between aging and cardiovascular risk, while 
subclinical inflammation and arterial stiffening are related to atherosclerosis progression. 
In this study, we examined the interrelationships between aging, high-sensitivity C-
reactive protein (hs-CRP), soluble CD 40 ligand (sCD40L) and arterial stiffness in 
essential hypertensives.
Methods: 295 newly diagnosed untreated non-diabetic patients with stage I to II essential 
hypertension [192 men, mean age=50±8 years, office blood pressure (BP)=148/95 
mmHg] were divided into two groups: Older group (mean age >or=60 years, n=43) 
and younger group (mean age<60 years, n=252). In all subjects arterial stiffness was 
evaluated on the basis of carotid to femoral pulse wave velocity (PWV), by means of a 
computerized method (Complior SP).
Results: Older compared to younger group had lower office and 24-h diastolic BP (90±8 
vs 96±9 mmHg and 74±9 vs 83±9 mmHg, respectively; p<0.0001 for both), while did 
not differ regarding sex, body mass index and metabolic profile (p=NS). Moreover, 
older compared to younger patients exhibited increased levels of hs-CRP (3.2±0.7 vs 
2.1±0.7 mg/l, p<0.05), sCD40L (6.1±1.5 vs 3±0.9 ng/ml, p<0.005) and PWV (8.8±1.5 
vs 7.9±1.2 m/sec, p=0.001). In the total population, age was associated with hs-CRP 
(r=0.220, p<0.05), sCD40L (r=0.140, p<0.05), and PWV (r=0.399, p<0.0001), while 
negatively related to 24-h diastolic BP (r=-0.319, p<0.0001). Furthermore, hs-CRP was 
correlated with PWV (r=0.233, p<0.05), while sCD40L was associated with 24-h diastolic 
BP (r=-0.286, p<0.005) and PWV (r=0.12, p<0.05). In multiple regression analysis, only 
age, hs-CRP and sCD40L were independent predictors of PWV (p<0.05). Analysis of 
covariance revealed that hs-CRP, sCD40L and PWV concentrations were significantly 
different between groups after adjusting for confounders (p<0.05 for all).
Conclusion: Hypertensives of more than 60 years of age compared to younger ones, 
exhibit pronounced inflammatory involvement as reflected by hs-CRP and sCD40L. 
Furthermore, low-grade inflammation seems to have a fundamental influence on arterial 
stiffening that characterizes cardiovascular aging.
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4:30 p.m.
809-7 Effect of Coronary Endothelial Dysfunction on Left 
Ventricular Function in Patients with Never-treated 
Hypertension
Hideki Okui, Shuichi Hamasaki, Sanemasa Ishida, Tetsuro Kataoka, Tetsuro Kataoka, 
Koji Orihara, Masakazu Ogawa, Takehiko Matsushita, Keishi Saihara, Takuro Shinsato, 
Takahiro Shirasawa, Yuichi Ninomiya, Takuro Kubozono, Hitoshi Ichiki, So Kuwahata, 
Takuro Takumi, Akiko Yoshikawa, Etsuko Mizoguchi, Aimi Fukushima, Kaai Tomita, Yumi 
Shimojima, Chuwa Tei, Kagoshima University, Kagoshima, Japan
Background: Hypertension is a pivotal risk factor for the development of vascular 
endothelial dysfunction. Additionally, endothelial dysfunction is an independent predictor 
of cardiovascular events. However, the association between coronary endothelial function 
and myocardial function in hypertensives has not been defined. The goal of the present 
study was to investigate the impact of coronary endothelial dysfunction on left ventricular 
function in never-treated hypertensive patients.
Methods: The study population included 59 hypertensive and male patients (age 64±14 
yrs, blood pressure 155±12/85±9 mmHg) who were free of coronary artery stenosis and 
pharmacologic therapies. Coronary endothelial function was evaluated by coronary blood 
flow (CBF) response to acetylcholine (Ach). Left ventricular function was assessed by Tei 
index (isovolumic contraction time plus isovolumic relaxation time divided by ejection time) 
using Doppler echocardiography. According to coronary endothelial function, patients 
were divided into 2 groups: 30 patients with normal coronary endothelial function (Ach-
induced %change in CBF > 0%) and 29 patients with coronary endothelial dysfunction 
(Ach-induced %change in CBF ≤ 0%).
Results: The 2 groups were comparable for age, body mass index, left ventricular mass 
index, and blood pressure. Compared to patients with normal coronary endothelial function, 
Tei index was significantly greater in patients with coronary endothelial dysfunction 
(0.42±0.07 VS 0.51±0.14, p<0.01). Further, %change in CBF negatively correlated with 
Tei index in patients with coronary endothelial dysfunction (r=-0.52, p<0.01). However, no 
significant correlation between %change in CBF and Tei index was seen in patients with 
normal coronary endothelial function. In multivariate analysis, %change in CBF was an 
independent predictor of Tei index among parameters linked with left ventricular function 
in patients with coronary endothelial dysfunction (p<0.01).
Conclusions: Coronary endothelial dysfunction may be a determinant of impairment of left 
ventricular function in patients with never-treated hypertension.
4:45 p.m.
809-8 The Resistive Index in Renal Peripheral Arteries 
Predicted Future Renal Dysfunction in Elder Patients
Mie Kurata, Takafumi Okura, Ken-ichi Miyoshi, Jun Irita, Masanori Jotoku, Tomikazu 
Fukuoka, Jitsuo Higaki, Akiko Goto, Ehime University Graduate School of Medicine, 
Toon city, Ehime, Japan
Background:Renal function is the important predictor of future cardiovascular events, 
and cystatine C is a good marker to estimate renal insufficiency especially for elder 
patients. Renal resistive index (RI), which estimated Doppler ultrasound have been found 
to correlate with renal vascular resistance. We assessed the hypothesis that RI has a 
potential to predict future renal function estimated by cystatine C in elderly patients with 
essential hypertension (EHT).
Methods:Study 1, We performed US and calculated RI in patients with EHT, further 
estimated what factors determined RI . We excluded patients who had creatinine over 
1.5 mg/dL or diabetic mellitus. We defiend over 75% tiles as high RI group. Study 2, 
We enrolled over 60 years old patients with EHT and had normal kidney function, and 
performed ultrasound to calculate RI. We estimated serum cystatine C at baseline and 
12months later, and compared the difference between high and not high RI groups. Anti-
hypertensive treatment was followed the guideline of Japanese society of hypertension.
Results:Study 1, Two hundred and twelve (male 138) patients were enrolled. Mean age 
was 61±5.6 years, mean SBP was 151±20 mmHg. In the logistic regression analysis 
revieled RI was determined significantly by age and pulse pressure (r=0.2404, p=0.0162, 
r=0.4746, p<0.0001, respectively) using age, pulse pressure, pulse rate, BMI, gender, 
creatinine, HbA1c, total cholesterol, and presence of proteinuria as covariants. The high 
RI group was defined over 0.693.
Study 2, Fifty seven patients was enrolled, not high RI group was 36 and high RI group 
was 21. There were no significant differences between two groups about age, baseline 
urine albumin creatinine ratio and cystatine C (69±5 years, 72±7 years, p=0.086, 68±135 
mg/gCr, 100±254 mg/gCr, p=0,590, 0.83±0.17 mg/dL, 0.85±0.21 mg/dL, p=0.645, 
respectively). After 12 months, SBP were no
significant difference between two groups, however, high RI group had significant higher 
change of cystatine C than not high RI group (0.13±0.12 mg/dL, 0.05±0.09mg/dL, 
p=0.002, respectively).
Conclusions:In conclusion, high RI predicts future renal insufficiency estimated by change 
of cystatine C in elder patients.
ACC.ORAL CONTRIBUTIONS
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Prevention of Atherosclerotic Disease
Tuesday, April 01, 2008, 8:00 a.m.-9:30 a.m.
McCormick Place, Room E450b
8:00 a.m.
814-4 Normal Weight Obesity: A Risk Factor for 
Cardiometabolic Dysregulations
Abel Romero-Corral, Francisco Lopez-Jimenez, Simona Boarin, Justo Sierra-Johnson, 
Virend K. Somers, Mayo Clinic, Rochester, MN
Backgroud: We hypothesized that a significant proportion of subjects despite having 
a normal body mass index (BMI) could have a high body fat content (defined as 
normal weight obesity, NWO) and consequently be at higher risk for cardiometabolic 
disturbances.
Methods: A cross-sectional study of 2,127 subjects with a normal BMI (18.5-24.9 
kg/m2) who had body composition assessment by bioelectrical impedance, fasting 
morning laboratory measurements and full assessment of anthropometric variables 
and cardiovascular risk factors from the Third National Health and Nutrition Examination 
Survey. We defined NWO as a normal BMI with high body fat % (>20% in men and 
>30% in women), and compared several cardiometabolic parameters, including metabolic 
syndrome (ATP-III criteria) and cardiovascular risk factors with subjects with a normal 
BMI and no excess in body fat (<20% in men and <30% in women).
Results: Women comprised 51% or the sample and 61 % of the total sample were NWO. 
When compared to subjects with a normal BMI and no excess in body fat, NWO subjects 
were older (44 ± 17 vs. 39 ± 16, p<0.0001). After controlling for age, sex and race, NWO 
subjects had significantly higher rates of several cardiometabolic parameters (Table).
Conclusions: NWO subjects had several cardiometabolic disturbances, including an 
altered lipid profile, high leptin and higher rates of metabolic syndrome. In addition, NWO 
appears to be highly prevalent, constituting more that half of the patients with a normal 
weight as defined by the BMI.
8:15 a.m.
814-5 Impact of Metabolic Syndrome With or Without Diabetes 
on Prognosis in the COURAGE Trial
David Joel Maron, John A. Spertus, Robert A. O’Rourke, G.B. John Mancini, Pamela M. 
Hartigan, Marcin Dada, Koon K. Teo, William S. Weintraub, William E. Boden, Vanderbilt 
University Medical Center, Nashville, TN
Background: The NCEP ATP III definition of metabolic syndrome (MS) requires >3 of 5 
criteria be present. One criterion, fasting glucose >100 mg/dL, includes people with diabetes 
(DM). We hypothesized that there is a continuum of increasing risk for death or MI among 3 
MS subsets: patients with no MS/no DM, MS/no DM, and MS with diabetes (MS/DM).
Methods: We studied 2,285 patients with coronary disease enrolled in the COURAGE 
Trial. Clinical classification of MS subsets was based upon presence of DM or fasting 
glucose >100-125 mg/dL; BMI > 28.8 kg/m2 (men) or > 26.7 kg/m2 (women); triglycerides 
>150 mg/dL; HDL <40 mg/dL (men) or <50 mg/dL (women); and history of hypertension 
or systolic blood pressure >130 mm Hg or diastolic blood pressure >85 mm Hg or 
treatment with hydrochlorothiazide. The incidence of death or MI was collected over 4.6 
years. The COURAGE Trial also allowed us to determine if the addition of percutaneous 
coronary intervention (PCI) to optimal medical therapy (OMT) reduced the risk of death or 
MI compared with OMT alone for each MS subset.
Results: 722 patients had no MS/no DM, 745 had MS/no DM, and 655 had MS/DM. DM 
status was not determined in 163 subjects. The Table shows the incidence of death or 
MI according to MS subset. There were no significant differences in event rates between 
PCI+OMT vs. OMT only for any of the MS subsets. 
Death/MI no MS/no DM MS/no DM MS/DM P (χ2)
No 625 618 493
<0.001
Yes 97 (25%) 127 (33%) 162 (42%)
Conclusions: We found a continuum of risk rising from no MS/no DM to MS/no DM to 
MS/DM for death or MI in the COURAGE Trial. The addition of PCI to OMT did not reduce 
death or MI for any MS subset.
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814-6 Impact of Chronic Statin Treatment Before the Onset 
of ST-Elevation Acute Myocardial Infarction on the 
Incidence of Plaque Rupture Detected by Intravascular 
Ultrasound
Fumiyuki Otsuka, Kiyoshi Hibi, Ikuyoshi Kusama, Mitsuaki Endou, Takayuki Mitsuhashi, 
Naohiro Komura, Masami Kosuge, Noriaki Iwahashi, Jyun Okuda, Kengo Tsukahara, 
Yoshio Tahara, Toshiaki Ebina, Kazuo Kimura, Satoshi Umemura, Yokohama City 
University Medical Center, Yokohama, Japan
Background: Previous landmark trials have shown that statin reduced cardiac events 
as early as 6 months after administration, suggesting that the benefit of statin is not 
completely explained by the modification of atheromatous plaque volume. Prevention of 
plaque rupture was advocated as alternative mechanism of this beneficial effect, however, 
the direct evidence regarding the role of statin in the development of plaque rupture is 
lacking. The aim of this study was to assess whether chronic statin treatment before the 
onset of ST-elevation myocardial infarction (STEMI) influences the incidence of plaque 
rupture detected by intravascular ultrasound (IVUS).
Methods: The study enrolled 301 consecutive patients (249 male) with STEMI who 
admitted within 6 hours from symptom onset. IVUS interrogation was performed prior to 
any percutaneous coronary intervention.
Results: Forty-two patients (14 %) receiving statin pre-treatment were older (66 vs 
62 years, p=0.011) with higher proportion of diabetes (45 vs 29 %, p=0.047) and had 
lower levels of low-density lipoprotein cholesterol (LDL-C) (111 vs 137 mg/dL, p<0.001) 
than those without statins. Plaque ruptures were detected in 190 patients (63 %), and 
the incidence of plaque rupture was significantly lower in patients with statins than in 
those without statins (40 vs 67 %, p=0.002). Univariate analysis revealed that current 
smoking (p=0.001), lower high-density lipoprotein cholesterol level (p<0.001), and lack of 
statin pre-treatment (p=0.002) were associated with higher incidence of plaque rupture. 
Meanwhile, LDL-C level was not associated with plaque rupture (p=0.363). Multiple 
logistic regression analysis demonstrated that statin pre-treatment remained a significant 
negative determinant of plaque rupture independent of age, sex, and other risk factors 
including diabetes and LDL-C level (odds ratio 0.369; 95% CI 0.178 to 0.767, p=0.008).
Conclusions: Chronic statin pre-treatment was associated with lower incidence of plaque 
rupture independent of LDL-C levels in STEMI, suggesting that prevention of plaque 
rupture may be one of the crucial mechanisms of beneficial effect of statin to reduce 
cardiac events.
8:45 a.m.
814-7 A prospective comparison of nuclear magnetic 
resonance lipoprotein profiles with standard lipids in 
predicting incident type 2 diabetes in 25,974 initially 
healthy women
Samia Mora, James D. Otvos, Aruna Pradhan, Julie E. Buring, Paul M. Ridker, Brigham 
and Women’s Hospital, Boston, MA
Background: It is unclear if nuclear magnetic resonance (NMR) lipoprotein profiles, 
which measure particle concentrations of high-, low-, and very-low-density lipoproteins 
(HDLNMR, LDLNMR, and VLDLNMR), predict type 2 diabetes (T2DM) independent of 
standard risk factors.
Methods and Results: In a prospective cohort of 25,974 initially healthy women, baseline 
lipoproteins were measured by NMR. During an 11-year follow-up, 1,103 incident 
T2DM cases occurred. Adjusting for age, smoking, blood pressure, body mass index, 
menopause, and hormone use (Table), total and small LDLNMR particle concentrations 
predicted increased risk of T2DM: hazard ratios (HRs) and 95% CIs for top vs bottom 
quintiles, 3.36 (2.56-4.41) and 6.50 (4.71-8.99), respectively. Large LDLNMR particle 
concentrations were inversely associated, HR 0.30 (0.14-0.36). HDLNMR and VLDLNMR 
particles showed variable risk associations. In comparison, total and LDL cholesterol did 
not predict T2DM, in contrast to HDL cholesterol, HR 0.16 (0.12-0.20) and triglycerides, 
HR 4.67 (3.40-6.41). Further adjustment for hemoglobin A1c, HDL cholesterol, and 
triglycerides attenuated the relation of small and large LDLNMR with T2DM, but both 
remained significant (Ptrend<0.001) with HRs 2.21 (1.55-3.16) and 0.69 (0.54-0.87), 
respectively.
Conclusions: Baseline NMR-measured lipoprotein profiles predicted incident T2DM 
in women, and remained significant after adjustment for risk factors, including HDL 
cholesterol and triglycerides.
Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 P for Trend
Total Cholesterol 1.00 0.76 1.01 0.91 0.97 0.56
LDL Cholesterol 1.00 0.83 0.94 0.82 1.01 0.80
HDL Cholesterol 1.00 0.60 0.32 0.25 0.16 <0.001
Triglycerides 1.00 1.50 1.73 2.93 4.67 <0.001
Total LDLNMR 1.00 1.12 1.90 2.33 3.36 <0.001
Small LDLNMR 1.00 1.74 3.10 4.34 6.50 <0.001
Large LDLNMR 1.00 0.64 0.46 0.46 0.30 <0.001
9:00 a.m.
814-8 Impact of Atherogenic Lipids on Progression of 
Coronary Atherosclerosis in Patients With High Levels 
of HDL Cholesterol
Adnan K. Chhatriwalla, Danielle M. Brennan, E. Murat Tuzcu, Steven E. Nissen, Stephen 
J. Nicholls, Cleveland Clinic, Cleveland, OH
Background: Despite substantial elevation of HDL cholesterol (HDL-C), the CETP inhibitor 
torcetrapib does not attenuate coronary atheroma progression. This analysis investigated 
clinical characteristics of patients who undergo plaque progression despite achieving high 
HDL-C levels with torcetrapib on a background of atorvastatin therapy.
Methods: The ILLUSTRATE study compared the efficacy of torcetrapib/atorvastatin and 
atorvastatin monotherapy on coronary atheroma progression determined by intravascular 
ultrasound. Torcetrapib treated patients achieving the highest quartile of HDL-C (>87 mg/
dL) were evaluated. Clinical characteristics of patients with substantial plaque progression 
(>5% increase in percent atheroma volume) and regression (>5% decrease in percent 
atheroma volume) were compared.
Results: Of 116 patients in the highest HDL-C quartile, 27 patients (23%) demonstrated 
plaque progression and 38 patients (33%) plaque regression. At baseline, there were 
no significant differences between the progression and regression groups with regard 
to levels of blood pressure, C-reactive protein (CRP), triglycerides, HDL-C or LDL-C. 
Furthermore, groups did not differ with regard to the level of percent atheroma volume 
at baseline (31.8 ± 9.9% vs. 35.3 ± 9.7%, p=0.16) and level of HDL-C on-treatment (106 
± 13 vs. 104 ± 16 mg/dL, p=0.29). Plaque progression was associated with higher on-
treatment levels of total cholesterol (205 ± 26 vs. 187 ± 30 mg/dL, p=0.01), LDL-C (78 ± 
20 vs. 64 ± 21 mg/dL, p=0.01), and apolipoprotein B (64 ± 11 vs. 58 ± 12 mg/dL, p=0.035) 
compared to patients with regression. No significant differences in on-treatment levels 
of blood pressure, triglycerides and CRP were observed between the progression and 
regression groups.
Conclusion: Levels of atherogenic lipids were higher in patients exhibiting plaque 
progression despite achieving high levels of HDL-C with torcetrapib. These findings 
highlight the importance of intensive management of both proatherogenic and protective 
lipids to achieve the greatest benefit in patients with established coronary artery 
disease.
9:15 a.m.
814-9 Clinical Tool to Simplify the Identification of High-Risk 
Primary Prevention Patients
Alan S. Brown, Eileen E. Ming, Peter W. Wilson, Christie Ballantyne, Steven M. Haffner, 
Neil Stone, John Foreyt, Gregg Fonarow, James McKenney, Scott Grundy, Midwest 
Heart Foundation, Lombard, IL
Background: According to NCEP ATP III guidelines patients with ≥2 ATP III risk factors 
(RFs) but without diabetes or established atherosclerotic vascular disease require 
Framingham (Fr) risk scoring to determine LDL goals. NHANES data was analyzed to 
identify persons who could be identified as moderately-high or high risk based on RFs or 
clinical characteristics rather than using the full Fr scoring system.
Methods: NHANES 2001-02 data were used to find US distribution of adults with no CHD 
risk equivalents and not taking statin who fall into each risk group by sex, age, CHD RFs, 
elements of Fr risk score and cholesterol levels.
Results: For men, 98.6% of those with ≥2 CHD RFs and age ≥55 and HDL< 60mg/dL 
(ie, age ≥55 & have ≥1 additional CHD RF) have Fr risk scores of ≥10% and thus are 
at moderately-high to high risk. For women, no specific characteristics with comparably 
high positive predictive value were found and hence could not alleviate the need for Fr 
scoring. In primary prevention patients the simple risk tool of men ≥55 with ≥1 additional 
RF identified with high reliability patients at moderately high or higher risk. For women and 
men under age 55 with multiple risk factors a simple risk tool could not be identified and 
Fr risk score should be calculated.
Conclusion: Based on these analyses men aged 55 or older with ≥1 additional NCEP 
RFs might qualify for and derive significant benefit from lipid lowering therapy. With the 
advent of generic statin therapy further analysis of cost/benefit of this strategy may be 
warranted.
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815 
Vascular Disease and Hypertension - Part I
Tuesday, April 01, 2008, 9:00 a.m.-10:30 a.m.
McCormick Place, 360º Education Theater, South Hall
9:00 a.m.
815-3 Single Nucleotide Polymorphisms (SNPs) Associated 
With Coronary Heart Disease That Predict Carotid Intima 
Media Thickness and Peripheral Arterial Disease in the 
Atherosclerosis Risk in Communities (ARIC) Study
Vijay Nambi, Alanna Morrison, Lance Bare, Josef Coresh, Hanyu Ni, Christie 
Ballantyne, Eric Boerwinkle, Baylor College of Medicine, Houston, TX, Uinversity of 
Texas, School of Public Health, Houston, TX
Background: Single nucleotide polymorphisms (SNPs) associated with coronary heart 
disease (CHD) may play a role in atherosclerosis of other arterial beds. In case-control 
studies of white subjects with myocardial infarction (MI), we previously tested 12,077 
SNPs and found 51 SNPs that were nominally associated with MI in 2 studies: Study-1 
(781 cases, 603 controls) and Study-2 (471 cases, 298 controls). We now tested the 
hypotheses that the risk alleles of these 51 SNPs may be associated with carotid intima-
media thickness (CIMT) and peripheral artery disease (PAD) in the ARIC study.
Methods: From a cohort of 14,215 individuals, those with abnormal CIMT (n=3314) and 
PAD (n=326) were identified and compared to the rest of the cohort. Prevalence of PAD 
was defined by an ankle brachial index of ≤ 0.90 in men and ≤ 0.85 in women. Age and 
gender stratified CIMT > 75th percentile was defined as abnormal. Logistic regression 
models, adjusted for age and gender, were used to assess the effect of each SNP and 
analyses were performed separately in Whites and African Americans.
Results: Compared to the rest of the cohort, individuals with PAD or abnormal CIMT 
were significantly older, had higher total cholesterol, low density lipoprotein cholesterol 
and triglycerides, had lower high density lipoprotein cholesterol and were more likely 
to be hypertensive, diabetic and smokers. Individuals with abnormal CIMT also had 
a significantly higher body mass index and waist to hip ratio. In African Americans, 
rs2477037, a G->C variant at 10573161 basepairs on chromosome 10 was associated 
with abnormal CIMT (OR = 1.21, 95% CI 1.04 - 1.40) and in Whites, rs3798220 in the 
LPA (apolipoprotein (a)) gene was significantly associated with abnormal CIMT (OR = 
1.38, 95% CI 1.07 - 1.78). None of these SNPs were significantly associated with risk 
of having PAD.
Conclusions: Functional SNPs associated with CHD in other studies were significantly 
associated with abnormal CIMT in the ARIC study. These SNPs need to be examined 
further in other cohorts for association with atherosclerosis of the various arterial beds.
9:15 a.m.
815-4 Plasma Asymmetrical-Dimethyl-Arginine Affects eNOS 
Vascular Superoxide Radical Production And Nitric 
Oxide Bioavailability In Human Arteries And Veins
Charalambos A. Antoniades, Cheerag Shirodaria, Paul Leeson, Dimitris Tousoulis, 
Alexis Antonopoulos, Cheerag Ratnatunga, Ravi Pillai, Tim Van-Assche, Christodoulos 
Stefanadis, Keith Channon, University of Oxford, Oxford, United Kingdom
Background: The exact effect of asymmetrical dimethylarginine (ADMA) on endothelial 
nitric oxide synthase (eNOS) in human vasculature is unclear. We examined the impact 
of plasma ADMA on endothelial NO bioavailability and vascular superoxide radical (O2-) 
production in patients with advanced atherosclerosis.
Methods: Paired samples of saphenous veins (SV) and internal mammary arteries (IMA) 
were collected from 160 patients undergoing CABG. The vasomotor responses of SV to 
acetylcholine (Ach) were evaluated ex-vivo. Vascular O2- (+/- eNOS inhibitor LNAME) 
was measured in paired SV and IMA, by lucigenin-enhanced chemiluminescence.
Results: High plasma ADMA was associated with decreased vasorelaxations of SV 
to Ach (Fig. a). Similarly, ADMA was associated with higher O2- in both SV and IMA 
(Fig b), while there was a rather weak association between plasma ADMA and the 
LNAME-inhibitable O2- in IMA (r=-0.259, p=0.008) but not in SV (r=-0.173, p=0.074). In 
multivariate linear regression, plasma ADMA was an independent predictor of vascular 
O2- (β(SE):3.39(0.416), p=0.0001), along with diabetes mellitus (p=0.042), dyslipidemia 
(p=0.018) and the angiographic extent of coronary atherosclerosis (p=0.048).
Conclusions: This is the first study demonstrating that ADMA has a direct impact 
on vascular NO bioavailability and O2- production in human vessels, in patients with 
coronary artery disease. However, further studies are required to elucidate the exact role 
of ADMA on eNOS coupling in human vessels. 
9:30 a.m.
815-5 Enhanced reverse cholesterol transport following 
treatment with ApoA-IMilano: Insight Into the 
Mechanism of Action
Giovanni Cimmino, Borja Ibanez, Gemma Vilahur, Walter S Speidl, Valentin Fuster, Lina 
Badimon, Juan J. Badimon, Mount Sinai School of Medicine, New York, NY, CSIC-ICCC, 
Barcelona, Spain
Background: We have recently shown, in an animal model of atherosclerosis, that short 
term treatment with apoA-IMilano (apoA-IM) induces a rapid regression and stabilization 
of the atherosclerotic plaques (JACC´07). However the mechanism of action responsible 
for these benefits remains unknown.
The aim of this work was to further delineate the mechanism of action responsible for 
the beneficial effects observed. We focused on the reverse cholesterol transport, via 
scavenger receptor B1 (SR-BI), and on the local and systemic inflammation.
Methods: Aortic atherosclerotic-lesions were induced in White New Zealand rabbits 
(n=16) by 9 months cholesterol diet plus 2 endothelial denudations. Thereafter, they were 
randomized to receive apoA-IM (2 doses, 75mg/Kg, in 4 days) or placebo. Four days after 
last dose, animals were euthanized.
Circulating levels of cholesterol and prostaglandin F1-α (PGF1-α) were determined pre- 
and post-treatment.
Hepatic and aortic tissues were processed for cholesterol content and gene-protein 
expression of SR-BI, inducible nitric oxide synthase (iNOS) and caspase-3.
Results: Despite similar circulating cholesterol levels in both groups at pre- and post-
treatment, tissue cholesterol content was lower in apoA-IM animals (liver: 6.8 ±4.3 µg/mg 
vs. 32.6 ± 3.5, p=0.017. aorta: 34.65 ± 5.4 vs. 59.8 ± 8.9, p=0.025).
Furtheremore, treated group also had a significant gene and protein up-regulation of SR-
BI both at the hepatic and aortic level compared to placebo (p<0.01 for all comparisons).
ApoA-IM administration also resulted in a reduction of systemic inflammation as depicted 
by a 38% reduction in circulating PGF1-α levels (p=0.02 vs. pre-treatment).
ApoA-IM group showed a significant down-regulation in aortic iNOS and caspase-3 
expression both at the gene and protein levels (p<0.01 vs. placebo for all comparisons)
Conclusions: The observed benefits associated with the administration or apoA-IM seems 
to be mediated via an enhanced reverse cholesterol transport (responsible for plaque 
regression), as suggested by the here reported up-regulation in hepatic and aortic SR-BI, 
and via the “pleiotropic”(?) diffuse anti-inflammatory effect .
9:45 a.m.
815-6 Gender and Race Predict Aortic Size among Type A 
Aortic Dissection Patients: Observations from the 
International Registry of Acute Aortic Dissection 
(IRAD)
Dane Genther, Eric Isselbacher, Mary Grzybowski, Jeanna V. Cooper, Kim Eagle, 
Thomas Tsai, Eduardo Bossone, Kevin M. Harris, Arturo Evangelista, Rossella Fattori, 
Vijay Ramanath, Christoph A. Nienaber, James Froehlich, Varbedian Fund for Aortic 
Research, University of Michigan Health System, Ann Arbor, MI
Background: Aortic diameter predicts dissection risk. Prior studies suggest this may be 
affected by gender. We assessed the relationship between gender and ascending aortic 
diameter (AAD) in patients presenting with acute type A aortic dissection (TA-AD).
Methods: From 1/1/96 to 12/11/06, we studied 744 patients from the International 
Registry of Aortic Dissection with TA-AD. Linear regressions were used to determine the 
best predictors of AAD, after controlling for gender and hypertension (HTN). Candidate 
independent variables included self-reported medical histories and demographics.
Results: Bivariate analyses showed that women who dissect have HTN more frequently 
(p=0.037), and men who dissect have a history of coronary artery bypass graft surgery 
(CABG) more frequently (p=0.034). On average, men dissected with an aorta 0.23 cm 
larger than women (p=0.0246). The regression model (table 1) shows gender*race 
interaction and a history of bicuspid aortic valve (BAV) predict aortic size. The model shows 
that AADs of nonwhite females are larger than white females while those of nonwhite 
males are smaller than white males, after controlling for BAV and HTN (p<.0001).
Conclusion: Women dissect at smaller diameters than men. This difference may nullify 
if diameter is normalized to height or body surface area. The gender difference interacts 
with race. These results challenge guidelines for surgical repair that do not consider 
gender or race. More studies are needed to confirm these results.
Table 1: 
Variable Beta Coefficient Standard Error of Beta Coefficient p-value
Intercept 5.1598 0.0894 <0.0001
Gender (Female) -0.3199 0.0984 0.0012
Race (Nonwhite) -0.6233 0.2084 0.0029
Gender*Race 0.7877 0.3867 0.0422
Hx of BAV 1.0728 0.3595 0.0030
Hx of HTN -0.0377 0.0992 0.7044
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815-7 Volumetric Analysis by Non Contrast Computed 
Tomography is Comparable to that of Contrast 
Enhanced Computed Tomography in the Follow-up 
of Patients with Endovascular Abdominal Aortic 
Aneurysm Repair
Preethi Nambi, Ranjita Sengupta, Raja Muthupillai, Neil Strickman, Zvonimir Krajcer, 
Benjamin Y.C. Cheong, Texas Heart Institute, Houston, TX
Background: Changes in abdominal aortic aneurysm volume (AV) in serial contrast-
enhanced computed tomography (CECT) is often used to detect endoleak in patients 
after endovascular abdominal aortic aneurysm repair (EVAR). We investigated if AV 
measured from non-contrast-CT (NCCT) is comparable to AV measured from CECT.
Methods: Abdominal AV of 159 consecutive patients (142 male, age: 74 ± 8 years, 46 in 
stage 3 chronic renal disease) who underwent EVAR were measured from 2 serial CT 
imaging sessions (CT1, CT2) at a tertiary care center. A standardized multi-detector CT 
protocol was used to obtain pre-contrast, arterial and delayed images. A single blinded 
observer measured AV by disc-summation method in both NCCT and CECT from the 
lowest renal artery to the aortic bifurcation on a commercial workstation (Vitrea™). A 
second blinded reader re-measured the AV by randomly choosing 10% of patients.
Results: A total of 318 pairs of AV were measured using NCCT and CECT. The mean 
AV measured using NCCT and CECT were similar, and were highly correlated (r2 = 
0.99, p > 0.001). The mean Δvolume measured between the CTs for NCCT and CECT 
were -0.8±12.7 and 0.2±12.7 cc respectively, reflecting close agreement. Inter-observer 
variability estimated using Bland-Altman analysis revealed negligible bias (Fig. 1, bias ± 
SD: 1.4± 4.8 cc).
Conclusions: AV measured using NCCT and CECT were equivalent. Therefore, NCCT 
can be used to follow-up patients after EVAR sparing them from nephrotoxic contrast 
and radiation burden. 
10:15 a.m.
815-8 Perioperative Cardiac Events Following Vascular 
Surgery are Predicted by the Revised Cardiac Index but 
are not Reduced in any Risk sub-group by Preoperative 
Coronary Revascularization: Results from the Coronary 
Artery Revascularization Prophylaxis (CARP) Trial
Santiago Garcia, Herbert B. Ward, Thomas Moritz, Fred Littooy, Steve Goldman, Gordon 
Pierpont, Greg Larsen, Domenic Reda, Edward O. McFalls, University of Minnesota, 
Minneapolis, MN, VA Medical Center, Minneapolis, MN
Background: The Revised Cardiac Index (RCI) is a validated risk score that predicts major 
complications following non-cardiac surgery. Among patients with documented coronary 
artery disease who undergo elective vascular surgery, the impact of preoperative coronary 
revascularization within risk subgroups of the RCI is unclear.
Methods: The Coronary Artery Revascularization Prophylaxis (CARP) Trial was a 
multicenter VA Trial that tested the long-term survival benefit of coronary revascularization 
(CR) prior to elective vascular surgery. We tested the utility of the RCI in predicting the 
composite end-point of death and non-fatal myocardial infarction (MI) at 30 days following 
vascular surgery and by Cox Regression Analysis, assessed the impact of CR on 
outcomes for each risk sub-group of the RCI.
Results: Of 510 randomized patients, 462 (91%) underwent their scheduled elective 
vascular operation and comprise the present cohort. As shown by the Table, the risk of 
the composite end-point of death and non-fatal MI increased with the number of risks 
enumerated by the RCI (OR=1.73, 95% CI= 1.26-2.38, p<0.001). The distribution of 
patients undergoing preoperative CR is shown for each risk sub-group of RCI and did not 
reduce cardiac events in any subset (OR=0.86, 95% CI= 0.50-1.49, p=0.598).
Conclusions: In CARP, the composite end-point of death and non-fatal MI was predicted 
by the number of risks enumerated by the Revised Cardiac Index and was not altered by 
preoperative coronary artery revascularization.
RCI (#) Patients (% Total) CR (% of RCI group) Events (% Total)
0 62 (13.4%) 26 (41.9%) 1 (1.6%)
1 169 (36.6%) 79 (46.8%) 22 (13.0%)
2 167 (36.2%) 84 (50.3%) 34 (20.4%)
≥3 64 (13.9%) 33 (51.6%) 15 (23.4%)
Total 462 (100%) 222 (48.1%) 72 (15.5%)
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1035-158 Evidence for no Global Effect of Metabolic Syndrome, 
per se, on Early Hypertensive Sequelae. Insights from 
the Hippokration Hellenic Hypertension (3H) Study
Costas Tsioufis, Dimitris Tsiachris, Dimitris Chatzis, Kyriakos Dimitriadis, Efstathios 
Taxiarchou, Costas Thomopoulos, Maria Selima, Dimitris Syrseloudis, Christodoulos 
Stefanadis, Ioannis Kallikazaros, Department of Cardiology, Hippokration Hospital, 
Athens, Greece
Background: In the present study we assessed the impact of MS and its separate 
components on markers of cardiovascular and renal damage in a population of essential 
hypertensives.
Methods: A total of 651 consecutive, untreated and non diabetic hypertensives (aged 
54±12 years, 340 males) that were included in the 3H Study, an ongoing registry of 
hypertension related target organ damage, underwent ambulatory blood pressure (BP) 
monitoring and assessment of cardiovascular and renal function. Left ventricular (LV) 
mass was indexed both for body surface area (BSA) and for height2.7. LV diastolic 
function was estimated by means of both conventional and tissue Doppler imaging (TDI) 
derived indexes. Arterial stiffness was evaluated on the basis of carotid to femoral pulse 
wave velocity (PWV), using Complior SP. Microalbuminuria was determined as albumin to 
creatinine ratio (ACR) 22-300mg/g in men and 31-300mg/g in women.
Results: MS (ATP III) was present in 201 hypertensives (30.9%). Subjects with MS 
compared with those without MS were more frequently smokers (p=0.038) and exhibited 
increased body mass index (p<0.001), 24-h systolic and 24-h pulse pressure (p=0.033 
and 0.005, respectively). Hypertensives with MS had increased logACR (by 0.1, p=0.01) 
and higher prevalence of microalbuminuria (17% vs. 8%, p<0.001). Both groups exhibited 
similar values of LV mass indexed for BSA, transmitral and TDI derived indexes and 
PWV (p=NS for all) while LV mass indexed for height2.7 (indicating obesity related LV 
hypertrophy) was higher in hypertensives with MS compared to those without (50 vs 
47.4 gr/m2.7, p=0.023). Multiple linear and logistic regression analysis revealed that MS 
was an independent predictor only of logACR (β=0.101, p=0.007) and microalbuminuria 
(OR=2.577, p<0.001) but not for LV mass indexed either way, diastolic function indices 
and PWV. Examining each separate component of MS, only BP predicted significantly all 
studied indices of organ damage.
Conclusions: The MS-induced amplification on hypertension sequelae is prominent 
concerning only the glomerulus level, while haemodynamic load seems to be the more 
consistent component of MS provoking cardiorenal changes.
10:00 a.m.
1035-159 Changing Prevalence of the Metabolic Syndrome in 
Ethnic Subgroups in the United States: Results from 
the National Health and Nutrition Examination Survey 
(1999-2004)
Andrew D. Sumner, Sherrine Eid, Bree Edris, James F. Reed, III, Lehigh Valley Hospital 
and Health Network, Allentown, PA
Background: The metabolic syndrome (MetSyn) is highly prevalent in the United States 
and is associated with increased cardiovascular disease (CVD) risk. The purpose of this 
study was to determine if the prevalence of the MetSyn and its components has changed 
in the US population and in ethnic subgroups age 40 years and older since 1999-2000.
Methods: We analyzed data from three National Health and Nutrition Examination Surveys 
between the years 1999-2004. The prevalence of the MetSyn (ATP III criteria) and 
associated cardiac risk factors was determined in 3,663 participants age 40 years and older 
with no prior history of CVD. Statistical analysis was performed using SPSS V15.0.
Results: The prevalence of the MetSyn among asymptomatic adults decreased slightly 
during the time period 1999-2004. The prevalence of the MetSyn remains highest in the 
MA/Other Hispanic population but decreased the greatest in this subgroup. Over one-third 
of the female MA/Other Hispanic population has MetSyn. The prevalence of abdominal 
obesity increased significantly over the study while the other factors contributing to 
MetSyn remained relatively stable. 
NHANES 
1999-2000
NHANES 
2001-2002
NHANES 
2003-2004
MetSyn - Total 
NH-White 
Male 
Female 
NH-Black 
Male 
Female 
MA/Other Hispanic 
Male 
Female
32.2% 
30.8% 
29.0% 
32.4% 
27.0% 
20.7% 
31.6% 
45.5% 
42.1% 
47.7%
32.7% 
33.2% 
33.1% 
33.4% 
24.1% 
18.4% 
28.8% 
38.7% 
36.3% 
41.1%
30.6% 
31.4% 
32.7% 
30.4% 
23.1% 
25.3% 
21.7% 
34.5% 
32.1% 
36.6%
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Conclusions: This study provides a nationally representative estimate of MetSyn 
prevalence in asymptomatic adults in the United States over a six year time period 
revealing that MetSyn continues to affect a large number of Americans. The prevalence 
of the MetSyn remains highest in MA/Other Hispanics. Aggressive strategies to reduce 
MetSyn and its components are warranted.
10:00 a.m.
1035-160 B-type Natriuretic Peptide Predicts Death in Coronary 
Artery Disease Patients, Even in the Absence of 
Clinical Heart Failure and Independent of Baseline Left 
Ventricular Ejection Fraction
Tami L. Bair, Heidi T. May, Dale G. Renlund, Abdallah G. Kfoury, Benjamin D. Horne, 
Qunyu Li, Kurt R. Jensen, Jeffrey L. Anderson, Donald L. Lappé, Joseph B. Muhlestein, 
Intermountain Medical Center, Salt Lake City, UT
Background: Elevated levels of B-type natriuretic peptide (BNP) are associated with 
worse short and long-term outcomes in patients with heart failure. Elevated BNP is also 
associated with increased short-term risk following myocardial infarction (MI). We sought 
to evaluate the predictive value of BNP among coronary artery disease (CAD) patients 
without heart failure.
Methods: Patients (N=710) free from a clinical diagnosis of heart failure who were 
diagnosed angiographically with CAD (>50% stenosis) were studied if they had a BNP 
measurement within 30 days of undergoing cardiac catheterization. Tertiles (T) of BNP 
(T1: < 86.3 pg/ml, T2: 86.31-266.5 pg/ml, T3: >266.5 pg/ml) were used to assess the 
incidence of MI and death (average length of follow-up: 1.0±0.9 years). Results were 
determined by Cox regression models with adjustment by presentation, treatment, left 
ventricular ejection fraction (LVEF) and the 7 traditional cardiovascular risk factors.
Results: Age averaged 65±12 years, 70% were male. BNP T3 was a significant predictor 
of death in both univariate (vs. T1: hazard ratio [HR]=7.46, p<0.0001) and multivariate 
analysis (HR=5.14, p<0.0001). T2 did not reach significance and an initially positive effect 
was washed out by multivariate adjustment (univariate: HR=1.55, p=0.31; multivariate: 
HR=1.19, p=0.69). Among those presenting with stable angina (n=422), T3 was especially 
predictive of death (adjusted HR=14.6, p<0.0001). For those with an available ejection 
fraction (EF) (n=390, 14% having an EF <40%), its addition to multivariate analysis 
enhanced the predictive value for T3 (HR=6.23, p=0.001). For those with normal EF 
(>50%), T3 remained highly predictive of future death (adjusted HR=21.5, p=0.003). No 
BNP tertile predicted MI (T2: adjusted HR=0.89, p=0.77; T3: adjusted HR=1.75, p=0.79).
Conclusions: Among CAD patients without heart failure, moderate to severe elevations of 
BNP (>266.5 pg/ml), independent of LVEF, were associated with a marked increase in the 
risk of death. Less marked elevations of BNP (100-266.4 pg/ml) did not produce added 
risk. BNP may be an important indicator of cardiovascular risk even among patients not 
meeting clinical criteria for heart failure.
10:00 a.m.
1035-161 Low Ankle Brachial Index Identifies Asymptomatic 
Persons with a High Cardiovascular Risk Above that 
Calculated by the Framingham Risk Score
Andrew D. Sumner, Sherrine Eid, Bree Edris, James F. Reed, III, Lehigh Valley Hospital 
and Health Network, Allentown, PA
Background: Peripheral artery disease (PAD), identified by a low ankle brachial index 
(ABI), identifies individuals at high risk for future cardiovascular disease (CVD) events. 
The Framingham Risk Score (FRS) estimates a patient’s future CVD risk. The purpose of 
this study is to determine if ABI screening in asymptomatic at risk patients identifies high 
CVD risk individuals above that identified by the FRS.
Methods: We analyzed data from three National Health and Nutrition Examination Surveys 
(1999-2004). The presence of PAD, defined by an ABI < 0.9, and the FRS was determined 
in 1720 participants (smokers age 50-69 and persons age 70 years and older) with no 
prior history of CVD. Statistical analysis was performed using SPSS V15.0.
Results: PAD was present in 11.5% of the study population. Seventeen percent of individuals 
were classified as high risk for future CVD events by the FRS. Nine percent of those at low 
to moderate risk by FRS had PAD. More women had PAD while being classified as low or 
moderate CVD risk by the FRS compared to men (11.1% vs 6.3% for men).
FRC Low (<10%) FRC Moderate (10-20%) FRC High (>20%) Total
PAD Absent 27.0% 47.2% 14.3% 88.5%
PAD Present 3.0% 5.9% 2.6% 11.5%
Total 30.0% 53.1% 16.9% 100%
Conclusions: This study demonstrates that performing ABI measurements in at risk 
asymptomatic patients identifies individuals at high risk for CVD events above that 
predicted by the FRS. These findings support the practice of screening asymptomatic 
smokers age 50-69 and persons age 70 years and older with no prior history of CVD for 
PAD. Prospective studies to evaluate the additive benefit of performing ABI in specific 
patient sub groups should be performed.
10:00 a.m.
1035-162 Non Cardiac Predictors of Sudden Cardiac Death after 
Coronary Revascularization
Kei Nishiyama, Satoshi Shizuta, Ryoji Taniguchi, Masanao Toma, Yutaka Furukawa, 
Yoshihisa Nakagawa, Takashi Konishi, Kazuo Yamanaka, Kazunobu Nishimura, 
Osamu Doi, Hirofumi Kambara, Katsuhiko Matsuda, Chuwa Tei, Ryuzo Sakata, 
Saeko Minematsu, Miya Hanazawa, Takeshi Morimoto, Satoshi Teramukai, Masanori 
Fukushima, Toru Kita, Takashi Kimura, CREDO-KYOTO Investigators, Department of 
Cardiovascular Medicine, Kyoto University Hospital, Kyoto, Japan
Background: It has not been demonstrated whether non-cardiac comorbidities affect the 
incidence of sudden cardiac death (SCD) after coronary revascularization.
Methods: We analyzed 9873 consecutive patients who underwent first elective PCI 
(n=6876) and CABG (n=2997) in 2000-2002 at 30 institutions of CREDO-KYOTO 
registry.
Results: Baseline clinical characteristics showed that COPD was diagnosed in 240 patients 
(2.4%), 391 (4.4%) had left ventricular (LV) dysfunction (EF<0.35), 130 (1.4%) had severe 
MR, 1643 (16.7%) had cerebrovascular disease (CVD), 1141 (11.6%) had peripheral 
artery disease, 408 (4.1%) had end-stage renal disease (ESRD), 2550 (25.9%) had prior 
myocardial infarction (MI), 6324 (64.0%) had multi-vessel disease (MVD), 956 (9.7%) had 
left-main coronary artery disease (LMCD), 3837 (38.9%) had DM, 104 (1.1%) had anemia 
(Hb < 8.0), 233 (2.4%) had chronic AF and 2433 (24.6%) were old-old (age>75). During 
long-term follow-up (median follow-up period = 42.8 months), 906 patients (9.4%) died, in 
which 376 (3.9%) died of cardiac death and 140 (1.5%) died of SCD. Multi-variate analyses 
(considering the results of uni-variate analyses) indicated that ESRD, COPD, old-old and 
peripheral artery were independent non-cardiac predictors of SCD and LV dysfunction, 
previous MI and AF were independent cardiac predictors of SCD (see figure).
Conclusion: ESRD, COPD, old-old and peripheral artery disease were independent non-
cardiac predictors of SCD after coronary revascularization.
10:00 a.m.
1035-163 Risk Factor Profile and the Predictors of Cardiovascular 
Events in Young Japanese Patients Undergoing First 
Coronary Revascularization: Perspectives From 
CREDO-Kyoto Registry
Yutaka Furukawa, Takahiro Doi, Naritatsu Saito, Neiko Ozasa, Satoshi Shizuta, Akira 
Miura, Hajime Kotoura, Masaki Aota, Jong-Dae Lee, Kuniyoshi Tanaka, Hiroshi Kato, 
Masaaki Takahashi, Izumi Miki, Chikako Hibi, Takeshi Morimoto, Satoshi Teramukai, 
Masanori Fukushima, Toru Kita, Takeshi Kimura, Kyoto University, Kyoto, Japan
Background: The prevalence of coronary artery disease (CAD) is increasing in young 
adults. This study aimed to characterize the carrying risk factors and the predictors of 
future cardiovascular events in young Japanese patients with CAD undergoing first 
revascularization therapy.
Methods: We have enrolled 9,877 patients who underwent first coronary revascularization 
(PCI or CABG) during 2000-2002 in the CREDO-Kyoto registry. After excluding patients 
with acute myocardial infarction (MI) or malignant disease, 9,381 patients were divided 
into the patients≤55 years (group Y) and the patients>55 years (group O). The prevalence 
of coronary risk factors and the predictors of future cardiovascular events were compared 
between the 2 groups. Risk factor profile was also analyzed in the selected subpopulation 
with a history of first MI within 1 year to the revascularization procedure.
Results: Group Y comprised 13.5% (1,264) of the 9,381 study subjects. Significantly more 
prevalent (p<0.0001) risk factors in Y than in O included male gender (Y vs O: 87.3% vs 
67.8%), BMI≥25 kg/m2 (44.1% vs 29.0%), current smoking (51.7% vs 24.7%), serum 
total cholesterol (C)≥220 mg/dL (36.4% vs 24.8%) and triglyceride≥150 mg/dL (52.5% 
vs 32.8%). Metabolic syndrome-like risk factor accumulation (BMI≥25 kg/m2 + at least 2 
of the followings: BP≥130/85mmHg, TG≥150mg/dL or HDL-C<40mg/dL, FBS≥110mg/dL) 
was also more prevalent in Y (29.8% vs 16.4%). Similar pattern of carrying risk factors 
was found in the patients with a recent history of MI, and risk factor profile of the group 
at age≤45 years (218 patients, 2.3%) was also analogous to group Y. Finally, analyses 
in 9,319 patients excluding in-hospital deaths revealed that high LDL-C (≥130mg/dL), 
renal disease (serum creatinine≥1.5mg/dL) were significant predictors of all-cause and 
cardiovascular mortalities, while low HDL-C and peripheral artery disease predicted 
future MI in group Y.
Conclusions: Accumulation of multiple risk factors is prevalent in young Japanese patients 
with CAD. Dyslipidemia may be associated with higher mortality and future MI in young 
patients with established CAD.
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1035-164 A Comparative Study of Coronary Calcium vs. Carotid 
Intima Media Thickness on Adjusting Framingham Risk 
Score Using Vascular Age Algorithms
Michael J. Durkin, Craig Chuhran, June Coccia, Lee Phillips, Martin E. Matsumura, Penn 
State College of Medicine/Lehigh Valley Hospital, Allentown, PA
Background: It is well established that the Framingham Risk Score (FRS) may 
underestimate cardiovascular (CV) risk. Determination of patients’ “vascular age” using 
subclinical atherosclerosis imaging of either coronary calcium (CAC) or carotid intima 
media thickness (cIMT) and substituting this for chronological age in the FRS calculation 
has been proposed as a means of better assessing CV risk using FRS. Prior studies have 
compared CAC and cIMT for the detection of subclinical atherosclerosis. In the present 
study we compared the effect of vascular age algorithms using CAC and cIMT on FRS 
within individual patients.
Methods: Patients (n=20, 12male) underwent assessment of CAC (Agatston Score) 
and cIMT (using automated edge detection software). Vascular age was calculated 
using linear regression equations derived from databases from the Multiethnic Study of 
Atherosclerosis (for CAC) and the Atherosclerosis in Communities Study (for cIMT). FRS 
was then recalculated using these numbers.
Results: The mean CAC score was 127 (range 0-1411) and mean cIMT was 0.78mm 
(range 0.57-1.10mm). The mean unadjusted FRS and 10yr CV risk% were 12.2 and 
8.7%, respectively. Using CAC to calculate vascular age yielded a mean increase of 11.2 
years to the chronologic age, and using cIMT yielded a mean increase of 13.7 years to 
the chronologic age (p=0.512 between CAC and cIMT adjusted ages). Adjusting FRS 
using CAC scores yielded mean values of 14.6 and 12.9% (p=0.02 and p=0.002 vs. 
values using chronologic age, respectively). Adjusting FRS using cIMT yielded mean 
values of 14.7 and 14.2% (p=0.018 and p<0.001 vs. values using chronologic age, 
respectively). Vascular age-adjusted FRS using CAC and cIMT demonstrated strong 
correlation (r=.729, p=0.003). A high-risk (10yr CV event risk >20%) FRS was calculated 
in 4/20pts using chronological age, and in 7/20 and 6/20 in the CAC and cIMT adjusted 
FRS, respectively.
Conclusions: In our patient cohort vascular age adjustments using both CAC and cIMT 
increased overall CV risk as assessed by FRS. CAC and cIMT appeared to yield similar 
information with regard to assessment of vascular age and adjustment of FRS for the 
presence of subclinical atherosclerosis.
10:00 a.m.
1035-165 Multi-Vessel Coronary Artery Disease on Coronary 
Angiography Indicates Increased Risk of Death Among 
Patients with End-Stage Renal Disease Undergoing 
Work-Up for Renal Transplantation
David Jones, Angela M. Taylor, Lewis C. Lipson, Ellen C. Keeley, Lawrence W. Gimple, 
Michael Ragosta, University of Virginia, Charlottesville, VA
Background: Patients (pt) with end-stage renal disease (ESRD) considered for renal 
transplantation (RT) often have coronary artery disease (CAD). The relationship of CAD 
seen on coronary angiography (CA) to long-term outcome in these pts is unclear and may 
be important for determining suitability for RT. We hypothesized that extent of CAD is an 
important determinant of outcome in ESRD pts.
Methods: From 1999-2006, 257 high-risk ESRD pts (presence of angina, prior CAD; or 
diabetes plus age >50, history of smoking, or dyslipidemia) underwent CA for pre-RT 
evaluation. Pts were divided into three groups based on number of vessels with ≥50% 
stenosis (No CAD, n=126; Single Vessel [1v] CAD, n=58; Multi-Vessel [≥2v] CAD, n=72). 
Long-term survival (median 3.3 yrs) was determined.
Results: Baseline characteristics were similar except: increased age and proportion of 
diabetes, dyslipidemia, and vascular disease in the 1v and ≥2v CAD groups compared 
to the No CAD group. 39% of pts with CAD underwent revascularization. Survival was 
significantly worse for pts with ≥2v CAD (Figure). By corrected Cox proportional hazards, 
≥2v CAD (HR 3.0, p<0.01) and history of CHF (HR 2.5, p<0.01) were associated with 
death, but absence of CAD was protective (HR 0.3, p<0.01). Revascularization did not 
impact survival.
Conclusions: ESRD pts with ≥2v CAD have an increased risk of death. Revascularization 
is not associated with improved survival. Thus, identifying CAD by CA is an important 
prognostic feature in evaluating ESRD patients for RT.
10:00 a.m.
1035-166 Glycemic Control and Cardiovascular Events in Type 
2 Diabetes Mellitus: A Meta-Analysis of Randomized 
Controlled Trials
Ahmad Khraisat, Amol A. Bahekar, Atul Trivedi, Eshraq AlJaghbeer, Janos Molnar, Rohit 
Arora, Sandeep Khosla, Rosalind Franklin University/Chicago Medical School, North 
Chicago, IL
Background: Uncertainty persists regarding the effect of intensive long term glycemic 
control on cardiovascular events in type 2 diabetes mellitus (DM-2).
Methods: We conducted searches of the published literature using Pubmed, Medline, CINAHL, 
and Cochrane data bases. Data abstraction was performed by 2 authors independently. Eight 
randomized controlled trials (N=11,651) comparing the effects of intensive glycemic control 
versus conventional treatment for DM-2 were identified. Heterogeneity was assessed by 
Cochran’s Q test. The studies were homogeneous; therefore the Mantel-Haenszel fixed-effect 
model was used to compute the relative risk (RR) across all study groups. Results were 
considered statistically significant if P value was <0.05.
Results: The RR of myocardial infarction (MI) was significantly decreased in the intensive 
treatment group, as compared to the control group 0.836 (CI: 0.751-0.931; P< 0.001). 
The RR for all cause mortality, heart failure, stroke/transient ischemic attack (TIA), and 
peripheral vascular events was 0.907 (0.766 - 1.074; P<0.257), 1.142 (0.566 - 2.303; P< 
0.712), 0.907 (0.766 - 1.074; P<0.257), 1.029 (0.840-1.261; P<0.780); respectively in the 
intensive treatment group, as compared to the control group.
Conclusions: Intensive glycemic control of DM-2 was associated with a significant 
decrease in the risk of MI. A trend towards decrease in all cause mortality and stroke/TIA 
was observed in the intensive glycemic control group but the results were not significant. 
10:00 a.m.
1035-167 High Prevalence of Overweight and Obesity Amongst 
First Generation Asian and Hispanic High School 
Students
Cyrus F. Buhari, Kelley Barnett, Vikrum Fagoora, Prakash C. Deedwania, University of 
California San Francisco, Fresno, Fresno, CA
Background: Recent epidemiologic studies among adults show higher prevalence of age-
adjusted obesity, diabetes, and metabolic syndrome among ethnic minorities. However, 
little is known about the prevalence of overweight and obesity among the first generation 
migrant minority adolescents in the community setting. Accordingly, we evaluated the 
prevalence of overweight and obesity in minority adolescent high school students.
Methods: A questionnaire consisting of 20 multiple-choice questions regarding personal 
and family health history, diet, and physical activity was distributed to adolescents at 3 
urban Fresno high schools with a significant proportion of minority students. Overweight 
and obesity were defined as over 85th and 95th percentile of age-specific BMI obtained 
from CDC growth charts.
Results: A total of 1167 adolescents were surveyed. The median age was 15 (range 
12-17). There were 198 Asians and 753 Hispanics. The remaining 216 were Caucasian, 
African American, American Indian/Alaska Native, Asian Pacific Islander, or mixed. 
Thirty-six percent were overweight/obese (16% overweight, 20% obese). The rates of 
overweight/obesity for Asians and Hispanics were 32% and 39%. Parental history of 
overweight/obesity identified higher prevalence of overweight/obesity in adolescents 
(38% Asians, 48% Hispanics). As little as 1 hour of daily physical activity index was 
associated with lower rates of overweight/obesity in both Asian and Hispanic (p=0.02) 
adolescents. Similarly, increasing levels of self-reported physical activity were associated 
with a progressive decrease in rates of overweight/obesity in these groups (p<0.001). 
However, no significant trend was seen with either owning a videogame console or 
computer, or with time spent on these devices. Surprisingly, there was a paradoxical trend 
of lower rate of overweight/obesity with â‰¥4 weekly visits to fast food restaurants for 
both Hispanic and Asian adolescents.
Conclusion: These results show a high prevalence of overweight/obesity amongst the 
first generation migrant minority adolescent high school students and increasing levels of 
physical activity is associated with progressively lower rates of overweight/obesity.
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10:00 a.m.
1035-168 Women Face Higher Risk for Decline in Left Ventricular 
Ejection Fraction Following Orthotopic Liver Transplant
James N. Kirkpatrick, Jeanine Romanelli, Kevin J. Duffy, Craig H. Scott, Martin St. John 
Sutton, Susan E. Wiegers, Martin G. Keane, University of Pennsylvania, Philadelphia, PA
Background:Chronic liver disease is associated with low systemic vascular resistance 
(SVR) which reverses post-orthotopic liver transplant (OLT), potentially resulting in left 
ventricular dysfunction. OLT patients with cardiac dysfunction are prone to organ failure 
and death.
Methods:80 consecutive patients undergoing OLT with transthoracic echocardiography 
prior to OLT and within one year following OLT were enrolled. Quantitative analysis of 
left ventricular end systolic and diastolic volumes were performed in blinded fashion, and 
these values were used to calculate left ventricular ejection fraction (LVEF) and stroke 
volume (SV).
Results:There were 50 men and 30 women, with a mean age of 50+10 years. There was 
a significant decline in LVEF after OLT (62+12% pre vs. 54+16% post, p<0.001). This 
correlated with a decline in SV from 62+23ml pre-OLT to 48+22ml post-OLT (p<0.001). 
Women had larger declines in LVEF than men (-14+19% vs. -4+17%, p<0.05) as well as 
SV (-20+23 ml vs. -9+25 ml, p<0.05). Twenty-one percent of patients had a decline in 
LVEF from a normal range to below 45%. More women had a depressed LVEF of <45% 
post-OLT (36.7% of women vs.16.0% of men, p<0.05). Postoperatively, there were no 
clinically significant differences in regurgitant valve disease, diastolic function or atrial size 
compared to preoperative studies.
Conclusions:Following OLT, LVEF and SV decrease. Women are at a higher risk than 
men for this decline. Careful pre-operative ventricular assessment, particularly of women, 
may identify patients at increased risk for post-operative dysfunction who may benefit 
from afterload reduction.
10:00 a.m.
1035-169 Relationship of white blood cell count and HDL-
cholesterol to coronary heart disease mortality 
(CHD) in a 30-year follow-up of Multiple Risk Factor 
Intervention Trial (MRFIT) cohort
Daniel A. Duprez, Jia Xu, Gregory Grandits, Jerome D. Cohen, Lewis Kuller, Richard 
Grimm, Jeremiah Stamler, James Neaton, University of Minnesota, Minneapolis, MN
Background: Atherogenesis is an active inflammatory process, rather than passive lipid 
infiltration. White blood cells (WBC) play a major role in this process. HDL-cholesterol 
(c) has anti-atherogenic properties. Thus the combined effects of HDL-c and WBC 
count on risk of coronary heart disease (CHD) mortality is of interest. We examined the 
bivariate relationship of baseline WBC count and HDL-c with CHD mortality in the MRFIT 
population during a follow-up of approximately 30 years.
Methods: Data are from MRFIT; 12,866 men aged 35 to 57 years at entry were followed 
for mortality from time of enrollement (1973-1976) to 2003. At baseline blood pressure 
(BP) was measured and a fasting blood sample was taken for the determination of 
total c, triglycerides, LDL-c and HDL-c, and WBC count. A COX regression model was 
used to estimate the hazard ratio (HR) for CHD mortality in relation to HDL-c and WBC 
count before and after adjustment for age, systolic BP, LDL-c, log triglycerides, smoking, 
ethnicity and BMI.
Results: Table 1 summarizes the results. Separate regressions for HDL-c and WBC, 
adjusting for each other as well as other covariates are calculated and HR and 95% CI 
for a 1-SD difference are given. HR (2,500/mm² WBC) = 1.07 (1.04, 1.11), P<0.001 and 
HR (10mg/dl HDL-c) = 0.87 (0.83, 0.91), P<0.001. There is no evidence for interaction 
(P = 0.697).
Conclusions: Higher baseline WBC count serves as a marker of inflammation and is a 
predictor of CHD mortality independently of HDL-c in men over long-term.
Table 1
WBC 
(/mm²)
HDL-c 
(mg/dl)
Number 
in Group
Rate (/1,000 
person years)
Rate (per 1,000 
person years) HR
Adjusted 
HR
P-
value
> 8,000 < 40 2,166 427 8.58
2.01 
(1.73, 
2.34)
1.85 
(1.56, 
2.18)
< 
0.001
> 8,000 > 40 1,784 274 6.62
1.55 
(1.31, 
1.83)
1.38 
(1.16, 
1.64)
< 
0.001
6,000-
8,000 < 40 2,292 396 7.33
1.70 
(1.45, 
1.98)
1.65 
(1.40, 
1.94)
< 
0.001
6,000-
8,000 > 40 2,411 351 6.07
1.40 
(1.19, 
1.63)
1.30 
(1.11, 
1.52)
< 
0.001
< 6,000 < 40 1,686 235 5.59
1.26 
(1.06, 
1.50)
1.23 
(1.03, 
1.47)
0.023
< 6,000 > 40 2,527 280 4.44 1.00 1.00
10:00 a.m.
1035-170 Association between Obesity and Left Ventricular 
Hypertrophy
Hirotsugu Mitsuhashi, Kunihiro Matsushita, Hideaki Ishii, Shigeo Iino, Hiroshi Yatsuya, 
Koji Tamakoshi, Toyoaki Murohara, Nagoya University Graduate School of Medicine, 
Nagoya, Japan
Background: Although there are reports investigating the association between left 
ventricular hypertrophy (LVH) and obesity (OB) in hypertensive patients (HP), hypertension 
(HTN) is a major associate with LVH and OB, and confounding the association. Moreover, 
since antihypertensives (AHT) are reported to imorpve LVH, they are also interfering the 
association. Thus, we investigated the association between LVH and OB in normotensive 
individuals (NI) and HP not taking ATH.
Methods: A total of 1018 NI and HP who underwent echocardiography (UCG) were 
enrolled in the study. Subjects whose ejection fractions (EF) were lower than 50%, 
who had valvular heart disease or old myocardial infarction were excluded. We divided 
subjects into three groups depending on their body mass indexes (BMI): normal (-24.9), 
overweight (25.0-29.9) and obese (30.0-). LV mass was calculated based on UCG 
measurements and indexed to height to the power of 2.7. LVH was defined as LV mass 
index >49 and 45g/m2.7 in male and female, respectively according to the guideline of 
the American Society of Echocardiography. Odds ratio (OR) by which subjects had LVH 
compared with normal group was calculated in each group separately in NI and in HP, and 
adjusted by potential confounding factors: gender, age, EF, systolic blood pressure (SBP), 
existence of diabetes (DM), hyperlipidemia (HL), and estimated glomerular filtration ratio 
(eGFR) with multivariate logistic regression analysis.
Results: Compared with the normal group, ORs in overweight (OW) and obese groups 
were significantly higher than unity (OR: 3.07, 95%CI: 2.21-4.24, p <0.001 and OR: 
9.24, 95%CI: 4.43-19.3, p <0.001, respectively) in NI. Similar results were obtained in 
HP (OR: 2.55, 95%CI: 1.76-3.69, p <0.001 and OR: 6.06, 95%CI: 2.64-13.9, p <0.001, 
respectively). Significant linear association betweem BMI and prevalence of LVH was 
obseved (p <0.001).
Conclusions: OW and obese subjects had significantly higher prevalence of LVH 
independent of gender, age, EF, SBP, eGFR, DM and HL compared with the normal 
group both in NI and HP. Degree of OB was also significantly associated with prevalence 
of LVH. Weight reduction might be effective to prevent or to improve LVH.
10:00 a.m.
1035-171 Is N-terminal Pro-Brain Natriuretic Peptide a Reliable 
Prognostic Marker in Heart Failure Patients with 
Chronic Kidney Disease?
Christian Bruch, Rainer Gradaus, Günter Breithardt, Hospital of the University of 
Münster, Münster, Germany
Background/Aim: In patients (pts) with chronic heart failure (CHF), N-terminal pro brain 
natriuretic peptide (NT-proBNP) predicts poor outcome. Clinical predictors of NT-proBNP 
and its usefulness in the presence of chronic kidney disease (CKD) are unknown.
Methods: We enrolled 341 pts with stable CHF (mean ejection fraction 37±14%, mean 
NYHA class 2.3±0.8). CKD defined as estimated glomerular filtration rate (eGFR) < 
60 ml/min/1.73 m² was present in 183 pts (54%). During a follow-up of 620±353 days, 
cardiac events (cardiac death, need for extracorporal assist device or urgent cardiac 
transplantation) and re-hospitalization data were analyzed.
Results: During follow-up, 57 pts (17%) suffered a cardiac event, and 64 pts (20%) were 
re-hospitalized due to worsening CHF. NT-proBNP was related to NYHA functional class 
(r=0.44, p<0.001), and inversely related to ejection fraction (r=0.52, p<0.001), and the 
eGFR (r=0.32, p<0.001).
By multivariate Cox analysis, a cardiac event was independently predicted by NT-proBNP 
(Hazard ratio (HR) 1.56, p<0.001), ejection fraction (HR 0.95, p=0.004), and serum 
sodium (HR 0.89, p=0.018). In the entire group, a NT-proBNP of 1470 pg/ml (derived 
from ROC analysis, area under the curve: 0.81±0.03) best separated pts with or without 
cardiac event. In pts without CKD, outcome was significantly worse in subjects with NT-
proBNP > 1474 pg/ml in comparison to pts with NT-proBNP < 1474 pg/ml (event-free 
survival rate 0% vs. 75%, Log Rank: 13.5, p<0.001). Likewise, in pts with CKD outcome 
was significantly worse in subjects with NT-proBNP > 1474 pg/ml in comparison to those 
with NT-proBNP < 1474 pg/ml (event-free survival rate 48% vs. 93%, Log Rank: 28.5, 
p<0.001). NT-proBNP was the only clinical variable that independently predicted re-
hospitalization due to worsening CHF (HR 1.26, p=0.023), and a cut-off value of 1474 
pg/ml also separated subjects with poor and intermediate prognosis in both the CKD and 
non-CKD group.
Conclusions: In CHF pts with and without CKD, NT-proBNP independently predicts 
morbidity and mortality. In such pts, NT-proBNP levels do not merely reflect reduced renal 
clearance, but also the severity of the underlying structural heart disease.
10:00 a.m.
1035-172 Pre-implant N-terminal pro-B-type Natriuretic Peptide 
Predicts Mortality and Morbidity following Cardiac 
Resynchronization Therapy
Paul William Foley, Kayvan Khadjooi, Shajil Chalil, Russell EA Smith, Sud 
Ramachandran, Michael P. Frenneaux, Francisco Leyva, Good Hope Hospital, University 
of Birmingham, Sutton Coldfield, United Kingdom
Background: The benefits of cardiac resynchronization therapy (CRT) are well established. 
It is also recognized, however, that the survival benefit of CRT is difficult to predict from 
pre-implant assessments, such as echocardiography. We sought to determine whether 
pre-implant N-terminal pro-B-type natriuretic peptide (NT pro-BNP) relates to mortality 
JACC March 11, 2008  ABSTRACTS - Vascular Disease, Hypertension and Prevention  A357 
Vascular D
isease, H
ypertension and P
revention
and morbidity following CRT.
Methods: 129 patients with heart failure [HF, age 68 ± 11 yrs, 105 male, LVEF <35%, 
NYHA class III (n=99) or IV (n=30), QRS = 155.1 ± 30.5 ms, (mean ± SD)] with ischemic 
(n=90) or non-ischemic (n=39) cardiomyopathy underwent CRT following optimisation of 
drug treatment.
Results: In analysis using receiver operator characteristic (ROC) curves, a NT pro-
BNP cut-off <1640 pg/mL identified survivors following CRT, with a sensitivity of 82% 
and a specificity of 67% [area under ROC curve = 0.76, p=0.006). When patients were 
dichotomized with respect to NT pro-BNP level < or ≥1640 pg/ml, marked differences 
emerged in the composite endpoints of death or unplanned hospitalization for major 
cardiovascular events (MCE) and death from any cause or unplanned hospitalization for 
HF (both p<0.0001, see Figure) as well as death from any cause and cardiovascular 
death (both p=0.0005) over a follow-up of up to 4.2 years (mean 657 days).
Conclusions: In patients undergoing CRT, a high pre-implant NT pro-BNP level is a strong 
predictor of mortality and morbidity. 
10:00 a.m.
1035-173 Platelet Reactivity is Increased in Patients with Type 
2 Diabetes in Association with Increased Body Mass 
Index: A BARI 2D Substudy
David J. Schneider, Regina Hardison, Nueza Lopes, Burton E. Sobel, Maria M. Brooks, 
University of Vermont, Burlington, VT, University of Pittsburgh, Pittsburgh, PA
Background: Derangements of metabolism and insulin sensitivity may contribute to the 
pro-thrombotic state seen with type 2 diabetes. We sought to determine whether metabolic 
control reflected by the HbA1C and triglyceride concentrations, insulin resistance, 
or both contribute to the pro-thrombotic state. Obesity has been associated with both 
inflammation (reflected by C-reactive protein - CRP) and insulin resistance. Nine of the 
BARI 2D clinical sites participated in our substudy where platelet function and markers 
of thrombin generation and activity were assessed. These sites enrolled 184 patients 
to be part of this substudy. Methods: Blood taken at the time of enrollment in BARI 2D 
was used to assess platelet function and to determine the concentration of prothrombin 
fragment 1.2 (PT1.2, released when prothrombin is activated) and fibrinopeptide A (FPA, 
released when fibrinogen is cleaved). Platelet activation was identified with the use of flow 
cytometry in response to 0, 0.2, and 1 µM adenosine diphosphate (ADP). Activation in 
the absence of agonist or in response to either concentration of ADP correlated positively 
(p<0.001). Associations were assessed with the use of a Spearman rank correlation.
Results: Neither the HbA1C nor the concentration of triglycerides in blood correlated 
with platelet function or the concentrations of either PT1.2 or FPA. Greater BMI was 
associated with increased platelet reactivity but not the concentration of PT1.2 or FPA. 
The percentage of platelets activated in response to 1 µM ADP was higher in patients 
with higher BMI (kg/m2) from <25 (median activation 4%) to 25-30 (median 6%) to 30-35 
(median 8%) to >35 (median 17%, p<0.005). Activation of platelets did not correlate with 
the concentration of CRP (p=NS), however, concentrations of CRP correlated positively 
with fasting insulin concentrations (p=0.04). Activation of platelets in the absence of 
agonist correlated positively with fasting insulin concentrations (p<0.04).Conclusions: In 
patients enrolled in this substudy of BARI 2D, a greater BMI was associated with higher 
platelet reactivity at the time of enrollment. Our results suggest that insulin sensitivity may 
influence platelet function.
10:00 a.m.
1035-174 Favorable Cardiovascular Risk Factor Profile is 
Associated with Reduced Prevalence of Coronary 
Artery Calcification and Inflammation in Asymptomatic 
Non-diabetic White Men
Erin D. Michos, Raul D. Santos, Venkata Narla, Shivda Pandey, Romeu Meneghelo, Jose 
AM Carvalho, Matthew J. Budoff, Khurram Nasir, Johns Hopkins School of Medicine, 
Baltimore, MD, Albert Einstein Hospital, Sao Paulo, Brazil
Background: Recent evidence indicates that middle-aged individuals with favorable levels 
of all major cardiovascular risk factors (CVRF) have much lower age-specific risks for 
incident cardiovascular disease (CVD) compared to those with higher CVRF. However, 
the relationship of absence of CVRF with subclinical CVD and inflammation is not well 
described.
Method: We studied 440 men (46±7 yrs) free of diabetes and clinical CVD who presented 
for electron-beam tomography in San Paulo, Brazil. Individuals were classified based on 
the number of following CVRF (smoking, SBP>130 mm Hg, LDL≥130 mg/dl, HDL<40 
mg/dl, triglycerides≥150 mg/dl, fasting glucose≥100 mg/dl, waist circumference>102 cm). 
Prevalent CAC was defined as Agatston scores >0. Elevated white blood cells (WBC) was 
defined as greater than the median [≥6.1 x10(9) cells/L].
Results: Only 10% of the cohort had 0 CVRF, whereas 1, 2, 3 and ≥4 CVRF was observed 
in 21%, 24%, 19%, and 26%, respectively. CAC was observed in 41% with increasing 
prevalence of CAC seen in those with increasing CVRF (0=18%, 1=31%, 2=39%, 3=45%, 
≥4=58%). Among those with no CVRF and detectable CAC, only 1 man had CAC>100, 
whereas the majority (82%) had CAC<10. In logistic regression analysis, a lower CVRF 
profile was associated with lower odds of CAC and inflammation (table).
Conclusions: Our study supports the notion that a favorable CVD profile is associated with 
less underlying atherosclerosis and inflammation and further highlights the importance of 
primary prevention of CVRF.
Odds for the Presence of CAC by 
CVRF profile (adjusted for age and 
WBC)
Odds for the Presence of Elevated 
WBC >=median (adjusted for age 
and CAC)
Odds Ratio 95% CI p-value Odds Ratio 95% CI p-value
>= 4 CVRF Reference Reference
3 CVRF 0.65 0.35-1.21 0.18 0.56 0.31-0.99 0.047
2 CVRF 0.50 0.28-0.90 0.02 0.55 0.32-0.95 0.032
1 CVRF 0.43 0.22-0.82 0.01 0.27 0.15-0.50 <0.001
0 CVRF 0.31 0.12-0.77 0.01 0.32 0.15-0.69 0.003
10:00 a.m.
1035-175 Role of ACE-inhibition on Cardiovascular Outcomes in 
Patients with Diabetic Nephropathy: A Meta-Analysis
Amol A. Bahekar, Sarvanan Balamuthusami, Lavanya Srinivasan, Sandeep Khosla, 
Rosalind Franklin University/Chicago Medical School, North Chicago, IL
Background: Studies have shown that ACE-inhibition decreases proteinuria and impedes 
the progression of renal dysfunction in patients with diabetic nephropathy (DN). The aim 
of our study is to evaluate the effects of ACE-inhibition on cardio-vascular (CV) outcomes 
in patients with renal insufficiency.
Methods: A systematic review of the literature was performed by 2 separate authors 
using Pubmed, Medline, Cochrane database, CINAHL and EMBASE search engines 
using relevant search words. Heterogeneity of the studies was assessed by Chi2 test. 
The studies were homogeneous; therefore the Mantel-Haenszel fixed-effect model was 
used to compute the relative risk (RR) across all study groups. Results were computed 
using 95% confidence intervals and were considered statistically significant if p value 
was <0.05.
Results: 6 randomized placebo controlled trials (N=42,160) were eligible for the meta-
analysis. The RR for developing heart failure was 0.82(0.69-0.97) p<0.05 when ACE 
inhibition was compared to placebo. The RR for CV mortality, stroke, overall vascular 
outcomes and total mortality were 1.15 (0.94-1.4): p=0.2, 1.07 (0.85-1.34) p=0.6, 0.95 
(0.88-1.02) p=0.2 and 1.07 (0.96-1.19) p=0.2 respectively when the ACE-inhibitor group 
was compared to placebo.
Conclusions: ACE-inhibition in DN significantly decreases the risk of developing heart 
failure when compared to placebo. There was no beneficial effect with ACE inhibition in 
decreasing the risk for total mortality or stroke in patients with DN. 
10:00 a.m.
1035-176 Duration of Hypoxia During Sleep is Associated with 
Increased Pulmonary Artery Systolic Pressure and 
Mortality
HYUNG J. CHUN, CHRISTINE H. WON, PRISCILLA S. SARINAS, RAJINDER K. 
CHITKARA, PAUL A. HEIDENREICH, Stanford University School of Medicine, Stanford, 
CA, Palo Alto VA Medical Center, Palo Alto, CA
Background: Although hypoxia occurs frequently in patients with sleep apnea, its value 
in predicting mortality is undefined. Our objective was to determine whether the duration 
of hypoxia is associated with elevated pulmonary artery systolic pressure (PASP) and 
increased mortality.
Methods: We performed a retrospective cohort study of 445 consecutive patients who 
underwent a polysomnography study followed by echocardiography. We compared the 
PASP from echocardiography and one year mortality between those with severe hypoxia 
(SH) (defined as ≥25% of sleep time with SaO2 less than 90%) and those without 
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Results: Of the 445 patients, 95 patients had SH (mean age 60 years, BMI 38.3, 95% 
male) compared to 350 with NSH (mean age 64 years, BMI 33.5, 95% male). The PASP 
was significantly higher in the SH group (42.9 mmHg vs. 36.0 mmHg, p=0.002). There 
was significantly worse one year mortality in the SH group (8.7% vs. 3.5%, p=0.037). 
The unadjusted hazard ratio for one year mortality with SH was 2.60 (CI 1.03-6.55, 
p=0.04), and was 3.38 (CI 1.20-9.55, p=0.02) after adjusting for age, BMI, and prevalence 
of ischemic heart disease, congestive heart failure, renal disease, and COPD. The 
association with mortality in SH was explained by increased PASP. In patients without 
a PASP measurement on the echocardiogram, severe hypoxia was independently 
associated with worse one year mortality.
Conclusions: Prolonged hypoxia during sleep is strongly associated with increased PASP 
and risk of one year mortality.
10:00 a.m.
1035-177 From Airway to Cardio-Renal Dysfunction: an 
Integrative Approach to Unmask Subclinical Target 
Organ Damage in Hypertensives with Obstructive Sleep 
Apnea
Costas Thomopoulos, Costas Tsioufis, Anastasia Amfilochiou, Kyriakos Dimitriadis, 
Dimitris Tsiachris, Maria Selima, Christodoulos Stefanadis, Ioannis Kallikazaros, 
Department of Cardiology, Hippokration Hospital, Athens, Greece
Background: We investigated whether established renal function parameters correlate 
with sleep parameters and cardiovascular adaptations in hypertensives with obstructive 
sleep apnea syndrome (OSAS).
Methods: 62 consecutive subjects (49 men, aged 48±7 years) with stage I-II untreated 
hypertension and OSAS diagnosed by polysomnography (PSG) [apnea/hypopnea index 
(AHI)>5] and a control group of 70 untreated hypertensives with negative PSG matched 
for age, sex, body mass index and smoking status were studied. In all subjects carotid 
- femoral pulse wave velocity (c-f PWV) was measured while serum creatinine levels 
(SCR), glomerular filtration rate (GFR) and albumin/creatinine excretion ratio (ACR) from 
a morning urine sample were also determined.
Results: Hypertensives with OSAS compared to those without OSAS demonstrated 
similar levels of waist to hip ratio (0.92 vs 0.92 p=NS), office systolic blood pressure 
(BP), and pulse pressure (150.7±8.6 vs 148±14 and 51.7±10 vs 52.2±12mmHg, p=NS 
for both cases), while diastolic BP was higher (99±9 vs. 95±8, p=0.03). Left ventricle 
mass index and relative wall thickness were similar (100±23 vs 97±22 g/m2 and 0.452 
vs 0.455 p=NS for both cases) while c-f PWV was increased in the OSAS group (8.2±1 
vs 7.2±0.9 m/sec p=0.0001). Albeit SCR and GFR did not differ between the two groups 
(0.96±0.18 vs 0.94±0.18mg/dl and 114±30 vs 116±27 ml/min, respectively, p=NS for 
both cases), logACR was significantly higher in OSAS subjects (1.07±0.31 vs 0.66±0.38 
mg/g p<0.0001). In different covariance analysis models the difference in c-f PWV and 
logACR remained significant even after adjustment for confounders (p<0.05 for both 
cases). In the entire study population c-f PWV was correlated with the presence of OSAS 
(r=0.40 p<0.001), systolic BP (r=0.25 p=0.01), logAHI (r=0.35 p<0.001), minimum oxygen 
saturation (mSO2) (r=-0.40, p<0.0001), while logACR was correlated with presence of 
OSAS (r=0.491 p<0.0001), logAHI (r=0.34 p<0.0001), mSO2 (r=-0.48 p<0.0001).
Conclusions: The presence of OSAS predicts increased levels of ACR and aortic 
stiffening in the setting of hypertension, a finding suggesting enhanced sub-clinical target 
organ damage.
10:00 a.m.
1035-178 Factors influencing Arterial stiffness in HIV infected 
patients
Ignatios Ikonomidis, John Lekakis, Sotirios Tsiodras, Ioannis Palios, Loukianos 
Rallidis, Anastasia Antoniadou, Garyfalia Poulakou, Periklis Panagopoulos, Antonios 
Papadopoulos, Helen Giamarellou, Dimitrios T. Kremastinos, University of Athens, 
Attikon Hospital, Athens, Greece
Background: The use of highly active antiretroviral therapy (HAART) in HIV (+) individuals 
reduced mortality rates but it has been associated with adverse metabolic effects and 
increase in the risk of myocardial infarction. Arterial stiffness is a marker of subclinical 
atherosclerosis with prognostic significance. The aim of the study was a) to examine the 
factors influencing arterial stiffness in HIV (+) individuals and b) to compared HIV patients 
with patients with hypertension, a disease with abnormal arterial stiffness.
Methods:Sixty-nine HIV (+) patients (mean age 41.8 ± 13 yrs, 88.5 % male) attending a 
tertiary care center were compared to 27 patients with never-treated hypertension and 
27 healthy subjects. Both control groups had similar age, sex and atherosclerotic risk 
factors to HIV patients. Of the 69 HIV patients, 45 were treated with HAART. Carotid to 
femoral pulse wave velocity (PWV-Complior apparatus) was used as estimate of arterial 
stiffness.
Results: By ANOVA, HIV patients treated with HAART had higher PWV compared to HIV 
patients without HAART and compared to normal controls (8.38 ±1.5 vs 7.4 ±1.3 vs 7.2 
±1.15 m/sec, p=0.007). No difference was found between HIV patients without HAART 
and healthy controls (p=0.9) or HIV patients treated with HAART and hypertensive 
subjects (8.38 ±1.5 vs. 9 ±1.1 p=0.19). Patients receiving HAART had higher glucose 
(p=0.032), total cholesterol (p<0.001), LDL-cholesterol (p=0.002) and triglycerides 
(p=0.03) compared to patients without HAART. In univariate regression analyses PWV 
was related with age, mean blood pressure, HAART, duration of HAART, total cholesterol, 
LDL-cholesterol and triglycerides (p < 0.05 for all associations), but not with viral load. 
In multivariate regression analysis HAART(p=0.03), mean blood pressure (p=0.01) and 
triglyceride levels (p=0.04) were the most important determinants for increased PWV
Conclusions: Compared to HIV-infected patients without HAART, those receiving HAART 
have increased arterial stiffness similar to that observed in hypertensive patients. Arterial 
stiffness is not related to viral load but to HAART and parameters of metabolic syndrome 
namely blood pressure and triglycerides.
10:00 a.m.
1035-179 Lifestyle Physical Activity Improves Arterial 
Compliance in Mildly Hypertensive, Sedentary, African-
American Women
Anand M. Pillai, Anupam Gupta, Josh Weinstock, Beth A. Staffileno, Steven M. 
Hollenberg, Cooper University Hospital, UMDNJ, Camden, NJ, Rush University Medical 
Center, Chicago, IL
Background: Low levels of physical activity (PA) and high rates of obesity predispose to 
hypertension and target organ injury, especially in African-American women. Lifestyle 
PA may be a feasible and acceptable preventive strategy in this population. This single-
blinded, randomized, parallel-group study examined the effects of lifestyle PA on BP 
indices, endothelial function, and vascular compliance in sedentary, untreated mildly 
hypertensive African-American women aged 18-45.
Methods: Women randomized to an 8-week intervention (n=12) were instructed to 
engage in lifestyle PA for 10-minutes, 3-times/day, 5-days/week at a prescribed heart 
rate corresponding to an intensity of 50-60% heart rate reserve. Women in the control 
group (n=10) continued their usual activities. Brachial artery flow-mediated dilation (FMD) 
was measured by brachial artery ultrasound and analyzed with edge detection software. 
Arterial elasticity (C1, C2) was assessed noninvasively by radial waveform analysis using 
a modified 2-element Windkessel model. Augmentation index (AI) was derived from 
transformed radial waveforms using proprietary software (Sphygmocor).
Results: The exercise group had a significant reduction in systolic BP (-6.4 mmHg), 
diastolic BP (-3.4 mmHg), and most pressure load indices. Endothelial function did 
not change significantly in either group. AI improved in the exercise group (39.9±5.4 
to 35.4±5.4, p=0.03) but not in controls (36.5±6.9 to 35.8±8.6, p=0.78). For the whole 
sample, AI correlated with C2 (r=-0.45, p<0.01) but not C1 (r=-0.19) or FMD (r=0.06).
Conclusions: Lifestyle PA reduced cuff BP and pressure load indices in this study, and 
there was a concomitant improvement in central arterial compliance. These findings may 
be clinically important given the strong correlation between obesity, hypertension and 
target organ damage, especially in African-Americans.
10:00 a.m.
1035-180 Comorbidities Convey Important Prognostic 
Information for Post MI Risk Stratification
Harel Gilutz, Ygal Plakht, Doron Zhager, Drora Fraser, Shimon Weitzman, Cardiology 
department, Soroka University Medical Center, Beer Sheva, Israel, Department of 
Epidemiology, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer 
Sheva, Israel
BACKGROUND: Scores based on conventional cardiovascular parameters are available 
for predicting mortality after myocardial infarction (MI). There is no validated risk model 
to predict post MI mortality integrating non cardiovascular comorbidities. OBJECTIVE: To 
create a new prognostic index for post-MI patients incorporating comorbidities based on 
simple available data.
METHOD: We retrospectively analyzed 2773 consecutive MI patients (age: 66±13 
years, 70% males) who were discharged during 2002-2004 and had one year of follow 
up. Post discharge annual mortality was 12.6%. Patient data included demographics, 
cardiovascular, laboratory and non cardiac discharge diagnosis. Two thirds of the patients 
were used as the study population and a third was used to validate the model. All cause 
mortality was the primary end point. Multifactorial logistic regression analysis was used 
to identify independent predictors. RESULTS: Out of 39 parameters that were introduced 
into multivariable mortality model, 18 were identified as independent predictors. Each 
parameter adds points (in brakes) to the model according to its independent relative risk: 
age 65-75y (1),>75 (3), hyponatremia (1), hyperkalemia (1), absence of echocardiography 
(1), severe Lt ventricular dysfunction (2), significant Lt ventricular hypertrophy (2), 
moderate or severe mitral regurgitation (3), moderate or severe pulmonary hypertension 
(2), CABG (-4), other reperfusion therapy (-2), old MI (1), renal failure (1), obesity (-1), 
gastro-intestinal hemorrhage (3), anemia (1), COPD (2), malignant neoplasm (3), alcohol 
or drug addiction (3), neurological disorders (3), schizophrenia or psychosis (3). Mean 
score was 2.36 (-4-+15). For each rise of one point the one year mortality increased by 
1.55 (CI: 1.47-1.64; p<0.001). There was no significance difference between the study 
and validation cohorts. A One year mortality for≤ 0 point was 0.3% and for patients with 
≥7 points was 45%
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CONCLUSION: Comorbidities convey important prognostic information and should be 
included in post MI risk models. The additional use of a simple available prognostic 
indicator provides a practical tool to identify patients who are at high risk of death.
10:00 a.m.
1035-181 The Combination of Depression and Abnormal Non-
Linear Heart Rate Variability Predicts Increased 
Cardiovascular Mortality in the Elderly: The 
Cardiovascular Health Study
Willem J. Kop, Phyllis K. Stein, Peter P. Domitrovich, Joshua I. Barzilay, John S. 
Gottdiener, University of Maryland, Baltimore, MD
Background: Abnormal autonomic nervous system (ANS) function plays an important role 
in cardiovascular disease (CVD). Depression is associated with impaired sympathetic 
and vagal tone. The predictive value of depression for CVD may therefore be mediated 
by altered ANS function.
Methods: Participants from the Cardiovascular Health Study (CHS) were included if 
they were free of prevalent CVD and if 24-hour ambulatory ECGs met quality criteria for 
spectral power analysis (N=914, age 71±5 yrs, 59% women, median follow-up 12.3 yrs). 
ANS indices were based on heart rate variability (HRV) analysis in the time, frequency, 
and non-linear domains. Depression was assessed using the Center for Epidemiological 
Studies Depression scale (CESD).
Results: Depression was associated with non-linear HRV indices (reduced short-term 
fractal scaling exponent (DFA1): 1.03±0.02 vs. 1.06±0.01; p = 0.040), but not with time 
or frequency domain HRV (p>0.10). Low DFA1 (<1.0) occurred more often in depressed 
vs. non-depressed individuals (41% vs. 29%,p=0.008). Depression (RR=1.7, p=0.009) 
and a reduced DFA1 (RR=2.2, p=0.0005) were independently predictive of CV mortality 
(Figure). The combined presence of depression and reduced DFA1 HRV was associated 
with elevated CV mortality risk (RR=3.7, p<0.0001). Results remained significant after 
statistically adjusting for age, sex, SBP, and diabetes. 
Conclusion: The combination of depression and reduced DFA1 HRV is associated with 
substantially increased risk of CV mortality.
10:00 a.m.
1035-182 Epidemiology of Incident Heart Failure in the Elderly: 
Gender and Racial Differences
Vasiliki Georgiopoulou, Andreas Kalogeropoulos, Syed A. Agha, Grigorios Giamouzis, 
Nicolas Rodondi, Melissa Garcia, Douglas Bauer, Suzanne Satterfield, Anne Newman, 
Andrew Smith, Tamara Harris, Stephen B. Kritchevsky, Javed Butler, Health ABC Study, 
Emory University, Atlanta, GA
Background: Although the epidemiology of prevalent HF has been described, the 
epidemiology of incident HF especially the gender and racial differences in the elderly 
are not well studied.
Methods: We studied 2935 subjects without baseline HF in the Health ABC study. Incident 
HF was defined as hospitalization for new onset HF. Incidence rates overall and by race/
gender were assessed. Post-HF mortality and predictors of mortality were assessed 
using proportional hazards models.
Results: Mean age was 73.6±2.9 yr with 47.9% men and 58.6% whites. Mean follow-up was 
6.5±1.8 yr. Incident HF rates are presented in Table. Overall, 611/2935 died, representing 
a cumulative mortality of 20.8% (annual: 3.1%). Compared to the 2677 subjects who did 
not develop HF (annual: 2.7%, cumulative: 18.3%), mortality among participants who 
developed HF was 6-fold higher in the 2.6±2.1 yr follow-up. Outcomes after newHF did not 
differ between gender and race subgroups. Multivariate predictors of mortality after new 
HF included increased HR (p=0.004), age (p=0.006), and reduced BMI (p=0.02). Ejection 
fraction (EF) was determined during HF hospitalization in 197/258 patients (mean 41±16%). 
Impaired EF (<50%) was a univariate but not a multivariate predictor of post HF survival.
Conclusion: Incident HF rate is high in the elderly and is associated with poor outcomes 
irrespective of race, gender, and EF.
Table: Incident HF and the risk for subsequent mortality and hospitalization 
Cohort N
Incident 
HF 
(N) 
Annual 
Incidence 
(%)
Cumulative 
Incidence 
(%)
Annual 
Mortality 
Post-HF 
(%)
Cumulative 
Mortality 
Post HF 
(%)
All-cause 
Rehospitalization 
Post HF 
(%)
Total 2935 258 1.36 8.8 18.0 46.9 70.5
Men 1407 140 1.58 10.0* 20.5 49.1 67.9
Women 1528 118 1.17 7.7 15.4 44.1 73.7
White 1720 135 1.18 7.8 18.0 44.4 67.4
Black 1215 123 1.63 10.1† 17.9 49.6 74.0
HF=heart failure, *p<0.05 vs. women, †p<0.05 vs. white
10:00 a.m.
1035-183 Incident Heart Failure Prediction in the Elderly: The 
Health ABC Heart Failure Score
Javed Butler, Andreas Kalogeropoulos, Vasiliki Georgiopoulou, Grigorios Giamouzis, 
Syed A. Agha, Nicolas Rodondi, Melissa Garcia, Douglas Bauer, Suzanne Satterfield, 
Anne Newman, Andrew Smith, Tamara Harris, Stephen Kritchevsky, for the Health ABC 
Study, Emory University, Atlanta
Background: Despite rising heart failure (HF) incidence and aging of the US population, 
there are no validated prediction models for incident HF. In this study we sought to develop 
a prediction model for 5-yr HF risk among elderly.
Methods: We studied 2935 participants (age 73.6±2.9 years, 47.9% males, 58.6% whites) 
enrolled in the Health ABC study. Cox models were used to assess the independent 
predictors of incident HF (defined as hospitalization for new onset HF). A prediction 
equation was developed and internally validated by bootstrapping, allowing the 
development of a 5-year risk score.
Results: Incident HF developed in 258 (8.8%) participants during 6.5±1.8 yr follow-
up. Independent predictors of new HF included age, history of coronary disease and 
smoking, baseline systolic blood pressure and heart rate, serum glucose, creatinine, and 
albumin levels, and left ventricular hypertrophy (Table). The Health ABC HF model had 
an optimism-corrected c-statistic 0.72 and good calibration (Hosmer-Lemeshow χ2 6.24, 
p=0.62). A point score was created to predict 5-yr HF risk into four groups corresponding 
to <5%, 5-10%, 10-20%, and >20% 5-yr risk. The actual 5-yr incident HF rates in these 
groups were 2.9%, 5.7%, 13.3%, and 36.8% respectively.
Conclusion: The Health ABC HF prediction model uses common clinical variables to 
predict incident HF risk in the elderly, an approach that can be used to target and treat 
high-risk individuals.
Table: Predictors of Incident Heart Failure 
Variable Wald χ2 P value BC Coefficient BC HR (95% CI)
Coronary Heart Disease 64.9 <0.001
Definite 1.10 3.02 (2.24-3.79)
Probable 0.43 1.55 (0.71-3.01)
Systolic BP, mmHg 35.8 <0.001 0.02 1.02 (1.01-1.02)
Smoking 19.9 <0.001
Current 0.83 2.28 (1.56-3.26)
Past 0.11 1.12 (0.83-1.47)
log (Creatinine, mg/dl) 17.5 <0.001 0.95 2.59 (1.68-4.04)
Heart Rate, bpm 13.4 <0.001 0.02 1.02 (1.01-1.03)
Albumin, gm/dl 13.1 <0.001 -0.75 0.47 (0.32-0.72)
Glucose, mg/dl 10.1 <0.001 0.005 1.005 (1.002-1.008)
Age (years) 7.7 0.005 0.06 1.07 (1.02-1.12)
Left Ventricular Hypertrophy 6.0 0.01 0.43 1.54 (1.06-2.11)
BC: Bias-Corrected
10:00 a.m.
1035-184 Cardiovascular Phenotype Predicting Incident Heart 
Failure in Diabetes: The Strong Heart Study
Giovanni de Simone, Richard B. Devereux, Marcello Chinali, Elisa T. Lee, James M. 
Galloway, Barbara V. Howard, Federico II University, Naples, Italy, Weill-Cornell Medical 
College, New York, NY
Background: We have previously shown that diabetes (DM) is a potent predictor of incident 
heart failure (HF), independent of a number of confounders including incident coronary 
heart disease. Whether a cardiac phenotype can be identified among participants with 
DM to predict high probability of HF is unknown.
Methods: At the 2nd exam of the Strong Heart Study (SHS) cohort, 2758 participants 
free of prevalent cardiovascular disease (1746 women) underwent echocardiographic 
evaluation. Among them, 189 developed HF within the following 7.5+1.8 years, 40 of 
whom also had acute incident myocardial infarction (MI). Baseline characteristics were 
analyzed by 2-way ANCOVA.
Results: After adjusting for age. sex, obesity, hypertension and incident MI, DM had 
LV mass index (LVMi) similar to non-DM, but increased relative wall thickness (RWT, 
p<0.0001), which was lower in participants with subsequent HF (p<0.001), with no 
interaction. Fractional shortening (FS) was similar in DM and non-DM but lower in subjects 
with future HF (p<0.0001), a difference greater in non-DM (p<0.05 for interaction). No 
effects were identified for the E/A ratio. Deceleration time of E velocity (DTE) was slightly 
influenced by DM, whereas it was prolonged in subjects with HF (p<0.0001), more in 
non-DM than in DM (p<0.001 for interaction). Controlling for age, sex, hypertension and 
obesity (forced in the Cox model), significant independent predictors of HF, by stepwise 
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backward entry, were incident MI (HR=3.3), DM (HR=2.8), low FS (HR=0.93/1%), high 
LVMi (HR=1.2/10 g/m-2.7), high left atrial dimension (HR=1.4/cm) and prolonged DTE 
(HR=1.1/25 msec). Among the 1272 participant with DM (868 women), together with 
incident MI (HR=4.4), HF was predicted by the same echo variables as in the whole 
population, with the addition of low RWT (HR=0.91/2nd decimal point). A last Cox model 
was also generated in DM after excluding participants with incident MI (n=40) and the 
above results were confirmed.
Conclusions: Diabetes predicts HF, independent of incident MI. Morphologic and functional 
characteristics that predict HF in DM are lower LV systolic and diastolic function, higher LV 
mass and less concentric LV geometry.
10:00 a.m.
1035-185 Postoperative Heart Rate Is a Predictor of 
Cardiovascular Events After Coronary Artery Bypass 
Surgery
Michael J. Frank, Victor Aboyans, Philippe Lacroix, Jerome Guilloux, Annabel Postil-
Francois, Marc Laskar, Dupuytren University Hospital, Limoges, France
Background: Rest heart rate (HR) is a proven marker of cardiovascular morbidity and 
mortality in the general population. We recently showed that HR was of prognostic interest 
in predicting early adverse events after coronary artery bypass graft surgery (CABG), but 
no data on the long-term outcome are currently available. Therefore, the objective of the 
present study was to assess the prognostic value of early post-operative HR in predicting 
cardiovascular events on a long-term follow-up.
Methods: 1022 consecutive patients referred to our institution for CABG were enrolled 
between 1998 and 2002 in a prospective cohort study. All event-free patients benefited 
from a medical follow-up examination 2 to 3 months after cardiac surgery, during 
which rest HR was measured on an ECG. The primary outcome was the occurrence 
of any cardiovascular (CV) event during follow-up: CV death, stroke, early coronary 
revascularization and peripheral vascular surgery. The secondary outcomes were all 
cause mortality, CV mortality, the occurrence of stroke or transient ischemic attack (TIA), 
and coronary events: recurrent angina, acute coronary syndrome (ACS) and myocardial 
infarction (MI). Statistical analysis was performed by usual methods.
Results: Mean age of patients was 66.9 years, 81.8% of which were men. The mean follow-
up after CABG was 3.5 ± 1.3 years, during which 191 patients (18.7%) met the primary 
outcome, including 105 deaths (68 of CV disease), 158 (15.5%) secondary coronary 
events (including 38 ACS), 61 cases of stroke and 42 cases requiring peripheral vascular 
surgery. These patients had a higher post-operative HR (72.3 bpm vs. 67.9 bpm, p<0.002). 
In the multivariate analysis, after adjustments for age, history of vascular events, existing 
peripheral arterial disease, LVEF<40%, unstable cardiac status, combined valvular and 
vascular surgery, perioperative MI and pre- and postoperative beta-blocker therapy, post-
operative HR remained a significant risk predictor (OR=1.022 per bpm p<0.001). Similar 
results were found for recurrence of coronary events, all cause and CV mortality.
Conclusions: Post-operative HR, even adjusted to beta-blocking therapy, is predictive of 
CV events after CABG surgery.
10:00 a.m.
1035-186 A Meta-Analysis of the Risk of Depression and 
Incidence of Discontinuation Due to Adverse Events of 
Rimonobant in Weight Loss Clinical Trials
Leonardo Tamariz, Andrew Fischer, Ana Palacio, Hermes Florez, William O’Neill, 
University of Miami, Miami, FL
Background: Rimonobant is a selective cannabinoid-1 receptor blocker used for the 
treatment of obesity and associated cardiometabolic risk. Obesity is associated with an 
increased risk of depression and other psychiatric disorders. The aim of this study was 
to evaluate the relationship between efficacy and depression as well as adverse effects 
leading to discontinuation of rimonobant in weight loss trials.
Methods: We selected all studies in the English literature in which 20 mg of rimonobant 
was compared to placebo using a randomized design to determine the efficacy for 
weight loss. We calculated the pooled odds ratio for 10% weight loss, depression and 
drug discontinuation due to any adverse effect using the Mantel-Haenzel fixed effects 
method.
Results: Four studies met our eligibility criteria: The studies included 2503 patients 
receiving rimonobant with a mean age that ranged from 44 to 55 years old, the percentage 
of women ranged from 48 to 81 and the mean body mass index ranged from 34 to 37. 
The odds ratio of reaching a 10% weight loss was 4.7 (95% C.I. 3.8-5.8) for rimonobant 
compared to placebo. The odds ratio of having depression was 1.9 (95% C.I. 1.2-3.2) for 
rimonobant compared to placebo (figure) and the odds ratio of rimonobant discontinuation 
was 2.1 (95% C.I. 1.7-2.6) compared to placebo.
Conclusion: Rimonobant is an effective pharmacological method for significant weight 
loss however carries a significant risk of depression as well as discontinuation due to 
adverse events in weight loss trials. 
10:00 a.m.
1035-187 Racial Variation in the Modification of the Metabolic 
Syndrome in Coronary Artery Disease Patients 
Attending Cardiac Rehabilitation
Todd M. Brown, Bonnie K. Sanderson, Monika Safford, Vera Bittner, University of 
Alabama at Birmingham, Birmingham, AL
Background: Cardiac rehabilitation (CR) modifies the metabolic syndrome (MS) in 
coronary artery disease (CAD) patients; the role of changes in body mass index (BMI) and 
functional capacity is unknown. Methods: We assessed if changes in BMI and functional 
capacity (6 minute walk distance) after CR were independently associated with reductions 
in MS components in African American (AA) and white CAD patients using multivariable 
linear regression, adjusting for age, gender, and baseline BMI and functional capacity. We 
used Adult Treatment Panel III MS criteria, substituting diabetes history for the glucose 
criterion. Because a history of hypertension or diabetes is not modifiable, we analyzed 
changes in the modifiable MS components (hypertriglyceridemia, low HDL-cholesterol, 
and central obesity). Results: Mean age in the 295 MS patients was 61.5 ± 10.1 years, 
34% were women, 27% AA. At baseline, mean BMI was 31.7 ± 5.5 kg/m2, mean 6 minute 
walk distance 386.0 ± 113.1 meters, and mean number of modifiable MS components 2.1 
± 0.7. Increases in functional capacity were associated with reductions in MS components 
in whites (p<0.001), but not AA. Decreasing BMI was associated with reductions in MS 
components in whites (p=0.01), with a similar trend in AA (p=0.072) (figure). Conclusion: 
Increases in functional capacity were associated with reductions in MS components in 
whites, but not AA. Further analyses in larger populations are necessary to assess if 
weight loss is more important in modifying the MS in AA with CAD. 
10:00 a.m.
1035-188 Prevalence and Correlates of Microalbuminuria in 
Essential Hypertensive Subjects: Data From the 
Hippokration Hellenic Hypertension (3H) Study
Costas Tsioufis, Kyriakos Dimitriadis, Costas Thomopoulos, Maria Selima, Dimitris 
Tsiachris, Dimitris Syrseloudis, Christodoulos Stefanadis, Ioannis Kallikazaros, 
Department of Cardiology, Hippokration Hospital, Athens, Greece
Background: Microalbuminuria (MA) is a marker of subclinical atherosclerosis progression 
and it is related to unfavorable outcome. In this study we sought to determine the 
prevalence of MA in a large cohort of hypertensives and to investigate the relations of 
the albumin to creatinine ratio (ACR), with diverse clinical and biochemical cardiovascular 
risk factors.
Methods: A total of 1178 consecutive essential hypertensive subjects [604 men, aged 56 
years, office blood pressure (BP)=144/90 mmHg] that were included in the Hippokration 
Hellenic Hypertension (3H) study, an ongoing registry of hypertension-related target 
organ damage, were considered for analysis. According to ACR values determined as 
the mean of two non-consecutive morning spot urine samples, patients were divided into 
those with MA (ACR=22-300 mg/g in men and ACR=30-300 mg/g in women) and those 
without MA (ACR<22 mg/g in men and ACR<30 in women). All participants underwent 
venous blood sampling for estimation of metabolic profile.
Results: 149 patients (12.6%) had MA and when compared to those without MA (n=1029) 
exhibited higher office systolic BP (149 vs 144 mmHg, p=0.001), left ventricular mass 
index (108.9 vs 102 g/m2, p=0.007), greater prevalence of type 2 diabetes (25 vs 12%, 
p<0.0001) and metabolic syndrome (50 vs 30%, p<0.0001). Moreover, microalbuminurics 
compared to normoalbuminurics had lower high-density lipoprotein (49.9 vs 53.5 g/dl, 
p<0.05), heightened triglycerides (149 vs 122 mg/dl, p<0.0001), fibrinogen (339 vs 
321 mg/dl, p=0.04) and homocysteine levels (14.1 vs 12.5 µmol/l, p=0.01). In the total 
population, ACR was associated with age (r=0.18, p=0.02), office systolic BP (r=0.109, 
JACC March 11, 2008  ABSTRACTS - Vascular Disease, Hypertension and Prevention  A361 
Vascular D
isease, H
ypertension and P
revention
p<0.0001), and triglycerides (r=0.122, p<0.05), while exhibited no relation to fibrinogen 
and homocysteine (p=NS). Multiple regression analysis revealed that office systolic BP 
and triglycerides were independent predictors of ACR (p<0.05).
Conclusion: Among hypertensives that participated in the 3H study, 12.6% had MA 
and were characterized by adverse clinical and biochemical phenotype. These findings 
suggest that ACR determination is a useful tool to improve cardiovascular risk stratification 
in this setting.
10:00 a.m.
1035-189 Rheumatoid Arthritis Increases Risk of Perioperative 
Cardiovascular Events: An Analysis Using the National 
Inpatient Sample of the Healthcare Cost and Utilization 
Project
Ali Yazdanyar, James E. Bost, Kwonho Jeong, Kevin Kraemer, Mary Chester Wasko, 
Mike Ward, University of Pittsburgh, Pittsburgh, PA
Background: Rheumatoid arthritis(RA) is associated with increased cardiovascular(CV) 
burden. Using population-based data, we examined the impact of RA on CV events 
among patients undergoing surgery during elective hospitalizations.
Methods: Using International Classification of Diseases ninth revision codes provided 
in the 2001 to 2004 Healthcare Cost and Utilization Project-National Inpatient Sample, 
we identified patients with RA and Osteoarthritis (OA), their comorbidities, and principal 
surgical procedure. We categorized procedures into low, intermediate, and high risk using 
American College of Cardiology guidelines. The composite CV endpoint included acute 
myocardial infarction (AMI), acute stroke, non-ST elevation MI, and congestive heart 
failure with pulmonary edema(CHF-Pe).
Results: The weighted sample included 18,205 RA and 509,413 OA patients. RA patients 
were younger (mean age:62.2 vs 67.2 years; p<0.01), more likely to be female (75.7% vs 
61.7%;p<0.01), have CHF without Pe (4.4% vs 3.1%;p<0.01), chronic renal disease(0.2% 
vs 0.1%;p=0.03),and less likely to be diabetic (11.6% vs 14.5%; p<0.01) or hypertensive 
(43.9% vs 56.6%; p<0.01) than OA patients. The proportions of coronary artery disease 
(13.6% vs 13.2%), atrial fibrillation (5.4% vs 5.5%), and valvular heart disease (0.9% 
vs 1.0%) were not statistically different. Fewer RA patients underwent intermediate risk 
surgery (81.4% vs 96.4%;p<0.01) while a greater proportion underwent low (10.6% vs 
2.0%; p<0.01) or high risk surgery (8.0% vs 1.6%;p<0.01). RA patients had a higher 
rate of the composite CV endpoint (0.4% vs 0.2%; p<0.01). In a multivariable logistic 
regression analysis adjusted for age, gender, race, comorbidities, and surgical risk, RA 
patients were more likely than OA to have the composite CV endpoint (odds ratio [OR] 
1.54; 95% confidence interval [CI] 0.97-2.44). In subgroup analysis, RA patients were 
more likely to have AMI (OR 1.67; 95%CI 1.02-2.76) than OA.
Conclusions: RA was associated with increased risk of composite CV event and AMI 
among patient undergoing surgery during elective hospitalizations. This finding has 
implications for perioperative CV risk assessment in patients with RA.
10:00 a.m.
1035-190 Prevalence and Distribution of Sub-Clinical 
Atherosclerosis by Screening Vascular Ultrasound in a 
Low and Intermediate Framingham Risk Cohort
John Postley, Alejandro Perez, Nathan D. Wong, Maria Chan, Julius M. Gardin, 
Columbia University, New York, NY
OBJECTIVE: Cardiovascular disease (CVD) is the leading cause of death in the US. 
Framingham Risk Score (FRS) fails to identify many with CVD. Although carotid (CP) and 
femoral (FP) plaque assessment by ultrasound has shown predictive sensitivity for CVD 
in outcome studies, none has addressed prevalence and distribution of these plaques in 
a cohort with low or intermediate FRS.
METHODS: Asymptomatic patients without CVD (n=484, 46% female) were screened 
for CP and FP by ultrasound. 404 (84%) were 32-65 years of age, 80 (16%) were 66-85 
years of age. The FRS components available were: age, gender, smoking history, total 
and HDL cholesterol, blood pressure and presence of diabetes. Low FRS was defined as 
<10% and intermediate FRS as 10-20% coronary heart disease event risk over 10 years. 
Bilateral carotid and femoral ultrasound evaluation was performed. Presence of plaque 
was defined as a >1.5 mm projection into the lumen.
RESULTS: Of 484 subjects, 194 had either CP or FP. Incidence of plaque varied by age 
and gender: 39% of men age 32-65 had plaque, while 76% of men age 66-85 had plaque 
(p<0.0001). 27% of women age 32-65 had plaque, while 71% of women age 66-85 had 
plaque (p<0.0001). Age had a significant impact on plaque distribution. Of those with 
plaque in the 32-65 age group, 82% of women and 67% of men (p=0.048) had either CP 
or FP but not both while 56% of men and 59% of women (p=0.82) age 66-85 had plaque in 
both locations. A comparison of plaque prevalence for FRS groups with risk <10 (low) and 
10-20 (intermediate) revealed 34% of those at low FRS and 68% of those at intermediate 
FRS to have either CP and/or FP present (p<0.0001), but if only carotid ultrasound were 
performed, these numbers were 25% and 53% (p<0.0001).CONCLUSIONS: This study 
confirms the utility of extracardiac vascular ultrasound assessment for the determination of 
subclinical CVD risk and underscores the importance of age and gender in the prevalence 
and distribution of plaque. A significant number of patients in low and intermediate FRS 
categories have subclinical disease which can be identified by ultrasound. Inclusion of 
both femoral and carotid ultrasound will identify additional persons at risk of CHD than 
the use of either technology alone.
10:00 a.m.
1035-191 Inflammatory Biomarkers of Cardiovascular Disease in 
a Ten-Year Cohort Study in Glasgow, Scotland
Mark Woodward, Gordon D. Lowe, Paul Welsh, Ann Rumley, Hugh Tunstall-Pedoe, 
Mount Sinai Medical Center, New York, NY, University of Glasgow, Glasgow, United 
Kingdom
Background: Inflammatory biomarkers, including high-sensitivity C-reactive protein 
(CRP), fibrinogen and interleukin (IL)-6, are increasingly being suggested as possible 
additional risk markers, adding to classic risk factors, for cardiovascular disease (CVD). 
Data on the inflammatory cytokines tumor necrosis factor alpha (TNF-α) and IL-18, and 
how their effects on CVD compare to the three more commonly researched inflammatory 
biomarkers, in general populations are sparse.
Methods: These five biomarkers were assayed from stored plasma samples collected 
during the fourth Glasgow MONICA survey (n=843 men; 955 women). Subjects were 
followed up, through record linkage, for 10 years, during which time 228 CVD events (49 
fatal) were recorded.
Results: Each of the five inflammatory biomarkers had an approximate log-linear 
relationship with the hazard ratio (HR) for CVD. HRs (95% confidence intervals), adjusted 
for age, sex, diabetes, systolic blood pressure, total and HDL-cholesterol, cigarettes 
smoked per day, family history of CVD and socio-economic status (SES), for a standardized 
continuous increase of half the distance between the quartiles were 1.24 (1.07-1.43) for 
fibrinogen, 1.19 (1.12-1.26) for CRP, 1.12 (1.03-1.21) for TNF-α, 1.12 (1.03-1.22) for IL-6 
and 1.02 (0.89-1.18) for IL-18. Similar results were found when restricting to the 1596 
without CVD at baseline (131 CVD events); p for homogeneity > 0.1. Unlike fibrinogen 
and IL-6, CRP and TNF-α retained significant effects after further adjustment for each of 
the other variables individually. Indeed, the HR for TNF-α after adjustment for fibrinogen, 
IL-6 and CRP, as well as standard risk factors and SES, was 1.12 (1.02-1.24), which is 
similar to the corresponding 1.17 (1.07-1.27) for CRP, adjusted for standard risk factors, 
SES, fibrinogen, IL-6 and TNF-α.
Conclusion: Along with the previously established inflammatory marker CRP, the cytokine 
TNF-α appears, in our data from a general population, to have a role as a risk marker for 
CVD, independent both of classic risk factors and other markers of inflammation. TNF-α 
may prove to be a useful aid to achieving better targeted treatments, if our findings can 
be confirmed elsewhere.
10:00 a.m.
1035-192 A New Paradigm in Cardiovascular Risk Scoring: 
National Initiative to Tackle Disease Associated With 
Low Socio-Economic Status in Scotland
Mark Woodward, Hugh Tunstall-Pedoe, Mount Sinai Medical Center, New York, NY, 
University of Dundee, Dundee, United Kingdom
Background: Scotland has one of the highest rates of cardiovascular disease (CVD) 
worldwide, this being widely attributed to high rates of smoking, poor diet and social 
deprivation. The latter is only partly explained by classic risk factors and is, therefore, not 
reflected in conventional risk scores, such as the Framingham score, which omit socio-
economic status (SES).
Methods: A CVD risk score, called ASSIGN, was derived from the Scottish Heart Health 
Extended Cohort (SHHEC) study: 6,540 men and 6,757 women free of CVD, followed 
up for 10-21 years (2,619 new CVD events). Variables included were to be any of a pre-
defined group of risk factors that had an independent association with CVD in SHHEC, 
both for men and women. This included an area-based measure of SES, derived from 
Census data. The new score was compared to the standard Framingham risk score.
Results: ASSIGN includes age, diabetes, systolic blood pressure, total and HDL-
cholesterol, cigarettes smoked per day, family history of CVD and SES. Body mass 
index, diastolic blood pressure, former smoking and left ventricular hypertrophy had 
no independent effects. ASSIGN showed similar overall discrimination of CVD to 
Framingham, but had clear superiority in assigning risk more equitably across SES 
groups, since Framingham systematically showed worse over-estimation of risk as 
SES increased. Observed to Framingham-based expected ratios by increasing fifth of 
SES were 31%, 40%, 58%, 75% and 83% for women (and similarly for men). This was 
explained by the clear dose-response effect of SES on CVD even after adjusting for all the 
other ASSIGN variables: the hazard ratios (95% confidence intervals) by increasing fifth 
of SES were 1, 1.03 (0.78-1.35), 1.39 (1.09-1.78), 1.68 (1.33-2.13) and 1.80 (1.44-2.26) 
in women (and similarly in men).
Conclusion: In 2007, the Scottish Intercollegiate Guidelines Network adopted ASSIGN 
into national guidelines for CVD risk assessment: asymptomatic individuals with an 
estimated risk of 20% or more in ten years are to be targeted for intervention. This should 
redistribute CVD preventive treatment more fairly across SES groups, whilst reducing the 
overall CVD burden.
10:00 a.m.
1035-193 Low Rates of Heart Disease Awareness in Women 
in an Urban Community: A Call for More Aggressive 
Outreach
Maria C. Mirant-Borde, Lance W. Weathers, Jayanthi Koneru, Luis Chug, Pedro J. 
Rivera, Raul E. Daza, Jacqueline Tamis Holland, St Luke’s Roosevelt Hospital Center, 
New Yok
Background: Nationwide surveys suggest that CVD awareness in minority women (W) is 
low, with only 34% of Hispanic W (HW) and 38% of Black W (BW) reporting heart disease 
as the leading cause of death in W. We hypothesized that CVD awareness in inner city 
minority groups would be much lower than rates reported for minority groups nationwide.
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Methods/Results: W registering for the medical clinic at St. Luke’s and Roosevelt 
Hospitals in the upper west side of NYC and consenting to the survey were interviewed by 
surveyors, fluent in English and Spanish. A total of 99 W were surveyed (Hispanic=73.7%; 
Black=19.2%; Caucasian=6.6%). The mean age was 56 + 13 years. Spanish was the 
primary language in 64.6% of patients. Among all patients, 48.5% reported a very good 
or adequate understanding of English, 35.4% had partial comprehension and 16.2% 
reported no understanding of English. Only 20.2% of W stated that heart disease was 
the leading cause of death in W (16.4% of HW, 31.6% of BW and 33.3% of Caucasian 
W). Older age (p=0.05), good/adequate comprehension of English (p=.17), and having a 
physician who spoke a patient’s native language (p=0.04) were the univariate predictors 
of a patient’s ability to recognize heart disease as the leading cause of death among W. 
Logistic regression analysis demonstrated that only older age, (OR 1.04, 95% CI 1-1.04, 
p=0.04) and having a physician who spoke a patient’s native language (OR 5.31, 95% 
CI 1.13-25.0; p=0.03) predicted awareness of CVD in W. Awareness of risk factors for 
developing CVD was also low with 20.2% of W unable to identify any CVD risk factor, and 
36.4% only able to identify one RF. When asked about measures to prevent CVD, 31.3% 
of W were unable to list any preventive measures, and 28.3% described only 1 measure. 
Symptoms of MI or stroke were poorly understood: (18.1% of W did not know any of 
the symptoms of MI, and 61% were unable to identify any symptoms of ischemic stroke).
Conclusions: The level of CVD awareness in a predominantly Hispanic/Black urban group 
of W is much lower than that reported for minorities nationwide. Outreach programs 
aimed to improve CVD awareness should focus on minority groups, and emphasize 
communication and education in a patient’s native language.
10:00 a.m.
1035-194 The Combination of High Uric Acid Levels With Non-
Dipping Status Affects Unfavorably the Indices of 
Subclinical Target Organ Damage and Atherosclerotic 
Process
Dimitris Syrseloudis, Costas Tsioufis, Kyriakos Dimitriadis, Costas Thomopoulos, 
Dimitris Tsiachris, Dimitris Soulis, Christodoulos Stefanadis, Ioannis Kallikazaros, 
Department of Cardiology, Hippokration Hospital, Athens, Greece
Background: The significance of uric acid (UA) as a risk factor for cardiovascular (CV) 
disease and hypertension has been questioned while a disturbed circadian blood 
pressure (BP) rhythm seems to bear an increased CV risk. We investigated the impact 
of increased levels of UA in various indices of subclinical target organ damage (TOD) in 
non- dipper essential hypertensive subjects.
Methods: 232 consecutive, subjects with newly diagnosed, untreated essential 
hypertension were classified according to 24h ambulatory BP monitoring in 131 non-
dippers (nocturnal BP fall <10% of day-time BP) and 101 dippers (the remaining subjects). 
Metabolic profile, hs- CRP, adiponectin and urine albumin to creatinine ratio (ACR) were 
determined in all non- dippers who were further subdivided into non- dippers with high 
(above the median value= 5.3 mg/dl- n=67) and non- dippers with low UA serum levels 
(< 5.3 mg/dl, n=64).
Results: Non- dippers with high compared to low UA did not differ regarding age, BMI, 
smoking and duration of hypertension (p=NS, for all cases) while they had increased 
waist to hip ratio (WHR) by 0.05 (p<0.0005) and triglyceride levels by 23.6 mg/dl (p=0.03). 
They also exhibited a higher left atrial volume index by 1.5 mm3/m2 (p=0.03) and a lower 
tissue Doppler imaging E to A wave ratio by 0.15 (p=0.002). 24h SBP and DBP was 
higher in the high UA group by 6.0 (p=0.01) and 6.1 mmHg (p<0.0005) respectively. Non- 
dippers, with high UA had higher levels of hs- CRP by 1.12 mg/L (p=0.02), lower levels 
of adiponectin by 1.89 µg/ml (p=0.04) and increased ACR by 23.4 mg/g (p=0.002). In 
the entire population hs-CRP (r=0.32, p<0.0005) and ACR (r=0.38, p<0.0005) correlated 
positively with UA while adiponectin (r= -0.23, p=0.006) correlated negatively with UA. The 
difference in hs- CRP, ACR and adiponectin remained significant even after adjustment 
for a number of covariates (p<0.05).
Conclusion: Non dipper hypertensives with high compared to low UA levels, exhibit 
more intense subclinical inflammation and lower anti-atherosclerotic potential as well as 
accelerated TOD, indicative of an additional risk imposed to non- dippers with high UA 
levels, additive to the one already imposed by their circadian BP rhythm pattern.
10:00 a.m.
1035-195 Soluble ST2 Plasma Concentrations Predict Mortality 
in Dyspneic Patients With Pulmonary Disease: Results 
From the ProBNP Investigation of Dyspnea in the 
Emergency Department (PRIDE) Study
Abelardo A. Martinez-Rumayor, Sandy M. Green, Aaron L. Baggish, Michelle 
O’Donoghue, James L. Januzzi, Massachusetts General Hospital, Boston, MA
Background: Elevation of the interleukin-1 receptor family member ST2 is prognostically 
meaningful among patients with heart failure (HF), but such elevations have also been 
reported among patients with pulmonary diseases. We therefore evaluated the potential 
utility of ST2 measurement for risk stratification of dyspneic patients with pulmonary 
diseases.
Methods: From a prospective study of natriuretic peptide testing in a cohort of 599 
consecutive acutely dyspneic subjects in the emergency department setting, a subset of 
236 subjects with an identified pulmonary disease diagnosis as a cause of their dyspnea 
were studied. ST2 was measured; using one-year survival as the reference standard, 
receiver operating characteristic curves were used to estimate sensitivity, specificity, 
positive and negative predictive values (PPV, NPV) of ST2 with area under the curve 
(AUC) generated. Cox proportional hazards models evaluated for independent predictors 
of one year death.
Results: 80 patients had exacerbation of COPD, 69 had exacerbation of asthma, 64 
had pneumonia, 18 had pulmonary embolism and 5 had bronchitis. The highest ST2 
concentrations were seen in patients with pneumonia (0.69 ng/ml, interquartile range 
[IQR]=0.14-2.29), followed by patients with chronic bronchitis (0.33 ng/ml, IQR=0.06-1.2) 
and emphysema (0.24 ng/ml, IQR=0.12-0.55). Concentrations of ST2 were significantly 
higher in decedents compared to survivors (1.14 ng/ml [IQR=0.28-2.2] vs 0.19 ng/
ml [IQR=0.08-0.59]; P <.001). ST2 had an AUC of 0.73 as a predictor of death (95% 
confidence intervals [CI]=0.62-0.83; P <.0001). ST2 >0.20 ng/ml, had sensitivity of 88%, 
specificity of 52%, PPV of 22% and NPV of 96% for death. In Cox proportional hazards 
analysis, ST2 >0.20 ng/ml had a hazard ratio for death of 6.14 (95% CI 1.80-21.0; P 
=.004). Mortality rates for patients with an ST2 level >0.20 ng/ml on enrollment diverged 
early and rose progressively over one year (P <.001).
Conclusions: In addition to its strong value in risk assessment of patients with HF, ST2 
is powerfully prognostic in patients with dyspnea related to non-cardiac/pulmonary 
diseases.
10:00 a.m.
1035-196 Prevalence of Metabolic Syndrome in Healthy Adults, 
and its Association With Chronic Kidney Disease
Mahmoud M. Ramadan, Yoshifusa Aizawa, Tohru Watanabe, Yoshimaru Usuda, Shigeru 
Sasaki, Division of Cardiology, Niigata University Graduate School of Medicine, Niigata, 
Japan, Niigata Association for Comprehensive Health Promotion and Research, Niigata, 
Japan
Background: metabolic syndrome (MS) is a constellation of ≥ 3 linked risk factors (RFs), 
which predisposes the individual to diabetes, cardiovascular and renal diseases. We 
aimed to estimate the prevalence of MS in healthy adults and investigate its possible 
association with chronic kidney disease (CKD).
Methods: we studied 309,032 healthy Japanese adults (104,290 males and 204,742 
females) aged 40-85 years and not under treatment for any chronic disease. MS was 
defined according to NCEP-ATPIII criteria, with using modified obesity cutoffs specified 
for Japanese people. CKD was defined as MDRD-estimated glomerular filtration rate < 
60 ml/min/1.73 m2.
Results: MS was found in 16.8% of subjects (18.2% of males, 16.0% of females). CKD 
existed in 13.8% of subjects, and was more prevalent in males (16.1% versus 12.6% for 
females). MS group showed a significantly (p<0.0001) higher prevalence of CKD (18.4%) 
compared to non-MS (12.8%) group. The prevalence of CKD showed a steady trend to 
increase as the RF number got higher (9.5%, 13.7%, 15.8%, 17.5%, 20.0% and 22.1 
% for 0, 1, 2, 3, 4 and 5 RFs respectively; p-for-trend < 0.0001). In multivariate logistic 
regression analysis, CKD was independently associated with some clinical and laboratory 
variables (shown in the table). Conclusions: the prevalence of MS in healthy adults was 
similar to that in the general population. The prevalence of CKD is closely linked with 
MS in a graded manner (the higher the number of MS components, the greater the 
prevalence of CKD). 
Variables β Odds ratio 95.0% CI for OR p-value
Male gender 0.307 1.359 1.320 - 1.399 <0.001*
Age (y) 0.081 1.085 1.083 - 1.086 <0.001*
Body mass index (Kg/m2) 0.043 1.044 1.040 - 1.048 <0.001*
Systolic blood pressure (mmHg) - 0.001 .999 0.998 - 1.000 0.174
Diastolic blood pressure (mmHg) 0.005 1.005 1.003 - 1.006 <0.001*
Fasting blood glucose (mg/dL) - 0.002 .998 0.997 - 1.001 0.210
Plasma triglycerides (mg/dL) 0.002 1.002 1.002 - 1.002 <0.001*
High-density lipoprotein-cholesterol 
(mg/dL) - 0.003 .997 0.996 - 0.998 <0.001*
Low-density lipoprotein-cholesterol 
(mg/dL) 0.002 1.002 1.002 - 1.003 <0.001*
Hemoglobin (gm/dL) - 0.159 .853 0.844 - 0.861 <0.001*
Hemoglobin A1c (%) 0.004 1.004 0.983 - 1.027 0.690
10:00 a.m.
1035-197 Paradoxically Lower PAI-1 With Advanced Age in 
Patients With Diabetes Enrolled in BARI 2D
Robert D. McBane, II, Regina Hardison, Burton E. Sobel, on behalf of the BARI 2D 
investigators and fibrinolysis writing group, University of Vermont, Colchester, VT, Mayo 
Clinic, Rochester, MN
Background: Down-regulation of fibrinolysis attributable to increased PAI-1 with age is 
well recognized (Cardiovasc. Res. 2005; 66:276) and has been implicated in excess 
cardiovascular morbidity and mortality in patients with diabetes. Accordingly, we sought 
to determine whether such a relationship between PAI-1 and age exists at baseline in 
patients with diabetes enrolled in the BARI 2D trial.
Methods and Results: 2,321 patients with diabetes and stable coronary artery disease 
enrolled in the BARI 2D trial were stratified into one of four age deciles (<50; 50-59; 
60-69; and ≥70 years). Tissue-type plasminogen activator (TPA) antigen, plasminogen 
activator inhibitor (PAI-1), fibrinogen, and D-Dimer at baseline were quantified by ELISA 
or chromogenic substrate (PAI-1 activity). PAI-1 antigen and activity and their ratios to 
TPA were all reduced in association with higher age (Table). The paradoxic increase of 
inhibition of fibrinolysis associated with advanced age was associated with higher fibrin 
D-Dimer indicative of increased thrombosis.
Conclusions: Both aging and diabetes are strong descriptors of cardiovascular mortality. 
However, in this cross-sectional analysis, patients enrolled in BARI 2D appear to 
have been self-selected with respect to a survival advantage potentially attributable 
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to preserved fibrinolysis that is likely to account for the paradoxically lower PAI-1 as a 
function of greater age.
Baseline Measures of Fibrinolytic System Stratified by Age (mean, median) 
Age < 50 
(n=195)
Age 50-59 
(n=727)
Age 60-69 
(n=897)
Age > 70 
(n=502) P-value
PAI-1 activity au/ml 26.1, 21 23.0, 18 19.0, 15 16.7, 13 <0.0001
PAI-1 antigen 32.9, 28 29.1, 24 25.4, 22 24.6, 20 <0.0001
TPA ng/ml 10.4, 10 10.1, 10 10.0, 10 10.3, 10 NS
PAI-1/TPA ratio 3.3. 3 2.9, 3 2.6, 2 2.5, 2 <0.001
Fibrinogen mg/dL 363, 344 367, 360 260, 350 378, 367 0.003
D-Dimer µg/ml 0.4, 0 0.4, 0 0.5, 0 0.7, 0 <0.001
10:00 a.m.
1035-198 A New Proposal for Cardiovascular Risk Stratification 
in Renal Transplant Candidates: Time to Review the 
American Society of Transplantation Guidelines?
Luis Henrique W. Gowdak, Rodolfo L. Arantes, Flavio J. de Paula, Luiz Antonio M. 
Cesar, Luiz Estevan Ianhez, Eduardo M. Krieger, Jose Jayme G. De Lima, Heart 
Institute (InCor), University of Sao Paulo Medical School, Sao Paulo, Brazil, Renal 
Transplant Unit, Department of Urology, University of Sao Paulo Medical School, Sao 
Paulo, Brazil
Background: Renal transplant candidates (RTC) are at increased risk of cardiovacular 
disease (CVD) and cardiovascular events (MACE). We compared the American Society 
of Transplantation (AST) Guidelines with that of a new, modified algorithm in predicting 
MACE in RTC.
Methods: 954 RTC (62% men, 53±11 years-old) were stratified according to the AST 
criteria as high- [HR] (age ≥ 50 years, or diabetes +, or CVD +), or low-risk [LR] (none 
of the above). Then, they were stratified by a new, modified algorithm according to the 
number of factors as very high- [VHR] (all 3 risk factors +), high- [HR] (any 2 risk factors 
+), intermediate- [IR] (only 1 risk factor +), or low-risk [LR] (none). During a median follow-
up of 24 (1 - 80) months, the primary endpoint (the composite incidence of fatal/non-fatal 
MACE) was determined and Kaplan-Meier curves constructed for the survival free of 
MACE for each clinical algorithm.
Results: The incidence of the primary endpoint was 18.6% in the overall population. By 
the original AST criteria, 22.5% of HR-RTC (n=747) and 4.4% of LR-RTC (n=207) (Fig. 
1) (P<.0001) had an event, whereas according to the new, modified AST criteria 4.4% 
of LR (n=207), 14.4% of IR (n=347), 21.5% of HR (n=260), and 44.3% of VHR (n=140) 
(P<.0001) (Fig. 2) had a MACE.
Conclusions: The new, modified clinical algorithm for risk stratification allowed the 
identification of a subgroup of RTC at extremely high-risk for MACE compared to patients 
with better prognosis that would be classified altogether as HR by the original AST. 
10:00 a.m.
1035-199 Utility of Indices of Arterial Stiffness in Cardiovascular 
Risk Stratification in the Clinical Practice
Ashan Gunarathne, Jeetesh Patel, Elizabeth Hughes, Gregory Lip, University 
department of Medicine, Birmingham, United Kingdom
Background: Indices of arterial stiffness are accepted as independent markers of 
CHD having prognostic and diagnostic impact. However, the clinical utility of Stiffness 
Index (SI) derived from Digital Volume Pulse (DVP) analysis, in CHD risk screening 
has not been investigated. Methods: Using a representative sampling approach (West 
Midlands, UK) we determined the performance of SI in discriminating categories of 
CHD risk (Framingham risk score) amongst 247 individuals (51% male, mean age 
(SD):55.2(10.3)). Arterial stiffness was measured by DVP photoplethysmography (PCA 2 
Micro medical) in a temperature controlled environment using a standardised approach. 
CHD risk assessment was performed in accordance with Joint British Society guide lines. 
Results: We identified 187 healthy and 60 individuals with established risk factors (33%: 
diabetes mellitus, 77.8%: hypertension, 61%: hypercholesteremia) Table 1. On univariate 
analysis SI was associated with CVD risk scores (R: 0.56, P=<0.001) and increased 
in an ordinal fashion across from low risk (<5%), medium (5-10%) high (11-19%) and 
highest risk (>20%) (Pseudo R-Square = 0.30; P<0.001). In ROC analysis SI was the 
most useful discriminator between low-medium and high risk. (AUC(CI):0.76(0.64-0.88), 
P=0.000) than total cholesterol, plasma glucose, systolic blood pressure & waist hip 
ratio. Conclusion: Non invasive measurements of arterial stiffness may aid the optimal 
stratification of CHD risk in an apparently healthy population. 
10:00 a.m.
1035-200 Awareness, Treatment and Control of the Combination 
of Hypertension and Hypercholesterolemia in a Primary 
Prevention Population in Chile
Monica Acevedo, Veronica Krämer, Rodrigo Tagle, Gastón Chamorro, Marcelo 
Fernandez, Lorena Orellana, Pontificia Universidad Católica de Chile, Santiago, Chile
Background:The treatment and control of hypertension (HTN) and hypercholesterolemia 
(HCHOL) have demonstrated a decrease in cardiovascular events. The coexistence of 
both risk factors (RF) determines a higher cardiovascular risk than each RF separately. 
AHA/ACC guidelines have improved awareness, treatment and control of individual RF. 
However, there are little published data about the awareness, treatment and control of 
both RF taken together. Objectives: To determine the prevalence, awareness, treatment 
and control of HTN and HCHOL individually and both together, in a primary prevention 
cohort. Methods: In subjects without known atherosclerotic disease, seen in an 
ambulatory setting, we performed a survey about cardiovascular RF, measured systolic 
and diastolic blood pressure, BMI, waist, and determined fasting lipids and glycemia. 
We also recorded pharmacological treatment. Treatment goals were defined according 
to AHA/ACC guidelines in primary prevention. Results: 2158 subjects (64% men, 56±13 
yo). Prevalence of HTN and HCHOL was 31% and 64%, respectively; 21% of the subjects 
presented both RF. Only 8% of these subjects were on treatment target for both goals, 
HTN and HCHOL. Awareness, treatment and control of the RF are shown in the table.
Conclusions: The coexistence of HTN and HCHOL is common and it negatively influences 
the awareness, treatment and control of these RF. These results emphasize the need of 
public policies pointing out that RF tend to cluster increasing cardiovascular risk
Risk Factor Prevalence Awareness Treatment Control
HTN 31% (n=665) 65% (n=432) 67% (n=333) 62% (n=207)
HCHOL 64% (n=1363) 68% (n=924) 27% (n=245) 54% (n=132)
HTN + HCHOL 21% (n=457) 48% (n=219) 43% (n=94) 37% (n=35)
10:00 a.m.
1035-201 Trends in Secondary Prevention Medication Utilization 
and Adherence in Older Women With Coronary Heart 
Disease
Jennifer G. Robinson, Robert Wallace, Hong Ren, Monika M. Safford, Barbara Cochrane, 
Marcia G. Ko, Mary Jo O’Sullivan, Kamal Masaki, University of Iowa, Iowa City, IA
Background: Women’s long-term patterns of secondary prevention medication adherence 
are not well described.
Methods: Postmenopausal women 50-79 years were eligible for randomization in the 
Women’s Health Initiative’s hormone and diet modification trials. Those with a self-
reported diagnosis of CHD at baseline or during the trial were included in the analysis 
(n=8550). Baseline visits occurred between 1993 and 1998 then annually until the trials 
ended in 2002 through 2005. Medications were recorded by trained staff at baseline and 
years 1, 3, 6 and 9. Repeated measures logistic regression models with an unstructured 
correlation matrix were used to evaluate odds of use.
Results: Utilization increased over time for statins (21% to 51%); aspirin (41% to 60%); 
beta-blockers (24% to 46%). Continuous adherence (use at every sequential visit) fell 
at each subsequent visit for statins (81%, 69%, 63%, 51%), aspirin (73%, 58%, 49%, 
43%), and beta-blockers (82%, 72%, 65%, 59%) [Table]. However, many women who 
discontinued a drug at a previous visit restarted the drug at a later visit: statins (80%), 
aspirin (69%), and beta-blockers (74%).
Conclusion: Efforts to improve long-term adherence should also target restarting drugs in 
patients who have discontinued them. 
Drug 
class
WHI visit 
after CHD 
diagnosis
On drug at 
previous 
visit 
N*
On drug at 
this visit 
N
Percent on 
drug at this & 
previous visit 
(95% CI)
Odds of 
drug use at 
every sequential 
visit 
(95% CI)
Women on 
medication at 
this visit with use 
reported for at least 
1 previous visit 
(95% CI)
Aspirin
1st 3104 2261 73 (71-74) 0.73 (0.71-0.74) 73 (71-74)
2nd 2082 1198 58 (55-60) 0.51 (0.47-0.54) 70 (68-72)
3rd 1327 647 49 (46-51) 0.34 (0.31-0.37) 69 (67-72)
4th 171 73 43 (35-50) 0.27 (0.23-0.32) 77 (70-83)
Statin
1st 2070 1675 81 (79-83) 0.81 (0.79-0.83) 81 (79-83)
2nd 1176 815 69 (66-72) 0.52 (0.48-0.58) 80 (77-82)
3rd 665 416 63 (59-66) 0.36 (0.31-0.40) 81 (78-84)
4th 74 38 51 (39-63) 0.26 (0.20-0.34) 84 (73-91)
Beta--
blocker
1st 1960 1616 82 (81-84) 0.82 (0.81-0.84) 82 (81-84)
2nd 1224 886 72 (70-75) 0.52 (0.48-0.58) 78 (76-80)
3rd 766 498 65 (62-68) 0.36 (0.32-0.41) 78 (75-81)
4th 96 57 59 (49-69) 0.31 (0.25-0.38) 74 (64-82)
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10:00 a.m.
1035-202 A Novel Coronary Heart Disease Risk Evaluation 
and Communication Program Improves Modifiable 
Risk Factors and Understanding in Patients With 
Hypertension: The Risk Evaluation and Communication 
Health Outcomes and Utilization Trial
Leif Erhardt, Joshua Benner, Martina Flammer, Robert A. Moller, Natasa Rajicic, Komal 
Changela, Carla Yunis, Spencer B. Cherry, Zbigniew Gaciong, Eric S. Johnson, Miriam 
CJM Sturkenboom, Juan Garcia-Puig, Xavier Girerd, on behalf of the REACH OUT 
Investigators, Lund University, Malmo, Sweden, ValueMedics Research, a Unit of IMS 
Health, Falls Church, VA
Background: Few studies have investigated the potential benefits of communicating 
patients’ predicted coronary heart disease (CHD) risk in clinical practice. This analysis of 
the Risk Evaluation And Communication Health Outcomes And Utilization Trial (REACH 
OUT) assessed changes in modifiable CHD risk factors and understanding among 
patients receiving a non-drug intervention program (INT) to evaluate and communicate 
predicted CHD risk. Methods: REACH OUT was a 6-month, prospective, controlled, 
cluster-randomized, multinational study. Hypertensive patients (45-64 y) with no 
cardiovascular disease or diabetes, and Framingham 10-year CHD risk ≥10%, received 
INT or usual care (U). Changes in modifiable risk factors, predicted CHD risk, and patients 
at treatment goal (%) were determined at baseline and Month 6. Patients receiving INT 
also completed a Knowledge, Attitudes, and Behavior Questionnaire at baseline and 
Month 6. Results: Mean modifiable risk (absolute % risk in excess of that for a non-
smoker of the same age, sex, and antihypertensive treatment status with “normal” blood 
pressure [BP] and cholesterol) was reduced by 55% with INT (192% to 87%, n = 524), 
and by 47% with U (221% to 117%, n = 461; P=0.034 for INT versus U at Month 6, after 
adjusting for baseline values). At Month 6, INT patients reported an increase in their 
understanding of the importance of exercise, healthy diet, and medication compliance, 
and of reducing BP/cholesterol. Among INT patients, 48% met BP goal (<140 mm Hg), 
52% low-density lipoprotein cholesterol goal (<130 mg/dL), and 25% both goals, versus 
32%, 43%, and 14% of U patients. Smoking cessation was higher with INT (29%) than 
U (21%). Weight loss was 0.8 kg greater with INT than U (-1.1 versus -0.4 kg; P=0.015). 
Conclusions: Reductions in modifiable risk factors were larger in patients receiving 
INT than U. This benefit may be due to the reported increase in understanding of the 
importance of risk factor modification, and adherence to lifestyle recommendations 
and drug therapy. However, residual modifiable risk remained in both groups; additional 
therapeutic intervention to further lower CHD risk in patients with multiple modifiable risk 
factors is therefore required.
10:00 a.m.
1035-203 Adipose Tissue and its Adipokines Are Powerful 
Determinants of Inflammation and Early Renal 
Impairment: A Clue to Pathogenesis of Atherosclerosis
Francesca Graziani, Luigi M. Biasucci, Giovanna Liuzzo, Vittoria Rizzello, Salvatore 
Brugaletta, Caterina Guidone, Andrea Piccioni, Grazia Alecce, Gertrude Mingrone, 
Filippo Crea, Catholic University, Rome, Italy
Background: Inflammation and early impairment of renal function are recognised causes 
of atherosclerosis progression. Expanded adipose tissue is considered an independent 
risk factor for coronary artery disease, although mechanisms by which it can influence 
initiation and progression of atherosclerosis are not fully understood. Thus, we investigated 
renal function and inflammatory activity in a cohort of healthy subjects with a wide range 
of body mass index (BMI).
Methods: We enrolled 99 consecutive healthy normoglycaemic subjects, with a BMI 
ranging from 20 to 55 kg/m2, without overt cardiovascular disease. Serum levels of leptin 
and adiponectin were measured by ELISA. Serum levels of high sensitive (hs) C- reactive 
protein (CRP) and Cystatin C were assessed by immunonefelometric assays. 
Results: Plasma levels of hs-C-reactive protein significantly correlated with BMI (R=0.42 
P<0.0001), waist circumference (R=0.43 P=0.0002) and leptin (R=0.34 P< 0.001). 
Cystatin C levels were significantly and directly correlated with BMI(R=0.24 p=0.023), 
waist circumference (R=0.31 p=0.005), leptin (R=0.39 p<0.0001) and adiponectin 
(R=0.381 p=0.001).
Conclusions: Our study demonstrates that CRP, a marker of inflammation and Cys C, a 
sensitive marker of renal function, are closely correlated with excessive accumulation of 
visceral adipose tissue and may play a role in the increased cardiovascular risk of obese 
subjects and in initiation and progression of atherosclerosis.
10:00 a.m.
1035-204 Morbid Obesity Abolish Gender Differences In 
Cardiovascular Risk Factors
Francesca Graziani, Luigi M. Biasucci, Giovanna Liuzzo, Vittoria Rizzello, Salvatore 
Brugaletta, Caterina Guidone, Andrea Piccioni, Grazia Alecce, Gertrude Mingrone, 
Filippo Crea, Catholic University, Rome, Italy
Background: Male gender is associated with an increased cardiovascular risk as 
compared to female gender. Furthermore, risk profile may differ between genders. Few 
data however exist on gender differences in risk profile of subjects with morbid obesity 
(MO). Interestingly, MO subjects are characterized by high estron levels also in males, 
due to expanded subcutaneous fat tissue. Therefore, aim of this study was to assess 
cardiovascular risk factors in lean, overweight, obese and morbidly obese in relation to 
gender differences.
Methods: We enrolled 71 healthy subjects, without diabetes and overt cardiovascular 
disease, allocated to 2 groups according to their body mass index (BMI): G1 was 
constituted by 48 patients with BMI ranging from 20 to 39.9 (23 F; 25 M) and G2 constituted 
by 23 MO (13 F;10 M; BMI>40). Anamnestic and anthropometric data were recorded for 
all patients; intima-media thickness was evaluated by vascular ultrasonography. Plasma 
levels of leptin was also assessed.
Results: in G1 weight (mean: 71 kg vs 88 kg; p < 0.0001), waist (mean 86 cm vs 99 cm; 
p<0.003), free fat mass (mean 46% vs 62%; p<0.004), triglycerides (mean 88 mg/dl vs 
147 mg/dl; p<0.004), leptin levels (mean 11 ng/ml vs 24 ng/ml; p<0.001), median IMT 
(mean 0.55 mm vs 0.7 mm; p<0.02), number of patients with carotid plaques (1 vs 11 pts 
p<0.001) and with hypertension (5 vs 13 pts p=0.004), were significantly lower in females 
vs males. Conversely HDL levels (mean 53 mg/dl vs 46 mg/dl; p<0.03) and estron levels 
(mean 158 pg/ml vs 111 pg/ml; p<0.02) were higher in females. In contrast no significant 
differences between males and females were found in G2 (morbidly obese) patients in 
any of the explored parameters.
Conclusions: Our study demonstrates that MO patients, at variance from patients with a 
BMI ranging from normality to obesity, do not present gender differences in cardiovascular 
risk profile. This is probably related to higher estron levels in males exhibiting MO, which 
makes them metabolically more similar to females. Thus, risk factor profile needs to be 
differentially assessed in subjects with MO as opposed to subjects without MO.
10:00 a.m.
1035-205 Variability in Levels of C-Reactive Protein Over Brief 
Intervals in Patients With Coronary Artery Disease
Arnon Blum, Rene Costello, Gloria Zalos, Mylinh Quan, Gyorgy Csako, Richard O. 
Cannon, III, NHLBI, Bethesda, MD
Background: High-sensitivity C-reactive protein (CRP) is being used as a biomarker in 
clinical trials. The reproducibility of this analyte in patients with coronary artery disease 
(CAD), however, has not been reported.
Methods: CRP levels in plasma were measured twice in 19 stable CAD patients (age 
70±9 years) within less than 2 weeks (7±4 days) using a high-sensitivity (0.1 mg/L), solid-
phase, chemiluminescent immunometric assay (inter-assay coefficients of variation [CVs] 
<10% for CRP levels between 1.3 to 94.0 mg/L). All patients received statins with no dose 
change for >3 months. None had a history or evidence of malignancy, chronic infection or 
inflammation, or recent trauma. There were no changes in medications between visits 1 
and 2, and no patient reported change in cardiac or general health during this interval.
Results: Blood pressure was unchanged between visits; heart rate was significantly 
lower at visit 2 (Table). White blood cell and platelet counts were unchanged. For the 
group, CRP was significantly lower at visit 2 compared with visit 1 (Wilcoxon matched 
pairs signed-ranks test), with reductions in 13 of 19 patients (68%). In 6 patients, CRP 
decreased >1.0 mg/L. CVs for repeat measurements ranged from 3.9 to 102.8% (median 
16.7%) in different patients.
Conclusions: Even in the absence of changes in health or medications, CRP levels may 
fluctuate over brief periods of time in CAD patients. Consequently, repeat measurements 
of CRP are needed to estimate the inflammatory status of these patients. 
Parameter Visit 1 Visit 2 P value
Systolic blood pressure (mm Hg) 129±14 128±13 0.7075
Diastolic blood pressure (mm Hg) 73±7 73±6 0.8585
Heart rate (bpm) 64±10 60±9 0.0210
White blood cells (per mm3) 6,294±1,405 6,271±1,512 1.000
Platelets (per mm3) 229,611±56,522 227,588±58,496 0.9746
CRP, high sensitivity (mg/L) 4.47±2.94 2.83±1.38 0.0095
Data= Mean ± SD
10:00 a.m.
1035-206 Cardiac Rehabilitation Effects on Lipids in Coronary 
Artery Disease Patients on Lipid-Lowering Therapies
Sushmitha Patibandla, Andrea Carlow, Maria Rodrigo, Gloria Zalos, Kevin Smith, 
Richard O. Cannon, III, NHLBI, Bethesda, MD
Background: Cardiac rehabilitation programs have reported favorable effects on lipid 
profile, although most data preceded the current era of aggressive medical management. 
We determined the impact of program participation on lipids in patients having levels at or 
near current ATP III guideline goals at entry.
Methods: Sixty-eight coronary artery disease (CAD) patients (58 men, 10 women; age 
64±10 years) on lipid-lowering therapies completed the 3-month program. At baseline, 34 
(50%) were overweight (BMI 25-30 kg/m2) and 17 (25%) were obese (BMI>30 kg/m2). 
Lipid management included 66 on statins, 11 on niacin, 8 on ezetimibe, 4 on fibrates and 
1 on a bile acid binder. Lipid levels were measured at baseline and following program 
completion.
Results: For the group, treadmill exercise improved by 83±77 minutes (P<0.001). There 
was no change in weight for the group as a whole (Table), although 4 overweight 
participants shifted to the lean category (BMI<25 kg/m2). Small but statistically significant 
reduction in non-HDL cholesterol and increase in HDL cholesterol levels were observed, 
with no significant changes in LDL cholesterol or triglycerides.
Conclusion: Cardiac rehabilitation participation improves fitness, but with minimal impact 
on weight. Patients on lipid-lowering therapies can achieve small changes in lipid levels, 
beyond which adjustments in drugs or drug doses may be required to achieve lower levels 
of LDL cholesterol deemed desirable based on recent clinical trial data. 
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Parameter Baseline Follow-up P value
Weight (kg) 86±20 86±20 0.8084
Total Cholesterol (mg/dL) 141±31 141±32 0.7428
LDL Cholesterol (mg/dL) 80±29 78±25 0.3859
HDL Cholesterol (mg/dL) 43±11 45±13 <0.001
Non-HDL Cholesterol (mg/dL) 98±30 96±29 <0.001
Triglycerides (mg/dL) 124±66 121±75 0.6373
Data= Mean±SD
10:00 a.m.
1035-207 Aspirin for Primary Prevention of Cardiovascular 
Events in Patients With Diabetes: A Meta-Analysis of 
Randomized Controlled Trials
Otavio Berwanger, Joao Bosco Oliveira, Erica Suzumura, Anna M. Buhler, Dinaldo 
Oliveira, Carlos B. Marx, Cardiac Hospital (HCor), Sao Paulo, Brazil
Background: Several guidelines recommend aspirin for diabetic patients without 
atherosclerosis, however no previous meta-analysis evaluating the strength of the 
evidence that support such recommendations is available.
Methods: Meta-analysis of randomized trials that evaluated aspirin therapy in patients 
with diabetes without atherosclerosis. We searched MEDLINE, EMBASE, Cochrane 
CENTRAL, and screened references from previous guidelines. We also searched for 
unpublished studies by contacting experts and by searching trial registries. 
Results: Five trials that randomized a total of 5,594 patients met eligibility criteria. Aspirin 
did not demonstrate statistically significant beneficial effects on the primary composite 
endpoint (cardiovascular mortality, nonfatal myocardial infarction, and nonfatal stroke) 
and on any of the individual efficacy and safety endpoints (Table).To assess the strength 
of this findings, we used methods adapted from formal interim monitoring boundaries 
applied to cumulative meta-analysis which demonstrated that the evidence fails to meet 
standards for foregoing additional studies.
Table - Effects of aspirin on patient-important endpoints in diabetic patients without 
atherosclerosis 
Endpoint Total number of 
events
Relative 
risk
95% Confidence 
interval
Primary 803 0.93 0.82 to 1.06
Cardiovascular 
mortality 543 0.89 0.76 to 1.04
Myocardial infarction 604 0.75 0.44 to 1.28
Stroke 189 1.15 0.87 to 1.52
All-cause mortality 759 0.94 0.82 to 1.07
Major bleeding 86 1.42 0.23 to 8.68
Conclusion: The current evidence that aspirin reduce cardiovascular events in diabetic 
patients without atherosclerosis is unreliable to allow definitive conclusions. The results of 
ongoing studies will help to further explore the role of aspirin in that population.
10:00 a.m.
1035-208 Brief Periods of Daily Exercise at the Workplace Along 
With Lifestyle and Nutritional Guidance Improve 
Cardiovascular Profile of Sedentary Employees
Aditi Desai, Margaret Lippincott, Arnon Blum, Janet DeJesus, Gloria Zalos, Kevin Smith, 
Andrea Carlow, Maria Rodrigo, Richard O. Cannon, III, NHLBI, Bethesda, MD
Background: A sedentary work force likely increases the risk of future cardiovascular 
disease. The National Heart, Lung and Blood Institute initiated the “Keep the Beat” 
program to encourage exercise during the workday, with provision of exercise facilities on 
campus, in addition to information about healthy lifestyle and nutrition. Our purpose was 
to determine the cardiovascular effects of participation in this program.
Methods: Seventy-two sedentary (30 with BMI>30 kg/m2) employees (58 women; 
average age: 45 years; range: 22-62 years) completed 3 months of participation. Vital 
signs, laboratory data and peak oxygen consumption (VO2) during treadmill exercise 
were determined at baseline and after 3 months. Brachial artery endothelium was tested 
by flow-mediated dilation (FMD), and circulating endothelial progenitor cells (EPCs) were 
measured by colony assay. Diaries were maintained to record weekly exercise.
Results: Brachial artery FMD at baseline was inversely associated with Framingham 
risk score (r=-0.3689, P<0.0001). Weekly exercise averaged 98±47 minutes. There was 
significant improvement in peak VO2 (+1.2±3.1 mL O2/kg/min; P=0.0028) and reduction 
in diastolic blood pressure (-2±8 mmHg; P=0.0478), total cholesterol (-8±25 mg/dL, 
P=0.0131), and LDL cholesterol (-7±19 mg/dL, P=0.004), but with marginal reduction in 
weight (-0.5±2.1 kg, P=0.0565). Finishers also showed significant improvement in brachial 
artery FMD (from 7.8±3.4 to 8.5±3.0 %, P=0.0096)--especially those with the lowest values 
at baseline (r=-0.5105, P<0.0001)--and increases in EPCs (P<0.001), although there 
was no relationship between these measurements. Improved endothelial function was 
independent of age or BMI at entry, or changes in weight or lipids during the program.
Conclusion: We conclude that brief periods of daily exercise achievable in the workplace, 
along with healthy lifestyle and nutrition information, have measurable health benefits, 
regardless of age, baseline adiposity or weight loss during participation, which may 
decrease cardiovascular risk, if sustained.
10:00 a.m.
1035-210 Nicotinic Acid in the Prevention of Cardiovascular 
Events: A Meta-Analysis of Randomized Placebo-
Controlled Trials
Sarabjeet Singh, Navneet Attri, Rohit Arora, Janos Molnar, Jasleen Duggal, Ahmad 
Khraisat, Chicago Medical School, Chicago, IL
Background:Data suggests that nicotinic acid (NA) may decrease the incidence of 
myocardial infarction (MI), stroke, revascularization and mortality, perhaps via HDL 
increase, however the results have been conflicting. We performed a meta-analysis of 
randomized placebo controlled trials to resolve these conflicts.
Methods: After conducting systemic review of literature, 7 studies (Coronary drug 
project,1975 ; Blankenhorn et al,1987 ; Carlson et al, 1988; Brown et al, 1990 ; Brown et 
al, 2001 ; Taylor et al, 2004 ; Whitney et al, 2005 ) were meta-analysed. Primary endpoint 
was mortality; secondary end points were MI, stroke and need for revascularization. The 
meta-analysis consisted of 5137 patients (NA, 1736; placebo , 3401). As the studies were 
homogenous for all outcomes, the combined relative risks (RR) across all the studies and 
the 95% confidence intervals were computed using the Mantel-Haenszel fixed-effect model. 
A two-sided alpha error of less than 0.05 was considered to be statistically significant.
Results:There were no significant differences in patient characteristics between the 
two groups. Compared to placebo the risk of mortality (P=0.07) were similar with NA. 
However, the risk of MI (P=0.001), stroke (P=0.01), need for revascularization (P=0.001) 
were significantly lower with NA (Figure 1).
Conclusions:The present meta-analysis suggests that NA may not decrease mortality. 
However NA may lower the incidence of MI, stroke and need for revascularization on 
follow-up significantly. 
10:00 a.m.
1035-211 Lipid-Associated Risk Factors for First Acute 
Myocardial Infarction in Three Countries with Extreme 
Difference in Myocardial Infarction Incidence. The FAMI 
Study
Nicole Cristell, Giacomo Ruotolo, Domenico Cianflone, Annalisa Pessina, Daniela 
Piraino, Neal Uren, Hui Li, Dayi Hu, Attilio Maseri, Università Vita Salute San Raffaele, 
Milan, Italy
The FAMI Study is a project of the prevalence of traditional risk factors in patients with 
their first Acute Myocardial Infarction (AMI). Strict inclusion criteria were hospital admission 
and blood sample within 6 hours of symptom onset, and no previous history of ischemic 
heart disease. Patients were enrolled from urban areas of China, Italy and Scotland. These 
countries were chosen for the difference in AMI incidence, being highest in Scotland, and 
lowest in China (8-fold difference), Italy is in an intermediate position. A total of 1002 patients 
and 710 controls were enrolled (431 patients and 328 controls in China, 353 patients and 
260 controls in Italy, and 218 patients and 122 controls in Scotland).
LDL and HDL cholesterol were significantly lower in Chinese than Italians and Scots, 
in both patients and controls. HDL cholesterol was significantly lower and apoB/apoAI 
higher in patients than controls in all 3 groups, independently of ethnicity. Triglycerides 
(TG) and LDL cholesterol were significantly higher in patients than controls in Italians, but 
not in the Scots or Chinese.
HDL cholesterol and apoB/apoAI are strong risk factors for first acute myocardial infarction, 
independently of AMI incidence and/or ethnicity. Triglycerides and LDL cholesterol 
appear to be risk factors for AMI only in some populations. Potential gene-environment 
interactions contributing to these ethnic differences are now under study. 
Italy Scotland China
Patients Controls Patients Controls Patients Controls
LDL 
Median (25th-75th 
percentile)
166.4§ 
(132.8-
209.3)
154.6 
(126.5-
186.0)
160.8 
(124.1-
195.6)
153.1 
(113.9-
180.4)
133.9 
(107.3-
164.1)
128.2 
(100.7-
159.6)
HDL
39.6* 
(32.7-
47.1)
46.5 
(40.2-
53.9)
40.9* 
(34.5-
49.1)
48.6 
(41.6-
56.1)
37.4* 
(33.0-
44.1)
42.4 
(35.8-
48.9)
TG
122.6* 
(82.0-
171.7)
105.3 
(72.5-
141.2)
121.9 
(82.3-
191.7)
111.9 
(75.1-
169.2)
128.9 
(87.2-
188.3)
128.6 
(90.7-
175.5)
ApoB/ApoAI
1.15* 
(0.95-
1.35)
0.99 
(0.85-
1.18)
1.15§ 
(0.92-
1.41)
1.01 
(0.80-
1.22)
1.10* 
(0.94-
1.30)
1.02 
(0.85-
1.18)
§p=0.005; *p<0.0001
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1035-212 Relationship between management of serum lipid levels 
and vulnerability of coronary plaque: An investigation 
with in vivo tissue characterization using Integrated 
Backscatter-Intravascular Ultrasound
Hiroki Takeuchi, Yoshihiro Morino, Yota Kawamura, Naoki Masuda, Takashi Matsukage, 
Teruhisa Tanabe, Yuji Ikari, Tokai University School of Medicine, Isehara, Japan
Background:Several randomized control trials have suggested that lipid lowering is 
significantly associated with reduction of cardiovascular events. Accordingly, strict lipid 
lowering therapy has been recommended. However, little investigation has been performed 
to verify the actual impact of management of serum lipid levels on the compositions of 
coronary atheromatous plaque from a histological viewpoint.
Methods:The study population consisted of 50 consecutive patients who received 
Integrated Backscatter-intravascular ultrasound assessment prior to percutaneous 
coronary intervention, which is an authorized method for in vivo tissue characterization 
with a capability of quantification of coronary plaque components. The occupation rate 
of lipid (%lipid volume) and fibrous tissue (%fibrous volume) within the stenotic coronary 
lesions were calculated and compared for the 20mm-length volumetric segments 
including the tightest cross section as a center. Each serum lipid level was categorized 
into two groups by the cut-off value shown in the table for comparison.
Results:A significant reduction of %lipid volume as well as a significant increase of 
%fibrous volume was demonstrated only in the group with serum LDL-cholesterol level 
less than 100mg/dl.
Conclusions:The management of serum concentrations of LDL-cholesterol is confirmed 
to be significantly associated with the composition of coronary plaque.
LDL-Cholesterol HDL-Cholesterol Triglyceride
Cut-off,mg/dl <100 100≤ p <40 40≤ p <150 150≤ p
n 20 30 9 41 31 19
%Lipid 
volume,(%) 29.1±8.7 39.1±17.7 0.02 34.7±14.0 35.2±16.0 NS 33.8±16.4 37.2±14.0 NS
%Fibrous 
volume,(%) 57.1±5.5 49.3±9.5 0.002 55.1±10.2 51.8±8.7 NS 52.6±9.2 52.1±8.9 NS
10:00 a.m.
1035-213 Effect of Increasing Metabolic Syndrome Score on 
Atherosclerotic Risk Profile and Coronary Artery 
Disease Angiographic Severity
Seong Bo Yoon, Myung-Hyun Kim, Pil-Ki Min, Young-Won Yoon, Bum-Kee Hong, 
Se-Joong Rim, Hyuck Moon Kwon, Yongdong Severance Hospital, Yonsei University 
College of Medicine, Seoul, South Korea
Background The metabolic syndrome (MS) has been reported as a potential risk factor of 
coronary artery disease (CAD). The purpose of this study was to determine whether there 
was a progressive relation between the number of markers of the MS_the MS score_and 
the degree of atherosclerotic risk profile, and to assess the relation between the MS score 
and CAD angiographic severity.
Methods We enrolled 632 patients who underwent coronary angiography for suspected 
CAD (394 men, 61.0 ± 10.6 yearrs). The subjects were divided into 6 groups based on 
their MS scores. MS was defined by the National Cholesterol Education Program criteria 
with waist criterion modified into BMI of more than 25 kg/m2. CAD was defined as 
>50% luminal diameter stenosis of at least one major epicardial coronary artery. CAD 
angiographic severity was evaluated with a Gensini scoring system.
Results Of the 632 patients enrolled, 497 (78.6%) had CAD and 283 (44.8%) was 
diagnosed as MS. In patients with MS, HTN was the most frequently observed marker, 
followed by low HDL, increased BMI, fasting glucose and TG. As the MS score increased, 
fibrinogen, cystatin C, s-insulin and the HOMA index increased, and the LDL size 
decreased. Similarly, an increasing MS score was significantly related to the severity of 
CAD at coronary angiography (p=0.001), as assessed by a Gensini scoring system.
Conclusions MS score provides a useful index of MS severity and the associated 
atherosclerotic risk factor profile. It also correlates with the angiographic severity of CAD.
MS score
Overall 
p 
value
0  
(N=38, 
6%)
1  
(N=109, 
17.2%)
2  
(N=202, 
32%)
3  
(N=155, 
24.5%)
4 
(N=99, 
15.7%)
5 
(N=29, 
4.6%)
HOMA 
index
1.42±1.07 1.73±1.66 2.19±2.83 3.08±3.83 3.74±4.50 6.50±7.52 0.001
CAD
2  
(68.4%)
78  
(71.6%) 161 (79.7%) 123 (79.4%)
86  
(86.9%)
23  
(79.3%) 0.081
Gensini 
score
10.8±17.8 12.6±16.5 17.9±27.0 19.0±26.3 24.3±30.2 31.5±37.8 0.001
10:00 a.m.
1035-214 Relation of High-Density Lipoprotein Cholesterol and 
Cigarette Smoking to the Incidence of Plaque Rupture 
Detected by Intravascular Ultrasound in ST-elevation 
Acute Myocardial Infarction
Fumiyuki Otsuka, Kiyoshi Hibi, Ikuyoshi Kusama, Mitsuaki Endou, Takayuki Mitsuhashi, 
Naohiro Komura, Masami Kosuge, Noriaki Iwahashi, Jyun Okuda, Kengo Tsukahara, 
Yoshio Tahara, Toshiaki Ebina, Kazuo Kimura, Satoshi Umemura, Yokohama City 
University Medical Center, Yokohama, Japan
Background: Recent advances in lipid lowering therapy enable us to reduce the risk 
of cardiovascular events in patients with hypercholesterolemia, while low level of high-
density lipoprotein cholesterol (HDL-C) remains an unsolved issue. Previous autopsy 
study showed that low HDL-C level, together with cigarette smoking, was associated with 
coronary plaque rupture and acute thrombosis. However, few in vivo data demonstrates 
the relationship among HDL-C level, smoking, and plaque rupture. The aim of this 
intravascular ultrasound (IVUS) study was to elucidate whether HDL-C level and smoking 
correlate with the incidence of plaque rupture in patients with ST-elevation myocardial 
infarction (STEMI).
Methods: The study includes 301 consecutive patients (249 male) with STEMI who 
admitted within 6 hours from symptom onset. IVUS interrogation was performed prior to 
any percutaneous coronary intervention.
Results: Plaque ruptures were detected in 190 patients (63%). Among several coronary 
risk factors, patients with low HDL-C level (defined as <40 mg/dL) (n=97) had higher 
incidence of plaque rupture than those with normal HDL-C level (≥40 mg/dL) (72 vs 59 %, 
p=0.035). Smokers (n=183) had higher incidence of plaque rupture than non-smokers as 
well (71 vs 51 %, p=0.001). Multiple logistic regression analysis including age, sex, and 
coronary risk factors demonstrated that low HDL-C level (odds ratio [OR] 2.001; 95% CI 
1.064 to 3.761, p=0.031) and smoking (OR 2.248; 95% CI 1.326 to 3.811, p=0.003) were 
independent determinants of plaque rupture. According to the presence of low HDL-C 
level and current smoking, patients were divided into 3 groups. Smokers with low HDL-C 
level (n=68) had higher incidence of plaque rupture compared with patients who had 
either low HDL-C level or smoking (n=144) and non-smokers with normal HDL-C level 
(n=89) (75 vs 68 vs 46 %, p=0.001).
Conclusions: Low HDL-C level and cigarette smoking were associated with higher 
incidence of plaque rupture in STEMI. Lifestyle intervention and pharmacological approach 
to raise HDL-C levels may reduce myocardial infarction caused by plaque rupture.
10:00 a.m.
1035-215 High triglycerides/HDL-cholesterol ratio predicsts 
extensive coronary disease
Protasio Lemos Da Luz, Desiderio Favarato, José R. Faria Neto, Pedro Lemos, Antonio 
Carlos P. Chagas, Heart Institute (InCor), University of São Paulo Medical School, São 
Paulo, Brazil
Background: Abnormal TG/HDL-C ratio reflects an atherogenic lipid profile, and a risk 
of precocity of coronary disease (CAD). We investigated the relationship between lipid 
variable with extension of CAD.
Methods: We studied 374 high risk patients submitted to diagnostic coronary angiography. 
Plasma lipids were measured and CAD extension was evaluated by Friesinger index. 
There were 220 males, 154 females, age 57+11,5 years old, total cholesterol (TC) was 
210.6± 50.4, triglycerides (TG) 173.8 ± 169.8; HDL-cholesterol 40.6±12.8, LDL-cholesterol 
137.3±46.2 mg/dL; average TG/HDL ratio was 5.1±4.1 and Friesenger index 6.6±4.7.
Results: The association between CAD extent, dichotomized by Friesenger ≥ 5 and 
lipid quartiles was all statistically significant by univariate logistic regression - TC 1.214 
(p= 0.0001); TG 1.247 (p=0.0001); HDL-C 1.113 (p= 0.006); LDL-C 1.219 (p=0.0001); 
and TG/HDL-C ratio 1.281 (p=0.0001). However, in a multivariate analysis by logistic 
regression only the TG/HDL ratio and HDL-C remained statistically related to the extent 
of CAD (OR quartile TG/HDL 1.731 p=0.005; OR for quartile HDL-C 0,827; p= 0.02 . Fig 
1 shows Friesinger index in relation to HDLc and TG/HDL ratio quartiles. The analysis 
by ROC curves showed that AUC were 0.628 (95%CI 0.529-0.687; p= 0.0001 for TG/
HDLratio and 0.361 (95%CI 0.302-0.420; p= 0.0001 for HDL-C.
Conclusions: Thus, controlled for the other lipid variables, TG/HDL ratio was the strongest 
lipid variable associated to extensive CAD.
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1035-216 Tobacco Cessation: Adherence to Treatment With 
Varenicline and Associated Abstinence Outcomes
J Taylor Hays, Martina Flammer, Theodore Lee, Simon Davies, Mayo Clinic College of 
Medicine, Rochester, MN, Pfizer, Inc, New York, NY
Background: Smoking cessation is critical for both primary and secondary prevention 
of heart disease. Adherence to a medication treatment schedule is key to optimizing 
smoking cessation outcomes.
Methods: Treatment adherence and abstinence outcomes were analyzed, using pooled 
data from two randomized, controlled, US trials of 1.0 mg twice daily varenicline and a 
multicenter, Asian trial using the same dose. All Randomized (RAND) and Completer 
Subjects (COMP; ie, subset of RAND subjects who took ≥1 dose of medication for ≥ 
80% of the 12-week treatment period) were analyzed for efficacy outcomes. The primary 
efficacy endpoint was carbon monoxide-confirmed continuous abstinence rate (CAR) 
from Weeks 9-12 in varenicline-treated subjects versus placebo for both populations.
Results: 
Continuous abstinence rates for all randomized and completer subjects
Studies CAR Weeks 9-12 - RAND CAR Weeks 9-12 - COMP
Varenicline 
n/N (%)
Placebo 
n/N (%) OR (95% CI)
Varenicline 
n/N (%)
Placebo 
n/N (%) OR (95% CI)
Pooled 
US data
306/696 
(44.0)
121/685 
(17.7)
3.66 (2.86-
4.68)*
287/483 
(59.4)
111/411 
(27.0)
4.15 (3.11-
5.55)*
Asian 
data
75/126 
(59.5)
40/124 
(32.3)
3.22 (1.89-
5.47)* 71/116 (61.2)
40/120 
(33.3)
3.37 (1.94-
5.84)*
*All P<0.0001 vs placebo. 
Abbreviations: CAR, continuous abstinence rate; CI, confidence interval; COMP, 
completer subjects; OR, odds ratio; RAND, all randomized subjects
A trend was found toward improved CARs and ORs in COMP versus RAND subjects 
in the US trials, but similar trends were not present in the Asian trial. Overall treatment 
adherence in the Asian trial, however, was very high (ie, varenicline: 92%; placebo: 97%) 
versus the US trials (ie, varenicline: 69%; placebo: 60%), resulting in a higher percentage 
of subjects achieving COMP status.
Conclusions: Smoking abstinence is improved with varenicline versus placebo. Moreover, 
greater adherence to a prescribed 12-week course of varenicline may improve abstinence 
outcomes and thus, tobacco cessation intervention with varenicline should include a 
discussion of adherence to optimize outcomes.
10:00 a.m.
1035-217 Smoking Cessation and Diabetes Risk: A Baseline 
Analysis from the COURAGE Trial
David Joel Maron, John A. Spertus, G.B. John Mancini, William L. Haskell, Robert A. 
O’Rourke, Koon K. Teo, Pamela M. Hartigan, Marcin Dada, William S. Weintraub, William 
E. Boden, Vanderbilt University Medical Center, Nashville, TN
Background: Weight gain after smoking cessation may diminish the beneficial impact of 
stopping smoking. Because weight gain increases the risk of developing diabetes, we 
postulated that smoking status might be related to the prevalence of diabetes among 
patients with stable coronary artery disease enrolled in the COURAGE Trial.
Methods: We explored the cross-sectional relationship between baseline smoking status 
and the presence of diabetes at entry in a cohort of 2,188 patients with coronary disease. 
Smoking status was ascertained by self report and classified as current smoker, never-
smoker, and ex-smoker. Diabetes was defined as fasting glucose >126 mg/dL, random 
glucose >200 mg/dL, or having a history of diabetes.
Results: 
Smoking Status % with Diabetes BMI
Current smoker 29% 28.7±4.7
Never-smoker 35% 29.7±5.2
Ex-smoker 38% 30.0±5.1
χ2 = 21.1; p=0.0003 p<0.0001
Conclusions: In the COURAGE population, current smokers had significantly lower BMI 
and lower risk for diabetes and ex-smokers had significantly higher BMI and higher 
risk for diabetes compared with never-smokers. These results are consistent with the 
prospective findings of the Multiple Risk Factor Intervention Trial, and provide rationale to 
couple smoking cessation with aggressive lifestyle intervention to avoid weight gain. The 
relationship between smoking status and diabetes risk merits further investigation.
10:00 a.m.
1035-218 Combating the Obesity Paradox -- Benefits and Safety 
of Purposeful Weight Loss in Overweight and Obese 
Coronary Patients
Carl J. Lavie, Jr., Richard V. Milani, Surya M. Artham, Ochsner Health System, New Orleans, LA
Although obesity is a strong CV risk factor, numerous studies have identified a strong paradox 
regarding obesity and subsequent prognosis in cardiac patients. Some investigators have 
even questioned the benefits and safety of weight reduction for obese cardiac patients. We 
studied 393 consecutive overweight and obese CAD patients (BMI ≥ 25 kg/m2, mean 30.4 
± 4.9 kg/m2; age 63 ± 10 years; 24% female) before and after phase II cardiac rehabilitation 
and exercise training (CRET) and divided patients by median weight loss (mean +2% vs 
-5%, respectively) to determine the impact of purposeful weight loss on CAD risk factors 
and mortality. Following CRET, those with higher weight loss had improvements in BMI (-
5%; p<0.0001), % fat (-8%; p<0.0001), peak VO2 (+16%; p<0.0001), LDL-cholesterol (-5%; 
p<0.02), HDL-cholesterol (+10%; p<0.0001), triglycerides (-17%; p<0.0001), C-reactive 
protein (CRP; -40%; p<0.0001), fasting glucose (-4%; p=0.02), behavioral factors (anxiety, 
depression, hostility, and somatization; all p<0.0001), and total quality of life score (+16%; 
p<0.0001). Those with lower weight loss had no significant improvements in % fat, LDL-
cholesterol, triglycerides, CRP, and fasting glucose and had less significant improvements 
in the other parameters compared to those with higher weight loss. During three-year 
follow-up, although mortality trended lower in those with greater compared to lower weight 
loss (3.1% vs 5.1%), these differences were not significant statistically (p=0.3). However, 
mortality was considerably lower in the overweight/obese group compared with 136 CRET 
patients with BMI < 25 mg/kg2 (4.1% vs 13.2%; p<0.001).
Conclusions: Purposeful weight loss with formal CRET is associated with only a trend for 
lower mortality during three-year follow-up, but this is associated with marked improvements 
in overall CAD risk profile, including obesity indices, exercise capacity, plasma lipids, 
inflammation, and adverse behavioral characteristics, in overweight and obese patients with 
CAD. Although an obesity paradox exists, these results support the safety and potential 
long-term benefits of purposeful weight loss in overweight/obese patients with CAD.
10:00 a.m.
1035-219 The Effect Of Individual Apolipoproteins On Endothelial 
Function And Thrombosis/Fibrinolysis System In 
Healthy Young Individuals
Kiriakoula Marinou, Dimitris Tousoulis, Charalambos Antoniades, Carmen Vasiliadou, 
George Latsios, Grigoris Vyssoulis, Penny Gounari, Gerasimos Siasos, Stella Brilli, 
Christos Pitsavos, Christodoulos Stefanadis, 1st Cardiology Department, Hippokration 
Hospital, Athens Medical School, Athens, Greece
Background: The role of lipids in atherogenesis is well established, but the mechanisms 
by which different lipoproteins affect endothelial function and induce atherothrombosis are 
still unclear. We examined the effect of lipid profile on endothelial function and thrombosis/
fibrinolysis systems, in a cohort of young low-risk individuals.
Methods: The study population consisted of 201 healthy subjects (aged 34.2±3.3 yrs) 
with no risk factors for atherosclerosis. The effect of total cholesterol, high density 
lipoprotein (HDL), low density lipoprotein (LDL), tryglycerides, apo-AI, apo-B and apo-
E on endothelium-dependent dilation (EDD) (estimated by using plethysmography) was 
examined. Plasma plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen 
activator (tPA) were determined by ELISA.
Results: EDD correlated with HDL (r=0.267, p=0.001), LDL (r=-0.355, p=0.0001), 
triglycerides (rho=-0.366, p=0.0001), apo-AI (r=0.240, p=0.004) and apo-B (r=-
0.277, p=0.005). PAI-1 was correlated with cholesterol (r=0.294, p=0.03), triglycerides 
(r=0.395, p=0.001) and ApoA1 (r=-0.314, p=0.020). tPA correlated with triglycerides 
(r=0.539, p=0.0001), HDL (r=-0.357, p=0.012), ApoA1 (r=-0.415, p=0.0001), ApoB 
(r=0.344, p=0.012) and PAI-1 (r=0.467, p=0.001). In multiple linear regression, LDL 
(β=-0.217(SE:0.098), p=0.028), apo-AI (β=0.277(SE:0.124), p=0.027) and age (β=-
916(SE:0.369), p=0.015) were independent predictors for EDD. PAI-1 was independently 
associated with ApoB (β=0.098(SE:0.047), p=0.042), ApoE (β=-1.7(SE:0.804), p=0.037), 
HDL (β=-0.151(SE:0.07), p=0.032) and cholesterol (β=0.062(SE:0.026), p=0.019). ApoB 
was the only independent predictor of tPA (β=0.037(SE:0.009), p=0.0001).
Conclusions: Elevated lipid levels, within the normal range, affect endothelial function 
and modify thrombosis/fibrinolysis system in young individuals. Apo-AI is an important 
determinant of endothelial function in these subjects, independently of other lipids. 
Apo-B, apo-E and HDL are independent predictors of the release of PAI-1. Therefore, 
measurement of individual apolipoproteins may be of important in risk stratification of 
young individuals
10:00 a.m.
1035-220 Global Coronary Heart Disease Risk Associated with 
Abdominal Obesity in U.S. Adults 2003-2004
Heli Ghandehari, Vy Le, Sachin Kamal-Bahl, Stanley L. Bassin, Nathan D. Wong, 
University of California, Irvine, Irvine, CA, Merck & Co, Inc., Whitehorse Station, NJ
Background: Obesity, especially abdominal obesity, is an increasing pubic health problem 
worldwide, but their comparative relation to risk of coronary heart disease (CHD) is not 
well-documented. We evaluated the inter-relation of both measures with estimated 10-
year risk of CHD among a recent population-based sample of U.S. adults
Methods: Among 4,323 adults (representing 188.8 million) (50.2% female, 11.2% 
Hispanic, 11.1% African-American, 72.2% White) aged 20-79, participants of the National 
Health and Nutrition Examination Survey (NHANES) 2003-2004, measures of body mass 
index (BMI) and waist circumference (WC) were performed, along with other CHD risk 
factors. We examined the association of BMI and WC categories with 10-year estimated 
CHD risk based on Framingham risk algorithms. High risk of CHD was based on a >20% 
10-year CHD risk, or pre-existing diabetes or cardiovascular disease.
Results: Overall, 42.3% of men and 60.1% of women (p< 0.001) were abdominally obese 
based on WC (>40 in for men and >35 in for women) vs. 30.9% of men and 33.4% of 
women (p=0.12) being classified as obese based on BMI standards (>30 kg/m2). Even 
among persons overweight by BMI (25-<30 kg/m2 ), abdominal obesity was present in 
35.1% of men and 78.9% of women (p< 0.001). Among persons with increased vs. normal 
WC, 27.9% vs. 12.6% of men and 20.2% vs. 7.1% of women were defined to be at high 
risk of CHD (p<0.01 for both men and women). Also, within those overweight by BMI, 
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high vs. normal WC was associated with a much greater prevalence of high CHD risk 
(31.4% vs. 12.1% in men and 19.9% vs. 7.8% in women, both p<0.01). From multiple 
logistic regression, after adjustment for age, gender, and ethnicity, the odds [and 95% 
confidence intervals] of high risk status associated with high vs. normal WC was 2.2 
[1.8-2.8] (p<0.01). This association persisted after adjustment for BMI (odds=1.6 [1.2-
2.1], p<0.01).
Conclusions: We demonstrate a substantially higher likelihood of high risk status for CHD 
in persons with vs. without abdominal obesity, even in persons classified as overweight 
by BMI criteria. Moreover, the association of WC with high-risk status was independent of 
BMI, further validating the significance of abdominal obesity.
10:00 a.m.
1035-221 Evidence for the causative role of oxidative stress in 
the development of contrast-induced nephropathy in 
patients with chronic kidney disease
Eisei Yamamoto, Hitoshi Takano, Shuji Kawashima, Hidekazu Kawanaka, Yasuhiro 
Takahashi, Gen Takagi, Nobuhiko Fujita, Satoshi Aoki, Kuniya Asai, Masahiro Yasutake, 
Morimasa Takayama, Kyoichi Mizuno, Nippon Medical School, Tokyo, Japan
Background: Although oxidative damage has been considered to play a critical role 
during the development of contrast-induced nephropathy (CIN), the definitive evidence 
supporting this theory is lacking in the clinical setting. To elucidate the mechanism of CIN, 
we investigated the relationship between reactive oxygen species (ROS) production and 
changes of renal damage makers after contrast media (CM) exposure. Methods: The 
prospective study was performed in consecutive 94 patients with chronic kidney disease 
(CKD; estimated GFR<50%) who underwent cardiac catheterization. Urine and blood 
samples were obtained before, 24 h, 48 h after contrast exposure for the measuring 
urinary 8-hydroxy-2’-deoxyguanosine (8-OHdG), urinary liver-type fatty acid-binding 
protein (L-FABP), serum cystatin C (CycC) and serum creatinine (sCr). Results: Only 
4 patients (5.3%) developed CIN that matched the conventional criteria defined by the 
increase of sCr (25% or 0.5 mg/dl). However, we found that the more sensitive marker 
of renal damage, CycC, and the specific marker of tublointerstitial damage, L- FABP, 
significantly elevated from 1.94±0.51 to 2.01±0.55 (mg/dl), from 41.9±66.2 to 60.1±87.6 
(mcg/g*creatinine), respectively, after the CM exposure (P<0.01, P<0.001). 8-OHdG, a 
marker of systemic production of ROS also increased from 13.4±6.9 to 22.2±14.0 (mcg/
g*creatinine)(P<0.001). The change of L-FABP 24 h later positively correlated with that 
of 8-OHdG (R=0.473, P<0.001). The elevation of CysC, 48 h after CM exposure was 
associated with L-FABP change 24 h later (R=0.308, P<0.01). In 35 patients, we carried 
out the entire procedure of catheter interventional treatment with the strictly limited 
volume of CM (< 20 ml). Under this condition, the increases in 8-OHdG and L-FABP 
were significantly attenuated compared with those in the remaining patients (96±201% 
vs. 209±279%, P<0.001, 44±162% vs. 147±249%,P<0.01, respectively). Conclusions: 
Tubulointerstitial damage by oxidative stress appeared to be the dominant cause of 
latent renal damage after CM exposure. Minimizing CM dose effectively suppressed the 
oxidative stress-dependent tublointerstitial injury.
10:00 a.m.
1035-222 Insulin Resistance and serum Leptin levels Predict 
5 - year Incidence of Obesity in Lean Cardiovascular 
Disease Free Individuals: the ATTICA Study
Christine Chrysohoou, Demosthenes Panagiotakos, Christos Pitsavos, John Skoumas, 
Akis Zeibekis, Karmen Vasiliadou, Lambros Papadimitriou, Constadina Masoura, 
Christodoulos Stefanadis, 1st Cardiology Clinic University of Athens, Athens, Greece
Background:We evaluated the 5-year incidence of obesity, in a sample of cardiovascular 
disease free adult men and women, from Greece. We also investigated the potential 
effect of several socio-demographic and lifestyle habits on weight change (i.e. gain or 
loss) and obesity incidence in these subjects. Methods:1514 men and 1528 women (>18 
y) without any clinical evidence of cardiovascular disease, living in Attica area, Greece, 
were enrolled in the ATTICA study from May 2001 to December 2002. The sampling 
was random, multi-stage (by city, age-group and sex), and included information about 
various socio-demographic, lifestyle, biochemical and clinical characteristics. In this 
work we analysed the data from 1771 subjects with BMI<25kg/m2 and without central 
obesity, according NCEP-ATPIII criteria. Diabetes mellitus and impaired fasting glucose 
were defined according to the established American Diabetes Association criteria. Insulin 
resistance was evaluated by HOMA-IR. Dietary habits were assessed through a validated 
food frequency questionnaire and a diet score (range 0-55) was developed (higher values 
means greater adherence to the Mediterranean diet). Furthermore, serum inflammatory 
markers, leptin and lipid levels were measured in all subjects. In 2006, we performed the 
5-year follow-up.
Results:The 5-year incidence of obesity was 21.8% in men and 11.9% in women. The 
men-to-women ratio demonstrates that more men than women developed obesity, while 
more women than men became overweight during the follow-up period. In the multivariate 
analysis, adherence to the Mediterranean diet seems to have a protective effect on the 
incidence of obesity (b=-0.238 +/- 0.094, p=0.013). Furthermore, age (0.98+/-0.57, 
p=0.09), HOMA (0.744+/-).384, p=0.05) and leptin levels (0.359+/-0.147, p=0.016) 
predict the occurrence of obesity, irrespective of other baseline characteristics of the 
participants.
Conclusions: Obesity remains a serious health problem for the Greek population, as 
the alarming rates of excess body weight continue to increase. Measures for preventing 
excess body weight should be urgently targeting in those with metabolic risk factors and 
lack of healthy diet.
10:00 a.m.
1035-223 Smoking Cessation Following Acute Coronary 
Syndrome
Sonia Grandi, Andre Gervais, Lawrence Joseph, Jennifer O’Loughlin, Gilles Paradis, 
Louise Pilote, Stephane Rinfret, Nizal Sarrafzadegan, Sat Sharma, Claude Lauzon, 
Habib Gamra, Howard Wightman, Sohrab Lutchmedial, Jean-Pierre Picard, Peter 
Giannoccaro, Thao Huynh, Jean G. Diodati, Francois Grondin, Peter Klinke, Andreas 
Wielgosz, Beth Abramson, Niels Schwarz, Mark J. Eisenberg, Jewish General Hospital, 
Montreal, QC, Canada
Background: Smokers with an enzyme-positive acute coronary syndrome (ACS) are 
advised to immediately quit smoking. Little is known, however, about the smoking 
behavior of patients immediately post-ACS.
Methods: We examined the efficacy of bupropion in smokers with ACS in an ongoing 
multi-center, double blind, placebo-controlled clinical trial. Smoking abstinence was 
biochemically-validated at clinic visits at 4, 9, 24, and 52 weeks post-ACS.
Results: At the time of analysis, data were available for 188 patients at baseline and 120 
patients at 52-week follow-up. Most patients were male (85%), and the mean age was 
55±10 years. Two-thirds of patients were admitted with a STEMI, and half underwent 
PCI or CABG during their index admission. Patients at admission smoked 33±13 years, 
had a median of 1 previous quit attempt (IQR=0-3), and 36% reported living with other 
smokers. Similar to previous trials, 34% of patients were lost to follow-up at 52 weeks. 
Assuming those lost to follow-up returned to smoking, a total of 65% were smoking at 
52 weeks (Figure). Among patients who returned for follow-up at 52 weeks (n=79), 44% 
returned to smoking. Of those patients who returned to smoking, the median number of 
cigarettes smoked per day decreased from 25 (IQR=15-25) prior to ACS to 5 (IQR=3-13) 
at 52 weeks (p<0.001).
Conclusions: Many patients return to smoking by 52 weeks post-ACS. Because half our 
patients were receiving bupropion, actual smoking rates in untreated patients are likely to 
be higher than those reported here. 
10:00 a.m.
1035-224 Short-Term Aspirin Treatment Decreases Wave 
Reflections in Never Treated Hypertensive Patients
Panagiota Pietri, Charalambos Vlachopoulos, Nikolaos Alexopoulos, Katerina Baou, 
Panagiotis Xaplanteris, Stella-Maria Kyvelou, Panagiotis Spanos, Gregory Vyssoulis, 
Christodoulos Stefanadis, 1st Department of Cardiology, Athens Medical School, 
Hippokration Hospital, Athens, Greece
Background. Wave reflections are predictors of cardiovascular outcomes and may 
be affected by different antihypertensive drugs. Aspirin exerts beneficial effects on 
cardiovascular disease through its anti-thrombotic and anti-inflammatory properties. 
Nevertheless, no data exist regarding the effect of low-dose aspirin on wave reflections. 
The purpose of this study was to evaluate the effect of low-dose aspirin on wave reflections 
in hypertensive patients.
Methods. We studied 11 patients (mean age = 46 years) with never treated, Grade I arterial 
hypertension. Patients were advised to take 160 mg of aspirin per day for two weeks. 
Wave reflections were assessed at baseline and two weeks after treatment by measuring 
heart rate-corrected augmentation index (AIx75) using the Sphygmocor device. We also 
evaluated the inflammatory status by measuring the levels of high-sensitivity C-reactive 
protein (hsCRP) and fibrinogen at baseline and two weeks after treatment.
Results. A statistical significant decrease was observed in AIx75 two weeks after aspirin 
intake (from 26.9±5.6 to 25.3±5.1 %, p=0.034). No difference was observed in systolic 
and diastolic blood pressures either peripheral or central (p=NS for all). Moreover, levels 
of hsCRP and fibrinogen did not significantly change (from 1.31±1.1 to 1.8±1.1mg/dl and 
328.3±49.3 to 318.8±57.9 mg/dl respectively, p=NS).
Conclusion. Short-term therapy with low-dose of aspirin decreases wave reflections 
in hypertensive patients independently of inflammatory state. This finding may have 
important clinical implications given that wave reflections are independent predictors of 
cardiovascular risk in hypertensive patients. However, further studies are warranted to 
confirm this observation.
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1035-225 Prediction of early and late mortality after acute 
myocardial infarction
Axel Bauer, Petra Barthel, Raphael Schneider, Anke Joeinig, Georg Schmidt, 1. Med. 
Klinik und Deutsches Herzzentrum, TU München, Munich, Germany
Background: Impaired left ventricular ejection fraction (LVEF) and autonomic dysfunction 
independently predict death after myocardial infarction (MI). This study analyzed the 
power of LVEF and autonomic function parameters assessed early after MI for the 
prediction of early and late deaths.
Methods: 2,343 survivors of acute MI were included. Risk stratification was performed 
within the second week after MI. LVEF was assessed by angiography or echocardiography, 
autonomic function was assessed by Heart Rate Turbulence (HRT) and Deceleration 
Capacity (DC). Severe Autonomic Failure (SAF) was assumed in the presence of HRT 
category 2 (Onset and Slope abnormal) and DC ≤4.5ms. Primary endpoint was death of 
any cause. Analyses were performed separately for early (1st year) and late (2nd to 5th 
year) follow-up periods.
Results: 181 patients died within the 5-year follow-up period. Out of these, 69 patients 
died within the 1st year and 112 patients thereafter. Table 1 shows multivariate hazard 
ratios (95% CI) and p-values of LVEF≤30% and SAF for both follow-up periods.
Conclusions: LVEF and SAF are significant predictors of early and late mortality after MI. 
SAF is particularly strong as predictor of late mortality. 
10:00 a.m.
1035-226 Lp-PLA2 expression in carotid artery plaques predicts 
long-term outcome, including cardiac events
Joerg Herrmann, Dallit Mannheim, Daniele Versari, Mario Goessl, Joseph McConnell, 
Frederick Meyer, Lilach Lerman, Amir Lerman, Mayo Clinic, Rochester, MN
Background: Circulating lipoprotein-associated phospholipase A2 (Lp-PLA2) has 
emerged as an independent marker for cardiovascular (CV) events. If this relates to 
the prognostic correlate of atherosclerotic plaque expression of Lp-PLA2 has, however, 
remained undefined and constitutes the objective for this study.
Methods: In 126 patients undergoing elective carotid endarterectomy, carotid artery 
plaque Lp-PLA2 expression was quantified by immunoblotting. Additional expression 
profiling was performed for CRP, NAD(P)H oxidase p67phox, and matrix metalloproteinase 
(MMP)-2 and -9. Macrophage and collagen plaque content was determined by quantitative 
immunostaining and Sirius red staining, respectively. The results were stratified according 
to the presence or absence of major CV events (cardiac death, nonfatal acute myocardial 
infarction and stroke) over a clinical follow-up period of 33±13 months.
Results: A summary of the results is provided in Table 1. Based on additional ROC 
analyses (AUC 0.71, p=0.04), expression values of Lp-PLA2 above a cutoff of 0.81 
increased the odds of a CV event more than 8-fold (OR 8.42, 95% CI 1.02-69.46, p=0.02). 
None of the classical CV risk factors was predictive of CV events in this cohort.
Conclusions: Lp-PLA2 expression in carotid artery plaques is a predictor of long-term 
outcome, including cardiac events. These findings support the concept of the vulnerable 
patient and further studies on the pathophysiological role Lp-PLA2 within this concept.
Table 1
Values are mean+/-SD No CV events (n=117) CV events (n=9) p-value
Lp-PLA2/β-actin density ratio 1.28±1.17 2.16±1.89 <0.05
CRP/β-actin density ratio 2.26±0.95 1.58±0.93 0.2
p67phox/β-actin density ratio 1.53±1.52 3.23±3.00 <0.05
MMP-2/β-actin density ratio 1.07±1.36 2.45±3.33 0.1
MMP-9/β-actin density ratio 1.20±1.51 2.64±1.00 <0.05
Macrophage content [% plaque area] 1.06±1.35 2.45±3.33 0.1
Collagen content [% plaque area] 3.10±7.64 2.33±1.81 0.1
10:00 a.m.
1035-227 Ethnic Differences in The Relation of Metabolic 
Syndrome Components to Left Ventricular Mass: 
Mexican Americans vs. Non-Hispanic Whites
Allebban Zuhair, Julius M. Gardin, Nathan D. Wong, Sharon K. Sklar, Renee B. Bess, 
Anne M. Spence, Harrirar A. Pershadsingh, St John Hospital and Medical Center, 
Detroit, MI, University of California-Irvine, Irvine, CA
Background. Metabolic syndrome (MetS) is associated with increased risk for 
cardiovascular disease (CVD). Mexican Americans (MA) exhibit increases in CVD risk 
factors compared to non-Hispanic Whites (NHW), but few data exist comparing the 
relation of MetS to subclinical CVD_e.g., left ventricular (LV) mass in MA vs. NHW.
Methods: Asymptomatic subjects (105 MA and 100 NHW, 50.7% female, aged 48 + 12 
yrs)-- were studied by echocardiography (echo), blood and urine tests. MetS was defined 
as ≥ 3 of the following: triglycerides > 150 mg/dL, HDL-cholesterol <50 mg/dL (women) 
and <40mg/dL (men), body mass index >30 kg/m2 , blood pressure >[U1] 135/80 mm/Hg 
or on medication, or fasting blood glucose >100 mg/dL or on medication for glucose. 
Echo LV mass was compared to presence or absence of MetS, and to number of MetS 
components
Results. LV mass was lower in MA compared to NHW in those without (114 ± 29 vs 197 
± 45 gm, p<0.001) and with MetS (152 ± 51 vs. 177 ± 45 gm, p< 0.01). LV mass/height 
2.7 was lower in MA vs NHW without MetS (p< 0.001). MA exhibited increased levels of 
each MetS component in conjunction with an increase in number of MetS components. Of 
interest, in MA, but not NHW, there was a significant (p<0.001) graded increase in echo 
LV mass with increasing MetS components (figure).
Conclusions. In asymptomatic MA, but not NHW adults, the number of MetS components 
were related to graded increases in LV mass. Whether this translates into increased CVD 
risk associated with MetS in MA requires further investigation.
10:00 a.m.
1035-228 Effects of Omega-3 Polyunsaturated Fatty Acids 
Supplementation on Mortality in Patients With 
Cardiovascular Disease - A Meta-analysis of 
Randomized, Controlled Trials
Antoinette de Waha, Rudolf Berger, Univ. Klinik für InnereMedizin II AKH-Wien, Vienna, 
Austria
Background: The effect of omega-3 polyunsaturated fatty acids on total mortality and 
cardiovascular endpoints as myocardial infarction, sudden death, restenosis rate 
after PTCA, occurrence of ICD shocks and heart failure death or episode of cardiac 
decompensation on patients with cardiovascular disease is unclear. We investigated the 
effects of supplemental intake of omega-3 fatty acids on patients with cardiovascular 
disease and calculated these effects in a meta-analysis of randomized, double-blind, 
controlled trials (RCT).
Methods: After a comprehensive literature search, RCTs that compared fish oil 
supplementation with placebo in patients with cardiovascular disease were analysed 
for relevant outcome data. Two investigators independently extracted trial data, applied 
inclusion criteria and performed quality assessment. 19 trials met inclusion criteria, 
published between 1966 and 2006 including 2442 patients in the intervention and 2383 
patients in the placebo groups.
Results: The pooled estimate showed a significant reduction of the total mortality by fish 
oil intake compared to placebo (relative risk 0.69, 95% confidence interval 0.52 to 0.92). 
No significant risk reduction could be detected concerning the endpoints myocardial 
infarction (RR 0.87, 95% CI 0.64-1.18), sudden death (RR 0.50, 95% CI 0.20-1.25), 
restenosis rate after PTCA (RR 0.96, 95% CI 0.83-1.11), occurrence of ICD shocks (RR 
0.94, 95% CI 0.71-1.26) and heart failure death or episode of cardiac decompensation 
(RR1.16, 95% CI 0.71-1.90).
Conclusion: This meta-analysis of RCTs suggests a significant reduction of total mortality 
by polyunsaturated fatty acid supplementation in patients with cardiovascular disease. 
Data on further cardiovascular endpoints are inconclusive.
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10:00 a.m.
1035-229 Declining Anxiety Level Improves Prognosis in Patients 
with Coronary Artery Disease
Yinong Young-Xu, Bradley V. Watts, Charles M. Blatt, Lown Research Foundation, 
Brookline, MA
Background:We examined whether declining anxiety level (AL) is associated with reduced 
risk of nonfatal myocardial infarction (MI) or total mortality among coronary artery disease 
(CAD) patients.
Methods:A prospective cohort study of 516 patients with CAD (mean age 68 years at 
entry, 82% males) with annual administration of the Symptom Questionnaire. Primary 
outcome was the composite of nonfatal MI and all-cause mortality.
Results:During an average follow-up of 3.4 years, we documented 44 nonfatal MIs and 19 
deaths. We categorized all anxiety scores into tertiles, fitting the intuitive classification of 
low, intermediate, and high level of anxiety. A reduction (or increase) in AL occurs when a 
patient’s anxiety score changed, during follow-up, from a higher to a lower tertile (or from 
a lower to a higher tertile). If a patient’s AL remains in the same tertile throughout follow-
up, we term it a steady AL. Compared to an increase in AL, a reduction in anxiety score 
was associated with a decreased risk of nonfatal MI or death; the age adjusted hazard 
ratio was 0.39 (95% confidence interval, 0.19 - 0.82; p=0.01). This is true for a steady 
anxiety state as well; the age adjusted hazard ratio was 0.49 (95% confidence interval, 
0.28 - 0.86; p=0.01). In multivariate time-varying Cox model after adjusting for age, sex, 
and many other potential confounders, these associations remained.
Conclusions:Declining or steady anxiety level over time is associated with a reduction in 
MI or death among patients with CAD. 
10:00 a.m.
1035-230 Use of Disease-Modifying Anti-Rheumatic Drugs and 
Cardiovascular Events in Patients with Rheumatoid 
Arthritis
Matthew Kaminski, Mehdi H. Shishehbor, Antonio Gutierrez, Mohammad R. Amini, 
Walter Coats, Meisam Moghbelli, Arman T. Askari, Cleveland Clinic, Cleveland, OH
Background: Patients with rheumatoid arthritis (RA) have increased cardiovascular 
morbidity and mortality, possibly due to the inflammatory nature of the disease. Prior 
studies on the effect of traditional disease-modifying anti-rheumatic drugs (DMARDs) on 
cardiovascular risk have been conflicting.
Methods: Medical records at our institution were reviewed for patients with diagnosis of RA 
between January 2000 and July 2006. Demographic, clinical, and medication data were 
then extracted. We collected data on major adverse cardiac events (MACE), including MI, 
unstable angina, hospitalization for congestive heart failure, stroke, and TIA. All-cause 
mortality was obtained by using the Social Security Death Index. We used multivariable 
logistic regression analysis to assess the association between use of DMARDs and 
MACE, including all-cause mortality.
Results: A total of 1723 consecutive patients with RA were identified. These patients 
experienced 250 MACE, including 58 deaths, over 6 year period. We found a significant 
univariate association between use of DMARDs and decreased MACE. After adjustment 
for several confounders including history of coronary artery disease, diabetes mellitus, 
hypertension, hyperlipidemia, current smoking, obesity, and concomitant medications 
(statins, aspirin, beta-blockers, NSAIDS), DMARD use remained independently 
associated with decreased MACE (OR 0.48; 95% CI 0.32-0.71).
Conclusions: In patients with RA, DMARD use was strongly associated with decreased 
MACE. Use of DMARDs may decrease risk for MACE, including MI, stroke, and death.
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817-3 Lack of Association Between Cyclooxygenase-1-
Dependent Platelet Function Assays and Adverse 
Clinical Outcomes in 700 Consecutive Aspirin-Treated 
Patients Presenting for Cardiac Catheterization
Andrew L. Frelinger, III, YouFu Li, Matthew D. Linden, Marc R. Barnard, Marsha L. Fox, 
Mark I. Furman, Alan D. Michelson, Center for Platelet Function Studies, University of 
Massachusetts Medical School, Worcester, MA
Background: Poor clinical outcome in aspirin-treated patients has been termed “aspirin 
resistance” and has been suggested to result from inadequate inhibition of platelet 
cyclooxygenase 1 (COX-1) by aspirin. In this prospective study we therefore sought to 
correlate COX-1-dependent and other platelet function assays with clinical outcomes. 
Methods: Blood was collected prior to percutaneous coronary intervention (PCI) from 
700 consecutive aspirin-treated (81 or 325 mg for ≥3 days) patients presenting to our 
cardiac catheterization laboratories for evaluation of coronary artery disease. Platelet 
function was tested by: 1) serum thromboxane (TX) B2; 2) whole blood flow cytometric 
detection of circulating and arachidonic acid-stimulated a) monocyte-platelet aggregates 
(MPAs), b) neutrophil-platelet aggregates, c) platelet surface activated GPIIb-IIIa, d) 
platelet surface P-selectin; 3) platelet function analyzer (PFA)-100 collagen-epinephrine 
(CEPI) and collagen-ADP (CADP) closure time (CT). Adverse clinical outcomes of all-
cause death, cardiovascular death, and major adverse cardiovascular events (MACE: 
cardiovascular death, MI, hospitalization for revascularization [CABG or PCI], acute 
coronary syndrome) were assessed by telephone interview and/or medical record review. 
Results: Follow-up was obtained for 562/700 (80%) of patients at 24.8 ± 0.3 months 
after platelet function testing. After adjustment for covariates (including gender, aspirin 
dose, TIMI score, VWF), elevated circulating MPAs was associated with all-cause death 
(p=0.001) and PFA-100 CADP CT <65 sec was associated with MACE (p = 0.034). 
Although patients were identified with markers of inadequate inhibition of platelet COX-1 
(elevated serum TXB2 and arachidonic acid-stimulated platelet markers, and shortened 
PFA-100 CEPI CT), these markers were not significantly associated with adverse clinical 
outcomes. Conclusions: Elevated circulating MPAs and PFA-100 CADP CT correlated 
with adverse clinical outcomes, but COX-1-dependent platelet function assays did not. 
This study suggests that mechanisms other than inadequate inhibition of COX-1 are 
responsible for clinical “aspirin resistance”.
11:15 a.m.
817-4 Small Artery Elasticity Predicts Development of 
Hypertension in Prehypertensive Patients: Results 
From a TROPHY Substudy
Daniel A. Duprez, Brunna Alves, Gregory Grandits, Shwana D. Nesbit, Brent M. Eagan, 
Stevo Julius, Jay N. Cohn, University of Minnesota, Minneapolis, MN
Background: A marker to identify pre-hypertensive individuals likely to develop 
hypertension would be a valuable clinical tool. The Trial of Preventing Hypertension 
(TROPHY) randomized 809 patients with pre-hypertensive blood pressures to treatment 
with candesartan 16 mg daily or placebo. Blinded treatment was continued for 2 years and 
follow-up for 4 years. The study end-point was development of blood pressure > 140/90 
mmHg or target organ damage requiring antihypertensive therapy. In a substudy we 
examined if small and/or large artery elasticity would be a predictor for the development 
of hypertension.
Methods: Pulse wave contour registration at the radial artery was performed using 
tonometry (HDI CV Profilor) at baseline in 129 subjects (41 female, 88 male; mean age 
49 ± 8 years) with prehypertension (blood pressure 136 ± 11/ 81 ± 7 mmHg). Large (LAE) 
and small artery (SAE) elasticity were derived from diastolic pulse contour analysis. LAE 
and SAE were divided into tertiles and the percentage of the subjects who developed 
hypertension by 4 years was calculated and also the odds ratio.
Results: SAE measurements were divided into tertiles (men: level 1, SAE < 5.4 ml/
mmHgx100; level 2, SAE 5.4 - 8.0 ml/mmHgx100; level 3, SAE > 8.0 ml/mmHg x 100; 
women: level 1, SAE < 2.7 ml/mmHgx100; level 2, SAE 2.7 - 5.4 ml/mmHgx100; level 3, 
SAE > 5.4 ml/mmHg x 100). Sixty two percent of the patients had developed hypertension 
by 4 years, 49% in SAE level 3, 65% in SAE level 2 and 72% in SAE level 1 (P = 0.03). The 
odds ratio for developing hypertension in SAE level 2 was 1.96 and in SAE level 1 was 
2.71 compared to SAE level 3 (P = 0.028). There was no differences among the tertiles of 
LAE in the prediction of hypertension.
Conclusions: Small artery elasticity, a guide to endothelial dysfunction, but not large 
artery elasticity appears to be a useful measurement to identify the risk of developing 
hypertension in patients with pre-hypertensive blood pressures. Changes in small artery 
function can be detected before the development of arterial hypertension.
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817-5 Prospective Study of Exercise-Induced Hypertension 
and Future Cardiovascular Mortality in 6,578 
Asymptomatic Individuals
Sandra A. D’Amore, Roger S. Blumenthal, A. Richey Sharrett, Rita F. Redberg, Kathryn 
M. Rexrode, Samia Mora, Brigham and Women’s Hospital, Boston, MA, Johns Hopkins 
University, Baltimore, MD
Background: Normotensive individuals with exaggerated blood pressure response 
to exercise seem more prone to future hypertension compared to those with normal 
responses. It is not clear if exaggerated BP response to exercise also predicts 
cardiovascular mortality.
Methods: A prospective study of 6,578 asymptomatic individuals performing treadmill 
tests [45% women, mean age 46 years, 74% untreated baseline BP<140/90mmHg 
(normotensives)]. Participants were grouped into 4 categories of maximum exercise 
systolic blood pressure (max ExSBP, in mmHg), corresponding to approximate quartiles.
Results: At 20-years follow-up, 385 cardiovascular disease (CVD) deaths occurred. 
In age- and sex-adjusted analyses, there was a significant association between 
max ExSBP and CVD death. Relative risks [RR (95% CI)] for max ExSBP of <160, 
161-180, 181-200, and >200mmHg were 1.00, 1.20 (0.82-1.75), 1.61 (1.11-2.32), 
and 1.89 (1.31-2.74) respectively; Ptrend <0.0001. With adjustment for diabetes, 
lipids, smoking, body mass index, and family history, corresponding RRs were 1.00, 
1.19 (0.82-1.76), 1.45 (1.00-2.11), and 1.62 (1.11-2.37); Ptrend=0.005. Comparing 
normotensives with max ExSBP <180mmHg, the adjusted RR for normotensives with 
max ExSBP >180mmHg was 1.41 (1.02-1.96), p=0.04; no ExSBP-related risk was 
seen in baseline hypertensive individuals. With further adjustment for baseline BP in 
the normotensive subgroup, max ExSBP did not remain associated with CVD mortality, 
but baseline BP did. Compared to normotensives with baseline BP <120/<80mmHg, 
normotensives with baseline BP of 120-129/80-84mmHg had adjusted RR of 1.18 
(0.79-1.76), and those with baseline BP of 130-139/85-89mmHg had adjusted RR of 
1.65 (1.11-2.46); Ptrend 0.01.
Conclusions: In asymptomatic individuals, baseline BP and max ExSBP >180mmHg were 
both associated with higher CVD mortality. Max ExSBP, however, did not offer incremental 
predictive value over baseline BP. Additionally, we found those with JNC-characterized 
pre-hypertension values 130-139/85-89mmHg had significantly increased risk of CVD 
mortality, and may warrant more aggressive treatment than currently recommended.
11:45 a.m.
817-6 Aortic Stiffness Measured by Pulse Wave Velocity 
Method Predicts Stroke in Patients With Hypertension
Rohit Bhuriya, Janos Molnar, Nishant Jalandhara, Sasikanth Adigopula, Saravanan 
Balamuthusamy, Rohit Arora, Rosalind Franklin University of Medicine and Science, 
North Chicago, IL
Background: Aortic stiffness measured by pulse wave velocity method (PWV), continues 
to be evaluated in the setting of hypertension with variable effects on stroke. We 
conducted a meta-analysis of clinical studies to evaluate the real effect of aortic stiffness, 
measured by carotid-femoral pulse wave velocity method, in predicting stroke in patients 
with hypertension.
Methods: Clinical studies measuring aortic stiffness by carotid-femoral PWV method 
and providing outcome data on stroke in patients with hypertension were included. A 
systematic review of the literature revealed 4 relevant studies involving a total of 7748 
subjects and averaging 5.5 years in duration. Statistical heterogeneity across the various 
trials was tested with the use of Cochran’s Q statistic and I2 was computed to quantify 
heterogeneity. The relative risk ratio was computed for each study. A two-sided alpha error 
of less than 0.05 was considered to be statistically significant (p<0.05).
Results: As the studies were heterogeneous, data were combined by means of a random-
effects model. Increased aortic stiffness, measured by carotid-femoral PWV method, was 
associated with a significant increase in stroke. The relative risk ratio for stroke was 3.168 
(95% CI 1.567 to 6.404) with p<0.05 (see figure 1).
Conclusions: Increased aortic stiffness, measured by pulse wave velocity method, is 
associated with a significant increase in stroke in patients with hypertension.
Noon
817-7 Interrelationships of Asymmetric Dimethylarginine 
With Urinary Albumin Excretion and Low-Grade 
Inflammation in Essential Hypertension
Kyriakos Dimitriadis, Costas Tsioufis, Maria Selima, Aliki Gennadi, Dimitris Tsiachris, 
Pavlos Toutouzas, Christodoulos Stefanadis, Ioannis Kallikazaros, Department of 
Cardiology, Hippokration Hospital, Athens, Greece
Background: Asymmetric dimethylarginine (ADMA) levels are elevated in endothelial 
dysfunction states, whereas microalbuminuria and subclinical inflammation are 
associated with atherosclerosis progression. In this study we examined the relationships 
of urinary albumin excretion, expressed as the albumin to creatinine ratio (ACR), with 
high-sensitivity C-reactive protein (hs-CRP) and ADMA in essential hypertensives.
Methods: Our population consisted of 158 newly diagnosed untreated non-diabetic 
patients with stage I to II essential hypertension [106 men, mean age=49 years, office 
blood pressure (BP)=151/97 mmHg]. According to the ACR values determined as the 
mean of two non-consecutive morning spot urine samples, the study population was 
divided into microalbuminurics (n=32) (mean ACR=30-300 mg/g) and normoalbuminurics 
(n=126) (mean ACR<30 mg/g).
Results: Microalbuminurics compared to normoalbuminurics were older (53±7 vs 49±6 
years, p<0.05), had higher 24-h systolic BP (144±11 vs 133±12 mmHg, p=0.001), while 
did not differ regarding sex, smoking status and metabolic profile (p=NS for all). Moreover, 
microalbuminurics compared to normoalbuminurics exhibited higher ADMA (0.61±0.04 
vs 0.55±0.03 µmol/l, p=0.001) and hs-CRP values (4.5±1.7 vs 2±1.1 mg/l, p<0.0001). 
In the total population, ACR was associated with 24-h systolic BP (r=0.263, p<0.0001), 
ADMA (r=0.366, p<0.0001) and hs-CRP (r=0.318, p<0.0001), while ADMA was related 
to waist to hip ratio (r=0.208, p<0.05), and 24-h pulse pressure (r=0.604, p<0.0001). 
Furthermore, multiple regression analysis revealed that hs-CRP (b=0.582, p<0.0001) 
and ADMA (b=0.238, p<0.0001) were independent predictors of ACR. By analysis of 
covariance it was revealed that ADMA and hs-CRP values were significantly different 
between groups after adjustment for confounders (p<0.05).
Conclusion: Microalbuminuria in essential hypertension is associated with pronounced 
inflammatory activation and endothelial dysregulation, as reflected by increased hs-CRP 
and ADMA levels. Moreover, ACR estimation could identify hypertensives with vascular 
dysfunction associated with ADMA and hs-CRP proatherosclerotic pathways.
12:15 p.m.
817-8 Comparative Antihypertensive Efficacy of the Oral 
Direct Renin Inhibitor Aliskiren, Irbesartan and Ramipril 
After a Missed Dose: a Double Blind Ambulatory Blood 
Pressure Monitoring Study
Paolo Palatini, Werner Jung, Eugene Shlyakhto, Jaco Botha, Manesh Bheda, Deborah 
L. Keefe, University of Padova, Padua, Italy, Novartis Pharmaceuticals Corporation, East 
Hanover, NJ
Background: Most patients occasionally miss a dose of antihypertensive therapy, 
highlighting the need for sustained blood pressure (BP) control beyond the 24-h dose 
interval.
Methods: 654 patients with hypertension (mean 24-h ambulatory diastolic BP [MADBP] 
≥85 mmHg) were randomized 1:1:1 to once-daily (qd) aliskiren 150 mg, irbesartan (IRB) 
150 mg or ramipril (RAM) 5 mg. Doses were doubled after 2 weeks. At Day 42, within 
each treatment group patients were again randomized equally to one day of placebo 
(‘missed dose’) on either Day 42 or Day 49; active treatment was continued on all other 
days. Patients with a successful 24-h ambulatory BP measurement at baseline and Day 
42/49 were included in analyses.
Results: The analysis population comprised 478 patients (aliskiren n=155; IRB n=171; 
RAM n=152). Compared with active dose, loss of BP-lowering effect after a missed dose 
was significantly smaller with aliskiren than IRB or RAM (Figure).
Least-squares mean reductions from baseline in 24-h ambulatory systolic BP (MASBP) and 
MADBP (primary endpoint) after a missed dose with aliskiren (-9.3/-7.0 mmHg, respectively) 
were significantly greater than RAM (-7.1/-5.0; p<0.01) and similar to IRB (-9.5/-7.3; p=NS). 
Treatments were well tolerated (overall adverse event incidence: 32.9-36.0%).
Conclusion: Aliskiren 300 mg qd (recommended frequency) provides sustained BP 
control beyond 24 h following a missed dose; loss of BP-lowering effect was significantly 
smaller than after a missed dose of IRB 300 mg or RAM 10 mg.
